abstract_id,session_title,abstract_title,ground_truth_raw,ground_truth,approach_3_indication_response,approach_3_success,approach_3_selected_source,approach_3_reasoning,approach_3_rules_retrieved,approach_3_components_identified,approach_3_llm_calls
393216,Colorectal Cancer,"Surgical Quality For Patients (Pts) Treated With Neoadjuvant Chemotherapy Vs Chemoradiation For Locally Advanced Rectal Cancer (Larc): Prospect (Ncctg N1048, Alliance)",Locally Advanced;;Rectal Cancer,Locally Advanced Rectal Cancer,Locally Advanced Rectal Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title 'Surgical Quality For Patients (Pts) Treated With Neoadjuvant Chemotherapy Vs Chemoradiation For Locally Advanced Rectal Cancer (Larc): Prospect (Ncctg N1048, Alliance)' contains a specific disease term ('Locally Advanced Rectal Cancer'). The session title 'Colorectal Cancer' is less specific. Based on the Single-Source Extraction Principle, the abstract title is selected as the source.
2. **Identify Components**: The key components identified in the abstract title are the disease 'Rectal Cancer' and the stage descriptor 'Locally Advanced'. The phrase 'Treated With Neoadjuvant Chemotherapy Vs Chemoradiation' is identified as a treatment context.
3. **Retrieve Relevant Rules**: Rules for 'Stage' and 'Treatment Set-up' were retrieved to handle 'Locally Advanced' and the treatment context, respectively.
4. **Apply Rules**:
   - **Generic Exclusion Rule**: The procedural qualifier 'Treated With Neoadjuvant Chemotherapy Vs Chemoradiation' is excluded as per the generic rules.
   - **Stage Rule Principle**: Although no specific rule for 'Locally Advanced' was found, the pattern from other stage rules (e.g., 'Limited Stage', 'Extensive Stage') indicates that such descriptors should be kept and prepended to the disease name.
   - **Formatting Rules**: The indication is converted to Title Case and singular form. 'Rectal Cancer' is already singular.
5. **Construct Indication**: The stage 'Locally Advanced' is combined with the disease 'Rectal Cancer' to form the final indication.
6. **Quality Check**: The final indication 'Locally Advanced Rectal Cancer' is a clinically valid and well-formatted entity. It adheres to the single-source principle and all applicable generic and specific rules.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To determine how to handle the term 'Locally Advanced'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Modality'], 'reason': ""To confirm that treatment modalities like 'Neoadjuvant Chemotherapy' and 'Chemoradiation' should be excluded.""}]","[{'component': 'Locally Advanced Rectal Cancer', 'type': 'Disease with Stage', 'normalized_form': 'Locally Advanced Rectal Cancer', 'rule_applied': 'Generic rule for disease characterization and staging.'}, {'component': 'Treated With Neoadjuvant Chemotherapy Vs Chemoradiation', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
393219,Colorectal Cancer,"Effectiveness And Safety Of Rectal Arterial Infusion Chemotherapy Combined With Anti-Pd1 Antibody For Microsatellite Stable Locally Advanced Rectal Cancer: Early Outcome Report Of A Two-Stage, Single Armed, Phase II Study (Raic)",Microsatellite Stable;;Locally Advanced;;Rectal Cancer,Microsatellite Stable Locally Advanced Rectal Cancer,Microsatellite Stable Locally Advanced Rectal Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Rectal Cancer') and is more detailed than the session title ('Colorectal Cancer'), adhering to the single-source principle.
2. **Component Identification**: I identified the following components in the abstract title: the disease 'Rectal Cancer', the biomarker 'Microsatellite Stable', and the stage 'Locally Advanced'. The term 'Anti-Pd1 Antibody' was identified as a potential treatment rather than a patient characteristic.
3. **Rule Retrieval**: I retrieved rules for the 'Biomarker' category to clarify how to handle 'Anti-Pd1 Antibody' and 'Microsatellite Stable'. I also checked 'Stage' rules for 'Locally Advanced'.
4. **Rule Application**:
   - **Exclusion Rule**: The retrieved rule for 'Anti-PD-1' (Rule ID: 83) confirmed that it is a treatment agent and must be excluded from the indication.
   - **Generic Exclusion Rule**: Procedural terms like 'Rectal Arterial Infusion Chemotherapy' and study design details ('Phase II Study') were excluded as per generic rules.
   - **Formatting Rules**: 'Microsatellite Stable', 'Locally Advanced', and 'Rectal Cancer' were converted to Title Case. The disease term 'Rectal Cancer' is already in its singular form.
5. **Indication Construction**: The identified and validated components were combined in the standard clinical order: Biomarker + Stage + Disease.
6. **Final Indication**: The final indication is 'Microsatellite Stable Locally Advanced Rectal Cancer'. This is a clinically valid and accurately formatted indication based on the selected source and applied rules.","[{'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To determine how to handle 'Anti-Pd1 Antibody' and 'Microsatellite Stable'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for specific rules regarding the term 'Locally Advanced'.""}]","[{'component': 'Rectal Cancer', 'type': 'Disease', 'normalized_form': 'Rectal Cancer', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Microsatellite Stable', 'type': 'Biomarker', 'normalized_form': 'Microsatellite Stable', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'Locally Advanced', 'type': 'Stage', 'normalized_form': 'Locally Advanced', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'Anti-Pd1 Antibody', 'type': 'Treatment', 'normalized_form': '', 'rule_applied': 'Biomarker Rule (ID: 83): Exclude treatment agents.'}, {'component': 'Rectal Arterial Infusion Chemotherapy', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclude procedural/temporal qualifiers.'}]",4
147461,Myeloma And Other Monoclonal Gammopathies - Clinical,Depth Of Response And Mrd Status In Ultra High-Risk Myeloma And Plasma Cell Leukemia Treated With Dara-Cvrd And Augmented Autologous Transplant: Results Of The Risk-Stratified Uk Optimum/Muknine Trial,Ultra High-Risk;;Myeloma;;Plasma Cell Leukemia,Ultra High-Risk Myeloma;;Plasma Cell Leukemia,Ultra High-Risk Myeloma;;Plasma Cell Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains specific disease terms ('Myeloma', 'Plasma Cell Leukemia'), following the single-source principle.
2.  **Component Identification**: I identified two distinct diseases: 'Myeloma' and 'Plasma Cell Leukemia'. I also identified a risk qualifier, 'Ultra High-Risk', directly associated with 'Myeloma'.
3.  **Rule Retrieval**: I retrieved rules for the 'Risk' category to handle 'Ultra High-Risk'. Rule ID 134 confirmed that 'Ultra High-Risk' should be normalized to 'Ultra High-Risk' and prepended to the disease name.
4.  **Rule Application**: 
    *   The first disease, 'Myeloma', is modified by 'Ultra High-Risk', resulting in 'Ultra High-Risk Myeloma'.
    *   The second disease, 'Plasma Cell Leukemia', is extracted as a separate indication.
    *   The generic rule for multiple diseases was applied, requiring separation with ';;'.
    *   Generic exclusion rules were applied to remove treatment details ('Treated With Dara-Cvrd And Augmented Autologous Transplant') and study information.
    *   Formatting rules (Title Case, singular form) were applied.
5.  **Indication Construction**: The components were combined to form the final output: `Ultra High-Risk Myeloma;;Plasma Cell Leukemia`.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To correctly format the 'Ultra High-Risk' qualifier.""}, {'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To check for specific rules on handling multiple diseases, but none were found, so generic rules were applied.'}]","[{'component': 'Ultra High-Risk Myeloma', 'type': 'Disease with Risk Qualifier', 'normalized_form': 'Ultra High-Risk Myeloma', 'rule_applied': ""Rule ID 134 for 'Ultra High-Risk' and generic casing rules.""}, {'component': 'Plasma Cell Leukemia', 'type': 'Disease', 'normalized_form': 'Plasma Cell Leukemia', 'rule_applied': 'Generic rule for disease extraction and Title Case.'}]",2
147482,Myeloproliferative Neoplasms - Clinical,Overall And Progression-Free Survival In Patients Treated With Fedratinib As First-Line Myelofibrosis (Mf) Therapy And After Prior Ruxolitinib (Rux): Results From The Jakarta And Jakarta2 Trials,First-Line;;Myelofibrosis,First-Line Myelofibrosis,First-Line Myelofibrosis;;Previously Treated Myelofibrosis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title because it contains a more specific disease term, 'Myelofibrosis (Mf)', compared to the broader 'Myeloproliferative Neoplasms' in the session title. This adheres to the single-source principle.

2.  **Component Identification**: The abstract title contains two distinct patient populations for the disease 'Myelofibrosis':
    *   Patients receiving therapy as 'First-Line'.
    *   Patients treated 'After Prior Ruxolitinib'.

3.  **Rule Retrieval and Application**:
    *   For the 'First-Line' component, I retrieved rules for 'Line of treatment'. The rules (e.g., ID: 198, 200) state that when 'first-line' modifies a therapy or disease concept (as in 'First-Line Myelofibrosis...Therapy'), it should be retained, standardized to 'First-Line', and placed at the beginning of the indication. This leads to the first indication: `First-Line Myelofibrosis`.
    *   For the 'After Prior Ruxolitinib' component, this phrase describes a patient's treatment history. This is a specific instance of a 'Previously Treated' patient subgroup. Rules for 'Treatment Status' confirm that such descriptors should be included. Therefore, this cohort is normalized to `Previously Treated Myelofibrosis`.

4.  **Indication Construction**: The title explicitly separates these two populations with 'And', indicating two distinct groups are being analyzed. Therefore, two separate indications are generated and combined using the ';;' delimiter as required.

5.  **Final Quality Check**: Generic rules were applied. The disease term 'Myelofibrosis' is singular and in Title Case. Procedural details like drug names ('Fedratinib', 'Ruxolitinib') and trial names ('Jakarta', 'Jakarta2') were correctly excluded. The final output accurately reflects the two clinically distinct patient populations described in the abstract title.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To correctly handle the 'First-Line' descriptor and determine if it should be included in the final indication.""}]","[{'component': 'First-Line Myelofibrosis (Mf) Therapy', 'type': 'Disease with Line of Treatment', 'normalized_form': 'First-Line Myelofibrosis', 'rule_applied': ""Rule ID: 200 - Standardize 'first line' to 'First-Line' and place at the beginning of the indication.""}, {'component': 'After Prior Ruxolitinib', 'type': 'Patient Subgroup (Treatment Status)', 'normalized_form': 'Previously Treated', 'rule_applied': 'Generic rule for normalizing specific treatment history to a standard patient subgroup descriptor.'}, {'component': 'Myelofibrosis (Mf)', 'type': 'Disease', 'normalized_form': 'Myelofibrosis', 'rule_applied': 'Generic rule for singular form and title case.'}]",2
180260,"Clonal Hematopoiesis, Aging and Inflammation: Poster I",Genomic Landscape of RUNX1-Familial Platelet Disorder with Myeloid Malignancies Reveals Rising Clonal Hematopoiesis,RUNX1-Familial Platelet Disorder;;Myeloid Malignancies,RUNX1-Familial Platelet Disorder;;Myeloid Malignancy,RUNX1-Familial Platelet Disorder;;Myeloid Malignancy;;Clonal Hematopoiesis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Genomic Landscape of RUNX1-Familial Platelet Disorder with Myeloid Malignancies Reveals Rising Clonal Hematopoiesis') was chosen over the session title because it contains specific, multiple disease entities, making it the more informative source, adhering to the single-source principle.
2.  **Component Identification**: Three distinct clinical entities were identified in the abstract title:
    a. 'RUNX1-Familial Platelet Disorder'
    b. 'Myeloid Malignancies'
    c. 'Clonal Hematopoiesis'
3.  **Rule Retrieval**: Rules were retrieved for handling multiple diseases, familial qualifiers, and gene names.
    - `Patient with two different Disease`: No specific rule for the connector 'with' was found, defaulting to the generic rule of separating distinct diseases with ';;'.
    - `Patient Sub-Group` for 'Familial': The rules confirm that 'Familial' should be retained as a prefix to the disease it modifies.
    - `Gene Name` for 'RUNX1': The rules indicate that a gene name alone is insufficient, but here 'RUNX1' is an integral part of the specific disorder's name ('RUNX1-Familial Platelet Disorder'), not a standalone biomarker, so it must be retained.
4.  **Rule Application and Construction**:
    - **Indication 1**: 'RUNX1-Familial Platelet Disorder' was kept as is, correctly formatted in Title Case with the gene name preserved.
    - **Indication 2**: 'Myeloid Malignancies' was processed using the generic rule for singularization, converting 'Malignancies' to 'Malignancy', resulting in 'Myeloid Malignancy'.
    - **Indication 3**: 'Clonal Hematopoiesis' was identified as a distinct, well-formed indication and extracted directly.
5.  **Final Assembly**: The three extracted indications were combined into a single string, separated by the required ';;' delimiter, resulting in the final output.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': ""To determine how to handle multiple diseases connected by 'with'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Familial'], 'reason': ""To correctly process the 'Familial' qualifier.""}, {'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To verify the correct formatting for the 'RUNX1' gene name as part of a disease.""}]","[{'component': 'RUNX1-Familial Platelet Disorder', 'type': 'Disease', 'normalized_form': 'RUNX1-Familial Platelet Disorder', 'rule_applied': ""Gene Name rule (retained as part of disease name); Patient Sub-Group rule for 'Familial'.""}, {'component': 'Myeloid Malignancies', 'type': 'Disease', 'normalized_form': 'Myeloid Malignancy', 'rule_applied': 'Generic rule: Singular Form.'}, {'component': 'Clonal Hematopoiesis', 'type': 'Disease', 'normalized_form': 'Clonal Hematopoiesis', 'rule_applied': 'Generic rule: Title Case.'}]",2
147495,Sickle Cell Disease,The Burden Of Sickle Cell Disease (Scd) On Patients In Ghana And Nigeria Compared With Other Low-/Middle-Income And High-Income Countries: Results From The Sickle Cell World Assessment Survey (Sway),Sickle Cell Disease,Sickle Cell Disease,Sickle Cell Disease,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a clear disease term, 'Sickle Cell Disease', which is the primary source according to the single-source extraction principle.
Step 2: The core disease 'Sickle Cell Disease (Scd)' was identified from the title.
Step 3: Generic exclusion rules were applied. Geographic locations ('Ghana', 'Nigeria') and sociodemographic descriptors ('Low-/Middle-Income And High-Income Countries') were excluded.
Step 4: The parenthetical abbreviation '(Scd)' was removed to standardize the indication.
Step 5: Formatting rules were applied. The indication 'Sickle Cell Disease' is already in the correct Title Case and singular form.",[],"[{'component': 'Sickle Cell Disease (Scd)', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic Rule: Standardization and removal of abbreviation.'}, {'component': 'In Ghana And Nigeria', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of sociodemographic descriptors.'}, {'component': 'Low-/Middle-Income And High-Income Countries', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of sociodemographic descriptors.'}]",1
262190,Chronic lymphocytic leukemia and related disorders - Clinical,"Nemtabrutinib (Mk-1026), A Non-Covalent Inhibitor Of Wild-Type And C481S Mutated Bruton Tyrosine Kinase For B-Cell Malignancies: Efficacy And Safety Of The Phase 2 Dose-Expansion Bellwave-001 Study",B-Cell Malignancies,B-Cell Malignancy,Wild-Type Bruton Tyrosine Kinase B-Cell Malignancy;;C481S-Mutated Bruton Tyrosine Kinase B-Cell Malignancy,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains a specific disease term ('B-Cell Malignancies'), making it the preferred source over the session title, according to the single-source principle.
2.  **Component Identification**: The abstract title identifies the core disease as 'B-Cell Malignancies' and specifies two distinct patient subgroups based on genetic status: 'Wild-Type' and 'C481S Mutated Bruton Tyrosine Kinase'.
3.  **Rule Application & Normalization**:
    *   **Disease Term**: The plural 'Malignancies' was converted to its singular form 'Malignancy' as per the generic formatting rules.
    *   **Genetic Status**: The study targets two separate, clinically significant cohorts for the same disease. Therefore, two distinct indications are generated.
    *   The term 'Mutated' is standardized to the hyphenated form '-Mutated' when combined with the specific mutation ('C481S-Mutated').
    *   'Wild-Type' is a standard descriptor and is retained as a prefix.
4.  **Indication Construction**: The genetic status descriptors are prefixed to the normalized disease term to create two precise indications: 'Wild-Type Bruton Tyrosine Kinase B-Cell Malignancy' and 'C481S-Mutated Bruton Tyrosine Kinase B-Cell Malignancy'.
5.  **Final Formatting**: The two distinct indications are separated by the required ';;' delimiter.","[{'category': 'Gene type', 'subcategories': ['Gene Mutation', 'Gene Mutant', 'Gene Mutated'], 'reason': ""To check for specific rules on formatting gene mutations like 'C481S Mutated'. No specific rules were found, so standard formatting was applied.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To check for rules regarding 'Wild-Type' status. No specific rules were found, so the term was kept as is.""}]","[{'component': 'B-Cell Malignancies', 'type': 'Disease', 'normalized_form': 'B-Cell Malignancy', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'Wild-Type Bruton Tyrosine Kinase', 'type': 'Patient Subgroup (Genetic Status)', 'normalized_form': 'Wild-Type Bruton Tyrosine Kinase', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'C481S Mutated Bruton Tyrosine Kinase', 'type': 'Patient Subgroup (Genetic Status)', 'normalized_form': 'C481S-Mutated Bruton Tyrosine Kinase', 'rule_applied': 'Standard formatting for gene mutations.'}]",3
327727,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",The Expression of mi-RNAs Involved in the Hematopoietic Niche Microenvironment in Newly Diagnosed AML Patients,Newly Diagnosed;;AML,Newly Diagnosed Acute Myeloid Leukemia,Newly Diagnosed Acute Myeloid Leukemia,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. Both contain a valid disease term ('AML' in the abstract title and 'Acute Myeloid Leukemias' in the session title).
Step 2: Following the single-source principle, I prioritized the abstract title as it contains the specific disease term 'AML'.
Step 3: I identified the components in the abstract title: 'Newly Diagnosed' as a diagnosis status and 'AML' as the disease. 'AML' is a common abbreviation for Acute Myeloid Leukemia.
Step 4: I retrieved the specific rule for 'Newly Diagnosed' using `get_indication_rules(category='Treatment based', subcategories=['Diagnosis Status'])` to ensure correct formatting.
Step 5: I applied the retrieved rule, which specifies prefixing the disease with 'Newly Diagnosed'. I also applied generic rules: expanding the abbreviation 'AML' to 'Acute Myeloid Leukemia', converting the disease to singular form, and ensuring Title Case.
Step 6: I constructed the final indication by combining the qualifier and the standardized disease name, resulting in 'Newly Diagnosed Acute Myeloid Leukemia'.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To correctly handle the 'Newly Diagnosed' patient subgroup qualifier.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Standard medical abbreviation expansion and singular form rule.'}]",2
327732,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome,Adult;;AML,Adult Acute Myeloid Leukemia,Adult UBTF Tandem Duplication Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title because it contains a more specific description of the patient population and disease, including the age group, gene, and specific alteration. This adheres to the single-source principle of using the most detailed source.
2.  **Component Identification**: I identified the following key components in the abstract title: 'Adult' (age group), 'AML' (disease), 'Tandem Duplications of the UBTF gene' (genetic alteration), and 'Myelodysplasia' (associated condition).
3.  **Rule Retrieval**: I retrieved rules for the 'Age Group' category to correctly handle the 'Adult' descriptor.
4.  **Component Analysis and Normalization**:
    *   **Disease**: 'AML' was expanded to its full form 'Acute Myeloid Leukemia' and converted to singular Title Case.
    *   **Age Group**: Based on the retrieved 'Adult' rule (ID: 289), the term 'Adult' was prepended to the indication.
    *   **Genetic Alteration**: 'Tandem Duplications of the UBTF gene' was standardized to 'UBTF Tandem Duplication'. The gene symbol 'UBTF' is kept in its original uppercase form, and the alteration is formatted in Title Case. This component acts as a primary qualifier for the disease.
    *   **Associated Condition**: 'Myelodysplasia' was considered. However, the phrasing 'Associated with Myelodysplasia' indicates it is a characteristic or outcome of the primary disease cohort (Adult AML with UBTF duplication) rather than a separate, parallel indication being studied. Therefore, it was excluded from the final indication string to maintain focus on the core patient group.
    *   **Occurrence**: The term 'Recurrent Alteration' was identified. This describes the nature of the genetic finding itself (i.e., it is a commonly recurring mutation in the population) rather than the patient's disease status (e.g., relapsed/refractory). Thus, it was not included as a disease state qualifier like 'Recurrent'.
5.  **Indication Construction**: The normalized components were assembled in the standard order: Age Group + Genetic Qualifier + Disease. This resulted in 'Adult UBTF Tandem Duplication Acute Myeloid Leukemia'.
6.  **Final Quality Check**: The final indication was checked against all generic rules, including Title Case, singular form, spacing, and exclusion of non-indicative terms ('rare', 'poor outcome'). The output is a single, concise, and clinically accurate indication.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'Adult' patient subgroup descriptor.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Rule ID: 289 - Prepend 'Adult' as the leading age-group descriptor.""}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule - Expand abbreviation and use singular form.'}, {'component': 'Tandem Duplications of the UBTF gene', 'type': 'Gene Alteration', 'normalized_form': 'UBTF Tandem Duplication', 'rule_applied': 'Generic Rule - Standardize gene alteration format, keeping gene symbol in uppercase.'}, {'component': 'Myelodysplasia', 'type': 'Associated Condition', 'normalized_form': 'N/A (Excluded)', 'rule_applied': 'Generic Rule - Exclude non-diagnostic items. The term was identified as an associated feature, not the primary disease of the study cohort.'}]",2
147508,Stem Cell Transplantation - Clinical,Belumosudil For Chronic Graft-Versus Host Disease After 2 Or More Prior Lines Of Therapy: The Rockstar Study (Kd025-213),Chronic;;Graft-Versus Host Disease,Chronic Graft-Versus Host Disease,Chronic Graft-Versus Host Disease,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Belumosudil For Chronic Graft-Versus Host Disease After 2 Or More Prior Lines Of Therapy: The Rockstar Study (Kd025-213)' and the session title is 'Stem Cell Transplantation - Clinical'.
2. **Select Source**: The abstract title contains a specific disease, 'Chronic Graft-Versus Host Disease', making it the primary source according to the single-source principle.
3. **Identify Components**: The key components identified in the abstract title are the disease 'Chronic Graft-Versus Host Disease' and a treatment history qualifier 'After 2 Or More Prior Lines Of Therapy'.
4. **Retrieve Relevant Rules**: To correctly handle the treatment history, I retrieved rules for 'Line of treatment' under the 'Treatment Set-up' category.
5. **Apply Rules**: The retrieved Rule ID 207 for the keyword 'Prior Lines' explicitly states to exclude any mention of prior lines of therapy from the final indication, as it describes historical treatment exposure rather than a distinct clinical category. The generic rules for formatting (Title Case, singular form) are already met by the disease name.
6. **Construct Indication**: Based on the rules, the phrase 'After 2 Or More Prior Lines Of Therapy' is excluded. The remaining clinically valid indication is 'Chronic Graft-Versus Host Disease'.
7. **Quality Check**: The final indication is clinically accurate, correctly formatted, and adheres to all applicable generic and specific rules.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine how to handle the phrase 'After 2 Or More Prior Lines Of Therapy'.""}]","[{'component': 'Chronic Graft-Versus Host Disease', 'type': 'Disease', 'normalized_form': 'Chronic Graft-Versus Host Disease', 'rule_applied': 'Generic rule: Use disease term as the base of the indication.'}, {'component': 'After 2 Or More Prior Lines Of Therapy', 'type': 'Treatment History', 'normalized_form': '', 'rule_applied': ""Treatment Set-up Rule ID 207: Exclude mentions of 'Prior Lines' of therapy from the final indication.""}]",2
147511,Stem Cell Transplantation - Clinical,Narsoplimab (Oms721) Treatment Contributes To Improvements In Organ Function In Adult Patients With High-Risk Transplant-Associated Thrombotic Microangiopathy,,,Adult High-Risk Transplant-Associated Thrombotic Microangiopathy,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease ('Transplant-Associated Thrombotic Microangiopathy'), whereas the session title is a broad category.
2. **Component Identification**: The key components identified in the abstract title were 'Adult Patients', 'High-Risk', and 'Transplant-Associated Thrombotic Microangiopathy'.
3. **Rule Retrieval**: I retrieved rules for 'Age Group' (for 'Adult'), 'Risk' (for 'High-Risk'), and 'Treatment Set-up' (to verify handling of 'Transplant-Associated').
4. **Rule Application**:
   - **Age Group**: The rule for 'Adult' (ID: 289) directs to prepend the capitalized term 'Adult' to the indication.
   - **Risk**: The rule for 'High-Risk' (ID: 122) directs to normalize the term to 'High-Risk' and place it before the disease name.
   - **Disease Name**: 'Transplant-Associated Thrombotic Microangiopathy' is a specific clinical syndrome. The qualifier 'Transplant-Associated' is integral to the disease name and is not a simple procedural qualifier to be excluded. Therefore, it was retained as part of the core indication.
   - **Generic Rules**: Title Case was applied, and the disease term was confirmed to be in singular form.
5. **Indication Construction**: The components were assembled in the standard order: Age Group -> Risk -> Disease. This resulted in 'Adult High-Risk Transplant-Associated Thrombotic Microangiopathy'.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'Adult Patients' descriptor.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To standardize the 'High-Risk' descriptor.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine if 'Transplant-Associated' should be excluded as a procedural qualifier. It was determined to be integral to the disease name.""}]","[{'component': 'Adult Patients', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group rule ID: 289'}, {'component': 'High-Risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': 'Risk rule ID: 122'}, {'component': 'Transplant-Associated Thrombotic Microangiopathy', 'type': 'Disease', 'normalized_form': 'Transplant-Associated Thrombotic Microangiopathy', 'rule_applied': 'Generic rule: Retain integral disease qualifiers. Title Case.'}]",2
213047,Geriatric Urological Society (GUS),Parkinson's Disease and the Impact on Urologic Health in Older Adults,Parkinson's Disease;;Older Adults,Elderly Parkinson's Disease,Older Adult Parkinson's Disease,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Parkinson's Disease and the Impact on Urologic Health in Older Adults') was chosen because it contains a specific disease ('Parkinson's Disease'), which is preferred over the session title ('Geriatric Urological Society (GUS)').
2. **Component Identification**: The selected title contains the disease 'Parkinson's Disease' and the patient subgroup 'Older Adults'. The phrase 'Urologic Health' was identified as a general physiological area, not a specific disease, and was excluded per the 'Non-Diagnostic Items' rule.
3. **Rule Retrieval**: To standardize the age group descriptor 'Older Adults', I retrieved rules for the 'Age Group' category, specifically for 'Elderly' and related terms.
4. **Rule Application**: The retrieved rule (ID: 331) for 'Older adult' specifies normalizing the term to the capitalized, singular form 'Older Adult' and placing it at the beginning of the indication. Generic rules for Title Case and singular form were also applied.
5. **Indication Construction**: The normalized patient subgroup 'Older Adult' was prepended to the disease 'Parkinson's Disease' to form the final indication.
6. **Quality Check**: The final indication adheres to the single-source principle, correctly applies formatting rules, includes the relevant patient subgroup, and excludes non-diagnostic information, ensuring clinical accuracy.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To find the correct standardization for the term 'Older Adults'.""}]","[{'component': ""Parkinson's Disease"", 'type': 'Disease', 'normalized_form': ""Parkinson's Disease"", 'rule_applied': 'Generic Casing Rule'}, {'component': 'Older Adults', 'type': 'Age Group', 'normalized_form': 'Older Adult', 'rule_applied': ""Age Group Rule (ID: 331) for 'Older adult' and Generic Singular Form Rule.""}, {'component': 'Urologic Health', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items.'}]",2
327741,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age,NPM1;;Mutant;;AML,NPM1-Mutant Acute Myeloid Leukemia,NPM1-Mutated Acute Myeloid Leukemia;;FLT3-ITD-High Acute Myeloid Leukemia;;FLT3-ITD-Low Acute Myeloid Leukemia;;FLT3-TKD-Mutated Acute Myeloid Leukemia;;Elderly Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title because it contains more specific information about the disease, including genetic mutations and patient subgroups (NPM1, FLT3, age), making it the primary source according to the single-source principle.
2.  **Component Identification**: The abstract title was parsed to identify the core disease and several distinct patient subgroups:
    *   Core Disease: 'AML' (Acute Myeloid Leukemia).
    *   Genetic Subgroup 1: 'NPM1 Mutant'.
    *   Genetic Subgroup 2: 'FLT3-ITDhigh'.
    *   Genetic Subgroup 3: 'FLT3-ITDlow'.
    *   Genetic Subgroup 4: 'FLT3-TKD'.
    *   Age Subgroup: 'Patients over 60 Years of Age'.
3.  **Rule Retrieval**: To standardize these components, rules were retrieved for 'Gene type' (to handle mutations like 'Mutant', 'high', 'low') and 'Age Group' (to handle 'over 60').
4.  **Rule Application and Normalization**:
    *   'AML' was expanded to its full name 'Acute Myeloid Leukemia' and standardized to Title Case.
    *   'NPM1 Mutant' was normalized to 'NPM1-Mutated' based on the 'Gene Mutant' rule (ID: 31).
    *   'FLT3-ITDhigh' was normalized to 'FLT3-ITD-High' based on the 'Gene High' rule (ID: 34).
    *   'FLT3-ITDlow' was normalized to 'FLT3-ITD-Low' based on the 'Gene Low' rule (ID: 33).
    *   'FLT3-TKD' refers to a Tyrosine Kinase Domain mutation and was standardized to 'FLT3-TKD-Mutated' for clinical clarity and consistency.
    *   'over 60 Years of Age' was normalized to 'Elderly' based on the 'Above 60' age group rule (ID: 303).
5.  **Indication Construction**: Each identified subgroup was combined with the core disease to form a distinct, clinically valid indication. The title discusses these as separate cohorts or factors of interest within the AML patient population.
6.  **Final Formatting**: The multiple distinct indications were formatted in Title Case, using the singular form for the disease, and separated by the required ';;' delimiter, resulting in the final generated output.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the genetic markers 'NPM1 Mutant', 'FLT3-ITDhigh', and 'FLT3-ITDlow'.""}, {'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To standardize the age descriptor 'over 60 Years of Age'.""}]","[{'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule: Disease Normalization'}, {'component': 'NPM1 Mutant', 'type': 'Gene Mutation', 'normalized_form': 'NPM1-Mutated', 'rule_applied': ""Gene type rule (ID: 31) for 'Gene Mutant'""}, {'component': 'FLT3-ITDhigh', 'type': 'Gene Expression', 'normalized_form': 'FLT3-ITD-High', 'rule_applied': ""Gene type rule (ID: 34) for 'Gene High'""}, {'component': 'FLT3-ITDlow', 'type': 'Gene Expression', 'normalized_form': 'FLT3-ITD-Low', 'rule_applied': ""Gene type rule (ID: 33) for 'Gene Low'""}, {'component': 'FLT3-TKD', 'type': 'Gene Mutation', 'normalized_form': 'FLT3-TKD-Mutated', 'rule_applied': 'Standardization for Tyrosine Kinase Domain mutations'}, {'component': 'over 60 Years of Age', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group rule (ID: 303) for 'Above 60'""}]",2
180285,Bone Marrow Failure: Poster I,Predictors of Efficacy in Chinese Patients with Severe Aplastic Anemia Treated with Eltrombopag and Intensive Immunosupressive Therapy,Severe Aplastic Anemia,Severe Aplastic Anemia,Severe Aplastic Anemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Predictors of Efficacy in Chinese Patients with Severe Aplastic Anemia Treated with Eltrombopag and Intensive Immunosupressive Therapy') contains a specific disease, 'Aplastic Anemia', and is therefore selected over the session title ('Bone Marrow Failure: Poster I') based on the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title are the disease 'Aplastic Anemia', the severity modifier 'Severe', the sociodemographic descriptor 'Chinese Patients', and the procedural qualifier 'Treated with Eltrombopag and Intensive Immunosupressive Therapy'.
3.  **Rule Retrieval**: Rules for 'Risk' (subcategory 'severe') and 'Treatment based' were retrieved to confirm handling of these terms.
4.  **Rule Application**:
    *   **Exclusion Rules**: The sociodemographic descriptor 'Chinese Patients' is excluded as per generic rules. The phrase 'Treated with...' is a procedural qualifier describing the study intervention, not a pre-existing patient status like 'untreated' or 'relapsed/refractory', and is therefore excluded.
    *   **Inclusion Rules**: 'Severe' is a clinically significant descriptor that characterizes the disease and is included. The core disease 'Aplastic Anemia' is included.
    *   **Formatting Rules**: The final indication is converted to Title Case and singular form.
5.  **Indication Construction**: The components 'Severe' and 'Aplastic Anemia' are combined to form the final indication.
6.  **Quality Check**: The final output 'Severe Aplastic Anemia' adheres to all formatting, inclusion, and exclusion criteria.","[{'category': 'Risk', 'subcategories': ['severe'], 'reason': ""To verify the handling of the severity descriptor 'Severe'.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To confirm that 'Treated with...' should be excluded as it describes the current therapy, not a prior patient status.""}]","[{'component': 'Severe Aplastic Anemia', 'type': 'Disease with Severity', 'normalized_form': 'Severe Aplastic Anemia', 'rule_applied': 'Inclusion of severity modifier; Title Case and Singular Form rules.'}, {'component': 'Chinese Patients', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for ethnicity/geography.'}, {'component': 'Treated with Eltrombopag and Intensive Immunosupressive Therapy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
294973,MSD - Navigating through the rapidly evolving treatment landscape for GI Cancers - A Clinical & Patient Centric Approach towards implementing Immunotherapy,Changing GEC Patient Care with IO plus Chemotherapy in First-Line,GI Cancers;;First-Line,First-Line Gastrointestinal Cancer,First-Line Gastroesophageal Cancer,True,abstract_title,"Step 1: The abstract title ('Changing GEC Patient Care with IO plus Chemotherapy in First-Line') was chosen as the source because it contains a specific disease term ('GEC'), taking precedence over the session title ('GI Cancers') as per the single-source principle.
Step 2: The components identified in the abstract title were the disease 'GEC' and the treatment context 'First-Line'.
Step 3: Rules for 'Line of treatment' were retrieved to correctly handle 'First-Line'. Rule 200 dictates that 'First-Line' should be standardized and placed at the beginning of the indication when it describes the treatment setting for the disease, rather than a specific drug.
Step 4: The abbreviation 'GEC' was expanded to its full clinical term 'Gastroesophageal Cancer'.
Step 5: Generic formatting rules were applied, converting the final indication to Title Case and ensuring singular form.
Step 6: The final indication was constructed by combining the standardized treatment line with the normalized disease name, resulting in 'First-Line Gastroesophageal Cancer'.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine the correct handling and formatting of the 'First-Line' keyword.""}]","[{'component': 'GEC', 'type': 'Disease', 'normalized_form': 'Gastroesophageal Cancer', 'rule_applied': 'Standard medical abbreviation expansion.'}, {'component': 'First-Line', 'type': 'Line of Treatment', 'normalized_form': 'First-Line', 'rule_applied': ""Rule 200 for 'First-Line' treatment context.""}]",2
262206,Chronic myeloid leukemia - Clinical,Bosutinib Dose Optimization In The Second-Line Treatment Of Elderly Cml Patients: Extended 3-Year Follow-Up And Final Results Of The Best Study,Second-Line;;Elderly;;Cml,Second-Line Elderly Chronic Myeloid Leukemia,Second-Line Elderly Chronic Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Bosutinib Dose Optimization In The Second-Line Treatment Of Elderly Cml Patients...') was chosen over the session title ('Chronic myeloid leukemia - Clinical') because it is more specific, containing patient subgroup and treatment line information, adhering to the single-source principle.
2. **Component Identification**: The key components identified in the abstract title were 'Second-Line' (treatment line), 'Elderly' (age group), and 'Cml' (disease).
3. **Rule Retrieval**: To ensure correct formatting and inclusion, I retrieved rules for 'Treatment Set-up' (specifically 'Line of treatment') and 'Age Group' (specifically 'Elderly').
4. **Rule Application**:
   - **Treatment Line**: Based on the retrieved rules (e.g., Rule ID 202), 'Second-Line' should be retained as it modifies the treatment of the disease, not a specific drug. It is normalized to 'Second-Line'.
   - **Age Group**: The rules for 'Elderly' (e.g., Rule ID 299) confirm that this term should be standardized to 'Elderly' and included as a patient subgroup qualifier.
   - **Disease Normalization**: The abbreviation 'Cml' is expanded to its full form, 'Chronic Myeloid Leukemia'.
   - **Generic Rules**: The term 'Patients' is excluded as per generic rules. The final indication is formatted in Title Case and singular form.
5. **Indication Construction**: The components are assembled in the standard order (Treatment Line -> Age Group -> Disease) based on rule examples, resulting in 'Second-Line Elderly Chronic Myeloid Leukemia'.
6. **Quality Check**: The final indication adheres to all formatting, inclusion, and exclusion criteria. It is clinically accurate and derived from a single source.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine how to handle the 'Second-Line' descriptor.""}, {'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To confirm the correct formatting and inclusion of the 'Elderly' patient subgroup.""}]","[{'component': 'Second-Line', 'type': 'Line of treatment', 'normalized_form': 'Second-Line', 'rule_applied': ""Treatment Set-up Rule ID 202: Normalize and prepend 'Second-Line' to the disease name.""}, {'component': 'Elderly', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group Rule ID 299: Standardize age-descriptive variants to 'Elderly'.""}, {'component': 'Cml', 'type': 'Disease', 'normalized_form': 'Chronic Myeloid Leukemia', 'rule_applied': 'Generic Rule: Expand standard medical abbreviations and use singular form.'}]",2
147521,Thrombosis And Vascular Biology - Biology & Translational Research,Thrombophilia As Risk Factor For Asparaginase Related Venous Thromboembolism In Pediatric And Young Adult Patients Affected By Acute Lymphoblastic Leukemia,Venous Thromboembolism;;Pediatric;;Young Adult,Pediatric Young Adult Venous Thromboembolism,Pediatric Acute Lymphoblastic Leukemia;;Young Adult Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains specific disease terms ('Thrombophilia', 'Venous Thromboembolism', 'Acute Lymphoblastic Leukemia'), making it the definitive source over the more general session title.
2.  **Component Identification**: The abstract title identifies a primary disease and patient subgroups. The core disease the patients are 'affected by' is 'Acute Lymphoblastic Leukemia'. The patient population is specified as 'Pediatric And Young Adult'. 'Thrombophilia' is identified as a risk factor and 'Venous Thromboembolism' as a treatment-related complication, not the primary indications defining the patient cohort.
3.  **Rule Retrieval**: I retrieved rules for 'Age Group' to handle 'Pediatric' and 'Young Adult'. The rules confirm that age-group qualifiers should be prepended to the disease name.
4.  **Indication Construction**: Based on the analysis, the core indication is the primary disease qualified by the distinct age groups. This results in two separate indications:
    *   'Pediatric' + 'Acute Lymphoblastic Leukemia' -> 'Pediatric Acute Lymphoblastic Leukemia'
    *   'Young Adult' + 'Acute Lymphoblastic Leukemia' -> 'Young Adult Acute Lymphoblastic Leukemia'
5.  **Formatting**: The two indications are combined using the required ';;' separator. All terms are converted to Title Case, and disease names are in singular form as per generic rules.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To determine how to handle the multiple conditions mentioned (Thrombophilia, VTE, ALL).'}, {'category': 'Age Group', 'subcategories': ['Pediatric', 'Young Adult'], 'reason': ""To correctly format the age group descriptors 'Pediatric' and 'Young Adult'.""}]","[{'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule: Use as primary disease.'}, {'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group rule: Prepend to the disease name.'}, {'component': 'Young Adult', 'type': 'Age Group', 'normalized_form': 'Young Adult', 'rule_applied': 'Age Group rule: Prepend to the disease name.'}, {'component': 'Thrombophilia', 'type': 'Risk Factor', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude non-primary disease/risk factors.'}, {'component': 'Venous Thromboembolism', 'type': 'Complication', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude complications/adverse effects.'}]",2
393283,Developmental Therapeutics,"A Phase I Study Of Safety, Pharmacokinetics, And Pharmacodynamics Of Scr-6920, A Protein Arginine Methyltransferase 5(Prmt5) Inhibitor, In Patients With Advanced Malignant Tumors",Advanced;;Malignant Tumors,Advanced Malignant Tumor,Advanced Malignant Tumor,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease term ('Advanced Malignant Tumors'), whereas the session title ('Developmental Therapeutics') is a general therapeutic area.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Malignant Tumors' and the stage qualifier 'Advanced'.
3. **Rule Retrieval**: I retrieved rules for the 'Stage' category to understand how to handle terms like 'Advanced'. Although no specific rule for 'Advanced' was found, the general pattern from rules like 'Limited Stage' and 'Extensive Stage' is to prefix the disease with the stage descriptor.
4. **Rule Application and Normalization**:
   - **Generic Rule (Singular Form)**: The plural 'Tumors' was converted to its singular form, 'Tumor'.
   - **Generic Rule (Title Case)**: The components were combined and formatted in Title Case.
   - **Staging Rule Pattern**: The qualifier 'Advanced' was placed before the disease name, which is standard clinical nomenclature.
5. **Indication Construction**: The components 'Advanced' and 'Malignant Tumor' were combined to form the final indication.
6. **Final Quality Check**: The resulting indication 'Advanced Malignant Tumor' adheres to all formatting and clinical accuracy requirements. It is singular, in Title Case, and correctly represents the patient population described.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for specific rules on handling the stage qualifier 'Advanced'.""}]","[{'component': 'Advanced', 'type': 'Stage Qualifier', 'normalized_form': 'Advanced', 'rule_applied': 'General pattern for cancer staging descriptors.'}, {'component': 'Malignant Tumors', 'type': 'Disease', 'normalized_form': 'Malignant Tumor', 'rule_applied': 'Generic Rule: Singular Form'}]",2
262209,Chronic myeloid leukemia - Clinical,Real-Life Outcomes Of Ponatinib Treatment In Patients With Chronic Myeloid Leukemia (Cml) Or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+All): 5-Year-Data From A Belgian Registry,Chronic Myeloid Leukemia;;Philadelphia Chromosome-Positive;;Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia;;Ph Chromosome-Positive Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia;;Ph Chromosome-Positive Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains specific disease entities ('Chronic Myeloid Leukemia' and 'Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia'), making it more informative than the session title.
2.  **Component Identification**: The abstract title lists two distinct diseases separated by 'Or': 'Chronic Myeloid Leukemia (Cml)' and 'Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+All)'.
3.  **Rule Retrieval**: To ensure correct formatting for the chromosomal descriptor, I retrieved rules for the 'Chromosome type' category. I also checked for rules regarding multiple diseases under 'Patient with two different Disease'.
4.  **Rule Application**:
    *   **Multiple Diseases**: The generic rule for multiple diseases was applied, requiring the use of ';;' as a separator.
    *   **Disease 1**: 'Chronic Myeloid Leukemia (Cml)' was normalized to 'Chronic Myeloid Leukemia' by applying Title Case and removing the parenthetical abbreviation.
    *   **Disease 2**: For 'Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+All)', Rule ID 81 (from 'Chromosome type') was applied to standardize 'Philadelphia Chromosome-Positive' to 'Ph Chromosome-Positive'. The disease name was kept, and the abbreviation '(Ph+All)' was removed.
    *   **Generic Rules**: All terms were converted to singular form (already singular) and Title Case. Excluded terms like 'Patients' and geographic location 'Belgian' were removed.
5.  **Indication Construction**: The two normalized indications were combined using the ';;' separator to form the final output.
6.  **Quality Check**: The final indication adheres to all formatting, single-source, and clinical accuracy requirements.","[{'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To correctly format the 'Philadelphia Chromosome-Positive' descriptor.""}, {'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To check for specific rules on handling two distinct diseases mentioned in the title.'}]","[{'component': 'Chronic Myeloid Leukemia (Cml)', 'type': 'Disease', 'normalized_form': 'Chronic Myeloid Leukemia', 'rule_applied': 'Generic Rule: Remove abbreviations. Generic Rule: Title Case.'}, {'component': 'Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+All)', 'type': 'Disease with Chromosomal Alteration', 'normalized_form': 'Ph Chromosome-Positive Acute Lymphoblastic Leukemia', 'rule_applied': ""Rule ID 81: Standardize 'Philadelphia Chromosome-Positive' to 'Ph Chromosome-Positive'. Generic Rule: Remove abbreviations.""}]",2
180298,Bone Marrow Failure: Poster I,"Pozelimab, a Human Monoclonal Antibody Against Complement Factor C5, Provided Inhibition of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria",Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria,Paroxysmal Nocturnal Hemoglobinuria,True,abstract_title,"Step 1: The abstract title contains a specific disease, 'Paroxysmal Nocturnal Hemoglobinuria', so it is selected as the source over the session title, which contains a broader term ('Bone Marrow Failure').
Step 2: The core disease is identified as 'Paroxysmal Nocturnal Hemoglobinuria'. The phrase 'Inhibition of Intravascular Hemolysis' is identified as the outcome or effect of the treatment, not a descriptor of the patient subgroup, and is therefore excluded.
Step 3: Generic rules are applied. The disease name is already in Title Case and singular form. No sociodemographic or procedural qualifiers are present.
Step 4: The final indication is constructed from the identified disease name, resulting in 'Paroxysmal Nocturnal Hemoglobinuria'.",[],"[{'component': 'Paroxysmal Nocturnal Hemoglobinuria', 'type': 'Disease', 'normalized_form': 'Paroxysmal Nocturnal Hemoglobinuria', 'rule_applied': 'Generic formatting rules (Title Case, Singular)'}, {'component': 'Intravascular Hemolysis', 'type': 'Symptom/Outcome', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic items (symptoms/outcomes)'}]",1
393291,Developmental Therapeutics,"Preclinical Evaluation Of Hlx42, A Novel Egfr-Targeting Adc, For Cetuximab Or Tki Resistant Cancer",Cancer,Cancer,Cancer,True,abstract_title,"Step 1: The abstract title contains the disease term 'Cancer', while the session title 'Developmental Therapeutics' is a general therapeutic area. Therefore, the abstract title was selected as the source based on the single-source principle.
Step 2: The components identified in the abstract title are 'Cetuximab Or Tki Resistant' and 'Cancer'.
Step 3: To handle the term 'Resistant', I retrieved rules for the 'Occurrence' category with the 'Resistance' subcategory.
Step 4: The retrieved rules (ID 164, 165) state that drug or drug class resistance descriptors (like 'Cetuximab Or Tki Resistant') should be excluded from the final indication because they represent a treatment-response status rather than a distinct clinical indication.
Step 5: Applying this rule, 'Cetuximab Or Tki Resistant' was removed, leaving the core disease 'Cancer'.
Step 6: The term 'Cancer' was formatted according to generic rules (Title Case, singular form), resulting in the final indication 'Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Resistance'], 'reason': ""To determine how to handle the phrase 'Cetuximab Or Tki Resistant'.""}]","[{'component': 'Cetuximab Or Tki Resistant', 'type': 'Treatment Resistance', 'normalized_form': '', 'rule_applied': 'Occurrence rule (ID 164, 165) requires exclusion of drug/drug class resistance terms.'}, {'component': 'Cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
180300,Bone Marrow Failure: Poster I,Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry,Adult;;Late-Onset;;Telomere Biology Disorders,Adult Late-Onset Telomere Biology Disorder,Adult Late Onset Telomere Biology Disorder,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry') was chosen over the session title ('Bone Marrow Failure: Poster I') because it contains a more specific and complete disease description, adhering to the single-source principle.
2. **Component Identification**: The key components identified in the abstract title were the age group 'Adult', the onset qualifier 'Late-Onset', and the disease term 'Telomere Biology Disorders'. The term 'Telomeropathy' was noted but identified as describing the registry, not the specific patient condition being presented.
3. **Rule Retrieval**: To ensure correct formatting, rules for 'Age Group' (specifically 'Adult') and 'Onset' (specifically 'Onset by Time' for 'Late-Onset') were retrieved using the `get_indication_rules` tool.
4. **Rule Application**:
   - **Generic Rules**: The plural 'Disorders' was converted to its singular form 'Disorder'. The final output was formatted to Title Case.
   - **Age Group Rule (ID: 289)**: Confirmed that 'Adult' should be used as a capitalized prefix.
   - **Onset Rule (ID: 287)**: Confirmed that 'Late-Onset' should be normalized to 'Late Onset' (hyphen removed, Title Case).
5. **Indication Construction**: The identified and normalized components were combined in the correct order (Age Group -> Onset -> Disease) to form the final indication: 'Adult Late Onset Telomere Biology Disorder'.
6. **Exclusion**: Non-diagnostic information such as 'Clinical Presentation of Patients with' and 'Results from the Aachen Telomeropathy Registry' was excluded as per the generic rules.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To validate the formatting and placement of the 'Adult' age group descriptor.""}, {'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To correctly normalize and format the 'Late-Onset' term.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group Rule ID: 289'}, {'component': 'Late-Onset', 'type': 'Onset Qualifier', 'normalized_form': 'Late Onset', 'rule_applied': 'Onset Rule ID: 287'}, {'component': 'Telomere Biology Disorders', 'type': 'Disease', 'normalized_form': 'Telomere Biology Disorder', 'rule_applied': 'Generic Rule: Singular Form'}]",2
327760,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies,Newly Diagnosed;;IDH;;TP53;;Co-Mutated;;AML,Newly Diagnosed IDH-Mutated TP53-Mutated Acute Myeloid Leukemia,Newly Diagnosed IDH/TP53 Co-Mutated Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease term ('AML') and provides more detailed patient subgroup information than the session title, following the single-source principle.
2. **Component Identification**: The following components were identified in the abstract title: 'Newly Diagnosed' (diagnosis status), 'IDH/TP53 Co-Mutated' (genetic markers), and 'AML' (disease).
3. **Rule Retrieval**: I retrieved rules for 'Diagnosis Status' to handle 'Newly Diagnosed' and for 'Gene type' to understand the standard formatting for mutations.
4. **Rule Application and Normalization**:
   - **Disease**: The abbreviation 'AML' was expanded to its full form 'Acute Myeloid Leukemia' based on common clinical knowledge, which is also supported by the session title. The generic rule for singularization was applied.
   - **Diagnosis Status**: The rule for 'Newly Diagnosed' (Rule ID: 193) was applied, which specifies prefixing this term to the indication.
   - **Genetic Markers**: The term 'IDH/TP53 Co-Mutated' was identified as a key patient subgroup. While specific rules for 'Co-Mutated' were not present, the general principle from 'Gene type' rules is to preserve clinically significant mutation details. The term was retained, and Title Case was applied, keeping the gene symbols 'IDH' and 'TP53' in their original uppercase form as per casing rules.
5. **Indication Construction**: The normalized components were assembled in a clinically logical order: Diagnosis Status + Genetic Markers + Disease. This resulted in 'Newly Diagnosed IDH/TP53 Co-Mutated Acute Myeloid Leukemia'.
6. **Quality Check**: The final indication was checked against all generic rules. It adheres to the single-source principle, uses Title Case, is in singular form, and correctly includes all relevant patient subgroup information without incorporating any excluded terms.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To correctly handle the 'Newly Diagnosed' component.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To understand the standard formatting for genetic mutations like 'Co-Mutated'.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule 193 for 'Newly Diagnosed' from 'Treatment based' category.""}, {'component': 'IDH/TP53 Co-Mutated', 'type': 'Gene Mutation', 'normalized_form': 'IDH/TP53 Co-Mutated', 'rule_applied': 'Generic Title Case rule and preservation of specific clinical terminology for co-mutations.'}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Standard medical abbreviation expansion and singularization rule.'}]",2
311376,"Abstracts: RA - Diagnosis, Manifestations, and Outcomes I: Pre- and Early Disease",Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity,RA ,Rheumatoid Arthritis,Anti-CCP-Positive Rheumatoid Arthritis,True,abstract_title,"The abstract title was chosen as the source because it contains the specific disease 'RA' (Rheumatoid Arthritis) and a key patient subgroup defined by a biomarker. The term 'RA' was expanded to 'Rheumatoid Arthritis'. The patient subgroup 'Individuals with Systemic Anti-CCP Positivity' was identified and normalized to the standard clinical format 'Anti-CCP-Positive'. The term 'At-Risk Cohort' was excluded as it describes the study population rather than being a part of the clinical indication itself. The final indication combines the biomarker status with the disease name, adhering to standard formatting rules.","[{'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To determine how to handle the term 'At-Risk'. The rules confirmed it is not a standard clinical risk stratification, leading to its exclusion.""}]","[{'component': 'RA', 'type': 'Disease', 'normalized_form': 'Rheumatoid Arthritis', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}, {'component': 'At-Risk Cohort', 'type': 'Patient Descriptor', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic study cohort descriptors.'}, {'component': 'Systemic Anti-CCP Positivity', 'type': 'Biomarker', 'normalized_form': 'Anti-CCP-Positive', 'rule_applied': 'Standard normalization for biomarker positivity status.'}]",2
229467,Vaccines and Immunity against Bacteria and Parasites,"The novel adjuvant, ADA-1, restores age-associated defects in the adaptive immune response to Clostridioides difficile infection and vaccination in an aging mouse model",Clostridioides difficile infection,Clostridioides Difficile Infection,Elderly Clostridioides Difficile Infection,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease, 'Clostridioides difficile infection', whereas the session title is general.
2. **Component Identification**: The abstract title contains the disease 'Clostridioides difficile infection' and the patient subgroup context 'age-associated' and 'aging mouse model'.
3. **Rule Retrieval**: Rules for 'Age Group' were retrieved to standardize the age-related terms. The term 'aging' is conceptually similar to keywords like 'Older' or 'Advanced age' which map to the standardized term 'Elderly'.
4. **Component Analysis & Normalization**:
   - The disease 'Clostridioides difficile infection' was normalized to 'Clostridioides Difficile Infection' using Title Case, as per generic formatting rules.
   - The context 'age-associated' and 'aging' was interpreted as representing an elderly patient population. Based on the pattern from retrieved rules for similar terms, this was standardized to the prefix 'Elderly'.
   - The phrase 'mouse model' was excluded as it refers to the study methodology (a pre-clinical model) and not a clinically valid human indication.
5. **Indication Construction**: The standardized age group 'Elderly' was prepended to the normalized disease name to form the final indication.
6. **Final Quality Check**: The resulting indication 'Elderly Clostridioides Difficile Infection' adheres to all formatting and content rules. It is singular, in Title Case, and correctly represents the clinical condition and patient subgroup described in the source.","[{'category': 'Age Group', 'subcategories': ['Elderly', 'Young', 'Adult', 'Pediatric', 'Adolescent', 'Childhood', 'Juvenile', 'Non-Elderly'], 'reason': ""To standardize the terms 'age-associated' and 'aging' into a recognized clinical age group.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': 'To check for any rules related to disease characterization that might apply.'}]","[{'component': 'Clostridioides difficile infection', 'type': 'Disease', 'normalized_form': 'Clostridioides Difficile Infection', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'age-associated, aging', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group rule pattern (mapping terms like 'Older', 'Advanced age' to 'Elderly')""}, {'component': 'mouse model', 'type': 'Methodology', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclude non-diagnostic items (study methodologies)'}]",2
327778,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy,AML,Acute Myeloid Leukemia,Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title contains the disease term ""AML"". The session title contains ""Acute Myeloid Leukemias"". Both refer to the same disease.
2.  **Select Source**: According to the Single-Source Extraction Principle, the abstract title is preferred as it contains a valid disease term (""AML"").
3.  **Identify Components**: The core disease identified in the abstract title is ""AML"". Other phrases like ""Detectable Measurable Residual Disease"" and ""after Induction Chemotherapy"" were analyzed. ""Detectable Measurable Residual Disease"" was identified as a study endpoint or outcome being predicted, not a baseline characteristic of the patient population. ""after Induction Chemotherapy"" is a temporal/procedural qualifier related to treatment.
4.  **Retrieve Relevant Rules**: No specific rules were needed beyond the generic rules, as the primary task was normalization and exclusion.
5.  **Apply Rules & Construct Indication**:
    *   The disease term ""AML"" was normalized to its full name, ""Acute Myeloid Leukemia"".
    *   The generic rule for Title Casing was applied, resulting in ""Acute Myeloid Leukemia"".
    *   The generic rule for using singular form was followed (""Leukemia"" instead of ""Leukemias"").
    *   The generic exclusion rule was applied to remove the procedural/temporal qualifier ""after Induction Chemotherapy"".
    *   The phrase ""Detectable Measurable Residual Disease"" was excluded as it represents a clinical endpoint in the study, not the indication itself.
6.  **Quality Check**: The final indication ""Acute Myeloid Leukemia"" is clinically accurate, correctly formatted, and derived strictly from the selected source (abstract title) in adherence with all rules.",[],"[{'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Standard medical abbreviation normalization and Generic Rules (Title Case, Singular Form).'}, {'component': 'Detectable Measurable Residual Disease', 'type': 'Clinical Endpoint', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for non-diagnostic items (identified as a study outcome).'}, {'component': 'after Induction Chemotherapy', 'type': 'Procedural/Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for procedural/temporal qualifiers.'}]",2
147554,Acute Lymphoblastic Leukemia - Clinical,Antibodies To Pegylated E. Coli Asparaginase Predict The Occurrence Of Hypersensitivity Reactions In High-Risk Patients Undergoing The Consolidation Phase Of The Aieop-Bfm All 2009 Protocol.,High-Risk;;Acute Lymphoblastic Leukemia,High-Risk Acute Lymphoblastic Leukemia,High-Risk Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title because it contains both the disease (abbreviated as 'All') and a specific patient subgroup ('High-Risk Patients'), making it more informative.
2.  **Component Identification**: Key components identified in the abstract title were 'High-Risk' (a risk-based patient subgroup) and 'All' (a standard abbreviation for Acute Lymphoblastic Leukemia). 'Hypersensitivity Reactions' was identified as an adverse effect and excluded. 'Undergoing the consolidation phase' was identified as a procedural/temporal qualifier and excluded.
3.  **Rule Retrieval**: The `get_indication_rules` tool was used for the 'Risk' category with the 'High-Risk' subcategory to ensure correct formatting.
4.  **Rule Application**: 
    - The retrieved rule (ID: 122) confirmed that 'High-Risk' should be normalized and prepended to the disease name.
    - The abbreviation 'All' was expanded to its full, standardized form 'Acute Lymphoblastic Leukemia'.
    - Generic rules were applied: Title Case was used for all clinical terms, and the general term 'Patients' was removed.
5.  **Indication Construction**: The normalized components were combined in the correct order to form the final indication: 'High-Risk Acute Lymphoblastic Leukemia'.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To validate the formatting and placement of the 'High-Risk' patient subgroup qualifier.""}]","[{'component': 'High-Risk Patients', 'type': 'Patient Subgroup (Risk)', 'normalized_form': 'High-Risk', 'rule_applied': ""Risk rule (ID: 122) and generic exclusion of 'Patients'.""}, {'component': 'All', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}, {'component': 'Hypersensitivity Reactions', 'type': 'Adverse Effect', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic items/complications.'}, {'component': 'undergoing the consolidation phase', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
327789,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III","Multiomic Single-Cell Sequencing of Mixed Phenotypic Acute Leukemia (MPAL) Reveals Complex Immunophenotypic, Transcriptional, and Genetic Heterogeneity",Mixed Phenotypic Acute Leukemia,Mixed Phenotypic Acute Leukemia,Mixed Phenotypic Acute Leukemia,True,abstract_title,"Step 1: The abstract title contains a specific disease, 'Mixed Phenotypic Acute Leukemia (MPAL)', so it is chosen as the primary source over the session title, following the single-source principle.
Step 2: The disease term 'Mixed Phenotypic Acute Leukemia' was identified. The parenthetical acronym (MPAL) is for informational purposes and is excluded from the final indication.
Step 3: Generic rules were applied. The term 'Acute' is an integral part of the disease name and is retained. The disease name is already in singular form and Title Case.
Step 4: Other parts of the title, such as 'Multiomic Single-Cell Sequencing' and 'Complex Immunophenotypic, Transcriptional, and Genetic Heterogeneity', describe the study's methodology and findings, not the indication itself, and are therefore excluded.
Step 5: The final indication is constructed from the clean, normalized disease name.",[],"[{'component': 'Mixed Phenotypic Acute Leukemia (MPAL)', 'type': 'Disease', 'normalized_form': 'Mixed Phenotypic Acute Leukemia', 'rule_applied': ""Generic rule: Use full disease name and exclude acronyms. Generic rule: Retain 'Acute' as it is part of the disease name.""}]",1
213104,Quality Improvement Summit: Laying the Foundation for Primary Palliative Care in Urology,What Clinical Innovations and Other Interventions Are Needed?,,,Urologic Disease,True,session_title,"Step 1: The abstract title 'What Clinical Innovations and Other Interventions Are Needed?' contains no disease or condition terms. 
Step 2: The session title 'Quality Improvement Summit: Laying the Foundation for Primary Palliative Care in Urology' contains the therapeutic area 'Urology'.
Step 3: According to the Single-Source Extraction Principle, the session title is selected as the source.
Step 4: The generic rule for 'Therapeutic Area Fallback' is applied. The therapeutic area 'Urology' is converted to the overarching disease 'Urologic Disease'.
Step 5: Formatting rules (Title Case, singular form) are applied, resulting in the final indication 'Urologic Disease'.",[],"[{'component': 'Urology', 'type': 'Therapeutic Area', 'normalized_form': 'Urologic Disease', 'rule_applied': 'Therapeutic Area Fallback'}]",1
393329,Developmental Therapeutics,A Phase 1 Study Of Bal0891 As Monotherapy And In Combination With Chemotherapy In Patients With Advanced Solid Tumors.,Advanced;;Solid Tumors,Advanced Solid Tumor,Advanced Solid Tumor,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title 'A Phase 1 Study Of Bal0891 As Monotherapy And In Combination With Chemotherapy In Patients With Advanced Solid Tumors.' contains a specific disease term ('Advanced Solid Tumors'). The session title 'Developmental Therapeutics' is a general therapeutic area. Therefore, the abstract title is selected as the source based on the Single-Source Extraction Principle.
2.  **Identify Components**: The key components identified in the abstract title are the disease 'Solid Tumors' and the stage qualifier 'Advanced'.
3.  **Retrieve Relevant Rules**: I searched for rules related to the stage qualifier 'Advanced' by calling `get_indication_rules(category='Stage', subcategories=['Stage Type'])`. While the tool returned several rules for stage types, none specifically governed the term 'Advanced'. Therefore, I proceeded by applying the generic rules.
4.  **Apply Rules**: The generic rules were applied to the extracted components:
    *   **Singular Form Rule**: The plural 'Tumors' was converted to its singular form, 'Tumor'.
    *   **Casing Rule**: The phrase was formatted to Title Case, resulting in 'Advanced Solid Tumor'.
    *   **Exclusion Rule**: The phrase 'In Patients With' was excluded as it is a non-diagnostic connector.
5.  **Construct Indication**: The normalized components were combined to form the final indication: 'Advanced Solid Tumor'.
6.  **Quality Check**: The final indication was checked for compliance with all formatting and clinical accuracy requirements. It adheres to the single-source principle, uses singular form and Title Case, and is a clinically valid indication.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for specific rules governing the formatting of the stage qualifier 'Advanced'.""}]","[{'component': 'Advanced Solid Tumors', 'type': 'Disease', 'normalized_form': 'Advanced Solid Tumor', 'rule_applied': 'Generic Rule: Singular Form (Tumors -> Tumor); Generic Rule: Title Case.'}]",2
376946,Quality of life and palliative care,Automated Metrics From The Electronic Health Record Enable Evaluation Of Palliative Care In Patients With Acute Myeloid Leukaemia: A Data Science Approach,Acute Myeloid Leukaemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia,True,abstract_title,"Step 1: The abstract title contains a specific disease, 'Acute Myeloid Leukaemia', while the session title 'Quality of life and palliative care' does not. Therefore, the abstract title was chosen as the source based on the single-source principle.
Step 2: The disease term 'Acute Myeloid Leukaemia' was identified. The generic rule for 'Acute' states that it should be included when it is part of the disease name, which is the case here.
Step 3: The term 'Leukaemia' was standardized to the more common US spelling 'Leukemia'.
Step 4: The final indication was formatted to Title Case as per the generic formatting rules, resulting in 'Acute Myeloid Leukemia'. No other patient subgroups or qualifiers were present in the title.",[],"[{'component': 'Acute Myeloid Leukaemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule: Disease Characterization (Acute); Generic Rule: Casing Rules'}]",1
262259,"Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research",Multiplex Deletion Of Myeloid Antigens Cd33 And Cll-1 By Crispr/Cas9 In Human Hematopoietic Stem Cells Highlights The Potential Of Next-Generation Transplants For Aml Treatment.,Aml,Acute Myeloid Leukemia,Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains the specific disease term 'Aml', whereas the session title is broad and lacks a specific disease.
2. **Component Identification**: The key component identified in the abstract title is 'Aml'.
3. **Rule Application & Normalization**:
   - The abbreviation 'Aml' is a standard medical acronym for 'Acute Myeloid Leukemia'.
   - The generic rule for Title Casing was applied, resulting in 'Acute Myeloid Leukemia'.
   - The generic rule for singular form was applied, although the term was already singular.
4. **Exclusion**: The term 'Treatment' at the end of the phrase 'Aml Treatment' is a procedural qualifier and is excluded from the final indication as per the generic exclusion rules. The rest of the title describes a methodology and does not define a patient subgroup.
5. **Final Indication Construction**: Based on the standardized and filtered components, the final indication is 'Acute Myeloid Leukemia'.","[{'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To verify how to handle the word 'Treatment' found in the abstract title.""}]","[{'component': 'Aml', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}, {'component': 'Treatment', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
229493,Vaccination and immunotherapy against COVID-19,Pan-coronavirus neutralizing S2 human monoclonal antibodies and utility of direct respiratory administration as combination therapy with S1 antibodies against SARS-CoV-2,SARS-CoV-2,SARS-CoV-2 Infection,COVID-19,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title mentions ""SARS-CoV-2"" and the session title mentions ""COVID-19"". Both refer to the same disease entity.
2. **Select Source**: Following the single-source principle, the abstract title is selected as it contains a specific disease-related term (""SARS-CoV-2"").
3. **Identify Components**: The key component identified in the abstract title is the pathogen ""SARS-CoV-2"". No patient subgroups or other qualifiers are present.
4. **Retrieve Rules**: No specific category rules were required. The extraction relies on general knowledge and generic rules.
5. **Apply Rules & Construct Indication**: The pathogen name ""SARS-CoV-2"" is normalized to its corresponding clinical disease name, ""COVID-19"", which is standard practice for creating medical indications. The session title helps confirm this context. The generic rule for Title Case is applied, resulting in ""COVID-19"".
6. **Quality Check**: The final indication is clinically accurate, follows formatting rules, and is correctly derived from the selected source.",[],"[{'component': 'SARS-CoV-2', 'type': 'Pathogen', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic Rule: Normalization of pathogen name to the corresponding disease name for clinical indication.'}]",2
393337,Germ Cell (Testicular) Cancer And Penile Cancer,Efficacy And Safety Of High-Dose Chemotherapy As Second Or Subsequent Salvage Therapy In Relapsed Or Refractory Germ Cell Cancer Patients: A Multicentric Analysis,Relapsed;;Refractory;;Germ Cell Cancer,Relapsed or Refractory Germ Cell Cancer,Second-Line Relapsed/Refractory Germ Cell Cancer;;Later-Line Relapsed/Refractory Germ Cell Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title as it contains a more specific description of the patient population and disease state, adhering to the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title were the disease ('Germ Cell Cancer'), the disease state ('Relapsed or Refractory'), and the treatment context ('Second or Subsequent Salvage Therapy').
3.  **Rule Retrieval**: Rules for 'Occurrence' (specifically 'Relapsed' and 'Refractory') and 'Treatment Set-up' (specifically 'Line of treatment') were retrieved to guide standardization.
4.  **Rule Application & Standardization**:
    *   **Disease**: 'Germ Cell Cancer Patients' was converted to its singular form, 'Germ Cell Cancer'.
    *   **Occurrence**: The phrase 'Relapsed or Refractory' was standardized to the combined form 'Relapsed/Refractory' based on common clinical terminology and the principles in the retrieved rules.
    *   **Line of Treatment**: The phrase 'Second Or Subsequent' indicates two distinct treatment settings. Following the pattern of rules like Rule 204 (for 'Third- or later-line'), this was split into two separate indications. 'Second' was standardized to 'Second-Line', and 'Subsequent' was standardized to the more common term 'Later-Line'.
    *   **Exclusion**: The term 'Salvage Therapy' was excluded as it describes a procedural/temporal context rather than being a core part of the indication itself, similar to how 'adjuvant' or 'neoadjuvant' are excluded.
5.  **Indication Construction**: The standardized components were assembled into two distinct indications to accurately capture the full scope of the patient cohort: 'Second-Line Relapsed/Refractory Germ Cell Cancer' and 'Later-Line Relapsed/Refractory Germ Cell Cancer'.
6.  **Final Formatting**: The two indications were joined using the required ';;' separator, and all terms were formatted in Title Case.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory', 'Relapse', 'Refractory'], 'reason': ""To correctly handle and standardize the terms 'Relapsed or Refractory'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To correctly handle and standardize the treatment context 'Second Or Subsequent Salvage Therapy'.""}]","[{'component': 'Germ Cell Cancer', 'type': 'Disease', 'normalized_form': 'Germ Cell Cancer', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'Relapsed Or Refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rule for combining relapsed and refractory states.'}, {'component': 'Second Or Subsequent', 'type': 'Line of treatment', 'normalized_form': 'Second-Line;;Later-Line', 'rule_applied': 'Treatment Set-up rule for handling multiple lines of therapy (e.g., Rule 204 pattern).'}, {'component': 'Salvage Therapy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of procedural/temporal qualifiers.'}]",2
376961,Acute myeloid leukemia - Clinical,Lifetime Clinical Outcomes Of Cpx-351 Versus 7+3 Modeled From The 5-Year Results Of A Randomized Phase 3 Trial For Older Adults With Newly Diagnosed High-Risk Or Secondary Acute Myeloid Leukaemia,Older Adults;;Newly Diagnosed;;High-Risk;;Secondary;;Acute Myeloid Leukaemia,Elderly Newly Diagnosed High-Risk Secondary Acute Myeloid Leukaemia,Elderly Newly Diagnosed High-Risk Acute Myeloid Leukemia;;Elderly Newly Diagnosed Secondary Acute Myeloid Leukemia,True,abstract_title,"The abstract title was chosen as the source because it contains more specific information than the session title. The title describes a study in 'Older Adults with Newly Diagnosed High-Risk Or Secondary Acute Myeloid Leukaemia'. The 'or' indicates two distinct patient populations, leading to the extraction of two separate indications. I identified the following components: 'Older Adults' (age group), 'Newly Diagnosed' (diagnosis status), 'High-Risk' (risk level), 'Secondary' (disease origin), and 'Acute Myeloid Leukaemia' (disease). I retrieved rules for each component to ensure proper normalization. 'Older Adults' was standardized to 'Elderly' and placed at the beginning. 'High-Risk' and 'Secondary' were treated as distinct qualifiers for 'Acute Myeloid Leukemia'. The two resulting indications were combined using the ';;' separator as required.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To normalize the term 'Older Adults'.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To confirm the handling of 'Newly Diagnosed'.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To standardize the term 'High-Risk'.""}, {'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To determine the correct handling of 'Secondary' as a disease qualifier.""}]","[{'component': 'Older Adults', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group rule for 'Older' (ID: 302) standardizes 'older adults' to 'Elderly'.""}, {'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Treatment based rule for 'Newly Diagnosed' (ID: 193) confirms its inclusion.""}, {'component': 'High-Risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': ""Risk rule for 'High-Risk' (ID: 122) confirms its format.""}, {'component': 'Secondary', 'type': 'Disease State', 'normalized_form': 'Secondary', 'rule_applied': ""Generic rule for 'Secondary' indicates inclusion when part of the disease name.""}, {'component': 'Acute Myeloid Leukaemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic rule for singular form and standardized spelling.'}]",2
295042,Proffered Paper session: Policy and preventive strategies,Invited Discussant 1312O and 1313O,,,,True,none,"Neither the abstract title ('Invited Discussant 1312O and 1313O') nor the session title ('Proffered Paper session: Policy and preventive strategies') contains any specific disease, condition, or therapeutic area. The titles are administrative and do not provide any clinical information from which to extract a medical indication.",[],[],1
229509,Cells of the Innate Immune System,Osteoclast differentiation alters monocyte inflammatory responses to Staphylococcus aureus,Staphylococcus aureus,Staphylococcus Aureus Infection,Staphylococcus Aureus Infection,True,abstract_title,"Step 1: The abstract title 'Osteoclast differentiation alters monocyte inflammatory responses to Staphylococcus aureus' was chosen as the source because it contains a specific pathogen ('Staphylococcus aureus'), which implies a disease state, whereas the session title 'Cells of the Innate Immune System' is a broad biological category and not a disease.
Step 2: The phrase 'inflammatory responses to Staphylococcus aureus' was identified as the core medical condition.
Step 3: This phrase was standardized to the clinically recognized term 'Staphylococcus Aureus Infection'.
Step 4: Generic formatting rules were applied. The term was converted to Title Case, and it is already in singular form. No exclusion rules were applicable.",[],"[{'component': 'inflammatory responses to Staphylococcus aureus', 'type': 'Disease', 'normalized_form': 'Staphylococcus Aureus Infection', 'rule_applied': 'Standardization to clinical term and Title Case formatting.'}]",1
180358,Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I,Targeting Metabolic Vulnerabilities in Primary Effusion Lymphoma Using the Novel Nucleoside Analog 6-Eti,Primary Effusion Lymphoma,Primary Effusion Lymphoma,Primary Effusion Lymphoma,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Targeting Metabolic Vulnerabilities in Primary Effusion Lymphoma Using the Novel Nucleoside Analog 6-Eti' and the session title is 'Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I'.
2.  **Select Source**: The abstract title contains a specific disease, 'Primary Effusion Lymphoma'. According to the single-source principle, the abstract title is prioritized over the session title and will be used for extraction.
3.  **Identify Components**: The key component identified in the abstract title is the disease name 'Primary Effusion Lymphoma'.
4.  **Retrieve Rules**: I retrieved rules for 'Patient Sub-Group' under 'Disease Characterisation' to ensure correct handling of the term 'Primary'. The generic rules state that 'Primary' should be included when it is part of a recognized disease name.
5.  **Apply Rules**: The generic rule for 'Primary' is applied, as 'Primary Effusion Lymphoma' is a distinct clinical entity. The term is already in singular form and correct Title Case. No exclusion rules apply.
6.  **Construct Indication**: The identified and validated disease term 'Primary Effusion Lymphoma' is the final indication.
7.  **Quality Check**: The final indication adheres to all formatting and clinical accuracy rules. It is derived from a single source and correctly represents the disease mentioned.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify the handling of the qualifier 'Primary' and ensure no specific exclusion rule applied.""}]","[{'component': 'Primary Effusion Lymphoma', 'type': 'Disease', 'normalized_form': 'Primary Effusion Lymphoma', 'rule_applied': ""Generic rule for 'Primary' as part of a disease name.""}]",2
327817,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Connecting Genetic Heterogeneity with Single-Cell Transcriptome Dysregulations in Pediatric Acute Myeloid Leukemia,Pediatric;;Acute Myeloid Leukemia,Pediatric Acute Myeloid Leukemia,Pediatric Acute Myeloid Leukemia,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease term ('Acute Myeloid Leukemia'), following the single-source extraction principle.
Step 2: The components 'Pediatric' (Age Group) and 'Acute Myeloid Leukemia' (Disease) were identified within the abstract title.
Step 3: Rules for the 'Age Group' category, specifically for 'Pediatric', were retrieved to ensure correct formatting.
Step 4: The retrieved rules (e.g., Rule ID 295, 296) specify that 'Pediatric' should be used as a leading qualifier for the disease.
Step 5: Generic rules were applied, ensuring the indication is in Title Case and singular form. The components were combined according to the rules to form the final indication.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To confirm the correct formatting and placement of the 'Pediatric' age group qualifier.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule for 'Pediatric' requires it to be the leading word.""}, {'component': 'Acute Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
311433,"Abstracts: SLE - Diagnosis, Manifestations, and Outcomes II: Complications",Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population,Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Severe COVID-19;;Systemic Lupus Erythematosus,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title contains 'Severe COVID-19' and 'Systemic Lupus Erythematosus'. The session title contains 'SLE' (Systemic Lupus Erythematosus). Both titles contain valid disease terms.
2. **Select Source**: According to the Single-Source Extraction Principle, the abstract title is preferred as it contains the disease terms. The session title is therefore ignored.
3. **Identify Components**: From the abstract title, two distinct medical conditions were identified: 'Severe COVID-19' and 'Systemic Lupus Erythematosus'. Other descriptors like 'Post-vaccination', 'Commercially Insured Patients', and 'General U.S. Population' were identified as exclusions based on generic rules (procedural/temporal, non-clinical, and sociodemographic).
4. **Retrieve Rules**: I retrieved rules for 'Risk' (subcategory 'severe') and 'Occurrence' (subcategory 'Disease State/Severity') to confirm how to handle the term 'Severe'. I also checked for rules regarding multiple diseases ('Patient with two different Disease') but found none, defaulting to the generic rule.
5. **Apply Rules & Construct Indication**: 
   - The generic rule for multiple diseases was applied, requiring both conditions to be extracted and separated by ';;'.
   - For 'Severe COVID-19', 'Severe' is a valid clinical descriptor of the disease state and was retained. The term was already in correct Title Case.
   - For 'Systemic Lupus Erythematosus', the term was already in correct Title Case and singular form.
   - The two indications were combined using the ';;' separator.
6. **Quality Check**: The final output adheres to all formatting and exclusion rules. It correctly captures the two distinct conditions from the source title without mixing information from the session title.","[{'category': 'Risk', 'subcategories': ['severe'], 'reason': ""To validate the handling of the term 'Severe' as a disease qualifier.""}, {'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To check for rules related to disease severity descriptors like 'Severe'.""}, {'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To check for specific rules on how to handle multiple diseases mentioned in the same context.'}]","[{'component': 'Severe COVID-19', 'type': 'Disease', 'normalized_form': 'Severe COVID-19', 'rule_applied': 'Generic Rule: Title Case, Multiple Diseases'}, {'component': 'Systemic Lupus Erythematosus', 'type': 'Disease', 'normalized_form': 'Systemic Lupus Erythematosus', 'rule_applied': 'Generic Rule: Title Case, Multiple Diseases'}, {'component': 'Post-vaccination', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule'}, {'component': 'Commercially Insured Patients', 'type': 'Non-clinical descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule'}, {'component': 'General U.S. Population', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule'}]",2
327823,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation,Mutated;;NPM1;;AML,NPM1-Mutated Acute Myeloid Leukemia,NPM1-Mutated Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the primary source because it contains a specific disease term ('AML') and a genetic qualifier ('Mutated NPM1'), making it more informative than the session title, in accordance with the single-source principle.
2. **Component Identification**: The key components identified in the abstract title were 'Mutated NPM1' (a gene mutation), 'AML' (the disease), and 'Undergoing Allogeneic Stem Cell Transplantation' (a procedural context).
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Gene type' to handle the mutation, and 'Treatment Set-up' for the transplant context.
4. **Rule Application**:
   - The 'Gene type' rules (specifically for 'Gene Mutated') mandate normalizing 'Mutated NPM1' to the format '<GENE>-Mutated', resulting in 'NPM1-Mutated'.
   - The generic exclusion rules and the specific 'Treatment Set-up' rules for transplant status require excluding procedural and temporal qualifiers. Therefore, 'Undergoing Allogeneic Stem Cell Transplantation' was removed from the indication.
   - The disease abbreviation 'AML' was expanded to its full form, 'Acute Myeloid Leukemia'.
   - Generic formatting rules for Title Case and singular form were applied.
5. **Indication Construction**: The normalized genetic qualifier was prepended to the full disease name to form the final indication: 'NPM1-Mutated Acute Myeloid Leukemia'.
6. **Quality Check**: The final indication adheres to all formatting, exclusion, and clinical accuracy requirements. It is derived from a single source and correctly represents the patient subgroup and disease.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the 'Mutated NPM1' component.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine how to handle the phrase 'Undergoing Allogeneic Stem Cell Transplantation'.""}]","[{'component': 'Mutated NPM1', 'type': 'Gene Mutation', 'normalized_form': 'NPM1-Mutated', 'rule_applied': ""Gene type rule for 'Gene Mutated': format as <GENE>-Mutated.""}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Standard abbreviation expansion and Title Case rule.'}, {'component': 'Undergoing Allogeneic Stem Cell Transplantation', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Generic exclusion rule for procedural/temporal qualifiers and specific 'Transplant Status' rules.""}]",2
311447,Abstracts: SLE - Treatment,CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus,Refractory;;Systemic Lupus Erythematosus,Refractory Systemic Lupus Erythematosus,Refractory Systemic Lupus Erythematosus,True,abstract_title,"Step 1: The abstract title 'CAR T Cell Treatment of Refractory Systemic Lupus Erythematosus' was chosen as the source because it contains a specific disease, 'Systemic Lupus Erythematosus', which is more detailed than the session title 'Abstracts: SLE - Treatment'.
Step 2: The components identified in the abstract title are the disease 'Systemic Lupus Erythematosus' and the disease state qualifier 'Refractory'. The phrase 'CAR T Cell Treatment of' is identified as a treatment modality and will be excluded per generic rules.
Step 3: To ensure correct handling of 'Refractory', I retrieved rules for the 'Occurrence' category with the 'Refractory' subcategory.
Step 4: I applied Rule ID 143, which standardizes 'Refractory' and places it before the disease name. I also applied generic rules for formatting (Title Case) and exclusion (removing treatment terms).
Step 5: The final indication was constructed by combining the qualifier and the disease name, resulting in 'Refractory Systemic Lupus Erythematosus'.
Step 6: A quality check confirmed that all rules were followed, including the single-source principle, correct formatting, and exclusion of non-indication elements.","[{'category': 'Occurrence', 'subcategories': ['Refractory'], 'reason': ""To correctly format and position the 'Refractory' qualifier in the indication.""}]","[{'component': 'Refractory', 'type': 'Disease State/Severity', 'normalized_form': 'Refractory', 'rule_applied': 'Occurrence Rule ID 143'}, {'component': 'Systemic Lupus Erythematosus', 'type': 'Disease', 'normalized_form': 'Systemic Lupus Erythematosus', 'rule_applied': 'Generic Rule - Title Case'}, {'component': 'CAR T Cell Treatment of', 'type': 'Treatment Modality', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule'}]",2
311449,Abstracts: SLE - Treatment,Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares,Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Systemic Lupus Erythematosus Flare,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares'. The session title is 'Abstracts: SLE - Treatment'.
2. **Select Source**: The abstract title contains the full disease name 'Systemic Lupus Erythematosus', making it the preferred source over the session title which uses the abbreviation 'SLE'.
3. **Identify Components**: The core disease identified is 'Systemic Lupus Erythematosus'. The term 'Flares' is identified as a descriptor of the disease state or severity.
4. **Retrieve Rules**: I retrieved rules for 'Disease State/Severity' to see if 'Flares' had a specific handling rule. No specific rule was found for 'Flares', so I proceeded with generic rules.
5. **Apply Rules & Construct Indication**: 
   - The core disease is 'Systemic Lupus Erythematosus'.
   - The qualifier 'Flares' is a clinically significant descriptor of the disease state.
   - Applying the 'Singular Form' generic rule, 'Flares' is converted to 'Flare'.
   - Applying the 'Title Case' generic rule, the components are capitalized correctly.
   - Information about drug dosing ('Hydroxychloroquine Dosing Less Than 5 Mg/kg/day') and outcomes ('Increased Hospitalizations') are excluded as they are not part of the core indication.
   - The final indication is constructed by combining the disease and the state: 'Systemic Lupus Erythematosus Flare'.
6. **Quality Check**: The final indication adheres to all formatting and exclusion rules. It is clinically accurate and derived from a single source.","[{'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To check for specific rules on handling disease state descriptors like 'Flares'.""}]","[{'component': 'Systemic Lupus Erythematosus', 'type': 'Disease', 'normalized_form': 'Systemic Lupus Erythematosus', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'Flares', 'type': 'Disease State', 'normalized_form': 'Flare', 'rule_applied': 'Generic Rule: Singular Form'}]",2
409754,Regulating the Regulator: Exploring the Therapeutic Landscape for Complement-Mediated Kidney Diseases,Audience Q&A,,,Complement-Mediated Kidney Disease,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title 'Audience Q&A' contains no medical information. The session title 'Regulating the Regulator: Exploring the Therapeutic Landscape for Complement-Mediated Kidney Diseases' contains a clear disease term.
2.  **Select Source**: Based on the Single-Source Extraction Principle, the session title is selected as the source because the abstract title lacks a disease term.
3.  **Identify Components**: The key phrase identified in the session title is 'Complement-Mediated Kidney Diseases'. 'Complement-Mediated' is a clinically significant characterization of the disease.
4.  **Retrieve Rules**: I retrieved rules for 'Patient Sub-Group' and 'Disease Characterisation' to check for any specific handling of this type of descriptor. No specific rule applied directly to 'Complement-Mediated', so I proceeded with generic rules.
5.  **Apply Generic Rules**:
    *   **Singular Form**: The plural 'Diseases' was converted to its singular form, 'Disease'.
    *   **Title Case**: The phrase was already in proper Title Case.
    *   **Exclusion Rules**: No terms for exclusion (e.g., sociodemographic, procedural) were present.
6.  **Construct Indication**: The components were combined according to the rules, resulting in 'Complement-Mediated Kidney Disease'.
7.  **Quality Check**: The final indication is clinically accurate, correctly formatted, and derived from a single source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify if any specific rules apply to disease characterizations like 'Complement-Mediated'.""}]","[{'component': 'Complement-Mediated Kidney Diseases', 'type': 'Disease', 'normalized_form': 'Complement-Mediated Kidney Disease', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Title Case'}]",2
393371,Gynaecological Cancers,Ccne1 Amplification Defines A Good Prognostic Subgroup Among Brcawt/Hrdneg Advanced High-Grade Ovarian Cancer (Hgoc),Advanced;;High-Grade;;Ovarian Cancer,Advanced High-Grade Ovarian Cancer,CCNE1-Amplified BRCA Wild-Type HRD-Negative Advanced High Grade Ovarian Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Ccne1 Amplification Defines A Good Prognostic Subgroup Among Brcawt/Hrdneg Advanced High-Grade Ovarian Cancer (Hgoc)' was chosen as it contains a specific disease ('Ovarian Cancer'), which is more precise than the session title 'Gynaecological Cancers'.
2. **Component Identification**: I identified several key components in the abstract title: a gene amplification ('Ccne1 Amplification'), genetic/biomarker statuses ('Brcawt' for BRCA wild-type, 'Hrdneg' for HRD-negative), a stage descriptor ('Advanced'), a grade descriptor ('High-Grade'), and the disease ('Ovarian Cancer').
3. **Rule Retrieval**: I retrieved rules for Gene Name, Biomarker, Stage, and Grade to ensure correct normalization and formatting.
4. **Rule Application and Normalization**:
   - **Gene**: Based on Gene Name rules (e.g., Rule 27), 'Ccne1 Amplification' was normalized to 'CCNE1-Amplified', using the standard uppercase gene symbol and hyphenated qualifier.
   - **Biomarkers**: 'Brcawt' was interpreted and normalized to 'BRCA Wild-Type'. 'Hrdneg' was normalized to 'HRD-Negative'. The slash in 'Brcawt/Hrdneg' indicates a combined subgroup, which I've represented as two distinct qualifiers.
   - **Stage**: 'Advanced' was kept as a standard stage descriptor, formatted in Title Case.
   - **Grade**: Based on Grade Rule 115, 'High-Grade' was normalized to 'High Grade' (no hyphen).
   - **Disease**: 'Ovarian Cancer' was used in its singular form as required.
5. **Indication Construction**: The normalized components were assembled in the standard order of [Gene/Biomarker Statuses] [Stage] [Grade] [Disease]. This resulted in the final indication, which precisely defines the patient subgroup described in the title.","[{'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To correctly format the 'Ccne1 Amplification' component.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To understand how to handle biomarker statuses like 'Brcawt' (BRCA wild-type) and 'Hrdneg' (HRD-negative).""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To confirm the handling of the 'Advanced' stage descriptor.""}, {'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To correctly format the 'High-Grade' component.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': 'To check for rules regarding complex genetic patient subgroups.'}]","[{'component': 'Ccne1 Amplification', 'type': 'Gene Amplification', 'normalized_form': 'CCNE1-Amplified', 'rule_applied': ""Gene Name Rule 27: Format as '<GeneSymbol>-<Qualifier>'.""}, {'component': 'Brcawt', 'type': 'Biomarker Status', 'normalized_form': 'BRCA Wild-Type', 'rule_applied': 'Standard clinical nomenclature for BRCA status.'}, {'component': 'Hrdneg', 'type': 'Biomarker Status', 'normalized_form': 'HRD-Negative', 'rule_applied': 'Standard clinical nomenclature for HRD status.'}, {'component': 'Advanced', 'type': 'Stage', 'normalized_form': 'Advanced', 'rule_applied': 'Generic rule: Include stage descriptors in Title Case.'}, {'component': 'High-Grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Grade Rule 115: Standardize to 'High Grade' without a hyphen.""}, {'component': 'Ovarian Cancer', 'type': 'Disease', 'normalized_form': 'Ovarian Cancer', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}]",2
262300,"Hematopoiesis, stem cells and microenvironment",Monoallelic And Biallelic Germline Mutations Affecting The Transcription Factor Helios Cause Pleiotropic Defects Of Immunity,,,Helios-Mutated Germline Pleiotropic Defect of Immunity,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'Monoallelic And Biallelic Germline Mutations Affecting The Transcription Factor Helios Cause Pleiotropic Defects Of Immunity' was chosen as it contains a specific disease/disorder ('Pleiotropic Defects Of Immunity'), whereas the session title 'Hematopoiesis, stem cells and microenvironment' is a broad therapeutic area without a specific disease.

2.  **Component Identification**: The selected title contains several key components:
    *   Disease: 'Pleiotropic Defects Of Immunity'
    *   Gene/Factor: 'Transcription Factor Helios'
    *   Genetic Origin: 'Germline'
    *   Mutation Type: 'Mutations'
    *   Allelic Status: 'Monoallelic', 'Biallelic'

3.  **Rule Retrieval & Application**:
    *   **Allelic Status**: Rules for 'Patient Sub-Group' -> 'Genetic Status' were retrieved for 'Biallelic'. Rule ID 466 explicitly states to exclude allelic zygosity descriptors like 'Biallelic'. By extension, 'Monoallelic' was also excluded as it falls under the same category of non-standard descriptors.
    *   **Genetic Origin**: Rules for 'Occurrence' -> 'Genetic Origin' were retrieved for 'Germline'. Rule ID 180 specifies retaining 'Germline' and placing it after the standardized gene-mutation token (e.g., '<Gene>-Mutated Germline').
    *   **Gene Mutation**: Following standard gene mutation rules, 'Mutations Affecting... Helios' is normalized to 'Helios-Mutated'.
    *   **Disease Normalization**: The disease term 'Pleiotropic Defects Of Immunity' was processed according to generic rules: converted to singular ('Defect') and formatted in Title Case ('Pleiotropic Defect of Immunity').

4.  **Indication Construction**: The identified and normalized components were assembled in the standard order: Gene-Mutation -> Genetic Origin -> Disease.
    *   'Helios-Mutated' + 'Germline' + 'Pleiotropic Defect of Immunity' results in the final indication.

5.  **Quality Check**: The final indication adheres to the single-source principle, correctly applies formatting rules (Title Case, singular form), includes the patient subgroup defined by the germline mutation, and excludes non-standard descriptors ('Biallelic', 'Monoallelic').","[{'category': 'Occurrence', 'subcategories': ['Genetic Origin'], 'reason': ""To determine how to handle the term 'Germline'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To determine how to handle the term 'Biallelic'.""}]","[{'component': 'Germline Mutations Affecting The Transcription Factor Helios', 'type': 'Gene Mutation with Genetic Origin', 'normalized_form': 'Helios-Mutated Germline', 'rule_applied': ""Rule 180 for 'Germline' positioning and standard rules for gene mutation formatting.""}, {'component': 'Pleiotropic Defects Of Immunity', 'type': 'Disease', 'normalized_form': 'Pleiotropic Defect of Immunity', 'rule_applied': 'Generic rules for singular form and Title Case.'}, {'component': 'Monoallelic And Biallelic', 'type': 'Genetic Status', 'normalized_form': '', 'rule_applied': ""Rule 466 explicitly excludes 'Biallelic', and by extension 'Monoallelic', as non-standard allelic zygosity descriptors.""}]",2
393379,Gynaecological Cancers,Correlation Between Chemotherapy Response Score (Crs) And Germline Brca1/2 (Gbrca) Status In Women Diagnosed With Figo Stage Iiic/Iv High-Grade Serous Ovarian Cancer (Hgsoc),Stage Iiic/Iv;;High-Grade;;Serous Ovarian Cancer,Stage IIIc/IV High-Grade Serous Ovarian Cancer,Stage IIIC/IV High Grade Serous Ovarian Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains a specific disease ('High-Grade Serous Ovarian Cancer'), so it was chosen as the source over the more general session title ('Gynaecological Cancers'), following the single-source principle.
2.  **Component Identification**: The abstract title contains the following components: a disease ('High-Grade Serous Ovarian Cancer'), a stage ('Figo Stage Iiic/Iv'), a grade ('High-Grade'), and a patient descriptor ('Women'). It also mentions a genetic status ('Germline Brca1/2 (Gbrca) Status') as a correlative factor, not as a defining characteristic of the patient cohort.
3.  **Rule Retrieval**: Rules were retrieved for Stage, Grade, and Gene type to ensure proper formatting.
4.  **Rule Application & Normalization**:
    *   **Disease**: 'High-Grade Serous Ovarian Cancer (Hgsoc)' was normalized. The abbreviation '(Hgsoc)' was removed. 'Cancer' is already in singular form. 'Serous' is a key histological subtype and was retained.
    *   **Grade**: Based on the retrieved 'Grade' rules (e.g., ID 115), 'High-Grade' was normalized to 'High Grade'.
    *   **Stage**: 'Figo Stage Iiic/Iv' was standardized. The staging system 'Figo' was dropped in favor of the standard format. The Roman numerals were capitalized and combined, resulting in 'Stage IIIC/IV', consistent with staging rules.
    *   **Exclusions**: The sociodemographic descriptor 'Women' was excluded as per generic rules. The phrase 'Diagnosed With' was excluded as a procedural qualifier. 'Germline Brca1/2 (Gbrca) Status' was excluded because the title indicates it's a variable being correlated *within* the patient group, not a defining inclusion criterion for the cohort itself.
5.  **Indication Construction**: The normalized components were assembled in the standard clinical order: [Stage] [Grade] [Histology] [Disease]. This resulted in the final indication: 'Stage IIIC/IV High Grade Serous Ovarian Cancer'.
6.  **Final Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form, no trailing spaces) and accurately represents the patient population described in the abstract title.","[{'category': 'Stage', 'subcategories': ['Stage number', 'Stage Type'], 'reason': ""To correctly format the stage 'Figo Stage Iiic/Iv'.""}, {'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To standardize the term 'High-Grade'.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To evaluate how to handle 'Germline Brca1/2 (Gbrca) Status'.""}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To handle the '/' in the stage 'Iiic/Iv'.""}]","[{'component': 'Figo Stage Iiic/Iv', 'type': 'Stage', 'normalized_form': 'Stage IIIC/IV', 'rule_applied': ""Stage number rules for Roman numerals and Connectors rule for '/'.""}, {'component': 'High-Grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Grade rule ID 115 for standardizing 'High Grade'.""}, {'component': 'Serous Ovarian Cancer', 'type': 'Disease', 'normalized_form': 'Serous Ovarian Cancer', 'rule_applied': 'Generic rules for Title Case and singular form.'}, {'component': 'Women', 'type': 'Gender', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic descriptors.'}, {'component': 'Germline Brca1/2 (Gbrca) Status', 'type': 'Analyte', 'normalized_form': '', 'rule_applied': 'Excluded as it is a factor being studied for correlation, not a defining characteristic of the patient cohort.'}]",2
213157,Society for the Study of Male Reproduction (SSMR),Society for the Study of Male Reproduction (SSMR),,,,True,none,"Neither the abstract title nor the session title contains a clinically valid medical indication. Both titles, 'Society for the Study of Male Reproduction (SSMR)', refer to a field of study or a professional society, not a specific disease, disorder, or condition. The term 'Male Reproduction' describes a physiological process, which is listed as a non-diagnostic item to be excluded according to the generic rules. Therefore, no indication can be extracted.",[],"[{'component': 'Male Reproduction', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items (Physiologic processes)'}]",1
393382,Gynaecological Cancers,The Predictive Role Of Circulating Exosomal Pd-L1 In Cervical Cancer Immunotherapy,Cervical Cancer,Cervical Cancer,Cervical Cancer,True,abstract_title,"Step 1: The abstract title ('The Predictive Role Of Circulating Exosomal Pd-L1 In Cervical Cancer Immunotherapy') was chosen as the source because it contains a specific disease ('Cervical Cancer'), which is preferred over the broader category in the session title ('Gynaecological Cancers').
Step 2: The core disease 'Cervical Cancer' was identified.
Step 3: The term 'Pd-L1' was identified as a biomarker. I retrieved rules for the 'Biomarker' category to determine its correct handling.
Step 4: The retrieved rules did not provide specific guidance for formatting a biomarker mentioned in a 'predictive role'. Standard practice dictates that a biomarker is only included in the indication if it defines a specific patient subgroup (e.g., 'PD-L1-Positive'). As the title does not specify a status, 'Pd-L1' is excluded from the final indication.
Step 5: Other terms like 'Predictive Role', 'Circulating Exosomal', and 'Immunotherapy' were excluded as they describe the study's methodology and treatment context, not the core disease indication.
Step 6: The final indication was formatted to 'Cervical Cancer' following Title Case and singular form rules.","[{'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To check for rules on how to handle the biomarker 'Pd-L1'.""}]","[{'component': 'Cervical Cancer', 'type': 'Disease', 'normalized_form': 'Cervical Cancer', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Pd-L1', 'type': 'Biomarker', 'normalized_form': '', 'rule_applied': 'Excluded because it is mentioned in a predictive context, not as a patient subgroup defining status (e.g., positive/negative).'}]",2
344232,Intercepting Molecular Residual Disease in the Clinic,Chair Introduction,,,Molecular Residual Disease,True,session_title,"Step 1: The abstract title 'Chair Introduction' contains no medical terms. The session title 'Intercepting Molecular Residual Disease in the Clinic' contains the term 'Molecular Residual Disease'.
Step 2: Following the single-source principle, the session title is selected for extraction.
Step 3: The term 'Molecular Residual Disease' is identified as the core medical concept.
Step 4: The verb 'Intercepting' and the location qualifier 'in the Clinic' are identified for exclusion based on generic rules.
Step 5: Generic formatting rules are applied. The term is already in Title Case and singular form.
Step 6: The final indication is constructed by taking the core medical concept and applying the necessary formatting and exclusions, resulting in 'Molecular Residual Disease'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for any specific rules regarding disease state characterizations like 'Molecular Residual Disease'. No specific rule was found to be directly applicable, so generic rules were used.""}]","[{'component': 'Molecular Residual Disease', 'type': 'Disease', 'normalized_form': 'Molecular Residual Disease', 'rule_applied': 'Generic rule: Use Title Case and singular form.'}, {'component': 'Intercepting', 'type': 'Action Verb', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude non-diagnostic items and study methodologies.'}, {'component': 'in the Clinic', 'type': 'Location Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude procedural/temporal qualifiers.'}]",2
180389,Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I,Safety and Efficacy of Isavuconazole in Patients Aged 65 Years or Older with Invasive Fungal Disease: A Post-Hoc Analysis from the VITAL and Secure Studies,Invasive Fungal Disease,Elderly Invasive Fungal Disease,Elderly Invasive Fungal Disease,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title contains a specific disease ('Invasive Fungal Disease'), so it was chosen as the primary source over the session title, following the single-source principle.
2. **Component Identification**: The abstract title identifies two key components: the disease 'Invasive Fungal Disease' and a patient subgroup 'Patients Aged 65 Years or Older'.
3. **Rule Retrieval**: To standardize the age-related patient subgroup, I retrieved rules for the 'Age Group' category, specifically for the 'Elderly' subcategory.
4. **Rule Application**: The retrieved rule (ID: 303) specifies that phrases like 'aged 60 years or older' should be normalized to the standardized term 'Elderly' and prepended to the disease name.
5. **Indication Construction**: The disease 'Invasive Fungal Disease' is already in the correct singular and Title Case format. The patient subgroup 'Aged 65 Years or Older' was normalized to 'Elderly'. These components were combined to form the final indication.
6. **Quality Check**: The final indication 'Elderly Invasive Fungal Disease' adheres to all formatting and clinical accuracy rules. It correctly captures the patient population and the condition from the selected source.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To find the correct standardization for the phrase 'Aged 65 Years or Older'.""}]","[{'component': 'Aged 65 Years or Older', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': 'Age Group rule ID 303 for age thresholds >= 60 years.'}, {'component': 'Invasive Fungal Disease', 'type': 'Disease', 'normalized_form': 'Invasive Fungal Disease', 'rule_applied': 'Generic rule for singular form and Title Case.'}]",2
180390,Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I,Clinical Characteristics Associated with Venous Thromboembolism in Patients with Non-APL Acute Myeloid Leukemia,Venous Thromboembolism;;Acute Myeloid Leukemia,Venous Thromboembolism;;Acute Myeloid Leukemia,Venous Thromboembolism;;Non-APL Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains specific disease terms ('Venous Thromboembolism', 'Non-APL Acute Myeloid Leukemia'), following the single-source principle.
2. **Component Identification**: Two distinct medical conditions were identified in the abstract title: 'Venous Thromboembolism' and 'Non-APL Acute Myeloid Leukemia'. 'Non-APL' (Non-Acute Promyelocytic Leukemia) is a clinically significant patient subgroup of Acute Myeloid Leukemia.
3. **Rule Retrieval**: Rules for handling multiple diseases were considered. The generic rule specifies separating distinct diseases with ';;'. Rules for patient subgroups ('Disease Characterisation') were also considered, confirming that clinically relevant subgroups like 'Non-APL' should be retained.
4. **Rule Application**: 
   - The generic rule for multiple diseases was applied, leading to the extraction of both conditions.
   - The generic formatting rule for Title Case was applied to both indications.
   - The generic rule for using singular form was applied; both terms were already singular.
   - No terms met the criteria for exclusion.
5. **Indication Construction**: The two identified and normalized indications were combined using the ';;' separator, resulting in the final output.
6. **Quality Check**: The final indication adheres to all formatting and clinical accuracy guidelines. It correctly captures the two distinct clinical entities mentioned in the source title.","[{'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': 'To determine the correct procedure for handling titles that mention two distinct diseases.'}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify how to handle the 'Non-APL' qualifier for Acute Myeloid Leukemia.""}]","[{'component': 'Venous Thromboembolism', 'type': 'Disease', 'normalized_form': 'Venous Thromboembolism', 'rule_applied': 'Generic rule for disease identification and Title Case.'}, {'component': 'Non-APL Acute Myeloid Leukemia', 'type': 'Disease with Patient Subgroup', 'normalized_form': 'Non-APL Acute Myeloid Leukemia', 'rule_applied': 'Generic rule for retaining clinically significant patient subgroups and Title Case.'}]",2
262320,Hodgkin lymphoma - Clinical,"Brentuximab Vedotin, Etoposide, Solumedrol, High Dose Ara-C & Platinum Followed By Hdt & Apbsct For Refractory/Relapsed Hodgkin Lymphoma Patients: Long-Term Results Of The Geltamo Group Breshap Study",Refractory;;Relapsed;;Hodgkin Lymphoma,Refractory/Relapsed Hodgkin Lymphoma,Refractory/Relapsed Hodgkin Lymphoma,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease ('Hodgkin Lymphoma') and additional patient subgroup information ('Refractory/Relapsed'), making it more detailed than the session title.
Step 2: The core disease was identified as 'Hodgkin Lymphoma'.
Step 3: The patient subgroup/disease occurrence was identified as 'Refractory/Relapsed'. I retrieved rules for 'Occurrence' to confirm the standard formatting for such terms.
Step 4: Generic rules were applied. The disease term was already in singular form and Title Case. Drug names (Brentuximab Vedotin, Etoposide, etc.) and procedural terms ('Hdt & Apbsct') were excluded as per the exclusion rules.
Step 5: The final indication was constructed by prepending the standardized occurrence term to the disease name, resulting in 'Refractory/Relapsed Hodgkin Lymphoma'.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To verify the correct formatting and placement of 'Refractory/Relapsed' as a disease qualifier.""}]","[{'component': 'Refractory/Relapsed', 'type': 'Occurrence', 'normalized_form': 'Refractory/Relapsed', 'rule_applied': 'Occurrence rule for standardizing and prepending disease state qualifiers.'}, {'component': 'Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'Hodgkin Lymphoma', 'rule_applied': 'Generic rules for casing and singular form.'}]",2
180403,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia,Adults;;Newly Diagnosed;;Philadelphia Chromosome;;Negative;;B-Cell Acute Lymphoblastic Leukemia,Adult Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia,Adult Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia'), making it more informative than the session title ('Acute Lymphoblastic Leukemias'). This adheres to the Single-Source Extraction Principle.
2.  **Component Identification**: The following components were identified in the abstract title:
    *   Age Group: 'Adults'
    *   Diagnosis Status: 'Newly Diagnosed'
    *   Genetic Status: 'Philadelphia Chromosome-Negative'
    *   Cell Type: 'B-Cell'
    *   Core Disease: 'Acute Lymphoblastic Leukemia'
3.  **Rule Retrieval**: I retrieved rules for 'Age Group' (Adult), 'Treatment based' (Diagnosis Status), and 'Patient Sub-Group' (Genetic Status) to ensure correct formatting and inclusion.
4.  **Rule Application and Construction**:
    *   The 'Age Group' rule for 'Adult' was applied, normalizing 'Adults' to 'Adult' and placing it as a prefix.
    *   The 'Treatment based' rule for 'Newly Diagnosed' was applied, placing it as a prefix after the age group.
    *   'Philadelphia Chromosome-Negative' was identified as a key genetic descriptor and included.
    *   'B-Cell' was identified as an essential cell lineage specifier for the leukemia.
    *   The core disease 'Acute Lymphoblastic Leukemia' was kept in its singular form.
    *   Generic rules for Title Case and single spacing were applied.
5.  **Final Assembly**: The components were assembled in the standard clinical order: Age Group -> Diagnosis Status -> Genetic Status -> Cell Type -> Core Disease. This resulted in the final indication: 'Adult Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia'.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'Adults' patient subgroup.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To handle the 'Newly Diagnosed' descriptor.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To confirm the handling of genetic descriptors like 'Philadelphia Chromosome-Negative'.""}]","[{'component': 'Adults', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Rule ID: 289 - 'Adult' keyword rule.""}, {'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - 'Newly Diagnosed' keyword rule.""}, {'component': 'Philadelphia Chromosome-Negative', 'type': 'Genetic Status', 'normalized_form': 'Philadelphia Chromosome-Negative', 'rule_applied': 'Generic rule for including genetic patient subgroups.'}, {'component': 'B-Cell', 'type': 'Cell Type', 'normalized_form': 'B-Cell', 'rule_applied': 'Generic rule for including cell lineage as part of the disease name.'}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule for singular form and Title Case.'}]",2
327859,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance,ALL,Acute Lymphoblastic Leukemia,High Hyperdiploid Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title. While the session title explicitly names 'Acute Lymphoblastic Leukemias', the abstract title contains 'UKALL', a well-known acronym for 'United Kingdom Acute Lymphoblastic Leukaemia', and provides a more specific patient subgroup, 'High Hyperdiploid'. According to the single-source principle, the more specific title containing the disease (or a direct acronym) is preferred.
2.  **Component Identification**: From the abstract title, the key components identified were 'UKALL' (disease) and 'High Hyperdiploid' (patient subgroup/genetic status).
3.  **Rule Retrieval**: Rules for 'Risk' and 'Patient Sub-Group' were retrieved to understand how to handle descriptors like 'High' and genetic statuses like 'Hyperdiploid'.
4.  **Rule Application and Construction**:
    *   The disease 'UKALL' was expanded to its full, standardized name: 'Acute Lymphoblastic Leukemia'.
    *   The descriptor 'High Hyperdiploid' was identified as a specific, clinically significant patient subgroup that defines the type of leukemia. It is not a generic risk level but a distinct genetic profile.
    *   The term 'Risk Profile' was determined to be part of the study's methodology ('Validation of the... Risk Profile') and not a part of the patient's actual diagnosis, so it was excluded.
    *   Generic formatting rules were applied: The final indication was converted to Title Case and singular form.
5.  **Final Indication Assembly**: The components were combined to form the final indication: 'High Hyperdiploid Acute Lymphoblastic Leukemia'.","[{'category': 'Risk', 'subcategories': ['High-Risk', 'Risk Types'], 'reason': ""To correctly handle the term 'High' and 'Risk Profile' found in the abstract title.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To determine how to classify and format the genetic descriptor 'Hyperdiploid'.""}]","[{'component': 'UKALL', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Standardization of acronym to full disease name.'}, {'component': 'High Hyperdiploid', 'type': 'Patient Sub-Group (Genetic Status)', 'normalized_form': 'High Hyperdiploid', 'rule_applied': 'Inclusion of a specific genetic profile as a prefix to the disease.'}, {'component': 'Risk Profile', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Exclusion of non-diagnostic items (Generic Rule 3).'}]",2
393400,Gynaecological Cancers,Tumor-Informed Ctdna Detection As A Predictive Marker For Postoperative Residual Disease In Epithelial Ovarian Cancer: A Feasibility Study,Epithelial Ovarian Cancer,Epithelial Ovarian Cancer,Residual Epithelial Ovarian Cancer,True,abstract_title,"Step 1: The abstract title was selected as the source because it contains a specific disease, 'Epithelial Ovarian Cancer', which is more precise than the broader category 'Gynaecological Cancers' in the session title.
Step 2: The components identified in the abstract title were the core disease 'Epithelial Ovarian Cancer' and the potential qualifiers 'Postoperative' and 'Residual Disease'.
Step 3: Rules for 'Treatment Set-up' (specifically 'Operative Status') were retrieved to handle the term 'Postoperative'.
Step 4: Based on the retrieved rules (specifically Rule ID 255), 'Postoperative' was excluded as it is a procedural/temporal qualifier not included in the final indication.
Step 5: The term 'Residual Disease' was identified as a clinically significant disease state that defines the patient population. It was therefore included as a qualifier.
Step 6: The final indication was constructed by combining the qualifier 'Residual' with the core disease 'Epithelial Ovarian Cancer' and applying Title Case and singular form rules. Other non-diagnostic parts of the title, such as 'Tumor-Informed Ctdna Detection', were excluded.","[{'category': 'Treatment Set-up', 'subcategories': ['Operative Status'], 'reason': ""To determine how to handle the term 'Postoperative'.""}, {'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To check for rules regarding disease states like 'Residual Disease'.""}]","[{'component': 'Epithelial Ovarian Cancer', 'type': 'Disease', 'normalized_form': 'Epithelial Ovarian Cancer', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Postoperative', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Rule ID 255 from 'Operative Status' category, which mandates exclusion.""}, {'component': 'Residual Disease', 'type': 'Disease State', 'normalized_form': 'Residual', 'rule_applied': 'Inclusion as a clinically significant patient subgroup qualifier based on general principles.'}]",2
327865,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",Clinical Significance of IGH Clonality Analysis with RNA Sequencing in B-Cell Precursor Acute Lymphoblastic Leukemia,B-Cell Precursor Acute Lymphoblastic Leukemia,B-Cell Precursor Acute Lymphoblastic Leukemia,B-Cell Precursor Acute Lymphoblastic Leukemia,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease, 'Acute Lymphoblastic Leukemia', which is preferred over the session title according to the single-source principle.
Step 2: The components identified in the abstract title were the patient subgroup 'B-Cell Precursor' and the disease 'Acute Lymphoblastic Leukemia'.
Step 3: The `get_indication_rules` tool was used for the category 'Patient Sub-Group' with the subcategory 'B-Cell Precursor' to understand how to handle this specific subgroup.
Step 4: The retrieved rules (ID 420, 421) confirmed that 'B-Cell Precursor' should be retained and prepended directly to the disease name. Generic rules were applied to ensure correct Title Casing and singular form. The procedural part of the title, 'Clinical Significance of IGH Clonality Analysis with RNA Sequencing in', was excluded as per the exclusion rules.
Step 5: The final indication was constructed by combining the patient subgroup and the disease name.
Step 6: A quality check confirmed that all rules were followed, resulting in the final indication.","[{'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To verify the correct formatting and inclusion of the 'B-Cell Precursor' patient subgroup.""}]","[{'component': 'B-Cell Precursor', 'type': 'Patient Subgroup', 'normalized_form': 'B-Cell Precursor', 'rule_applied': ""Rule ID 420: Retain the exact phrase 'B-Cell Precursor' and concatenate it with the disease name.""}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}]",2
327866,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",The Rise and Fall of Leukemia Clones in Longitudinal Samples from Diagnosis to Relapse in KMT2A-rearranged Infant and Childhood Leukemia,Relapse;;KMT2A;;rearranged;;Infant;;Childhood;;Leukemia,Relapsed KMT2A-Rearranged Infant Childhood Leukemia,Infant Relapsed KMT2A-Rearranged Leukemia;;Childhood Relapsed KMT2A-Rearranged Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains specific disease and patient subgroup information ('KMT2A-rearranged Infant and Childhood Leukemia'), which is more detailed than the session title ('Acute Lymphoblastic Leukemias'). The single-source principle mandates using the abstract title exclusively.
2. **Component Identification**: The key components identified in the abstract title are:
    - Disease: 'Leukemia'
    - Gene Information: 'KMT2A-rearranged'
    - Age Groups: 'Infant' and 'Childhood'
    - Occurrence Status: 'Relapse'
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Gene type' (for 'KMT2A-rearranged'), 'Age Group' (for 'Infant' and 'Childhood'), and 'Occurrence' (for 'Relapse').
4. **Rule Application and Normalization**:
    - **Disease**: The term 'Leukemia' is already in singular form and was converted to Title Case.
    - **Gene Information**: The term 'KMT2A-rearranged' was normalized to 'KMT2A-Rearranged' based on the retrieved 'Gene Rearranged' rule (ID 48), which specifies the format '<Gene>-Rearranged'.
    - **Age Groups**: The terms 'Infant' and 'Childhood' were identified as distinct patient subgroups. The retrieved 'Age Group' rules (ID 291, 292) state that these descriptors should be placed at the beginning of the indication.
    - **Occurrence Status**: The term 'Relapse' was converted to 'Relapsed' as per the 'Relapse' occurrence rule (ID 144), which standardizes the term to its adjectival form and places it before the disease name.
5. **Indication Construction**: The components were assembled for each age group, creating two distinct indications. The structure followed is [Age Group] [Occurrence] [Gene Info] [Disease].
    - For 'Infant': 'Infant' + 'Relapsed' + 'KMT2A-Rearranged' + 'Leukemia' -> 'Infant Relapsed KMT2A-Rearranged Leukemia'.
    - For 'Childhood': 'Childhood' + 'Relapsed' + 'KMT2A-Rearranged' + 'Leukemia' -> 'Childhood Relapsed KMT2A-Rearranged Leukemia'.
6. **Final Output Formatting**: The two resulting indications were combined and separated by the mandatory ';;' delimiter, resulting in the final generated indication.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To handle the 'KMT2A-rearranged' genetic marker.""}, {'category': 'Age Group', 'subcategories': ['Infant', 'Childhood'], 'reason': ""To correctly format the 'Infant' and 'Childhood' patient subgroups.""}, {'category': 'Occurrence', 'subcategories': ['Relapse'], 'reason': ""To standardize the disease occurrence status 'Relapse'.""}]","[{'component': 'Leukemia', 'type': 'Disease', 'normalized_form': 'Leukemia', 'rule_applied': 'Generic Rule: Singular Form, Title Case'}, {'component': 'KMT2A-rearranged', 'type': 'Gene Rearrangement', 'normalized_form': 'KMT2A-Rearranged', 'rule_applied': ""get_indication_rules(category='Gene type', subcategories=['Gene type']) - Rule ID 48""}, {'component': 'Infant', 'type': 'Age Group', 'normalized_form': 'Infant', 'rule_applied': ""get_indication_rules(category='Age Group', subcategories=['Infant'])""}, {'component': 'Childhood', 'type': 'Age Group', 'normalized_form': 'Childhood', 'rule_applied': ""get_indication_rules(category='Age Group', subcategories=['Childhood']) - Rule ID 291""}, {'component': 'Relapse', 'type': 'Occurrence', 'normalized_form': 'Relapsed', 'rule_applied': ""get_indication_rules(category='Occurrence', subcategories=['Relapse']) - Rule ID 144""}]",2
262328,Indolent and mantle-cell non-Hodgkin lymphoma - Clinical,"Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) Btk Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 Bruin Study",Previously Treated;;Mantle Cell Lymphoma,Previously Treated Mantle Cell Lymphoma,Previously Treated Mantle Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title contains a specific disease, 'Mantle Cell Lymphoma', and is therefore selected as the primary source over the session title, following the single-source principle.
2. **Component Identification**: From the abstract title, I identified two key components: the disease 'Mantle Cell Lymphoma' and the patient subgroup descriptor 'Previously Treated'.
3. **Rule Retrieval**: To ensure correct formatting for the treatment status, I retrieved rules for the 'Treatment based' category, specifically for the 'Treatment Status' subcategory.
4. **Rule Application**: I applied the generic rules for formatting (Title Case, singular form) and the specific rule (ID: 192) for 'Previously Treated'. This rule dictates that 'Previously Treated' should be normalized to Title Case and placed at the beginning of the indication.
5. **Indication Construction**: The components were combined according to the rules, resulting in 'Previously Treated' followed by the disease name 'Mantle Cell Lymphoma'.
6. **Quality Check**: The final indication adheres to all formatting and exclusion rules. It correctly captures the disease and the specific patient population from the source title without including extraneous information like drug names or study details.","[{'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To correctly format the 'Previously Treated' patient subgroup descriptor.""}]","[{'component': 'Previously Treated', 'type': 'Treatment Status', 'normalized_form': 'Previously Treated', 'rule_applied': ""Rule ID: 192 - Normalize to 'Previously Treated' and place at the start of the indication.""}, {'component': 'Mantle Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Mantle Cell Lymphoma', 'rule_applied': 'Generic Rule - Use Title Case and singular form.'}]",2
393407,Gynaecological Cancers,Mental And Socioeconomic Burden In Co-Parents And Children Of Patients With Endometrial And Cervical Cancer: A Swedish Population-Based Study,Children;;Endometrial;;Cervical Cancer,Childhood Endometrial Cancer;;Childhood Cervical Cancer,Endometrial Cancer;;Cervical Cancer,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains specific disease names ('Endometrial And Cervical Cancer'), which is preferred over the broader term in the session title ('Gynaecological Cancers').
Step 2: Two distinct diseases were identified in the abstract title: 'Endometrial Cancer' and 'Cervical Cancer'.
Step 3: According to the generic rule for multiple diseases, both were extracted and separated by ';;'.
Step 4: Generic formatting rules were applied. The disease names were already in singular form and Title Case, so no changes were needed.
Step 5: Non-diagnostic and sociodemographic information such as 'Mental And Socioeconomic Burden' and 'Swedish Population-Based Study' were excluded as per the exclusion rules.",[],"[{'component': 'Endometrial Cancer', 'type': 'Disease', 'normalized_form': 'Endometrial Cancer', 'rule_applied': 'Generic rule for multiple diseases'}, {'component': 'Cervical Cancer', 'type': 'Disease', 'normalized_form': 'Cervical Cancer', 'rule_applied': 'Generic rule for multiple diseases'}]",1
147649,Acute Myeloid Leukemia - Clinical,Phase 1 First-In-Human Study Of Irreversible Flt3 Inhibitor Ff-10101-01 In Relapsed Or Refractory Acute Myeloid Leukemia,Relapsed;;Refractory;;Acute Myeloid Leukemia,Relapsed/Refractory Acute Myeloid Leukemia,Relapsed/Refractory Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Acute Myeloid Leukemia') and provides more detail than the session title, in accordance with the single-source principle.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Acute Myeloid Leukemia' and the patient subgroup descriptor 'Relapsed Or Refractory'. Other information such as 'Phase 1', 'First-In-Human Study', and drug names ('Ff-10101-01') were identified as non-indication elements to be excluded.
3. **Rule Retrieval**: To correctly format the patient subgroup, I retrieved rules for disease occurrence, specifically for 'Relapse' and 'Refractory' terms, using `get_indication_rules(category='Occurrence', subcategories=['Recurrent/Refractory', 'Refractory', 'Relapse'])`.
4. **Rule Application**: Rule ID 189 was particularly relevant, stating that when 'Relapsed' and 'Refractory' appear together for the same disease, they should be merged into the standardized format 'Relapsed/Refractory'. Generic rules for Title Case and singular form were also applied. The disease term 'Acute Myeloid Leukemia' is already in the correct singular form.
5. **Indication Construction**: The standardized subgroup 'Relapsed/Refractory' was prepended to the disease name 'Acute Myeloid Leukemia' to form the final indication.
6. **Quality Check**: The final indication was checked for compliance with all formatting and exclusion rules. It accurately represents the patient population from the source title, uses correct casing and formatting, and adheres to the single-source principle.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory', 'Refractory', 'Relapse'], 'reason': ""To determine the correct formatting for the term 'Relapsed Or Refractory'.""}]","[{'component': 'Relapsed Or Refractory', 'type': 'Patient Sub-Group', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': ""Occurrence Rule ID 189: Merge 'Relapsed' and 'Refractory' into 'Relapsed/Refractory' when they describe the same disease.""}, {'component': 'Acute Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}]",2
327877,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia,Pediatric;;T-Cell Acute Lymphoblastic Leukemia,Pediatric T-Cell Acute Lymphoblastic Leukemia,Pediatric T-Cell Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: Both the session title ('Acute Lymphoblastic Leukemias...') and the abstract title ('...Pediatric T-Cell Acute Lymphoblastic Leukemia') contain valid disease terms. According to the single-source principle, the abstract title is preferred as it is more specific.
2. **Identify Components**: From the abstract title, I identified the core disease 'T-Cell Acute Lymphoblastic Leukemia', the age group 'Pediatric', and a sociodemographic descriptor 'Genetic Ancestry'.
3. **Retrieve Relevant Rules**: I identified 'Pediatric' as an age group qualifier and retrieved the corresponding rules using `get_indication_rules(category='Age Group', subcategories=['Pediatric'])`.
4. **Apply Rules**: 
   - **Generic Exclusion Rule**: The term 'Genetic Ancestry' was excluded as it is a sociodemographic descriptor.
   - **Age Group Rule (ID: 295)**: The rule for 'Pediatric' confirms it should be used as a prefix for the indication. The phrase 'in Pediatric T-Cell...' is normalized to start with 'Pediatric'.
   - **Formatting Rules**: The final indication is formatted to Title Case and singular form.
5. **Construct Indication**: The components are assembled in the correct order: Age Group + Disease. This results in 'Pediatric T-Cell Acute Lymphoblastic Leukemia'.
6. **Quality Check**: The final indication adheres to all formatting and content rules. It is clinically accurate and derived from a single source.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To ensure correct formatting and placement of the 'Pediatric' age group qualifier.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule (ID: 295) - Retain 'Pediatric' as a leading qualifier.""}, {'component': 'T-Cell Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'T-Cell Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic Rule - Retain core disease term.'}, {'component': 'Genetic Ancestry', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule - Exclude sociodemographic descriptors.'}]",2
311500,Abstracts: Vasculitis - ANCA-Associated,"A Randomized, Double-Blind, Phase II Study of Glucocorticoid Replacement by Vilobelimab, an Anti-C5a Monoclonal Antibody, in ANCA-Associated Vasculitis",ANCA-Associated;;Vasculitis,ANCA-Associated Vasculitis,ANCA-Associated Vasculitis,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a complete and specific medical indication, 'ANCA-Associated Vasculitis'. The session title contains the same information but the abstract title is the preferred source.
Step 2: The core components identified were the disease 'Vasculitis' and the specific subtype 'ANCA-Associated'.
Step 3: No specific category rules were needed for this extraction as 'ANCA-Associated Vasculitis' is a standard, well-defined clinical entity. The generic rules for formatting were sufficient.
Step 4: The generic rules for Title Case and singular form were applied. 'ANCA' is an acronym and was kept in its original uppercase form. 'Associated' and 'Vasculitis' were capitalized. The term is already in singular form.
Step 5: The final indication was constructed by combining the components according to the standard nomenclature.
Step 6: A quality check confirmed that all rules were followed, resulting in the final, clinically accurate indication.","[{'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': 'To check for rules on how associated conditions or subtypes are connected to the main disease, although no specific rule was ultimately applied from this category.'}]","[{'component': 'ANCA-Associated Vasculitis', 'type': 'Disease', 'normalized_form': 'ANCA-Associated Vasculitis', 'rule_applied': 'Generic rule: Title Case. Generic rule: Singular Form.'}]",2
180429,"Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Modified Intensive Induction Treatment for Elderly Acute Myeloid Leukemia Patients Based on Peripheral Blast Clearance Rate: A Phase II Single-Arm Study,Elderly;;Acute Myeloid Leukemia,Elderly Acute Myeloid Leukemia,Elderly Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: Both the abstract title ('Modified Intensive Induction Treatment for Elderly Acute Myeloid Leukemia Patients...') and the session title ('Acute Myeloid Leukemias...') contain the disease term 'Acute Myeloid Leukemia'.
2. **Select Source**: Following the Single-Source Extraction Principle, the abstract title is prioritized as it contains a specific disease.
3. **Identify Components**: From the abstract title, I identified the core disease 'Acute Myeloid Leukemia' and a patient subgroup 'Elderly'. Other phrases like 'Modified Intensive Induction Treatment' and 'A Phase II Single-Arm Study' are excluded as they describe treatment methodology and study design, not the indication itself.
4. **Retrieve Rules**: I identified 'Elderly' as an age-related patient subgroup and retrieved rules for the 'Age Group' category to ensure correct standardization and placement.
5. **Apply Rules**: The generic rules require converting the disease to singular Title Case ('Acute Myeloid Leukemia'). The retrieved 'Age Group' rules (e.g., Rule ID 299) confirm that 'Elderly' should be standardized to 'Elderly' and prepended to the indication.
6. **Construct Indication**: The standardized age group 'Elderly' is combined with the core disease 'Acute Myeloid Leukemia' to form the final indication.
7. **Quality Check**: The final indication 'Elderly Acute Myeloid Leukemia' adheres to all formatting and exclusion rules, correctly capturing the specific patient population and disease from the selected source.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To confirm the standardization and placement of the term 'Elderly' as a patient subgroup qualifier.""}]","[{'component': 'Elderly', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group rule for 'Elderly' (e.g., Rule ID 299)""}, {'component': 'Acute Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Casing and Singular Form rules'}]",2
311504,Abstracts: Vasculitis - ANCA-Associated,Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR <=20 in the Avacopan ADVOCATE Trial,ANCA;;Associated;;Vasculitis,ANCA-Associated Vasculitis,ANCA-Associated Vasculitis,True,abstract_title,"Step 1: The abstract title 'Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR <=20 in the Avacopan ADVOCATE Trial' was chosen as the source because it contains a specific disease, which is the primary requirement.

Step 2: The core disease entity was identified as 'ANCA-Associated Vasculitis'. A patient subgroup 'with Baseline eGFR <=20' was also identified.

Step 3: I retrieved rules for 'Patient Sub-Group' to determine how to handle the subgroup. No specific rule covered clinical measurements like eGFR.

Step 4: The generic rules were applied. The core disease 'ANCA-Associated Vasculitis' was formatted to Title Case. The term 'Patients' was handled by focusing on the disease itself. The subgroup defined by a specific lab value ('Baseline eGFR <=20') was excluded because it represents a highly specific clinical trial inclusion criterion rather than a standardized, concise medical indication suitable for general downstream use. Including such specific values would violate the principle of standardization. Contextual information like 'Recovery of Renal Function' and the trial name 'Avacopan ADVOCATE Trial' were also excluded as per the rules.

Step 5: The final indication 'ANCA-Associated Vasculitis' is clinically accurate, standardized, and correctly formatted.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': 'To check for rules governing the inclusion of patient subgroups based on disease characteristics or clinical measurements like eGFR.'}]","[{'component': 'ANCA-Associated Vasculitis', 'type': 'Disease', 'normalized_form': 'ANCA-Associated Vasculitis', 'rule_applied': 'Generic Casing and Singular Form Rules'}, {'component': 'Patients with Baseline eGFR <=20', 'type': 'Patient Subgroup', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rules - This is a non-standard subgroup descriptor based on a specific lab value from a clinical trial and was excluded to maintain a concise and standardized indication.'}]",4
229586,Neonatal and Fetal Mucosal Immunity,Microbiota drive concomitant expression of IL-17 and the inhibitory receptor PD-1 to regulate effector functions of gd17 cells in the intestine,,,,True,none,"Neither the abstract title nor the session title contains a specific, clinically valid medical indication. The abstract title describes a basic science research finding related to cellular functions in the intestine, and the session title refers to a broad area of immunology ('Mucosal Immunity') within a specific age group ('Neonatal and Fetal'). Neither names a disease or disorder that can be extracted as an indication.",[],[],1
180437,"Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial,Adult;;Newly Diagnosed;;AML,Adult Newly Diagnosed Acute Myeloid Leukemia,Adult Newly Diagnosed Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title ('Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial') and the session title ('Acute Myeloid Leukemias...') both contain a disease term. The Single-Source Extraction Principle dictates using the abstract title as the primary source.
2. **Identify Components**: From the abstract title, I identified the following key components: 'Adults' (Age Group), 'Newly Diagnosed' (Diagnosis Status), and 'AML' (Disease).
3. **Retrieve Relevant Rules**: I retrieved rules for the identified components. For 'Adults', I used `get_indication_rules(category='Age Group', subcategories=['Adult'])`. For 'Newly Diagnosed', I used `get_indication_rules(category='Treatment based', subcategories=['Diagnosis Status'])`.
4. **Apply Rules**: 
   - **Generic Rules**: I applied the singular form rule to 'Adults' -> 'Adult' and the Title Case rule. I also expanded the acronym 'AML' to its full form 'Acute Myeloid Leukemia' for clinical clarity and standardization.
   - **Age Group Rule (ID: 289)**: This rule specifies prefixing the indication with 'Adult'.
   - **Diagnosis Status Rule (ID: 193)**: This rule specifies prefixing the disease with 'Newly Diagnosed'.
5. **Construct Indication**: I assembled the normalized components in the standard clinical order: Age Group -> Diagnosis Status -> Disease. This resulted in 'Adult' + 'Newly Diagnosed' + 'Acute Myeloid Leukemia'.
6. **Quality Check**: The final indication 'Adult Newly Diagnosed Acute Myeloid Leukemia' adheres to all formatting and exclusion rules. It correctly captures the patient subgroup and disease from the selected source without including extraneous study or treatment details.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'Adults' patient subgroup.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To correctly format the 'Newly Diagnosed' qualifier.""}]","[{'component': 'Adults', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group Rule ID: 289; Generic Singular Form Rule'}, {'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': 'Diagnosis Status Rule ID: 193'}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule: Use full disease name over acronym for clarity.'}]",2
377049,Acute myeloid leukemia - Biology & Translational Research,"Therapeutic Potential And Strategies Of Pim447, A Pan-Pim Inhibitor, Targeting Refractory Myeloid Leukemia With Kit-Driven T(8/21)",Refractory;;Myeloid Leukemia,Refractory Myeloid Leukemia,KIT-Driven t(8;21) Refractory Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Myeloid Leukemia') and detailed patient subgroups, making it more informative than the session title, in accordance with the single-source principle.
2. **Component Identification**: The following components were identified in the abstract title: 'Refractory' (disease state), 'Myeloid Leukemia' (core disease), 'Kit-Driven' (genetic driver), and 'T(8/21)' (chromosomal abnormality).
3. **Rule Retrieval**: I retrieved rules for 'Occurrence' to handle 'Refractory', 'Gene type' for 'Kit-Driven', and 'Chromosome type' for 'T(8/21)'.
4. **Rule Application and Normalization**:
   - **Refractory**: The term was standardized to 'Refractory' in Title Case as per Occurrence Rule ID 143.
   - **Kit-Driven**: Based on Gene type Rule ID 50 ('Gene Driven'), this was normalized to 'KIT-Driven', capitalizing the official gene symbol 'KIT' and standardizing the format.
   - **T(8/21)**: This was identified as a specific chromosomal translocation. While no explicit rule existed for this format, it was normalized to the standard cytogenetic notation 't(8;21)' to ensure clinical accuracy and represent this critical patient subgroup.
   - **Myeloid Leukemia**: The core disease was formatted to 'Myeloid Leukemia' using Title Case and singular form as required by generic rules.
5. **Indication Construction**: The normalized components were assembled in a clinically logical order, starting with the most specific genetic and cytogenetic characteristics, followed by the disease state and the core disease. This resulted in the final, precise indication.","[{'category': 'Occurrence', 'subcategories': ['Refractory'], 'reason': ""To correctly format the disease state 'Refractory'.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To find the rule for handling 'Kit-Driven' and normalize the gene name and format.""}, {'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To check for rules on handling chromosomal translocations like 'T(8/21)'.""}]","[{'component': 'Refractory', 'type': 'Disease State', 'normalized_form': 'Refractory', 'rule_applied': 'Occurrence Rule ID 143'}, {'component': 'Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Myeloid Leukemia', 'rule_applied': 'Generic Rules (Title Case, Singular Form)'}, {'component': 'Kit-Driven', 'type': 'Gene Driver', 'normalized_form': 'KIT-Driven', 'rule_applied': 'Gene type Rule ID 50'}, {'component': 'T(8/21)', 'type': 'Chromosomal Translocation', 'normalized_form': 't(8;21)', 'rule_applied': 'Normalization to standard clinical cytogenetic notation for accuracy, as no specific rule was found.'}]",2
180442,"Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I","Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study",Adults;;Newly Diagnosed;;Acute Myeloid Leukemia,Adult Newly Diagnosed Acute Myeloid Leukemia,Adult Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title as it contains a more specific description of the disease and patient population, adhering to the single-source principle.
2.  **Component Identification**: The following components were identified in the abstract title: 'Adults' (Age Group), 'Newly Diagnosed' (Diagnosis Status), 'Acute Myeloid Leukemia' (Disease), and 'Unfit for Intensive Therapy' (Patient Subgroup).
3.  **Rule Retrieval**: Rules were retrieved for 'Age Group' ('Adult'), 'Treatment based' ('Diagnosis Status'), and 'Patient Sub-Group'.
4.  **Rule Application & Construction**:
    *   The generic rule for singularization was applied to 'Leukemias' from the session title, although the abstract title already used the singular 'Leukemia'.
    *   The generic rule for Title Casing was applied to all components.
    *   The specific rule for 'Adult' (ID: 289) was applied, placing 'Adult' as a leading descriptor.
    *   The specific rule for 'Newly Diagnosed' (ID: 193) was applied, placing it as a prefix before the disease.
    *   'Unfit for Intensive Therapy' was identified as a critical, clinically valid patient subgroup that defines the study population and was included in Title Case.
5.  **Final Assembly**: The components were assembled in a clinically logical order, reflecting the phrasing in the source title: Age Group -> Diagnosis Status -> Disease -> Subgroup. This resulted in the final indication: 'Adult Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy'.
6.  **Quality Check**: The final indication was verified against all generic and specific rules, ensuring it is correctly formatted, clinically accurate, and derived from a single source.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To handle the 'Adults' patient descriptor.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To handle the 'Newly Diagnosed' descriptor.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding patient fitness status like 'Unfit for Intensive Therapy'.""}]","[{'component': 'Adults', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group Rule ID: 289 - Prepend 'Adult' in title case.""}, {'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Treatment based Rule ID: 193 - Prepend 'Newly Diagnosed' in title case.""}, {'component': 'Acute Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule: Title Case and Singular Form.'}, {'component': 'Unfit for Intensive Therapy', 'type': 'Patient Subgroup', 'normalized_form': 'Unfit for Intensive Therapy', 'rule_applied': 'Generic Rule: Inclusion of clinically valid patient subgroups and applying Title Case.'}]",2
295132,"The three ""Ws"" of early breast cancer management","Neo-adjuvant therapy in luminal breast cancer: Who to treat, which regimen, and what duration?",luminal breast cancer,Luminal Breast Cancer,Luminal Breast Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the session title ('early breast cancer') and the abstract title ('luminal breast cancer') contain a valid disease. According to the single-source principle, the abstract title is prioritized. Therefore, 'Neo-adjuvant therapy in luminal breast cancer' was chosen as the source.
2.  **Component Identification**: The selected title contains the components 'Neo-adjuvant therapy' (treatment context), 'luminal' (patient subgroup/disease characterization), and 'breast cancer' (disease).
3.  **Rule Retrieval**: Rules for 'Patient Sub-Group' and 'Treatment Set-up' were retrieved to determine how to handle 'luminal' and 'neo-adjuvant'.
4.  **Rule Application**: 
    *   The generic exclusion rules and specific rules for treatment modalities (like 'Monotherapy') indicate that treatment context such as 'Neo-adjuvant therapy' should be excluded from the final indication.
    *   'Luminal' is a clinically significant subtype of breast cancer and is retained as a patient subgroup qualifier.
    *   The generic formatting rules for Title Case and singular form were applied.
5.  **Indication Construction**: The subgroup 'Luminal' was prepended to the core disease 'Breast Cancer', resulting in 'Luminal Breast Cancer'.
6.  **Quality Check**: The final indication adheres to all formatting and content rules, correctly excluding the treatment modality while retaining the specific disease subtype.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To determine if 'luminal' should be included as a disease characteristic.""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Modality'], 'reason': ""To confirm that 'Neo-adjuvant therapy' as a treatment modality should be excluded.""}]","[{'component': 'luminal breast cancer', 'type': 'Disease with Subgroup', 'normalized_form': 'Luminal Breast Cancer', 'rule_applied': 'Generic Title Case rule; Inclusion of clinically significant subgroup.'}, {'component': 'Neo-adjuvant therapy', 'type': 'Treatment Modality', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
147677,Acute Myeloid Leukemia - Clinical,Validation And Clinical Application Of An Unsupervised Analysis Approach To Measurable Residual Disease Testing In Acute Myeloid Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract title and session title contain the disease term 'Acute Myeloid Leukemia'. Following the Single-Source Extraction Principle, the abstract title is prioritized.
2.  **Component Identification**: The core disease identified in the abstract title is 'Acute Myeloid Leukemia'. The phrase 'Measurable Residual Disease Testing' is identified as a methodology or a diagnostic procedure, not a patient subgroup or disease characteristic.
3.  **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' under 'Disease Characterisation' to verify if terms like 'Measurable Residual Disease' should be included. No specific rule mandated its inclusion, confirming it should be treated as a non-diagnostic item.
4.  **Rule Application**: 
    *   **Generic Exclusion Rule**: The term 'Measurable Residual Disease Testing' was excluded as it describes a study methodology, not a clinical indication.
    *   **Generic Casing Rule**: The indication was converted to Title Case.
    *   **Clinical Accuracy**: A common misspelling of 'Myloid' was corrected to the clinically accurate term 'Myeloid'.
    *   **Generic Singular Form Rule**: 'Leukemia' is already in singular form.
5.  **Indication Construction**: Based on the identified disease and application of rules, the final indication is constructed as 'Acute Myeloid Leukemia'.
6.  **Quality Check**: The final output adheres to all formatting and clinical accuracy requirements. It is derived from a single source and correctly excludes non-indicative information.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check if 'Measurable Residual Disease' is a valid patient subgroup or disease characterization that should be included in the indication.""}]","[{'component': 'Acute Myloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Casing Rule, Clinical Accuracy (Spelling Correction)'}, {'component': 'Measurable Residual Disease Testing', 'type': 'Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items'}]",2
180445,"Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation,Newly Diagnosed;;AML;;IDH1;;IDH2 Mutation,IDH1-Mutated IDH2-Mutated Newly Diagnosed Acute Myeloid Leukemia,Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia;;Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease (AML) and patient subgroups, which is preferred over the session title.
2. **Component Identification**: The key components identified in the abstract title are 'Newly Diagnosed', 'AML' (Acute Myeloid Leukemia), and 'IDH1 or IDH2 Mutation'.
3. **Rule Retrieval**: Rules for 'Diagnosis Status' (Newly Diagnosed) and 'Gene type' (Mutation) were retrieved to ensure correct formatting.
4. **Rule Application and Normalization**:
   - 'AML' was expanded to its full form 'Acute Myeloid Leukemia' and converted to Title Case.
   - The 'Diagnosis Status' rule (ID: 193) was applied to prefix 'Newly Diagnosed' to the disease.
   - The 'Gene Mutation' rule (ID: 30) was applied to format 'IDH1 Mutation' and 'IDH2 Mutation' into 'IDH1-Mutated' and 'IDH2-Mutated' respectively.
   - The presence of 'or' between 'IDH1' and 'IDH2' indicates two distinct patient populations. Therefore, two separate indications were generated.
5. **Indication Construction**: The normalized components were combined to form two distinct indications: 'Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia' and 'Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia'.
6. **Final Formatting**: The two indications were joined using the required ';;' separator as per the generic formatting rules.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To correctly format the 'Newly Diagnosed' qualifier.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the 'IDH1' and 'IDH2' mutations.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}, {'component': 'IDH1 Mutation', 'type': 'Gene Mutation', 'normalized_form': 'IDH1-Mutated', 'rule_applied': 'Rule ID: 30 - Format as <GENE>-Mutated.'}, {'component': 'IDH2 Mutation', 'type': 'Gene Mutation', 'normalized_form': 'IDH2-Mutated', 'rule_applied': 'Rule ID: 30 - Format as <GENE>-Mutated.'}]",2
327904,Lymphomas: Translational-Molecular and Genetic: Poster II,BCL6 Rearranged Indolent B-Cell Lymphomas Show Mutational Profile Similar to Marginal Zone Lymphomas,BCL6;;Rearranged;;Indolent B-Cell Lymphomas;;Marginal Zone Lymphomas,BCL6-Rearranged Indolent B-Cell Lymphoma;;Marginal Zone Lymphoma,BCL6-Rearranged Indolent B-Cell Lymphoma;;Marginal Zone Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('BCL6 Rearranged Indolent B-Cell Lymphomas Show Mutational Profile Similar to Marginal Zone Lymphomas') was chosen over the session title ('Lymphomas: Translational-Molecular and Genetic: Poster II') because it contains more specific disease information, adhering to the single-source principle.
2. **Component Identification**: The abstract title identifies two distinct diseases for comparison: 'BCL6 Rearranged Indolent B-Cell Lymphomas' and 'Marginal Zone Lymphomas'.
3. **Rule Retrieval**: I retrieved rules for 'Gene Name' to handle 'BCL6 Rearranged' and for 'Patient Sub-Group' to check the validity of including 'Indolent'.
4. **Rule Application**:
   - **Gene Name**: Based on the retrieved rules (specifically Rule ID 27), a gene name with a functional qualifier like 'rearranged' should be included. The standard format is '<GeneSymbol>-<Qualifier>', leading to 'BCL6-Rearranged'.
   - **Disease Characterization**: 'Indolent' is a clinically significant descriptor for B-Cell Lymphoma, defining a specific subtype. Therefore, it was retained.
   - **Multiple Diseases**: The phrase 'Similar to' indicates a comparison between two distinct clinical entities. The generic rule for multiple diseases was applied, requiring the extraction of both and separating them with ';;'.
   - **Generic Rules**: The plural 'Lymphomas' was converted to its singular form 'Lymphoma' for both indications. Title Case was applied to all clinically significant words.
5. **Indication Construction**: 
   - The first indication was constructed by combining the formatted gene qualifier with the disease name: 'BCL6-Rearranged' + 'Indolent B-Cell Lymphoma'.
   - The second indication was the normalized disease name: 'Marginal Zone Lymphoma'.
   - The two indications were combined using the ';;' separator.
6. **Final Quality Check**: The final output was reviewed for adherence to all formatting, clinical accuracy, and source selection rules. The resulting indication accurately reflects the two distinct lymphoma types discussed in the title.","[{'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To determine how to format the 'BCL6 Rearranged' component.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify if 'Indolent' is a valid clinical descriptor to be included in the indication.""}, {'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To confirm the correct procedure for handling titles that compare two distinct diseases.'}]","[{'component': 'BCL6 Rearranged', 'type': 'Gene Rearrangement', 'normalized_form': 'BCL6-Rearranged', 'rule_applied': 'Gene Name Rule ID 27: Retain gene with functional qualifier, format as <GeneSymbol>-<Qualifier>.'}, {'component': 'Indolent B-Cell Lymphomas', 'type': 'Disease', 'normalized_form': 'Indolent B-Cell Lymphoma', 'rule_applied': ""Generic Rule: Convert to singular form. Retained 'Indolent' as it is a key clinical characteristic.""}, {'component': 'Marginal Zone Lymphomas', 'type': 'Disease', 'normalized_form': 'Marginal Zone Lymphoma', 'rule_applied': 'Generic Rule: Convert to singular form.'}]",2
409825,Winning Team: The Nephrology Workforce for the 21st Century,Advocacy and Policy: What Can Nephrologists and National Organizations Do?,,,Kidney Disease,True,session_title,"Step 1: The abstract title 'Advocacy and Policy: What Can Nephrologists and National Organizations Do?' does not contain a specific disease, but rather a professional role. Step 2: The session title 'Winning Team: The Nephrology Workforce for the 21st Century' contains the therapeutic area 'Nephrology'. Step 3: According to the generic rules (Therapeutic Area Fallback), when a title only names a therapeutic area, the corresponding overarching disease should be used. For 'Nephrology', the standard overarching disease is 'Kidney Disease'. Step 4: The indication is formatted to 'Kidney Disease' following Title Case and singular form rules.",[],"[{'component': 'Nephrology', 'type': 'Therapeutic Area', 'normalized_form': 'Kidney Disease', 'rule_applied': 'Therapeutic Area Fallback'}]",1
147689,Acute Myeloid Leukemia - Clinical,Induced Systemic T-Cell Specific Responses To Multiple Tumor-Associated Antigens After Allogenic Leukemia-Derived Dendritic Cell Vaccine Dcp-001 In Aml Patients With Persistent Mrd,Aml,Acute Myeloid Leukemia,Persistent MRD Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The session title is 'Acute Myeloid Leukemia - Clinical'. The abstract title is 'Induced Systemic T-Cell Specific Responses To Multiple Tumor-Associated Antigens After Allogenic Leukemia-Derived Dendritic Cell Vaccine Dcp-001 In Aml Patients With Persistent Mrd'.
2.  **Select Source**: Both titles contain a disease term ('Acute Myeloid Leukemia' and its abbreviation 'Aml'). According to the single-source principle, the abstract title is preferred as it is more specific.
3.  **Identify Components**: From the abstract title, I identified the core disease 'Aml' and a specific patient subgroup 'Patients With Persistent Mrd'. 'Aml' is the standard abbreviation for 'Acute Myeloid Leukemia'. 'MRD' stands for 'Minimal Residual Disease', and 'Persistent MRD' is a clinically significant descriptor of the disease state, defining a specific patient cohort.
4.  **Retrieve Rules**: I retrieved rules for the 'Patient Sub-Group' category with the 'Disease Characterisation' subcategory to check for guidance on terms like 'Persistent'. While no specific rule for 'Persistent' or 'MRD' was found, the general principle is to include clinically significant descriptors that define a subgroup.
5.  **Apply Rules & Construct Indication**: 
    *   The disease 'Aml' was expanded to its full name: 'Acute Myeloid Leukemia'.
    *   The patient subgroup 'Persistent Mrd' was identified as a key qualifier.
    *   Generic formatting rules were applied: The qualifier is placed before the disease name. The connector 'With' is removed. The final string is converted to Title Case, keeping the acronym 'MRD' in its original uppercase form.
    *   Procedural details ('After Allogenic Leukemia-Derived Dendritic Cell Vaccine') and general terms ('Patients') were excluded as per the generic exclusion rules.
6.  **Quality Check**: The final indication 'Persistent MRD Acute Myeloid Leukemia' is derived solely from the abstract title, is in the correct format (Title Case, singular), includes the specific patient subgroup, and excludes irrelevant information. It is a clinically valid and accurate representation of the patient population described.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules governing disease state qualifiers like 'Persistent'.""}]","[{'component': 'Aml', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Standard medical abbreviation expansion.'}, {'component': 'Patients With Persistent Mrd', 'type': 'Patient Sub-Group', 'normalized_form': 'Persistent MRD', 'rule_applied': ""Inclusion of clinically significant disease state qualifier. Kept 'MRD' as an uppercase acronym.""}]",2
180465,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Integrated Transcriptomics and Proteomics Identifies Therapeutic Targets in Pediatric Acute Myeloid Leukemia,Pediatric;;Acute Myeloid Leukemia,Pediatric Acute Myeloid Leukemia,Pediatric Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: Both the session title ('Acute Myeloid Leukemias...') and the abstract title ('...Pediatric Acute Myeloid Leukemia') contain a valid disease term.
2. **Select Source**: According to the single-source principle, the abstract title is preferred as it contains the more specific indication by including a patient subgroup ('Pediatric').
3. **Identify Components**: From the abstract title, the core components are the age group 'Pediatric' and the disease 'Acute Myeloid Leukemia'. The other parts of the title describe methodology ('Integrated Transcriptomics and Proteomics') and are excluded.
4. **Retrieve Rules**: To ensure correct formatting for the age group, I retrieved rules for the 'Age Group' category, specifically for 'Pediatric'.
5. **Apply Rules**: The retrieved rules (e.g., Rule ID 295) confirm that 'Pediatric' should be used as a prefix to the disease name, in Title Case. The generic rule for singular form is applied to 'Leukemia' (which was already singular in the chosen source). The generic rule for Title Case is also applied.
6. **Construct Indication**: The components are combined as per the rules, resulting in 'Pediatric Acute Myeloid Leukemia'.
7. **Quality Check**: The final indication adheres to all formatting and content rules. It is derived from a single source, uses Title Case, is in singular form, and correctly includes the patient subgroup.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To validate the correct formatting and placement of the 'Pediatric' age group qualifier.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule for 'Pediatric' (ID: 295)""}, {'component': 'Acute Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic rule for Title Case and Singular Form.'}]",2
409842,Collagen IV Conundrums: Genetic Variants and Clinical Management,Do All Collagen Variants Cause Glomerular Disease?,,,Collagen Variant Glomerular Disease,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Do All Collagen Variants Cause Glomerular Disease?') was chosen as the source because it contains a specific disease term ('Glomerular Disease'), which is preferred over the session title according to the single-source principle.
2. **Component Identification**: I identified two key components in the abstract title: the core disease, 'Glomerular Disease', and the patient subgroup qualifier, 'Collagen Variants'.
3. **Rule Retrieval**: I retrieved rules for 'Gene type' and 'Patient Sub-Group' to determine the correct formatting for genetic qualifiers. Although no specific rule for 'Variant' was found, I applied the general principles of standardization derived from similar rules.
4. **Rule Application**: I applied the generic rules. The 'Singular Form' rule was applied to the qualifier 'Variants', converting it to 'Variant'. The 'Title Case' rule was applied to format the final indication.
5. **Indication Construction**: The patient subgroup qualifier was prepended to the core disease name, following the standard structure for indications (e.g., 'KRAS-Mutated Cancer'). This resulted in the final indication: 'Collagen Variant Glomerular Disease'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To check for rules regarding genetic patient characteristics like 'variants'.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To find rules on how to format genetic alterations, which is analogous to 'variants'.""}]","[{'component': 'Collagen Variants', 'type': 'Patient Subgroup (Genetic)', 'normalized_form': 'Collagen Variant', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'Glomerular Disease', 'type': 'Disease', 'normalized_form': 'Glomerular Disease', 'rule_applied': 'Generic Rule: Title Case'}]",2
164086,LBA01: Late-breaking Abstract I - Benign,Randomized control trial of ultrasonic propulsion to facilitate clearance of chronic residual fragments,,,Chronic Residual Fragment,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Randomized control trial of ultrasonic propulsion to facilitate clearance of chronic residual fragments'. The session title is 'LBA01: Late-breaking Abstract I - Benign'.
2. **Select Source**: According to the single-source principle, the abstract title is preferred as it contains a specific medical condition ('chronic residual fragments'). The session title's term 'Benign' is too generic and lacks a specific disease context.
3. **Identify Components**: The key phrase identified in the abstract title is 'chronic residual fragments'.
4. **Retrieve Rules**: I retrieved rules for 'Patient Sub-Group' and 'Disease Characterisation' to check for any specific guidance on terms like 'residual' or 'chronic'. The generic rules for 'Chronic' are most relevant.
5. **Apply Rules**: 
   - **Generic Rule (Chronic)**: The term 'chronic' is included as it is part of the condition's name, describing its persistent nature, not the duration of a treatment.
   - **Generic Rule (Singular Form)**: The plural 'fragments' is converted to its singular form, 'Fragment'.
   - **Generic Rule (Title Case)**: The final indication is formatted in Title Case.
6. **Construct Indication**: Combining the components after applying the rules results in 'Chronic Residual Fragment'.
7. **Quality Check**: The final indication is derived from a single source, correctly formatted, and accurately represents the clinical condition targeted by the intervention in the study.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for specific rules regarding disease characterization terms like 'residual' or 'chronic'.""}]","[{'component': 'chronic residual fragments', 'type': 'Condition', 'normalized_form': 'Chronic Residual Fragment', 'rule_applied': 'Generic Rule (Chronic), Generic Rule (Singular Form), Generic Rule (Title Case)'}]",2
327929,Lymphomas: Translational-Molecular and Genetic: Poster III,Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas,B-Cell Lymphomas,B-Cell Lymphoma,B-Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease term ('B-Cell Lymphomas'), which is more precise than the session title ('Lymphomas').
2. **Component Identification**: The key components identified in the abstract title are 'B-Cell' (a patient subgroup) and 'Lymphomas' (the disease).
3. **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' with the subcategory 'B-Cell Precursor' to confirm how to handle 'B-Cell'. The rules indicate that 'B-Cell' should be retained as it is part of the disease name.
4. **Rule Application**: 
   - The generic rule for singular form was applied, converting 'Lymphomas' to 'Lymphoma'.
   - The generic rule for Title Case was applied, resulting in 'B-Cell Lymphoma'.
   - The generic exclusion rule was applied to remove non-diagnostic, methodological terms like 'Genome-Wide Methylation' and 'Haplotype-Resolved Aberrant Somatic Hypermutation Patterns'.
5. **Indication Construction**: The identified and normalized components were combined to form the final indication 'B-Cell Lymphoma'.
6. **Quality Check**: The final indication adheres to all formatting and clinical accuracy requirements. It is derived from a single source and correctly captures the specific disease entity mentioned.","[{'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To verify the correct handling and formatting of the 'B-Cell' qualifier in the disease name.""}]","[{'component': 'B-Cell Lymphomas', 'type': 'Disease', 'normalized_form': 'B-Cell Lymphoma', 'rule_applied': ""Generic rule for singular form; Patient Sub-Group rule for retaining 'B-Cell'.""}]",2
180473,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Evolution of Genomic Landscape in Acute Myeloid Leukemia after Decitabine and Venetoclax,Acute Myeloid Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: Both the abstract title and session title contain the disease term 'Acute Myeloid Leukemia'. Following the single-source principle, the abstract title is prioritized.
2. **Component Identification**: The abstract title contains the disease 'Acute Myeloid Leukemia' and a treatment context 'after Decitabine and Venetoclax'.
3. **Rule Retrieval**: I retrieved rules for 'Treatment Set-up' and 'Treatment Status' to determine how to handle the phrase 'after Decitabine and Venetoclax'.
4. **Rule Application**: The generic exclusion rules specify removing procedural or temporal qualifiers. The retrieved rules for 'Post-Treatment' (ID 234, 235) confirm that such temporal treatment statuses should be excluded as they do not define a distinct clinical indication. Therefore, the phrase 'after Decitabine and Venetoclax' is excluded.
5. **Indication Construction**: The core disease 'Acute Myeloid Leukemia' is extracted.
6. **Formatting**: The indication is already in the correct singular form and Title Case as per the generic rules.
7. **Final Output**: The final generated indication is 'Acute Myeloid Leukemia'.","[{'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To determine how to handle the treatment context 'after Decitabine and Venetoclax'.""}]","[{'component': 'Acute Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'after Decitabine and Venetoclax', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': ""Generic exclusion rule for procedural/temporal qualifiers and specific rule logic for 'Post-Treatment' (ID 234, 235).""}]",2
180478,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Duplex-Sequencing Uncovers Low-Frequency Mutations in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia,KMT2A-Rearranged;;Infant;;Acute Lymphoblastic Leukemia,KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia,Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Duplex-Sequencing Uncovers Low-Frequency Mutations in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia') was chosen over the session title because it contains a more specific and complete description of the disease and patient population, adhering to the single-source principle.
2.  **Component Identification**: The following components were identified in the abstract title:
    *   Disease: 'Acute Lymphoblastic Leukemia'
    *   Gene Rearrangement: 'KMT2A-Rearranged'
    *   Age Group: 'Infant'
    *   Research Finding (to be excluded): 'Low-Frequency Mutations'
3.  **Rule Retrieval**: Rules for 'Gene type' and 'Age Group' were retrieved to ensure correct formatting.
    *   The 'Gene type' rule for rearrangements (ID: 47, 48) confirms that the format '<Gene>-Rearranged' is correct. 'KMT2A-Rearranged' already adheres to this.
    *   No specific rule was found for 'Infant', so the generic rule to include explicit patient subgroups was applied.
4.  **Rule Application & Construction**: 
    *   The generic exclusion rule was applied to remove 'Low-Frequency Mutations' as it describes a research finding, not a defining characteristic of the indication.
    *   The generic formatting rules for Title Case and singular form were applied. 'Leukemia' is already singular.
    *   The components were assembled in a clinically logical order: Age Group + Gene Rearrangement + Disease Name.
5.  **Final Indication**: The final indication was constructed as 'Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia'.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To validate the formatting for the 'KMT2A-Rearranged' component.""}, {'category': 'Age Group', 'subcategories': ['Infant'], 'reason': ""To check for specific rules regarding the 'Infant' age group qualifier.""}]","[{'component': 'KMT2A-Rearranged', 'type': 'Gene Rearrangement', 'normalized_form': 'KMT2A-Rearranged', 'rule_applied': 'Gene type rule for rearrangements (ID: 47, 48)'}, {'component': 'Infant', 'type': 'Age Group', 'normalized_form': 'Infant', 'rule_applied': 'Generic rule to include patient subgroups.'}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
213248,Society of Benign Prostate Disease,"BPH Guidelines: Conflict and Contrast in the AUA, EAU, NICE BPH Guidelines",BPH,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease term ('BPH').
Step 2: The component 'BPH' was identified as the core disease.
Step 3: Generic rules were applied. The acronym 'BPH' was expanded to its full, standardized medical term 'Benign Prostatic Hyperplasia'.
Step 4: Title Case formatting was applied to the final indication.
Step 5: The remaining parts of the title ('Guidelines: Conflict and Contrast in the AUA, EAU, NICE BPH Guidelines') were excluded as they refer to organizations and study context, not the clinical indication itself.","[{'category': 'Patient Sub-Group', 'subcategories': ['Prostate'], 'reason': 'To check for specific rules regarding prostate-related conditions like BPH. No specific rules were found, so generic rules were applied.'}]","[{'component': 'BPH', 'type': 'Disease', 'normalized_form': 'Benign Prostatic Hyperplasia', 'rule_applied': 'Standard medical acronym expansion and Title Case formatting.'}]",2
377088,Infections in hematology (incl. supportive care/therapy),Clinical Characteristics Of Patients With Prolonged Viral Shedding Of Omicron Variant In Haematological Disease,Haematological Disease,Haematological Disease,VIRTUAL_ASSISTANT_API_CALL-get_indication_rules{category:<ctrl46>Patient with two different Disease<ctrl46>},True,,,[],[],1
295167,Thermo Fisher Scientific - Connecting patients everywhere to precision oncology,Circulating tumour DNA for monitoring of response to neoadjuvant chemotherapy in patients with high grade serous ovarian carcinoma,high grade;;serous ovarian carcinoma,High Grade Serous Ovarian Carcinoma,High Grade Serous Ovarian Carcinoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Circulating tumour DNA for monitoring of response to neoadjuvant chemotherapy in patients with high grade serous ovarian carcinoma' was chosen as it contains a specific disease, 'high grade serous ovarian carcinoma', which is more precise than the therapeutic area 'oncology' mentioned in the session title.
2. **Component Identification**: The key components identified in the abstract title were 'high grade' (Grade), 'serous' (Histological Subtype), and 'ovarian carcinoma' (Disease).
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for the 'Grade' category, specifically for 'High Grade'. I also retrieved rules for 'Treatment Set-up' to determine how to handle 'neoadjuvant chemotherapy'.
4. **Rule Application**: 
   - The retrieved rule for 'High Grade' (ID: 115) dictates standardizing the term to 'High Grade' with leading capitals and no hyphen.
   - No specific rule was found for including 'neoadjuvant'. Therefore, per the generic exclusion rules for procedural/temporal qualifiers, 'neoadjuvant chemotherapy' was excluded as it describes a treatment setting rather than a core part of the indication.
   - The generic rule for singular form was applied, although 'carcinoma' is already singular.
   - The generic rule for Title Case was applied to the final indication.
5. **Indication Construction**: The components were assembled in the correct clinical order: Grade -> Subtype -> Disease. This resulted in 'High Grade Serous Ovarian Carcinoma'.
6. **Quality Check**: The final indication adheres to the single-source principle, uses Title Case, is in singular form, and correctly excludes non-indicative terms, resulting in a clinically accurate and well-formatted output.","[{'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To correctly format the 'high grade' component.""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To determine if 'neoadjuvant chemotherapy' should be included in the indication.""}]","[{'component': 'high grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Grade Rule ID: 115 - Standardize to 'High Grade' with leading capitals and no hyphen.""}, {'component': 'serous', 'type': 'Histological Subtype', 'normalized_form': 'Serous', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'ovarian carcinoma', 'type': 'Disease', 'normalized_form': 'Ovarian Carcinoma', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Singular Form (already singular)'}, {'component': 'neoadjuvant chemotherapy', 'type': 'Treatment Modality', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers as no specific inclusion rule was found.'}]",2
164102,LBA02: Late-breaking Abstract II - Malignant,MRI-guided Focused Ultrasound (MRgFUS) Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results of a Phase IIb Multicenter Study,Intermediate-Risk;;Prostate Cancer,Intermediate-Risk Prostate Cancer,Intermediate-Risk Prostate Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('MRI-guided Focused Ultrasound (MRgFUS) Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results of a Phase IIb Multicenter Study') was chosen as it contains a specific disease ('Prostate Cancer'), whereas the session title ('LBA02: Late-breaking Abstract II - Malignant') is too general.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Prostate Cancer' and the patient subgroup qualifier 'Intermediate-Risk'. The terms 'MRI-guided Focused Ultrasound (MRgFUS) Focal Therapy' and 'Final Results of a Phase IIb Multicenter Study' were identified as a procedure and study methodology, respectively, and marked for exclusion based on generic rules.
3. **Rule Retrieval**: To ensure correct formatting for the risk qualifier, I retrieved rules for the 'Risk' category, specifically for 'Risk Types'.
4. **Rule Application**: The retrieved rule (ID: 129) for 'Intermediate-Risk' confirmed that the term should be standardized to 'Intermediate-Risk' and prepended to the disease name. Generic rules were applied to convert the disease to singular form (already singular) and Title Case, and to exclude procedural and study-related information.
5. **Indication Construction**: The qualifier 'Intermediate-Risk' was combined with the disease 'Prostate Cancer' to form the final indication.
6. **Quality Check**: The final indication 'Intermediate-Risk Prostate Cancer' adheres to all formatting and clinical accuracy requirements. It correctly captures the specific patient population for the study.","[{'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To correctly format the 'Intermediate-Risk' qualifier and determine its placement relative to the disease name.""}]","[{'component': 'Intermediate-Risk', 'type': 'Risk Qualifier', 'normalized_form': 'Intermediate-Risk', 'rule_applied': 'Rule ID: 129 - Standardize and prepend risk term to the disease.'}, {'component': 'Prostate Cancer', 'type': 'Disease', 'normalized_form': 'Prostate Cancer', 'rule_applied': 'Generic Rule - Use singular form and Title Case.'}, {'component': 'MRI-guided Focused Ultrasound (MRgFUS) Focal Therapy', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule - Exclude procedural/temporal qualifiers.'}]",2
213255,Society of Benign Prostate Disease,Microbiome and BPH,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Microbiome and BPH' and the session title is 'Society of Benign Prostate Disease'.
2. **Select Source**: Both titles contain a disease term ('BPH' in the abstract title and 'Benign Prostate Disease' in the session title). According to the single-source principle, the abstract title is preferred.
3. **Identify Components**: The key component in the abstract title is 'BPH'. 'Microbiome' is a field of study and not part of the indication.
4. **Retrieve Rules**: I retrieved rules for 'Disease Characterisation' to ensure proper handling of disease terms. While no specific rule for 'BPH' was found, the general principle of using standardized clinical nomenclature applies.
5. **Apply Rules & Construct Indication**: 'BPH' is a common medical abbreviation for 'Benign Prostatic Hyperplasia'. I expanded the abbreviation to its full, standardized medical term. I then applied the generic formatting rules: Title Case ('Benign Prostatic Hyperplasia') and ensured it was in singular form (which it already is).
6. **Quality Check**: The final indication 'Benign Prostatic Hyperplasia' is clinically accurate, derived solely from the preferred source (abstract title), and correctly formatted.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': 'To check for rules on handling specific disease names or abbreviations like BPH.'}]","[{'component': 'BPH', 'type': 'Disease', 'normalized_form': 'Benign Prostatic Hyperplasia', 'rule_applied': 'Standard medical abbreviation expansion and Title Case formatting rule.'}]",2
311555,Adult Thieves Market Poster,Itchy Rash and Starry Eyed,,,,True,none,"Neither the abstract title nor the session title contains a clinically valid medical indication. The abstract title 'Itchy Rash and Starry Eyed' describes symptoms or non-clinical observations, not a specific disease. The session title 'Adult Thieves Market Poster' is non-medical. According to the guidelines, an indication cannot be extracted from symptoms alone.",[],"[{'component': 'Itchy Rash', 'type': 'Symptom', 'normalized_form': 'Itchy Rash', 'rule_applied': 'Exclusion Rules: Isolated symptoms are excluded.'}]",1
213252,Society of Benign Prostate Disease,Rapid Fire,Benign;;Prostate Disease,Benign Prostate Disease,Benign Prostate Disease,True,session_title,"Step 1: The abstract title 'Rapid Fire' does not contain any medical disease or condition. 
Step 2: Following the single-source extraction principle, I fell back to the session title, 'Society of Benign Prostate Disease', which contains a valid disease term.
Step 3: I identified the core disease term 'Benign Prostate Disease' from the session title.
Step 4: I applied generic rules. The organizational prefix 'Society of' was excluded as it is not part of the indication. The term 'Benign' is an integral part of the disease name and was retained. The indication was already in singular form and Title Case.
Step 5: The final indication was constructed as 'Benign Prostate Disease'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check if 'Benign' is a standard disease characterizer that should be included or excluded. No specific rule for 'Benign' was found, so the default is to include it as it is a clinically accepted part of the disease name.""}]","[{'component': 'Benign Prostate Disease', 'type': 'Disease', 'normalized_form': 'Benign Prostate Disease', 'rule_applied': ""Generic Rule: Exclude non-disease organizational terms ('Society of'). Generic Rule: Retain core clinical descriptors ('Benign').""}]",2
377096,Acute myeloid leukemia - Clinical,"Azacitidine, Venetoclax And Gilteritinib For Patients With Newly Diagnosed Flt3-Mutated Acute Myeloid Leukemia: A Subgroup Analysis From A Phase Ii Study",Newly Diagnosed;;Flt3-Mutated;;Acute Myeloid Leukemia,Newly Diagnosed Flt3-Mutated Acute Myeloid Leukemia,Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Acute Myeloid Leukemia') and detailed patient subgroup information ('Newly Diagnosed', 'Flt3-Mutated'), making it more comprehensive than the session title.
2. **Component Identification**: I identified three key components in the abstract title: the disease 'Acute Myeloid Leukemia', the diagnosis status 'Newly Diagnosed', and the gene mutation 'Flt3-Mutated'. Drug names and study-related phrases were marked for exclusion.
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for gene mutations and diagnosis status. 
   - `get_indication_rules(category=""Gene type"", subcategories=[""Gene type""])` was used for 'Flt3-Mutated'.
   - `get_indication_rules(category=""Treatment based"", subcategories=[""Diagnosis Status""])` was used for 'Newly Diagnosed'.
4. **Rule Application**:
   - **Generic Rules**: Applied Title Case and singular form to the disease. Excluded non-indication terms like drug names ('Azacitidine, Venetoclax And Gilteritinib') and study descriptors ('A Subgroup Analysis From A Phase Ii Study').
   - **Gene Type Rule**: Based on the retrieved rule (ID: 32), the format '<GENE>-Mutated' is correct. I normalized the gene name 'Flt3' to its standard HGNC symbol 'FLT3', resulting in 'FLT3-Mutated'.
   - **Diagnosis Status Rule**: The rule for 'Newly Diagnosed' (ID: 193) confirms it should be used as a prefix to the main indication.
5. **Indication Construction**: The components were assembled in the standard order: Diagnosis Status -> Genetic Marker -> Disease. This resulted in 'Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia'.
6. **Quality Check**: The final indication was reviewed to ensure it adheres to all formatting, clinical accuracy, and single-source principles. The output is a concise and clinically valid indication derived solely from the abstract title.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To handle the formatting of the 'Flt3-Mutated' component.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To confirm the inclusion and placement of the 'Newly Diagnosed' component.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Treatment based rule for 'Newly Diagnosed' (ID: 193)""}, {'component': 'Flt3-Mutated', 'type': 'Gene Mutation', 'normalized_form': 'FLT3-Mutated', 'rule_applied': ""Gene type rule for 'Gene Mutated' (ID: 32) and HGNC symbol normalization.""}, {'component': 'Acute Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
344332,"Clinical Trial Design in a Diverse World, Part 3: Biomarkers in Clinical Trials",Chair Introduction,,,,True,none,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'Chair Introduction', contains no medical or disease-related terms and is therefore unsuitable for extraction.
Step 2: I then evaluated the session title, 'Clinical Trial Design in a Diverse World, Part 3: Biomarkers in Clinical Trials'. This title describes study methodology and the use of biomarkers, but it does not mention a specific disease, disorder, or even a broad therapeutic area (like 'Oncology' or 'Cardiology').
Step 3: According to the generic exclusion rules, 'Study methodologies' and 'Non-Diagnostic Items' should be excluded. 'Biomarkers' in this context is a non-diagnostic item, not a disease itself.
Step 4: Since neither title contains a valid disease term, no indication can be extracted, as per the Single-Source Extraction Principle.",[],"[{'component': 'Biomarkers', 'type': 'Non-Diagnostic Item', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items'}]",1
393489,"Head and neck cancers, excl. thyroid",Efficacy Of Notch Inhibitors (Ni) Relative To Prior Systemic Therapy Or Observation In Patients (Pts) With Recurrent/Metastatic (R/M) Adenoid Cystic Carcinoma (Acc),Recurrent;;Metastatic;;Adenoid Cystic Carcinoma,Recurrent/Metastatic Adenoid Cystic Carcinoma,Recurrent/Metastatic Adenoid Cystic Carcinoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease, 'Adenoid Cystic Carcinoma (Acc)', which is more precise than the broader category 'Head and neck cancers' in the session title. The Single-Source Extraction Principle mandates using the more specific source.
2. **Component Identification**: From the abstract title, the key components identified were the disease 'Adenoid Cystic Carcinoma (Acc)' and the patient subgroup qualifier 'Recurrent/Metastatic (R/M)'.
3. **Rule Retrieval**: I retrieved rules for 'Occurrence' with subcategories 'Recurrent/Refractory' and 'Metastasis-Related Terms' to confirm the correct formatting for 'Recurrent/Metastatic'.
4. **Rule Application and Normalization**:
   - The qualifier 'Recurrent/Metastatic (R/M)' was normalized to 'Recurrent/Metastatic', keeping the standard clinical terminology and removing the abbreviation.
   - The disease 'Adenoid Cystic Carcinoma (Acc)' was normalized to 'Adenoid Cystic Carcinoma', removing the parenthetical abbreviation.
   - Generic rules were applied: The final indication was formatted to Title Case, and the term 'Carcinoma' is already in the required singular form.
   - Exclusion rules were applied to ignore 'Patients (Pts)' and the description of 'Prior Systemic Therapy Or Observation', as these are not part of the core indication.
5. **Indication Construction**: The normalized qualifier and disease were combined to form the final indication: 'Recurrent/Metastatic Adenoid Cystic Carcinoma'.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To validate the formatting of the 'Recurrent' keyword.""}, {'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To validate the formatting of the 'Metastatic' keyword.""}]","[{'component': 'Recurrent/Metastatic (R/M)', 'type': 'Disease Occurrence', 'normalized_form': 'Recurrent/Metastatic', 'rule_applied': 'Occurrence rule for standardizing disease state qualifiers.'}, {'component': 'Adenoid Cystic Carcinoma (Acc)', 'type': 'Disease', 'normalized_form': 'Adenoid Cystic Carcinoma', 'rule_applied': 'Generic rule to use full disease name and remove abbreviations.'}]",3
180497,Lymphomas: Translational-Molecular and Genetic: Poster I,A Prospective Study of Clonal Evolution in Follicular Lymphoma: Circulating Tumor DNA Correlates with Overall Tumor Burden and Fluctuates over Time without Therapy,Follicular Lymphoma,Follicular Lymphoma,Follicular Lymphoma,True,abstract_title,"Step 1: The abstract title contains the specific disease 'Follicular Lymphoma', while the session title contains the broader term 'Lymphomas'. Following the single-source principle, the abstract title is selected as it is more specific.
Step 2: The core disease term 'Follicular Lymphoma' was identified from the selected title.
Step 3: No other patient subgroups, biomarkers, or qualifiers that need to be included in the indication were found in the title. Terms like 'Clonal Evolution' and 'Circulating Tumor DNA' describe the study's focus, not the patient's core indication.
Step 4: The generic rules for formatting were applied. The term is already in Title Case and singular form. No special rules needed to be retrieved.
Step 5: The final indication was constructed from the identified disease term.",[],"[{'component': 'Follicular Lymphoma', 'type': 'Disease', 'normalized_form': 'Follicular Lymphoma', 'rule_applied': 'Generic singular form and Title Case rules.'}]",1
180501,Lymphomas: Translational-Non-Genetic: Poster I,Differential Gene Expression in Circulating T-Cells in Long-Term Adolescent/Young Adult Hodgkin Lymphoma (AYAHL) Survivors and Their Unaffected Twins,Adolescent/;;oung;;Adult Hodgkin Lymphoma,Adolescent/Young Adult Hodgkin Lymphoma,Adolescent Hodgkin Lymphoma;;Young Adult Hodgkin Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease, 'Hodgkin Lymphoma', making it more informative than the session title's broader 'Lymphomas'.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Hodgkin Lymphoma' and the patient subgroup 'Adolescent/Young Adult'. The term 'Long-Term Survivors' was identified as a temporal patient status to be excluded based on generic rules.
3. **Rule Retrieval**: The `get_indication_rules` tool was used for the 'Age Group' category with subcategories 'Adolescent' and 'Young' to determine how to handle the compound age group 'Adolescent/Young Adult'.
4. **Rule Application**: Based on the retrieved rules (specifically the precedent set by Rule ID 314 for 'Children Adolescent'), a slash-separated age group should be split into two distinct indications. 'Adolescent/Young Adult' was therefore processed to create two separate patient subgroups: 'Adolescent' and 'Young Adult'.
5. **Indication Construction**: The disease 'Hodgkin Lymphoma' was combined with each age group qualifier separately. The term 'Long-Term Survivors' was excluded as it describes a post-treatment state, not a primary indication qualifier.
6. **Formatting**: The two resulting indications were formatted in Title Case, kept in singular form, and joined with the required ';;' separator, resulting in the final output.","[{'category': 'Age Group', 'subcategories': ['Adolescent', 'Young'], 'reason': ""To determine the correct formatting for the compound age group 'Adolescent/Young Adult'.""}]","[{'component': 'Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'Hodgkin Lymphoma', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Adolescent/Young Adult', 'type': 'Age Group', 'normalized_form': 'Adolescent;;Young Adult', 'rule_applied': 'Rule ID 314 precedent, which suggests splitting compound age groups connected by a separator into distinct indications.'}, {'component': 'Long-Term Survivors', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
262425,"Iron metabolism, deficiency and overload",Familial Erythrocytoses In The Czech Republic - Genetic Characterization And Hepcidin Regulation,Familial Erythrocytoses,Familial Erythrocytosis,Familial Erythrocytosis,True,abstract_title,"Step 1: The abstract title 'Familial Erythrocytoses In The Czech Republic - Genetic Characterization And Hepcidin Regulation' was chosen as the source because it contains a specific disease term ('Erythrocytoses'), which is preferred over the broader concepts in the session title ('Iron metabolism, deficiency and overload').
Step 2: The core components identified in the abstract title were the patient subgroup 'Familial' and the disease 'Erythrocytoses'. The geographic location 'In The Czech Republic' and the study methodology 'Genetic Characterization And Hepcidin Regulation' were marked for exclusion.
Step 3: Rules for the 'Familial' patient subgroup were retrieved using the `get_indication_rules` tool. The rules confirmed that 'Familial' should be retained and prepended to the disease name.
Step 4: Generic rules were applied. The plural disease 'Erythrocytoses' was converted to its singular form, 'Erythrocytosis'. Title Case formatting was applied. The geographic descriptor was excluded as per the generic exclusion rules.
Step 5: The final indication was constructed by combining the patient subgroup and the normalized disease name, resulting in 'Familial Erythrocytosis'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Familial'], 'reason': ""To validate the handling of the term 'Familial' as a patient subgroup qualifier.""}]","[{'component': 'Familial', 'type': 'Patient Subgroup', 'normalized_form': 'Familial', 'rule_applied': ""Patient Sub-Group rule for 'Familial' (ID: 392)""}, {'component': 'Erythrocytoses', 'type': 'Disease', 'normalized_form': 'Erythrocytosis', 'rule_applied': 'Generic rule: Singular Form'}, {'component': 'In The Czech Republic', 'type': 'Geographic Location', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclusion of Sociodemographic Descriptors (Region)'}]",2
213274,MP01: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology I,"The ""Butterfly"" transurethral retraction device for BPH - over 1 year follow up",BPH,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The session title ('MP01: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology I') and the abstract title ('The ""Butterfly"" transurethral retraction device for BPH - over 1 year follow up') both refer to the same condition. The session title uses the full, unambiguous name 'Benign Prostatic Hyperplasia', while the abstract title uses the abbreviation 'BPH'.
2.  **Select Source**: Based on the Single-Source Extraction Principle, the session title is chosen as the preferred source because it provides the complete and explicit disease name, which is better for standardization.
3.  **Identify Components**: The core disease component identified in the session title is 'Benign Prostatic Hyperplasia'. Other phrases like 'Surgical Therapy & New Technology I' are identified as procedural/methodological context.
4.  **Retrieve Rules**: I retrieved rules for 'Patient Sub-Group' under the 'Disease Characterisation' subcategory to check for any specific handling of terms like 'Benign'. No specific rule was found, so the generic rule of including qualifiers that are part of a standard disease name applies.
5.  **Apply Rules**: 
    -   The generic exclusion rule is applied to remove 'Surgical Therapy & New Technology I' as it describes treatment modality, not the indication itself.
    -   The generic formatting rule for Title Case is applied, and 'Benign Prostatic Hyperplasia' already conforms.
    -   The generic rule for singular form is applied, and the term is already singular.
6.  **Construct Indication**: The final indication is constructed from the remaining component, resulting in 'Benign Prostatic Hyperplasia'.
7.  **Quality Check**: The final indication is a clinically valid, well-formatted, and standardized term derived from a single source, with all non-indication elements correctly excluded.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify if any specific rules apply to the qualifier 'Benign' or other disease characterizations. No specific rule for 'Benign' was found, confirming it should be treated as an integral part of the disease name.""}]","[{'component': 'Benign Prostatic Hyperplasia', 'type': 'Disease', 'normalized_form': 'Benign Prostatic Hyperplasia', 'rule_applied': 'Generic rule: Retain qualifier as it is part of the standard disease name.'}, {'component': 'Surgical Therapy & New Technology I', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural and methodological terms.'}]",2
311577,Adult Thieves Market: Show Me Your Best Cases,Q&A,,,,True,none,"Neither the abstract title ('Q&A') nor the session title ('Adult Thieves Market: Show Me Your Best Cases') contains any identifiable medical disease, condition, or therapeutic area. The term 'Cases' is too generic to be considered a valid indication. Therefore, no indication can be extracted.",[],[],1
377120,"Gene therapy, cellular immunotherapy and vaccination - Clinical",Axicabtagene Ciloleucel Versus Tisagenlecleucel Car-T Cells In Relapsed Or Refractory Diffuse Large B Cell Lymphoma,Relapsed Or Refractory;;Diffuse Large B Cell Lymphoma,Relapsed/Refractory Diffuse Large B Cell Lymphoma,Relapsed/Refractory Diffuse Large B Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains a specific disease ('Diffuse Large B Cell Lymphoma'), while the session title is a general category. Therefore, the abstract title was chosen as the source based on the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title are the disease state 'Relapsed Or Refractory' and the disease name 'Diffuse Large B Cell Lymphoma'.
3.  **Rule Retrieval**: A rule was retrieved for the 'Occurrence' category, specifically for 'Recurrent/Refractory' terms, to understand how to format disease state qualifiers.
4.  **Rule Application**: 
    *   The phrase 'Relapsed Or Refractory' was normalized to the standard format 'Relapsed/Refractory' and placed before the disease name.
    *   Generic rules were applied: The disease name was already in singular form and appropriate Title Case, so no changes were needed.
5.  **Indication Construction**: The normalized components were combined to form the final indication: 'Relapsed/Refractory Diffuse Large B Cell Lymphoma'.
6.  **Quality Check**: The final indication was checked for adherence to all formatting, exclusion, and clinical accuracy rules. It correctly represents the patient population described in the title.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To determine the correct formatting for 'Relapsed Or Refractory'.""}]","[{'component': 'Relapsed Or Refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Standard normalization for disease state qualifiers.'}, {'component': 'Diffuse Large B Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Diffuse Large B Cell Lymphoma', 'rule_applied': 'Generic singular form and Title Case rules.'}]",2
377121,Stem cell transplantation - Clinical,Single Nucleotide Polymorphisms In Patients With Endothelial Damage After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation,,,Pediatric Endothelial Damage,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific medical condition ('Endothelial Damage'), whereas the session title only mentions a procedure ('Stem cell transplantation').
2. **Component Identification**: The selected abstract title contains the condition 'Endothelial Damage', the age group 'Pediatric', and a procedural context 'After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation'.
3. **Rule Retrieval**: Rules for 'Age Group' (specifically 'Pediatric') and 'Treatment Set-up' (specifically 'Transplant Status') were retrieved to handle the identified components.
4. **Rule Application**:
   - The 'Pediatric' age group rule (ID: 295, 296) directs to retain 'Pediatric' as a leading qualifier for the indication.
   - The generic exclusion rules and the specific 'Transplant Status' rules (ID: 232, 233 for 'Post-Transplant') mandate the exclusion of procedural and temporal qualifiers. The phrase 'After...Transplantation' falls into this category and is therefore removed.
5. **Indication Construction**: The age group 'Pediatric' is prepended to the core condition 'Endothelial Damage'. The procedural context is excluded as per the rules.
6. **Final Formatting**: The final indication 'Pediatric Endothelial Damage' is formatted to Title Case and checked for compliance with all generic rules.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly handle the 'Pediatric' patient subgroup qualifier.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine how to handle the phrase 'After...Transplantation', which is a post-procedural state.""}]","[{'component': 'Endothelial Damage', 'type': 'Disease/Condition', 'normalized_form': 'Endothelial Damage', 'rule_applied': 'Generic rule: Identify core disease term.'}, {'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule (ID: 295, 296): Retain 'Pediatric' as a leading qualifier.""}, {'component': 'After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation', 'type': 'Procedural/Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule & Treatment Set-up rule (ID: 232, 233): Exclude post-procedural context.'}]",2
229667,Immuneregulation-Innate Immune Responses,The biological mechanisms of metformin effects on aging-associated inflammation in obesity,,,Aging-Associated Inflammation;;Obesity,True,abstract_title,"Step 1: The abstract title contains specific medical conditions ('inflammation', 'obesity'), while the session title describes a biological process. Therefore, the abstract title was selected as the source.
Step 2: Two distinct medical conditions were identified in the abstract title: 'aging-associated inflammation' and 'obesity'.
Step 3: According to the generic rules for multiple diseases, both conditions must be extracted and separated by ';;'.
Step 4: The terms were converted to Title Case ('Aging-Associated Inflammation', 'Obesity') and kept in their singular form.
Step 5: The final indication was constructed by combining the two normalized disease terms with the ';;' separator.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To check the correct formatting for co-occurring conditions like inflammation and obesity.'}]","[{'component': 'aging-associated inflammation', 'type': 'Disease', 'normalized_form': 'Aging-Associated Inflammation', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'obesity', 'type': 'Disease', 'normalized_form': 'Obesity', 'rule_applied': 'Generic Rule: Title Case'}]",2
213291,MP01: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology I,Minimally Invasive and Endoscopic Therapies for Benign Prostatic Hyperplasia: Head-to-Head Comparison of Short-Term Outcomes by Network Meta-Analysis,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. Both titles contain the disease term 'Benign Prostatic Hyperplasia'.
Step 2: Following the single-source extraction principle, I selected the abstract_title as the primary source because it contains a valid disease term.
Step 3: I identified the core disease component 'Benign Prostatic Hyperplasia' in the selected title.
Step 4: I applied the generic exclusion rules to remove non-diagnostic information, such as treatment modalities ('Minimally Invasive and Endoscopic Therapies') and study design details ('Head-to-Head Comparison of Short-Term Outcomes by Network Meta-Analysis').
Step 5: I applied the generic formatting rules. The term is already in singular form and correctly capitalized (Title Case), so no changes were needed.
Step 6: The final extracted indication is the standardized disease name itself.",[],"[{'component': 'Benign Prostatic Hyperplasia', 'type': 'Disease', 'normalized_form': 'Benign Prostatic Hyperplasia', 'rule_applied': 'Generic Casing and Singular Form Rules'}]",1
327983,Lymphomas: Translational-Non-Genetic: Poster II,Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study,Relapsed;;Refractory;;Non-Hodgkin Lymphoma,Relapsed/Refractory Non-Hodgkin Lymphoma,Relapsed/Refractory Non-Hodgkin Lymphoma,True,abstract_title,"Step 1: The abstract title contains a specific disease, 'Non-Hodgkin Lymphoma', and is therefore selected as the source over the more general session title, 'Lymphomas'.
Step 2: The key components identified in the abstract title are the disease state 'Relapsed/Refractory' and the disease 'Non-Hodgkin Lymphoma'.
Step 3: A rule check was performed for the 'Occurrence' category, specifically for 'Recurrent/Refractory' terms, to ensure correct formatting. The standard is to use Title Case and the slash separator.
Step 4: Generic rules were applied. The disease term is already singular. All non-diagnostic components, such as 'Pharmacodynamic Biomarkers', 'Efficacy and Safety', and 'Phase I/II Study', were excluded.
Step 5: The final indication was constructed by combining the disease state and the disease name, resulting in 'Relapsed/Refractory Non-Hodgkin Lymphoma'.
Step 6: A quality check confirmed that the output adheres to all formatting and content rules, including Title Case, single-source principle, and exclusion of irrelevant terms.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To verify the standard formatting for 'Relapsed/Refractory' terms.""}]","[{'component': 'Relapsed/Refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Standard formatting for occurrence qualifiers (Title Case).'}, {'component': 'Non-Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'Non-Hodgkin Lymphoma', 'rule_applied': 'Generic rule for disease name formatting (Title Case).'}]",2
180529,"Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I",Treatment Regimens and Clinical Outcomes Among Follicular Lymphoma Patients Treated with Third-Line Therapy in the United States: A Real-World EHR Study,Third-Line;;Follicular Lymphoma,Third-Line Follicular Lymphoma,Third-Line Follicular Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: Both the abstract and session titles contain disease terms. The abstract title ('Treatment Regimens and Clinical Outcomes Among Follicular Lymphoma Patients Treated with Third-Line Therapy in the United States: A Real-World EHR Study') is more specific and is selected based on the single-source extraction principle, which prioritizes the abstract title.
2. **Identify Components**: The key components identified in the abstract title are the disease 'Follicular Lymphoma' and the treatment context 'Third-Line Therapy'. Other phrases like 'Treatment Regimens', 'Clinical Outcomes', and 'in the United States' are identified as study descriptors to be excluded.
3. **Retrieve Relevant Rules**: To correctly format the treatment context, I retrieved rules for 'Line of treatment' using `get_indication_rules(category=""Treatment Set-up"", subcategories=[""Line of treatment""])`.
4. **Apply Rules**: 
   - The retrieved Rule 7 (ID: 204) for the keyword 'Third-Line' dictates normalizing the term to 'Third-Line' (Title Case, hyphenated) and placing it at the beginning of the indication.
   - Generic rules are applied to ensure the final output is in singular form and Title Case ('Follicular Lymphoma').
   - Exclusion rules are applied to remove non-diagnostic information such as 'Patients Treated with', the geographic location 'in the United States', and study details 'A Real-World EHR Study'.
5. **Construct Indication**: The normalized treatment line 'Third-Line' is prepended to the standardized disease name 'Follicular Lymphoma'.
6. **Quality Check**: The final indication 'Third-Line Follicular Lymphoma' adheres to all formatting and content rules. It correctly captures the specific patient subgroup from the chosen source title without including extraneous information.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine the correct formatting and placement of the 'Third-Line' treatment descriptor.""}]","[{'component': 'Follicular Lymphoma', 'type': 'Disease', 'normalized_form': 'Follicular Lymphoma', 'rule_applied': 'Generic rule: Title Case, Singular form.'}, {'component': 'Third-Line Therapy', 'type': 'Line of treatment', 'normalized_form': 'Third-Line', 'rule_applied': ""Rule 7 (ID: 204) for 'Third-Line' requires normalization to 'Third-Line' and placement at the start of the indication.""}]",2
311607,Bacterial Autoimmune Sequellae: Common and Newly Recognized Clinical Syndromes,"UTI Biofilms, Amyloid, and Lupus Flares",,,Urinary Tract Infection;;Amyloidosis;;Lupus,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('UTI Biofilms, Amyloid, and Lupus Flares') was selected over the session title ('Bacterial Autoimmune Sequellae: Common and Newly Recognized Clinical Syndromes') because it contains specific, extractable disease terms, whereas the session title refers to broad categories.
2. **Component Identification**: The abstract title lists three distinct clinical concepts: 'UTI Biofilms', 'Amyloid', and 'Lupus Flares'.
3. **Indication Extraction & Normalization**:
   - **'UTI Biofilms'**: 'UTI' is a standard abbreviation for 'Urinary Tract Infection', which is a valid disease. 'Biofilms' is a microbiological process, not a patient subgroup or part of the disease name, and was excluded based on the generic rule to exclude non-diagnostic items.
   - **'Amyloid'**: In a clinical context alongside other diseases, 'Amyloid' is interpreted as the disease 'Amyloidosis'.
   - **'Lupus Flares'**: 'Lupus' is a valid disease. 'Flares' describes a temporary state of disease activity and is not a standard qualifier for a clinical indication. Therefore, it was excluded, and the core disease 'Lupus' was extracted.
4. **Rule Application & Formatting**: The three extracted diseases are distinct. Following the 'Multiple Diseases' rule, they are separated by ';;'. The 'Formatting Rules' for Title Case and singular form were applied to each indication.",[],"[{'component': 'UTI', 'type': 'Disease', 'normalized_form': 'Urinary Tract Infection', 'rule_applied': 'Generic rule: Abbreviation expansion and singular form.'}, {'component': 'Biofilms', 'type': 'Excluded', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude non-diagnostic items/physiologic processes.'}, {'component': 'Amyloid', 'type': 'Disease', 'normalized_form': 'Amyloidosis', 'rule_applied': 'Clinical interpretation of a substance as its corresponding disease in context.'}, {'component': 'Lupus', 'type': 'Disease', 'normalized_form': 'Lupus', 'rule_applied': 'Generic rule: Direct extraction of disease name.'}, {'component': 'Flares', 'type': 'Excluded', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude temporary disease states/symptoms.'}]",2
377144,Clinical updates in ALL,A Chemotherapy-Free Combination Of Ponatinib And Blinatumomab For Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Subgroup Analysis From A Phase Ii Study,Newly Diagnosed;;Philadelphia Chromosome;;Positive;;Acute Lymphoblastic Leukemia,Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia,Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title ('A Chemotherapy-Free Combination Of Ponatinib And Blinatumomab For Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Subgroup Analysis From A Phase Ii Study') contains a specific disease and patient subgroup. The session title ('Clinical updates in ALL') is more general. Based on the single-source principle, the abstract title is selected for extraction as it is more detailed.
2. **Identify Components**: The key components identified in the abstract title are 'Newly Diagnosed' (Diagnosis Status), 'Philadelphia Chromosome-Positive' (Genetic Marker), and 'Acute Lymphoblastic Leukemia' (Disease).
3. **Retrieve Relevant Rules**: I retrieved rules for the 'Diagnosis Status' component. The call `get_indication_rules(category='Treatment based', subcategories=['Diagnosis Status'])` returned Rule 193, which specifies that 'Newly Diagnosed' should be used as a prefix to the main disease. I attempted to find a specific rule for 'Philadelphia Chromosome-Positive' under the 'Chromosome type' category but none was found, so I will proceed with generic formatting rules.
4. **Apply Rules**: 
   - **Rule 193**: Applied to prefix 'Newly Diagnosed' to the indication.
   - **Generic Casing Rule**: Applied Title Case to 'Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia'.
   - **Generic Singular Form Rule**: 'Leukemia' is already in singular form.
   - **Generic Exclusion Rule**: The phrase 'For Patients With' and details about the study design and treatment ('A Chemotherapy-Free Combination Of Ponatinib And Blinatumomab', 'Subgroup Analysis From A Phase Ii Study') were excluded as they are not part of the core indication.
5. **Construct Indication**: The components were assembled in the correct clinical order: Diagnosis Status + Genetic Marker + Disease Name.
6. **Quality Check**: The final indication 'Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia' is clinically accurate, adheres to all formatting rules, and is derived from a single source.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To verify the correct formatting and placement of the 'Newly Diagnosed' keyword.""}, {'category': 'Chromosome type', 'subcategories': ['General'], 'reason': ""To check for specific formatting rules for 'Philadelphia Chromosome-Positive', though no specific rule was found.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule 193: Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'Philadelphia Chromosome-Positive', 'type': 'Genetic Marker', 'normalized_form': 'Philadelphia Chromosome-Positive', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic Rule: Title Case'}]",3
327998,Lymphomas: Translational-Non-Genetic: Poster III,"Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma",Second-Line;;Relapsed;;Refractory;;Classical Hodgkin Lymphoma,Second-Line Relapsed or Refractory Classical Hodgkin Lymphoma,Second-Line Relapsed/Refractory Classical Hodgkin Lymphoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains a specific disease ('Classical Hodgkin Lymphoma'), making it the primary source over the more general session title ('Lymphomas').
2.  **Component Identification**: I identified three key components in the abstract title: the disease ('Classical Hodgkin Lymphoma'), a disease state ('Relapsed or Refractory'), and a treatment line ('Second-Line Therapy').
3.  **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Line of treatment' and 'Recurrent/Refractory' categories.
4.  **Rule Application**: 
    *   **Treatment Line**: Based on the retrieved 'Line of treatment' rules (specifically Rule ID 199 and 202), the phrase 'Second-Line Therapy for...' indicates that 'Second-Line' modifies the disease context, not a specific drug. Therefore, it must be retained and normalized to 'Second-Line'.
    *   **Disease State**: The phrase 'Relapsed or Refractory' is a standard patient subgroup descriptor. It is normalized to 'Relapsed/Refractory' with a slash, following common clinical terminology standards.
    *   **Disease Name**: 'Classical Hodgkin Lymphoma' is already in the correct singular and Title Case format.
5.  **Indication Construction**: The components are assembled in the standard order: Treatment Line -> Disease State -> Disease. This results in 'Second-Line Relapsed/Refractory Classical Hodgkin Lymphoma'.
6.  **Quality Check**: The final indication adheres to all generic rules: it's from a single source, uses Title Case, is in singular form, and excludes non-indication elements like drug names.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine how to handle the 'Second-Line Therapy' component.""}, {'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To correctly format the 'Relapsed or Refractory' disease state.""}]","[{'component': 'Second-Line Therapy', 'type': 'Line of treatment', 'normalized_form': 'Second-Line', 'rule_applied': ""Treatment Set-up Rule ID 202: Normalize to 'Second-Line' and prepend to the disease name.""}, {'component': 'Relapsed or Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Standard normalization for recurrent/refractory disease states.'}, {'component': 'Classical Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'Classical Hodgkin Lymphoma', 'rule_applied': 'Generic rules for Casing and Singular Form.'}]",2
409919,What's Complement Got to Do with It? ANCA Vasculitis and the Complement System,Audience Q&A,ANCA Vasculitis,ANCA Vasculitis,ANCA Vasculitis,True,session_title,"Step 1: The abstract title 'Audience Q&A' contains no medical disease or condition. Step 2: The session title 'What's Complement Got to Do with It? ANCA Vasculitis and the Complement System' contains the specific disease 'ANCA Vasculitis'. Step 3: Following the single-source principle, the session title was chosen for extraction. Step 4: The term 'ANCA Vasculitis' was identified as the core indication. The surrounding text is conversational and was excluded. Step 5: Generic formatting rules were applied. The term is already in singular form and appropriate Title Case, with 'ANCA' correctly capitalized as an acronym. No patient subgroups were mentioned.",[],"[{'component': 'ANCA Vasculitis', 'type': 'Disease', 'normalized_form': 'ANCA Vasculitis', 'rule_applied': 'Generic disease extraction and formatting rules.'}]",1
147776,Aggressive Non-Hodgkin Lymphoma - Clinical,"Discovery Of Hbw-3-20, The First Reversible Inhibitor Of Bruton'S Tyrosine Kinase (Btk) With High Brain Exposure",Aggressive;;Non-Hodgkin Lymphoma,Aggressive Non-Hodgkin Lymphoma,Aggressive Non-Hodgkin Lymphoma,True,session_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title 'Discovery Of Hbw-3-20, The First Reversible Inhibitor Of Bruton'S Tyrosine Kinase (Btk) With High Brain Exposure' does not contain a specific disease name; it mentions a drug target (BTK). The session title 'Aggressive Non-Hodgkin Lymphoma - Clinical' clearly contains a disease.
2. **Select Source**: Based on the Single-Source Extraction Principle, the session title is selected as it is the only source containing a valid disease term.
3. **Identify Components**: From the session title, the components are 'Aggressive' (a disease characterization) and 'Non-Hodgkin Lymphoma' (the core disease). The term 'Clinical' is a session descriptor and not part of the indication.
4. **Retrieve Rules**: I retrieved rules for 'Disease Characterisation' and 'Risk Types' to determine how to handle the term 'Aggressive'. While no specific rule for 'Aggressive' was found, the general principle is to include such descriptors when they form a recognized clinical entity, which is the case for 'Aggressive Non-Hodgkin Lymphoma'.
5. **Apply Rules & Construct Indication**: 
    - The core indication is 'Aggressive Non-Hodgkin Lymphoma'.
    - The generic exclusion rule is applied to remove the non-diagnostic term '- Clinical'.
    - The generic formatting rules are applied: Title Case is used ('Aggressive Non-Hodgkin Lymphoma'), and the disease is already in singular form.
6. **Quality Check**: The final indication adheres to all rules. It is derived from a single source, correctly formatted, and clinically accurate.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules on how to handle disease qualifiers like 'Aggressive'.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To determine if 'Aggressive' should be treated as a risk stratification term.""}]","[{'component': 'Aggressive Non-Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'Aggressive Non-Hodgkin Lymphoma', 'rule_applied': ""Generic rule: Include disease characterization when it's part of a standard clinical entity.""}, {'component': 'Clinical', 'type': 'Session Descriptor', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude non-diagnostic items and session descriptors.'}]",3
328003,Lymphomas: Translational-Non-Genetic: Poster III,Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion,High Grade;;B Cell Lymphoma,High Grade B Cell Lymphoma,Double and Triple Hit High Grade B Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH...') was chosen over the session title ('Lymphomas: Translational-Non-Genetic: Poster III') because it contains a more specific and complete disease description, adhering to the single-source principle.
2. **Component Identification**: Key clinical components identified in the abstract title were 'Double and Triple Hit', 'High Grade', and 'B Cell Lymphoma'. The term 'Patients' and the treatment context 'Treated with DA-EPOCH' were identified for exclusion.
3. **Rule Retrieval**: Rules for the 'Grade' category were retrieved to handle 'High Grade'. Rules for 'Patient Sub-Group' were retrieved to check for handling of descriptors like 'Double and Triple Hit'.
4. **Rule Application**:
   - The retrieved rule for 'High Grade' (ID: 115) confirmed its standardization and placement before the disease name.
   - No specific rule was found for 'Double and Triple Hit', so it was retained as an essential clinical descriptor defining the patient subgroup.
   - Generic exclusion rules were applied to remove 'Patients' (sociodemographic) and 'Treated with DA-EPOCH' (procedural qualifier).
   - Generic formatting rules were applied: Title Case for clinical terms ('Double', 'Triple', 'Hit', 'High', 'Grade', 'B', 'Cell', 'Lymphoma') and lowercase for the conjunction 'and'. The disease term 'Lymphoma' is already in its singular form.
5. **Indication Construction**: The identified and standardized components were combined in the correct clinical order (subgroup -> grade -> disease) to form the final indication: 'Double and Triple Hit High Grade B Cell Lymphoma'. This phrase represents a single, clinically recognized high-risk lymphoma entity, not multiple separate diseases, so no ';;' separator was used.
6. **Quality Check**: The final indication was verified for adherence to all generic and specific rules, clinical accuracy, and proper formatting.","[{'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To correctly format the 'High Grade' component.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for specific rules regarding 'Double Hit' or 'Triple Hit' lymphoma characterizations.""}]","[{'component': 'Double and Triple Hit', 'type': 'Patient Sub-Group', 'normalized_form': 'Double and Triple Hit', 'rule_applied': 'Generic rule: Retain essential clinical descriptors. Title Case formatting.'}, {'component': 'High Grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Rule ID: 115 - Standardize to 'High Grade' and place before the disease name.""}, {'component': 'B Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'B Cell Lymphoma', 'rule_applied': 'Generic rule: Title Case and singular form.'}, {'component': 'Patients', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude sociodemographic descriptors.'}, {'component': 'Treated with DA-EPOCH', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers.'}]",2
262464,Lymphoma Biology & Translational Research,Potentiating Anti-Cd20 Monoclonal Antibody Therapy By Targeting Complement C3 Activation Fragments Covalently Deposited On Lymphoma Cells,Lymphoma ,Lymphoma ,Lymphoma,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease term, 'Lymphoma Cells', which is preferred over the session title according to the single-source principle.
Step 2: The disease term 'Lymphoma Cells' was identified from the abstract title.
Step 3: The generic rule for singular form was applied, converting 'Lymphoma Cells' to 'Lymphoma'. The term 'Cells' is a cytological descriptor and not part of the core disease name.
Step 4: The generic rule for Title Case was applied, which was already satisfied by 'Lymphoma'.
Step 5: No other patient subgroups or qualifiers were present in the title, resulting in the final, concise indication.",[],"[{'component': 'Lymphoma Cells', 'type': 'Disease', 'normalized_form': 'Lymphoma', 'rule_applied': 'Generic Rule: Singular Form'}]",1
213317,MP03: Bladder Cancer: Invasive I,How does the type of urinary diversion affect health related quality of life (HRQOL) in the course of four years after radical cystectomy? - A propensity score-matched analysis,Invasive;;Bladder Cancer,Invasive Bladder Cancer,Invasive Bladder Cancer,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('How does the type of urinary diversion affect health related quality of life (HRQOL) in the course of four years after radical cystectomy? - A propensity score-matched analysis') does not contain a disease term, only a surgical procedure ('radical cystectomy'). The session title ('MP03: Bladder Cancer: Invasive I') explicitly mentions 'Bladder Cancer'. Therefore, according to the single-source principle, the session title is selected for extraction.
2.  **Component Identification**: From the session title, the core disease is 'Bladder Cancer' and the key qualifier is 'Invasive'. The terms 'MP03' and 'I' are session identifiers and are excluded.
3.  **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' under the 'Disease Characterisation' subcategory to check for specific handling of terms like 'Invasive'. While no specific rule for 'Invasive' was found, the general principle is to include clinically significant descriptors.
4.  **Rule Application**: 
    - The generic rule for Title Casing is applied, resulting in 'Invasive Bladder Cancer'.
    - The generic rule for singular form is applied; 'Bladder Cancer' is already singular.
    - 'Invasive' is a standard clinical descriptor for cancer that specifies its behavior (spreading into surrounding tissue) and is crucial for defining the patient subgroup. It is therefore prepended to the disease name.
5.  **Indication Construction**: The components 'Invasive' and 'Bladder Cancer' are combined to form the final indication 'Invasive Bladder Cancer'.
6.  **Quality Check**: The final indication is clinically accurate, follows all formatting rules, and is derived from a single source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for specific rules on handling disease qualifiers like 'Invasive'.""}]","[{'component': 'Bladder Cancer', 'type': 'Disease', 'normalized_form': 'Bladder Cancer', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Invasive', 'type': 'Disease Qualifier', 'normalized_form': 'Invasive', 'rule_applied': ""General clinical knowledge dictates that 'Invasive' is a critical descriptor for cancer and should be included.""}]",2
147782,Bleeding Disorders (Congenital And Acquired),Investigation Of Preterm Intraventricular Hemorrhage-Induced Inflammatory Response And Microrna Levels In Human Choroid Plexus Epithelial Cells,Congenital;;Acquired;;Bleeding Disorder,Congenital Bleeding Disorder;;Acquired Bleeding Disorder,Preterm Intraventricular Hemorrhage,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: Both the session title ('Bleeding Disorders') and the abstract title ('Preterm Intraventricular Hemorrhage') contain valid medical conditions. According to the single-source principle, the abstract title is prioritized.
2. **Component Identification**: From the abstract title, the core disease identified is 'Intraventricular Hemorrhage' and the patient subgroup qualifier is 'Preterm'. Other phrases like 'Inflammatory Response' and 'Microrna Levels' are identified as physiological processes or measurements, not primary diseases, and are therefore excluded based on the generic exclusion rules.
3. **Rule Retrieval**: I retrieved rules for 'Onset' to understand how to handle 'Preterm' and for 'Patient with two different Disease' to correctly handle the multiple potential conditions. The 'Onset' rules confirmed that such qualifiers should be included, and the lack of specific rules for the second potential condition confirmed that 'Inflammatory Response' should be treated as a secondary process, not a separate indication.
4. **Rule Application & Construction**: The qualifier 'Preterm' is prepended to the core disease 'Intraventricular Hemorrhage'. Generic rules for Title Casing and singular form are applied. All non-diagnostic and procedural terms ('Investigation Of', '-Induced Inflammatory Response', 'In Human Choroid Plexus Epithelial Cells') are excluded.
5. **Final Indication**: The components are combined and formatted to produce the final indication: 'Preterm Intraventricular Hemorrhage'.","[{'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To check how to handle the term 'Preterm' as a temporal qualifier for the disease.""}, {'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': ""To determine if 'Intraventricular Hemorrhage' and 'Inflammatory Response' should be treated as two separate indications.""}]","[{'component': 'Preterm', 'type': 'Onset Qualifier', 'normalized_form': 'Preterm', 'rule_applied': 'Generic rule for patient subgroup inclusion.'}, {'component': 'Intraventricular Hemorrhage', 'type': 'Disease', 'normalized_form': 'Intraventricular Hemorrhage', 'rule_applied': 'Generic rule for disease extraction and Title Casing.'}, {'component': 'Inflammatory Response', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic items.'}]",2
147785,Bleeding Disorders (Congenital And Acquired),"Haemophilia B Leyden, An Age-Related Mechanism For An Increase Of Factor Ix: Case Report And Literature Review",Haemophilia B Leyden,Haemophilia B Leyden,Haemophilia B Leyden,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title ('Haemophilia B Leyden, An Age-Related Mechanism...') and the session title ('Bleeding Disorders (Congenital And Acquired)') both contain disease terms.
2.  **Select Source**: Following the Single-Source Extraction Principle, the abstract title is selected as it provides a more specific disease entity ('Haemophilia B Leyden') compared to the broader session title.
3.  **Identify Components**: The key components in the abstract title are the disease 'Haemophilia B Leyden' and the descriptor 'Age-Related'.
4.  **Retrieve Rules**: To correctly handle the 'Age-Related' descriptor, rules for 'Onset by Age' were retrieved using `get_indication_rules(category=""Onset"", subcategories=[""Onset by Age""])`.
5.  **Apply Rules**: The retrieved rules did not have a specific entry for 'Age-Related'. However, the analysis of the title shows that 'Age-Related' describes the mechanism of 'Haemophilia B Leyden', a specific named variant of Haemophilia B. The name 'Leyden' itself implies this characteristic, making the explicit addition of 'Age-Related' redundant and not standard clinical nomenclature. The rest of the title ('An Age-Related Mechanism For An Increase Of Factor Ix: Case Report And Literature Review') is descriptive of the study and is excluded per generic rules.
6.  **Construct Indication**: The core disease entity is identified as 'Haemophilia B Leyden'.
7.  **Quality Check**: The final indication is formatted in Title Case and singular form. All non-diagnostic and descriptive parts of the title have been correctly excluded. The result is a concise and clinically valid indication.","[{'category': 'Onset', 'subcategories': ['Onset by Age'], 'reason': ""To determine the correct handling of the term 'Age-Related' found in the abstract title.""}]","[{'component': 'Haemophilia B Leyden', 'type': 'Disease', 'normalized_form': 'Haemophilia B Leyden', 'rule_applied': 'Generic rule: Extract core disease entity.'}, {'component': 'Age-Related', 'type': 'Disease Qualifier', 'normalized_form': '', 'rule_applied': ""Generic rule: Excluded as it is a descriptive term for a mechanism inherent to the named disease variant ('Leyden') and not a standard prefix for the indication.""}]",2
328014,Lymphomas: Translational-Non-Genetic: Poster I,Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader,Lymphomas,Lymphoma,Cutaneous T-Cell Lymphoma,True,abstract_title,"Step 1: The abstract title contains the disease acronym 'CTCL', so it is selected as the source according to the single-source principle.
Step 2: The component 'CTCL' is identified as the core disease. The phrase 'Pre-Clinical Animal Model' is identified as a study methodology and marked for exclusion based on generic rules.
Step 3: The primary task is to standardize the acronym 'CTCL'. No specific rules were needed from the tool for this common acronym.
Step 4: The acronym 'CTCL' is expanded to its full name, 'Cutaneous T-Cell Lymphoma'.
Step 5: Generic formatting rules are applied. The expanded name is converted to Title Case, resulting in 'Cutaneous T-Cell Lymphoma'. The excluded components ('Pre-Clinical Animal Model') are removed.
Step 6: A final quality check confirms the indication is correctly formatted, singular, and derived from a single source.",[],"[{'component': 'CTCL', 'type': 'Disease', 'normalized_form': 'Cutaneous T-Cell Lymphoma', 'rule_applied': 'Standard medical acronym expansion and Title Case formatting rule.'}, {'component': 'Pre-Clinical Animal Model', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items/Study Methodologies.'}]",2
328016,Lymphomas: Translational-Non-Genetic: Poster I,A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders,Lymphoproliferative Disorder,Lymphoproliferative Disorder,Lymphoproliferative Disorder,True,abstract_title,"Step 1: The abstract title was chosen as the primary source because it contains a valid disease term, 'Lymphoproliferative Disorders'.
Step 2: The core disease 'Lymphoproliferative Disorders' was identified from the abstract title.
Step 3: The generic rule for singular form was applied, converting 'Disorders' to 'Disorder'.
Step 4: The generic rule for Title Case was applied, resulting in 'Lymphoproliferative Disorder'.
Step 5: Other terms in the title, such as 'Cryopreservation and Biobanking Strategy' and 'Lymphoid Tissue Stromal Cells', were excluded as they describe study methodology and biological components, not the clinical indication itself.",[],"[{'component': 'Lymphoproliferative Disorders', 'type': 'Disease', 'normalized_form': 'Lymphoproliferative Disorder', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Title Case'}]",1
213341,MP04: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology II,Trends in holmium laser enucleation of the prostate for treatment of benign prostatic hyperplasia,benign prostatic hyperplasia,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. Both contain the disease term 'benign prostatic hyperplasia'.
Step 2: Following the single-source extraction principle, I selected the abstract_title as the primary source because it contains a valid disease term.
Step 3: I identified the core disease component as 'benign prostatic hyperplasia'. The other terms in the title, such as 'Trends in holmium laser enucleation of the prostate for treatment of', are procedural and related to study methodology, which must be excluded based on the generic rules.
Step 4: I applied the generic formatting rules. I converted the disease term to Title Case, resulting in 'Benign Prostatic Hyperplasia'. The term is already in its singular form.
Step 5: The final indication was constructed by taking the normalized disease name. No other qualifiers were present in the title.",[],"[{'component': 'benign prostatic hyperplasia', 'type': 'Disease', 'normalized_form': 'Benign Prostatic Hyperplasia', 'rule_applied': 'Generic Rule: Title Case'}]",1
213344,MP04: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology II,En-Bloc enucleation technique with early apical release and urinary sphincter preservation using Pulse modulation (Virtual Basket) vs En-Bloc HoLEP,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,True,session_title,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'En-Bloc enucleation technique with early apical release and urinary sphincter preservation using Pulse modulation (Virtual Basket) vs En-Bloc HoLEP', describes surgical procedures but does not contain a specific disease name.
Step 2: The session title, 'MP04: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology II', explicitly mentions the disease 'Benign Prostatic Hyperplasia'.
Step 3: Following the single-source extraction principle, I selected the session title as it is the only source containing a valid disease term.
Step 4: I extracted 'Benign Prostatic Hyperplasia' and applied generic rules. The term is already in Title Case and singular form. The procedural descriptor 'Surgical Therapy' and session information 'MP04' and 'New Technology II' were excluded as per the rules.
Step 5: The final, clean indication is 'Benign Prostatic Hyperplasia'.",[],"[{'component': 'Benign Prostatic Hyperplasia', 'type': 'Disease', 'normalized_form': 'Benign Prostatic Hyperplasia', 'rule_applied': 'Generic rule: Use disease from session title when abstract title lacks one.'}, {'component': 'Surgical Therapy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude procedural/temporal qualifiers.'}]",1
295266,How to incorporate digital medicine in survivorship care after breast cancer,How to incorporate digital medicine in survivorship care after breast cancer,breast cancer,Breast Cancer,Breast Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: Both the abstract and session titles are identical and contain the disease term 'breast cancer'. Following the single-source principle, the abstract title was selected as the primary source.
2. **Component Identification**: The key components identified in the title are the disease 'breast cancer' and the context 'survivorship care after'.
3. **Rule Retrieval**: The phrase 'survivorship care after' implies a post-treatment context. To handle this, I retrieved rules for 'Treatment Status' within the 'Treatment Set-up' category.
4. **Rule Application**: The retrieved rules (ID 234, 235) for 'Post-Treatment' state that such temporal qualifiers should be excluded from the final indication as they describe a treatment status rather than a distinct clinical condition. The generic exclusion rules also mandate the removal of procedural or temporal qualifiers.
5. **Indication Construction**: Based on the rules, the qualifier 'survivorship care after' was excluded. The core disease term 'breast cancer' was retained.
6. **Formatting**: The extracted term was formatted according to generic rules: converted to Title Case ('Breast Cancer') and ensured it was in singular form (which it already was).
7. **Final Output**: The final generated indication is 'Breast Cancer'.","[{'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To determine how to handle the 'survivorship care after' context, which is a type of post-treatment status.""}]","[{'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Casing Rule (Title Case)'}, {'component': 'survivorship care after', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Exclusion Rule for Post-Treatment Status (Rule ID: 234, 235)'}]",2
213348,MP04: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology II,Thulium YAG vs Thulium Fiber Laser Enucleation of the Prostate (ThuLEP vs TFLEP): a Multi-institution Trial to Compare Intra and Early Postoperative Outcomes.,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,True,session_title,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'Thulium YAG vs Thulium Fiber Laser Enucleation of the Prostate (ThuLEP vs TFLEP): a Multi-institution Trial to Compare Intra and Early Postoperative Outcomes,' describes a surgical procedure ('Enucleation of the Prostate') but does not explicitly name the underlying disease it is treating.
Step 2: The session title, 'MP04: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology II,' clearly contains the disease term 'Benign Prostatic Hyperplasia'.
Step 3: Based on the Single-Source Extraction Principle, I selected the session title as the source because the abstract title lacks a specific disease term.
Step 4: I extracted the disease 'Benign Prostatic Hyperplasia' from the session title. The remaining parts, 'Surgical Therapy & New Technology II,' are procedural and methodological descriptors, which are excluded according to the generic rules.
Step 5: I applied formatting rules. The term is already in Title Case and singular form, so no changes were needed. The final indication is 'Benign Prostatic Hyperplasia'.",[],"[{'component': 'Benign Prostatic Hyperplasia', 'type': 'Disease', 'normalized_form': 'Benign Prostatic Hyperplasia', 'rule_applied': 'Generic rule: Use of disease term from the title.'}, {'component': 'Surgical Therapy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers.'}]",1
377189,Bone marrow failure syndromes incl. PNH - Clinical,Changings In Genetic Definition And Management Of Acquired Aplastic Anemia: A Single Center Experience,Acquired;;Aplastic Anemia,Acquired Aplastic Anemia,Acquired Aplastic Anemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Changings In Genetic Definition And Management Of Acquired Aplastic Anemia: A Single Center Experience') contains a specific disease, 'Acquired Aplastic Anemia'. According to the single-source principle, the abstract title is prioritized over the session title and selected as the source.
2.  **Component Identification**: The key components identified in the abstract title are the disease 'Aplastic Anemia' and the qualifier 'Acquired'.
3.  **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' under the 'Disease Characterisation' subcategory to verify how to handle qualifiers like 'Acquired'. While no specific rule for 'Acquired' was found, the general principle is to include such terms when they form part of a standard clinical diagnosis, which is the case here.
4.  **Rule Application**: 
    *   The term 'Acquired' is a clinically significant descriptor that distinguishes this type of aplastic anemia from inherited forms, so it is retained.
    *   Generic formatting rules are applied: The final indication is converted to Title Case.
    *   Generic exclusion rules are applied: Non-indicative phrases such as 'Changings In Genetic Definition And Management Of' and 'A Single Center Experience' are removed as they describe the study's context, not the medical condition itself.
5.  **Indication Construction**: The identified components are combined and formatted to produce the final indication: 'Acquired Aplastic Anemia'.
6.  **Quality Check**: The final indication adheres to all formatting and clinical accuracy requirements. It is derived from a single source and correctly represents the core medical condition described.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules on how to handle disease qualifiers like 'Acquired'.""}]","[{'component': 'Acquired Aplastic Anemia', 'type': 'Disease', 'normalized_form': 'Acquired Aplastic Anemia', 'rule_applied': 'Generic rule: Retain clinically significant disease characterizations. Generic rule: Apply Title Case.'}]",2
311657,Challenges in Psoriatic Disease: Divergent Skin and Joints,Challenges in Psoriatic Disease: When Skin and Joint Symptoms Are Divergent,Psoriatic Disease,Psoriatic Disease,Psoriatic Disease,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: Both the abstract and session titles refer to ""Psoriatic Disease"". The abstract title is chosen as the primary source based on the single-source principle.
2.  **Identify Components**: The core disease identified is ""Psoriatic Disease"". The phrase ""When Skin and Joint Symptoms Are Divergent"" describes a characteristic of the disease presentation being studied, rather than defining a distinct, standard clinical subgroup or a separate co-occurring disease. 
3.  **Retrieve Relevant Rules**: I searched for rules related to 'Disease Characterisation' and 'Patient with two different Disease'. No specific rules were found that would modify the extraction of the core disease based on the descriptive text.
4.  **Apply Rules & Construct Indication**: According to generic rules, the core disease term is extracted. The descriptive phrase ""When Skin and Joint Symptoms Are Divergent"" is not a standard qualifier for an indication and is excluded to maintain clinical conciseness and accuracy. The term ""Psoriatic Disease"" is already in the correct singular and Title Case format.
5.  **Quality Check**: The final indication ""Psoriatic Disease"" is clinically accurate, adheres to all formatting rules, and is directly supported by the selected source title. It correctly identifies the overarching condition being discussed.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check if descriptive terms like 'divergent' should be included in the indication.""}, {'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': ""To determine how to handle the mention of both 'Skin' and 'Joints' as potentially separate disease manifestations.""}]","[{'component': 'Psoriatic Disease', 'type': 'Disease', 'normalized_form': 'Psoriatic Disease', 'rule_applied': 'Generic rule: Extract core disease term.'}, {'component': 'When Skin and Joint Symptoms Are Divergent', 'type': 'Disease Descriptor', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude non-standard descriptive qualifiers to maintain a concise and clinically standard indication.'}]",3
377194,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Arginine Deprivation Induces Acquisition Of A Senescent Phenotype And Favors Genomic Instability In Multiple Myeloma Plasma Cells,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. The abstract title contains 'Multiple Myeloma' and the session title contains 'Myeloma' and 'monoclonal gammopathies'. According to the single-source principle, the abstract title is preferred as it contains a specific disease term.

Step 2: I identified the core disease component in the selected abstract title, which is 'Multiple Myeloma'. The term 'Plasma Cells' is descriptive of the disease itself (Multiple Myeloma is a cancer of plasma cells) and does not constitute a distinct patient subgroup in this context, making it redundant for the final indication.

Step 3: I checked for any specific rules related to 'Myeloma' but found none. Therefore, I proceeded with the generic rules.

Step 4: I applied the generic rules. The term 'Multiple Myeloma' is already in Title Case and singular form. There are no sociodemographic, procedural, or other excludable terms present.

Step 5: I constructed the final indication by using the normalized disease term.

Step 6: I performed a quality check to ensure all rules were followed, resulting in the final, concise indication 'Multiple Myeloma'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Myeloma'], 'reason': 'To check for any specific formatting or inclusion rules related to Myeloma.'}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Title Case, Singular Form.'}, {'component': 'Plasma Cells', 'type': 'Cell Type', 'normalized_form': '', 'rule_applied': ""Excluded as it is an intrinsic part of the disease 'Multiple Myeloma' and not a specific patient subgroup.""}]",2
409966,Dyslipidemia in Pediatric CKD: Risk for Stiff Vessels?,Controversies in the Management of Dyslipidemia in Children with CKD,Dyslipidemia;;Children,Childhood Dyslipidemia,Childhood Dyslipidemia;;Childhood CKD,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title, 'Controversies in the Management of Dyslipidemia in Children with CKD', was chosen as it clearly contains the diseases and patient population, aligning with the single-source principle.
2.  **Component Identification**: I identified two distinct medical conditions, 'Dyslipidemia' and 'CKD' (Chronic Kidney Disease), and one patient subgroup descriptor, 'Children'.
3.  **Rule Retrieval**: I retrieved rules for the 'Age Group' category, specifically for the keyword 'Children'. The rules (e.g., ID 293, 294) mandate replacing 'Children' with the prefix 'Childhood' and placing it before the associated disease names.
4.  **Rule Application**: 
    *   Applying the age group rule, 'Dyslipidemia in Children' was transformed into 'Childhood Dyslipidemia'.
    *   The context '...in Children with CKD' links the age group to CKD as well, resulting in 'Childhood CKD'.
    *   The generic rule for multiple diseases was applied, which requires listing all distinct indications separated by ';;'.
    *   The generic rule for casing was applied, ensuring 'Childhood', 'Dyslipidemia', and 'Chronic Kidney Disease' (implied by CKD) are in Title Case, while the acronym 'CKD' remains in its original uppercase form.
    *   Non-diagnostic terms like 'Controversies in the Management of' were excluded as per the generic exclusion rules.
5.  **Indication Construction**: The individual components were combined to form the final output: `Childhood Dyslipidemia;;Childhood CKD`.
6.  **Quality Check**: The final indication adheres to all formatting, separation, and content rules. It accurately reflects the two core conditions present in the specified pediatric patient group.","[{'category': 'Age Group', 'subcategories': ['Childhood'], 'reason': ""To correctly handle the 'Children' patient subgroup descriptor.""}, {'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': 'To check for specific rules on handling multiple diseases in the same title, though none were found, defaulting to the generic rule.'}]","[{'component': 'Dyslipidemia', 'type': 'Disease', 'normalized_form': 'Dyslipidemia', 'rule_applied': 'Generic disease identification'}, {'component': 'CKD', 'type': 'Disease', 'normalized_form': 'CKD', 'rule_applied': 'Generic disease identification; Acronym casing rule'}, {'component': 'Children', 'type': 'Age Group', 'normalized_form': 'Childhood', 'rule_applied': 'Age Group rule (ID: 293/294)'}]",2
393583,Hepatocellular Carcinoma (Hcc),"Comparative Efficacy Of Systemic Sequential Regorafenib After Sorafenib Or Lenvatinib Treatment Failure For Advanced Hepatocellular Carcinoma: A Retrospective, Multi-Center, Real-World Study",Advanced;;Hepatocellular Carcinoma,Advanced Hepatocellular Carcinoma,Advanced Hepatocellular Carcinoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: Both the abstract and session titles contain the disease 'Hepatocellular Carcinoma'. As per the single-source principle, the abstract title is prioritized as it provides more specific information.
2. **Component Identification**: The abstract title contains the core disease 'Hepatocellular Carcinoma' and a stage qualifier 'Advanced'. It also includes the phrase 'After Sorafenib Or Lenvatinib Treatment Failure'.
3. **Rule Retrieval**: I retrieved rules for 'Stage' and 'Treatment based' to understand how to handle these components. The 'Stage' rules confirm that stage descriptors like 'Advanced' should be prepended to the disease name. The 'Treatment based' rules do not have a specific rule for 'Treatment Failure'.
4. **Rule Application**: 
   - The stage 'Advanced' is included and prepended to the disease name.
   - The phrase 'After Sorafenib Or Lenvatinib Treatment Failure' is identified as a procedural/temporal qualifier describing the patient's treatment history. According to the generic exclusion rules, such qualifiers are not part of the core indication and are therefore excluded.
   - The generic formatting rules (Title Case, singular form) are applied.
5. **Indication Construction**: The components are combined to form 'Advanced Hepatocellular Carcinoma'.
6. **Quality Check**: The final indication is clinically accurate, follows all formatting and exclusion rules, and is derived from a single source.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To verify the handling of the stage descriptor 'Advanced'.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To determine how to handle the phrase 'Treatment Failure'.""}]","[{'component': 'Advanced', 'type': 'Stage', 'normalized_form': 'Advanced', 'rule_applied': 'Generic rule for prepending stage qualifiers.'}, {'component': 'Hepatocellular Carcinoma', 'type': 'Disease', 'normalized_form': 'Hepatocellular Carcinoma', 'rule_applied': 'Generic rule for singular form and title case.'}, {'component': 'After Sorafenib Or Lenvatinib Treatment Failure', 'type': 'Procedural/Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
262514,Myelodysplastic syndromes - Clinical,Clinical Significance Of Routine High-Resolution Strucural Variant Profiling In Myelodysplastic Syndromes,Myelodysplastic Syndromes,Myelodysplastic Syndrome,Myelodysplastic Syndrome,True,abstract_title,"Step 1: The abstract title contains the disease 'Myelodysplastic Syndromes' and is therefore selected as the primary source.
Step 2: The core disease term 'Myelodysplastic Syndromes' was identified.
Step 3: The generic rule for singular form was applied, converting 'Syndromes' to 'Syndrome'.
Step 4: The generic rule for Title Case was applied, resulting in 'Myelodysplastic Syndrome'.
Step 5: Other phrases in the title such as 'Clinical Significance Of Routine High-Resolution Strucural Variant Profiling' were identified as non-diagnostic study methodologies and excluded as per the exclusion rules.",[],"[{'component': 'Myelodysplastic Syndromes', 'type': 'Disease', 'normalized_form': 'Myelodysplastic Syndrome', 'rule_applied': 'Generic Rule: Singular Form'}]",1
262522,Myelodysplastic syndromes - Clinical,Runx1 Variants With High Variant Allele Frequency In Myeloid Neoplasms. Germline Or Not?,Myeloid Neoplasms,Myeloid Neoplasm,Runx1-Mutated Myeloid Neoplasm,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains a specific disease term ('Myeloid Neoplasms'), so it is selected as the source according to the single-source principle, and the session title is disregarded.
2.  **Component Identification**: The selected title contains the components 'Runx1 Variants' (a genetic descriptor) and 'Myeloid Neoplasms' (a disease).
3.  **Rule Retrieval**: The `get_indication_rules` tool was used for the 'Gene type' category to determine how to handle 'Variants'. While no explicit rule for 'Variant' exists, the rule for 'Gene Mutation' (ID: 30) provides the closest and most clinically appropriate standardization, which is to convert genetic variations into the format '<GENE>-Mutated'.
4.  **Rule Application**: 
    *   The genetic component 'Runx1 Variants' is normalized to 'Runx1-Mutated' based on the logic of the Gene Mutation rule.
    *   The disease term 'Myeloid Neoplasms' is converted to its singular form, 'Myeloid Neoplasm', as per the generic formatting rules.
    *   The phrase 'With High Variant Allele Frequency' is excluded as it describes a technical measurement detail rather than a standard clinical subgroup.
    *   The question 'Germline Or Not?' is excluded as it is part of the study's research question, not the indication itself.
5.  **Indication Construction**: The normalized components are combined to form the final indication: 'Runx1-Mutated Myeloid Neoplasm'.
6.  **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form, proper gene formatting) and exclusion criteria.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To find the correct formatting for the genetic component 'Runx1 Variants'.""}]","[{'component': 'Runx1 Variants', 'type': 'Gene Variant', 'normalized_form': 'Runx1-Mutated', 'rule_applied': ""Applied logic from 'Gene Mutation' rule (ID: 30) as the closest standard for 'Variants'.""}, {'component': 'Myeloid Neoplasms', 'type': 'Disease', 'normalized_form': 'Myeloid Neoplasm', 'rule_applied': 'Generic Rule: Singular Form'}]",2
164220,Society for Pediatric Urology (SPU),Panel Discussion,,,Pediatric Urological Disease,True,session_title,"Step-by-step extraction process:
1.  **Analyze Titles**: The `abstract_title` ('Panel Discussion') contains no medical terms. The `session_title` ('Society for Pediatric Urology (SPU)') contains the terms 'Pediatric' and 'Urology'.
2.  **Select Source**: Based on the Single-Source Extraction Principle, the `session_title` is selected as it is the only source containing relevant medical information.
3.  **Identify Components**: The components identified are the age group 'Pediatric' and the therapeutic area 'Urology'.
4.  **Retrieve Rules**: I retrieved rules for the 'Age Group' category and 'Pediatric' subcategory to handle the age qualifier. I also applied the generic rule for Therapeutic Area Fallback.
5.  **Apply Rules**: 
    - The generic rule for Therapeutic Area Fallback was applied to convert 'Urology' into a standard disease term, 'Urological Disease'.
    - The retrieved 'Pediatric' age group rule (ID: 295, 296) dictates that 'Pediatric' should be used as a prefix to the disease name.
    - Generic formatting rules (Title Case, singular form) were applied.
6.  **Construct Indication**: The components were combined according to the rules: the age group 'Pediatric' was prepended to the normalized disease 'Urological Disease'.
7.  **Final Indication**: The resulting indication is 'Pediatric Urological Disease'.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly handle the 'Pediatric' age group qualifier found in the session title.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule (ID: 295) - Retain 'Pediatric' as a leading qualifier.""}, {'component': 'Urology', 'type': 'Therapeutic Area', 'normalized_form': 'Urological Disease', 'rule_applied': 'Generic Rule: Therapeutic Area Fallback - Convert TA to an overarching disease.'}]",2
409981,Power of Large Biorepositories in Diabetic Kidney Disease,Power of the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repositories,Diabetic Kidney Disease,Diabetic Kidney Disease,Diabetic Kidney Disease,True,session_title,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'Power of the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Repositories', names an institute and broad disease areas, not a specific indication. The session title, 'Power of Large Biorepositories in Diabetic Kidney Disease', contains a clear and specific medical indication.
Step 2: Based on the Single-Source Extraction Principle, I selected the session title as it provides a specific, clinically valid disease.
Step 3: I identified the core disease component 'Diabetic Kidney Disease' from the session title.
Step 4: I applied the generic formatting rules. The term is already in Title Case and singular form. I excluded the non-diagnostic parts of the title ('Power of Large Biorepositories in').
Step 5: The final constructed indication is 'Diabetic Kidney Disease'.",[],"[{'component': 'Diabetic Kidney Disease', 'type': 'Disease', 'normalized_form': 'Diabetic Kidney Disease', 'rule_applied': 'Generic rule: Use title case and singular form.'}]",1
147837,Chronic Lymphocytic Leukemia And Related Disorders - Biology & Translational Research,Influence Of Inflammatory Cytokines On S100A Proteins Expression In Cll Patients,Cll,Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,True,abstract_title,"Step 1: The abstract title was chosen as the primary source because it contains a specific disease term, 'Cll'.
Step 2: 'Cll' was identified as a standard abbreviation for 'Chronic Lymphocytic Leukemia'.
Step 3: The term 'S100A Proteins Expression' was identified as a potential biomarker. I retrieved rules for the 'Gene Name' category to determine its inclusion.
Step 4: According to Gene Name rules (specifically Rule ID 28 and 29), a gene or protein mentioned without a specific, clinically actionable qualifier (like '-Positive', '-Mutated', '-Overexpressing') should be excluded from the final indication. The title describes a study *of* the expression, not a patient subgroup *defined by* the expression status.
Step 5: Based on the rules, 'S100A Proteins Expression' was excluded.
Step 6: The abbreviation 'Cll' was expanded and normalized to 'Chronic Lymphocytic Leukemia' following Title Case and singular form generic rules.","[{'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To determine how to handle the 'S100A Proteins Expression' component.""}]","[{'component': 'Cll', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Standard medical abbreviation expansion and Generic Formatting Rules (Title Case, Singular Form).'}, {'component': 'S100A Proteins Expression', 'type': 'Biomarker', 'normalized_form': '', 'rule_applied': 'Gene Name Rule 29: Exclude standalone gene/protein names that are not linked to a specific molecular qualifier (e.g., mutation, positive status).'}]",2
262527,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Characterization Of Multiple Myeloma Cell Lines With Acquired-Resistance To Proteasome Inhibitors Highlights A Link Between Resistance And Metabolic Deregulation,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease term, 'Multiple Myeloma', which is preferred over the broader terms in the session title ('Myeloma and other monoclonal gammopathies').
2. **Component Identification**: The key components identified in the abstract title are the disease 'Multiple Myeloma' and the qualifier 'Acquired-Resistance To Proteasome Inhibitors'.
3. **Rule Retrieval**: To correctly handle the resistance qualifier, I retrieved rules for the 'Occurrence' category with the subcategory 'Resistance'.
4. **Rule Application**: The retrieved rules (ID: 164, 165) explicitly state that drug or drug-class resistance (e.g., 'Resistant to Proteasome Inhibitors') should not be included in the final indication because it describes a treatment response status rather than a distinct clinical indication. The generic rule to exclude non-diagnostic items was applied to remove 'Cell Lines', as it refers to a research model.
5. **Indication Construction**: Based on the rules, the resistance qualifier was excluded. The core disease 'Multiple Myeloma' was retained.
6. **Formatting**: The indication 'Multiple Myeloma' was already in the correct singular and Title Case format.
7. **Final Output**: The final generated indication is 'Multiple Myeloma'.","[{'category': 'Occurrence', 'subcategories': ['Resistance'], 'reason': ""To determine how to handle the phrase 'Acquired-Resistance To Proteasome Inhibitors'.""}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Use disease term from the selected source.'}, {'component': 'Acquired-Resistance To Proteasome Inhibitors', 'type': 'Resistance Qualifier', 'normalized_form': '', 'rule_applied': 'Occurrence rule (ID: 164, 165) - Exclude drug/drug class resistance from the indication.'}, {'component': 'Cell Lines', 'type': 'Research Model', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule - Exclude non-diagnostic items/study methodologies.'}]",2
409986,A Rocky Course: Bones and Stones Through the Life Span,Novel Therapies in the Management of Genetic Stone Disease: Cystinuria and PH1,Cystinuria;;PH1;;Genetic Stone Disease,Cystinuria;;Primary Hyperoxaluria Type 1;;Genetic Stone Disease,Cystinuria;;PH1,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title ('Novel Therapies in the Management of Genetic Stone Disease: Cystinuria and PH1') contains specific disease names, while the session title ('A Rocky Course: Bones and Stones Through the Life Span') is more general. Based on the Single-Source Extraction Principle, the abstract title is selected.
2.  **Identify Components**: The abstract title explicitly lists two distinct diseases: 'Cystinuria' and 'PH1' (Primary Hyperoxaluria Type 1), which are presented as specific types of 'Genetic Stone Disease'. The most precise indications are the specific diseases mentioned.
3.  **Retrieve Relevant Rules**: No specific category rules were needed as the extraction relies on identifying multiple diseases and applying generic formatting rules.
4.  **Apply Rules**: The generic rule for multiple diseases is applied, which requires separating each distinct disease with a ';;' delimiter. The Casing Rules are applied to ensure 'Cystinuria' is in Title Case, and the acronym 'PH1' is preserved in its original form.
5.  **Construct Indication**: The two identified diseases are combined using the specified delimiter.
6.  **Quality Check**: The final indication 'Cystinuria;;PH1' is checked for adherence to all formatting and content rules. It accurately reflects the specific diseases discussed in the abstract title and follows all formatting requirements.",[],"[{'component': 'Cystinuria', 'type': 'Disease', 'normalized_form': 'Cystinuria', 'rule_applied': 'Generic rule for disease identification and Title Case.'}, {'component': 'PH1', 'type': 'Disease', 'normalized_form': 'PH1', 'rule_applied': 'Generic rule for disease identification and preserving acronyms.'}]",2
311696,Development of Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis (CNO) and Chronic Recurrent Multifocal Osteomyelitis (CRMO),Proposed ACR/EULAR Classification Criteria for CNO,Pediatric;;Chronic Nonbacterial Osteomyelitis,Pediatric Chronic Nonbacterial Osteomyelitis,Pediatric Chronic Nonbacterial Osteomyelitis;;Chronic Recurrent Multifocal Osteomyelitis,True,session_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The session title is 'Development of Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis (CNO) and Chronic Recurrent Multifocal Osteomyelitis (CRMO)'. The abstract title is 'Proposed ACR/EULAR Classification Criteria for CNO'.
2. **Select Source**: The session title is chosen as the source because it contains the full, unabbreviated names of the medical conditions, providing more specific information than the abstract title which only uses the abbreviation 'CNO'.
3. **Identify Components**: Two distinct diseases are identified in the session title:
    - Disease 1: 'Pediatric Chronic Nonbacterial Osteomyelitis (CNO)' which includes an age group ('Pediatric') and the disease name.
    - Disease 2: 'Chronic Recurrent Multifocal Osteomyelitis (CRMO)' which includes an occurrence qualifier ('Recurrent') and the disease name.
4. **Retrieve Rules**: Rules for 'Age Group' (specifically 'Pediatric') and 'Occurrence' (specifically 'Recurrence-Related Terms') were retrieved to ensure correct formatting.
5. **Apply Rules & Construct Indication**:
    - **Generic Rules**: The non-diagnostic phrase 'Development of Proposed Classification Criteria for' and the parenthetical abbreviations '(CNO)' and '(CRMO)' are excluded. The final indications are formatted in Title Case and singular form.
    - **Age Group Rule**: The 'Pediatric' rule (ID: 295) confirms that 'Pediatric' should be retained as a leading qualifier for the first disease.
    - **Occurrence Rule**: The 'Recurrent' rule (ID: 139) confirms that 'Recurrent' should be kept as a qualifier for the second disease.
    - **Construction**: The two distinct indications are extracted and combined using the ';;' separator as required by the formatting rules.
6. **Quality Check**: The final output adheres to the single-source principle, correctly identifies and separates both diseases, applies Title Case, and removes excluded elements, resulting in a high-quality, clinically accurate indication.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To validate the handling of the 'Pediatric' patient subgroup qualifier.""}, {'category': 'Occurrence', 'subcategories': ['Recurrence-Related Terms'], 'reason': ""To ensure the correct formatting of the 'Recurrent' disease qualifier.""}]","[{'component': 'Pediatric Chronic Nonbacterial Osteomyelitis', 'type': 'Disease with Age Group', 'normalized_form': 'Pediatric Chronic Nonbacterial Osteomyelitis', 'rule_applied': ""Age Group rule for 'Pediatric' and Generic Title Case rule.""}, {'component': 'Chronic Recurrent Multifocal Osteomyelitis', 'type': 'Disease with Occurrence', 'normalized_form': 'Chronic Recurrent Multifocal Osteomyelitis', 'rule_applied': ""Occurrence rule for 'Recurrent' and Generic Title Case rule.""}]",2
344465,Contributions of the Tumor Glycome to Immune Suppression and Immunotherapy Resistance and Opportunities for Therapeutic Intervention,Chairperson,,,Tumor,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The `abstract_title` ('Chairperson') contains no medical or disease terms. The `session_title` ('Contributions of the Tumor Glycome to Immune Suppression and Immunotherapy Resistance and Opportunities for Therapeutic Intervention') contains the term 'Tumor'.
2.  **Select Source**: Based on the Single-Source Extraction Principle, the `session_title` is selected as it is the only one containing a potential disease term.
3.  **Identify Components**: The key components in the selected title are 'Tumor', 'Immune Suppression', and 'Immunotherapy Resistance'.
4.  **Retrieve Rules**: To correctly handle 'Immunotherapy Resistance', I retrieved rules for the 'Occurrence' category, specifically the 'Resistance' subcategory.
5.  **Apply Rules**: 
    - The retrieved rules (ID 164, 165) state that resistance descriptors (e.g., 'Drug-Resistant') should not be included in the final indication as they represent a treatment-response status, not a distinct clinical entity. I extended this principle to 'Immunotherapy Resistance' and excluded it.
    - 'Immune Suppression' is a physiological process/complication, not a primary disease, and is excluded under the 'Non-Diagnostic Items' generic rule.
    - The term 'Tumor' is identified as the core disease.
    - The generic rule for singular form is applied, but 'Tumor' is already singular.
    - The generic rule for Title Case is applied.
6.  **Construct Indication**: After applying all rules and exclusions, the only remaining valid component is 'Tumor'.
7.  **Quality Check**: The final indication 'Tumor' adheres to all formatting and content rules. It is derived from a single source and is clinically valid.","[{'category': 'Occurrence', 'subcategories': ['Resistance'], 'reason': ""To determine how to handle the term 'Immunotherapy Resistance' found in the session title.""}]","[{'component': 'Tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': 'Generic rule: Title Case, Singular form.'}, {'component': 'Immune Suppression', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic items and physiologic processes.'}, {'component': 'Immunotherapy Resistance', 'type': 'Treatment Status', 'normalized_form': '', 'rule_applied': 'Retrieved Rule (ID 164/165): Exclude resistance descriptors as they represent treatment-response status, not a distinct indication.'}]",2
344467,Contributions of the Tumor Glycome to Immune Suppression and Immunotherapy Resistance and Opportunities for Therapeutic Intervention,Reprogramming the tumor-immune microenvironment by targeting galectin-glycan interactions,,,Tumor,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains the disease term 'tumor', following the single-source extraction principle.
Step 2: The term 'tumor' was identified as the sole medical indication component in the title. The surrounding text describes biological mechanisms and therapeutic strategies, not patient subgroups or disease characteristics.
Step 3: The generic rules for formatting were applied. The term 'tumor' was converted to Title Case to become 'Tumor'. The term was already in singular form.
Step 4: No other specific patient subgroups, biomarkers, or disease stages were mentioned in the selected title, resulting in the final concise indication.",[],"[{'component': 'tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': 'Generic Rule - Casing'}]",1
295316,Sex and gender differences in oncology: From prevention to care,Gender differences in colorectal cancer screening,colorectal cancer,Colorectal Cancer,Colorectal Cancer,True,abstract_title,"Step 1: The abstract title contains a specific disease, 'colorectal cancer', while the session title contains a broader therapeutic area, 'oncology'. Following the single-source principle, the more specific abstract title is selected.
Step 2: The components identified in the abstract title are 'Gender differences' and 'colorectal cancer screening'.
Step 3: The generic exclusion rules are applied. 'Gender differences' is excluded as a sociodemographic descriptor. 'screening' is excluded as it refers to a procedure/methodology, not the disease itself.
Step 4: The remaining disease term 'colorectal cancer' is normalized according to formatting rules: converted to Title Case and ensured it is in singular form, resulting in 'Colorectal Cancer'.",[],"[{'component': 'Gender differences', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude sociodemographic descriptors (Gender).'}, {'component': 'colorectal cancer', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic Formatting Rule: Title Case and Singular Form.'}, {'component': 'screening', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic items and study methodologies.'}]",1
147864,Chronic Lymphocytic Leukemia And Related Disorders - Clinical,Effectiveness And Safety Of Ibrutinib In Chronic Lymphocytic Leukemia (Cll) And Mantle Cell Lymphoma (Mcl) In Belgian Routine Clinical Practice With A 3-Year Follow-Up,Chronic Lymphocytic Leukemia;;Mantle Cell Lymphoma,Chronic Lymphocytic Leukemia;;Mantle Cell Lymphoma,Chronic Lymphocytic Leukemia;;Mantle Cell Lymphoma,True,abstract_title,"Step 1: The abstract title contains specific disease names ('Chronic Lymphocytic Leukemia (Cll) And Mantle Cell Lymphoma (Mcl)'), so it is selected as the source over the session title, following the single-source principle.
Step 2: Two distinct diseases were identified in the abstract title: 'Chronic Lymphocytic Leukemia' and 'Mantle Cell Lymphoma'.
Step 3: The generic rule for multiple diseases was applied, which requires separating each distinct disease with a ';;' delimiter.
Step 4: Generic formatting rules were applied. The disease names were already in singular form and appropriate Title Case. Extraneous information such as the drug name ('Ibrutinib'), study location ('Belgian'), and study context ('Effectiveness And Safety', 'Routine Clinical Practice', '3-Year Follow-Up') were excluded as per the rules.
Step 5: The final indications were combined to produce the output 'Chronic Lymphocytic Leukemia;;Mantle Cell Lymphoma'.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To confirm the correct procedure for handling titles that mention multiple distinct diseases.'}]","[{'component': 'Chronic Lymphocytic Leukemia (Cll)', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Generic Rule: Singular Form, Title Case, Exclusion of abbreviation'}, {'component': 'Mantle Cell Lymphoma (Mcl)', 'type': 'Disease', 'normalized_form': 'Mantle Cell Lymphoma', 'rule_applied': 'Generic Rule: Singular Form, Title Case, Exclusion of abbreviation'}]",2
393627,Investigational Immunotherapy,Tertiary Lymphoid Structures Localization And Maturation Heterogeneities Correlate With Divergent Clinical Outcomes And Immune Responses Of Clear Cell Renal Cell Carcinoma,Clear Cell Renal Cell Carcinoma,Clear Cell Renal Cell Carcinoma,Clear Cell Renal Cell Carcinoma,True,abstract_title,"Step 1: The abstract title contains a specific disease term, 'Clear Cell Renal Cell Carcinoma', while the session title, 'Investigational Immunotherapy', describes a therapeutic area. Following the single-source principle, the abstract title is selected.
Step 2: The core disease is identified as 'Clear Cell Renal Cell Carcinoma'. Other parts of the title, such as 'Tertiary Lymphoid Structures Localization And Maturation Heterogeneities', describe study findings and not the patient subgroup or the core indication itself.
Step 3: The generic rules for formatting are applied. The disease name is already in Title Case and singular form. No components require retrieval of specific rules from the tool.
Step 4: The final indication is constructed from the identified disease name, resulting in 'Clear Cell Renal Cell Carcinoma'.",[],"[{'component': 'Clear Cell Renal Cell Carcinoma', 'type': 'Disease', 'normalized_form': 'Clear Cell Renal Cell Carcinoma', 'rule_applied': 'Generic Casing and Singular Form Rules'}]",1
213405,"MP07: Bladder & Urethra: Anatomy, Physiology & Pharmacology",Medications mostly associated with haematuria: assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries,haematuria,Haematuria,Haematuria,True,abstract_title,"Step 1: The abstract title contains the medical condition 'haematuria', while the session title only lists anatomical locations ('Bladder & Urethra') and fields of study. Therefore, the abstract title is selected as the source.
Step 2: The term 'haematuria' is identified as the core medical indication.
Step 3: Generic formatting rules are applied. The term is converted to Title Case ('Haematuria'). It is already in singular form.
Step 4: All other parts of the title, such as 'Medications mostly associated with' and 'assessment of the EudraVigilance (EV) and Food and Drug Administration (FDA) Pharmacovigilance databases entries', are excluded as they describe the study's methodology and not the disease or patient population.",[],"[{'component': 'haematuria', 'type': 'Disease', 'normalized_form': 'Haematuria', 'rule_applied': 'Generic Casing Rule (Title Case)'}]",1
164257,Society of Urologic Oncology (SUO),Controversies in the Management of High-Risk Prostate Cancer,High-Risk;;Prostate Cancer,High-Risk Prostate Cancer,High-Risk Prostate Cancer,True,abstract_title,"Step 1: The abstract title 'Controversies in the Management of High-Risk Prostate Cancer' was chosen as the source because it contains a specific disease ('Prostate Cancer'), which is preferred over the therapeutic area ('Urologic Oncology') in the session title.
Step 2: The components identified in the abstract title are the disease 'Prostate Cancer' and the risk qualifier 'High-Risk'.
Step 3: The `get_indication_rules` tool was called for the category 'Risk' and subcategory 'High-Risk' to ensure correct formatting and placement of the risk qualifier.
Step 4: The retrieved rule (ID: 122) confirmed that 'High-Risk' should be normalized and prepended to the disease name. Generic rules were applied to use Title Case, ensure singular form, and exclude non-diagnostic terms like 'Controversies in the Management of'.
Step 5: The components were combined according to the rules to form the final indication 'High-Risk Prostate Cancer'.
Step 6: A quality check confirmed that all rules, including the single-source principle, formatting, and exclusions, were correctly applied.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To validate the formatting and placement of the 'High-Risk' qualifier.""}]","[{'component': 'High-Risk', 'type': 'Risk Qualifier', 'normalized_form': 'High-Risk', 'rule_applied': ""Rule ID: 122 - Normalize risk variants to 'High-Risk' and prepend to the disease name.""}, {'component': 'Prostate Cancer', 'type': 'Disease', 'normalized_form': 'Prostate Cancer', 'rule_applied': 'Generic Rule - Use Title Case and singular form.'}]",2
393639,Investigational Immunotherapy,Analysis Of Pulmonary Adverse Events Associated With Immune Checkpoint Inhibitors Based On Faers And Vigibase Database,,,,True,none,"The abstract title 'Analysis Of Pulmonary Adverse Events Associated With Immune Checkpoint Inhibitors Based On Faers And Vigibase Database' focuses on adverse events (side effects) related to a class of drugs (Immune Checkpoint Inhibitors) and does not mention the primary disease or condition being treated. The session title 'Investigational Immunotherapy' describes a broad therapeutic area, not a specific medical indication. Since neither source contains a valid disease or disorder, no indication can be extracted.",[],"[{'component': 'Pulmonary Adverse Events', 'type': 'Adverse Event', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Complications or adverse effects should be excluded.'}]",1
262567,Myeloma and other monoclonal gammopathies - Clinical,Efficacy And Safety Of Daratumumab Monotherapy In Newly Diagnosed Patients With Stage 3B Light Chain Amyloidosis: A Phase 2 Study By The European Myeloma Network,Newly Diagnosed;;Stage 3B;;Light Chain Amyloidosis,Newly Diagnosed Stage 3B Light Chain Amyloidosis,Newly Diagnosed Stage IIIB Light Chain Amyloidosis,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Light Chain Amyloidosis'), which is preferred over the broader categories in the session title ('Myeloma', 'monoclonal gammopathies') per the single-source principle.
2. **Component Identification**: From the abstract title, I identified the following components: the core disease 'Light Chain Amyloidosis', a diagnosis status 'Newly Diagnosed', and a disease stage 'Stage 3B'.
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Stage number' and 'Diagnosis Status'.
4. **Rule Application**:
   - The rule for 'Diagnosis Status' (ID: 193) confirmed that 'Newly Diagnosed' should be used as a prefix.
   - The rules for 'Stage number' (e.g., ID: 95, 96) indicated that stage numbers with letters should be converted to Roman numerals while retaining the letter. Therefore, 'Stage 3B' was normalized to 'Stage IIIB'.
   - Generic rules for Title Casing and singular form were applied.
5. **Indication Construction**: The identified and normalized components were combined in a clinically logical order, resulting in 'Newly Diagnosed Stage IIIB Light Chain Amyloidosis'.
6. **Quality Check**: The final indication adheres to all formatting and exclusion rules, is derived from a single source, and accurately represents the patient population described in the title.","[{'category': 'Stage', 'subcategories': ['Stage number'], 'reason': ""To correctly format the 'Stage 3B' component.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To handle the 'Newly Diagnosed' patient subgroup.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease.""}, {'component': 'Stage 3B', 'type': 'Stage', 'normalized_form': 'Stage IIIB', 'rule_applied': 'Rule pattern from Stage number rules (e.g., ID 95, 96) - Convert Arabic numeral to Roman numeral.'}, {'component': 'Light Chain Amyloidosis', 'type': 'Disease', 'normalized_form': 'Light Chain Amyloidosis', 'rule_applied': 'Generic Rule - Title Case and singular form.'}]",2
262569,Myeloma and other monoclonal gammopathies - Clinical,High Responses Rates With Single Agent Belantamab Mafodotin In Relapsed Systemic Al Amyloidosis,Relapsed;;Systemic;;Al Amyloidosis,Relapsed Systemic Al Amyloidosis,Relapsed Systemic AL Amyloidosis,True,abstract_title,"Step 1: The abstract title 'High Responses Rates With Single Agent Belantamab Mafodotin In Relapsed Systemic Al Amyloidosis' was chosen as the source because it contains a specific disease term ('Systemic Al Amyloidosis'), which is preferred over the session title according to the single-source principle.
Step 2: The components identified in the title were the disease state 'Relapsed' and the disease name 'Systemic Al Amyloidosis'.
Step 3: Rules for the 'Occurrence' category, specifically for 'Relapse', were retrieved to ensure correct formatting. Rule 144 confirmed that 'Relapsed' should be standardized to Title Case and placed before the disease name.
Step 4: The generic rule for Title Casing was applied. The disease 'Al Amyloidosis' was normalized to the standard clinical representation 'AL Amyloidosis'.
Step 5: The final indication was constructed by combining the standardized components: 'Relapsed' + 'Systemic AL Amyloidosis', resulting in 'Relapsed Systemic AL Amyloidosis'.","[{'category': 'Occurrence', 'subcategories': ['Relapse'], 'reason': ""To correctly format the term 'Relapsed' as a disease state qualifier.""}]","[{'component': 'Relapsed', 'type': 'Occurrence', 'normalized_form': 'Relapsed', 'rule_applied': 'Occurrence Rule 144: Standardize to Title-case and position before the disease name.'}, {'component': 'Systemic Al Amyloidosis', 'type': 'Disease', 'normalized_form': 'Systemic AL Amyloidosis', 'rule_applied': ""Generic Rule: Apply Title Case and standardize clinical acronyms ('Al' -> 'AL').""}]",2
164266,Society for Basic Urologic Research (SBUR),Welcome and Introductory Remarks,,,Urologic Disease,True,session_title,"Step 1: The abstract title 'Welcome and Introductory Remarks' contains no medical or disease terms and is discarded.
Step 2: The session title 'Society for Basic Urologic Research (SBUR)' contains the term 'Urologic', which is a therapeutic area.
Step 3: According to the 'Therapeutic Area Fallback' generic rule, when a title only specifies a therapeutic area, a valid overarching disease should be used.
Step 4: The therapeutic area 'Urologic' is converted to the standard overarching disease name 'Urologic Disease'.
Step 5: The final indication is formatted to Title Case and non-disease terms ('Society for Basic', 'Research', '(SBUR)') are excluded.",[],"[{'component': 'Urologic', 'type': 'Therapeutic Area', 'normalized_form': 'Urologic Disease', 'rule_applied': 'Therapeutic Area Fallback'}]",1
328106,"Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I",Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma,Relapsed;;Refractory;;Mantle Cell Lymphoma,Relapsed/Refractory Mantle Cell Lymphoma,Relapsed/Refractory Mantle Cell Lymphoma,True,abstract_title,"Step 1: The abstract title contains a specific disease, 'Mantle Cell Lymphoma', so it is selected as the primary source over the session title, following the single-source principle.
Step 2: I identified the core disease 'Mantle Cell Lymphoma' and the patient subgroup qualifier 'Relapsed/Refractory'.
Step 3: I retrieved rules for 'Occurrence' to correctly format 'Relapsed/Refractory'. The retrieved rule, while for a slightly different keyword, confirms the standard practice of placing this qualifier before the disease name.
Step 4: I applied the generic rules. The disease term is already singular. I ensured the final output uses Title Case, resulting in 'Relapsed/Refractory Mantle Cell Lymphoma'.
Step 5: The final indication was constructed by combining the qualifier and the disease name.
Step 6: A quality check confirmed that all rules were followed, including single-source selection, formatting, and inclusion of the relevant patient subgroup.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To verify the correct formatting and placement of the 'Relapsed/Refractory' qualifier.""}]","[{'component': 'Relapsed/Refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rule for Recurrent/Refractory terms and Title Case rule.'}, {'component': 'Mantle Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Mantle Cell Lymphoma', 'rule_applied': 'Generic singular form and Title Case rules.'}]",2
377263,Myeloma and other monoclonal gammopathies - Clinical,Role Of Interleukin 6 And Angiopoietins 1 And 2 In The Evolution Of Patients Diagnosed With Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Role Of Interleukin 6 And Angiopoietins 1 And 2 In The Evolution Of Patients Diagnosed With Multiple Myeloma'. The session title is 'Myeloma and other monoclonal gammopathies - Clinical'.
2.  **Select Source**: Both titles contain disease terms. The abstract title contains 'Multiple Myeloma', which is a very specific disease. The session title contains 'Myeloma' and 'monoclonal gammopathies'. According to the single-source principle, the abstract title is preferred as it provides a complete and specific indication.
3.  **Identify Components**: The key component in the abstract title is the disease 'Multiple Myeloma'. The phrase 'Diagnosed With' is a descriptor of the patient's status.
4.  **Retrieve Rules**: I retrieved rules for 'Diagnosis Status' to determine if 'Diagnosed With' should be included. The available rule was for 'Newly Diagnosed', which does not apply here. General exclusion rules state that procedural or temporal qualifiers should be excluded.
5.  **Apply Rules**: 
    *   The disease term is 'Multiple Myeloma'.
    *   The phrase 'Patients Diagnosed With' is a descriptor of the patient population and is excluded under the generic rules for procedural/temporal qualifiers.
    *   The disease name is already in singular form and proper Title Case.
6.  **Construct Indication**: The final indication is constructed from the core disease term identified.
7.  **Quality Check**: The final indication 'Multiple Myeloma' is clinically accurate, correctly formatted (Title Case, singular), and adheres to the single-source principle. All non-diagnostic elements have been correctly excluded.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To check how to handle the phrase 'Diagnosed With' found in the abstract title.""}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Use core disease name.'}, {'component': 'Diagnosed With', 'type': 'Patient Status', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers.'}]",2
213425,MP08: Pediatric Urology: Penis & Scrotum,Long Term Fertility Implications Following Adolescent Testicular Torsion: A Retrospective Analysis of a New York State All-Payer Database,,,Adolescent Testicular Torsion,True,abstract_title,"Step 1: The abstract title contains a specific disease ('Testicular Torsion'), while the session title contains a therapeutic area and anatomical locations. Therefore, the abstract title was chosen as the source based on the single-source principle.
Step 2: The core components were identified from the abstract title: the disease 'Testicular Torsion' and the patient subgroup 'Adolescent'.
Step 3: To ensure correct formatting for the age group, a rule lookup was performed for 'Adolescent' using `get_indication_rules`.
Step 4: Generic exclusion rules were applied to remove non-diagnostic information, including the outcome ('Long Term Fertility Implications'), the temporal qualifier ('Following'), and study design details ('A Retrospective Analysis of a New York State All-Payer Database').
Step 5: The retrieved rules (specifically ID 318 and 319) confirmed that 'Adolescent' should be prepended to the disease name.
Step 6: The final indication was constructed by combining the normalized patient subgroup and the disease, resulting in 'Adolescent Testicular Torsion'.","[{'category': 'Age Group', 'subcategories': ['Adolescent'], 'reason': ""To verify the correct formatting and placement of the 'Adolescent' patient subgroup qualifier.""}]","[{'component': 'Adolescent', 'type': 'Age Group', 'normalized_form': 'Adolescent', 'rule_applied': 'Age Group rule ID 318/319: Prepend singular, Title Case age group to the disease name.'}, {'component': 'Testicular Torsion', 'type': 'Disease', 'normalized_form': 'Testicular Torsion', 'rule_applied': 'Generic Rule: Use Title Case and singular form for disease names.'}]",3
295345,Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?,Presentation by Expert,Chronic lymphocytic leukemia,Chronic Lymphocytic Leukemia,First-Line Chronic Lymphocytic Leukemia,True,session_title,"Step-by-step explanation of the extraction process:
1.  **Source Selection**: The abstract title 'Presentation by Expert' contains no medical information. The session title 'Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?' contains a clear disease and treatment context. Therefore, the session title was selected as the source based on the single-source principle.
2.  **Component Identification**: The key components identified in the session title are the disease 'Chronic lymphocytic leukemia (CLL)' and the treatment context 'first-line therapy'.
3.  **Rule Retrieval**: To correctly handle 'first-line therapy', I retrieved rules for the 'Treatment Set-up' category, specifically for the 'Line of treatment' subcategory.
4.  **Rule Application**:
    *   **Generic Rules**: The disease name was converted to Title Case ('Chronic Lymphocytic Leukemia'). The parenthetical abbreviation '(CLL)' was excluded as it is redundant.
    *   **Specific Rules**: Based on the retrieved 'Line of treatment' rules (specifically Rule ID 199 and 200), the phrase 'first-line therapy' is retained because 'first-line' is followed by the generic word 'therapy'. The rules mandate standardizing it to 'First-Line' and placing it at the beginning of the indication.
5.  **Indication Construction**: The standardized treatment line 'First-Line' was prepended to the normalized disease name 'Chronic Lymphocytic Leukemia' to form the final indication.
6.  **Quality Check**: The final indication adheres to all formatting and content rules. It is clinically accurate, correctly cased, and derived from a single source.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine how to handle the 'first-line therapy' context.""}]","[{'component': 'Chronic lymphocytic leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'first-line therapy', 'type': 'Line of treatment', 'normalized_form': 'First-Line', 'rule_applied': ""Treatment Set-up Rule ID 200: Standardize to 'First-Line' and place at the beginning of the indication.""}]",2
393651,Melanoma And Other Skin Tumours,Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy After Relapse On A Prior Adjuvant Checkpoint Inhibitor And Subsequent Surgical Resection In Patients With Braf V600-Mutated Stage Iii/Iv Melanoma,Braf V600-Mutated;;Stage Iii/Iv;;Melanoma,Braf V600-Mutated Stage III/IV Melanoma,BRAF V600-Mutated Stage III/IV Melanoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains a specific disease ('Melanoma') and detailed patient subgroup information, making it more informative than the session title ('Melanoma And Other Skin Tumours').
2.  **Component Identification**: The key components identified in the abstract title are:
    *   Disease: 'Melanoma'
    *   Gene Mutation: 'Braf V600-Mutated'
    *   Stage: 'Stage Iii/Iv'
    *   Excluded Terms: Phrases describing treatment history ('After Relapse On A Prior Adjuvant Checkpoint Inhibitor And Subsequent Surgical Resection') were identified for exclusion based on generic rules against procedural/temporal qualifiers.
3.  **Rule Retrieval and Application**:
    *   **Gene Mutation**: Although no specific rule was found for 'Gene Mutated' via the tool, standard formatting was applied. The gene symbol 'Braf' was capitalized to 'BRAF' as per convention. The descriptor 'Mutated' was appended with a hyphen, resulting in 'BRAF V600-Mutated'.
    *   **Staging**: Rules for 'Stage number' were retrieved. These rules confirm the use of capitalized Roman numerals. Therefore, 'Stage Iii/Iv' was normalized to 'Stage III/IV'.
    *   **Disease**: The disease term 'Melanoma' was already in the correct singular form and was formatted to 'Melanoma' (Title Case).
4.  **Indication Construction**: The normalized components were combined in a clinically standard order (Gene -> Stage -> Disease) to form the final indication.
5.  **Final Quality Check**: The generated indication was reviewed to ensure it adheres to all formatting rules (Title Case, singular form, proper capitalization of gene symbols and Roman numerals) and exclusion criteria, resulting in a concise and clinically accurate indication.","[{'category': 'Gene type', 'subcategories': ['Gene Mutated'], 'reason': ""To check for specific formatting rules for gene mutations like 'Braf V600-Mutated'.""}, {'category': 'Stage', 'subcategories': ['Stage number'], 'reason': ""To validate the formatting for cancer staging, specifically for 'Stage Iii/Iv'.""}]","[{'component': 'Melanoma', 'type': 'Disease', 'normalized_form': 'Melanoma', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'Braf V600-Mutated', 'type': 'Gene Mutation', 'normalized_form': 'BRAF V600-Mutated', 'rule_applied': 'Generic rule: Casing for gene symbols (all-caps)'}, {'component': 'Stage Iii/Iv', 'type': 'Stage', 'normalized_form': 'Stage III/IV', 'rule_applied': 'Stage rule: Use of capitalized Roman numerals for staging (ID: 92, 93)'}, {'component': 'After Relapse On A Prior Adjuvant Checkpoint Inhibitor And Subsequent Surgical Resection', 'type': 'Procedural/Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclusion of procedural and treatment history terms'}]",2
393652,Melanoma And Other Skin Tumours,Adjuvant Treatment With Anti-Pd-1 In Acral Melanoma Patients: A Nationwide Study,Acral Melanoma,Acral Melanoma,Acral Melanoma,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: Both the abstract title ('Adjuvant Treatment With Anti-Pd-1 In Acral Melanoma Patients: A Nationwide Study') and the session title ('Melanoma And Other Skin Tumours') contain disease terms. The abstract title is more specific.
2. **Select Source**: Based on the Single-Source Extraction Principle, the abstract title is selected as the source because it contains a specific disease term ('Acral Melanoma').
3. **Identify Components**: The key components identified in the abstract title are 'Adjuvant Treatment' (treatment context), 'Acral' (disease subtype/patient subgroup), and 'Melanoma' (disease).
4. **Retrieve Rules**: Rules for 'Treatment Set-up' and 'Patient Sub-Group' were retrieved to determine how to handle 'Adjuvant' and 'Acral'.
5. **Apply Rules**: 
   - The generic exclusion rule for procedural/temporal qualifiers is applied to 'Adjuvant Treatment', as it describes the treatment setting rather than the core indication. It is therefore excluded.
   - 'Acral' is a clinically significant subtype of melanoma that defines a specific patient population. It is not a generic descriptor and is retained as part of the indication.
   - The term 'Patients' is removed as it is a generic descriptor.
   - The phrase 'A Nationwide Study' is excluded as it describes the study methodology.
6. **Construct Indication**: The specific subtype 'Acral' is combined with the core disease 'Melanoma'.
7. **Formatting**: The final indication is formatted to Title Case and singular form, resulting in 'Acral Melanoma'.
8. **Quality Check**: The final indication adheres to all formatting and exclusion rules, is derived from a single source, and is clinically accurate.","[{'category': 'Treatment Set-up', 'subcategories': ['Treatment Modality'], 'reason': ""To determine how to handle the term 'Adjuvant Treatment'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify if 'Acral' is a standard patient subgroup descriptor.""}]","[{'component': 'Adjuvant Treatment', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}, {'component': 'Acral Melanoma', 'type': 'Disease', 'normalized_form': 'Acral Melanoma', 'rule_applied': 'Inclusion of specific disease subtype and application of Title Case and singular form rules.'}]",2
262579,Myeloma and other monoclonal gammopathies - Clinical,Survival Outcomes Of Patients With Multiple Myeloma In France: A Cohort Study Using The French National Healthcare Database (Snds),Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: The abstract title was chosen as the primary source because it contains a specific disease term, 'Multiple Myeloma', which is more precise than the terms in the session title ('Myeloma and other monoclonal gammopathies').
Step 2: The core disease 'Multiple Myeloma' was identified from the abstract title.
Step 3: The generic exclusion rule for sociodemographic descriptors was applied to remove the geographic location 'In France'.
Step 4: Generic formatting rules (Title Case, singular form) were applied. The term 'Multiple Myeloma' already adheres to these standards, so no changes were needed.
Step 5: The final indication was constructed from the standardized disease term.",[],"[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Casing and Singular Form Rules'}, {'component': 'In France', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Sociodemographic Descriptors'}]",1
262577,Myeloma and other monoclonal gammopathies - Clinical,Incidence And Clinical Outcome Of Sars-Cov-2 Infection After Vaccination In Patients With Monoclonal Gammopathy Of Undetermined Significance (Mgus),Sars-Cov-2 Infection;;Monoclonal Gammopathy,Sars-Cov-2 Infection;;Monoclonal Gammopathy,SARS-CoV-2 Infection;;Monoclonal Gammopathy Of Undetermined Significance,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains specific disease terms ('Sars-Cov-2 Infection', 'Monoclonal Gammopathy Of Undetermined Significance').
Step 2: Two distinct diseases were identified in the title. The generic rule for multiple diseases was applied, requiring extraction of all diseases separated by ';;'.
Step 3: The first disease, 'Sars-Cov-2 Infection', was normalized to 'SARS-CoV-2 Infection' to maintain the standard acronym format.
Step 4: The second disease, 'Monoclonal Gammopathy Of Undetermined Significance (Mgus)', was processed. The parenthetical abbreviation '(Mgus)' was removed, and the full disease name was retained in Title Case.
Step 5: The procedural qualifier 'After Vaccination' was excluded as per the generic exclusion rules.
Step 6: The two extracted and normalized indications were combined using the ';;' separator to produce the final output.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To confirm the correct procedure for handling titles that mention two distinct diseases.'}, {'category': 'Patient Sub-Group', 'subcategories': ['Abbreviation'], 'reason': ""To check for rules regarding the handling of abbreviations like '(Mgus)'.""}]","[{'component': 'Sars-Cov-2 Infection', 'type': 'Disease', 'normalized_form': 'SARS-CoV-2 Infection', 'rule_applied': 'Generic Casing Rule - Maintain original all-caps form for acronyms.'}, {'component': 'Monoclonal Gammopathy Of Undetermined Significance (Mgus)', 'type': 'Disease', 'normalized_form': 'Monoclonal Gammopathy Of Undetermined Significance', 'rule_applied': 'Generic Formatting Rule - Remove parenthetical abbreviations when the full term is present.'}, {'component': 'After Vaccination', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule - Exclude procedural/temporal qualifiers.'}]",2
295352,Young Oncologist Brunch 2: How to write and respond to a critical peer review,How to write and respond to a critical peer review,,,Cancer,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract_title 'How to write and respond to a critical peer review' contains no medical or disease-related terms. The session_title 'Young Oncologist Brunch 2: How to write and respond to a critical peer review' contains the term 'Oncologist'. Based on the single-source principle, the session_title is selected as it is the only one containing a relevant term.
2.  **Component Identification**: The key components in the session_title are 'Young' and 'Oncologist'.
3.  **Rule Retrieval**: Rules for the age group 'Young' were retrieved to determine its applicability. The term 'Oncologist' relates to the therapeutic area of Oncology.
4.  **Rule Application**: 
    *   The retrieved rules for 'Young' (IDs 308, 309) indicate that this term should be excluded as a non-specific age descriptor. Furthermore, in this context, 'Young' describes the professional (the oncologist), not a patient subgroup, so it is excluded under the sociodemographic exclusion rule.
    *   The generic rules specify a fallback for therapeutic areas. 'Oncologist' implies the therapeutic area 'Oncology', which is mapped to the overarching disease 'Cancer'.
5.  **Indication Construction**: The only valid component is 'Cancer', derived from 'Oncologist'.
6.  **Formatting**: The term 'Cancer' is already in singular form and Title Case. No further formatting is needed.","[{'category': 'Age Group', 'subcategories': ['Young'], 'reason': ""To determine how to handle the term 'Young' found in the session title.""}]","[{'component': 'Oncologist', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': 'Therapeutic Area Fallback generic rule (Oncology -> Cancer).'}, {'component': 'Young', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': ""Generic exclusion rule for sociodemographic descriptors and specific rule ID 308 for 'Young'. The term describes the professional, not a patient cohort.""}]",2
377273,Bone marrow failure syndromes incl. PNH - Biology & Translational Research,Preliminary Exploration On Lag-3 Expression Of Bone Marrow-Derived Macrophages In Severe Aplastic Anemia,Severe;;Aplastic Anemia,Severe Aplastic Anemia,Severe Aplastic Anemia,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Preliminary Exploration On Lag-3 Expression Of Bone Marrow-Derived Macrophages In Severe Aplastic Anemia'. The session title is 'Bone marrow failure syndromes incl. PNH - Biology & Translational Research'.
2.  **Select Source**: The abstract title contains a specific disease ('Severe Aplastic Anemia'). According to the single-source principle, the abstract title is prioritized over the session title.
3.  **Identify Components**: The key components in the abstract title are the disease 'Aplastic Anemia' and the severity qualifier 'Severe'. The other parts of the title ('Preliminary Exploration On Lag-3 Expression Of Bone Marrow-Derived Macrophages In') describe the study's methodology and are not part of the core indication.
4.  **Retrieve Rules**: I retrieved rules for the 'severe' keyword under the 'Risk' category to confirm how to handle severity descriptors. The rules confirm that such descriptors should be included and normalized.
5.  **Apply Rules**: 
    *   **Generic Rule (Exclusion)**: Excluded the methodological parts of the title.
    *   **Generic Rule (Title Case)**: Applied Title Case to the final indication, resulting in 'Severe Aplastic Anemia'.
    *   **Generic Rule (Singular Form)**: The term 'Anemia' is already in its singular form.
6.  **Construct Indication**: The final indication is constructed by combining the severity qualifier with the disease name.
7.  **Quality Check**: The final indication adheres to all formatting and content rules. It is sourced exclusively from the abstract title and accurately represents the core medical condition.","[{'category': 'Risk', 'subcategories': ['severe'], 'reason': ""To verify the correct handling and formatting of the severity descriptor 'Severe'.""}]","[{'component': 'Severe Aplastic Anemia', 'type': 'Disease with Severity', 'normalized_form': 'Severe Aplastic Anemia', 'rule_applied': ""Generic rules for Title Case, Singular Form, and Exclusion. The retrieved rule for 'severe' confirmed that severity is a valid qualifier to include.""}]",2
410042,"APOL1, Nephrotic Syndrome, and HNF1B: Expanding Phenotypes and Mechanisms in Genetic Diseases",Common Variants in Mendelian Disease Genes as Risk Factors for CKD,CKD,Chronic Kidney Disease,Chronic Kidney Disease;;Mendelian Disease,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract_title is 'Common Variants in Mendelian Disease Genes as Risk Factors for CKD'. The session_title is 'APOL1, Nephrotic Syndrome, and HNF1B: Expanding Phenotypes and Mechanisms in Genetic Diseases'.
2. **Select Source**: The abstract_title contains specific disease terms ('Mendelian Disease', 'CKD') and is therefore selected as the primary source, following the Single-Source Extraction Principle.
3. **Identify Components**: The abstract_title identifies two distinct conditions: 'Mendelian Disease' and 'CKD' (Chronic Kidney Disease). The phrase 'as Risk Factors for' links them but both are valid medical conditions.
4. **Retrieve Rules**: I checked for rules related to 'Risk' and 'Patient with two different Disease'. The 'Risk' rules apply to specific stratifications (e.g., 'High-Risk', 'Low-Risk') and not the general term 'Risk Factors', so they are not applicable for modifying the indication. The generic rule for multiple diseases is to extract all of them.
5. **Apply Rules & Construct Indication**:
   - **Disease Identification**: Both 'Mendelian Disease' and 'CKD' are identified as distinct diseases mentioned in the title.
   - **Normalization**: 'CKD' is expanded to its full form 'Chronic Kidney Disease'.
   - **Formatting**: Both terms are converted to Title Case and singular form as per generic rules.
   - **Multiple Diseases**: According to the rule for multiple diseases, when a title mentions more than one distinct condition, all should be extracted and separated by ';;'. The title discusses variants in Mendelian Disease genes as risk factors for Chronic Kidney Disease, making both concepts central to the subject.
6. **Final Output**: The two extracted and normalized indications are combined using the ';;' separator, resulting in 'Chronic Kidney Disease;;Mendelian Disease'.","[{'category': 'Patient with two different Disease', 'subcategories': [], 'reason': ""To check how to handle titles with multiple potential diseases like 'Mendelian Disease' and 'CKD'.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To determine how to handle the term 'Risk Factors' found in the abstract title.""}]","[{'component': 'CKD', 'type': 'Disease', 'normalized_form': 'Chronic Kidney Disease', 'rule_applied': 'Abbreviation expansion and Title Case rule.'}, {'component': 'Mendelian Disease', 'type': 'Disease', 'normalized_form': 'Mendelian Disease', 'rule_applied': 'Title Case and Singular form rule.'}, {'component': 'Risk Factors', 'type': 'Qualifier', 'normalized_form': '', 'rule_applied': ""General exclusion rule. 'Risk Factors' is a study descriptor, not a standard clinical patient subgroup like 'High-Risk' or 'Low-Risk', and is therefore excluded from the final indication.""}]",2
344512,"New Insights into Cancer Initiation, Evolution, Therapy and Survivorship through Big Data Analysis",Ordered and selective patterns of cancer genome evolution revealed by lineage tracing of sporadic p53 loss,cancer,Cancer ,TP53-Depleted Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Ordered and selective patterns of cancer genome evolution revealed by lineage tracing of sporadic p53 loss') was chosen over the session title because it contains a specific genetic event ('p53 loss') linked to a disease ('cancer'), making it more specific.
2. **Component Identification**: The key components identified in the abstract title are the disease 'cancer' and the genetic event 'p53 loss'.
3. **Rule Retrieval**: Rules for the 'Gene type' category were retrieved to correctly handle the genetic event 'p53 loss'.
4. **Rule Application**: 
   - The disease term 'cancer' was normalized to 'Cancer' using the generic Title Case and singular form rules.
   - The genetic event 'p53 loss' was processed. The gene 'p53' is standardized to its official HGNC symbol 'TP53'. The term 'loss' is handled by rules for gene depletion/deficiency (e.g., Rule ID 76 for 'Gene Depleted' which covers 'loss of'). This transforms 'TP53 loss' into the standardized format 'TP53-Depleted'.
5. **Indication Construction**: The normalized components were combined, with the genetic qualifier preceding the disease, resulting in 'TP53-Depleted Cancer'.
6. **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular, no excluded terms) and is clinically accurate.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To find the correct rule for handling the 'p53 loss' genetic event.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': 'To check for any other rules related to genetic status that might apply.'}]","[{'component': 'cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic Title Case and singular form rules.'}, {'component': 'p53 loss', 'type': 'Gene Depletion', 'normalized_form': 'TP53-Depleted', 'rule_applied': ""Rule for 'Gene Depleted' (ID: 76), which standardizes 'loss of' a gene to the '<Gene>-Depleted' format, and standardization of 'p53' to 'TP53'.""}]",2
295362,ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer,State of the art first-line management of patients with advanced RCC,advanced;;RCC,Advanced Renal Cell Carcinoma,First-Line Advanced Renal Cell Carcinoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('State of the art first-line management of patients with advanced RCC') was chosen over the session title because it contains a specific disease term ('RCC') and provides a complete context for the indication. The Single-Source Extraction Principle dictates using the abstract title first.
2.  **Component Identification**: I identified three key components in the abstract title: 'first-line' (treatment line), 'advanced' (disease stage), and 'RCC' (disease).
3.  **Rule Retrieval**: I retrieved rules for 'Stage', 'Treatment Set-up', and 'Patient Sub-Group' to correctly handle these components.
4.  **Component Normalization & Rule Application**:
    *   **Disease**: 'RCC' is a standard medical acronym for 'Renal Cell Carcinoma'. This was expanded and normalized to 'Renal Cell Carcinoma' in Title Case, following generic formatting rules.
    *   **Stage**: The term 'advanced' was identified as a stage descriptor. Based on staging rules, it is prepended to the disease name and formatted as 'Advanced'.
    *   **Treatment Line**: The term 'first-line' modifies 'management', which is a generic term. According to the retrieved 'Line of treatment' rules (specifically Rule ID 199 and 200), when a line descriptor is not followed by a specific drug name, it should be retained, normalized to 'First-Line', and placed at the beginning of the indication.
5.  **Indication Construction**: The normalized components were assembled in the correct clinical order: Treatment Line -> Stage -> Disease. This resulted in 'First-Line Advanced Renal Cell Carcinoma'.
6.  **Exclusion**: Non-diagnostic phrases like 'State of the art', 'management of', and 'patients with' were excluded as per the generic exclusion rules.
7.  **Final Quality Check**: The final indication was checked for compliance with all formatting rules (Title Case, singular form, no trailing spaces) and clinical accuracy.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To determine the correct handling and formatting of the term 'advanced'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To verify whether 'first-line' should be included in the indication and how to format it.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': 'To check for any other rules related to disease characterization that might apply.'}]","[{'component': 'first-line', 'type': 'Line of treatment', 'normalized_form': 'First-Line', 'rule_applied': ""Treatment Set-up rule (ID: 200) for retaining and standardizing line of treatment when modifying a generic term like 'management'.""}, {'component': 'advanced', 'type': 'Stage', 'normalized_form': 'Advanced', 'rule_applied': 'Generic rule for prepending stage descriptors to the disease name and applying Title Case.'}, {'component': 'RCC', 'type': 'Disease', 'normalized_form': 'Renal Cell Carcinoma', 'rule_applied': 'Standard medical acronym expansion and generic formatting rules (Title Case, singular form).'}]",2
311747,"Experts Roundtable: Current and Future Payment Models, MIPS, and Other Hot Topics in Practice Management",Q&A,,,,True,none,"Neither the abstract title ('Q&A') nor the session title ('Experts Roundtable: Current and Future Payment Models, MIPS, and Other Hot Topics in Practice Management') contains any specific disease, disorder, or clinically relevant medical term. The titles refer to practice management and a Q&A session, from which no medical indication can be extracted.",[],[],1
393665,Melanoma And Other Skin Tumours,First-Line Nivolumab Plus Ipilimumab In Advanced Melanoma Patients Previously Treated With Adjuvant Systemic Therapy.,Advanced;;Melanoma,Advanced Melanoma,Advanced Melanoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'First-Line Nivolumab Plus Ipilimumab In Advanced Melanoma Patients Previously Treated With Adjuvant Systemic Therapy' contains a specific disease ('Melanoma') and is therefore selected as the primary source over the session title, following the Single-Source Extraction Principle.

2.  **Component Identification**: The selected title contains the following components:
    *   Line of Treatment: 'First-Line'
    *   Disease: 'Melanoma'
    *   Stage: 'Advanced'
    *   Patient History: 'Previously Treated With Adjuvant Systemic Therapy'

3.  **Rule Retrieval**: 
    *   To handle 'First-Line', rules for 'Treatment Set-up' (subcategory 'Line of treatment') were retrieved.
    *   To handle 'Advanced', rules for 'Stage' (subcategory 'Stage Type') were retrieved.
    *   To handle 'Previously Treated' and 'Adjuvant', rules for 'Treatment Set-up' (subcategory 'Treatment Status') were retrieved.

4.  **Rule Application**:
    *   **Line of Treatment ('First-Line')**: Rule 199 ('Treatment Set-up') states that line-of-treatment descriptors like 'first-line' should be excluded when immediately followed by a specific drug name. In the title, 'First-Line' is followed by 'Nivolumab Plus Ipilimumab'. Therefore, 'First-Line' is excluded from the indication.
    *   **Patient History ('Previously Treated With Adjuvant Systemic Therapy')**: The generic exclusion rule for 'Procedural/Temporal Qualifiers' mandates the removal of terms describing treatment history like 'previously treated'. Additionally, Rule 209 ('Treatment Set-up') specifically requires excluding 'Adjuvant'. The entire phrase 'Previously Treated With Adjuvant Systemic Therapy' is therefore excluded.
    *   **Stage ('Advanced')**: 'Advanced' is a standard clinical stage descriptor and is retained.
    *   **Disease ('Melanoma')**: The core disease term is retained.
    *   **Formatting**: The components are combined and formatted according to generic rules: 'Advanced' + 'Melanoma' -> 'Advanced Melanoma'. Title Case is applied, and the term is already singular.

5.  **Final Indication Construction**: After applying all rules, the only remaining components are the stage 'Advanced' and the disease 'Melanoma'. Combining these results in the final indication: 'Advanced Melanoma'.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment', 'Treatment Status'], 'reason': ""To correctly handle the terms 'First-Line', 'Previously Treated', and 'Adjuvant'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To determine how to process the stage descriptor 'Advanced'.""}]","[{'component': 'First-Line', 'type': 'Line of Treatment', 'normalized_form': '', 'rule_applied': 'Rule 199 (Treatment Set-up): Exclude line-of-treatment when followed by a drug name.'}, {'component': 'Advanced Melanoma', 'type': 'Disease with Stage', 'normalized_form': 'Advanced Melanoma', 'rule_applied': 'Generic Rule: Retain stage descriptors. Generic Rule: Use Title Case and singular form.'}, {'component': 'Previously Treated With Adjuvant Systemic Therapy', 'type': 'Patient Treatment History', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule (Procedural/Temporal Qualifiers) and Rule 209 (Treatment Set-up): Exclude treatment history and 'Adjuvant'.""}]",2
295365,ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer,Q&A and discussion,advanced;;renal cancer,Advanced Renal Cancer,Advanced Renal Cancer,True,session_title,"Step 1: The abstract title 'Q&A and discussion' contains no medical information. The session title 'ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer' contains a clear disease term.
Step 2: Based on the single-source principle, the session title was selected for extraction.
Step 3: The components identified in the session title are the disease 'renal cancer' and the stage qualifier 'advanced'.
Step 4: I retrieved rules for the 'Stage' category to understand how to handle terms like 'advanced'. Although no specific rule for 'advanced' was found, the general pattern is to prefix the disease with the stage descriptor.
Step 5: The generic rules for formatting were applied. 'renal cancer' was converted to 'Renal Cancer' (Title Case). The qualifier 'advanced' was also capitalized and placed before the disease.
Step 6: The final indication was constructed by combining the qualifier and the disease, resulting in 'Advanced Renal Cancer'.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for rules on how to handle the stage descriptor 'advanced'.""}]","[{'component': 'advanced renal cancer', 'type': 'Disease with Stage', 'normalized_form': 'Advanced Renal Cancer', 'rule_applied': 'Generic rule for Title Case and singular form. Pattern observed from Stage rules where the stage descriptor precedes the disease name.'}]",2
344518,Late-Breaking Research: Chemistry,BI 907828: A highly potent MDM2-p53 antagonist suitable for intermittent dose schedules,,,,True,none,"The abstract title describes a drug (BI 907828) and its mechanism of action (MDM2-p53 antagonist) but does not explicitly state a disease, disorder, or patient population. The session title, 'Late-Breaking Research: Chemistry', is a broad, non-clinical research area. According to the single-source principle, a disease or condition must be present in one of the titles to extract an indication. Since neither title contains a valid medical indication, no extraction is possible.",[],[],1
377287,Infections and SCT complications,"A Novel Approach Of Dual Metagenomics Next-Generation Sequencing For Early Diagnosis Of Blood Stream Infection In Hematologic Patients With Febrile Neutropenia: A Multicenter, Prospective Study",Febrile Neutropenia,Febrile Neutropenia,Blood Stream Infection;;Febrile Neutropenia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('A Novel Approach Of Dual Metagenomics Next-Generation Sequencing For Early Diagnosis Of Blood Stream Infection In Hematologic Patients With Febrile Neutropenia: A Multicenter, Prospective Study') was chosen over the session title ('Infections and SCT complications') because it contains specific, well-defined medical conditions, adhering to the single-source principle.
2.  **Component Identification**: The abstract title clearly identifies two distinct medical conditions: 'Blood Stream Infection' and 'Febrile Neutropenia'. The term 'Hematologic Patients' describes the patient population but is a broad descriptor of a patient type rather than a specific disease qualifier, so it is excluded based on the principle of creating concise, disease-focused indications.
3.  **Rule Retrieval**: I initiated a search for rules related to handling multiple diseases ('Patient with two different Disease') and patient characterization ('Patient Sub-Group'). No specific rule for combining these particular conditions was found, so I proceeded with the generic rules.
4.  **Rule Application**: The generic rule for 'Multiple Diseases' was applied. This rule mandates that if a title mentions multiple distinct diseases, all should be extracted and separated by a double semicolon (';;').
5.  **Indication Construction**: The identified diseases were normalized according to the generic formatting rules:
    *   'Blood Stream Infection' was kept as is (already Title Case and singular).
    *   'Febrile Neutropenia' was kept as is (already Title Case and singular).
    *   The two indications were combined using the ';;' separator.
6.  **Final Quality Check**: The final output 'Blood Stream Infection;;Febrile Neutropenia' was reviewed to ensure it is clinically accurate, follows all formatting guidelines (Title Case, singular, no trailing spaces), and adheres to the single-source principle.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To check for specific rules on how to handle two distinct conditions mentioned for the same patient group.'}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To determine if 'Hematologic Patients' should be included as a qualifier.""}]","[{'component': 'Blood Stream Infection', 'type': 'Disease', 'normalized_form': 'Blood Stream Infection', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'Febrile Neutropenia', 'type': 'Disease', 'normalized_form': 'Febrile Neutropenia', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'Hematologic Patients', 'type': 'Patient Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Broad patient group descriptors are excluded to maintain conciseness.'}]",2
410057,Maternal and Environmental Factors: Effect on Kidney Formation and Function,Mechanisms of Kidney Injury and Lower Endowment in the Extreme Preterm,Kidney Injury,Kidney Injury,Extreme Preterm Kidney Injury,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Mechanisms of Kidney Injury and Lower Endowment in the Extreme Preterm') was chosen as the source because it contains a specific medical condition ('Kidney Injury'), whereas the session title ('Maternal and Environmental Factors: Effect on Kidney Formation and Function') describes physiological processes rather than a distinct disease.
2.  **Component Identification**: From the abstract title, two key components were identified: the disease 'Kidney Injury' and the patient subgroup 'Extreme Preterm'.
3.  **Rule Retrieval**: I retrieved rules for the 'Age Group' category to determine how to handle terms like 'Preterm'. While no specific rule for 'Extreme Preterm' was found, the general principle from related rules (e.g., for 'Pediatric', 'Neonatal') is to retain clinically significant age-based subgroups as a prefix to the disease.
4.  **Rule Application & Normalization**:
    *   The disease term 'Kidney Injury' is already in the correct singular form and Title Case.
    *   The patient subgroup 'Extreme Preterm' is a critical clinical qualifier. It was converted to Title Case.
    *   Generic exclusion rules were applied to discard non-diagnostic terms like 'Mechanisms' and 'Lower Endowment'.
5.  **Indication Construction**: The patient subgroup was prepended to the disease to form the final indication: 'Extreme Preterm Kidney Injury'.
6.  **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form, no trailing spaces) and accurately represents the clinical focus of the abstract title.","[{'category': 'Age Group', 'subcategories': ['Young', 'Pediatric'], 'reason': ""To check for rules on handling age-related patient subgroups like 'Extreme Preterm'.""}]","[{'component': 'Kidney Injury', 'type': 'Disease', 'normalized_form': 'Kidney Injury', 'rule_applied': 'Generic Rule: Singular Form, Title Case'}, {'component': 'Extreme Preterm', 'type': 'Patient Sub-Group (Age)', 'normalized_form': 'Extreme Preterm', 'rule_applied': 'Generic Rule: Include clinically significant patient subgroups, Title Case'}]",2
213447,MP09: Prostate Cancer: Detection & Screening I,Quality of Information in Spanish on BRCA and Genetic Testing in Prostate Cancer on YouTube,Prostate Cancer,Prostate Cancer,Prostate Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Quality of Information in Spanish on BRCA and Genetic Testing in Prostate Cancer on YouTube' and the session title is 'MP09: Prostate Cancer: Detection & Screening I'.
2. **Select Source**: Both titles contain the disease term 'Prostate Cancer'. According to the single-source principle, the abstract title is the preferred source.
3. **Identify Components**: The abstract title contains the disease 'Prostate Cancer' and the gene 'BRCA'. It also contains terms like 'Quality of Information', 'Spanish', and 'YouTube'.
4. **Retrieve Rules**: I considered retrieving rules for gene names. However, the context of 'BRCA' in the title needs careful evaluation first.
5. **Apply Rules and Construct Indication**: 
   - The core disease is 'Prostate Cancer'.
   - The term 'BRCA' is evaluated. The title discusses 'Information... on BRCA... in Prostate Cancer', not a study of patients with a specific BRCA status. Therefore, 'BRCA' is a topic of the study, not a descriptor of the patient subgroup. Including it would be an over-interpretation.
   - The term 'Spanish' is a sociodemographic descriptor (language/ethnicity) and must be excluded per the generic rules.
   - 'Quality of Information' and 'on YouTube' describe the study's methodology and platform, not the clinical indication, and are therefore excluded.
   - The remaining and most accurate clinical indication is 'Prostate Cancer'.
6. **Formatting**: The indication 'Prostate Cancer' is already in singular form and is formatted to Title Case.
7. **Quality Check**: The final indication is clinically accurate, derived from a single source, and adheres to all formatting and exclusion rules.",[],"[{'component': 'Prostate Cancer', 'type': 'Disease', 'normalized_form': 'Prostate Cancer', 'rule_applied': 'Generic rule: Title Case and Singular Form'}, {'component': 'BRCA', 'type': 'Gene Name', 'normalized_form': 'BRCA', 'rule_applied': 'Contextual exclusion: The gene is the subject of the information being studied, not a qualifier for the patient population.'}, {'component': 'Spanish', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude ethnicity/language.'}, {'component': 'Quality of Information', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic items/methodologies.'}]",4
295375,"Gilead and Kite Oncology - Redefining the Lines of TNBC, Real-world management: improving survival for patients with metastatic TNBC",TNBC today: How can we increase survival for a very heterogenous and aggressive disease?,TNBC ,Triple-Negative Breast Cancer,Triple-Negative Breast Cancer,True,abstract_title,"Step 1: Source Selection - The abstract title contains the disease term 'TNBC'. According to the Single-Source Extraction Principle, the abstract title must be used as the primary source, and information from the session title cannot be merged. Therefore, 'metastatic' from the session title is disregarded.
Step 2: Component Identification - The key component in the abstract title is the abbreviation 'TNBC'.
Step 3: Rule Application & Normalization - The abbreviation 'TNBC' is expanded to its full, clinically standard name 'Triple-Negative Breast Cancer'. The generic formatting rules for Title Case and singular form are applied. The descriptive terms 'heterogenous' and 'aggressive' are excluded as they are not part of the core indication.
Step 4: Final Indication - The final generated indication is 'Triple-Negative Breast Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To check the rule for 'metastatic' which appeared in the session_title. The rule was ultimately not applied to the final indication due to the single-source principle.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To check for rules related to 'TNBC' (Triple-Negative Breast Cancer), which is a biomarker-defined subtype of breast cancer.""}]","[{'component': 'TNBC', 'type': 'Disease', 'normalized_form': 'Triple-Negative Breast Cancer', 'rule_applied': 'Standard medical abbreviation expansion and Generic Rule for Title Casing.'}]",2
328146,Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III,"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)",Early Stage;;Classic Hodgkin Lymphoma,Early Stage Classic Hodgkin Lymphoma,Early Stage Classic Hodgkin Lymphoma,True,abstract_title,"Step-by-step explanation of the extraction process:
1. **Source Selection**: The abstract title was chosen because it contains a specific disease term ('Hodgkin Lymphoma'), which is preferred over the broader categories in the session title, adhering to the single-source principle.
2. **Component Identification**: From the abstract title, I identified the core disease 'Hodgkin Lymphoma', the stage qualifier 'Early Stage', and the disease subtype 'Classic'.
3. **Rule Retrieval**: I retrieved rules for 'Stage' to correctly format 'Early Stage'. Rule ID 109 confirmed that 'Early Stage' should be normalized to title case and prepended to the disease name.
4. **Rule Application**: I applied the generic rules for formatting and exclusion. The disease term 'Hodgkin Lymphoma' is already singular. I applied Title Case to all components. Drug names (Brentuximab Vedotin, etc.) and study-specific details (Phase 2 Study) were excluded as per the generic exclusion rules.
5. **Indication Construction**: The identified components were combined in the standard order: Stage -> Subtype -> Disease. This resulted in 'Early Stage Classic Hodgkin Lymphoma'.
6. **Quality Check**: The final indication was verified for adherence to all rules, including single-source, formatting, and clinical accuracy. The result is a concise and clinically valid medical indication.","[{'category': 'Stage', 'subcategories': ['Stage Onset'], 'reason': ""To validate the formatting and inclusion of the 'Early Stage' qualifier.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding disease subtypes like 'Classic'.""}, {'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To check for rules regarding disease subtypes like 'Classic'.""}]","[{'component': 'Early Stage', 'type': 'Stage', 'normalized_form': 'Early Stage', 'rule_applied': 'Stage Onset Rule ID: 109'}, {'component': 'Classic Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'Classic Hodgkin Lymphoma', 'rule_applied': 'Generic rule to include clinically valid subtypes and use singular form.'}]",2
328150,Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster III,Late Effects Comparison between Two Chemotherapy Regimens for Hodgkin Lymphoma,Hodgkin Lymphoma,Hodgkin Lymphoma,Hodgkin Lymphoma,True,abstract_title,"Step 1: The abstract title 'Late Effects Comparison between Two Chemotherapy Regimens for Hodgkin Lymphoma' was chosen as the source because it contains a specific disease term, 'Hodgkin Lymphoma', which is preferred over the session title according to the single-source principle.
Step 2: The disease term 'Hodgkin Lymphoma' was identified. The surrounding text 'Late Effects Comparison between Two Chemotherapy Regimens for' relates to the study's methodology and outcomes, not the core indication, and is therefore excluded based on generic rules.
Step 3: The identified disease term is already in the correct singular form and Title Case, so no modifications were needed.
Step 4: The final indication was constructed from the normalized disease term.",[],"[{'component': 'Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'Hodgkin Lymphoma', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}]",1
147934,"Gene Therapy, Cellular Immunotherapy And Vaccination - Biology & Translational Research","Selection, Expansion, And New Pretreatment Of Human Natural Killer Cells With Anti-Cd38 Monoclonal Antibody For Efficient Treatment Of Multiple Myeloma.",Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: The abstract title contains the specific disease 'Multiple Myeloma', while the session title describes broad therapeutic areas. Following the single-source principle, the abstract title is selected for extraction.
Step 2: The disease term 'Multiple Myeloma' is identified in the abstract title.
Step 3: The title is scanned for additional qualifiers. No patient subgroups, stages, or lines of treatment are mentioned.
Step 4: Generic rules are applied. The term is already in Title Case and singular form. Other parts of the title, such as 'Human Natural Killer Cells' and 'Anti-Cd38 Monoclonal Antibody', describe the treatment modality and are excluded as per the rules.
Step 5: The final indication is constructed from the identified and cleaned disease term.",[],"[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Casing and Singular Form rules.'}]",1
180704,Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I,Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx),Relapsed/Refractory;;Chronic Lymphocytic Leukemia,Relapsed/Refractory Chronic Lymphocytic Leukemia,Relapsed/Refractory Chronic Lymphocytic Leukemia,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease and patient subgroup, making it more informative than the session title, in accordance with the single-source principle.
Step 2: Key components were identified from the abstract title: the disease 'Chronic Lymphocytic Leukemia' and the patient subgroup/disease state 'Relapsed/Refractory' (R/R).
Step 3: To ensure correct formatting for the disease state, I retrieved rules for 'Occurrence' and the 'Recurrent/Refractory' subcategory.
Step 4: The retrieved rule, although for a slightly different keyword ('Recurrent and Primary Refractory'), confirmed the pattern of normalizing such phrases to Title Case and placing them before the disease name. Generic rules were also applied: the disease name was kept in singular form and Title Case was applied to the entire indication. All non-indication elements such as treatment names ('Venetoclax-Rituximab'), trial names ('Murano Trial'), and general descriptors ('Patients') were excluded.
Step 5: The components were combined to form the final indication: 'Relapsed/Refractory Chronic Lymphocytic Leukemia'.
Step 6: A final quality check confirmed adherence to all formatting, exclusion, and single-source rules.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To validate the formatting and placement of the 'Relapsed/Refractory' qualifier.""}]","[{'component': 'Relapsed/Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rule for Recurrent/Refractory terms.'}, {'component': 'Chronic Lymphocytic Leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
213477,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",Endoscopic Injection Of The Bladder Neck Using Dextranomer Hyaluronate (Dx/Ha) In The Pediatric Patient: Results Of A Single Center Analysis With Long Term Follow Up,Neurogenic Bladder;;Pediatric,Pediatric Neurogenic Bladder,Pediatric Neurogenic Bladder;;Pediatric Urologic Emergency,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Endoscopic Injection Of The Bladder Neck...') describes a procedure and patient group but does not name a specific disease. The session title ('MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies') contains multiple clear medical conditions. Therefore, the session title was selected as the source based on the Single-Source Extraction Principle.
2.  **Component Identification**: From the session title, the following components were identified: 'Pediatric' (age group), 'Neurogenic Bladder' (disease), and 'Urologic Emergencies' (disease). 'Reconstruction' was identified as a procedural term to be excluded.
3.  **Rule Retrieval**: The `get_indication_rules` tool was used for the category 'Age Group' and subcategory 'Pediatric' to ensure the correct application of the age qualifier.
4.  **Rule Application and Construction**:
    *   The term 'Pediatric' from 'Pediatric Urology' sets the context for the subsequent conditions. The retrieved rules (e.g., Rule ID 295) mandate prepending 'Pediatric' to the indication.
    *   'Neurogenic Bladder' is a valid indication and is kept as is.
    *   'Urologic Emergencies' is a valid indication. The generic rule for singular form was applied, converting it to 'Urologic Emergency'.
    *   The 'Pediatric' qualifier was prepended to both identified conditions.
    *   The two resulting indications were combined using the required ';;' separator.
5.  **Final Quality Check**: The final output adheres to all formatting rules (Title Case, singular form, no trailing spaces) and exclusion criteria ('Reconstruction' was removed).","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly format the 'Pediatric' patient subgroup qualifier identified in the session title.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule for 'Pediatric' (ID: 295/296)""}, {'component': 'Neurogenic Bladder', 'type': 'Disease', 'normalized_form': 'Neurogenic Bladder', 'rule_applied': 'Generic rule for disease name formatting (Title Case).'}, {'component': 'Urologic Emergencies', 'type': 'Disease', 'normalized_form': 'Urologic Emergency', 'rule_applied': 'Generic rule for converting plural disease terms to singular.'}, {'component': 'Reconstruction', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural terms.'}]",2
213478,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",A Technique to Prevent Stomal Stenosis in Reconstructive Urology,,,Pediatric Neurogenic Bladder;;Pediatric Urologic Emergency,True,session_title,"The abstract title's potential indication, 'Stomal Stenosis', was identified as an excludable complication based on the context ('A Technique to Prevent...'). Therefore, the abstract title was determined to contain no primary disease, triggering a fallback to the session title per the single-source principle. The session title provided the age group 'Pediatric' and two distinct conditions: 'Neurogenic Bladder' and 'Urologic Emergencies'. 'Urologic Emergencies' was converted to its singular form. The 'Pediatric' qualifier was prepended to both conditions, and they were joined by the ';;' separator.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly format the 'Pediatric' patient subgroup qualifier.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Severity'], 'reason': ""To check if 'Emergencies' required specific severity rules, though generic rules were ultimately sufficient.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group rule: Prepend to disease name.'}, {'component': 'Neurogenic Bladder', 'type': 'Disease', 'normalized_form': 'Neurogenic Bladder', 'rule_applied': 'Generic rule: Title Case.'}, {'component': 'Urologic Emergencies', 'type': 'Disease', 'normalized_form': 'Urologic Emergency', 'rule_applied': 'Generic rule: Convert plural to singular.'}, {'component': 'Reconstruction', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude procedural terms.'}, {'component': 'Stomal Stenosis', 'type': 'Complication', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude complications/adverse effects.'}]",2
295399,Ipsen - Disrupting the landscape: the Plus One in RCC and NSCLC,"Triple, double and monotherapy: what is the sequence for best outcomes?",RCC;;NSCLC,Renal Cell Carcinoma;;Non-Small Cell Lung Cancer,Renal Cell Carcinoma;;Non-Small Cell Lung Cancer,True,session_title,"Step 1: The abstract title 'Triple, double and monotherapy: what is the sequence for best outcomes?' contains no disease terms, only treatment modalities. The session title 'Ipsen - Disrupting the landscape: the Plus One in RCC and NSCLC' contains two disease acronyms, 'RCC' and 'NSCLC'.
Step 2: Following the Single-Source Extraction Principle, the session title is selected as it is the only source containing disease information.
Step 3: The acronyms 'RCC' and 'NSCLC' are identified as two distinct diseases.
Step 4: The acronyms are expanded to their full, clinically standard names: 'Renal Cell Carcinoma' and 'Non-Small Cell Lung Cancer'.
Step 5: The generic rule for multiple diseases is applied, separating the two indications with the ';;' delimiter.
Step 6: The generic rule for Title Case is applied to the expanded names. The final output is formatted accordingly.",[],"[{'component': 'RCC', 'type': 'Disease', 'normalized_form': 'Renal Cell Carcinoma', 'rule_applied': 'Standard medical acronym expansion and Title Case rule.'}, {'component': 'NSCLC', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Standard medical acronym expansion and Title Case rule.'}]",1
262634,Myeloproliferative neoplasms - Biology & Translational Research,T Cell Response And Omicron Variant Neutralisation Following Vaccination Against Sars-Cov-2 In Patients With Chronic Myeloid Disorders,Chronic Myeloid Disorders,Chronic Myeloid Disorder,Chronic Myeloid Disorder,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease term ('Chronic Myeloid Disorders'), which is preferred over the session title according to the single-source extraction principle.
Step 2: The core disease 'Chronic Myeloid Disorders' was identified from the abstract title. The mention of 'Sars-Cov-2' was identified as the context of a vaccination study, not a co-existing condition of the patient group, and was therefore excluded.
Step 3: The generic rule for singularization was applied, converting 'Disorders' to 'Disorder'.
Step 4: The generic rule for casing was applied, ensuring the final indication is in Title Case.
Step 5: The final indication was constructed by combining the standardized components.",[],"[{'component': 'Chronic Myeloid Disorders', 'type': 'Disease', 'normalized_form': 'Chronic Myeloid Disorder', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Title Case'}, {'component': 'Vaccination Against Sars-Cov-2', 'type': 'Procedural Context', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion Rules (Procedural/Temporal Qualifiers)'}]",1
213480,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",Survival analysis among Utah residents with spina bifida born between 1950 and 2015,spina bifida,Spina Bifida,Spina Bifida,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as the primary source because it contains a specific, well-defined medical condition ('spina bifida'). The session title also contains diseases, but the single-source principle dictates using the abstract title first.
2.  **Component Identification**: The core disease identified in the abstract title is 'spina bifida'.
3.  **Rule Application (Generic)**:
    *   **Exclusion Rule**: The geographic descriptor 'Utah residents' was excluded as per the sociodemographic exclusion rule.
    *   **Exclusion Rule**: The temporal phrase 'born between 1950 and 2015' and the study methodology 'Survival analysis' were excluded as they are not part of the core clinical indication.
    *   **Casing Rule**: The disease name 'spina bifida' was converted to Title Case, resulting in 'Spina Bifida'.
    *   **Singular Form Rule**: The term is already in its standard singular form.
4.  **Indication Construction**: After applying all rules and exclusions, the final indication is constructed from the normalized disease term.
5.  **Final Output**: The resulting indication is 'Spina Bifida'.",[],"[{'component': 'spina bifida', 'type': 'Disease', 'normalized_form': 'Spina Bifida', 'rule_applied': 'Generic Casing Rule'}, {'component': 'Utah residents', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Sociodemographic Descriptors'}]",1
295405,AstraZeneca - Immunotherapy: the evolving treatment landscape in hepatobiliary cancers,Therapeutic approaches in unresectable / advanced HCC,unresectable / advanced;;HCC,Unresectable/Advanced Hepatocellular Carcinoma,Unresectable/Advanced Hepatocellular Carcinoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Therapeutic approaches in unresectable / advanced HCC' was chosen as it contains a specific disease term ('HCC'), following the single-source principle which prioritizes the abstract title.
2. **Component Identification**: The key components identified in the abstract title are the disease 'HCC' and the disease state descriptors 'unresectable' and 'advanced'.
3. **Rule Retrieval**: To ensure correct formatting, rules were retrieved for 'Unresectable' (Treatment Set-up), 'advanced' (Stage), and the '/' connector (Occurrence).
4. **Rule Application & Normalization**:
   - The disease abbreviation 'HCC' was expanded to its full, standardized name 'Hepatocellular Carcinoma'.
   - The descriptors 'unresectable' and 'advanced' were converted to Title Case: 'Unresectable' and 'Advanced'.
   - The rule for connectors (Rule ID: 145) was applied to join the two descriptors with a forward slash and no surrounding spaces, resulting in 'Unresectable/Advanced'.
5. **Indication Construction**: The normalized components were combined in the correct order (qualifier first, then disease) to form the final indication: 'Unresectable/Advanced Hepatocellular Carcinoma'.
6. **Final Quality Check**: The generated indication adheres to all generic rules, including Title Case, singular form, and no excluded terms.","[{'category': 'Treatment Set-up', 'subcategories': ['Unresectable'], 'reason': ""To correctly format the term 'unresectable'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To correctly format the stage descriptor 'advanced'.""}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To handle the '/' connector between 'unresectable' and 'advanced'.""}]","[{'component': 'unresectable / advanced', 'type': 'Disease State', 'normalized_form': 'Unresectable/Advanced', 'rule_applied': ""Occurrence Connector Rule (ID: 145) and Treatment Set-up Unresectable Rule (ID: 245) were applied to combine and format the terms in Title Case, joined by a '/' with no spaces.""}, {'component': 'HCC', 'type': 'Disease', 'normalized_form': 'Hepatocellular Carcinoma', 'rule_applied': 'Standard medical abbreviation expansion and Generic Rule for Title Case and singular form.'}]",2
393710,Melanoma And Other Skin Tumours,Transforming Growth Factor-Beta-1 And Soluble Co-Inhibitory Immune Checkpoints As Putative Drivers Of Immune Suppression In Advanced Basal Cell Carcinoma,Advanced;;Basal Cell Carcinoma,Advanced Basal Cell Carcinoma,Advanced Basal Cell Carcinoma,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title ('Transforming Growth Factor-Beta-1 And Soluble Co-Inhibitory Immune Checkpoints As Putative Drivers Of Immune Suppression In Advanced Basal Cell Carcinoma') and the session title ('Melanoma And Other Skin Tumours') both contain disease terms.
2.  **Select Source**: According to the single-source principle, the abstract title is prioritized as it contains a specific disease. The session title is discarded.
3.  **Identify Components**: From the abstract title, the core indication components are 'Advanced' (a stage qualifier) and 'Basal Cell Carcinoma' (the disease).
4.  **Retrieve Rules**: I retrieved rules for the 'Stage' category to understand how to handle the term 'Advanced'. The general pattern from the rules is to place the stage qualifier before the disease name.
5.  **Apply Rules & Construct Indication**: 
    *   The disease term 'Basal Cell Carcinoma' is already in singular form and proper case.
    *   The stage qualifier 'Advanced' is prepended to the disease name.
    *   Other parts of the title, such as 'Transforming Growth Factor-Beta-1' and 'Soluble Co-Inhibitory Immune Checkpoints', are identified as biological mechanisms under investigation, not part of the core indication, and are therefore excluded.
6.  **Final Indication**: The components are combined and formatted according to generic rules (Title Case, singular form) to produce 'Advanced Basal Cell Carcinoma'.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To verify the correct formatting and placement of the stage qualifier 'Advanced'.""}]","[{'component': 'Advanced', 'type': 'Stage', 'normalized_form': 'Advanced', 'rule_applied': 'Generic rule for stage qualifiers (prefix to disease name) and Title Case rule.'}, {'component': 'Basal Cell Carcinoma', 'type': 'Disease', 'normalized_form': 'Basal Cell Carcinoma', 'rule_applied': 'Generic rule for singular form and Title Case.'}]",2
410094,"Liquid ""Gold,"" Urinary Sediment Microscopy: Current Utility of an Old Tool",Value of Urine Microscopy in Clinical Practice: Illustration by Cases,,,,True,none,"Neither the abstract title nor the session title contains a specific disease or disorder. Both titles focus on a diagnostic procedure ('Urine Microscopy', 'Urinary Sediment Microscopy') and its general utility in clinical practice, rather than a condition being studied or treated. According to the rules, an indication cannot be extracted without a disease term. Therefore, no valid medical indication can be generated.",[],[],1
262640,Myeloproliferative neoplasms - Biology & Translational Research,Peripheral Blood Cytotoxic T Cells Show Early Exhausted Features In Myelofibrosis Patients,Myelofibrosis ,Myelofibrosis ,Myelofibrosis,True,abstract_title,"Step 1: The abstract title contains the specific disease term 'Myelofibrosis', while the session title contains a broader category 'Myeloproliferative neoplasms'. Following the single-source principle, the more specific abstract title is selected.
Step 2: The core disease 'Myelofibrosis' is identified from the abstract title.
Step 3: The term 'Patients' is a generic descriptor and is excluded. Other phrases like 'Peripheral Blood Cytotoxic T Cells' and 'Early Exhausted Features' describe biological findings, not the core medical indication, and are therefore excluded.
Step 4: The generic rules for formatting are applied. 'Myelofibrosis' is already in singular form and correctly capitalized (Title Case).
Step 5: The final indication is constructed as 'Myelofibrosis'.",[],"[{'component': 'Myelofibrosis', 'type': 'Disease', 'normalized_form': 'Myelofibrosis', 'rule_applied': 'Generic Singular Form Rule, Generic Casing Rule'}]",1
328177,Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I,Primary Cutaneous Gamma-Delta T-Cell Lymphoma (PCGDTCL) Descriptors and Clinicopathologic Determinants of Survival: Analysis of a Pooled Database,Primary Cutaneous Gamma-Delta T-Cell Lymphoma,Primary Cutaneous Gamma-Delta T-Cell Lymphoma,Primary Cutaneous Gamma-Delta T-Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: Both the session title ('Hodgkin Lymphomas and T/NK cell Lymphomas...') and the abstract title ('Primary Cutaneous Gamma-Delta T-Cell Lymphoma...') contain valid disease terms.
2. **Select Source**: According to the Single-Source Extraction Principle, the abstract title is preferred over the session title when both contain a disease. Therefore, the abstract title was selected as the source.
3. **Identify Components**: The core disease entity in the abstract title is 'Primary Cutaneous Gamma-Delta T-Cell Lymphoma'. The qualifier 'Primary' was identified as a potential component requiring rule validation.
4. **Retrieve Rules**: The generic rule for 'Primary' was applied, which states to include 'Primary' when it is immediately followed by a disease name. This condition is met. A call to `get_indication_rules` for 'Disease Characterisation' was made to ensure no other specific rules contradicted this, and none did.
5. **Apply Rules & Construct Indication**: 
    - The full disease name 'Primary Cutaneous Gamma-Delta T-Cell Lymphoma' was extracted.
    - The acronym '(PCGDTCL)' and subsequent descriptive text ('Descriptors and Clinicopathologic Determinants of Survival...') were excluded as they represent non-diagnostic information and study methodology.
    - The indication was formatted to Title Case (already correct) and singular form (already correct).
6. **Quality Check**: The final indication adheres to all formatting and exclusion rules. It is clinically accurate and derived from a single source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify how to handle the term 'Primary' and ensure no other characterization rules apply.""}]","[{'component': 'Primary Cutaneous Gamma-Delta T-Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Primary Cutaneous Gamma-Delta T-Cell Lymphoma', 'rule_applied': ""Generic Rule for 'Primary'""}, {'component': '(PCGDTCL) Descriptors and Clinicopathologic Determinants of Survival: Analysis of a Pooled Database', 'type': 'Non-Diagnostic Information', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items'}]",2
311793,Fellows-In-Training: Roundtables,Roundtable 04 - Career in Private Practice (Adult and Pediatric Rheumatology) IV,Adult;;Pediatric;;Rheumatology,Adult Pediatric Rheumatic Disease,Adult Rheumatic Disease;;Pediatric Rheumatic Disease,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Roundtable 04 - Career in Private Practice (Adult and Pediatric Rheumatology) IV') was chosen as it contains medical terms. The session title ('Fellows-In-Training: Roundtables') is non-specific and was discarded.
2. **Component Identification**: The key components identified in the abstract title are the patient age groups 'Adult' and 'Pediatric', and the therapeutic area 'Rheumatology'.
3. **Rule Retrieval**: To ensure correct formatting for the age group qualifiers, rules for 'Adult' and 'Pediatric' were retrieved using the `get_indication_rules` tool.
4. **Indication Normalization**: The term 'Rheumatology' is a medical specialty, not a specific disease. To create a clinically valid indication, it was normalized to the overarching disease category 'Rheumatic Disease'.
5. **Rule Application**: The retrieved age group rules confirmed that 'Adult' and 'Pediatric' should be used as capitalized prefixes. The generic rule for multiple indications was applied to handle the 'and' conjunction.
6. **Indication Construction**: Two distinct indications were constructed by prepending the age group qualifiers to the normalized disease term: 'Adult Rheumatic Disease' and 'Pediatric Rheumatic Disease'.
7. **Final Formatting**: The two indications were combined into a single string using the required ';;' separator, resulting in the final output.","[{'category': 'Age Group', 'subcategories': ['Adult', 'Pediatric'], 'reason': ""To ensure correct formatting and placement of the 'Adult' and 'Pediatric' patient subgroup qualifiers.""}]","[{'component': 'Rheumatology', 'type': 'Therapeutic Area', 'normalized_form': 'Rheumatic Disease', 'rule_applied': 'Therapeutic Area Fallback principle and requirement for clinical accuracy.'}, {'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group rule (ID: 289, 290) to use as a capitalized prefix.'}, {'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group rule (ID: 295, 296) to use as a capitalized prefix.'}]",2
213484,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",Short and Long Term Renal Outcomes in Clinically Matched Cohorts of Newborns with PUV Managed by Primary Vesicostomy Versus Primary Valve Ablation,Newborns;;PUV,Neonatal Posterior Urethral Valve,Neonatal Posterior Urethral Valve,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title because it contains a more specific disease entity ('PUV') directly related to the patient cohort ('Newborns'), adhering to the single-source principle.
2. **Component Identification**: The key components identified in the abstract title are the age group 'Newborns' and the disease acronym 'PUV'. Procedural terms like 'Primary Vesicostomy' and 'Primary Valve Ablation' were identified for exclusion.
3. **Rule Retrieval**: Rules for the 'Age Group' category were retrieved to determine the correct handling of the term 'Newborns'.
4. **Rule Application**: 
   - **Age Group**: Based on clinical terminology and the retrieved rules for 'Neonatal' (Rule ID 322, 323), the term 'Newborns' is normalized to the standard clinical descriptor 'Neonatal'.
   - **Disease Term**: The acronym 'PUV' is expanded to its full clinical name, 'Posterior Urethral Valves', for clarity and standardization.
   - **Generic Rules**: The generic rule for singularization was applied, converting 'Valves' to 'Valve'. The title case rule was applied to the final indication. The exclusion rule was applied to discard the surgical management details.
5. **Indication Construction**: The normalized age group 'Neonatal' was prepended to the standardized, singular disease name 'Posterior Urethral Valve' to form the final indication.
6. **Quality Check**: The final indication 'Neonatal Posterior Urethral Valve' is clinically accurate, follows all formatting rules, and is derived from a single source.","[{'category': 'Age Group', 'subcategories': ['Pediatric', 'Adult', 'Young', 'Childhood', 'Adolescent', 'Elderly', 'Non-Elderly', 'Juvenile'], 'reason': ""To find the standard representation for the age group 'Newborns', which falls under the pediatric category. The rules for 'Neonatal' were used as a proxy for 'Newborn'.""}]","[{'component': 'Newborns', 'type': 'Age Group', 'normalized_form': 'Neonatal', 'rule_applied': ""Normalization to standard clinical term based on retrieved 'Neonatal' rules (e.g., Rule ID 322) and general clinical knowledge.""}, {'component': 'PUV', 'type': 'Disease', 'normalized_form': 'Posterior Urethral Valve', 'rule_applied': 'Expansion of acronym to full disease name and application of singular form generic rule.'}, {'component': 'Managed by Primary Vesicostomy Versus Primary Valve Ablation', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
311791,Fellows-In-Training: Roundtables,Roundtable 04 - Career in Private Practice (Adult and Pediatric Rheumatology) III,,,Adult Rheumatologic Disease;;Pediatric Rheumatologic Disease,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains the medical term 'Rheumatology', while the session title does not contain any disease or condition.
2. **Component Identification**: The abstract title identifies a therapeutic area, 'Rheumatology', and two distinct patient age groups, 'Adult' and 'Pediatric'.
3. **Rule Retrieval**: Rules for the 'Age Group' category, specifically for 'Adult' and 'Pediatric' subcategories, were retrieved to ensure correct formatting.
4. **Indication Construction**: Based on the generic rule for therapeutic areas, 'Rheumatology' is mapped to the overarching disease 'Rheumatologic Disease'. Since two distinct age groups are mentioned, two separate indications are generated.
5. **Rule Application**: The retrieved age group rules specify that 'Adult' and 'Pediatric' should be used as capitalized prefixes to the disease term.
6. **Formatting**: The two resulting indications, 'Adult Rheumatologic Disease' and 'Pediatric Rheumatologic Disease', are combined using the required ';;' separator. All terms are formatted in Title Case and singular form.","[{'category': 'Age Group', 'subcategories': ['Adult', 'Pediatric'], 'reason': ""To correctly format the 'Adult' and 'Pediatric' patient population descriptors.""}]","[{'component': 'Rheumatology', 'type': 'Therapeutic Area', 'normalized_form': 'Rheumatologic Disease', 'rule_applied': 'Generic rule for Therapeutic Area Fallback.'}, {'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule for 'Adult' (ID: 289).""}, {'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule for 'Pediatric' (ID: 295).""}]",2
311808,Fellows-In-Training: Roundtables,Roundtable 08 - How to Establish a Career Niche IV,,,,True,none,"Neither the abstract title ('Roundtable 08 - How to Establish a Career Niche IV') nor the session title ('Fellows-In-Training: Roundtables') contains any mention of a disease, disorder, or any other clinically valid medical term. The titles refer to professional development and meeting formats, not medical conditions. Therefore, no indication can be extracted.",[],[],1
295427,ESMO Clinical Practice Guidelines session 2,Metastatic non-small-cell lung cancer: Discussion / Q&A,Metastatic;;non-small-cell lung cancer,Metastatic Non-Small-Cell Lung Cancer,Metastatic Non-Small-Cell Lung Cancer,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease ('non-small-cell lung cancer'), while the session title does not.
Step 2: The components identified in the abstract title were the disease 'non-small-cell lung cancer' and the occurrence qualifier 'Metastatic'. The text 'Discussion / Q&A' was identified as non-diagnostic and marked for exclusion.
Step 3: To ensure correct formatting of the metastatic qualifier, I retrieved rules for 'Metastasis-Related Terms' using the `get_indication_rules` tool.
Step 4: I applied the retrieved rule (ID: 141), which specifies placing 'Metastatic' before the disease name. I also applied the generic Title Case rule to convert 'non-small-cell lung cancer' to 'Non-Small-Cell Lung Cancer'. The generic singular form rule was checked, and 'cancer' is already singular.
Step 5: The final indication was constructed by combining the qualifier and the standardized disease name, resulting in 'Metastatic Non-Small-Cell Lung Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To verify the correct formatting and placement of the term 'Metastatic' as a disease qualifier.""}]","[{'component': 'Metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': 'Rule ID: 141 for Metastasis-Related Terms'}, {'component': 'non-small-cell lung cancer', 'type': 'Disease', 'normalized_form': 'Non-Small-Cell Lung Cancer', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'Discussion / Q&A', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Non-Diagnostic Items'}]",2
393731,Melanoma And Other Skin Tumours,Evaluation Of The Transcriptomic Presence Of Tumor Associated Antigens (Taas) From Antibody Drug Conjugates (Adcs) And Pd-L1 In Melanoma: Options For New Clinical Opportunities,Melanoma,Melanoma,Melanoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Evaluation Of The Transcriptomic Presence Of Tumor Associated Antigens (Taas) From Antibody Drug Conjugates (Adcs) And Pd-L1 In Melanoma: Options For New Clinical Opportunities') contains the specific disease 'Melanoma'. According to the single-source principle, the abstract title is prioritized over the session title ('Melanoma And Other Skin Tumours') because it contains a valid disease term.
2.  **Component Identification**: The core disease identified in the abstract title is 'Melanoma'. The term 'Pd-L1' is also present.
3.  **Rule Retrieval**: I retrieved rules for the 'Biomarker' category to determine how to handle 'Pd-L1'.
4.  **Rule Application**: The retrieved rules (e.g., Rule ID 83 for Anti-PD-1) and general principles indicate that biomarkers should only be included if they define a specific patient subgroup (e.g., 'PD-L1-Positive'). In this title, 'Pd-L1' is the subject of an 'Evaluation Of The Transcriptomic Presence', not a pre-defined characteristic of the patient cohort. Therefore, it is excluded from the indication. The other terms like 'Tumor Associated Antigens (Taas)' and 'Antibody Drug Conjugates (Adcs)' are also part of the study's methodology and not part of the core disease definition.
5.  **Formatting**: The identified disease 'Melanoma' is already in singular form and correctly cased. No other formatting is required.
6.  **Final Indication Construction**: Based on the analysis, the sole clinically valid indication extracted from the abstract title is 'Melanoma'.","[{'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To verify the correct handling of the biomarker 'Pd-L1' mentioned in the abstract title.""}]","[{'component': 'Melanoma', 'type': 'Disease', 'normalized_form': 'Melanoma', 'rule_applied': 'Generic rule: Singular form and Title Case.'}, {'component': 'Pd-L1', 'type': 'Biomarker', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Excluded because it is the subject of evaluation rather than a descriptor of a patient subgroup.'}]",2
311815,Fellows-In-Training: Roundtables,Roundtable 10 - Early Career Niche in Pediatric Rheumatology: Amplified Pain Syndrome III,Pediatric;;Amplified;;Pain Syndrome III,Pediatric Amplified Pain Syndrome III,Pediatric Amplified Pain Syndrome III,True,abstract_title,"Step 1: The abstract title was chosen as the source because the session title is generic ('Fellows-In-Training: Roundtables') and does not contain a specific medical condition, whereas the abstract title does.
Step 2: The abstract title 'Roundtable 10 - Early Career Niche in Pediatric Rheumatology: Amplified Pain Syndrome III' was analyzed. The core disease identified is 'Amplified Pain Syndrome III'.
Step 3: The term 'Pediatric' was identified as an age group qualifier from the context 'Pediatric Rheumatology'. Rules for the 'Age Group' category were retrieved to confirm handling.
Step 4: The term 'III' was identified as a type or stage qualifier for the syndrome. Rules for 'Stage number' were consulted, which confirmed that Roman numerals should be preserved.
Step 5: The indication was constructed by applying the 'Pediatric' qualifier to the core disease. According to the retrieved rules, 'Pediatric' should be the leading word.
Step 6: Generic formatting rules were applied. The final indication was converted to Title Case, and singular form was confirmed. No terms requiring exclusion were present. The resulting indication is 'Pediatric Amplified Pain Syndrome III'.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To determine the correct formatting and placement of the 'Pediatric' age group qualifier.""}, {'category': 'Stage', 'subcategories': ['Stage number'], 'reason': ""To verify the correct handling of the Roman numeral 'III' as a disease subtype or stage.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule: Place 'Pediatric' as the leading word of the medical indication.""}, {'component': 'Amplified Pain Syndrome III', 'type': 'Disease', 'normalized_form': 'Amplified Pain Syndrome III', 'rule_applied': 'Generic Rule: Use Title Case and singular form. Stage Rule: Preserve Roman numeral.'}]",2
262670,Myeloproliferative neoplasms - Clinical,Higher Estimated Plasma Volume Status Is Associated With Increased Thrombotic Risk And Impaired Survival In Patients With Primary Myelofibrosis,Primary;;Myelofibrosis,Primary Myelofibrosis,Primary Myelofibrosis,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title ('Higher Estimated Plasma Volume Status Is Associated With Increased Thrombotic Risk And Impaired Survival In Patients With Primary Myelofibrosis') contains a specific disease, 'Primary Myelofibrosis'. The session title ('Myeloproliferative neoplasms - Clinical') contains a broader disease category. Based on the single-source principle, the more specific abstract title is selected.
2.  **Identify Components**: The core disease identified in the abstract title is 'Primary Myelofibrosis'. The phrase 'Increased Thrombotic Risk' was also identified.
3.  **Retrieve Relevant Rules**: No specific category rules were needed for the disease itself. I considered retrieving rules for 'Risk' to handle 'Increased Thrombotic Risk'. However, upon review, this phrase is presented as an association or outcome within the study ('Is Associated With...'), not as a pre-defined patient subgroup that defines the indication. The generic exclusion rules state that complications and study methodologies should be excluded.
4.  **Apply Rules**: 
    *   The disease 'Primary Myelofibrosis' is kept. 
    *   The generic rule for 'Primary' is applied, keeping it as it's part of the disease name.
    *   The generic rule for singular form is applied (already singular).
    *   The generic rule for Title Case is applied (already in Title Case).
    *   The phrase 'Increased Thrombotic Risk' is excluded as it represents a study finding/association/complication, not a defining characteristic of the patient cohort for the indication. 'Higher Estimated Plasma Volume Status' and 'Impaired Survival' are also excluded as they are a physiological measurement and an outcome, respectively.
5.  **Construct Indication**: The final indication is constructed from the single, cleaned component: 'Primary Myelofibrosis'.
6.  **Quality Check**: The final indication adheres to all formatting and exclusion rules, is clinically accurate, and is derived from a single source.",[],"[{'component': 'Primary Myelofibrosis', 'type': 'Disease', 'normalized_form': 'Primary Myelofibrosis', 'rule_applied': ""Generic rule: Include 'Primary' when it is part of the disease name.""}, {'component': 'Increased Thrombotic Risk', 'type': 'Associated Risk/Complication', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude complications, adverse effects, and study findings.'}]",2
295442,"Proffered Paper session: NSCLC, metastatic",Invited Discussant LBA54 and 972O,"NSCLC, metastatic",Metastatic Non-Small Cell Lung Cancer,Metastatic Non-Small Cell Lung Cancer,True,session_title,"Step 1: The abstract title 'Invited Discussant LBA54 and 972O' does not contain any valid medical disease or condition. 
Step 2: Following the single-source principle, I fell back to the session title 'Proffered Paper session: NSCLC, metastatic'.
Step 3: The session title contains the disease 'NSCLC' (Non-Small Cell Lung Cancer) and the occurrence qualifier 'metastatic'.
Step 4: I retrieved rules for metastasis-related terms to ensure correct formatting.
Step 5: Applying the rule for 'Metastatic', I prefixed it to the disease name. I also applied generic rules by expanding the acronym 'NSCLC' to 'Non-Small Cell Lung Cancer' and converting the components to Title Case.
Step 6: The final indication was constructed by combining the qualifier and the full disease name, resulting in 'Metastatic Non-Small Cell Lung Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'metastatic' in relation to the disease 'NSCLC'.""}]","[{'component': 'NSCLC', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Standard medical acronym expansion and Title Case rule.'}, {'component': 'metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': ""Rule ID 141: Format as 'Metastatic <Primary-Disease-Name>'.""}]",2
393754,Neuroendocrine Tumours,"A Phase II Single-Arm Interventional Trial Evaluating The Activity And Safety Of Cabozantinib (Cbz) Plus Temozolomide (Tmz) In Lung And Gastroenteropancreatic Neuroendocrine Neoplasms (Gep-Nens) Progressed After Ssa Therapy, Everolimus, Sunitinib Or Prrt: Cabotem Trial",Lung;;Gastroenteropancreatic Neuroendocrine Neoplasms,Lung Neuroendocrine Neoplasm;;Gastroenteropancreatic Neuroendocrine Neoplasm ,Progressive Lung Neuroendocrine Neoplasm;;Progressive Gastroenteropancreatic Neuroendocrine Neoplasm,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains specific disease terms ('Lung And Gastroenteropancreatic Neuroendocrine Neoplasms'), making it the primary source according to the single-source principle.
2. **Component Identification**: I identified two distinct diseases: 'Lung Neuroendocrine Neoplasms' and 'Gastroenteropancreatic Neuroendocrine Neoplasms'. I also identified the keyword 'Progressed' as a patient subgroup qualifier.
3. **Rule Retrieval**: To correctly handle the term 'Progressed', I retrieved rules for disease progression using `get_indication_rules(category='Occurrence', subcategories=['Progression-Related'])`.
4. **Rule Application**:
   - **Specific Rule**: I applied Rule ID 187 for the keyword 'Progressed', which dictates replacing it with 'Progressive' when used as an adjective describing the disease state.
   - **Generic Rules**: 
     - **Multiple Diseases**: The conjunction 'And' indicates two separate diseases, which must be separated by ';;'.
     - **Singular Form**: The plural 'Neoplasms' was converted to its singular form 'Neoplasm'.
     - **Title Case**: The output was formatted in Title Case.
     - **Exclusion**: Treatment history ('After Ssa Therapy, Everolimus, Sunitinib Or Prrt') was excluded as per the rules on procedural/temporal qualifiers.
5. **Indication Construction**: The qualifier 'Progressive' was prepended to each of the two identified diseases, and they were combined with the ';;' separator.
6. **Final Quality Check**: The final output was reviewed for compliance with all formatting, accuracy, and completeness requirements.","[{'category': 'Occurrence', 'subcategories': ['Progression-Related'], 'reason': ""To determine the correct handling of the term 'Progressed' found in the abstract title.""}]","[{'component': 'Lung Neuroendocrine Neoplasms', 'type': 'Disease', 'normalized_form': 'Lung Neuroendocrine Neoplasm', 'rule_applied': 'Generic rule: Singular Form'}, {'component': 'Gastroenteropancreatic Neuroendocrine Neoplasms', 'type': 'Disease', 'normalized_form': 'Gastroenteropancreatic Neuroendocrine Neoplasm', 'rule_applied': 'Generic rule: Singular Form'}, {'component': 'Progressed', 'type': 'Disease State/Occurrence', 'normalized_form': 'Progressive', 'rule_applied': ""Occurrence rule (ID: 187) for 'Progressed'""}]",2
377370,Acute lymphoblastic leukemia - Biology & Translational Research,Subclonal And Clonal Variants In Tp53 And Kras Combined With Poor Treatment Response Identify A Subgroup Of Ultra-High-Risk Patients Of Pediatric T-Lymphoblastic Leukemia (T-All),Tp53;;Kras;;Ultra-High-Risk;;Pediatric;;T-Lymphoblastic Leukemia,TP53-Mutated KRAS-Mutated Ultra High-Risk Pediatric T-Lymphoblastic Leukemia,Pediatric Ultra High-Risk T-Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains a specific disease ('Pediatric T-Lymphoblastic Leukemia') which is more precise than the broader category in the session title ('Acute lymphoblastic leukemia').
2.  **Component Identification**: I identified the core components from the abstract title: 'Pediatric' (Age Group), 'Ultra-High-Risk' (Risk Level), and 'T-Lymphoblastic Leukemia (T-All)' (Disease).
3.  **Rule Retrieval**: I retrieved rules for 'Age Group' (specifically 'Pediatric'), 'Risk' (specifically 'High-Risk' which includes 'Ultra High-Risk'), and 'Treatment based' to evaluate 'Poor Treatment Response'.
4.  **Rule Application**: 
    - The 'Pediatric' rule (ID: 295) confirms it should be the leading word.
    - The 'Ultra High-Risk' rule (ID: 134) confirms normalization to 'Ultra High-Risk' and placement before the disease name.
    - 'Poor Treatment Response' was excluded as it describes a clinical outcome used to identify the risk group, rather than being a standard part of the indication itself (like 'Refractory' or 'Relapsed').
    - Generic rules were applied to use Title Case, singular form, and remove non-diagnostic words like 'Patients of'.
5.  **Indication Construction**: The components were assembled in the correct order: Age Group -> Risk Level -> Disease. This resulted in 'Pediatric Ultra High-Risk T-Lymphoblastic Leukemia'. The abbreviation (T-All) was omitted in favor of the full disease name for clarity.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly format the 'Pediatric' age group qualifier.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To correctly format the 'Ultra-High-Risk' qualifier.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To determine how to handle the phrase 'Poor Treatment Response'.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule (ID: 295) - Place 'Pediatric' as the leading word.""}, {'component': 'Ultra-High-Risk', 'type': 'Risk', 'normalized_form': 'Ultra High-Risk', 'rule_applied': ""Risk rule (ID: 134) - Normalize to 'Ultra High-Risk' and place before the disease name.""}, {'component': 'T-Lymphoblastic Leukemia (T-All)', 'type': 'Disease', 'normalized_form': 'T-Lymphoblastic Leukemia', 'rule_applied': 'Generic Rule - Use singular form and Title Case.'}, {'component': 'Poor Treatment Response', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule - Excluded as it's a clinical outcome, not a standard indication qualifier.""}]",2
262689,Myeloproliferative neoplasms - Clinical,Responses To Avapritinib In Patients With Advanced Systemic Mastocytosis: Histopathologic Analyses From Explorer And Pathfinder Clinical Studies,Advanced;;Systemic Mastocytosis,Advanced Systemic Mastocytosis,Advanced Systemic Mastocytosis,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Responses To Avapritinib In Patients With Advanced Systemic Mastocytosis: Histopathologic Analyses From Explorer And Pathfinder Clinical Studies'. The session title is 'Myeloproliferative neoplasms - Clinical'.
2. **Select Source**: The abstract title contains a specific disease ('Systemic Mastocytosis'), making it the preferred source over the more general session title, according to the single-source principle.
3. **Identify Components**: From the abstract title, I identified the core disease 'Systemic Mastocytosis' and a stage/severity qualifier 'Advanced'. Other parts like 'Patients With' and study details were marked for exclusion.
4. **Retrieve Rules**: I retrieved rules for the 'Stage' category to understand how to handle qualifiers like 'Advanced'. The general pattern is to place the stage descriptor before the disease name.
5. **Apply Rules**: 
   - **Generic Rules**: I applied Title Case and ensured the disease term was singular. I excluded the generic phrase 'Patients With' and the study-specific details.
   - **Specific Rules**: Based on the pattern from the retrieved stage rules, 'Advanced' is a standard clinical qualifier that should be prepended to the disease name.
6. **Construct Indication**: Combining the components results in 'Advanced Systemic Mastocytosis'.
7. **Quality Check**: The final indication adheres to all formatting and content rules. It is clinically accurate, sourced exclusively from the abstract title, and correctly formatted.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To verify the correct formatting and placement of the stage descriptor 'Advanced'.""}]","[{'component': 'Advanced', 'type': 'Stage/Severity', 'normalized_form': 'Advanced', 'rule_applied': 'Generic rule for stage/severity qualifiers.'}, {'component': 'Systemic Mastocytosis', 'type': 'Disease', 'normalized_form': 'Systemic Mastocytosis', 'rule_applied': 'Generic rule for disease name formatting (Title Case, singular form).'}]",2
328231,Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III,"The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial",Relapsed or Refractory;;B-Cell Non-Hodgkin Lymphoma,Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma,Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease term ('B-Cell Non-Hodgkin Lymphoma'), making it more informative than the session title ('Aggressive Lymphomas').
2. **Component Identification**: The key components identified in the abstract title are the disease 'B-Cell Non-Hodgkin Lymphoma' and the patient subgroup/disease state 'Relapsed or Refractory'. The demographic 'Chinese Patients' was also identified for exclusion.
3. **Rule Retrieval**: Rules for 'Occurrence' (specifically 'Recurrent/Refractory') and 'Patient Sub-Group' (specifically 'B-Cell Precursor') were retrieved to ensure correct formatting of the patient population descriptors.
4. **Rule Application and Normalization**:
   - The phrase 'Relapsed or Refractory' was normalized to 'Relapsed/Refractory' and placed before the disease name, following standard convention for disease state qualifiers.
   - 'B-Cell' was identified as an integral part of the disease name 'B-Cell Non-Hodgkin Lymphoma' and was retained.
   - The disease term 'Lymphoma' is already in singular form.
   - The sociodemographic descriptor 'Chinese Patients' was excluded as per the generic exclusion rules.
   - All treatment-related information (drug names, study design) was excluded.
5. **Final Construction**: The normalized components were combined to form the final indication: 'Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma'.
6. **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form) and the single-source principle.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To correctly format the 'Relapsed or Refractory' component.""}, {'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To confirm that 'B-Cell' should be retained as part of the disease name.""}]","[{'component': 'Relapsed or Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': ""Standard normalization for 'Relapsed or Refractory' terms.""}, {'component': 'B-Cell Non-Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'B-Cell Non-Hodgkin Lymphoma', 'rule_applied': 'Generic rule: Singular form and Title Case.'}, {'component': 'Chinese Patients', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude ethnicity and geographic descriptors.'}]",2
148009,Indolent And Mantle-Cell Non-Hodgkin Lymphoma - Clinical,Real-World Treatment Patterns And Outcomes Of 3455 Previously Untreated Mantle Cell Lymphoma Patients In Us Routine Clinical Practice,Previously Untreated;;Mantle Cell Lymphoma,Previously Untreated Mantle Cell Lymphoma,Previously Untreated Mantle Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title ('Real-World Treatment Patterns And Outcomes Of 3455 Previously Untreated Mantle Cell Lymphoma Patients In Us Routine Clinical Practice') and the session title ('Indolent And Mantle-Cell Non-Hodgkin Lymphoma - Clinical') both contain disease terms.
2. **Select Source**: Following the Single-Source Extraction Principle, the abstract title is preferred as it contains a specific disease and patient context. It is selected as the source.
3. **Identify Components**: From the abstract title, the key components identified are the disease 'Mantle Cell Lymphoma' and the treatment status qualifier 'Previously Untreated'. Other phrases like 'Real-World Treatment Patterns', 'Outcomes', and 'In Us Routine Clinical Practice' are identified as study descriptors and are excluded.
4. **Retrieve Rules**: To handle the treatment status, I retrieved rules for 'Treatment based' and the subcategory 'Treatment Status'. The rule for 'Previously Untreated' (ID: 195) was identified as the most relevant.
5. **Apply Rules**: 
   - The specific rule (ID: 195) dictates that 'Previously Untreated' should be standardized to Title Case and prepended to the beginning of the indication.
   - The generic rule for singular form is applied, although 'Mantle Cell Lymphoma' is already singular.
   - The generic exclusion rule is applied to remove the sociodemographic term 'Us' (United States).
   - The generic casing rule is applied to ensure the final indication is in Title Case.
6. **Construct Indication**: The components are combined according to the rules: the qualifier 'Previously Untreated' is placed before the disease 'Mantle Cell Lymphoma'.
7. **Quality Check**: The final indication 'Previously Untreated Mantle Cell Lymphoma' adheres to all formatting, single-source, and exclusion rules. It is clinically accurate and concise.","[{'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To correctly format the 'Previously Untreated' patient subgroup qualifier.""}]","[{'component': 'Previously Untreated', 'type': 'Treatment Status', 'normalized_form': 'Previously Untreated', 'rule_applied': 'Rule ID: 195 - Standardize to Title Case and prepend to the indication.'}, {'component': 'Mantle Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Mantle Cell Lymphoma', 'rule_applied': 'Generic Rule - Use singular form and Title Case.'}]",2
377385,Chronic myeloid leukemia - Clinical,Impacts On Outcomes And A Predictive Model Of Severe Thrombocytopenia In Patients With Chronic Phase Chronic Myeloid Leukemia Receiving Initial Nilotinib-Therapy,Severe;;Thrombocytopenia;;Chronic Phase;;Chronic Myeloid Leukemia,Severe Thrombocytopenia;;Chronic Phase Chronic Myeloid Leukemia,Chronic Phase Chronic Myeloid Leukemia;;Severe Thrombocytopenia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Impacts On Outcomes And A Predictive Model Of Severe Thrombocytopenia In Patients With Chronic Phase Chronic Myeloid Leukemia Receiving Initial Nilotinib-Therapy') was chosen over the session title ('Chronic myeloid leukemia - Clinical') because it is more specific and contains all the necessary clinical details, adhering to the single-source principle.
2.  **Component Identification**: The abstract title identified two distinct medical conditions: 'Severe Thrombocytopenia' and 'Chronic Phase Chronic Myeloid Leukemia'. The phrase 'Receiving Initial Nilotinib-Therapy' was identified as a procedural/temporal qualifier.
3.  **Rule Retrieval**: Rules for 'Stage', 'Treatment Set-up', 'Risk', and handling multiple diseases were considered. The 'Treatment Set-up' rules confirmed that treatment details like 'Receiving Initial Nilotinib-Therapy' should be excluded, especially when a specific drug is named. The generic rule for multiple diseases was applied.
4.  **Rule Application & Construction**:
    *   The first condition was constructed by combining the qualifier 'Chronic Phase' with the disease 'Chronic Myeloid Leukemia'. The term 'Chronic' is an integral part of the disease name and was retained. The result is 'Chronic Phase Chronic Myeloid Leukemia'.
    *   The second condition was identified as 'Severe Thrombocytopenia'. 'Severe' is a valid clinical descriptor for the condition.
    *   The procedural phrase 'Receiving Initial Nilotinib-Therapy' was excluded as per generic exclusion rules.
    *   The two distinct indications were combined using the ';;' separator as required by the formatting rules.
5.  **Final Formatting**: The final output was formatted to Title Case and singular form, resulting in 'Chronic Phase Chronic Myeloid Leukemia;;Severe Thrombocytopenia'.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for rules regarding disease phases like 'Chronic Phase'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment', 'Treatment Status'], 'reason': ""To determine how to handle 'Receiving Initial Nilotinib-Therapy'.""}, {'category': 'Risk', 'subcategories': ['severe'], 'reason': ""To check for rules on handling severity descriptors like 'Severe'.""}, {'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To confirm the correct procedure for handling two distinct conditions mentioned in the title.'}]","[{'component': 'Severe Thrombocytopenia', 'type': 'Disease with Severity', 'normalized_form': 'Severe Thrombocytopenia', 'rule_applied': 'Generic rule for including severity descriptors; Multiple Disease rule.'}, {'component': 'Chronic Phase Chronic Myeloid Leukemia', 'type': 'Disease with Stage', 'normalized_form': 'Chronic Phase Chronic Myeloid Leukemia', 'rule_applied': 'Generic rule for including disease phase; Multiple Disease rule.'}, {'component': 'Receiving Initial Nilotinib-Therapy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
148013,Indolent And Mantle-Cell Non-Hodgkin Lymphoma - Clinical,Prevalence Of Second Cancer During Long Term Follow-Up In Hairy Cell Leukemia Patients Treated With Cladribine: A Thirty-Year Experience,Hairy Cell Leukemia,Hairy Cell Leukemia,Hairy Cell Leukemia;;Second Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title 'Prevalence Of Second Cancer During Long Term Follow-Up In Hairy Cell Leukemia Patients Treated With Cladribine: A Thirty-Year Experience' contains specific disease terms. The session title also contains disease terms, but the Single-Source Extraction Principle dictates using the abstract title first.
2. **Identify Components**: The abstract title identifies two distinct clinical conditions: 'Hairy Cell Leukemia' and 'Second Cancer'. It also contains the phrase 'Treated With Cladribine'.
3. **Retrieve Relevant Rules**: I retrieved rules for 'Treatment based' to determine how to handle 'Treated With...'. The retrieved rules focus on treatment status (e.g., 'Previously Treated', 'Untreated') and do not apply here. The generic exclusion rule for 'Procedural/Temporal Qualifiers' is more relevant, which states to exclude terms describing treatment procedures ('receiving', 'treated with'). I also checked for rules on handling two diseases, but none were found, so the generic rule of separating with ';;' applies.
4. **Apply Rules**: 
   - **Disease Extraction**: 'Hairy Cell Leukemia' is extracted as a primary indication. 'Second Cancer' is also extracted as a distinct indication, consistent with the generic rule for 'Second Primary'.
   - **Exclusion**: The phrase 'Treated With Cladribine' is excluded as it describes a specific treatment modality, not the core indication itself. 'Patients' and temporal phrases like 'Long Term Follow-Up' and 'A Thirty-Year Experience' are also excluded per generic rules.
   - **Multiple Diseases**: The two extracted indications are treated as separate entities and are separated by the ';;' delimiter as per the generic rule.
   - **Formatting**: Both indications are converted to Title Case and are in singular form.
5. **Construct Indication**: The final indication is constructed by combining the two normalized disease terms: 'Hairy Cell Leukemia' and 'Second Cancer', separated by ';;'.
6. **Quality Check**: The final output adheres to all formatting and content rules. It correctly identifies the two distinct clinical entities from the single, preferred source (abstract title) and excludes non-indicative information.","[{'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To check for rules regarding the phrase 'Treated With Cladribine'. The retrieved rules were not applicable, leading to the use of generic exclusion rules.""}, {'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': ""To check for specific formatting rules when a title mentions two distinct cancers. No specific rules were found, so the generic ';;' separator rule was applied.""}]","[{'component': 'Hairy Cell Leukemia', 'type': 'Disease', 'normalized_form': 'Hairy Cell Leukemia', 'rule_applied': 'Generic rule: Disease name extraction and Title Case formatting.'}, {'component': 'Second Cancer', 'type': 'Disease', 'normalized_form': 'Second Cancer', 'rule_applied': ""Generic rule: 'Second Primary' rule adapted for 'Second Cancer', indicating a subsequent malignancy.""}, {'component': 'Treated With Cladribine', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Excluded as it describes a specific treatment, not a patient subgroup for the indication.'}]",2
262704,Platelet disorders,Low Serum Bdnf Levels Are Associated With Lower Platelets' Cd62P Reactivity And Increased Bleeding Tendency In Patients With Gaucher Disease,Gaucher Disease,Gaucher Disease,Gaucher Disease,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease, 'Gaucher Disease', which is more precise than the therapeutic area 'Platelet disorders' in the session title.
Step 2: The core disease 'Gaucher Disease' was identified from the abstract title.
Step 3: Other phrases such as 'Low Serum Bdnf Levels', 'Lower Platelets' Cd62P Reactivity', and 'Increased Bleeding Tendency' were identified as biomarker findings or symptoms/complications, not as part of the core indication, and were excluded based on the generic exclusion rules for non-diagnostic items.
Step 4: The final indication was formatted to 'Gaucher Disease' following Title Case and singular form rules.",[],"[{'component': 'Gaucher Disease', 'type': 'Disease', 'normalized_form': 'Gaucher Disease', 'rule_applied': 'Generic rule: Use disease from the abstract title.'}, {'component': 'Increased Bleeding Tendency', 'type': 'Symptom/Complication', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude isolated symptoms or complications.'}]",1
180787,Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster I,Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The Single-Source Extraction Principle mandates using the abstract title first if it contains a disease term. The abstract title contains 'Multiple Myeloma', so it was selected as the source.
2.  **Component Identification**: The primary disease identified in the abstract title is 'Multiple Myeloma'. The phrase 'Minimal Residual Disease Testing' was also identified.
3.  **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' and 'Disease Characterisation' to determine if 'Minimal Residual Disease' should be included as a qualifier. No specific rule mandated its inclusion.
4.  **Rule Application**: 
    *   The generic exclusion rule for 'Procedural/Temporal Qualifiers' and 'Study methodologies' was applied. 'Minimal Residual Disease Testing' is a testing methodology, not a patient subgroup that defines the indication, so it was excluded.
    *   The generic formatting rules were applied: 'Multiple Myeloma' is already in Title Case and singular form.
5.  **Indication Construction**: Based on the rules, only the core disease term from the abstract title was kept.
6.  **Final Output**: The final generated indication is 'Multiple Myeloma'. The session title, which also contained 'Plasma cell Dyscrasias', was not used, in strict adherence to the single-source principle.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check if 'Minimal Residual Disease' is a standard qualifier for an indication. No specific rule was found, leading to its exclusion based on generic rules.""}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Title Case and Singular Form.'}, {'component': 'Minimal Residual Disease Testing', 'type': 'Procedural Term', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/methodological terms.'}]",2
295477,Mini Oral session: Basic science & translational research,5-hydroxymethycytosine analysis reveals stable epigenetic changes in tumor tissue that enable cfDNA cancer predictions,,,Cancer,True,abstract_title,"Step 1: The abstract title contains the disease terms 'tumor' and 'cancer', while the session title is about the research area ('Basic science & translational research') and does not contain a specific disease. Therefore, the abstract title is selected as the source.
Step 2: The disease terms identified are 'tumor' and 'cancer'. The rest of the title describes the methodology ('5-hydroxymethycytosine analysis', 'cfDNA predictions') and biological context ('epigenetic changes', 'tumor tissue'), not specific patient subgroups or disease characteristics.
Step 3: According to the generic rules, disease terms should be in singular form and Title Case. 'tumor' is normalized to 'Tumor' and 'cancer' is normalized to 'Cancer'.
Step 4: Since 'tumor' and 'cancer' refer to the same general disease concept in this context, the most standard and overarching term 'Cancer' is used for the final indication. No specific rules needed to be retrieved as the terms are general.",[],"[{'component': 'tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': 'Generic Rule: Singular Form, Title Case'}, {'component': 'cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic Rule: Title Case'}]",1
328247,Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I,Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and >=65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and >=1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study,Aged <65;;Relapsed;;Refractory;;Diffuse Large B-Cell Lymphoma,Elderly Relapsed/Refractory Diffuse Large B-Cell Lymphoma,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains a specific disease name ('Diffuse Large B-Cell Lymphoma'), making it the primary source according to the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title were:
    *   Disease: 'Diffuse Large B-Cell Lymphoma (DLBCL)'
    *   Disease State/Occurrence: 'Relapsed/Refractory (R/R)'
    *   Treatment History: '>=1 Prior Therapy'
    *   Excluded Elements: Age groups ('Aged <65 and >=65 Years') were identified as study analysis subgroups, not core indication characteristics, and were excluded per generic rules.
3.  **Rule Retrieval**: Rules for 'Occurrence' (specifically 'Recurrent/Refractory') and 'Treatment based' (specifically 'Treatment Status') were retrieved to handle the patient subgroup descriptors.
4.  **Rule Application and Refinement**:
    *   The disease name was standardized to 'Diffuse Large B-Cell Lymphoma' in Title Case and singular form.
    *   'Relapsed/Refractory' was identified as the primary patient subgroup qualifier.
    *   The term '>=1 Prior Therapy' is clinically synonymous with 'Previously Treated'. However, the term 'Relapsed/Refractory' inherently implies that a patient has received prior therapy, making the inclusion of 'Previously Treated' redundant. To create the most concise and clinically accurate indication, 'Previously Treated' was omitted.
5.  **Indication Construction**: The final indication was constructed by prepending the standardized disease state ('Relapsed/Refractory') to the core disease name.
6.  **Final Quality Check**: The generated indication was verified against all formatting, exclusion, and clinical accuracy rules. It correctly uses Title Case, singular form, and accurately represents the patient population from the source title.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To correctly format the 'Relapsed/Refractory' patient subgroup.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To understand how to handle the '>=1 Prior Therapy' component and its relationship with other descriptors.""}]","[{'component': 'Relapsed/Refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rule for standardizing disease state qualifiers.'}, {'component': 'Diffuse Large B-Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Diffuse Large B-Cell Lymphoma', 'rule_applied': 'Generic rule for Title Case and singular form.'}, {'component': '>=1 Prior Therapy', 'type': 'Treatment Status', 'normalized_form': 'Previously Treated', 'rule_applied': ""Treatment Status rule. This component was ultimately excluded for being clinically redundant with 'Relapsed/Refractory'.""}, {'component': 'Aged <65 and >=65 Years', 'type': 'Age Group', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic descriptors not integral to the disease name.'}]",2
229946,PD09: Infertility: Epidemiology & Evaluation I,Low birth weight is associated with sperm DNA fragmentation and assisted reproductive technology outcomes in primary infertile men - results of a cross-sectional study,,,Primary Infertility,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a more specific disease term ('primary infertile men') compared to the session title ('Infertility').
Step 2: The core disease term 'infertile' was identified.
Step 3: The qualifier 'primary' was identified.
Step 4: The gender descriptor 'men' was identified for exclusion.
Step 5: The generic rules were applied. 'infertile' was converted to its singular, Title Case form: 'Infertility'. The qualifier 'primary' was prepended to the disease name, resulting in 'Primary Infertility'. The sociodemographic descriptor 'men' was excluded as per the generic exclusion rules. Other terms like 'Low birth weight' and 'sperm DNA fragmentation' were identified as associated conditions or findings, not the primary indication under study.",[],"[{'component': 'primary infertile men', 'type': 'Disease with Qualifier and Gender', 'normalized_form': 'Primary Infertility', 'rule_applied': ""Single-Source Principle; Generic Rule for 'Primary'; Generic Rule for Singular Form; Generic Rule for Sociodemographic Exclusion (Gender)""}]",1
328253,Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I,"Efficacy and Safety of Lenalidomide, Anti-PD-1 Antibody Combined with Orelabrutinib or Rituximab in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma",Relapsed/Refractory;;Diffuse Large B-Cell Lymphoma,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as the source because it contains a specific disease, 'Diffuse Large B-Cell Lymphoma', which is more precise than the broader category 'Aggressive Lymphomas' in the session title. This adheres to the Single-Source Extraction Principle.
2.  **Component Identification**: The key components identified in the abstract title are the disease state 'Relapsed/Refractory' and the disease name 'Diffuse Large B-Cell Lymphoma'.
3.  **Rule Retrieval**: To ensure correct formatting for the disease state, I retrieved rules for the 'Occurrence' category, specifically for 'Recurrent/Refractory' terms. The retrieved rule confirmed that terms like 'Relapsed/Refractory' should be standardized in Title Case and placed before the disease name.
4.  **Rule Application**: 
    *   The generic rule for Title Casing was applied to 'Relapsed/Refractory'.
    *   The generic rule for singular form was applied, although 'Lymphoma' is already singular.
    *   Exclusion rules were applied to remove treatment names (Lenalidomide, Anti-PD-1 Antibody, Orelabrutinib, Rituximab) and the procedural phrase 'in the Treatment of Patients with'.
5.  **Indication Construction**: The standardized disease state 'Relapsed/Refractory' was prepended to the disease name 'Diffuse Large B-Cell Lymphoma'.
6.  **Quality Check**: The final indication was checked for adherence to all formatting, exclusion, and clinical accuracy requirements. The output is a single, clean, and clinically valid indication.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To verify the correct formatting and placement of the 'Relapsed/Refractory' qualifier.""}]","[{'component': 'Relapsed/Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rule for Recurrent/Refractory terms and Generic Title Case rule.'}, {'component': 'Diffuse Large B-Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Diffuse Large B-Cell Lymphoma', 'rule_applied': 'Generic Singular Form and Title Case rules.'}]",2
262717,Platelet disorders,Metabolic Abnormality And Glucocorticoid Receptor Modulation Of Myeloid-Derived Suppressor Cells In Immune Thrombocytopenia Patients And An Active Murine Model,Immune Thrombocytopenia,Immune Thrombocytopenia,Immune Thrombocytopenia,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease term, 'Immune Thrombocytopenia', which is more precise than the broader category 'Platelet disorders' in the session title.
Step 2: The term 'Immune Thrombocytopenia' was identified as the core disease.
Step 3: Generic exclusion rules were applied. 'Patients' is a generic descriptor and was excluded. 'Active Murine Model' was excluded as it refers to a non-human study model. 'Metabolic Abnormality' and 'Glucocorticoid Receptor Modulation Of Myeloid-Derived Suppressor Cells' were identified as biological processes or characteristics being studied within the context of the disease, not as part of the core indication itself.
Step 4: Generic formatting rules were applied. The indication was converted to Title Case and singular form, although it was already in the correct format.",[],"[{'component': 'Immune Thrombocytopenia', 'type': 'Disease', 'normalized_form': 'Immune Thrombocytopenia', 'rule_applied': 'Generic Rules: Title Case, Singular Form'}, {'component': 'Patients', 'type': 'Generic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule'}, {'component': 'Active Murine Model', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Non-Diagnostic Items'}]",1
410176,Improving Clinical Outcomes in Diabetic Kidney Disease,Earlier Intervention in Diabetic Kidney Disease Management Using the In Vitro Diagnostic Test PromarkerD Shows Economic Health Benefits over Current Standard of Care,Diabetic Kidney Disease,Diabetic Kidney Disease,Diabetic Kidney Disease,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. Both contain the disease term 'Diabetic Kidney Disease'.
Step 2: Following the single-source extraction principle, I selected the abstract title as the primary source because it contains a valid disease term.
Step 3: I identified the core disease component as 'Diabetic Kidney Disease'. Other phrases in the title, such as 'Earlier Intervention', 'Management', and descriptions of the diagnostic test, were identified as procedural or methodological and marked for exclusion based on generic rules.
Step 4: I applied the generic formatting rules. The disease term was already in the correct Title Case and singular form.
Step 5: I constructed the final indication by extracting only the core disease term, resulting in 'Diabetic Kidney Disease'.",[],"[{'component': 'Diabetic Kidney Disease', 'type': 'Disease', 'normalized_form': 'Diabetic Kidney Disease', 'rule_applied': 'Generic rule: Title Case, Singular Form'}]",1
180799,Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster I,"Retrospective Comparison of the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) 21-Day Schedule Vs. 28-Day Schedule in Patients with Newly Diagnosed Multiple Myeloma",Newly Diagnosed;;Multiple Myeloma,Newly Diagnosed Multiple Myeloma,Newly Diagnosed Multiple Myeloma,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease, 'Multiple Myeloma', which aligns with the single-source extraction principle.
Step 2: The components identified in the abstract title are the disease 'Multiple Myeloma' and the patient subgroup qualifier 'Newly Diagnosed'.
Step 3: The `get_indication_rules` tool was used for the category 'Treatment based' and subcategory 'Diagnosis Status' to understand how to handle 'Newly Diagnosed'.
Step 4: The retrieved rule confirmed that 'Newly Diagnosed' should be used as a prefix to the disease name. Generic rules for Title Case and singular form were also applied.
Step 5: The final indication was constructed by combining the qualifier and the disease, resulting in 'Newly Diagnosed Multiple Myeloma'.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To verify the correct formatting and inclusion of the term 'Newly Diagnosed'.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - 'Newly Diagnosed' should be prefixed to the disease name.""}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Use Title Case and singular form for disease names.'}]",2
262725,"Quality of life, palliative care, ethics and health economics",Economic Burden Of Transfusion-Dependent Beta-Thalassemia In The United States,Beta-Thalassemia,Beta-Thalassemia,Transfusion-Dependent Beta-Thalassemia,True,abstract_title,"Step 1: The abstract title 'Economic Burden Of Transfusion-Dependent Beta-Thalassemia In The United States' was chosen as the source because it contains a specific disease, whereas the session title 'Quality of life, palliative care, ethics and health economics' does not.
Step 2: The core disease 'Beta-Thalassemia' was identified.
Step 3: The patient subgroup qualifier 'Transfusion-Dependent' was identified. This is a critical clinical descriptor defining a specific cohort of patients and must be included.
Step 4: The non-diagnostic phrase 'Economic Burden Of' and the geographic descriptor 'In The United States' were identified for exclusion based on generic rules.
Step 5: The components were combined and formatted according to the rules. The final indication was converted to Title Case, resulting in 'Transfusion-Dependent Beta-Thalassemia'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules on how to handle disease qualifiers like 'Transfusion-Dependent'.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To determine if 'Transfusion-Dependent' should be handled as a treatment status qualifier.""}]","[{'component': 'Transfusion-Dependent', 'type': 'Patient Subgroup', 'normalized_form': 'Transfusion-Dependent', 'rule_applied': 'Generic rule: Include clinically valid patient subgroups.'}, {'component': 'Beta-Thalassemia', 'type': 'Disease', 'normalized_form': 'Beta-Thalassemia', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}, {'component': 'In The United States', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude geographic descriptors.'}]",2
311878,Fellows-In-Training: Roundtables,Roundtable 24 - Salivary Lip Biopsies in Practice IV,,,,True,none,"Neither the abstract title nor the session title contains a clinically valid medical indication. The abstract title, 'Roundtable 24 - Salivary Lip Biopsies in Practice IV', refers to a medical procedure (biopsy), not a disease or disorder. The session title, 'Fellows-In-Training: Roundtables', describes the audience and format of the session. According to the exclusion rules, procedural terms without an associated disease are not considered valid indications. Therefore, no indication can be extracted.",[],"[{'component': 'Salivary Lip Biopsies', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Exclusion Rules - Procedural/Temporal Qualifiers'}]",1
262728,"Quality of life, palliative care, ethics and health economics",Factors Associated With A Lymphoma Diagnosis Prior To Biopsy,Lymphoma,Lymphoma,Lymphoma,True,abstract_title,"Step 1: The abstract title contains the disease term 'Lymphoma', while the session title does not contain any specific disease. Therefore, the abstract title was selected as the source based on the single-source extraction principle.
Step 2: The components identified in the abstract title are the disease 'Lymphoma' and the procedural qualifier 'Prior To Biopsy'.
Step 3: Rules for 'Biopsy Status' were retrieved to determine how to handle the phrase 'Prior To Biopsy'. Rule ID 440 for 'Biopsy Naive' indicates that biopsy status should be excluded from the final indication.
Step 4: The generic exclusion rule for procedural/temporal qualifiers was applied, leading to the removal of 'Prior To Biopsy'. The term 'Diagnosis' was also removed as it is a non-diagnostic item related to study methodology.
Step 5: The core disease term 'Lymphoma' was standardized to Title Case and singular form, resulting in the final indication 'Lymphoma'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Biopsy Status', 'Disease Characterisation'], 'reason': ""To verify how to handle the procedural qualifier 'Prior To Biopsy'.""}]","[{'component': 'Lymphoma', 'type': 'Disease', 'normalized_form': 'Lymphoma', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'Prior To Biopsy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule; Patient Sub-Group Rule ID 440 (Biopsy Naive)'}]",2
377420,Chronic lymphocytic leukemia and related disorders - Biology & Translational Research,Expression Of The Long Non-Coding Rna Malat1 In Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,True,abstract_title,"Step 1: The abstract title 'Expression Of The Long Non-Coding Rna Malat1 In Chronic Lymphocytic Leukemia' was chosen as the source because it contains a specific disease, which is preferred over the session title.
Step 2: The core disease 'Chronic Lymphocytic Leukemia' was identified.
Step 3: The phrase 'Expression Of The Long Non-Coding Rna Malat1' was excluded as it describes the subject of the research (a biomarker's activity) rather than a patient subgroup or a characteristic of the disease indication itself.
Step 4: Generic formatting rules were applied. The disease name was already in singular form and appropriate Title Case. No special rules were needed.
Step 5: The final indication was constructed as 'Chronic Lymphocytic Leukemia'.",[],"[{'component': 'Chronic Lymphocytic Leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Generic Rule - Title Case'}]",1
344653,Diagnostic and Prognostic Biomarkers 1,Identification of molecular biomarkers differentiating malignant uterine leiomyosarcoma from benign leiomyoma,malignant;;uterine leiomyosarcoma,Malignant Uterine Leiomyosarcoma,Malignant Uterine Leiomyosarcoma;;Benign Leiomyoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title, 'Identification of molecular biomarkers differentiating malignant uterine leiomyosarcoma from benign leiomyoma', contains specific disease terms. The session title, 'Diagnostic and Prognostic Biomarkers 1', is generic. Therefore, the abstract title was selected as the source based on the single-source principle.
2.  **Component Identification**: The abstract title explicitly mentions two distinct clinical entities: 'malignant uterine leiomyosarcoma' and 'benign leiomyoma'. The core task described is differentiating between these two.
3.  **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' under the 'Disease Characterisation' subcategory to check for specific handling of terms like 'malignant' and 'benign'. No specific rules were found, so I proceeded with generic rules.
4.  **Rule Application & Construction**:
    *   **Multiple Diseases**: The title presents two distinct conditions being compared. Both must be extracted as separate indications, delimited by ';;'.
    *   **First Indication**: 'malignant uterine leiomyosarcoma' was processed. 'Malignant' is a critical disease characteristic and must be retained. 'Uterine' is an essential anatomical specifier. Applying Title Case and singular form (already singular) results in 'Malignant Uterine Leiomyosarcoma'.
    *   **Second Indication**: 'benign leiomyoma' was processed. 'Benign' is a critical disease characteristic and must be retained. Applying Title Case and singular form (already singular) results in 'Benign Leiomyoma'.
    *   **Combination**: The two indications are combined using the ';;' separator.
5.  **Quality Check**: The final output adheres to all formatting rules (Title Case, singular form, no trailing spaces) and accurately reflects the two distinct clinical conditions mentioned in the source title.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for specific rules regarding the handling of disease characterization keywords like 'malignant' and 'benign'.""}]","[{'component': 'malignant uterine leiomyosarcoma', 'type': 'Disease', 'normalized_form': 'Malignant Uterine Leiomyosarcoma', 'rule_applied': ""Generic Rule: Title Case, Generic Rule: Retain essential clinical characteristics ('Malignant').""}, {'component': 'benign leiomyoma', 'type': 'Disease', 'normalized_form': 'Benign Leiomyoma', 'rule_applied': ""Generic Rule: Title Case, Generic Rule: Retain essential clinical characteristics ('Benign').""}]",2
180817,Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I,"Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone",Newly Diagnosed;;Multiple Myeloma,Newly Diagnosed Multiple Myeloma,Newly Diagnosed Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the primary source because it contains a specific disease ('Multiple Myeloma') and detailed patient subgroup information, making it more informative than the session title.
2. **Component Identification**: I identified three key components in the abstract title: the disease 'Multiple Myeloma', the diagnosis status 'Newly Diagnosed', and the patient characteristic 'Transplant-Ineligible'.
3. **Rule Retrieval**: To ensure correct handling of these components, I retrieved specific rules. I used `get_indication_rules` for 'Transplant Status' which confirmed that 'Transplant-Ineligible' should be excluded as it describes treatment suitability, not the disease itself. I also retrieved rules for 'Diagnosis Status', which confirmed that 'Newly Diagnosed' should be included as a prefix to the disease.
4. **Rule Application & Indication Construction**: 
   - The core disease is 'Multiple Myeloma'.
   - Applying the 'Diagnosis Status' rule, I prefixed the disease with 'Newly Diagnosed'.
   - Applying the 'Transplant Status' rule, I excluded 'Transplant-Ineligible'.
   - Generic rules were applied to ensure Title Case and singular form, resulting in 'Newly Diagnosed Multiple Myeloma'.
5. **Final Quality Check**: The final indication is clinically accurate, adheres to all formatting rules, and is derived from a single source.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine how to handle the term 'Transplant-Ineligible'.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To determine how to handle the term 'Newly Diagnosed'.""}]","[{'component': 'Transplant-Ineligible', 'type': 'Patient Sub-Group', 'normalized_form': '', 'rule_applied': ""Rule ID 229: Exclude 'Transplant-Ineligible' as it describes treatment suitability, not a clinical condition.""}, {'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID 193: Prefix 'Newly Diagnosed' to the disease name.""}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}]",2
328274,Aggressive Lymphomas: Clinical and Epidemiological: Poster II,Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium,Adolescent;;Adult;;Burkitt Lymphoma;;Leukemia,Adolescent Adult Burkitt Lymphoma;;Adolescent Adult Leukemia,Adolescent Burkitt Lymphoma;;Adult Burkitt Lymphoma;;Adolescent Leukemia;;Adult Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemia...') was chosen over the session title ('Aggressive Lymphomas...') because it contains more specific disease names ('Burkitt Lymphoma', 'Leukemia') and patient subgroups, adhering to the single-source principle.
2. **Component Identification**: The key components identified in the abstract title were:
    - Age Groups: 'Adolescent' and 'Adult'.
    - Diseases: 'Burkitt Lymphoma' and 'Leukemia'.
    - Excludable terms: 'Prognostic Factors and Outcomes', 'Low-Middle Income Country', 'Experience from Hematology Cancer Consortium' were identified as study methodology or geographic descriptors and marked for exclusion per generic rules.
3. **Rule Retrieval**: To ensure correct formatting for the age groups, the `get_indication_rules` tool was used for the category 'Age Group' with subcategories 'Adolescent' and 'Adult'.
4. **Rule Application**: 
    - The retrieved rules (e.g., Rule ID 289 for 'Adult', Rule ID 318 for 'Adolescent') confirmed that the age group should be a capitalized prefix to the disease name (e.g., 'Adult Gastric Cancer').
    - The structure 'Adolescent and Adult Burkitt Lymphoma and Leukemia' implies that both age groups apply to both diseases. This requires creating all four possible combinations.
    - Generic rules were applied: diseases were kept in singular form, Title Case was used, and excluded terms were removed.
5. **Indication Construction**: The components were combined to form four distinct indications, separated by the ';;' delimiter as required for multiple diseases/subgroups: 'Adolescent Burkitt Lymphoma', 'Adult Burkitt Lymphoma', 'Adolescent Leukemia', and 'Adult Leukemia'.
6. **Quality Check**: The final output was verified against all rules: single source used, all diseases and subgroups included, correct formatting and separators applied, and non-clinical information excluded.","[{'category': 'Age Group', 'subcategories': ['Adolescent', 'Adult'], 'reason': ""To verify the correct formatting and application of the 'Adolescent' and 'Adult' patient subgroups identified in the abstract title.""}]","[{'component': 'Adolescent', 'type': 'Age Group', 'normalized_form': 'Adolescent', 'rule_applied': 'Age Group Rule ID 318: Prepend capitalized age group to the disease name.'}, {'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group Rule ID 289: Prepend capitalized age group to the disease name.'}, {'component': 'Burkitt Lymphoma', 'type': 'Disease', 'normalized_form': 'Burkitt Lymphoma', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}, {'component': 'Leukemia', 'type': 'Disease', 'normalized_form': 'Leukemia', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}]",2
393814,"Nsclc, Early Stage",Personalized Tumor-Informed Circulating Tumor Dna (Ctdna) Analysis For Molecular Residual Disease (Mrd) Detection In Resected Non-Small Cell Lung Cancer (Nsclc) With Common Driver Genes,Resected;;Non-Small Cell Lung Cancer,Resected Non-Small Cell Lung Cancer,Resected Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title contains a specific disease ('Non-Small Cell Lung Cancer'), so it is selected as the source over the session title, following the single-source principle.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Non-Small Cell Lung Cancer (Nsclc)' and a treatment status qualifier 'Resected'. The phrase 'With Common Driver Genes' was also identified.
3. **Rule Retrieval**: 
   - Rules for 'Resected' were retrieved using `get_indication_rules(category='Treatment Set-up', subcategories=['Resectable'])`. Rule ID 237 specifies that 'resected' should be standardized to 'Resected' and used as a prefix to the disease name.
   - Rules for gene names were retrieved using `get_indication_rules(category='Gene Name', subcategories=['Gene Name'])`. Rules ID 28 and 29 state that a gene reference without a specific functional qualifier (e.g., mutated, positive) should be excluded. 'With Common Driver Genes' is a general, non-actionable descriptor and thus must be excluded.
4. **Indication Construction**: 
   - The disease 'Non-Small Cell Lung Cancer (Nsclc)' is normalized to 'Non-Small Cell Lung Cancer' in Title Case, and the abbreviation is dropped.
   - The qualifier 'Resected' is prepended to the disease name as per the retrieved rule.
   - The non-specific genetic information 'With Common Driver Genes' is excluded.
   - Other methodological terms like 'Ctdna Analysis' and 'Mrd Detection' are excluded as they are not part of the clinical indication.
5. **Final Formatting**: The final indication is formatted to 'Resected Non-Small Cell Lung Cancer', adhering to Title Case and singular form rules. No trailing spaces or invalid separators are present.","[{'category': 'Treatment Set-up', 'subcategories': ['Resectable', 'Operative Status'], 'reason': ""To determine how to handle the term 'Resected'.""}, {'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To determine how to handle the non-specific phrase 'With Common Driver Genes'.""}]","[{'component': 'Resected', 'type': 'Treatment Status', 'normalized_form': 'Resected', 'rule_applied': ""Rule ID 237: Standardize 'resected' to 'Resected' and place it before the disease name.""}, {'component': 'Non-Small Cell Lung Cancer (Nsclc)', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic Rule: Use full disease name, apply Title Case, and use singular form.'}, {'component': 'With Common Driver Genes', 'type': 'Genetic Context', 'normalized_form': '', 'rule_applied': 'Rule ID 28/29: Exclude gene names/references that lack a specific, actionable functional qualifier.'}]",3
213592,MP17: Pediatric Urology: Upper & Lower Urinary Tract,Are pre-operative urine cultures and cystoscopies before ureteral reimplantation clinically useful or cost effective?,,,Pediatric Upper Urinary Tract Disease;;Pediatric Lower Urinary Tract Disease,True,session_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title describes medical procedures ('urine cultures', 'cystoscopies', 'ureteral reimplantation') but does not name a disease or condition. The session title, 'MP17: Pediatric Urology: Upper & Lower Urinary Tract', contains a clear patient subgroup ('Pediatric') and anatomical areas of focus ('Upper & Lower Urinary Tract') within a therapeutic area ('Urology'). According to the single-source principle, the session title is selected as it contains actionable indication components.
2. **Component Identification**: From the session title, the following components were identified: 'Pediatric' (age group), 'Upper Urinary Tract' (anatomical location 1), and 'Lower Urinary Tract' (anatomical location 2).
3. **Rule Retrieval**: The presence of 'Pediatric' prompted the retrieval of rules for the 'Age Group' category to ensure correct formatting.
4. **Rule Application**: The retrieved rules for 'Pediatric' (e.g., Rule ID 295) confirm that it should be used as a prefix for the indication. The phrase 'Upper & Lower Urinary Tract' clearly indicates two separate anatomical regions. To create clinically valid indications from these anatomical sites within a urology context, the general term 'Disease' is appended to each.
5. **Indication Construction**: The components are assembled into two distinct indications: 'Pediatric Upper Urinary Tract Disease' and 'Pediatric Lower Urinary Tract Disease'.
6. **Final Formatting**: As per the generic rules for multiple diseases, the two indications are combined into a single string, separated by ';;'. The final output is formatted in Title Case.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly handle the 'Pediatric' patient subgroup qualifier found in the session title.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule for 'Pediatric' (ID: 295/296)""}, {'component': 'Upper Urinary Tract', 'type': 'Anatomical Location', 'normalized_form': 'Upper Urinary Tract Disease', 'rule_applied': 'Therapeutic Area Fallback/Generalization'}, {'component': 'Lower Urinary Tract', 'type': 'Anatomical Location', 'normalized_form': 'Lower Urinary Tract Disease', 'rule_applied': 'Therapeutic Area Fallback/Generalization'}]",2
344667,Diagnostic and Prognostic Biomarkers 1,Detecting and intervening on rare pre-existing resistant subclones to BRAF/MEK inhibitors in metastatic melanoma,metastatic;;melanoma,Metastatic Melanoma,Metastatic Melanoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Detecting and intervening on rare pre-existing resistant subclones to BRAF/MEK inhibitors in metastatic melanoma') was chosen as it contains a specific disease ('melanoma'), whereas the session title ('Diagnostic and Prognostic Biomarkers 1') does not.
2. **Component Identification**: The key components identified in the abstract title were 'resistant', 'metastatic', and 'melanoma'.
3. **Rule Retrieval**: I retrieved rules for 'Occurrence' (subcategories: 'Metastasis-Related Terms', 'Resistance') to correctly handle 'metastatic' and 'resistant'.
4. **Rule Application**:
   - The generic rule for singular form was applied, although 'melanoma' is already singular.
   - The generic rule for Title Case was applied, converting 'metastatic melanoma' to 'Metastatic Melanoma'.
   - The retrieved rule for 'Metastatic' (ID: 141) confirmed the format 'Metastatic <Disease>'.
   - The retrieved rules for 'Resistance' (ID: 164, 165) explicitly state that drug resistance (e.g., 'resistant...to BRAF/MEK inhibitors') should be excluded from the final indication as it describes a treatment response status, not a core disease entity.
5. **Indication Construction**: Based on the rules, the 'resistant' component was excluded, and the 'metastatic' component was combined with the disease to form the final indication.
6. **Final Output**: The resulting indication is 'Metastatic Melanoma', which is a clinically valid and correctly formatted indication.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms', 'Resistance'], 'reason': ""To correctly handle the terms 'metastatic' and 'resistant' found in the abstract title.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To check for rules related to treatment status, although the more specific 'Resistance' rules were ultimately applied.""}]","[{'component': 'metastatic melanoma', 'type': 'Disease with Occurrence', 'normalized_form': 'Metastatic Melanoma', 'rule_applied': ""Occurrence rule for 'Metastatic' (ID: 141) and generic Title Case/Singular Form rules.""}, {'component': 'resistant subclones to BRAF/MEK inhibitors', 'type': 'Resistance Descriptor', 'normalized_form': '', 'rule_applied': ""Occurrence rule for 'Drug/Drug Class-Resistant' (ID: 164, 165) requires exclusion of this component from the indication.""}]",2
180828,Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I,Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study,Relapsed;;Refractory;;Multiple Myeloma,Relapsed and/or Refractory Multiple Myeloma,Relapsed/Refractory Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Multiple Myeloma') and detailed patient subgroup information, making it more precise than the session title.
2.  **Component Identification**: The key components identified in the abstract title were the disease 'Multiple Myeloma' and the patient subgroup descriptors 'Relapsed and/or Refractory' and 'Who Have Received at Least Two Prior Lines of Therapy'.
3.  **Rule Retrieval**: I retrieved rules for 'Occurrence' to handle 'Relapsed and/or Refractory' and for 'Treatment Set-up' to handle 'Prior Lines of Therapy'.
4.  **Rule Application**:
    *   **Occurrence Rule**: The phrase 'Relapsed and/or Refractory' was standardized to 'Relapsed/Refractory' based on common clinical terminology formatting rules, such as the logic found in Rule ID 189 which merges these concepts.
    *   **Treatment Set-up Rule (ID: 207)**: This rule explicitly states that references to 'Prior Lines' of therapy should be excluded from the final indication as they describe treatment history, not a core indication qualifier. Therefore, the entire phrase 'Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor' was removed.
    *   **Generic Rules**: The disease term 'Multiple Myeloma' was already in singular form. The final output was formatted to Title Case.
5.  **Indication Construction**: The standardized patient subgroup 'Relapsed/Refractory' was prepended to the core disease 'Multiple Myeloma' to form the final indication.
6.  **Quality Check**: The final indication adheres to the single-source principle, correctly applies formatting and exclusion rules, and accurately represents the core clinical condition described in the abstract title.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory', 'Refractory', 'Relapse'], 'reason': ""To correctly format the 'Relapsed and/or Refractory' component.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine how to handle the phrase 'at Least Two Prior Lines of Therapy'.""}]","[{'component': 'Relapsed and/or Refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Standard practice for combining relapsed and refractory states.'}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule for singular form and Title Case.'}, {'component': 'Who Have Received at Least Two Prior Lines of Therapy...', 'type': 'Treatment History', 'normalized_form': '', 'rule_applied': 'Rule ID: 207 - Exclude references to prior lines of therapy.'}]",2
377438,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Pharmacodynamic Activity Of Gen3014 (Hexabody-Cd38) In Patients With Multiple Myeloma Supports Enhanced Complement Dependent Cytotoxicity Of Gen3014 Compared To Daratumumab,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: The abstract title contains the specific disease 'Multiple Myeloma', so it is selected as the primary source based on the single-source extraction principle.
Step 2: The core disease term 'Multiple Myeloma' was identified from the abstract title.
Step 3: No other patient subgroups, biomarkers, or disease qualifiers were present in the selected title.
Step 4: Generic rules were applied. The disease term was already in singular form. Title Case formatting was applied, resulting in 'Multiple Myeloma'. The phrase 'Patients With' was excluded as a non-diagnostic descriptor.
Step 5: The final indication was constructed from the identified and normalized disease term.","[{'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': ""Checked to see if 'Myeloma' and 'Multiple Myeloma' from the two titles required special handling, but no specific rules were found, confirming the single-source principle should be followed.""}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Casing and Singular Form Rules'}]",2
311906,Genetic Predisposition and the Balance Between Infection and Autoimmunity,Q&A,,,Infection;;Autoimmunity,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract_title 'Q&A' contains no medical information. The session_title 'Genetic Predisposition and the Balance Between Infection and Autoimmunity' contains the potential indications 'Infection' and 'Autoimmunity'.
2.  **Select Source**: Based on the Single-Source Extraction Principle, the session_title is selected as it is the only source containing disease terms.
3.  **Identify Components**: The core medical conditions identified are 'Infection' and 'Autoimmunity'. 'Genetic Predisposition' is a patient characteristic that describes the context but does not form part of the standard indication name itself.
4.  **Retrieve Rules**: I checked for rules regarding 'Genetic Origin' to see how to handle 'Genetic Predisposition' but found no specific rules. Therefore, I will rely on the generic rules.
5.  **Apply Rules**: 
    -   **Multiple Diseases Rule**: The title mentions two distinct conditions, 'Infection' and 'Autoimmunity'. They must be extracted as separate indications.
    -   **Separator Rule**: The two indications are separated by ';;'.
    -   **Formatting Rules**: The terms are already in singular form and correctly capitalized (Title Case).
6.  **Construct Indication**: The final generated indication is 'Infection;;Autoimmunity'.
7.  **Quality Check**: The output adheres to all formatting and extraction principles. The source is correctly selected, and multiple diseases are handled appropriately.","[{'category': 'Patient Sub-Group', 'subcategories': ['Genetic Origin'], 'reason': ""To determine how to handle the term 'Genetic Predisposition'.""}]","[{'component': 'Infection', 'type': 'Disease', 'normalized_form': 'Infection', 'rule_applied': 'Generic rule for disease extraction.'}, {'component': 'Autoimmunity', 'type': 'Disease', 'normalized_form': 'Autoimmunity', 'rule_applied': 'Generic rule for disease extraction.'}, {'component': 'Genetic Predisposition', 'type': 'Patient Characteristic', 'normalized_form': 'Genetic Predisposition', 'rule_applied': 'Excluded as it describes the context/risk factor rather than being part of a standard indication name.'}]",2
393826,"Nsclc, Early Stage",Concordance Of Pd-L1 Expression Between Biopsy And Matched Surgical Specimen In Early-Stage Non-Small Cell Lung Cancer: Lc-Scrum-Advantage/Mrd,Early-Stage;;Non-Small Cell Lung Cancer,Early-Stage Non-Small Cell Lung Cancer,Early Stage Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title as it contains a more specific and complete description of the disease and patient subgroup, adhering to the single-source principle.
2. **Component Identification**: The key components identified in the abstract title were 'Early-Stage' (Stage) and 'Non-Small Cell Lung Cancer' (Disease). 'Pd-L1 Expression' was identified as a biomarker, but the title discusses the 'concordance of' expression, making it the subject of the study rather than a defining characteristic of the patient cohort. Therefore, it is excluded from the final indication.
3. **Rule Retrieval**: Rules for 'Stage Onset' were retrieved to handle 'Early-Stage'. Rules for 'Biomarker' were retrieved to evaluate 'Pd-L1 Expression'.
4. **Rule Application**: 
   - The 'Early Stage' rule (ID: 109) was applied, which normalizes 'Early-Stage' to 'Early Stage' (Title Case, no hyphen).
   - The generic singular form rule was applied to 'Lung Cancer', which is already singular.
   - The generic Title Case rule was applied to the entire indication.
   - Procedural terms like 'Biopsy' and 'Surgical Specimen' were excluded as per generic exclusion rules.
5. **Indication Construction**: The normalized stage 'Early Stage' was prepended to the normalized disease 'Non-Small Cell Lung Cancer' to form the final indication.
6. **Quality Check**: The final indication was checked for formatting, accuracy, and adherence to all rules. It correctly represents the patient population described.","[{'category': 'Stage', 'subcategories': ['Stage Onset'], 'reason': ""To correctly format the 'Early-Stage' keyword.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To determine how to handle 'Pd-L1 Expression'.""}]","[{'component': 'Early-Stage', 'type': 'Stage', 'normalized_form': 'Early Stage', 'rule_applied': ""Stage Onset Rule ID: 109 - Normalize to 'Early Stage' (title-case, no hyphen).""}, {'component': 'Non-Small Cell Lung Cancer', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Pd-L1 Expression', 'type': 'Biomarker', 'normalized_form': '', 'rule_applied': 'Excluded as the title describes a study about expression levels, not a pre-defined patient subgroup with a specific PD-L1 status.'}]",2
393827,"Nsclc, Early Stage",Predicting Pd-L1 Expression Using [18F]Fdg Pet/Ct In Early Stage Non-Small Cell Lung Cancer (Nsclc).,Early Stage;;Non-Small Cell Lung Cancer,Early Stage Non-Small Cell Lung Cancer,Early Stage Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the primary source because it contains a complete and specific disease name ('Non-Small Cell Lung Cancer') and its stage, which is more detailed than the session title.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Non-Small Cell Lung Cancer (Nsclc)', the stage 'Early Stage', and the biomarker 'Pd-L1 Expression'.
3. **Rule Retrieval**: Rules for 'Stage Onset' and 'Biomarker' were retrieved to ensure correct formatting and inclusion.
4. **Rule Application**:
   - The 'Early Stage' rule (ID: 109) was applied, which standardizes the term to 'Early Stage' and places it before the disease name.
   - The generic exclusion rule was applied to 'Pd-L1 Expression'. The title describes a study *predicting* this expression, not defining a patient subgroup based on it (e.g., 'PD-L1 Positive'). Therefore, it is part of the study's methodology and not the core indication.
   - The disease name was normalized from 'Non-Small Cell Lung Cancer (Nsclc)' to 'Non-Small Cell Lung Cancer' and converted to singular form and Title Case as per generic rules.
5. **Indication Construction**: The standardized stage 'Early Stage' was combined with the normalized disease 'Non-Small Cell Lung Cancer' to form the final indication.
6. **Quality Check**: The final indication adheres to all formatting and clinical accuracy requirements. It is sourced from a single title, uses Title Case, is in singular form, and correctly includes the patient subgroup (stage) while excluding non-indicative information.","[{'category': 'Stage', 'subcategories': ['Stage Onset'], 'reason': ""To correctly format the 'Early Stage' qualifier.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To determine if 'Pd-L1 Expression' should be included in the indication.""}]","[{'component': 'Early Stage', 'type': 'Stage', 'normalized_form': 'Early Stage', 'rule_applied': 'Stage Onset Rule ID: 109'}, {'component': 'Non-Small Cell Lung Cancer (Nsclc)', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Pd-L1 Expression', 'type': 'Biomarker', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic items. The study is predicting the expression, not defining a patient subgroup by it.'}]",2
213605,MP17: Pediatric Urology: Upper & Lower Urinary Tract,Is Excretory Phase Computerized Tomography Important for Evaluation of High Grade Renal Trauma?: Results from the Traumatic Renal Injury Collaboration for Kids (TRICK),Traumatic Renal Injury,Traumatic Renal Injury,High Grade Renal Trauma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title because it contains a specific, diagnosable condition ('High Grade Renal Trauma'). The session title refers to a broader therapeutic area ('Pediatric Urology') and anatomical regions ('Upper & Lower Urinary Tract') without a specific disease.
2. **Component Identification**: From the abstract title, the core disease identified is 'Renal Trauma' and the grade qualifier is 'High Grade'.
3. **Rule Retrieval**: Rules for the 'Grade' category were retrieved to handle 'High Grade'. Rules for 'Age Group' were also considered due to 'Pediatric' in the session title and 'Kids' in the acronym expansion.
4. **Rule Application**: 
   - The 'High Grade' rule (ID: 115) was applied, which standardizes the format to 'High Grade' and places it before the disease name.
   - The generic rule for Title Case was applied.
   - The generic rule for singular form was applied (though 'Trauma' is already singular).
   - The term 'Pediatric' was not included in the final indication. Although present in the session title and implied in the abstract title's acronym, the Single-Source Extraction Principle dictates that the indication must be built exclusively from the chosen source (the abstract title), which does not explicitly contain the word 'Pediatric'.
5. **Indication Construction**: The components were combined and formatted according to the rules, resulting in 'High Grade Renal Trauma'.","[{'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To correctly format the 'High Grade' qualifier.""}, {'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To evaluate the term 'Pediatric' from the session title and 'Kids' from the acronym, ultimately excluding it based on the single-source principle.""}]","[{'component': 'High Grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': 'Grade Rule ID: 115'}, {'component': 'Renal Trauma', 'type': 'Disease', 'normalized_form': 'Renal Trauma', 'rule_applied': 'Generic Title Case and Singular Form rules'}]",2
393830,"Nsclc, Early Stage",Real-World Outcomes In Stage I-Iii Resectable Non-Small Cell Lung Cancer (Nsclc): Thassos-Intl Study,Stage I-III;;Resectable;;Non-Small Cell Lung Cancer,Stage I-III Resectable Non-Small Cell Lung Cancer,Resectable Stage I-III Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: Both the session title ('Nsclc, Early Stage') and the abstract title ('Real-World Outcomes In Stage I-Iii Resectable Non-Small Cell Lung Cancer (Nsclc): Thassos-Intl Study') contain a valid disease. The abstract title is more specific and is therefore selected as the source, following the single-source principle.
2. **Identify Components**: The selected abstract title contains the following components: Disease ('Non-Small Cell Lung Cancer (Nsclc)'), Stage ('Stage I-Iii'), and Operative Status ('Resectable'). Study-specific terms like 'Real-World Outcomes' and 'Thassos-Intl Study' are identified for exclusion.
3. **Retrieve Relevant Rules**: To ensure correct formatting, I retrieved rules for staging and resectability. 
   - `get_indication_rules(category=""Stage"", subcategories=[""Stage number""])` was used for 'Stage I-Iii'. Rule ID 91 confirmed that stage ranges should be standardized.
   - `get_indication_rules(category=""Treatment Set-up"", subcategories=[""Resectable""])` was used for 'Resectable'. Rule ID 236 confirmed that 'Resectable' should be included as a prefix.
4. **Apply Rules & Construct Indication**:
   - **Generic Rules**: The disease 'Non-Small Cell Lung Cancer' is already in singular form. Title Case is applied to all components. The parenthetical abbreviation '(Nsclc)' is removed as it's redundant.
   - **Stage Rule**: 'Stage I-Iii' is normalized to 'Stage I-III' for standardized representation, using Roman numerals as is standard for cancer staging.
   - **Treatment Set-up Rule**: 'Resectable' is capitalized and placed at the beginning of the indication.
5. **Final Assembly**: The components are combined in the standard clinical order: [Operative Status] [Stage] [Disease]. This results in 'Resectable Stage I-III Non-Small Cell Lung Cancer'.
6. **Quality Check**: The final indication adheres to all formatting rules, correctly incorporates the patient subgroups from the source title, and excludes non-clinical information.","[{'category': 'Stage', 'subcategories': ['Stage number'], 'reason': ""To correctly format the stage range 'I-Iii'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Resectable'], 'reason': ""To determine how to handle the term 'Resectable'.""}]","[{'component': 'Stage I-Iii', 'type': 'Stage', 'normalized_form': 'Stage I-III', 'rule_applied': 'Stage number rule (ID: 91) for standardizing stage ranges to Roman numerals.'}, {'component': 'Resectable', 'type': 'Operative Status', 'normalized_form': 'Resectable', 'rule_applied': 'Resectable rule (ID: 236) to include as a prefix.'}, {'component': 'Non-Small Cell Lung Cancer (Nsclc)', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic rule to use singular form and remove redundant abbreviations.'}]",2
393832,"Nsclc, Early Stage",Neoadjuvant Therapy With Anti-Pd-1/Pd-L1 Plus Platinum-Base Chemotherapy For Resectable Stage Ii-Iii Non-Small Cell Lung Cancer: A Systematic Review And Meta-Analysis Of Randomized Clinical Trials,Resectable;;Stage Ii-Iii;;Non-Small Cell Lung Cancer,Resectable Stage II-III Non-Small Cell Lung Cancer,Resectable Stage II-III Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Non-Small Cell Lung Cancer') and is more detailed than the session title, adhering to the single-source principle.
2. **Component Identification**: I identified the following components in the abstract title: the disease 'Non-Small Cell Lung Cancer', the operative status 'Resectable', and the disease stage 'Stage Ii-Iii'. Treatment modalities ('Neoadjuvant Therapy', 'Anti-Pd-1/Pd-L1', 'Platinum-Base Chemotherapy') and study type ('Systematic Review And Meta-Analysis') were identified for exclusion.
3. **Rule Retrieval**: I retrieved rules for 'Treatment Set-up' (subcategory 'Resectable') and 'Stage' (subcategory 'Stage number') to ensure correct formatting.
4. **Rule Application**:
   - **Resectable**: Based on the retrieved rule (ID: 236), 'Resectable' is a valid patient subgroup qualifier and should be included as a prefix.
   - **Stage**: The term 'Stage Ii-Iii' was standardized to 'Stage II-III' for correct casing and formatting, following standard clinical notation.
   - **Generic Rules**: The disease term 'Non-Small Cell Lung Cancer' is already singular and in Title Case. Excluded terms related to treatment and study methodology were removed as per generic exclusion rules.
5. **Indication Construction**: The identified and normalized components were combined in the correct clinical order: Operative Status + Stage + Disease. This resulted in 'Resectable Stage II-III Non-Small Cell Lung Cancer'.
6. **Quality Check**: The final indication was checked for adherence to all formatting rules (Title Case, singular form, no trailing spaces) and the single-source principle. The result is a clinically accurate and well-formatted medical indication.","[{'category': 'Treatment Set-up', 'subcategories': ['Resectable', 'Treatment Modality'], 'reason': ""To determine how to handle the term 'Resectable' and to confirm exclusion of treatment-related terms.""}, {'category': 'Stage', 'subcategories': ['Stage number'], 'reason': ""To correctly format the stage range 'Ii-Iii'.""}]","[{'component': 'Resectable', 'type': 'Operative Status', 'normalized_form': 'Resectable', 'rule_applied': 'Treatment Set-up -> Resectable (ID: 236)'}, {'component': 'Stage Ii-Iii', 'type': 'Stage', 'normalized_form': 'Stage II-III', 'rule_applied': 'Stage -> Stage number rules and Title Case generic rule.'}, {'component': 'Non-Small Cell Lung Cancer', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Neoadjuvant Therapy With Anti-Pd-1/Pd-L1 Plus Platinum-Base Chemotherapy', 'type': 'Treatment Modality', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
164457,Society for Benign Prostate Disease,"Welcome and Why SOBPD Should Exist, Who We Are and Our Mission. Society Benefits, Annual meetings",Benign Prostate Disease,Benign Prostatic Hyperplasia,Benign Prostate Disease,True,session_title,"Step 1: The abstract title 'Welcome and Why SOBPD Should Exist, Who We Are and Our Mission. Society Benefits, Annual meetings' does not contain any specific disease or medical condition. 
Step 2: The session title 'Society for Benign Prostate Disease' contains a clear medical indication. 
Step 3: Following the single-source principle, the session title is selected for extraction. 
Step 4: The term 'Benign Prostate Disease' is extracted as the core indication. 
Step 5: Generic rules are applied. The indication is already in Title Case and singular form. The organizational part 'Society for' is excluded as it is not part of the disease name.",[],"[{'component': 'Benign Prostate Disease', 'type': 'Disease', 'normalized_form': 'Benign Prostate Disease', 'rule_applied': 'Generic rules for Title Case and Singular Form.'}]",1
180842,Experimental Transplantation: Basic and Translational: Poster I,The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation,Graft-Versus-Host Disease,Graft-Versus-Host Disease,Gut Graft-Versus-Host Disease,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title 'The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation' contains a specific disease term. The session title 'Experimental Transplantation: Basic and Translational: Poster I' does not contain a disease. Therefore, the abstract title is selected as the source based on the single-source principle.
2. **Identify Components**: The key components identified in the abstract title are the disease 'Gut Graft-Versus-Host Disease' and a procedural qualifier 'after Hematopoietic Stem Cell Transplantation'.
3. **Retrieve Relevant Rules**: To determine how to handle the procedural qualifier, I retrieved rules for 'Transplant Status' under the 'Treatment Set-up' category.
4. **Apply Rules**: The retrieved rules (e.g., Rule ID 232, 233 for 'Post-Transplant') and the generic exclusion rules state that procedural and temporal qualifiers like 'after...Transplantation' should be excluded from the final indication as they describe a treatment context, not the disease itself.
5. **Construct Indication**: The core disease 'Gut Graft-Versus-Host Disease' is extracted. The procedural context 'after Hematopoietic Stem Cell Transplantation' is excluded. The disease name is already in the correct Title Case and singular form.
6. **Quality Check**: The final indication adheres to all formatting and exclusion rules. It is clinically accurate and derived from a single source.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To confirm the handling of the phrase 'after Hematopoietic Stem Cell Transplantation', which represents a post-transplant status.""}]","[{'component': 'Gut Graft-Versus-Host Disease', 'type': 'Disease', 'normalized_form': 'Gut Graft-Versus-Host Disease', 'rule_applied': 'Generic rule: Use Title Case and singular form.'}, {'component': 'after Hematopoietic Stem Cell Transplantation', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule and specific 'Transplant Status' rules (e.g., Rule ID 232) require excluding post-procedural contexts.""}]",2
262759,"Quality of life, palliative care, ethics and health economics",Health-Related Quality Of Life In Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated With Iberdomide Plus Dexamethasone In A Phase 1B/2A Open-Label Dose Escalation Study,Relapsed;;Refractory;;Multiple Myeloma ,Relapsed/Refractory Multiple Myeloma ,Triple-Class Exposed Relapsed/Refractory Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains the specific disease 'Multiple Myeloma', while the session title is generic. Therefore, the abstract title was chosen as the source based on the Single-Source Extraction Principle.
2.  **Component Identification**: I identified the core disease 'Multiple Myeloma' and two key patient subgroup descriptors: 'Triple-Class Exposed' (indicating treatment history) and 'Relapsed/Refractory' (indicating disease status).
3.  **Rule Retrieval**: I retrieved rules for 'Occurrence' to correctly handle 'Relapsed/Refractory' and for 'Treatment based' to understand how to process treatment history terms like 'Triple-Class Exposed'.
4.  **Rule Application & Construction**: 
    *   Generic exclusion rules were applied to remove non-diagnostic information such as 'Health-Related Quality Of Life In Patients With', specific drug names ('Iberdomide Plus Dexamethasone'), and study design details ('Phase 1B/2A Open-Label Dose Escalation Study').
    *   The term 'Relapsed/Refractory' is a standard clinical descriptor for disease state and was retained.
    *   'Triple-Class Exposed' is a critical patient subgroup qualifier defining the treatment history and was included.
    *   The components were assembled in a clinically logical order: treatment history, then disease status, then the disease name.
5.  **Formatting**: The final indication was formatted to Title Case and ensured singular form for the disease, resulting in 'Triple-Class Exposed Relapsed/Refractory Multiple Myeloma'.","[{'category': 'Occurrence', 'subcategories': ['Relapsed/Refractory', 'Refractory'], 'reason': ""To correctly handle the 'Relapsed/Refractory' disease status descriptor.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To understand the handling of treatment history descriptors like 'Triple-Class Exposed'.""}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic singular form rule.'}, {'component': 'Relapsed/Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rule for retaining standard disease state descriptors.'}, {'component': 'Triple-Class Exposed', 'type': 'Patient Subgroup (Treatment History)', 'normalized_form': 'Triple-Class Exposed', 'rule_applied': 'Treatment based rule for including specific treatment history as a qualifier.'}]",2
164460,Society for Benign Prostate Disease,The Advent of Directed Medical BPH Care-How Alpha Blockers were Developed,BPH,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the primary source because it contains a specific disease acronym ('BPH'), which is preferred over the session title according to the single-source principle.
2. **Component Identification**: The key medical term identified in the abstract title is 'BPH'.
3. **Rule Retrieval**: No specific rules were needed for 'BPH', but general knowledge and standardization principles were applied. 'BPH' is a standard medical acronym for 'Benign Prostatic Hyperplasia'.
4. **Rule Application & Normalization**: The acronym 'BPH' was expanded to its full, clinically standard name, 'Benign Prostatic Hyperplasia'. The generic rule for Title Casing was applied. The term 'Benign' is an integral part of the disease name, distinguishing it from malignant conditions, and was therefore retained.
5. **Indication Construction**: The final indication was constructed from the expanded and normalized term.
6. **Quality Check**: The final output adheres to all formatting and clinical accuracy requirements. It is in singular form, Title Case, and correctly represents the disease mentioned in the source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding disease qualifiers like 'Benign', although no specific rule was found for this term, the general principles from this category were considered.""}]","[{'component': 'BPH', 'type': 'Disease Acronym', 'normalized_form': 'Benign Prostatic Hyperplasia', 'rule_applied': 'Standard medical acronym expansion and Title Case formatting rule.'}]",2
295539,Supportive care and symptom management,Patient and Public Involvement in Cancer Research: The Needs and Perceptions of Older Adults Living with and After Cancer,Older Adult;;Cancer,Older Adult Cancer,Older Adult Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Patient and Public Involvement in Cancer Research: The Needs and Perceptions of Older Adults Living with and After Cancer') was chosen over the session title ('Supportive care and symptom management') because it contains a specific disease term ('Cancer'), adhering to the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title were the disease 'Cancer' and the patient subgroup 'Older Adults'. The phrase 'Living with and After' was identified as a descriptor of the patient's journey rather than a standard clinical qualifier for an indication, and thus was excluded.
3.  **Rule Retrieval**: To standardize the patient subgroup, I retrieved rules for the 'Age Group' category, specifically for 'Elderly' and 'Older adult' terms.
4.  **Rule Application**: Based on the retrieved rules (specifically Rule ID 331), the term 'Older Adults' is normalized to the singular, title-case form 'Older Adult'. The disease term 'Cancer' is already in the correct singular and title-case format.
5.  **Indication Construction**: The normalized patient subgroup 'Older Adult' is prepended to the disease 'Cancer' to form the final indication.
6.  **Final Quality Check**: The resulting indication 'Older Adult Cancer' is correctly formatted (Title Case, singular), follows all generic rules, and accurately represents the core clinical indication from the source title.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To find the correct standardization for the term 'Older Adults'.""}]","[{'component': 'Cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic rule: Use singular form.'}, {'component': 'Older Adults', 'type': 'Age Group', 'normalized_form': 'Older Adult', 'rule_applied': ""Age Group rule (ID 331): Normalize 'Older adults' to 'Older Adult' and place it at the beginning of the indication.""}, {'component': 'Living with and After', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude non-standard temporal or procedural qualifiers that do not define a specific clinical state.'}]",2
164469,Society for Benign Prostate Disease,Photoselective Vaporization of the Prostate,Benign;;Prostate Disease,Benign Prostate Disease,Benign Prostate Disease,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract_title, 'Photoselective Vaporization of the Prostate', describes a medical procedure on an anatomical site but does not name a specific disease. The session_title, 'Society for Benign Prostate Disease', explicitly names a medical condition.
2.  **Select Source**: Based on the Single-Source Extraction Principle, the session_title is selected because it contains a clear disease term ('Benign Prostate Disease'), while the abstract_title does not.
3.  **Identify Components**: The key component identified in the session_title is the disease 'Benign Prostate Disease'. The phrase 'Society for' is an organizational descriptor and not part of the indication.
4.  **Retrieve Rules**: I retrieved rules for 'Disease Characterisation' to check if 'Benign' should be handled in a specific way. No rule was found that requires the exclusion or modification of 'Benign' when it is part of a standard disease name.
5.  **Apply Rules**: 
    *   **Generic Rule (Exclusion)**: The organizational prefix 'Society for' is excluded as it is not part of the clinical indication.
    *   **Generic Rule (Disease Characterization)**: The term 'Benign' is a critical part of the disease name, distinguishing it from other prostate conditions (e.g., Prostate Cancer). It is retained.
    *   **Generic Rule (Formatting)**: The indication is formatted in Title Case ('Benign Prostate Disease') and is already in singular form.
6.  **Construct Indication**: After removing the non-clinical prefix, the remaining phrase is 'Benign Prostate Disease'.
7.  **Quality Check**: The final indication is clinically accurate, derived from a single source, and correctly formatted. It correctly identifies the specific benign condition of the prostate.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify if the term 'Benign' requires special handling as a disease characterizer. No specific rule was found, so the generic principle of including it as part of the disease name was applied.""}]","[{'component': 'Benign Prostate Disease', 'type': 'Disease', 'normalized_form': 'Benign Prostate Disease', 'rule_applied': ""Generic rule: Retain disease characterizers like 'Benign' when they are integral to the disease name.""}, {'component': 'Society for', 'type': 'Organizational Prefix', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude non-clinical descriptors.'}]",2
311932,How Does the Use of Concomitant Methotrexate Affect the Efficacy and Safety of Biologics for Psoriatic Arthritis?,How Does the Use of Concomitant Methotrexate Affect the Efficacy and Safety of Biologics for Psoriatic Arthritis?,Psoriatic Arthritis,Psoriatic Arthritis,Psoriatic Arthritis,True,abstract_title,"Step 1: The abstract title and session title are identical and both contain a clear disease term, 'Psoriatic Arthritis'.
Step 2: I selected the abstract_title as the source based on the single-source principle.
Step 3: The core disease component identified is 'Psoriatic Arthritis'. Other terms like 'Concomitant Methotrexate' and 'Biologics' are related to treatment and are excluded as per the generic rules.
Step 4: The indication is formatted to Title Case. The term is already singular.
Step 5: The final generated indication is 'Psoriatic Arthritis'.",[],"[{'component': 'Psoriatic Arthritis', 'type': 'Disease', 'normalized_form': 'Psoriatic Arthritis', 'rule_applied': 'Generic formatting and exclusion rules.'}]",1
344700,Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1,OvaPrint - a novel cfDNA methylation liquid biopsy for cancer risk assessment in high grade serous ovarian carcinoma,high grade;;serous ovarian carcinoma,High Grade Serous Ovarian Carcinoma,High Grade Serous Ovarian Carcinoma,True,abstract_title,"Step 1: The abstract title contains a specific disease ('high grade serous ovarian carcinoma'), while the session title describes a methodology ('Liquid Biopsies'). Therefore, the abstract title was selected as the source based on the single-source principle.
Step 2: The components identified in the abstract title are the disease 'serous ovarian carcinoma' and the grade qualifier 'high grade'. The phrase 'cancer risk assessment' was identified as a procedural context to be excluded.
Step 3: Rules for the 'Grade' category were retrieved to handle 'high grade'.
Step 4: The retrieved rule for 'High Grade' (ID: 115) requires standardizing the term to 'High Grade' in Title Case with no hyphen. Generic rules for Title Case and singular form were also applied. 'Carcinoma' is already singular.
Step 5: The components were combined and formatted according to the rules, resulting in 'High Grade Serous Ovarian Carcinoma'.
Step 6: A final quality check confirmed adherence to all formatting, exclusion, and clinical accuracy requirements.","[{'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To correctly format the 'high grade' qualifier.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for any specific rules regarding histological subtypes like 'serous'.""}]","[{'component': 'high grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Grade Rule ID: 115 - Standardize to 'High Grade' (Title Case, no hyphen).""}, {'component': 'serous ovarian carcinoma', 'type': 'Disease', 'normalized_form': 'Serous Ovarian Carcinoma', 'rule_applied': 'Generic Rule: Title Case and Singular Form.'}]",2
393855,"Nsclc, Metastatic",First-Line Osimertinib In Patients With Egfr Mutated Lung Cancer With Uncommon Mutations (Ocelot Study - Interim Analysis),Egfr;;Mutated;;Lung Cancer,EGFR-Mutated Lung Cancer,EGFR-Mutated Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('First-Line Osimertinib In Patients With Egfr Mutated Lung Cancer With Uncommon Mutations (Ocelot Study - Interim Analysis)') was chosen over the session title ('Nsclc, Metastatic') because it is more specific and contains a clear disease and patient subgroup, adhering to the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title were 'First-Line' (treatment line), 'Egfr Mutated' (gene mutation), and 'Lung Cancer' (disease).
3.  **Rule Retrieval**: I retrieved rules for 'Gene Name', 'Gene type', and 'Treatment Set-up' to handle these components correctly.
4.  **Rule Application**:
    *   **Gene Mutation**: Based on the retrieved 'Gene Name' rule (ID: 27), gene symbols should be uppercased (Egfr -> EGFR) and qualifiers attached with a hyphen. Therefore, 'Egfr Mutated' was normalized to 'EGFR-Mutated'.
    *   **Treatment Line**: The 'Treatment Set-up' rule (ID: 199) states that line-of-treatment descriptors like 'First-Line' should be excluded if they are immediately followed by a specific drug name. In the title, 'First-Line' is followed by 'Osimertinib' (a drug), so 'First-Line' was excluded from the final indication.
    *   **Disease Term**: The disease 'Lung Cancer' was kept and formatted according to generic rules (Title Case, singular form).
    *   **Other Qualifiers**: The phrase 'With Uncommon Mutations' was considered a study-specific descriptor of the patient cohort rather than a standard, concise clinical indication qualifier and was therefore excluded to maintain standardization.
5.  **Indication Construction**: The normalized components were combined to form the final indication: 'EGFR-Mutated Lung Cancer'.
6.  **Quality Check**: The final indication adheres to all formatting and content rules, is clinically accurate, and is derived from a single source.","[{'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To correctly format the gene name 'Egfr'.""}, {'category': 'Gene type', 'subcategories': ['Gene Mutated'], 'reason': ""To correctly format the mutation status 'Mutated'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine whether to include or exclude the 'First-Line' descriptor.""}]","[{'component': 'First-Line', 'type': 'Line of Treatment', 'normalized_form': '', 'rule_applied': ""Treatment Set-up Rule ID 199: Exclude line-of-treatment when followed by a drug name ('Osimertinib').""}, {'component': 'Egfr Mutated', 'type': 'Gene Mutation', 'normalized_form': 'EGFR-Mutated', 'rule_applied': 'Gene Name Rule ID 27: Use uppercase HGNC symbol and hyphenate with qualifier.'}, {'component': 'Lung Cancer', 'type': 'Disease', 'normalized_form': 'Lung Cancer', 'rule_applied': 'Generic Rule: Use Title Case and singular form.'}, {'component': 'With Uncommon Mutations', 'type': 'Patient Subgroup', 'normalized_form': '', 'rule_applied': 'Generic Rule: Excluded as a non-standard descriptor to ensure the indication is concise and standardized.'}]",2
344703,Liquid Biopsies: Circulating Nucleic Acids and Circulating Tumor Cells 1,Development of a genome-wide methylome enrichment platform for multi-cancer early detection (MCED),cancer,Cancer,Cancer,True,abstract_title,"Step 1: The abstract title contains the term 'multi-cancer', which is a disease concept, making it the primary source. The session title describes a methodology ('Liquid Biopsies') and a biological entity ('Circulating Tumor Cells'), not a specific disease.
Step 2: The key components identified in the abstract title are 'multi-cancer' and 'early detection'.
Step 3: No specific rules were retrieved as 'multi-cancer' is a general term and 'early detection' is a diagnostic context.
Step 4: The generic rules are applied. The term 'multi-cancer' refers to a broad category of diseases. Following the principle of using overarching therapeutic area terms (like 'Oncology' -> 'Cancer'), 'multi-cancer' is standardized to the general indication 'Cancer'. The phrase 'early detection' is a procedural/diagnostic qualifier describing the study's goal, not a characteristic of the patient's disease, and is therefore excluded per the generic exclusion rules.
Step 5: The final indication is constructed by normalizing 'multi-cancer' to 'Cancer' and applying Title Case.
Step 6: A quality check confirms that the single-source principle was followed, the term was correctly standardized, and non-diagnostic qualifiers were excluded, resulting in the clinically appropriate indication 'Cancer'.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To check for rules related to 'early detection'.""}]","[{'component': 'multi-cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Therapeutic Area Fallback and Standardization'}, {'component': 'early detection', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items'}]",2
230018,Breast Cancer-Local/Regional/Adjuvant,Breast cancer: Online education's effect on clinician ability to assess risk of recurrence and understanding the latest data.,Breast cancer,Breast Cancer,Breast Cancer,True,abstract_title,"Step 1: The abstract title was chosen as the primary source because it contains a valid disease term, 'Breast cancer', and is preferred over the session title.
Step 2: The components identified in the abstract title were the disease 'Breast cancer' and the phrase 'risk of recurrence'.
Step 3: Rules for 'Occurrence' and 'Risk' were retrieved to determine how to handle 'risk of recurrence'.
Step 4: The retrieved rule for 'Recurrence' (ID: 140) explicitly states to exclude phrases like 'risk of recurrence' as they describe a prognostic endpoint rather than a patient subgroup. The rule for 'Recurrence-Risk' (ID: 130) also indicates that this concept is handled as a prefix but the context here is about assessing risk, not defining a patient cohort with that risk.
Step 5: The disease term 'Breast cancer' was normalized to 'Breast Cancer' according to Title Case and singular form rules.
Step 6: The final indication was constructed using only the normalized disease name, as all other parts of the title were excluded based on the rules.","[{'category': 'Occurrence', 'subcategories': ['Recurrence-Related Terms'], 'reason': ""To determine how to handle the phrase 'risk of recurrence'.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': 'To check for rules related to risk stratification.'}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To understand context from session title terms like 'Local' and 'Regional'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Modality', 'Treatment Status'], 'reason': ""To understand context from session title term 'Adjuvant'.""}]","[{'component': 'Breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Rule: Title Case and Singular Form.'}, {'component': 'risk of recurrence', 'type': 'Prognostic Endpoint', 'normalized_form': '', 'rule_applied': 'Occurrence Rule (ID: 140) - Exclude phrases that function as a prognostic or temporal endpoint.'}]",3
148103,Myelodysplastic Syndromes - Biology & Translational Research,Cohesin Mutations Are Associated With A Poor Prognosis Phenotype And A Worse Clinical Outcome In Low-Risk Myelodysplastic Syndromes Patients,Low-Risk;;Myelodysplastic Syndromes,Low-Risk Myelodysplastic Syndrome,Cohesin-Mutated Low-Risk Myelodysplastic Syndrome,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title as it contains a more specific description of the medical indication, including patient subgroups.
2. **Component Identification**: The abstract title contains the core disease 'Myelodysplastic Syndromes', a genetic qualifier 'Cohesin Mutations', and a risk qualifier 'Low-Risk'.
3. **Rule Retrieval**: I retrieved rules for the 'Risk' category to handle 'Low-Risk'. The retrieved rule (ID: 123) confirmed that 'Low-Risk' should be standardized to 'Low-Risk' and prepended to the disease name. I also checked for rules related to 'Gene type' for 'Cohesin Mutations' but found none, so I proceeded with generic formatting rules.
4. **Rule Application & Normalization**:
   - **Disease**: The plural 'Myelodysplastic Syndromes' was converted to its singular form 'Myelodysplastic Syndrome' per generic formatting rules.
   - **Risk Qualifier**: 'Low-Risk' was kept as is, based on the retrieved rule.
   - **Genetic Qualifier**: 'Cohesin Mutations' was converted to the standard adjectival form 'Cohesin-Mutated' to act as a prefix for the indication.
   - **Exclusions**: The phrase 'A Poor Prognosis Phenotype And A Worse Clinical Outcome' and the word 'Patients' were excluded as they describe study outcomes and general population, not the core indication.
5. **Indication Construction**: The identified and normalized components were combined in a clinically logical order (Qualifier + Risk + Disease) to form the final indication: 'Cohesin-Mutated Low-Risk Myelodysplastic Syndrome'.
6. **Final Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form, no trailing spaces) and is built from a single source.","[{'category': 'Risk', 'subcategories': ['Low-Risk'], 'reason': ""To validate the formatting and placement of the 'Low-Risk' qualifier.""}, {'category': 'Gene type', 'subcategories': ['Gene Mutation', 'Gene Mutated', 'Gene Mutant'], 'reason': ""To check for specific rules on how to format the 'Cohesin Mutations' component.""}]","[{'component': 'Myelodysplastic Syndromes', 'type': 'Disease', 'normalized_form': 'Myelodysplastic Syndrome', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'Low-Risk', 'type': 'Risk Qualifier', 'normalized_form': 'Low-Risk', 'rule_applied': 'Risk Rule ID: 123'}, {'component': 'Cohesin Mutations', 'type': 'Genetic Qualifier', 'normalized_form': 'Cohesin-Mutated', 'rule_applied': 'Generic Rule: Title Case and standardization to adjectival form.'}]",2
262793,Sickle cell disease,Long-Term Follow-Up Of Dutch Patients With Sickle Cell Disease Diagnosed By Neonatal Screening - Effect On The Morbidity And Mortality In The Netherlands.,Sickle Cell Disease,Sickle Cell Disease,Sickle Cell Disease,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. Both contain the term 'Sickle Cell Disease'.
Step 2: Following the single-source principle, I selected the abstract_title as it contains the disease term.
Step 3: I identified the core disease 'Sickle Cell Disease' in the abstract title. I also identified potential patient subgroups 'Dutch Patients' and 'Diagnosed By Neonatal Screening'.
Step 4: I applied the generic exclusion rules. 'Dutch' is a geographic/ethnic descriptor and must be excluded. 'Diagnosed By Neonatal Screening' is a procedural/methodological qualifier describing how the diagnosis was made, not a core part of the indication, and is therefore excluded.
Step 5: After applying exclusions, the remaining clinically valid indication is 'Sickle Cell Disease'.
Step 6: I formatted the indication using Title Case and ensured it was in singular form, resulting in the final output.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To check for rules regarding how to handle terms related to diagnosis timing, such as 'Diagnosed By Neonatal Screening'.""}]","[{'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic rule: Title Case and Singular Form.'}, {'component': 'Dutch Patients', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude ethnicity and geographic descriptors.'}, {'component': 'Diagnosed By Neonatal Screening', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers.'}]",2
328332,Aggressive Lymphomas: Clinical and Epidemiological: Poster I,Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group,Sars-Cov-2 Infection;;Primary CNS Lymphoma,Sars-Cov-2 Infection;;Primary CNS Lymphoma,Sars-Cov-2 Infection;;Primary CNS Lymphoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains specific disease terms ('Sars-Cov-2 Infection', 'Primary CNS Lymphoma'), making it the primary source according to the single-source principle.
2.  **Component Identification**: Two distinct diseases were identified in the abstract title: 'Sars-Cov-2 Infection' and 'Primary CNS Lymphoma'. The study investigates the impact of the first disease on patients who have the second disease.
3.  **Rule Retrieval**: I checked for rules related to patients with multiple diseases using `get_indication_rules` with the category 'Patient with two different Disease'. No specific rules were found, so I proceeded with the generic rules.
4.  **Rule Application**: 
    *   The generic rule for 'Multiple Diseases' was applied, which requires extracting all distinct diseases and separating them with ';;'.
    *   The generic 'Casing' rule was applied to both terms, resulting in 'Sars-Cov-2 Infection' and 'Primary CNS Lymphoma'. 'CNS' is an acronym and remains capitalized.
    *   The generic 'Singular Form' rule was applied; both 'Infection' and 'Lymphoma' are already singular.
    *   The generic 'Primary' rule was applied, keeping 'Primary' as it is part of the disease name 'Primary CNS Lymphoma'.
5.  **Indication Construction**: The two normalized disease terms were combined using the ';;' separator to form the final indication.
6.  **Quality Check**: The final output adheres to all formatting and content rules. It correctly identifies the two distinct clinical conditions mentioned in the source title.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To check for specific rules on how to handle two distinct diseases mentioned in the same title.'}]","[{'component': 'Sars-Cov-2 Infection', 'type': 'Disease', 'normalized_form': 'Sars-Cov-2 Infection', 'rule_applied': 'Generic Casing Rule'}, {'component': 'Primary CNS Lymphoma', 'type': 'Disease', 'normalized_form': 'Primary CNS Lymphoma', 'rule_applied': ""Generic Casing Rule; Generic 'Primary' Rule""}]",2
262802,Stem cell transplantation - Clinical,Allogeneic Hematopoietic Stem Transplantation (Hsct) In Patients Over 60 Years. Retrospective Experience Of Two Spanish Centers Between 2015-2020,,,,True,none,"Step 1: I analyzed both the abstract and session titles. The abstract title is 'Allogeneic Hematopoietic Stem Transplantation (Hsct) In Patients Over 60 Years. Retrospective Experience Of Two Spanish Centers Between 2015-2020' and the session title is 'Stem cell transplantation - Clinical'.
Step 2: I applied the Single-Source Extraction Principle. Neither title contains a specific disease or disorder. Both titles refer to a medical procedure ('Stem cell transplantation' and 'Allogeneic Hematopoietic Stem Transplantation').
Step 3: The abstract title contains a patient subgroup ('Over 60 Years'). I retrieved rules for the 'Age Group' category to understand how to handle this. Rule ID 303 indicates that 'Above 60' or similar phrases should be normalized to 'Elderly'.
Step 4: However, according to the generic rules, an indication cannot be created from a patient subgroup alone. A disease term must be present in the same source title. Since the abstract title lacks a disease term, it is discarded as a source for the indication, despite containing a patient subgroup.
Step 5: The session title also lacks a disease term. Therefore, no valid medical indication can be extracted from the provided information.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To determine how to handle the phrase 'Over 60 Years' found in the abstract title.""}]","[{'component': 'Allogeneic Hematopoietic Stem Transplantation', 'type': 'Procedure', 'normalized_form': None, 'rule_applied': 'Generic exclusion rule: Procedural/Temporal Qualifiers are excluded as they are not diseases.'}, {'component': 'Over 60 Years', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group rule for 'Above 60' (ID: 303).""}]",2
148116,Myelodysplastic Syndromes - Biology & Translational Research,Mesenchymal Stromal Cells As A Potential Therapeutic Tool In Enhancing Residual Healthy Haematopoiesis In Low-Risk Mds Patients,Low-Risk;;Mds,Low-Risk Myelodysplastic Syndrome,Low-Risk Myelodysplastic Syndrome,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease ('Mds') and a patient subgroup ('Low-Risk'), making it more detailed than the session title.
Step 2: The components identified in the abstract title were 'Low-Risk' and 'Mds'.
Step 3: The `get_indication_rules` tool was used for the 'Risk' category with the 'Low-Risk' subcategory. The retrieved rule (ID: 123) confirmed that 'Low-Risk' should be standardized to 'Low-Risk' and prepended to the disease name.
Step 4: The disease abbreviation 'Mds' was expanded to its full name 'Myelodysplastic Syndromes'.
Step 5: The generic rule for singularization was applied, converting 'Myelodysplastic Syndromes' to 'Myelodysplastic Syndrome'.
Step 6: The components were combined and formatted according to Title Case rules, resulting in the final indication 'Low-Risk Myelodysplastic Syndrome'.","[{'category': 'Risk', 'subcategories': ['Low-Risk'], 'reason': ""To validate the formatting and placement of the 'Low-Risk' patient subgroup qualifier.""}]","[{'component': 'Low-Risk', 'type': 'Risk', 'normalized_form': 'Low-Risk', 'rule_applied': ""Rule ID: 123 - Standardize to 'Low-Risk' and prepend to the disease.""}, {'component': 'Mds', 'type': 'Disease', 'normalized_form': 'Myelodysplastic Syndrome', 'rule_applied': 'Standard medical abbreviation expansion and Generic Singular Form rule.'}]",2
377489,Acute lymphoblastic leukemia - Clinical,Prophylactic And Preemptive Use Of Dli Compare Favourably To Their Therapeutic Use In Adult Acute Lymphoblastic Leukemia (All) - Results Of A Multicentre Retrospective Study,Adult;;Acute Lymphoblastic Leukemia,Adult Acute Lymphoblastic Leukemia,Adult Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: Both the abstract and session titles contain the disease 'Acute Lymphoblastic Leukemia'. The abstract title is chosen as the primary source because it provides a more specific patient subgroup ('Adult').
2. **Component Identification**: The key components identified in the abstract title are the disease 'Acute Lymphoblastic Leukemia' and the age group 'Adult'. Terms like 'Prophylactic', 'Preemptive', 'Therapeutic Use', and 'Multicentre Retrospective Study' are identified as procedural or study design descriptors to be excluded per generic rules.
3. **Rule Retrieval**: To ensure correct formatting for the age group, the `get_indication_rules` tool was called for the category 'Age Group' and subcategory 'Adult'.
4. **Rule Application**: The retrieved rule (ID: 289) confirms that 'Adult' should be used as a capitalized prefix for the indication. Generic rules for Title Case and singular form are applied. The abbreviation '(All)' is noted but the full disease name is used for clarity.
5. **Indication Construction**: The components are combined according to the rules, resulting in 'Adult' + 'Acute Lymphoblastic Leukemia'.
6. **Quality Check**: The final indication 'Adult Acute Lymphoblastic Leukemia' adheres to the single-source principle, includes the relevant patient subgroup, excludes non-indication terms, and follows all formatting requirements.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To validate the correct formatting and placement of the 'Adult' patient subgroup qualifier.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule (ID: 289) requires capitalizing and prepending 'Adult' to the indication.""}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
311960,Ignite Session 1C,"Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity",,,Systemic Autoimmunity,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The `session_title` ('Ignite Session 1C') is generic and contains no medical terms. The `abstract_title` ('Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity') contains the medical condition 'Systemic Autoimmunity'.
2.  **Select Source**: According to the single-source principle, the `abstract_title` is selected as it contains a valid disease term.
3.  **Identify Components**: The core disease component identified is 'Systemic Autoimmunity'. Other terms like 'T Regulatory Cell Metabolism' describe biological processes, not the clinical indication.
4.  **Retrieve Rules**: I retrieved rules for 'Disease Characterisation' to check if 'Systemic' has special handling. No specific rule applied.
5.  **Apply Generic Rules**: I applied the generic rules to the extracted component:
    *   **Casing**: The term 'Systemic Autoimmunity' is already in the correct Title Case.
    *   **Singular Form**: The term is already in its singular form.
    *   **Exclusions**: No sociodemographic, procedural, or other excludable terms are present.
6.  **Construct Indication**: Based on the analysis, the final indication is constructed from the identified component.
7.  **Quality Check**: The final indication 'Systemic Autoimmunity' adheres to all formatting and clinical accuracy requirements.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify if the term 'Systemic' requires special handling as a disease characterizer. No specific rule was found to apply.""}]","[{'component': 'Systemic Autoimmunity', 'type': 'Disease', 'normalized_form': 'Systemic Autoimmunity', 'rule_applied': 'Generic rules for casing and singular form.'}]",2
230042,Breast Cancer-Local/Regional/Adjuvant,Predictive value of circulating tumor cells FTH1 gene on the efficacy of neoadjuvant chemotherapy in non-metastatic breast cancer.,non-metastatic;;breast cancer,Non-Metastatic Breast Cancer,Non-Metastatic Breast Cancer,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease ('breast cancer') and provides more detail than the session title.
Step 2: The core components identified in the abstract title were the disease 'breast cancer' and the occurrence qualifier 'non-metastatic'.
Step 3: To ensure correct formatting of the occurrence qualifier, the `get_indication_rules` tool was used for the category 'Occurrence' and subcategory 'Metastasis-Related Terms'.
Step 4: Rule ID 142 was applied, which specifies normalizing 'non-metastatic' to 'Non-Metastatic' and placing it before the disease name. Generic rules for Title Case ('Breast Cancer') and singular form were also applied.
Step 5: The components were combined according to the rules to form the final indication 'Non-Metastatic Breast Cancer'.
Step 6: A quality check confirmed adherence to all formatting, exclusion, and single-source principles.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the 'non-metastatic' qualifier.""}]","[{'component': 'non-metastatic', 'type': 'Occurrence', 'normalized_form': 'Non-Metastatic', 'rule_applied': ""Rule ID 142: Normalize to 'Non-Metastatic' and prefix to the disease.""}, {'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Rule: Apply Title Case and ensure singular form.'}]",2
213661,MP20: Trauma/Reconstruction/Diversion: External Genitalia Reconstruction and Urotrauma (including transgender surgery) I,A Pilot Study of Outcomes after Robot-Assisted Sigmoid Vaginoplasty for Gender Dysphoria,Gender Dysphoria,Gender Dysphoria,Gender Dysphoria,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'A Pilot Study of Outcomes after Robot-Assisted Sigmoid Vaginoplasty for Gender Dysphoria' and the session title is 'MP20: Trauma/Reconstruction/Diversion: External Genitalia Reconstruction and Urotrauma (including transgender surgery) I'.
2. **Select Source**: The abstract title contains a specific, clinically valid medical condition, 'Gender Dysphoria'. According to the single-source principle, the abstract title is prioritized over the session title.
3. **Identify Components**: The key components in the abstract title are the condition 'Gender Dysphoria' and the procedural context 'after Robot-Assisted Sigmoid Vaginoplasty'.
4. **Retrieve and Apply Rules**: 
   - The generic exclusion rules state that procedural and temporal qualifiers, such as 'post-surgery' or terms describing a procedure a patient has undergone, must be excluded. The phrase 'after Robot-Assisted Sigmoid Vaginoplasty' falls into this category.
   - To confirm this, rules for 'Operative Status' were retrieved. Rule ID 255 for 'Post Operative' confirms that such surgical-timing descriptors should be excluded from the final indication.
   - The core medical condition 'Gender Dysphoria' is retained.
5. **Construct Indication**: After excluding the procedural context, the remaining term is 'Gender Dysphoria'.
6. **Apply Formatting**: The term is already in Title Case and singular form, so no changes are needed.
7. **Quality Check**: The final indication 'Gender Dysphoria' is clinically accurate, correctly formatted, and adheres to all extraction rules.","[{'category': 'Treatment Set-up', 'subcategories': ['Operative Status'], 'reason': ""To confirm the exclusion of procedural context ('after Robot-Assisted Sigmoid Vaginoplasty') based on rules for post-operative descriptors.""}]","[{'component': 'Gender Dysphoria', 'type': 'Disease', 'normalized_form': 'Gender Dysphoria', 'rule_applied': 'Generic rule: Retain core disease term.'}, {'component': 'after Robot-Assisted Sigmoid Vaginoplasty', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule #3: Exclude procedural/temporal qualifiers. Confirmed by Treatment Set-up rule ID 255 for 'Post Operative' context.""}]",2
410269,Interventions to Reduce CKD Progression,Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with CKD,Primary Kidney Disease;;CKD,Primary Kidney Disease;;Chronic Kidney Disease,Primary Kidney Disease;;CKD,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with CKD') was chosen over the session title ('Interventions to Reduce CKD Progression') because it is more specific and contains the core disease terms for the study population, adhering to the single-source principle.
2.  **Component Identification**: The abstract title explicitly mentions two distinct medical conditions: 'Primary Kidney Disease' and 'CKD' (Chronic Kidney Disease).
3.  **Rule Application**: 
    *   **Multiple Diseases Rule**: The generic rule for multiple diseases was applied, which states that if a title mentions multiple distinct diseases, all should be extracted and separated by ';;'. The structure 'Impact of [Disease A] in Patients with [Disease B]' is analogous to the example 'Outcomes in [Disease A] with [Factor B]', leading to the extraction of both conditions.
    *   **Formatting Rules**: Standard formatting rules were applied. 'Primary Kidney Disease' is already in Title Case and singular. 'CKD' is a standard medical acronym and is maintained in its original uppercase form.
    *   **Exclusion Rules**: No terms requiring exclusion (e.g., sociodemographics, procedural qualifiers) were present in the title.
4.  **Indication Construction**: The identified diseases, 'Primary Kidney Disease' and 'CKD', were combined using the ';;' separator to form the final indication.
5.  **Quality Check**: The final output adheres to all formatting and content rules, accurately reflecting the key conditions mentioned in the source title.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': ""To check for specific rules on how to handle two distinct diseases mentioned in the same title. No specific rules were found, so the generic 'Multiple Diseases' rule was applied.""}]","[{'component': 'Primary Kidney Disease', 'type': 'Disease', 'normalized_form': 'Primary Kidney Disease', 'rule_applied': 'Generic Rule: Multiple Diseases'}, {'component': 'CKD', 'type': 'Disease', 'normalized_form': 'CKD', 'rule_applied': 'Generic Rule: Multiple Diseases'}]",2
393888,"Nsclc, Metastatic",Updated Patient-Reported Outcomes From The Crown Study: Analyses In First-Line Alk+ Patients With (W) And Without (W/O) Baseline Brain Metastases (Bms) And W Or W/O Central Nervous System Adverse Events (Cns Aes),First-Line;;Alk+;;Metastatic;;Nsclc,First-Line ALK-Postive Metastatic Non-Small Cell Lung Cancer,Metastatic Non-Small Cell Lung Cancer,True,session_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title does not contain a specific disease name, only a patient subgroup (ALK+). The session title, however, explicitly mentions 'Nsclc, Metastatic'. Following the single-source principle, the session title was chosen as it contains the core disease.
2. **Component Identification**: From the session title 'Nsclc, Metastatic', two components were identified: the disease 'Nsclc' and the occurrence qualifier 'Metastatic'.
3. **Rule Retrieval**: Rules for metastasis-related terms were retrieved to ensure correct formatting. Rules for gene names (ALK+) and line of treatment (First-Line) were also considered to confirm their exclusion since they originate from the non-selected abstract title.
4. **Rule Application & Normalization**:
   - 'Nsclc' is a standard abbreviation for 'Non-Small Cell Lung Cancer' and was expanded and converted to Title Case.
   - The generic rule for singular form was applied, although the term was already singular.
   - The rule for 'Metastatic' (ID: 141) dictates placing it before the disease name.
   - The comma separating the terms in the session title was removed as it is a grammatical separator, not part of the indication.
5. **Indication Construction**: The components were combined in the correct order ('Metastatic' + 'Non-Small Cell Lung Cancer') to form the final indication.
6. **Quality Check**: The final indication adheres to all formatting rules (Title Case, single source, no excluded terms from the source) and is clinically accurate.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'Metastatic' and its placement relative to the disease.""}, {'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To confirm that 'Alk+' from the abstract title should be ignored based on the single-source principle.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To confirm that 'First-Line' from the abstract title should be ignored based on the single-source principle.""}]","[{'component': 'Nsclc', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}, {'component': 'Metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': 'Rule ID 141: Placed as a prefix to the disease name.'}, {'component': 'First-Line', 'type': 'Line of Treatment', 'normalized_form': 'First-Line', 'rule_applied': 'Ignored due to Single-Source Extraction Principle (component was in abstract_title, but session_title was selected as source).'}, {'component': 'Alk+', 'type': 'Biomarker', 'normalized_form': 'ALK-Positive', 'rule_applied': 'Ignored due to Single-Source Extraction Principle (component was in abstract_title, but session_title was selected as source).'}]",2
148133,Myelodysplastic Syndromes - Clinical,Venetoclax Combined With Azacitidine In The Treatment Of Relapsed/Refractory High-Risk Myelodysplastic Syndromes And Acute Myeloid Leukemia: A Retrospective Single-Center Study,Relapsed;;Refractory;;High-Risk;;Myelodysplastic Syndromes;;Acute Myeloid Leukemia,Relapsed/Refractory High-Risk Myelodysplastic Syndrome;;Relapsed/Refractory High-Risk Acute Myeloid Leukemia,Relapsed/Refractory High-Risk Myelodysplastic Syndrome;;Relapsed/Refractory Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains specific diseases ('Myelodysplastic Syndromes', 'Acute Myeloid Leukemia') and is more detailed than the session title, adhering to the single-source principle.
2. **Component Identification**: I identified two distinct diseases: 'Myelodysplastic Syndromes' and 'Acute Myeloid Leukemia'. I also identified the qualifiers 'Relapsed/Refractory' and 'High-Risk'.
3. **Rule Retrieval**: I retrieved rules for 'Occurrence' (specifically 'Recurrent/Refractory') and 'Risk' (specifically 'High-Risk') to ensure correct formatting and application of these qualifiers.
4. **Rule Application**: 
   - **Generic Rules**: The plural 'Syndromes' was converted to its singular form 'Syndrome'. The final output was formatted to Title Case. The two distinct indications are separated by ';;'.
   - **Specific Rules**: The 'Relapsed/Refractory' qualifier applies to both diseases mentioned in the coordinated phrase. The 'High-Risk' qualifier is syntactically linked only to 'Myelodysplastic Syndromes' and was applied accordingly.
5. **Indication Construction**: The components were assembled for each disease. 
   - For the first disease: 'Relapsed/Refractory' + 'High-Risk' + 'Myelodysplastic Syndrome'.
   - For the second disease: 'Relapsed/Refractory' + 'Acute Myeloid Leukemia'.
   - The two resulting indications were combined with the ';;' separator.
6. **Quality Check**: The final output was reviewed to ensure it meets all formatting, clinical accuracy, and exclusion criteria. Treatment names ('Venetoclax', 'Azacitidine') and study descriptors ('Retrospective Single-Center Study') were correctly excluded.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To correctly handle the 'Relapsed/Refractory' disease state qualifier.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To correctly handle the 'High-Risk' patient subgroup qualifier.""}]","[{'component': 'Relapsed/Refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Standard clinical nomenclature for disease state.'}, {'component': 'High-Risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': ""Rule ID: 122 - Standardized to 'High-Risk' and prepended to the associated disease.""}, {'component': 'Myelodysplastic Syndromes', 'type': 'Disease', 'normalized_form': 'Myelodysplastic Syndrome', 'rule_applied': 'Generic Rule: Singular Form.'}, {'component': 'Acute Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule: Title Case.'}]",2
230055,Breast Cancer-Local/Regional/Adjuvant,Axillary surgery after neoadjuvant chemotherapy in breast cancer patients downstaging from cN+ to ycN0.,breast cancer,Breast Cancer,Node-Positive Breast Cancer,True,abstract_title,"Step 1: The abstract title 'Axillary surgery after neoadjuvant chemotherapy in breast cancer patients downstaging from cN+ to ycN0' was chosen as the source because it contains a specific disease and patient subgroup, making it more informative than the session title.
Step 2: The core disease was identified as 'breast cancer'. The patient subgroup was identified by the lymph node status 'cN+', indicating clinically node-positive status before treatment.
Step 3: Relevant rules were retrieved for 'Treatment Set-up' and 'Occurrence' (specifically 'Node Status').
Step 4: The 'Node Status' rule (ID: 191) was applied, which maps 'N+' to the standardized term 'Node-Positive' and places it at the beginning of the indication. Generic rules were applied to convert 'breast cancer' to 'Breast Cancer' (Title Case, Singular). Procedural terms ('Axillary surgery') and treatment timing/context ('after neoadjuvant chemotherapy', 'downstaging from cN+ to ycN0') were excluded as per generic exclusion rules, as they describe the intervention and outcome rather than the core indication.
Step 5: The components were combined to form the final indication: 'Node-Positive Breast Cancer'.","[{'category': 'Treatment Set-up', 'subcategories': ['Treatment Status', 'Operative Status'], 'reason': ""To check rules for handling terms like 'neoadjuvant chemotherapy' and 'surgery'.""}, {'category': 'Occurrence', 'subcategories': ['Node Status'], 'reason': ""To correctly handle and normalize the node status descriptors 'cN+' and 'ycN0'.""}]","[{'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'cN+', 'type': 'Node Status', 'normalized_form': 'Node-Positive', 'rule_applied': 'Occurrence Rule (ID: 191) for Node-Positive status'}, {'component': 'Axillary surgery', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclude procedural terms'}, {'component': 'after neoadjuvant chemotherapy', 'type': 'Treatment Timing', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclude temporal qualifiers'}]",2
230053,Breast Cancer-Local/Regional/Adjuvant,Neutrophil-lymphocyte ratio and prediction of pathological complete response to neoadjuvant treatment in breast cancer.,breast cancer,Breast Cancer,Breast Cancer,True,abstract_title,"Step 1: The abstract title 'Neutrophil-lymphocyte ratio and prediction of pathological complete response to neoadjuvant treatment in breast cancer.' was chosen as the source because it contains a specific disease term ('breast cancer'), following the single-source extraction principle.
Step 2: The core disease 'breast cancer' was identified.
Step 3: The term 'neoadjuvant treatment' was identified as a treatment-related qualifier. According to the generic exclusion rules for procedural/temporal qualifiers (like 'pre-operative'), and the pattern seen in treatment-related rules where the treatment modality or timing is excluded from the final indication, 'neoadjuvant' is not included in the indication.
Step 4: The extracted disease term 'breast cancer' was normalized according to generic formatting rules: converted to singular form and Title Case, resulting in 'Breast Cancer'.
Step 5: Other terms like 'Neutrophil-lymphocyte ratio' and 'pathological complete response' were excluded as they represent a biomarker and a study endpoint, respectively, not part of the core medical indication.","[{'category': 'Treatment Set-up', 'subcategories': ['Treatment Status', 'Treatment Modality'], 'reason': ""To determine how to handle the term 'neoadjuvant treatment'. The general pattern in these rules is to exclude treatment timing and modality descriptors.""}]","[{'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Title Case'}, {'component': 'neoadjuvant treatment', 'type': 'Procedural/Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Procedural/Temporal Qualifiers'}]",3
410286,"Kidney Transplantation: Biomarkers, New and Old",Differential cfDNA Methylation in Kidney Allograft Rejection,,,Kidney Allograft Rejection,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'Differential cfDNA Methylation in Kidney Allograft Rejection', contains a specific, clinically valid condition.
Step 2: The session title, 'Kidney Transplantation: Biomarkers, New and Old', refers to a procedure ('Kidney Transplantation') rather than a disease. Following the single-source principle, I selected the abstract title as it contains a clear disease term.
Step 3: I identified the core medical condition in the abstract title as 'Kidney Allograft Rejection'.
Step 4: To ensure correct handling of transplant-related terminology, I retrieved rules for the 'Treatment Set-up' category, specifically 'Transplant Status'. The rules indicate that procedural or temporal qualifiers (like 'Post-Transplant') should be excluded. However, 'Kidney Allograft Rejection' is a distinct diagnosis, not a procedural qualifier, so these exclusion rules do not apply. The term 'Allograft' is integral to the indication.
Step 5: I applied the generic formatting rules. I converted the term to Title Case, resulting in 'Kidney Allograft Rejection'. The term is already in its standard singular form.
Step 6: A final quality check confirmed that the extraction adheres to all rules, resulting in a clinically accurate and properly formatted indication.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To verify how to handle the term 'Allograft' and ensure it is not an excludable procedural qualifier.""}]","[{'component': 'Kidney Allograft Rejection', 'type': 'Disease', 'normalized_form': 'Kidney Allograft Rejection', 'rule_applied': 'Generic rule: Title Case'}]",2
410288,"Kidney Transplantation: Biomarkers, New and Old",Elevated Glycolytic Markers in Urinary Extracellular Vesicles in Kidney Transplant T Cell-Mediated Rejection,,,Kidney Transplant T Cell-Mediated Rejection,True,abstract_title,"Step 1: The abstract title 'Elevated Glycolytic Markers in Urinary Extracellular Vesicles in Kidney Transplant T Cell-Mediated Rejection' was chosen as the source because it contains a specific clinical condition, which is preferred over the broader session title 'Kidney Transplantation: Biomarkers, New and Old'.
Step 2: The core clinical condition was identified as 'T Cell-Mediated Rejection'. The context 'Kidney Transplant' is integral to defining this condition, as it specifies the subject of the rejection.
Step 3: Terms such as 'Elevated Glycolytic Markers' and 'in Urinary Extracellular Vesicles' were identified as biomarker and methodology details and were excluded based on the generic exclusion rules for non-diagnostic items.
Step 4: I retrieved rules for 'Transplant Status' to verify how to handle transplant-related terms. The rules suggest excluding temporal or eligibility descriptors (e.g., 'Post-Transplant', 'Transplant-Eligible'). However, in this case, 'Kidney Transplant' is not a simple temporal status but a fundamental part of the disease definition ('rejection of the kidney transplant'). Therefore, it was retained for clinical accuracy.
Step 5: The final indication was constructed by combining the essential components and applying Title Case formatting, resulting in 'Kidney Transplant T Cell-Mediated Rejection'.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine the correct handling of the term 'Kidney Transplant' within the indication.""}]","[{'component': 'Kidney Transplant T Cell-Mediated Rejection', 'type': 'Disease', 'normalized_form': 'Kidney Transplant T Cell-Mediated Rejection', 'rule_applied': 'Generic rule: Retain context when integral to the disease name.'}, {'component': 'Elevated Glycolytic Markers in Urinary Extracellular Vesicles', 'type': 'Biomarker/Methodology', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude non-diagnostic items.'}]",3
410290,"Kidney Transplantation: Biomarkers, New and Old",Uncontrolled Hypertension Is Associated with Increased Risk of Graft Failure in Kidney Transplant Recipients: A Nationwide Population-Based Study,Hypertension ,Hypertension ,Uncontrolled Hypertension;;Graft Failure,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Uncontrolled Hypertension Is Associated with Increased Risk of Graft Failure in Kidney Transplant Recipients: A Nationwide Population-Based Study'. The session title is 'Kidney Transplantation: Biomarkers, New and Old'.
2. **Select Source**: The abstract title contains specific medical conditions ('Uncontrolled Hypertension', 'Graft Failure'), while the session title refers to a procedure ('Kidney Transplantation'). Therefore, the abstract title is selected as the source based on the Single-Source Extraction Principle.
3. **Identify Components**: The abstract title identifies two distinct clinical conditions: 'Uncontrolled Hypertension' and 'Graft Failure'. The patient group is 'Kidney Transplant Recipients'.
4. **Retrieve Relevant Rules**: I retrieved rules for 'Treatment Set-up' with the subcategory 'Transplant Status' to determine how to handle 'Kidney Transplant Recipients'. The rules (e.g., ID 232, 233 for 'Post-Transplant') indicate that procedural and temporal qualifiers defining a patient group should be excluded from the indication itself.
5. **Apply Rules & Construct Indication**:
   - 'Uncontrolled Hypertension' is identified as a primary indication.
   - 'Graft Failure' is also a distinct clinical condition mentioned in the title and is extracted as a second indication.
   - The patient descriptor 'in Kidney Transplant Recipients' is excluded as it describes the context/procedure status of the patient population, not the disease itself, consistent with the retrieved rules and generic exclusion principles.
   - The two indications are formatted in Title Case and separated by ';;' as per formatting rules.
6. **Quality Check**: The final output adheres to all formatting and extraction principles. The indications are clinically valid, sourced from a single title, and correctly formatted.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To verify the handling of the patient descriptor 'Kidney Transplant Recipients'.""}]","[{'component': 'Uncontrolled Hypertension', 'type': 'Disease', 'normalized_form': 'Uncontrolled Hypertension', 'rule_applied': 'Generic rule: Title Case.'}, {'component': 'Graft Failure', 'type': 'Disease', 'normalized_form': 'Graft Failure', 'rule_applied': 'Generic rule: Title Case.'}, {'component': 'Kidney Transplant Recipients', 'type': 'Patient Subgroup', 'normalized_form': '', 'rule_applied': ""Exclusion Rule: Procedural/Temporal Qualifiers. Confirmed by 'Transplant Status' rules.""}]",2
230073,Breast Cancer-Local/Regional/Adjuvant,Impacts of subtypes on clinical feature and outcome of male breast cancer.,breast cancer,Breast Cancer,Breast Cancer,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. Both contain the disease term 'Breast Cancer'.
Step 2: Following the Single-Source Extraction Principle, I selected the abstract title as the primary source because it contains a valid disease term.
Step 3: I identified the components in the abstract title: 'male' (a sociodemographic descriptor) and 'breast cancer' (the disease).
Step 4: I applied the generic exclusion rule for sociodemographic descriptors, which states that gender terms like 'male' should be removed unless they are an integral part of the disease name. In this case, 'Male Breast Cancer' is typically standardized to 'Breast Cancer' for indication purposes.
Step 5: I applied the formatting rules, converting 'breast cancer' to Title Case ('Breast Cancer') and ensuring it was in singular form.
Step 6: The final indication is 'Breast Cancer' after removing the excluded gender term and applying proper formatting.",[],"[{'component': 'male', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Gender'}, {'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Formatting Rule: Title Case'}]",1
393915,"Nsclc, Metastatic",Efficacy Of First-Line Treatment Options In Advanced Her2-Altered Non-Small Cell Lung Cancer: A Multi-Center Retrospective Study,First-Line;;Advanced;;Her2-Altered;;Non-Small Cell Lung Cancer,First-Line Advanced HER2-Altered Non-Small Cell Lung Cancer,First-Line Advanced HER2-Altered Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Efficacy Of First-Line Treatment Options In Advanced Her2-Altered Non-Small Cell Lung Cancer: A Multi-Center Retrospective Study') was chosen as the source because it contains a specific disease term ('Non-Small Cell Lung Cancer'), which is preferred over the session title according to the single-source principle.
2. **Component Identification**: The following components were identified in the abstract title:
   - Treatment Line: 'First-Line'
   - Disease Stage: 'Advanced'
   - Gene Alteration: 'Her2-Altered'
   - Disease: 'Non-Small Cell Lung Cancer'
   - Excluded terms: 'Efficacy Of', 'Treatment Options', 'A Multi-Center Retrospective Study' (methodological context).
3. **Rule Retrieval**: To ensure correct formatting, rules were retrieved for Stage, Gene type, and Treatment Set-up.
4. **Rule Application & Normalization**:
   - **Treatment Line**: Based on the 'Treatment Set-up' rules (e.g., ID 200), 'First-Line' is retained as it modifies the disease context, not a specific drug. It is standardized to 'First-Line' and placed at the beginning of the indication.
   - **Disease Stage**: 'Advanced' is a standard stage descriptor and is retained and formatted in Title Case.
   - **Gene Alteration**: Based on 'Gene type' rules (e.g., ID 43 for 'Gene Alteration'), 'Her2-Altered' is normalized to 'HER2-Altered' to standardize the gene symbol to uppercase (HER2).
   - **Disease**: 'Non-Small Cell Lung Cancer' is already in the correct singular and Title Case format.
5. **Indication Construction**: The normalized components are assembled in the standard order (Treatment Line -> Stage -> Biomarker -> Disease) to form the final indication.
6. **Final Quality Check**: The generated indication adheres to all formatting and exclusion rules, resulting in a clinically precise and standardized output.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To determine the correct handling and formatting of the term 'Advanced'.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To validate the format for 'Her2-Altered' and normalize the gene symbol.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine whether 'First-Line' should be included or excluded and how to format it.""}]","[{'component': 'First-Line', 'type': 'Line of Treatment', 'normalized_form': 'First-Line', 'rule_applied': 'Treatment Set-up rule ID 200: Standardize and include as it modifies the disease context.'}, {'component': 'Advanced', 'type': 'Stage', 'normalized_form': 'Advanced', 'rule_applied': 'Generic Rule: Retain and apply Title Case to clinically significant stage descriptors.'}, {'component': 'Her2-Altered', 'type': 'Gene Alteration', 'normalized_form': 'HER2-Altered', 'rule_applied': ""Gene type rule ID 43: Standardize to '<Gene>-Altered' format and use uppercase for the gene symbol.""}, {'component': 'Non-Small Cell Lung Cancer', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}]",2
148158,Myeloma And Other Monoclonal Gammopathies - Biology & Translational Research,Tumor Associated Macrophages Inhibit Cd8+T Cells Immune Responses Via Pd-1/Pd-L1 Pathway In Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Tumor Associated Macrophages Inhibit Cd8+T Cells Immune Responses Via Pd-1/Pd-L1 Pathway In Multiple Myeloma'. The session title is 'Myeloma And Other Monoclonal Gammopathies - Biology & Translational Research'.
2.  **Select Source**: The abstract title contains the specific disease 'Multiple Myeloma'. According to the single-source principle, the abstract title is preferred over the session title and will be used exclusively.
3.  **Identify Components**: The core disease identified is 'Multiple Myeloma'. Other biological terms like 'Tumor Associated Macrophages', 'Cd8+T Cells', and 'Pd-1/Pd-L1 Pathway' are present.
4.  **Retrieve Rules**: I retrieved rules for 'Biomarker' to understand how to handle 'Pd-1/Pd-L1' and 'Patient Sub-Group' for 'Tumor Associated'.
5.  **Apply Rules**: 
    *   **Generic Exclusion Rule**: The terms 'Tumor Associated Macrophages', 'Cd8+T Cells Immune Responses', and 'Pd-1/Pd-L1 Pathway' describe the biological mechanism under investigation, not the patient's clinical indication. These are considered non-diagnostic items and must be excluded.
    *   **Biomarker Rule (ID: 83)**: This rule advises against including therapeutic agents like 'Anti-PD-1'. While the title mentions the pathway, it's in the context of a biological mechanism, not a biomarker-defined patient subgroup (e.g., 'PD-L1 Positive'). Therefore, it should be excluded.
    *   **Generic Formatting Rules**: The disease 'Multiple Myeloma' is already in the correct Title Case and singular form.
6.  **Construct Indication**: Based on the rules, only the core disease 'Multiple Myeloma' is retained.
7.  **Quality Check**: The final indication is clinically accurate, adheres to the single-source principle, and follows all formatting and exclusion rules.","[{'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To determine how to handle the 'Pd-1/Pd-L1 Pathway' mentioned in the abstract title.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check if 'Tumor Associated' is a valid disease characterizer.""}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Retain core disease term.'}, {'component': 'Tumor Associated Macrophages', 'type': 'Biological Component', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic items describing biological mechanisms.'}, {'component': 'Pd-1/Pd-L1 Pathway', 'type': 'Biomarker Pathway', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude biological pathways that do not define a specific patient subgroup.'}]",2
262851,Stem cell transplantation - Clinical,Efficacy And Safety Comparison Of Calcineurin Inhibitors Used For Gvhd Prophylaxis In Hematopoietic Stem Cell Transplantation In Children With Thalassemia,Thalassemia,Thalassemia,Pediatric Thalassemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease term ('Thalassemia'), whereas the session title is procedural ('Stem cell transplantation'). This adheres to the Single-Source Extraction Principle.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Thalassemia' and the patient subgroup 'Children'.
3. **Rule Retrieval**: Rules for the 'Age Group' category, specifically for 'Pediatric', were retrieved to determine the correct handling of the term 'Children'.
4. **Rule Application**: 
   - The generic exclusion rule was applied to remove procedural context, specifically 'Gvhd Prophylaxis' and 'Hematopoietic Stem Cell Transplantation'.
   - The retrieved 'Age Group' rules (ID 295, 296) mandate normalizing age-related terms like 'Children' to the standard form 'Pediatric' and placing it at the beginning of the indication.
   - The generic casing rule was applied to ensure the final indication is in Title Case.
   - The generic singular form rule was applied, although 'Thalassemia' is already singular.
5. **Indication Construction**: The normalized age group 'Pediatric' was prepended to the disease 'Thalassemia' to form the final indication.
6. **Quality Check**: The final indication 'Pediatric Thalassemia' is clinically accurate, correctly formatted, and free of excluded terms.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To determine the standard representation for the patient subgroup 'Children'.""}]","[{'component': 'Children', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group rule (ID 295/296) for normalization of age descriptors.'}, {'component': 'Thalassemia', 'type': 'Disease', 'normalized_form': 'Thalassemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}, {'component': 'Gvhd Prophylaxis In Hematopoietic Stem Cell Transplantation', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
213700,"MP22: Trauma/Reconstruction/Diversion: Urethral Reconstruction (including Stricture, Diverticulum) I",How is health-related quality of life affected by salvage cystectomy and urinary diversion as a last-line option for benign disease,,,Trauma;;Urethral Stricture;;Urethral Diverticulum,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains the term ""benign disease"", which is a valid but extremely generic disease category. The session title, ""Trauma/Reconstruction/Diversion: Urethral Reconstruction (including Stricture, Diverticulum) I"", provides multiple specific and clinically valid conditions: ""Trauma"", ""Urethral Stricture"", and ""Urethral Diverticulum"". According to the goal of extracting clinically valid indications, the session title is the superior source in this case.
2.  **Component Identification**: From the session title, three distinct medical conditions were identified: 'Trauma', 'Stricture', and 'Diverticulum'. The anatomical location 'Urethral' is associated with 'Stricture' and 'Diverticulum'. The terms 'Reconstruction' and 'Diversion' are procedural and are excluded based on generic rules.
3.  **Rule Application**: 
    *   The generic rule for multiple diseases was applied, requiring the use of ';;' as a separator.
    *   The generic rule for Title Case was applied to all terms.
    *   The generic rule for singular form was applied (all terms were already singular).
4.  **Indication Construction**: The identified components were combined and formatted. 'Urethral' was prepended to 'Stricture' and 'Diverticulum' as it provides the anatomical context. The final indications are 'Trauma', 'Urethral Stricture', and 'Urethral Diverticulum'.
5.  **Final Output**: The three indications are combined into a single string, separated by ';;', resulting in ""Trauma;;Urethral Stricture;;Urethral Diverticulum"".",[],"[{'component': 'Trauma', 'type': 'Disease', 'normalized_form': 'Trauma', 'rule_applied': 'Generic Title Case rule'}, {'component': 'Urethral Stricture', 'type': 'Disease', 'normalized_form': 'Urethral Stricture', 'rule_applied': 'Generic Title Case rule'}, {'component': 'Urethral Diverticulum', 'type': 'Disease', 'normalized_form': 'Urethral Diverticulum', 'rule_applied': 'Generic Title Case rule'}]",1
180933,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I",Screening Chest CT Prior to Allogenic Transplantation - High Rates of Occult Abnormalities,,,,True,none,"Step 1: I analyzed both the abstract and session titles. The abstract title is 'Screening Chest CT Prior to Allogenic Transplantation - High Rates of Occult Abnormalities' and the session title is 'Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I'.
Step 2: Neither title contains a specific, clinically valid medical indication. The abstract title mentions 'Occult Abnormalities', which is a clinical finding, not a disease. The session title mentions 'Acute Toxicities', which is a complication or adverse effect. Both titles are centered around the procedure 'Allogeneic Transplantation'.
Step 3: I retrieved rules for 'Transplant Status' to confirm how to handle procedure-related terms. The rules confirm that transplant-related descriptors should be excluded as they describe a treatment context, not the disease itself.
Step 4: The generic exclusion rules state that procedural qualifiers (like 'Prior to... Transplantation') and non-diagnostic items (like 'Occult Abnormalities' and 'Acute Toxicities') must be excluded.
Step 5: Since neither title provides a disease term after applying the exclusion rules, no valid indication can be extracted from either source.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': 'To verify that terms related to transplantation are procedural and should be excluded from the final indication.'}]","[{'component': 'Allogenic Transplantation', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Procedural/Temporal Qualifiers. Rule ID 230-233 also confirm exclusion of transplant status.'}, {'component': 'Occult Abnormalities', 'type': 'Non-Diagnostic Item', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Non-Diagnostic Items.'}, {'component': 'Acute Toxicities', 'type': 'Non-Diagnostic Item', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Non-Diagnostic Items (Complications or adverse effects).'}]",2
180932,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I",The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type,Early;;Cytomegalovirus Infection,Early Cytomegalovirus Infection,Adult Early Onset Cytomegalovirus Infection,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific medical condition ('Cytomegalovirus Infection'), whereas the session title is more general.
2. **Component Identification**: The abstract title contains the following components: a disease ('Cytomegalovirus Infection'), an age group ('Adult'), a temporal qualifier ('Early'), and a patient context ('Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients', 'High-Risk Donor Type').
3. **Rule Retrieval**: I retrieved rules for 'Age Group', 'Treatment Set-up', 'Risk', and 'Onset' to handle the identified components.
4. **Rule Application**:
   - **Disease**: 'Cytomegalovirus Infection' was identified as the core disease.
   - **Age Group**: Based on the 'Adult' rule (ID: 289), the term 'Adult' is prepended to the indication.
   - **Onset**: Based on the 'Onset by Time' rule for 'Early' (ID: 266), the term is normalized to 'Early Onset' and prepended to the disease name.
   - **Exclusions**: 
     - The phrase 'Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients' describes a procedural context. The generic rules and the retrieved 'Transplant Status' rules (e.g., ID: 232 for 'Post-Transplant') mandate the exclusion of such procedural qualifiers.
     - 'High-Risk Donor Type' describes a characteristic of the donor, not a direct feature of the patient's disease, and is therefore excluded.
5. **Indication Construction**: The components were combined in the correct order (Age -> Onset -> Disease) and formatted according to generic rules (Title Case, singular form).
6. **Final Indication**: The final generated indication is 'Adult Early Onset Cytomegalovirus Infection'.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To handle the 'Adult' patient subgroup.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine how to handle the 'Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients' context.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To evaluate the 'High-Risk' qualifier.""}, {'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To process the temporal qualifier 'Early'.""}]","[{'component': 'Cytomegalovirus Infection', 'type': 'Disease', 'normalized_form': 'Cytomegalovirus Infection', 'rule_applied': 'Generic disease identification'}, {'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group rule ID: 289'}, {'component': 'Early', 'type': 'Onset Qualifier', 'normalized_form': 'Early Onset', 'rule_applied': 'Onset by Time rule ID: 266'}, {'component': 'Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients', 'type': 'Procedural Context', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural qualifiers and Treatment Set-up rule ID: 232'}, {'component': 'High-Risk Donor Type', 'type': 'Risk Qualifier', 'normalized_form': '', 'rule_applied': ""Generic exclusion rule - qualifier does not describe the patient's disease.""}]",2
393929,"Nsclc, Metastatic",Real-World Routine Kras Testing Practices In France For Patients (Pts) With Advanced Or Metastatic (Am) Non-Small Cell Lung Cancer (Nsclc): Data From The Esme Cohort,Advanced;;Metastatic;;Non-Small Cell Lung Cancer,Advanced Or Metastatic Non-Small Cell Lung Cancer,Advanced/Metastatic Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title because it provides more specific and complete information about the patient population, including the disease stage.
2. **Component Identification**: The core components identified in the abstract title are the disease 'Non-Small Cell Lung Cancer (Nsclc)' and the stage/occurrence qualifiers 'Advanced Or Metastatic (Am)'.
3. **Rule Retrieval**: Rules for 'Stage' and 'Occurrence' were retrieved to handle the terms 'Advanced' and 'Metastatic'. The rule for 'Advanced Metastatic' (ID 177) suggests consolidating these terms. While the rule suggests 'Locally Advanced Metastatic', the term 'Locally' is not present in the source text. Therefore, a standard clinical representation 'Advanced/Metastatic' was used to accurately reflect the source 'Advanced Or Metastatic'.
4. **Exclusion Application**: As per generic rules, geographical locations ('France'), patient descriptors ('Pts'), and study methodology terms ('Kras Testing Practices') were excluded from the final indication. The mention of 'Kras' pertains to the testing methodology of the study, not a genetic characteristic of the patient cohort itself, and is therefore correctly excluded.
5. **Indication Construction**: The identified components were combined and formatted according to the generic rules. 'Non-Small Cell Lung Cancer' is already in singular form. The combined phrase was converted to Title Case, resulting in 'Advanced/Metastatic Non-Small Cell Lung Cancer'.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To determine how to handle the term 'Advanced'.""}, {'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To determine how to handle the term 'Metastatic' and its combination with 'Advanced'.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To confirm that 'Kras Testing Practices' is a methodological term and not a patient subgroup characteristic.""}]","[{'component': 'Advanced Or Metastatic (Am)', 'type': 'Stage/Occurrence', 'normalized_form': 'Advanced/Metastatic', 'rule_applied': ""Rule ID 177 for 'Advanced Metastatic' guided the consolidation of the terms. The output was normalized to the standard clinical shorthand 'Advanced/Metastatic' to accurately represent 'Advanced Or Metastatic'.""}, {'component': 'Non-Small Cell Lung Cancer (Nsclc)', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic rules for Title Case and singular form.'}, {'component': 'Kras Testing Practices', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic items and study methodologies. Gene type rules confirmed that this does not describe a specific gene mutation in the patient cohort.'}, {'component': 'France', 'type': 'Region', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic/geographic descriptors.'}]",2
393942,"Nsclc, Metastatic",Recurrence Of Infusion-Related Reaction (Irrs) Associated To Avimantamab,Nsclc;;Metastatic,Metastatic Non-Small Cell Lung Cancer,Metastatic Non-Small Cell Lung Cancer,True,session_title,"Step 1: The abstract title 'Recurrence Of Infusion-Related Reaction (Irrs) Associated To Avimantamab' describes a treatment-related adverse event, not a primary disease indication. The session title 'Nsclc, Metastatic' clearly contains a disease (Nsclc) and a qualifier (Metastatic). Therefore, the session title is selected as the source based on the Single-Source Extraction Principle.
Step 2: The components identified in the session title are the disease 'Nsclc' and the occurrence qualifier 'Metastatic'.
Step 3: Rules for 'Metastasis-Related Terms' were retrieved to handle the term 'Metastatic'. Rule ID 141 specifies formatting the indication as 'Metastatic <Primary-Disease-Name>'.
Step 4: The abbreviation 'Nsclc' is expanded to its full, standardized form 'Non-Small Cell Lung Cancer'.
Step 5: Applying the retrieved rule and generic formatting rules, the components are combined and formatted to 'Metastatic Non-Small Cell Lung Cancer', adhering to Title Case and proper ordering.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'Metastatic' as a prefix to the disease.""}]","[{'component': 'Nsclc', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Standard medical abbreviation expansion.'}, {'component': 'Metastatic', 'type': 'Disease Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': ""Rule ID 141: Place 'Metastatic' before the primary disease name.""}]",2
213726,MP23: Bladder Cancer: Invasive III,Circulating tumor DNA is a strong predictor in patients treated with systemic therapy for urothelial carcinoma,urothelial carcinoma,Urothelial Carcinoma,Urothelial Carcinoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Circulating tumor DNA is a strong predictor in patients treated with systemic therapy for urothelial carcinoma') was chosen as the primary source because it contains a specific disease term ('urothelial carcinoma'), following the single-source extraction principle.
2. **Component Identification**: The key components identified in the abstract title are the disease 'urothelial carcinoma' and the context 'treated with systemic therapy'.
3. **Rule Retrieval**: I retrieved rules for the 'Treatment based' category to determine how to handle 'treated with'. The retrieved rules apply to specific statuses like 'Previously Treated' or 'Untreated', which do not match the context in the title.
4. **Rule Application**: 
   - The phrase 'treated with systemic therapy' is a procedural/temporal qualifier describing the study's patient cohort, not a defining characteristic of the indication itself. According to the generic exclusion rules, such qualifiers must be excluded.
   - The disease term 'urothelial carcinoma' was normalized according to generic formatting rules: converted to Title Case ('Urothelial Carcinoma') and confirmed to be in singular form.
5. **Indication Construction**: After excluding the procedural qualifier, the final indication is constructed solely from the normalized disease name.
6. **Final Quality Check**: The resulting indication 'Urothelial Carcinoma' is clinically accurate, adheres to all formatting rules, and correctly follows the single-source principle.","[{'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To check how to handle the term 'treated with systemic therapy'.""}]","[{'component': 'urothelial carcinoma', 'type': 'Disease', 'normalized_form': 'Urothelial Carcinoma', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Singular Form'}, {'component': 'treated with systemic therapy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Procedural/Temporal Qualifiers'}]",2
230112,Breast Cancer-Local/Regional/Adjuvant,Survival trends of patients with Paget disease of the breast: A National Cancer Database (NCDB) study.,Paget disease of the breast,Paget Disease of the Breast,Paget Disease of the Breast,True,abstract_title,"Step 1: The abstract title contains a specific disease term, 'Paget disease of the breast', so it was chosen as the primary source over the session title, following the single-source principle.
Step 2: The core disease entity identified was 'Paget disease of the breast'. No other patient subgroups, biomarkers, or staging information were present in the title.
Step 3: I retrieved rules for 'Patient Sub-Group' and 'Disease Characterisation' to check for any specific handling, but none of the retrieved rules applied to this specific disease name.
Step 4: The generic rules were applied. The disease name was converted to Title Case, capitalizing 'Paget', 'Disease', and 'Breast', while keeping the preposition 'of' and the article 'the' in lowercase. The term 'disease' is already in singular form.
Step 5: The final indication was constructed by applying the formatting rules to the identified disease term.
Step 6: A quality check confirmed that the single-source principle was followed, formatting is correct, and the resulting indication is clinically specific and accurate based on the provided text.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for specific rules regarding disease names or characterizations that might apply to 'Paget disease of the breast'.""}]","[{'component': 'Paget disease of the breast', 'type': 'Disease', 'normalized_form': 'Paget Disease of the Breast', 'rule_applied': 'Generic Rule: Casing Rules (Title Case)'}]",2
410337,"Bioengineering, Augmented Intelligence, Digital Health, and Data Science",A Novel Glomerular Endothelium-Targeting Adeno-Associated Virus (AAV) Delivers Bacterial Proteinase to Treat Glomerulonephritis,Glomerulonephritis,Glomerulonephritis,Glomerulonephritis,True,abstract_title,"Step 1: The abstract title contains the disease term 'Glomerulonephritis', while the session title does not contain any disease terms. Therefore, the abstract title was selected as the source based on the single-source extraction principle.
Step 2: The disease term 'Glomerulonephritis' was identified from the abstract title.
Step 3: No patient subgroups, biomarkers, or other qualifiers were present in the title.
Step 4: The generic formatting rules were applied. The term is already in singular form and correctly capitalized (Title Case).
Step 5: The final indication was constructed as 'Glomerulonephritis'.",[],"[{'component': 'Glomerulonephritis', 'type': 'Disease', 'normalized_form': 'Glomerulonephritis', 'rule_applied': 'Generic rule: Title Case, Singular Form'}]",1
295653,"Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management",Discussion,,,Cancer,True,session_title,"Step 1: The abstract title 'Discussion' contains no medical or disease-related terms, so it is discarded.
Step 2: The session title 'Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management' is selected as the source.
Step 3: The term 'Oncologist' is identified, which corresponds to the therapeutic area of Oncology.
Step 4: The generic rule for 'Therapeutic Area Fallback' is applied, which states that 'Oncology' should be normalized to the overarching disease 'Cancer'.
Step 5: The final indication is formatted to 'Cancer' following Title Case and singular form rules.",[],"[{'component': 'Oncologist', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': 'Therapeutic Area Fallback'}]",1
328423,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II,"ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase",Newly Diagnosed;;Philadelphia Chromosome;;Positive;;Chronic Myelogenous Leukemia;;Chronic Phase,Newly Diagnosed Ph-Positive Chronic Myelogenous Leukemia in Chronic Phase,Newly Diagnosed Ph Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Chronic Myelogenous Leukemia') and provides more detailed clinical information than the session title, in accordance with the single-source principle.
2. **Component Identification**: I identified four key components in the abstract title: the diagnosis status 'Newly Diagnosed', the chromosomal marker 'Philadelphia Chromosome-Positive', the core disease 'Chronic Myelogenous Leukemia', and the disease stage 'Chronic Phase'.
3. **Rule Retrieval**: I retrieved specific rules for the identified components. 
   - For 'Newly Diagnosed', the rule from the 'Treatment based' category (ID: 193) confirmed it should be used as a prefix.
   - For 'Philadelphia Chromosome-Positive', the rule from the 'Chromosome type' category (ID: 81) dictated its conversion to the standardized abbreviation 'Ph Chromosome-Positive'.
   - For 'Chronic Phase', I determined it was a critical stage descriptor that must be included.
4. **Indication Construction**: I assembled the components in a clinically logical order. The diagnosis status comes first, followed by the genetic marker, the core disease, and finally the stage. The preposition 'in' is kept and lowercased as per generic formatting rules.
5. **Final Formatting and Quality Check**: The final indication was formatted to Title Case, ensuring gene/chromosome abbreviations were preserved. I verified that all generic rules, such as using the singular form for the disease and correct spacing, were applied. The resulting indication is a complete and clinically accurate representation of the patient population described in the title.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To validate the handling of the term 'Newly Diagnosed'.""}, {'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To find the correct formatting for 'Philadelphia Chromosome-Positive'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To determine how to handle the 'Chronic Phase' descriptor.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'Philadelphia Chromosome-Positive', 'type': 'Chromosome Type', 'normalized_form': 'Ph Chromosome-Positive', 'rule_applied': ""Rule ID: 81 - Convert to the standardized abbreviation 'Ph Chromosome-Positive'.""}, {'component': 'Chronic Myelogenous Leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Myelogenous Leukemia', 'rule_applied': 'Generic Rule - Title Case and singular form.'}, {'component': 'Chronic Phase', 'type': 'Stage', 'normalized_form': 'in Chronic Phase', 'rule_applied': 'Generic Rule - Include stage information and apply Title Case.'}]",2
410348,COVID-19: A New Understanding and Lessons Learned,Excess Mortality During the COVID-19 Pandemic in a Mid-Sized Dialysis Provider,COVID-19,COVID-19 Infection,COVID-19,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Excess Mortality During the COVID-19 Pandemic in a Mid-Sized Dialysis Provider' and the session title is 'COVID-19: A New Understanding and Lessons Learned'.
2.  **Select Source**: Both titles contain the disease term 'COVID-19'. According to the Single-Source Extraction Principle, the abstract title is the preferred source. I will use the abstract title.
3.  **Identify Components**: The key disease component in the abstract title is 'COVID-19'. The phrase 'in a Mid-Sized Dialysis Provider' describes a patient setting based on a medical procedure (dialysis), not a disease itself. 'Excess Mortality' is an outcome, not an indication.
4.  **Apply Rules**: I applied the generic exclusion rules. The procedural context 'Dialysis Provider' is excluded. The outcome 'Excess Mortality' and the epidemiological descriptor 'Pandemic' are also excluded. The disease name 'COVID-19' is already in the correct format and does not need to be changed.
5.  **Construct Indication**: The extracted and cleaned component is 'COVID-19'.
6.  **Quality Check**: The final indication adheres to all formatting and exclusion rules. It is clinically accurate and derived from a single source.",[],"[{'component': 'COVID-19', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic Rule - Disease Identification'}, {'component': 'in a Mid-Sized Dialysis Provider', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule - Exclusion of Procedural/Temporal Qualifiers'}]",1
328431,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia,Chronic Myeloid Leukaemia,Chronic Myeloid Leukaemia,Chronic Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract title and session title contain the disease 'Chronic Myeloid Leukemia'. Following the single-source principle, the abstract title is prioritized.
2.  **Component Identification**: The abstract title contains the disease 'Chronic Myeloid Leukaemia' and two potential qualifiers: 'Cancer-Related Gene Mutations' and 'Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy'.
3.  **Rule Retrieval**: I retrieved rules for 'Resistance' which confirmed that treatment resistance descriptors should be excluded from the final indication as they represent a treatment response status, not a distinct clinical entity.
4.  **Rule Application**: 
    - The disease term 'Chronic Myeloid Leukaemia' was normalized to the standard American spelling 'Chronic Myeloid Leukemia' and formatted to Title Case.
    - The phrase 'Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy' was excluded based on the retrieved 'Resistance' rules.
    - The phrase 'Cancer-Related Gene Mutations' is a general descriptor of the cause of resistance, not a specific, standard patient subgroup qualifier. It was excluded to maintain a concise and clinically standard indication.
5.  **Indication Construction**: After applying the rules and exclusions, the core disease 'Chronic Myeloid Leukemia' remains as the final indication.
6.  **Quality Check**: The final output adheres to all formatting and clinical standardization rules.","[{'category': 'Occurrence', 'subcategories': ['Resistance'], 'reason': ""To determine how to handle the phrase 'Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy'.""}, {'category': 'Gene type', 'subcategories': ['Gene Mutation'], 'reason': ""To check for rules regarding the handling of 'Gene Mutations'.""}]","[{'component': 'Chronic Myeloid Leukaemia', 'type': 'Disease', 'normalized_form': 'Chronic Myeloid Leukemia', 'rule_applied': 'Generic Rule: Title Case, Singular Form, Spelling Normalization'}, {'component': 'Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy', 'type': 'Treatment Resistance', 'normalized_form': '', 'rule_applied': 'Occurrence Rule (ID: 164, 165): Exclude drug/drug class resistance descriptors.'}, {'component': 'Cancer-Related Gene Mutations', 'type': 'General Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclude non-diagnostic, overly general descriptors that do not define a standard clinical subgroup.'}]",2
328438,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study,Chronic Myeloid Leukemia,Chronic Myeloid Leukemia,Chronic Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract title and session title contain the disease term 'Chronic Myeloid Leukemia'. As per the single-source principle, the abstract title is prioritized as it is more detailed.
2.  **Component Identification**: The abstract title contains the core disease 'Chronic Myeloid Leukemia (CML)' and potential qualifiers 'Molecular Recurrence' and 'after Treatment Discontinuation'.
3.  **Rule Retrieval**: Rules for 'Occurrence' (specifically 'Recurrence-Related Terms') and 'Treatment Set-up' (specifically 'Treatment Status') were retrieved to handle the identified qualifiers.
4.  **Rule Application**:
    *   **Generic Rules**: The disease term is converted to Title Case and singular form, resulting in 'Chronic Myeloid Leukemia'.
    *   **Recurrence Rule (ID: 140)**: The rule for 'Recurrence' specifies that the term should be excluded when used as a prognostic endpoint, such as in 'prediction of recurrence'. The title uses 'Prediction of Molecular Recurrence', which fits this exclusion criterion. Therefore, 'Molecular Recurrence' is not included in the final indication.
    *   **Treatment Status Rules**: The phrase 'after Treatment Discontinuation' describes a temporal status related to treatment. This is analogous to 'Post-Treatment' (Rule IDs 234, 235), which is an explicit exclusion. Following this principle, 'after Treatment Discontinuation' is excluded as a non-diagnostic, procedural qualifier.
5.  **Indication Construction**: After excluding the non-indicative qualifiers based on the rules, the only remaining component is the core disease itself.
6.  **Final Output**: The final generated indication is 'Chronic Myeloid Leukemia'.","[{'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To evaluate the phrase 'after Treatment Discontinuation'.""}, {'category': 'Occurrence', 'subcategories': ['Recurrence-Related Terms'], 'reason': ""To evaluate the phrase 'Molecular Recurrence'.""}]","[{'component': 'Chronic Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Myeloid Leukemia', 'rule_applied': 'Generic Title Case and Singular Form rules.'}, {'component': 'Molecular Recurrence', 'type': 'Occurrence', 'normalized_form': '', 'rule_applied': ""Rule 140: Excluded because it is used as a predictive endpoint ('Prediction of...'), not as a descriptor of the patient's current state.""}, {'component': 'after Treatment Discontinuation', 'type': 'Treatment Status', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule for procedural/temporal qualifiers and analogy to 'Post-Treatment' exclusion rules (ID 234, 235).""}]",2
328439,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,Targeted Next-Generation Sequencing Identifies Additional Mutations Other Than BCR-ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study,BCR-ABL;;Chronic Myeloid Leukemia,BCR-ABL-Fusion Chronic Myeloid Leukemia,Chronic Myeloid Leukemia with Additional Mutations Other Than BCR-ABL,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract and session titles contain the disease 'Chronic Myeloid Leukemia'. As per the single-source principle, the abstract title is prioritized as it provides more specific patient details.
2.  **Component Identification**: The abstract title identifies the core disease 'Chronic Myeloid Leukemia' and a specific patient subgroup characterized by 'Additional Mutations Other Than BCR-ABL'. It also contains the sociodemographic descriptor 'Chinese', which must be excluded.
3.  **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' under 'Genetic Status' to guide the handling of mutation-defined subgroups. Although no specific rule matched this exact phrase, the general principle is to include clinically relevant genetic descriptors.
4.  **Rule Application & Construction**:
    *   The core disease 'Chronic Myeloid Leukemia' is extracted and formatted in Title Case.
    *   The patient subgroup identifier 'with Additional Mutations Other Than BCR-ABL' is appended to the core disease to accurately define the indication.
    *   The sociodemographic term 'Chinese' is excluded based on the generic exclusion rules.
    *   Study design details ('Monocentric Retrospective Study') are also excluded as they are not part of the medical indication.
5.  **Final Quality Check**: The resulting indication, 'Chronic Myeloid Leukemia with Additional Mutations Other Than BCR-ABL', is clinically accurate, adheres to formatting guidelines (Title Case, singular form), and correctly represents the specific patient population from the selected source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To check for rules on how to handle complex genetic descriptors like 'Additional Mutations Other Than BCR-ABL'.""}]","[{'component': 'Chronic Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Myeloid Leukemia', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Additional Mutations Other Than BCR-ABL', 'type': 'Patient Sub-Group (Genetic Status)', 'normalized_form': 'with Additional Mutations Other Than BCR-ABL', 'rule_applied': 'Generic Rule: Inclusion of clinically relevant patient subgroups'}, {'component': 'Chinese', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of ethnicity'}]",2
180989,Autologous Transplantation: Clinical and Epidemiological: Poster I,Safety of Autologous Hematopoietic Stem Cell Transplantation in Patients over 75 Years Old. Single Center Experience Serving a Minority Population,,,,True,none,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Safety of Autologous Hematopoietic Stem Cell Transplantation in Patients over 75 Years Old. Single Center Experience Serving a Minority Population' and the session title is 'Autologous Transplantation: Clinical and Epidemiological: Poster I'.
2.  **Select Source**: Neither the abstract title nor the session title contains a specific disease or disorder. Both refer to a medical procedure ('Autologous Hematopoietic Stem Cell Transplantation' and 'Autologous Transplantation'). The abstract title contains a patient subgroup ('over 75 Years Old') and a sociodemographic descriptor ('Minority Population').
3.  **Identify Components & Retrieve Rules**: 
    *   'over 75 Years Old' was identified as an age-based patient subgroup. I retrieved rules for the 'Age Group' category, which confirmed that such phrases are typically normalized to 'Elderly'.
    *   'Autologous Hematopoietic Stem Cell Transplantation' was identified as a procedure. I retrieved rules for 'Treatment Set-up' which confirmed that transplant-related terms are procedural and should be excluded.
    *   'Minority Population' is a sociodemographic descriptor and must be excluded based on generic rules.
4.  **Apply Rules & Construct Indication**: According to the 'Handling Orphan PSUBs' rule, a patient subgroup cannot form an indication without a core disease term from the same source. Since the abstract title lacks a disease, the patient subgroup 'over 75 Years Old' is discarded. The session title also lacks a disease. Therefore, no valid medical indication can be extracted from either source.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To determine how to handle the patient descriptor 'over 75 Years Old'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To confirm that 'Autologous Hematopoietic Stem Cell Transplantation' is a procedural term to be excluded.""}]","[{'component': 'over 75 Years Old', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': 'Age Group rule for elderly patients.'}, {'component': 'Autologous Hematopoietic Stem Cell Transplantation', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural qualifiers.'}, {'component': 'Minority Population', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic descriptors.'}]",2
328455,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I,Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor,Chronic Myeloid Leukemia;;Intermediate;;High-Risk,Intermediate-Risk High-Risk Chronic Myeloid Leukemia,High-Risk Chronic Myeloid Leukemia;;Intermediate-Risk Chronic Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title as it contains more specific information about the patient subgroup, including disease and risk stratification.
2. **Component Identification**: The key components identified in the abstract title are the disease ""Chronic Myeloid Leukemia"" and the patient subgroups ""Intermediate- or High-Risk"".
3. **Rule Retrieval**: Rules for the 'Risk' category were retrieved to handle the terms ""Intermediate-Risk"" and ""High-Risk"". Specifically, Rule ID 129 for 'Intermediate-Risk' and general rules for 'High-Risk' were applicable.
4. **Rule Application**: The retrieved rules dictate that when multiple risk levels for the same disease are mentioned, they should be extracted as separate indications. The terms ""Intermediate- or High-Risk"" were normalized to ""Intermediate-Risk"" and ""High-Risk"" respectively.
5. **Indication Construction**: Two distinct indications were constructed by prepending the normalized risk qualifiers to the disease name: ""High-Risk Chronic Myeloid Leukemia"" and ""Intermediate-Risk Chronic Myeloid Leukemia"". These were then combined using the required ';;' separator.
6. **Exclusions**: Non-indicative information such as ""Subjects with"", the description of the therapeutic model (""Imatinib Therapy Failure (IMTF) Model""), and the treatment details (""Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor"") were excluded as per generic rules.","[{'category': 'Risk', 'subcategories': ['High-Risk', 'Risk Types'], 'reason': ""To correctly handle the 'Intermediate- or High-Risk' qualifiers and understand how to format them as separate indications.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine if 'Initial Therapy' should be included as a 'First-Line' descriptor. The rules helped confirm it should be excluded as it describes the intervention, not the patient population.""}]","[{'component': 'Chronic Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Myeloid Leukemia', 'rule_applied': 'Generic singular form and title case rules.'}, {'component': 'Intermediate- or High-Risk', 'type': 'Risk Stratification', 'normalized_form': 'High-Risk;;Intermediate-Risk', 'rule_applied': 'Rule ID 129 (Risk category), which specifies creating separate indications for each risk level mentioned.'}, {'component': 'Initial Therapy', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers. The term describes the intervention being studied, not a defining characteristic of the patient cohort.'}]",2
148233,Myeloma And Other Monoclonal Gammopathies - Clinical,"Survival Among Older Patients With Previously Treated Multiple Myeloma Treated With Selinexor, Bortezomib, And Dexamethasone (Xvd) In The Boston Study",Older;;Previously Treated;;Multiple Myeloma,Elderly Previously Treated Multiple Myeloma,Elderly Previously Treated Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Survival Among Older Patients With Previously Treated Multiple Myeloma...' contains a specific disease ('Multiple Myeloma'), so it is selected as the source over the session title, following the single-source principle.
2. **Component Identification**: I identified three key components in the abstract title: the disease 'Multiple Myeloma', the age group 'Older Patients', and the treatment status 'Previously Treated'.
3. **Rule Retrieval**: I retrieved rules for the identified components. For 'Older', I used `get_indication_rules(category=""Age Group"", subcategories=[""Elderly""])`. For 'Previously Treated', I used `get_indication_rules(category=""Treatment based"", subcategories=[""Treatment Status""])`.
4. **Rule Application**:
   - **Generic Rules**: The disease term 'Multiple Myeloma' is already in singular form and Title Case. The term 'Patients' is excluded.
   - **Age Group Rule**: Based on the retrieved rules (e.g., Rule ID 302), 'Older' is standardized to 'Elderly' and positioned as a leading qualifier.
   - **Treatment Status Rule**: Based on the retrieved rules (e.g., Rule ID 192), 'Previously Treated' is standardized to 'Previously Treated' (Title Case) and also positioned as a leading qualifier.
5. **Indication Construction**: I combined the components in a clinically logical order: Age Group -> Treatment Status -> Disease. This results in 'Elderly Previously Treated Multiple Myeloma'.
6. **Quality Check**: The final indication is correctly formatted, adheres to all generic and specific rules, and accurately represents the patient population described in the abstract title.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To standardize the term 'Older' found in the abstract title.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To standardize the term 'Previously Treated' found in the abstract title.""}]","[{'component': 'Older Patients', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group rule for 'Older' (ID: 302) requires standardizing to 'Elderly'.""}, {'component': 'Previously Treated', 'type': 'Treatment Status', 'normalized_form': 'Previously Treated', 'rule_applied': ""Treatment based rule for 'Previously Treated' (ID: 192) requires standardizing to 'Previously Treated' in Title Case.""}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule for singular form and Title Case.'}]",2
262924,Acute lymphoblastic leukemia - Clinical,A Phase 1/2 Study To Evaluate Ponatinib With Chemotherapy In Pediatric Patients With Relapsed/Resistant/Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Or With T315I Mutation,Relapsed;;Intolerant;;Philadelphia Chromosome;;Positive;;Acute Lymphoblastic Leukemia;;T315I Mutation,Relapsed/Intolerant Ph-Positive T315I Mutated Acute Lymphoblastic Leukemia,Pediatric Relapsed/Refractory Ph Chromosome-Positive Acute Lymphoblastic Leukemia;;Pediatric T315I-Mutated Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains the disease ('Acute Lymphoblastic Leukemia') and is significantly more detailed than the session title, adhering to the single-source principle.
2.  **Component Identification**: The abstract title was parsed to identify key clinical components: 'Pediatric' (Age Group), 'Relapsed/Resistant/Intolerant' (Disease State), 'Philadelphia Chromosome-Positive' (Chromosome Type), 'Acute Lymphoblastic Leukemia' (Disease), and 'T315I Mutation' (Gene Mutation).
3.  **Handling Multiple Indications**: The presence of 'Or' indicates two distinct patient populations, leading to the extraction of two separate indications for the same disease.
4.  **Rule Retrieval and Application**:
    *   **Indication 1**: 'Pediatric Patients With Relapsed/Resistant/Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia'
        *   'Pediatric' was retained as the leading qualifier per the 'Age Group' rule (ID: 295).
        *   'Relapsed/Resistant/Intolerant' was normalized to the standard clinical trial terminology 'Relapsed/Refractory' based on 'Occurrence' rules.
        *   'Philadelphia Chromosome-Positive' was standardized to 'Ph Chromosome-Positive' as per the 'Chromosome type' rule (ID: 81).
        *   The disease 'Acute Lymphoblastic Leukemia' was kept in its standard Title Case singular form.
    *   **Indication 2**: '[Pediatric Patients] With T315I Mutation [Acute Lymphoblastic Leukemia]'
        *   The context implies this group is also 'Pediatric' with 'Acute Lymphoblastic Leukemia'.
        *   'T315I Mutation' was normalized to 'T315I-Mutated' following the 'Gene type' rule for mutations (ID: 30), which specifies the '<GENE>-Mutated' format.
5.  **Final Construction**: The normalized components for both indications were assembled in the correct clinical order (Age -> State -> Genetic Marker -> Disease). The two resulting indications were then combined into a single string using the required ';;' separator.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly format the 'Pediatric' patient subgroup qualifier.""}, {'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory', 'Resistance', 'Relapse'], 'reason': ""To standardize the terms 'Relapsed/Resistant/Intolerant' into a clinically accepted format.""}, {'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To apply the standard abbreviation and formatting for 'Philadelphia Chromosome-Positive'.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the 'T315I Mutation' into the standard '<GENE>-Mutated' format.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group Rule ID: 295'}, {'component': 'Relapsed/Resistant/Intolerant', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rules for standardizing treatment status.'}, {'component': 'Philadelphia Chromosome-Positive', 'type': 'Chromosome Type', 'normalized_form': 'Ph Chromosome-Positive', 'rule_applied': 'Chromosome type Rule ID: 81'}, {'component': 'T315I Mutation', 'type': 'Gene Mutation', 'normalized_form': 'T315I-Mutated', 'rule_applied': 'Gene type Rule ID: 30'}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic formatting rule (Title Case, singular).'}]",2
410383,Kidney Transplantation: New Translational Insights,Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database,,,,True,none,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database', and the session title, 'Kidney Transplantation: New Translational Insights', both revolve around the concept of 'Kidney Transplant'.

Step 2: I identified 'Kidney Transplant Recipients' and 'Kidney Transplantation' as the key patient population descriptors.

Step 3: To determine how to handle these terms, I used the `get_indication_rules` tool for the category 'Treatment Set-up' and subcategory 'Transplant Status'.

Step 4: The retrieved rules (e.g., Rule ID 232 for 'Post-Transplant') clearly state that transplant-related statuses should be excluded from the final indication because they describe a procedural or temporal status rather than a distinct clinical disease entity. The generic exclusion rules also state to exclude 'Procedural/Temporal Qualifiers'.

Step 5: Applying this rule, I must exclude 'Kidney Transplant Recipients' from the abstract title and 'Kidney Transplantation' from the session title. After excluding these terms, neither title contains any remaining disease or disorder. Therefore, a valid medical indication cannot be extracted from either source.

Step 6: Since no indication could be formed, the selected source is 'none' and the generated indication is an empty string.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine the correct handling of terms like 'Kidney Transplant Recipients' and 'Kidney Transplantation'.""}]","[{'component': 'Kidney Transplant Recipients', 'type': 'Patient Sub-Group', 'normalized_form': '', 'rule_applied': 'Rule 232 (Post-Transplant) and Generic Exclusion Rule for Procedural/Temporal Qualifiers. The term describes a patient status based on a past procedure and is not a disease.'}, {'component': 'Kidney Transplantation', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Rule 232 (Post-Transplant) and Generic Exclusion Rule for Procedural/Temporal Qualifiers. The term describes a medical procedure, not a disease.'}]",2
377619,Bleeding disorders (congenital and acquired),Discontinuation Of Treatment With Thrombopoietin Receptor Agonists In Patients With Immune Thrombocytopenia: A Single-Center Clinical Experience,Immune Thrombocytopenia,Immune Thrombocytopenia,Immune Thrombocytopenia,True,abstract_title,"Step 1: The abstract title contains the specific disease 'Immune Thrombocytopenia', while the session title contains a broader category 'Bleeding disorders'. Following the single-source principle, the abstract title is selected for extraction.
Step 2: The core disease component identified in the abstract title is 'Immune Thrombocytopenia'. Other phrases like 'Discontinuation Of Treatment With Thrombopoietin Receptor Agonists' and 'A Single-Center Clinical Experience' are identified as procedural/treatment context and study methodology, respectively.
Step 3: I retrieved rules for 'Patient Sub-Group' and 'Disease Characterisation' to ensure no specific qualifiers were missed. The retrieved rules were not applicable to the identified components.
Step 4: The generic exclusion rules were applied. The procedural/temporal qualifier 'Discontinuation Of Treatment With...' was excluded. The study methodology 'A Single-Center Clinical Experience' was also excluded.
Step 5: The remaining component 'Immune Thrombocytopenia' was formatted according to the generic rules: Title Case was verified, and the term is already in its singular form.
Step 6: A quality check confirmed that the single-source principle was followed, all non-diagnostic elements were excluded, and the final indication is a clinically valid, standardized term.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check if any specific disease characterization rules apply to the term 'Immune'.""}]","[{'component': 'Immune Thrombocytopenia', 'type': 'Disease', 'normalized_form': 'Immune Thrombocytopenia', 'rule_applied': 'Generic Rule - Casing and Singular Form'}, {'component': 'Discontinuation Of Treatment With Thrombopoietin Receptor Agonists', 'type': 'Procedural/Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule - Exclusion of procedural/temporal qualifiers'}]",2
213784,MP26: Stone Disease: Epidemiology & Evaluation I,Rural Hospital Location is Associated with Higher Reported Prices for Ureteroscopy with Laser Lithotripsy Among Commercially Insured Patients,Stone Disease,Stone Disease,Stone Disease,True,session_title,"Step 1: The abstract title 'Rural Hospital Location is Associated with Higher Reported Prices for Ureteroscopy with Laser Lithotripsy Among Commercially Insured Patients' does not contain a specific disease term; it describes a procedure and a patient population based on insurance. 
Step 2: The session title 'MP26: Stone Disease: Epidemiology & Evaluation I' explicitly mentions 'Stone Disease'.
Step 3: Following the Single-Source Extraction Principle, the session title is selected as it is the only source containing a valid disease.
Step 4: The term 'Stone Disease' is extracted. The other parts of the title ('MP26', 'Epidemiology & Evaluation I') are excluded as they represent a session code and study methodology, not part of the clinical indication.
Step 5: The extracted term is already in the correct singular and Title Case format.",[],"[{'component': 'Stone Disease', 'type': 'Disease', 'normalized_form': 'Stone Disease', 'rule_applied': 'Generic rule: Use disease term from the selected source.'}]",1
394009,"Nsclc, Metastatic",Challenge Of Systemic First-Line Treatment Of Elderly Lung Cancer Patients,First-Line;;Elderly;;Lung Cancer,First-Line Elderly Lung Cancer,First-Line Elderly Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title ('Challenge Of Systemic First-Line Treatment Of Elderly Lung Cancer Patients') and the session title ('Nsclc, Metastatic') both contain valid disease terms.
2. **Select Source**: According to the single-source principle, the abstract title is preferred when it contains a disease. I selected the abstract title as it provides more specific patient subgroup and treatment context information.
3. **Identify Components**: From the abstract title, I identified the following components: 'First-Line' (Line of treatment), 'Elderly' (Age Group), and 'Lung Cancer' (Disease).
4. **Retrieve Relevant Rules**: I retrieved rules for the 'Age Group' category with the subcategory 'Elderly' to standardize the age descriptor. I also retrieved rules for 'Treatment Set-up' with the subcategory 'Line of treatment' to handle the 'First-Line' descriptor.
5. **Apply Rules**:
   - **Generic Rules**: I applied Title Case, converted the disease to its singular form ('Lung Cancer'), and excluded non-diagnostic words like 'Challenge Of', 'Systemic Treatment Of', and 'Patients'.
   - **Age Group Rules**: Based on the retrieved rules (e.g., Rule ID 299), 'Elderly' is the correct standardized term and should be included as a prefix.
   - **Treatment Set-up Rules**: Based on the retrieved rules (e.g., Rule ID 200), 'First-Line' is the correct standardized, hyphenated term. The rules indicate it should be placed before other descriptors.
6. **Construct Indication**: I assembled the components in the standard order: Line of Treatment, then Patient Subgroup, then Disease. This resulted in 'First-Line' + 'Elderly' + 'Lung Cancer'.
7. **Quality Check**: The final indication 'First-Line Elderly Lung Cancer' adheres to all formatting and content rules. It is clinically accurate, derived from a single source, and correctly formatted.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To correctly format the patient age group descriptor 'Elderly'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To correctly format the 'First-Line' treatment descriptor.""}]","[{'component': 'First-Line', 'type': 'Line of Treatment', 'normalized_form': 'First-Line', 'rule_applied': ""Treatment Set-up Rule ID 200: Standardize to 'First-Line' and place at the beginning of the indication.""}, {'component': 'Elderly', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group Rule ID 299: Standardize to 'Elderly' and use as a prefix.""}, {'component': 'Lung Cancer', 'type': 'Disease', 'normalized_form': 'Lung Cancer', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}]",2
344862,Targeting the Tumor Microenvironment,"Mini-tumors: Pre-clinical HCI assays to screen anti-cancer drugs in the context of organoids, cancer-associated fibroblasts and immune cells",cancer,Cancer,Cancer,True,abstract_title,"Step 1: The abstract title was selected as the source because it contains the term 'anti-cancer drugs', which clearly indicates the disease context, whereas the session title refers to the 'Tumor Microenvironment', a biological context rather than a specific disease.
Step 2: The abstract title does not specify a particular type of cancer but refers to a method for screening 'anti-cancer drugs'.
Step 3: According to the generic rules, when only a therapeutic area is mentioned without a specific disease, a valid overarching disease term should be used. The term 'anti-cancer' falls under the therapeutic area of Oncology.
Step 4: The 'Therapeutic Area Fallback' rule was applied, which maps 'Oncology' to the indication 'Cancer'.
Step 5: The final indication was formatted to 'Cancer' in Title Case and singular form.",[],"[{'component': 'anti-cancer', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': 'Therapeutic Area Fallback'}]",1
148257,Myeloma And Other Monoclonal Gammopathies - Clinical,Overall And Complete Response Rates As Potential Surrogates For Overall Survival In Relapsed Refractory Multiple Myeloma,Relapsed;;Refractory;;Multiple Myeloma,Relapsed Refractory Multiple Myeloma,Relapsed/Refractory Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains a specific disease, 'Multiple Myeloma', so it was chosen as the source according to the single-source principle.
2.  **Component Identification**: I identified two key components in the abstract title: the disease 'Multiple Myeloma' and the patient subgroup/disease state 'Relapsed Refractory'.
3.  **Rule Retrieval**: I retrieved rules for the 'Occurrence' category, specifically for 'Recurrent/Refractory' terms, to understand how to format phrases like 'Relapsed Refractory'.
4.  **Rule Application**: 
    *   The retrieved rules guide the normalization of such terms. I standardized 'Relapsed Refractory' to 'Relapsed/Refractory'.
    *   Generic rule for Title Case was applied to the entire indication.
    *   Generic rule for singular form was checked; 'Myeloma' is already singular.
5.  **Indication Construction**: The normalized disease state 'Relapsed/Refractory' was prepended to the disease name 'Multiple Myeloma' to form the final indication.
6.  **Quality Check**: The final indication was checked for compliance with all formatting, exclusion, and clinical accuracy rules. It adheres to the single-source principle, uses correct casing and formatting, and accurately represents the clinical condition described.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To determine the correct formatting for the term 'Relapsed Refractory'.""}]","[{'component': 'Relapsed Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rule for standardizing recurrent/refractory terms.'}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
295712,"Empowering young cancer nurses academically, clinically and in career progression",The impact of an Education WhatsApp Group to support nurses working in an acute oncology/haematology setting during the Covid-19 pandemic,Covid-19,Covid-19 Infection,Cancer;;Hematologic Malignancy,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains more specific medical terms ('acute oncology/haematology') compared to the session title ('cancer').
Step 2: The term 'oncology/haematology' was identified as representing two distinct therapeutic areas.
Step 3: According to the therapeutic area fallback rule, 'oncology' is mapped to the general disease term 'Cancer'.
Step 4: In the context of an oncology setting, 'haematology' is interpreted as 'Hematologic Malignancy'.
Step 5: The qualifier 'acute' was excluded because it describes the clinical 'setting' rather than being an intrinsic part of the disease name itself, aligning with the principle of excluding non-diagnostic context.
Step 6: The two extracted indications were formatted in Title Case, kept in singular form, and separated by ';;' as per the multiple disease rule.",[],"[{'component': 'oncology', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': 'Generic Rule: Therapeutic Area Fallback'}, {'component': 'haematology', 'type': 'Therapeutic Area', 'normalized_form': 'Hematologic Malignancy', 'rule_applied': 'Clinical Interpretation in an Oncology Context'}, {'component': 'acute', 'type': 'Contextual Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Non-Diagnostic Items (describes setting, not disease)'}]",1
230183,Breast Cancer-Metastatic,Treatment of alpelisib induced hyperglycemia with sodium-glucose cotransporter-2 inhibitors: A single institution experience.,hyperglycemia ,Hyperglycemia ,Metastatic Breast Cancer,True,session_title,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'Treatment of alpelisib induced hyperglycemia...', describes a study on managing a treatment side effect (hyperglycemia), not a primary disease indication. The session title, 'Breast Cancer-Metastatic', clearly states a primary disease.
Step 2: Based on the Single-Source Extraction Principle, I selected the session title as it contains the core disease entity.
Step 3: I identified the components in the session title as 'Breast Cancer' (disease) and 'Metastatic' (disease state).
Step 4: I retrieved the specific rule for 'Metastatic' using the get_indication_rules tool, which confirmed the standard format is 'Metastatic <Disease>'.
Step 5: I applied the retrieved rule and the generic formatting rules (Title Case, singular form). The hyphen in 'Breast Cancer-Metastatic' was interpreted as a separator for the qualifier.
Step 6: I constructed the final indication by combining the components according to the rules, resulting in 'Metastatic Breast Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'Metastatic' as a prefix to the disease name.""}]","[{'component': 'Breast Cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic rule: Title Case, Singular form.'}, {'component': 'Metastatic', 'type': 'Disease State', 'normalized_form': 'Metastatic', 'rule_applied': ""Rule ID 141: Format as 'Metastatic <Primary-Disease-Name>'.""}]",2
394023,"Nsclc, Metastatic",Gut Microbiome Is Associated With The Clinical Response To Anti-Pd-1 Based Immunotherapy In Untreated Advanced Non-Small-Cell Lung Cancer,Untreated;;Advanced;;Non-Small-Cell Lung Cancer,Untreated Advanced Non-Small-Cell Lung Cancer,Untreated Advanced Non-Small-Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease term ('Non-Small-Cell Lung Cancer') and provides more detail than the session title.
2. **Component Identification**: I identified three key components in the abstract title: the treatment status 'Untreated', the disease stage 'Advanced', and the disease itself 'Non-Small-Cell Lung Cancer'.
3. **Rule Retrieval**: I retrieved rules for treatment status and stage. Specifically, the rule for 'Untreated' (ID: 196) from the 'Treatment based' category dictates that 'Untreated' should be placed at the beginning of the indication.
4. **Rule Application & Normalization**: 
   - Applied the 'Untreated' rule to position it at the start.
   - 'Advanced' is a standard stage descriptor and is placed before the disease name.
   - The disease name 'Non-Small-Cell Lung Cancer' was already in the correct singular and title case format.
   - Generic rules for Title Case and singular form were applied to the entire indication.
5. **Indication Construction**: The components were assembled in the standard clinical order: [Treatment Status] [Stage] [Disease]. This resulted in 'Untreated Advanced Non-Small-Cell Lung Cancer'.
6. **Quality Check**: The final indication adheres to the single-source principle, uses correct formatting (Title Case, no trailing spaces), and accurately reflects the patient population described in the title.","[{'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To find the correct formatting and placement for the term 'Untreated'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To find rules related to the formatting of the disease stage 'Advanced'.""}]","[{'component': 'Untreated', 'type': 'Treatment Status', 'normalized_form': 'Untreated', 'rule_applied': ""Rule ID: 196 - 'Untreated' is placed at the beginning of the indication.""}, {'component': 'Advanced', 'type': 'Stage', 'normalized_form': 'Advanced', 'rule_applied': 'Standard clinical nomenclature for staging.'}, {'component': 'Non-Small-Cell Lung Cancer', 'type': 'Disease', 'normalized_form': 'Non-Small-Cell Lung Cancer', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
410410,Glomerular Diseases: From Multiomics to Mechanisms,IFNg-Induced APOL1 Expression and Pyroptotic Angiopathy in Human Kidney Organoids Mirrors a Nephrotic Gene Signature in Patient Biopsies,Glomerular Disease,Glomerular Disease,Glomerular Disease,True,session_title,"Step 1: Analyze Input Titles
- The abstract_title is 'IFNg-Induced APOL1 Expression and Pyroptotic Angiopathy in Human Kidney Organoids Mirrors a Nephrotic Gene Signature in Patient Biopsies'. It contains the term 'Pyroptotic Angiopathy', which is a pathological condition. It also mentions a 'Nephrotic Gene Signature', which is a characteristic rather than a standalone disease.
- The session_title is 'Glomerular Diseases: From Multiomics to Mechanisms'. It contains the clear and clinically established disease category 'Glomerular Diseases'.

Step 2: Select the Source
- According to the Single-Source Extraction Principle, the abstract title should be preferred as it contains a disease term ('Angiopathy').
- However, the term 'Pyroptotic Angiopathy' describes a specific, mechanism-based pathological finding within a preclinical model ('in Human Kidney Organoids'). The title's focus is on mirroring a 'Nephrotic Gene Signature', not on treating patients with this specific type of angiopathy.
- The session title, 'Glomerular Diseases', provides a broader, more clinically relevant context for the research described in the abstract. It represents the overarching therapeutic area and patient population.
- In this case, the session title provides a more clinically valid and standard indication than the specific mechanistic term from the abstract title. Therefore, the session title is selected as the source for the indication.

Step 3: Construct Indication
- The disease term identified in the session title is 'Glomerular Diseases'.
- Applying the generic rule for singular form, 'Glomerular Diseases' is converted to 'Glomerular Disease'.
- Applying the generic rule for casing, the indication is formatted to 'Glomerular Disease'.

Step 4: Quality Check
- The final indication 'Glomerular Disease' is a single, clinically valid term.
- It adheres to all formatting rules (Title Case, singular form, no excluded terms).
- The selection of the session title is justified by the goal of extracting a clinically valid indication, as the abstract title focuses on a preclinical mechanism.",[],"[{'component': 'Glomerular Diseases', 'type': 'Disease', 'normalized_form': 'Glomerular Disease', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'Pyroptotic Angiopathy', 'type': 'Disease', 'normalized_form': 'Pyroptotic Angiopathy', 'rule_applied': 'Discarded in favor of the more clinically relevant term from the session title.'}]",1
230186,Care Delivery and Regulatory Policy,Characteristics and outcomes of COVID-19 in adult cancer patients: Tertiary cancer center experience.,COVID-19;;adult;;cancer,COVID-19 Infection;;Adult Cancer,Adult COVID-19;;Adult Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'Characteristics and outcomes of COVID-19 in adult cancer patients: Tertiary cancer center experience.' was chosen as it contains specific medical conditions ('COVID-19', 'cancer'), whereas the session title 'Care Delivery and Regulatory Policy' does not.
2.  **Component Identification**: The abstract title identifies two distinct medical conditions ('COVID-19' and 'cancer') within a specific patient population ('adult cancer patients').
3.  **Rule Retrieval**: Rules for the 'Age Group' category were retrieved to handle the term 'adult'. Rules for 'Patient with two different Disease' were also queried to confirm handling of concurrent conditions.
4.  **Rule Application**:
    *   **Multiple Diseases**: The generic rule for multiple diseases was applied. The title describes a cohort of patients defined by two conditions (cancer and COVID-19). Both are extracted as separate indications, separated by ';;'.
    *   **Age Group**: The retrieved rule for 'Adult' (ID: 289) specifies prefixing the indication with 'Adult'. This prefix is applied to both identified conditions.
    *   **Formatting**: Generic rules were applied to ensure Title Case ('Cancer') and singular form. 'COVID-19' is maintained in its standard uppercase form.
    *   **Exclusion**: The phrase 'Tertiary cancer center experience' describes the study setting and is correctly excluded from the indication.
5.  **Indication Construction**: The components were combined according to the rules: the 'Adult' prefix was added to both 'COVID-19' and 'Cancer', and the two resulting indications were joined with the ';;' separator.
6.  **Final Output**: The final generated indication is 'Adult COVID-19;;Adult Cancer'.","[{'category': 'Patient with two different Disease', 'subcategories': [], 'reason': 'To check for specific rules on handling patients with concurrent diseases like COVID-19 and cancer.'}, {'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'adult' patient subgroup descriptor.""}]","[{'component': 'COVID-19', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic rule for disease identification.'}, {'component': 'cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic rule for Title Case and singular form.'}, {'component': 'adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule (ID: 289) to prefix the indication with 'Adult'.""}]",2
344870,Targeting the Tumor Microenvironment,"A half-life extended, tumor-activated IL-12 increased the infiltration of effector immune cells into the tumor microenvironment and demonstrated anti-tumor activity in syngeneic mouse models",tumor ,Tumor ,Tumor,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains the term 'tumor', indicating a disease context. The session title also contains 'Tumor' but the abstract title is preferred.
Step 2: The core disease term identified is 'tumor'.
Step 3: Generic rules were applied. The term was converted to singular (already singular) and Title Case, resulting in 'Tumor'.
Step 4: The phrase 'in syngeneic mouse models' was identified as a study methodology/model descriptor and excluded as per the generic exclusion rules, as it does not define a human patient subgroup.
Step 5: The final indication is constructed as 'Tumor', representing the general disease area being investigated.",[],"[{'component': 'tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Singular Form'}, {'component': 'in syngeneic mouse models', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclude Non-Diagnostic Items (Study methodologies)'}]",1
394030,"Nsclc, Metastatic","Harmoni: Randomized, Double-Blind, Multi-Center, Phase III Clinical Study Of Ivonescimab Or Placebo Combined With Pemetrexed And Carboplatin In Patients With Egfr-Mutant Locally Advanced Or Metastatic Non-Squamous Nsclc Who Have Progression Following Egfr-Tki Treatment", Egfr;;Mutant;;Locally Advanced;;Metastatic;;Non-Squamous Nsclc,EGFR-Mutant Locally Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer,EGFR-Mutant Progressive Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title as it contains a detailed description of the disease and patient population, adhering to the single-source principle.
2.  **Component Identification**: I identified the following key components from the abstract title: 'Egfr-Mutant' (Gene Mutation), 'Locally Advanced Or Metastatic' (Disease Stage/Occurrence), 'Non-Squamous Nsclc' (Disease), and 'Who Have Progression Following Egfr-Tki Treatment' (Progression/Treatment Status).
3.  **Rule Retrieval**: I retrieved rules for 'Gene type', 'Stage', 'Occurrence', and 'Treatment based' to guide the standardization of these components.
4.  **Rule Application & Standardization**:
    *   **Disease Name**: 'Nsclc' was expanded to its full form 'Non-Small Cell Lung Cancer' and standardized to Title Case along with its subtype, resulting in 'Non-Squamous Non-Small Cell Lung Cancer'.
    *   **Gene Mutation**: 'Egfr-Mutant' was standardized to 'EGFR-Mutant', ensuring the gene symbol is in uppercase as per standard convention.
    *   **Stage/Occurrence**: The phrase 'Locally Advanced Or Metastatic' was identified. While Rule 177 suggests consolidating 'advanced' and 'metastatic' into 'Locally Advanced Metastatic', the explicit use of 'or' in a clinical trial title is significant and was retained for precision. The phrase was converted to Title Case: 'Locally Advanced or Metastatic'.
    *   **Progression Status**: The clause 'Who Have Progression Following Egfr-Tki Treatment' clearly defines the disease state. Based on Occurrence Rule 184 ('Progressive'), this was concisely and accurately standardized to the term 'Progressive'.
5.  **Indication Construction**: The standardized components were assembled in a clinically logical order: Gene Mutation -> Progression Status -> Stage -> Disease Name. This resulted in the final indication: 'EGFR-Mutant Progressive Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer'.
6.  **Final Quality Check**: The final indication is fully compliant with all generic rules (Title Case, singular form, no excluded terms) and accurately represents the specific patient population from the source title.","[{'category': 'Gene type', 'subcategories': ['Gene Mutant', 'Gene Mutated'], 'reason': ""To standardize the formatting of 'Egfr-Mutant'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To handle the 'Locally Advanced' component.""}, {'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms', 'Progression-Related'], 'reason': ""To standardize 'Metastatic' and 'Progression Following... Treatment'.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To correctly interpret the patient's treatment history ('Following Egfr-Tki Treatment').""}]","[{'component': 'Egfr-Mutant', 'type': 'Gene Mutation', 'normalized_form': 'EGFR-Mutant', 'rule_applied': 'Generic rule for gene symbol capitalization.'}, {'component': 'Locally Advanced Or Metastatic', 'type': 'Disease Stage/Occurrence', 'normalized_form': 'Locally Advanced or Metastatic', 'rule_applied': ""Occurrence Rule ID 177 (adapted to retain 'or') and Title Case rule.""}, {'component': 'Non-Squamous Nsclc', 'type': 'Disease', 'normalized_form': 'Non-Squamous Non-Small Cell Lung Cancer', 'rule_applied': 'Generic rule for Title Case and abbreviation expansion.'}, {'component': 'Who Have Progression Following Egfr-Tki Treatment', 'type': 'Progression Status', 'normalized_form': 'Progressive', 'rule_applied': ""Occurrence Rule ID 184 ('Progressive') to concisely represent the patient's disease state.""}]",2
394031,"Nsclc, Metastatic",Tropion-Lung07: A Phase III Trial Of Datopotamab Deruxtecan (Dato-Dxd) Plus Pembrolizumab (Pembro) With Or Without Platinum Chemotherapy (Pt-Ct) As First-Line (1L) Therapy In Advanced/Metastatic (Adv/Met) Non-Small Cell Lung Cancer (Nsclc) With Pd-L1 Expression,First-Line;;Advanced;;Metastatic;;Non-Small Cell Lung Cancer,First-Line Advanced/Metastatic Non-Small Cell Lung Cancer,First-Line Advanced Metastatic PD-L1-Positive Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease, 'Non-Small Cell Lung Cancer', and provides more detail than the session title, adhering to the single-source principle.
2. **Component Identification**: The following key components were identified in the abstract title: 'First-Line (1L)', 'Advanced/Metastatic (Adv/Met)', 'Non-Small Cell Lung Cancer (Nsclc)', and 'With Pd-L1 Expression'.
3. **Rule Retrieval**: I retrieved rules for 'Treatment Set-up' (specifically 'Line of treatment'), 'Occurrence' (for 'Metastasis-Related Terms' and 'Progression-Related'), and 'Biomarker' to guide normalization.
4. **Component Normalization & Rule Application**:
   - **Line of Treatment**: Based on Treatment Set-up Rule ID 201, '1L' was normalized to 'First-Line'. Rule ID 199 confirmed that 'First-Line' should be retained because it modifies the generic term 'Therapy', not a specific drug.
   - **Disease State**: 'Advanced/Metastatic (Adv/Met)' was combined and normalized to 'Advanced Metastatic', a standard clinical descriptor for this stage of cancer.
   - **Biomarker**: 'With Pd-L1 Expression' was interpreted as a positive biomarker status. Following common clinical terminology patterns (e.g., HER2-Positive), it was normalized to 'PD-L1-Positive'. The casing for 'PD-L1' was standardized to all-caps as per generic rules.
   - **Disease Name**: 'Non-Small Cell Lung Cancer (Nsclc)' was used as the core disease, with the abbreviation removed and Title Case applied.
5. **Final Indication Construction**: The normalized components were assembled in the standard clinical order: Line of Treatment -> Disease State -> Biomarker -> Disease Name. This resulted in the final, clinically precise indication.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To handle the 'First-Line (1L)' component.""}, {'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms', 'Progression-Related'], 'reason': ""To handle the 'Advanced/Metastatic (Adv/Met)' component.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To find rules for handling the 'Pd-L1 Expression' component.""}]","[{'component': 'First-Line (1L)', 'type': 'Line of Treatment', 'normalized_form': 'First-Line', 'rule_applied': 'Treatment Set-up Rule ID 201'}, {'component': 'Advanced/Metastatic (Adv/Met)', 'type': 'Disease State', 'normalized_form': 'Advanced Metastatic', 'rule_applied': 'Generic normalization for clinical clarity.'}, {'component': 'Non-Small Cell Lung Cancer (Nsclc)', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic Rule: Casing and abbreviation removal.'}, {'component': 'With Pd-L1 Expression', 'type': 'Biomarker', 'normalized_form': 'PD-L1-Positive', 'rule_applied': 'Generic Rule: Biomarker casing and standardization to common clinical phrasing.'}]",2
148272,Myeloma And Other Monoclonal Gammopathies - Clinical,Survival And Outcomes Of Newly-Diagnosed Multiple Myeloma Patients Stratified By Transplant Status Diagnosed Between 2007-2018: Real-World Analysis From The Canadian Myeloma Research Group Database,Newly-Diagnosed;;Multiple Myeloma,Newly-Diagnosed Multiple Myeloma,Newly Diagnosed Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Survival And Outcomes Of Newly-Diagnosed Multiple Myeloma Patients...') was chosen as the source because it contains a specific disease term ('Multiple Myeloma'), following the single-source extraction principle which prioritizes the abstract title.
2. **Component Identification**: Key components identified in the abstract title were the disease 'Multiple Myeloma' and the qualifier 'Newly-Diagnosed'. The phrase 'Stratified By Transplant Status' was identified as a methodological descriptor.
3. **Rule Retrieval**: To ensure correct handling of these components, I retrieved rules for 'Diagnosis Status' and 'Transplant Status'.
   - `get_indication_rules(category=""Treatment based"", subcategories=[""Diagnosis Status""])` was called for 'Newly-Diagnosed'.
   - `get_indication_rules(category=""Treatment Set-up"", subcategories=[""Transplant Status""])` was called for 'Transplant Status'.
4. **Rule Application**:
   - The rule for 'Newly Diagnosed' (ID: 193) confirms that it should be included as a prefix to the disease name.
   - The rules for 'Transplant Status' (IDs: 228-233) indicate that such terms should be excluded as they describe procedural suitability or study methodology, not a core part of the clinical indication.
   - Generic rules were applied: 'patients' was converted to singular 'patient' and then removed as it's a population descriptor, not part of the disease name. The disease 'Multiple Myeloma' is already singular. Title Case was applied.
5. **Indication Construction**: The qualifier 'Newly Diagnosed' was combined with the disease 'Multiple Myeloma'. The descriptor 'Transplant Status' was excluded per the rules. The final indication was formatted to 'Newly Diagnosed Multiple Myeloma'.
6. **Quality Check**: The final indication adheres to all formatting and clinical accuracy requirements. It is derived from a single source and correctly excludes non-clinical information.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To verify the correct formatting and inclusion of the term 'Newly-Diagnosed'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine if 'Transplant Status' should be included in the final indication.""}]","[{'component': 'Newly-Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - 'Newly Diagnosed' should be prefixed to the disease name.""}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}, {'component': 'Transplant Status', 'type': 'Treatment Status', 'normalized_form': '', 'rule_applied': 'Rule IDs: 228-233 - Transplant status descriptors are excluded as they represent procedural suitability, not a disease state.'}]",3
262962,Acute myeloid leukemia - Clinical,Acute Promyelocytic Leukemia And Thrombosis: How To Identify The High-Risk Patients?,Acute Promyelocytic Leukemia;;Thrombosis,Acute Promyelocytic Leukemia;;Thrombosis,High-Risk Acute Promyelocytic Leukemia;;Thrombosis,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Acute Promyelocytic Leukemia And Thrombosis: How To Identify The High-Risk Patients?') was chosen over the session title ('Acute myeloid leukemia - Clinical') because it is more specific and contains all the necessary components for a detailed indication, adhering to the single-source principle.
2. **Component Identification**: I identified two distinct medical conditions: 'Acute Promyelocytic Leukemia' and 'Thrombosis'. I also identified a patient subgroup qualifier: 'High-Risk'.
3. **Rule Retrieval**: To ensure correct formatting for the risk qualifier, I retrieved rules for the 'Risk' category, specifically for 'High-Risk'.
4. **Rule Application and Construction**:
   - The generic rule for multiple diseases was applied, requiring both 'Acute Promyelocytic Leukemia' and 'Thrombosis' to be extracted and separated by ';;'.
   - The retrieved rule for 'High-Risk' (Rule ID: 122) guided the normalization of 'high-risk' to 'High-Risk' and its placement as a prefix to the primary associated disease.
   - The qualifier 'High-Risk' is contextually linked to the patients with 'Acute Promyelocytic Leukemia', resulting in the combined indication 'High-Risk Acute Promyelocytic Leukemia'.
   - 'Thrombosis' is extracted as a second, separate indication.
5. **Final Formatting**: The final output was formatted using Title Case, singular forms for diseases, and the ';;' separator, with all non-essential terms like 'patients' excluded as per generic rules.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To correctly format and apply the 'High-Risk' patient subgroup qualifier.""}]","[{'component': 'Acute Promyelocytic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Promyelocytic Leukemia', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'Thrombosis', 'type': 'Disease', 'normalized_form': 'Thrombosis', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'High-Risk', 'type': 'Patient Subgroup (Risk)', 'normalized_form': 'High-Risk', 'rule_applied': 'Risk rule (ID: 122) for normalization and placement.'}]",2
181042,Health Services Research-Non-Malignant Conditions: Poster I,Improving Completion Rates of Transcranial Doppler Ultrasounds in Children with Sickle Cell Disease Using Quality Improvement Efforts: In-Clinic Vs. Population-Based Assessments,Children;;Sickle Cell Disease ,Childhood Sickle Cell Disease ,Childhood Sickle Cell Disease,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease ('Sickle Cell Disease'), whereas the session title contains a broad, non-specific category ('Non-Malignant Conditions').
Step 2: The components identified in the abstract title were the disease 'Sickle Cell Disease' and the patient subgroup 'Children'.
Step 3: The `get_indication_rules` tool was used for the 'Age Group' category with subcategories 'Childhood' and 'Pediatric' to determine the correct handling of the term 'Children'.
Step 4: Based on the retrieved rules (specifically Rule ID 293 and 294), the term 'Children' is standardized to 'Childhood' and placed as a prefix to the disease name. The prepositional phrase 'in Children with' is removed and replaced by the single prefix.
Step 5: The final indication was constructed by combining the normalized age group and the disease, resulting in 'Childhood Sickle Cell Disease'. This adheres to Title Case and singular form generic rules.","[{'category': 'Age Group', 'subcategories': ['Childhood', 'Pediatric'], 'reason': ""To correctly format the patient subgroup 'Children'.""}]","[{'component': 'Children', 'type': 'Age Group', 'normalized_form': 'Childhood', 'rule_applied': ""Age Group Rule ID 293/294: Replace 'Children' with the prefix 'Childhood'.""}, {'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic Rule: Use Title Case and singular form.'}]",2
181043,Health Services Research-Non-Malignant Conditions: Poster I,Integrative Hematology Oncology Fellowship Program: A National Survey Based Analysis of Need,,,Non-Malignant Condition,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Integrative Hematology Oncology Fellowship Program: A National Survey Based Analysis of Need' and the session title is 'Health Services Research-Non-Malignant Conditions: Poster I'.
2.  **Select Source**: According to the Single-Source Extraction Principle, the abstract title is preferred if it contains a disease/condition term. The abstract title contains 'Hematology Oncology', which are medical specialties (therapeutic areas), not specific diseases. The rest of the title describes a survey about a fellowship program. Since it lacks a direct disease term, I fall back to the session title.
3.  **Identify Components**: The session title contains the term 'Non-Malignant Conditions'.
4.  **Apply Rules**: I applied the generic rules to this component. The 'Singular Form' rule was used to convert 'Conditions' to 'Condition'. The 'Casing' rule confirmed that 'Non-Malignant Condition' follows Title Case. Methodological terms like 'Health Services Research' and 'Poster I' were excluded.
5.  **Construct Indication**: The identified and normalized component 'Non-Malignant Condition' is the final indication.
6.  **Quality Check**: The final indication is clinically consistent with the session title's context and adheres to all formatting and extraction rules. Using the session title avoids the clinical contradiction of extracting 'Cancer' (from 'Oncology' in the abstract title) for a presentation explicitly categorized under 'Non-Malignant Conditions'.",[],"[{'component': 'Non-Malignant Conditions', 'type': 'Disease Characterisation', 'normalized_form': 'Non-Malignant Condition', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Casing'}]",2
181049,Health Services Research-Non-Malignant Conditions: Poster I,The Telemedicine Experience for Individuals with Sickle Cell Disease,Sickle Cell Disease,Sickle Cell Disease,Sickle Cell Disease,True,abstract_title,"Step 1: The abstract title 'The Telemedicine Experience for Individuals with Sickle Cell Disease' was chosen as the source because it contains a specific disease name, 'Sickle Cell Disease', which is preferred over the broader category 'Non-Malignant Conditions' in the session title.
Step 2: The core disease 'Sickle Cell Disease' was identified. The surrounding text 'The Telemedicine Experience for Individuals with' was identified as contextual information about the study and patient population, not part of the clinical indication itself.
Step 3: Generic exclusion rules were applied to remove the non-diagnostic study methodology ('The Telemedicine Experience') and the general patient descriptor ('for Individuals with').
Step 4: The extracted disease name was checked against formatting rules. It is already in the correct singular form and Title Case.
Step 5: The final indication was constructed as 'Sickle Cell Disease' after removing all non-clinical text.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify how to handle descriptive phrases like 'Individuals with' and confirm they should be excluded as non-essential patient characterizations.""}]","[{'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic rule: Extract core disease name.'}, {'component': 'The Telemedicine Experience for Individuals with', 'type': 'Non-Diagnostic Information', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude non-diagnostic items and procedural/temporal qualifiers.'}]",2
377658,Acute myeloid leukemia - Clinical,Early Severe Adverse Events Of Acute Myeloid Leukemia Therapy Depending On The Induction Therapy Regimen,Acute Myeloid Leukemia ,Acute Myeloid Leukemia ,Acute Myeloid Leukemia,True,abstract_title,"Step 1: The abstract title contains the disease 'Acute Myeloid Leukemia', so it is selected as the primary source based on the single-source principle.
Step 2: The components identified in the abstract title are 'Early Severe Adverse Events' and 'Acute Myeloid Leukemia'.
Step 3: The phrase 'Early Severe Adverse Events' describes complications or adverse effects of therapy, not the disease itself. According to the generic exclusion rules, complications and adverse effects must be excluded.
Step 4: The term 'Acute' is an integral part of the disease name 'Acute Myeloid Leukemia' and is retained as per the disease characterization rules.
Step 5: The remaining term 'Acute Myeloid Leukemia' is already in the correct singular and Title Case format.
Step 6: The final indication is constructed from the core disease term after applying all relevant exclusion and formatting rules.","[{'category': 'Risk', 'subcategories': ['severe'], 'reason': ""To check how to handle the term 'Severe'. The retrieved rule was for 'High-Risk' and confirmed that 'Severe' in the context of 'Adverse Events' should not be part of the indication.""}]","[{'component': 'Severe Adverse Events', 'type': 'Adverse Effect', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude complications or adverse effects.'}, {'component': 'Acute Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': ""Generic Rule: Retain 'Acute' as it is part of the disease name. Formatting Rule: Apply Title Case.""}]",2
394045,Oesophagogastric Cancer,"Camrelizumab Plus Chemotherapy Versus Concurrent Chemoradiotherapy As Neoadjuvant Therapy For Resectable Thoracic Oesophageal Squamous Cell Cancer (Revo): A Multicenter, Randomized, Open-Label, Phase II Trial",Resectable;;Thoracic Oesophageal Squamous Cell Cancer ,Resectable Thoracic Oesophageal Squamous Cell Cancer ,Resectable Thoracic Oesophageal Squamous Cell Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title contains a specific disease ('Thoracic Oesophageal Squamous Cell Cancer'), making it the preferred source over the more general session title ('Oesophagogastric Cancer'), in accordance with the single-source principle.
2. **Component Identification**: From the abstract title, I identified the core disease 'Thoracic Oesophageal Squamous Cell Cancer' and a key patient subgroup qualifier 'Resectable'. Terms related to therapy ('Camrelizumab Plus Chemotherapy', 'Neoadjuvant Therapy') and study design ('Phase II Trial') were identified for exclusion.
3. **Rule Retrieval**: I retrieved rules for 'Resectable' under the 'Treatment Set-up' category to confirm its inclusion and formatting. I also checked 'Patient Sub-Group' rules for 'Disease Characterisation' to ensure terms like 'Thoracic' and 'Squamous Cell' are retained as they are integral parts of the disease definition.
4. **Rule Application**: 
   - The 'Resectable' rule (ID: 236) confirms that 'Resectable' should be kept as a prefix to the disease name.
   - Generic rules were applied: The disease term 'Cancer' is already singular. The final output was formatted to Title Case. Excluded terms related to treatment and study methodology.
5. **Indication Construction**: The components were assembled in the correct clinical order: Operative Status + Anatomic Site + Disease Name + Histology. This resulted in 'Resectable Thoracic Oesophageal Squamous Cell Cancer'.
6. **Quality Check**: The final indication is derived from a single source, is in singular Title Case, includes all relevant clinical descriptors, and excludes non-indication elements, adhering to all specified rules.","[{'category': 'Treatment Set-up', 'subcategories': ['Resectable', 'Treatment Status'], 'reason': ""To verify the handling of the term 'Resectable' found in the abstract title.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding histological subtypes like 'Squamous Cell' and anatomical sites like 'Thoracic'.""}]","[{'component': 'Resectable', 'type': 'Operative Status', 'normalized_form': 'Resectable', 'rule_applied': 'Treatment Set-up, Resectable Rule (ID: 236)'}, {'component': 'Thoracic Oesophageal Squamous Cell Cancer', 'type': 'Disease', 'normalized_form': 'Thoracic Oesophageal Squamous Cell Cancer', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}]",2
213817,"MP28: Health Services Research: Practice Patterns, Quality of Life and Shared Decision Making III","Burden of depression and anxiety in men with high-risk, intermediate-risk or low-risk prostate cancer",high-risk;;intermediate-risk;;low-risk;;prostate cancer,High-Risk Prostate Cancer;;Intermediate-Risk Prostate Cancer;;Low-Risk Prostate Cancer,Depression;;Anxiety;;High-Risk Prostate Cancer;;Intermediate-Risk Prostate Cancer;;Low-Risk Prostate Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Burden of depression and anxiety in men with high-risk, intermediate-risk or low-risk prostate cancer') contains specific disease terms ('depression', 'anxiety', 'prostate cancer'), while the session title does not. Therefore, the abstract title was selected as the source, adhering to the single-source principle.
2.  **Component Identification**: The selected title contains multiple medical conditions: 'depression', 'anxiety', and 'prostate cancer'. It also includes risk-based patient subgroups for prostate cancer: 'high-risk', 'intermediate-risk', and 'low-risk'. The gender descriptor 'men' was identified for exclusion.
3.  **Rule Retrieval**: To ensure correct formatting of the risk stratifiers, rules for the 'Risk' category were retrieved using `get_indication_rules(category='Risk', subcategories=['High-Risk', 'Low-Risk', 'Risk Types'])`.
4.  **Rule Application**:
    *   **Generic Exclusion Rule**: The sociodemographic term 'men' was excluded.
    *   **Generic Multiple Disease Rule**: 'Depression', 'Anxiety', and the various forms of 'Prostate Cancer' were identified as distinct indications to be extracted and separated by ';;'.
    *   **Retrieved Risk Rules (ID 122, 123, 129)**: These rules guided the normalization of 'high-risk', 'low-risk', and 'intermediate-risk' to 'High-Risk', 'Low-Risk', and 'Intermediate-Risk' respectively. Rule 129 specifically directs the creation of a separate indication for each risk level when multiple are mentioned for the same disease.
    *   **Generic Formatting Rules**: All terms were converted to Title Case and singular form.
5.  **Indication Construction**: The identified components were combined according to the applied rules. 'Depression' and 'Anxiety' were extracted as standalone indications. The prostate cancer indications were constructed by prepending the normalized risk level to the disease, resulting in three separate indications: 'High-Risk Prostate Cancer', 'Intermediate-Risk Prostate Cancer', and 'Low-Risk Prostate Cancer'.
6.  **Final Output**: All five indications were combined into a single string, delimited by ';;', resulting in the final output.","[{'category': 'Risk', 'subcategories': ['High-Risk', 'Low-Risk', 'Risk Types'], 'reason': ""To correctly format the risk stratifiers 'high-risk', 'intermediate-risk', and 'low-risk' found in the abstract title.""}]","[{'component': 'depression', 'type': 'Disease', 'normalized_form': 'Depression', 'rule_applied': 'Generic Title Case Rule'}, {'component': 'anxiety', 'type': 'Disease', 'normalized_form': 'Anxiety', 'rule_applied': 'Generic Title Case Rule'}, {'component': 'high-risk prostate cancer', 'type': 'Disease with Risk Subgroup', 'normalized_form': 'High-Risk Prostate Cancer', 'rule_applied': 'Risk Rule ID 122'}, {'component': 'intermediate-risk prostate cancer', 'type': 'Disease with Risk Subgroup', 'normalized_form': 'Intermediate-Risk Prostate Cancer', 'rule_applied': 'Risk Rule ID 129'}, {'component': 'low-risk prostate cancer', 'type': 'Disease with Risk Subgroup', 'normalized_form': 'Low-Risk Prostate Cancer', 'rule_applied': 'Risk Rule ID 123'}, {'component': 'men', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Gender'}]",2
312127,Ignite Session 8A,Genetic Interactions Between T-Cell Receptor Polymorphisms and HLA Amino Acids Contribute to the Risk of Rheumatoid Arthritis,Rheumatoid Arthritis,Rheumatoid Arthritis,Rheumatoid Arthritis,True,abstract_title,"Step 1: The abstract title contains the disease term 'Rheumatoid Arthritis', while the session title 'Ignite Session 8A' does not. Therefore, the abstract title was selected as the source based on the single-source extraction principle.
Step 2: The core disease 'Rheumatoid Arthritis' was identified in the abstract title.
Step 3: The phrase 'Risk of' was identified as a potential qualifier. I retrieved rules for the 'Risk' category to determine how to handle this phrase.
Step 4: The retrieved rules for 'Risk Types' apply to specific, established clinical risk stratifications like 'High-Risk' or 'Poor-Risk'. The phrase 'Risk of' describes the focus of the study (etiology) rather than a defined patient subgroup with the disease. Therefore, it is excluded from the final indication as per generic rules to only include the core disease.
Step 5: The extracted disease term 'Rheumatoid Arthritis' was formatted according to generic rules: it is already in singular form and Title Case. The final indication is 'Rheumatoid Arthritis'.","[{'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To determine how to handle the phrase 'Risk of' found in the abstract title.""}]","[{'component': 'Rheumatoid Arthritis', 'type': 'Disease', 'normalized_form': 'Rheumatoid Arthritis', 'rule_applied': 'Generic rule: Extract core disease.'}, {'component': 'Risk of', 'type': 'Qualifier', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude non-diagnostic study context. The retrieved specific risk rules did not apply to this general phrase.'}]",2
262973,Acute myeloid leukemia - Clinical,Efficacy Of Azacitidine And Venetoclax In Aml Patients May Be Limited By Interactionwith Posaconazole And Lack Of Standardised Treatment Protocol. Real World Data From 3 Major Centres In Singapore.,Aml,Acute Myeloid Leukemia,Acute Myeloid Leukemia,True,session_title,"Step 1: I analyzed both the abstract and session titles. The session title contains the full disease name 'Acute myeloid leukemia', while the abstract title uses the abbreviation 'Aml'.
Step 2: Following the single-source principle, I selected the session title as it provides the most direct and complete disease name.
Step 3: I identified the core disease component 'Acute myeloid leukemia' from the session title. The term '- Clinical' was identified as a non-diagnostic session descriptor to be excluded.
Step 4: I applied the generic formatting rules. I converted the disease name to Title Case ('Acute Myeloid Leukemia') and ensured it was in singular form.
Step 5: I constructed the final indication by taking the processed disease name and excluding the non-diagnostic term.
Step 6: A quality check confirmed that all rules were followed, resulting in the final, clean indication.",[],"[{'component': 'Acute myeloid leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'Clinical', 'type': 'Session Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Non-Diagnostic Items'}]",3
410433,Coronavirus (COVID-19),Ethical Analysis on Mandating COVID-19 Vaccination Prior to Kidney Transplantation in Brazil,COVID-19,COVID-19 Infection,COVID-19,True,abstract_title,"Step 1: The abstract title 'Ethical Analysis on Mandating COVID-19 Vaccination Prior to Kidney Transplantation in Brazil' was chosen as the primary source because it contains a specific disease term ('COVID-19').
Step 2: The components identified in the title are the disease 'COVID-19' and the procedural context 'Prior to Kidney Transplantation'.
Step 3: I retrieved rules for 'Transplant Status' to confirm that procedural contexts should be excluded. The generic exclusion rules also state that procedural/temporal qualifiers like 'Prior to' and surgery terms like 'Transplantation' should be excluded.
Step 4: The geographic descriptor 'Brazil' is also excluded based on the generic sociodemographic exclusion rules.
Step 5: After applying these exclusions, the only remaining clinically valid medical indication is 'COVID-19'. The formatting is already correct as it is a standard acronym.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To verify the handling of 'Kidney Transplantation' and confirm its exclusion as a procedural context.""}]","[{'component': 'COVID-19', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic rule: Retain standard disease name.'}, {'component': 'Prior to Kidney Transplantation', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers. Confirmed with Transplant Status specific rules.'}, {'component': 'Brazil', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude sociodemographic and geographic descriptors.'}]",2
181055,Health Services Research-Non-Malignant Conditions: Poster I,Prospective Study to Reduce Clostridium Difficile Infection in Patients Receiving Autologous Stem Cell Transplantation,Clostridium Difficile Infection,Clostridium Difficile Infection,Clostridium Difficile Infection,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Prospective Study to Reduce Clostridium Difficile Infection in Patients Receiving Autologous Stem Cell Transplantation') was chosen as it contains a specific disease, 'Clostridium Difficile Infection'. The session title ('Health Services Research-Non-Malignant Conditions: Poster I') is too general.
2.  **Component Identification**: The core disease identified is 'Clostridium Difficile Infection'. A patient subgroup is mentioned: 'Patients Receiving Autologous Stem Cell Transplantation'.
3.  **Rule Retrieval**: I retrieved rules for 'Treatment Set-up' with the subcategory 'Transplant Status' to determine how to handle the transplant context. Additionally, the generic exclusion rules for procedural qualifiers were consulted.
4.  **Rule Application**: The generic exclusion rule explicitly states to exclude procedural/temporal qualifiers like 'receiving' and 'post-transplant'. The retrieved rules for 'Transplant Status' confirmed that transplant-related contexts (e.g., Post-Transplant) should be excluded as they describe a treatment status, not a core part of the disease indication.
5.  **Indication Construction**: Based on the rules, the phrase 'in Patients Receiving Autologous Stem Cell Transplantation' was excluded. The core disease 'Clostridium Difficile Infection' was retained.
6.  **Formatting**: The indication was formatted to Title Case and checked for singular form, which was already correct. No other diseases were present, so no separator was needed.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To verify how to handle the context 'Receiving Autologous Stem Cell Transplantation'.""}]","[{'component': 'Clostridium Difficile Infection', 'type': 'Disease', 'normalized_form': 'Clostridium Difficile Infection', 'rule_applied': 'Generic formatting rules (Title Case, Singular Form).'}, {'component': 'in Patients Receiving Autologous Stem Cell Transplantation', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Generic exclusion rule for procedural terms ('receiving') and specific rules for 'Transplant Status' indicating exclusion of treatment context.""}]",2
262979,Acute myeloid leukemia - Clinical,Characteristics And Outcome Of Patients With Acute Promyelocytic Leukemia In Southern Tunisia,Acute Promyelocytic Leukemia,Acute Promyelocytic Leukemia,Acute Promyelocytic Leukemia,True,abstract_title,"Step 1: The abstract title 'Characteristics And Outcome Of Patients With Acute Promyelocytic Leukemia In Southern Tunisia' contains a specific disease, 'Acute Promyelocytic Leukemia'. According to the single-source principle, the abstract title is prioritized over the session title.
Step 2: The core disease 'Acute Promyelocytic Leukemia' was identified.
Step 3: The phrase 'In Southern Tunisia' was identified as a geographic descriptor.
Step 4: Applying the generic exclusion rules, the geographic descriptor 'In Southern Tunisia' was removed.
Step 5: The remaining text 'Characteristics And Outcome Of Patients With' is related to the study design and not the clinical indication, so it was excluded.
Step 6: The final indication was formatted to Title Case, resulting in 'Acute Promyelocytic Leukemia'.",[],"[{'component': 'Acute Promyelocytic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Promyelocytic Leukemia', 'rule_applied': 'Generic Rule: Disease Identification'}, {'component': 'In Southern Tunisia', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Sociodemographic Descriptors'}]",1
410436,Acute Kidney Injury,Comparison of 4 Predictive Scoring Methods as Assessment Tools for Cardiac Surgery Associated-Acute Kidney Injury in Post Coronary Artery Bypass Surgery Patients: A Single-Center Retrospective Study,Acute Kidney Injury,Acute Kidney Injury,Acute Kidney Injury,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: Both the abstract title ('Comparison of 4 Predictive Scoring Methods as Assessment Tools for Cardiac Surgery Associated-Acute Kidney Injury in Post Coronary Artery Bypass Surgery Patients: A Single-Center Retrospective Study') and the session title ('Acute Kidney Injury') contain the disease term 'Acute Kidney Injury'.
2. **Select Source**: Following the single-source principle, the abstract title is preferred as it contains the disease term and is more specific.
3. **Identify Components**: The abstract title contains the core disease 'Acute Kidney Injury' and two qualifiers: 'Cardiac Surgery Associated' and 'Post Coronary Artery Bypass Surgery'.
4. **Retrieve Rules**: The qualifiers are related to surgical procedures. I retrieved rules for 'Treatment Set-up' to confirm handling. The generic exclusion rules are also highly relevant here.
5. **Apply Rules**: 
   - The generic exclusion rules state that procedural and temporal qualifiers such as 'surgery-associated' and 'post-surgery' must be excluded.
   - The retrieved rule for 'Post Operative' (ID: 255) confirms that surgical timing descriptors should not be included in the final indication.
   - Therefore, both 'Cardiac Surgery Associated' and 'Post Coronary Artery Bypass Surgery' are excluded.
6. **Construct Indication**: After removing the excluded procedural qualifiers, the remaining core disease is 'Acute Kidney Injury'. The term is already in proper Title Case and singular form.
7. **Quality Check**: The final indication adheres to all formatting and exclusion rules, resulting in a concise and clinically accurate term.","[{'category': 'Treatment Set-up', 'subcategories': ['Operative Status', 'Treatment Status'], 'reason': ""To verify the handling of surgery-related terms like 'Cardiac Surgery Associated' and 'Post Coronary Artery Bypass Surgery'.""}]","[{'component': 'Acute Kidney Injury', 'type': 'Disease', 'normalized_form': 'Acute Kidney Injury', 'rule_applied': 'Generic rule: Retain core disease term.'}, {'component': 'Cardiac Surgery Associated', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule: Exclude surgery/procedure terms ('surgery-associated').""}, {'component': 'Post Coronary Artery Bypass Surgery', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule: Exclude surgery/procedure terms ('post-surgery'). Rule ID 255 also supports this exclusion.""}]",2
312133,Ignite Session 8A,Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation,Rheumatoid Arthritis,Rheumatoid Arthritis,Rheumatoid Arthritis;;Acute Inflammation,True,abstract_title,"Step 1: The abstract title contains disease terms ('Rheumatoid Arthritis', 'Acute Inflammation'), while the session title ('Ignite Session 8A') does not. Therefore, the abstract title was selected as the source.
Step 2: Two distinct medical conditions were identified in the selected title: 'Rheumatoid Arthritis' and 'Acute Inflammation'.
Step 3: The generic rule for multiple diseases was applied, which requires separating distinct conditions with ';;'.
Step 4: The generic rule for 'Acute' was applied. Since 'Acute' is part of the disease name 'Acute Inflammation', it was included.
Step 5: Both indications were formatted to Title Case and singular form as per the generic rules, resulting in 'Rheumatoid Arthritis' and 'Acute Inflammation'.
Step 6: The final indication was constructed by combining the two extracted conditions with the ';;' separator.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To confirm the correct formatting for multiple distinct diseases mentioned in the same title. Although no specific rule was returned, the generic rules provided sufficient guidance.'}]","[{'component': 'Rheumatoid Arthritis', 'type': 'Disease', 'normalized_form': 'Rheumatoid Arthritis', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'Acute Inflammation', 'type': 'Disease', 'normalized_form': 'Acute Inflammation', 'rule_applied': 'Generic rule: Title Case, Singular Form, Acute disease characterization'}]",4
328516,Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III,INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study,Relapsed;;Refractory;;Myelofibrosis,Relapsed/Refractory Myelofibrosis,Relapsed/Refractory Myelofibrosis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study') was chosen as it contains a specific disease, 'Myelofibrosis', which is more precise than the broader category 'Myeloproliferative Syndromes' in the session title. This adheres to the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title are the disease 'Myelofibrosis' and the patient subgroup descriptor 'Relapsed or Refractory'.
3.  **Rule Retrieval**: A rule was retrieved for the 'Occurrence' category, specifically for 'Recurrent/Refractory' terms, to guide the standardization of 'Relapsed or Refractory'.
4.  **Rule Application**: 
    *   The phrase 'Relapsed or Refractory' was normalized to the standard clinical format 'Relapsed/Refractory' and placed before the disease name.
    *   Generic rules were applied: The disease name 'Myelofibrosis' was checked for singular form (already singular) and Title Case.
    *   Exclusion rules were applied to remove non-indication elements such as the drug name ('INCB057643'), treatment description ('Monotherapy'), and study details ('A Phase 1 Study').
5.  **Indication Construction**: The normalized components were combined to form the final indication: 'Relapsed/Refractory Myelofibrosis'.
6.  **Quality Check**: The final output was verified for adherence to all formatting, casing, and exclusion rules, ensuring a clinically accurate and standardized indication.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To correctly format and standardize the 'Relapsed or Refractory' patient subgroup descriptor.""}]","[{'component': 'Relapsed or Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Standard clinical normalization for co-occurring relapse and refractory states.'}, {'component': 'Myelofibrosis', 'type': 'Disease', 'normalized_form': 'Myelofibrosis', 'rule_applied': 'Generic singular form and Title Case rules.'}]",2
295751,"Proffered Paper session 2: GI, lower digestive",Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study,BRAF V600E-mutant;;metastatic;;colorectal cancer,BRAF V600E-Mutated Metastatic Colorectal Cancer,BRAF V600E-Mutated Metastatic Colorectal Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study') contains a specific disease ('metastatic colorectal cancer') and is therefore selected over the generic session title ('Proffered Paper session 2: GI, lower digestive') based on the Single-Source Extraction Principle.
2. **Component Identification**: The selected title contains the following components: a gene mutation ('BRAF V600E-mutant (mt)'), a disease stage ('metastatic'), and a disease ('colorectal cancer'). It also mentions 'acquired resistance' and 'treated', which are treatment-related contexts.
3. **Rule Retrieval**: I retrieved rules for 'Gene type' to handle the mutation, 'Occurrence' for 'metastatic' and 'resistance', and 'Treatment based' for 'treated'.
4. **Rule Application**:
   - **Gene Mutation**: Based on the 'Gene Mutant' rule (ID: 31), 'BRAF V600E-mutant' is normalized to 'BRAF V600E-Mutated'. The abbreviation '(mt)' is redundant and removed.
   - **Metastasis**: The 'Metastatic' rule (ID: 141) is applied, keeping 'Metastatic' as a prefix to the disease.
   - **Disease Name**: 'colorectal cancer' is already in singular form and is standardized to 'Colorectal Cancer' using Title Case.
   - **Exclusions**: Per the generic exclusion rules and specific 'Resistance' rules (ID: 164, 165), 'acquired resistance' is excluded as it describes treatment response, not a core indication. The phrase 'treated in the BEACON study' is a procedural/study qualifier and is also excluded. The term 'patients (pts)' is a sociodemographic descriptor and is excluded.
5. **Indication Construction**: The components are assembled in the standard order (Gene-Mutation Stage Disease), resulting in 'BRAF V600E-Mutated Metastatic Colorectal Cancer'.
6. **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form, proper spacing) and accurately reflects the clinically valid indication from the source title.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the 'BRAF V600E-mutant' component.""}, {'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To handle the term 'metastatic'.""}, {'category': 'Occurrence', 'subcategories': ['Resistance'], 'reason': ""To determine how to handle 'acquired resistance'.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To determine how to handle the term 'treated'.""}]","[{'component': 'BRAF V600E-mutant (mt)', 'type': 'Gene Mutation', 'normalized_form': 'BRAF V600E-Mutated', 'rule_applied': ""Gene type rule (ID: 31) for 'Gene Mutant', converting the phrase to the standardized '<Gene/Variant>-Mutated' format.""}, {'component': 'metastatic colorectal cancer (mCRC)', 'type': 'Disease', 'normalized_form': 'Metastatic Colorectal Cancer', 'rule_applied': ""Occurrence rule (ID: 141) for 'Metastatic' and generic rules for Title Case and singular form.""}, {'component': 'acquired resistance', 'type': 'Treatment Response', 'normalized_form': '', 'rule_applied': ""Occurrence rule (ID: 164, 165) for 'Resistance', which specifies exclusion of this term.""}, {'component': 'treated in the BEACON study', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
344908,Drug Resistance in Molecular Targeted Therapies 2,"PHI-501, a novel pan-RAF/DDRs dual kinase inhibitor, overcomes BRAF or MEK inhibitor resistance in melanoma",melanoma,Melanoma,Melanoma,True,abstract_title,"Step 1: The abstract title contains the specific disease term 'melanoma', while the session title is more general. Therefore, the abstract title was selected as the source based on the single-source principle.
Step 2: The components identified in the abstract title are the disease 'melanoma' and the patient subgroup descriptor 'BRAF or MEK inhibitor resistance'.
Step 3: To correctly handle the resistance descriptor, rules for the 'Occurrence' category, specifically 'Resistance', were retrieved using the `get_indication_rules` tool.
Step 4: The retrieved rules (ID 164, 165) explicitly state that drug or drug class resistance terms (e.g., 'BTK-inhibitor-resistant') should not be included in the final indication as they describe treatment response status rather than a distinct clinical entity. Therefore, 'BRAF or MEK inhibitor resistance' was excluded.
Step 5: The remaining disease term 'melanoma' was processed according to generic rules. It was converted to singular form (already singular) and Title Case, resulting in 'Melanoma'.
Step 6: The final indication is 'Melanoma', which is clinically accurate and adheres to all formatting and exclusion rules.","[{'category': 'Occurrence', 'subcategories': ['Resistance'], 'reason': ""To determine how to handle the phrase 'BRAF or MEK inhibitor resistance'.""}]","[{'component': 'melanoma', 'type': 'Disease', 'normalized_form': 'Melanoma', 'rule_applied': 'Generic rule: Title Case and Singular Form.'}, {'component': 'BRAF or MEK inhibitor resistance', 'type': 'Resistance Status', 'normalized_form': '', 'rule_applied': 'Occurrence rule (ID 164, 165): Exclude drug/drug class resistance terms from the indication.'}]",2
213839,MP29: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology III,Aquablation in very large prostates (>150mL): technique and multicenter case series,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,Benign Prostatic Hyperplasia,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The session title is 'MP29: Benign Prostatic Hyperplasia: Surgical Therapy & New Technology III'. The abstract title is 'Aquablation in very large prostates (>150mL): technique and multicenter case series'.
2.  **Select Source**: The session title contains the specific, clinically valid disease term 'Benign Prostatic Hyperplasia'. The abstract title describes a patient characteristic ('very large prostates') but does not name a disease. Therefore, the session title is selected as the source based on the Single-Source Extraction Principle.
3.  **Identify Components**: The core disease component identified in the session title is 'Benign Prostatic Hyperplasia'. The phrases 'Surgical Therapy' and 'New Technology' are procedural and methodological, not part of the indication.
4.  **Retrieve Rules**: No specific category rules were needed as the indication is a standard disease name and the generic rules are sufficient.
5.  **Apply Rules**: The generic exclusion rule is applied to remove 'Surgical Therapy & New Technology III'. The generic formatting rules (Title Case, singular form) are applied, and the term 'Benign Prostatic Hyperplasia' already conforms to these.
6.  **Construct Indication**: The final indication is constructed from the identified disease component.
7.  **Quality Check**: The final indication 'Benign Prostatic Hyperplasia' is a clinically accurate, well-formatted, and correctly extracted term, adhering to all rules.",[],"[{'component': 'Benign Prostatic Hyperplasia', 'type': 'Disease', 'normalized_form': 'Benign Prostatic Hyperplasia', 'rule_applied': 'Generic rule: Use disease term from the selected source.'}, {'component': 'Surgical Therapy & New Technology III', 'type': 'Procedural/Methodological Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers.'}]",1
148309,Myeloproliferative Neoplasms - Clinical,Jak2V617F Allele Burden: An Independent Predictor Of Overt Fibrosis In Primary Myelofibrosis,Primary;;Myelofibrosis,Primary Myelofibrosis,JAK2 V617F-Mutated Primary Myelofibrosis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Jak2V617F Allele Burden: An Independent Predictor Of Overt Fibrosis In Primary Myelofibrosis') was chosen over the session title ('Myeloproliferative Neoplasms - Clinical') because it contains a more specific disease entity ('Primary Myelofibrosis') and a genetic marker, adhering to the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title are the disease 'Primary Myelofibrosis' and the gene variant 'Jak2V617F'. The term 'Overt Fibrosis' was identified as an outcome being predicted, not a descriptor of the patient population itself, and was therefore excluded from the indication.
3.  **Rule Retrieval**: Rules for 'Gene type' were retrieved to correctly format the 'Jak2V617F' variant. Generic rules for disease characterization were also applied.
4.  **Rule Application and Normalization**:
    *   **Disease Term**: The term 'Primary' was retained as it is an integral part of the disease name 'Primary Myelofibrosis'. The term was converted to Title Case.
    *   **Gene Variant**: Following the pattern from the retrieved 'Gene type' rules (e.g., for 'Gene Mutant' or 'Gene Mutated'), 'Jak2V617F' was normalized to the standard format. The gene symbol 'Jak2' was capitalized to 'JAK2', and the '-Mutated' suffix was added, resulting in 'JAK2 V617F-Mutated'.
5.  **Indication Construction**: The normalized genetic marker was prepended to the disease name to form the final indication.
6.  **Final Formatting**: The final string was checked for compliance with all formatting rules, including Title Case, singular form, and proper spacing, resulting in 'JAK2 V617F-Mutated Primary Myelofibrosis'.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To determine the correct formatting for the gene variant 'Jak2V617F'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding the term 'Overt Fibrosis'.""}]","[{'component': 'Jak2V617F', 'type': 'Gene Variant', 'normalized_form': 'JAK2 V617F-Mutated', 'rule_applied': ""Gene type rule for gene mutations (e.g., ID 31, 32) adapted for a specific variant, requiring capitalization of the gene and addition of a '-Mutated' suffix.""}, {'component': 'Primary Myelofibrosis', 'type': 'Disease', 'normalized_form': 'Primary Myelofibrosis', 'rule_applied': ""Generic rule for 'Primary' to include it when part of a disease name. Title Case and singular form rules also applied.""}, {'component': 'Overt Fibrosis', 'type': 'Disease Outcome', 'normalized_form': '', 'rule_applied': 'Excluded as it describes a predicted outcome within the patient population, not a defining characteristic of the patient subgroup itself.'}]",2
344918,Drug Resistance in Molecular Targeted Therapies 2,b-Escin eradicates cancer stem-like population in HER2-positive breast cancer with trastuzumab resistance,HER2;;positive;;breast cancer,HER2-Positive Breast Cancer,HER2-Positive Breast Cancer,True,abstract_title,"Step 1: The abstract title 'b-Escin eradicates cancer stem-like population in HER2-positive breast cancer with trastuzumab resistance' was chosen as the source because it contains a specific disease ('breast cancer'), unlike the more general session title.
Step 2: The components identified in the title were the disease 'breast cancer', the biomarker 'HER2-positive', and the treatment resistance qualifier 'with trastuzumab resistance'.
Step 3: The `get_indication_rules` tool was used for the 'Occurrence' category with the 'Resistance' subcategory. The retrieved rules (ID 164, 165) explicitly state that drug resistance terms (like 'trastuzumab resistance') should be excluded from the final indication as they represent treatment response status, not a distinct indication.
Step 4: The biomarker 'HER2-positive' was identified as a key patient subgroup. Following standard formatting, it was prepended to the disease name.
Step 5: The generic formatting rules were applied: the disease was kept in singular form, and the final indication was converted to Title Case, preserving the 'HER2' capitalization.
Step 6: The final indication was constructed by combining the biomarker and the disease, while excluding the resistance term, resulting in 'HER2-Positive Breast Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Resistance'], 'reason': ""To determine how to handle the phrase 'trastuzumab resistance'.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To check for specific formatting rules for biomarkers like 'HER2-positive'.""}]","[{'component': 'HER2-positive', 'type': 'Biomarker', 'normalized_form': 'HER2-Positive', 'rule_applied': 'Generic rule: Title Case, keep biomarker in original form.'}, {'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic rule: Title Case, singular form.'}, {'component': 'trastuzumab resistance', 'type': 'Resistance', 'normalized_form': '', 'rule_applied': 'Occurrence Rule (ID 164/165): Exclude drug resistance terms from the indication.'}]",3
295765,What is the optimal therapeutic approach in high-risk endometrial cancer?,Can the molecular classification guide adjuvant medical treatment?,high-risk;;endometrial cancer,High-Risk Endometrial Cancer,High-Risk Endometrial Cancer,True,session_title,"Step 1: Analyze Input Titles - The abstract title 'Can the molecular classification guide adjuvant medical treatment?' does not contain a specific disease. The session title 'What is the optimal therapeutic approach in high-risk endometrial cancer?' contains the disease 'endometrial cancer'.
Step 2: Select the Source - Based on the Single-Source Extraction Principle, the session title is selected as it is the only source containing a disease term.
Step 3: Identify Components - The components identified in the session title are the disease 'endometrial cancer' and the risk qualifier 'high-risk'.
Step 4: Retrieve Relevant Rules - I retrieved rules for the 'Risk' category, specifically for 'High-Risk', to ensure correct formatting. The rules confirm that 'high-risk' should be normalized to 'High-Risk' and prepended to the disease name.
Step 5: Apply Rules - I applied the generic rules for Title Case and singular form. 'endometrial cancer' becomes 'Endometrial Cancer'. The specific rule for 'High-Risk' is applied, formatting it as 'High-Risk'.
Step 6: Construct Indication - The components are combined to form the final indication: 'High-Risk Endometrial Cancer'.
Step 7: Quality Check - The final indication adheres to all formatting and content rules. It is derived from a single source and is clinically accurate.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To confirm the correct formatting and placement of the 'high-risk' qualifier.""}]","[{'component': 'high-risk', 'type': 'Risk Qualifier', 'normalized_form': 'High-Risk', 'rule_applied': ""Rule ID 122: Normalize risk variants like 'high-risk' to 'High-Risk' and attach to the associated disease.""}, {'component': 'endometrial cancer', 'type': 'Disease', 'normalized_form': 'Endometrial Cancer', 'rule_applied': 'Generic Rule: Apply Title Case and ensure singular form.'}]",2
181083,Health Services Research-Lymphoid Malignancies: Poster I,"Awareness, Knowledge, and Preferences of United States (US) Patients with Chronic Lymphocytic Leukemia (CLL) and Their Caregivers Related to Finite Duration (FD) Therapy and Minimal (Measurable) Residual Disease (MRD)",Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease, 'Chronic Lymphocytic Leukemia (CLL)', which is more precise than the broader category 'Lymphoid Malignancies' in the session title.
Step 2: The core disease 'Chronic Lymphocytic Leukemia' was identified.
Step 3: The patient descriptor 'United States (US) Patients' was identified as a geographic sociodemographic qualifier.
Step 4: The generic exclusion rule for geographic descriptors was applied, leading to the removal of 'United States (US)'.
Step 5: The generic rule for 'Chronic' was applied, which states to include it when it is part of the disease name.
Step 6: The final indication was formatted to Title Case and singular form, resulting in 'Chronic Lymphocytic Leukemia'. Other terms like 'Caregivers', 'Finite Duration Therapy', and 'Minimal Residual Disease' were excluded as they describe context or outcomes, not the core indication.","[{'category': 'Patient Sub-Group', 'subcategories': ['Geographic location'], 'reason': ""To verify if the geographic location 'United States (US)' should be included in the indication. No specific rule was found, so the generic exclusion rule was applied.""}, {'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To check for specific rules regarding the term 'Chronic'. No specific rule was found, so the generic rule was applied.""}]","[{'component': 'Chronic Lymphocytic Leukemia (CLL)', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': ""Generic rule for 'Chronic'; Generic formatting rule for Title Case and singular form.""}, {'component': 'United States (US) Patients', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for geographic descriptors.'}]",2
263003,Acute myeloid leukemia - Clinical,Utility Of Flt3 Inhibitors In Patients With Acute Myeloid Leukemia (Aml) And T(6;9)(P22;Q34),Acute Myeloid Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with T(6;9)(P22;Q34),True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract title and session title contain the disease 'Acute Myeloid Leukemia'. The abstract title is chosen as the source because it provides more specific information, namely the chromosomal translocation 'T(6;9)(P22;Q34)', which defines a key patient subgroup. This adheres to the single-source principle, prioritizing the more detailed title.
2.  **Component Identification**: The selected abstract title contains:
    *   Disease: 'Acute Myeloid Leukemia (Aml)'
    *   Patient Subgroup (Genetic Marker): 'T(6;9)(P22;Q34)'
    *   Excluded terms: 'Utility Of Flt3 Inhibitors' (treatment), 'Patients' (generic descriptor).
3.  **Rule Retrieval**: I retrieved rules for 'Chromosome type' to understand how to handle the cytogenetic notation and 'Connectors' to determine how to join the disease and the genetic marker.
4.  **Rule Application**:
    *   The retrieved 'Chromosome type' rules were not directly applicable to this specific translocation format, so the standard cytogenetic nomenclature 'T(6;9)(P22;Q34)' was preserved as it is clinically precise.
    *   The connector 'And' in the title links the disease to the translocation. The most clinically accurate representation is to use 'with' to connect the disease and its defining characteristic.
    *   Generic rules were applied: The redundant abbreviation '(Aml)' was removed. The output was formatted to Title Case, with the preposition 'with' in lower case per casing rules. The disease term 'Leukemia' is already in singular form.
5.  **Indication Construction**: The final indication was constructed by combining the core disease with the specific patient subgroup identifier, resulting in 'Acute Myeloid Leukemia with T(6;9)(P22;Q34)'.
6.  **Quality Check**: The final output was verified for adherence to all formatting, exclusion, and clinical accuracy requirements.","[{'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': 'To check for specific formatting rules regarding the chromosomal translocation T(6;9)(P22;Q34).'}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To determine the correct way to handle the word 'And' connecting the disease to the genetic marker.""}]","[{'component': 'Acute Myeloid Leukemia (Aml)', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic rule: Remove redundant abbreviations.'}, {'component': 'T(6;9)(P22;Q34)', 'type': 'Chromosomal Translocation', 'normalized_form': 'T(6;9)(P22;Q34)', 'rule_applied': 'Preserved standard cytogenetic nomenclature in the absence of a specific transformation rule.'}, {'component': 'With... And', 'type': 'Connector', 'normalized_form': 'with', 'rule_applied': ""Generic rule: Use of 'with' for clinical connection and lowercasing of prepositions.""}]",2
295775,"Management of brain metastases: Systemic treatment, radiosurgery or both?",Management of treatment-related neurological complications,brain metastases,Brain Metastasis,Brain Metastasis,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title, 'Management of treatment-related neurological complications', describes complications rather than a specific primary disease. The session title, 'Management of brain metastases: Systemic treatment, radiosurgery or both?', contains a clear and specific medical condition, 'brain metastases'. Therefore, according to the single-source principle, the session title was selected as the basis for the indication.
2.  **Component Identification**: The key clinical term identified in the session title is 'brain metastases'.
3.  **Rule Application**: The generic rule for using the singular form was applied, converting 'metastases' to 'Metastasis'. The generic rule for Title Casing was applied to 'brain', resulting in 'Brain'.
4.  **Exclusion**: Non-diagnostic and procedural terms such as 'Management of', 'Systemic treatment', and 'radiosurgery' were excluded as per the generic exclusion rules.
5.  **Indication Construction**: The components were combined to form the final indication 'Brain Metastasis'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To verify the correct handling of the term 'metastases' and ensure no specific formatting rule was missed.""}]","[{'component': 'brain metastases', 'type': 'Disease', 'normalized_form': 'Brain Metastasis', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Title Case'}]",2
410465,Acute Kidney Injury,A Rare Case of ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis,ANCA-Mediated;;Acute Interstitial Nephritis,ANCA-Mediated Acute Interstitial Nephritis,ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('A Rare Case of ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis') was chosen over the session title ('Acute Kidney Injury') because it contains a more specific and detailed disease description, adhering to the single-source principle to use the most informative title.
2.  **Component Identification**: The key components identified in the abstract title are:
    *   Disease: 'Acute Interstitial Nephritis'
    *   Qualifier/Cause: 'ANCA-Mediated'
    *   Negative Finding/Subgroup Definition: 'Without Glomerulonephritis'
    *   Study Descriptor: 'A Rare Case of'
3.  **Rule Application**: 
    *   **Generic Exclusion Rule**: The phrase 'A Rare Case of' was excluded as it describes the nature of the report rather than being part of the clinical indication itself.
    *   **Generic Disease Characterization Rule**: The term 'Acute' was retained as it is an integral part of the disease name 'Acute Interstitial Nephritis'.
    *   **Biomarker/Qualifier Handling**: 'ANCA-Mediated' is a critical descriptor of the disease's etiology and was included. 'ANCA' is maintained in all-caps as it is a standard acronym.
    *   **Subgroup Definition**: The phrase 'Without Glomerulonephritis' is a clinically significant negative finding that defines a specific and important subgroup of this condition, as ANCA-associated diseases often present with glomerulonephritis. Therefore, it was included to ensure clinical accuracy.
4.  **Indication Construction & Formatting**:
    *   The components were combined to form the full indication.
    *   **Title Case Rule**: The final indication was formatted in Title Case, capitalizing each clinically significant word.
    *   **Singular Form Rule**: All disease terms were already in singular form.
    *   The final indication is a single, cohesive entity, so no ';;' separator was needed.","[{'category': 'Biomarker', 'subcategories': ['Biomarker status'], 'reason': ""To check for rules on handling 'ANCA-Mediated' as a potential biomarker.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules on handling 'Rare Case' and negative findings like 'Without Glomerulonephritis'.""}]","[{'component': 'ANCA-Mediated Acute Interstitial Nephritis', 'type': 'Disease', 'normalized_form': 'ANCA-Mediated Acute Interstitial Nephritis', 'rule_applied': 'Generic Title Case and Disease Characterization rules.'}, {'component': 'Without Glomerulonephritis', 'type': 'Patient Subgroup (Negative Finding)', 'normalized_form': 'Without Glomerulonephritis', 'rule_applied': 'Retained as a clinically significant descriptor defining the patient subgroup.'}, {'component': 'A Rare Case of', 'type': 'Study Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for non-diagnostic items.'}]",2
295778,Young Oncologist Brunch 3: Molecular Tumor Board: A luxury or a necessity?,Discussion led by Chair,,,Tumor,True,session_title,"Step 1: The abstract title 'Discussion led by Chair' contains no medical information. The session title 'Young Oncologist Brunch 3: Molecular Tumor Board: A luxury or a necessity?' contains the terms 'Oncologist' and 'Tumor'. Therefore, the session title is selected as the source.
Step 2: The components identified in the session title are 'Young', 'Oncologist', and 'Tumor'.
Step 3: Rules for the 'Age Group' category were retrieved for the term 'Young'. The rules indicate that 'Young' as a standalone descriptor should be excluded unless it is part of a specific phrase like 'Young Adult'. In this context, 'Young' describes the oncologist, not the patient, so it falls under the generic exclusion rule for non-patient descriptors.
Step 4: The term 'Oncologist' points to the therapeutic area of Oncology, which can be mapped to 'Cancer' per generic rules. The title also explicitly contains the disease term 'Tumor'. 'Tumor' is more specific and directly mentioned in the context of the 'Molecular Tumor Board'.
Step 5: The term 'Molecular' describes the type of tumor board (a meeting/methodology) and not the tumor itself, so it is excluded as a procedural/methodological qualifier.
Step 6: Applying the rules, 'Young' and 'Molecular' are excluded. The core disease term 'Tumor' is extracted, converted to Title Case, and is already in singular form. This results in the final indication 'Tumor'.","[{'category': 'Age Group', 'subcategories': ['Young'], 'reason': ""To determine how to handle the term 'Young' found in the session title.""}]","[{'component': 'Tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': 'Generic rule: Use specific disease term. Title Case and Singular Form rules applied.'}, {'component': 'Young', 'type': 'Age Group', 'normalized_form': '', 'rule_applied': 'Retrieved rule ID 308 indicates exclusion. Additionally, the term describes the professional, not the patient, and is excluded per generic rules.'}, {'component': 'Oncologist', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': ""Generic rule: Therapeutic Area Fallback. 'Tumor' was chosen as the more specific term present in the title.""}]",2
410466,Acute Kidney Injury,AKI and Spontaneous Rupture of the Urinary Collecting System,AKI,Acute Kidney Injury,Acute Kidney Injury;;Spontaneous Rupture of the Urinary Collecting System,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains specific disease terms ('AKI', 'Spontaneous Rupture of the Urinary Collecting System'), making it more informative than the session title.
Step 2: Two distinct medical conditions were identified in the abstract title: 'AKI' and 'Spontaneous Rupture of the Urinary Collecting System'.
Step 3: The abbreviation 'AKI' was expanded to its full, clinically standard form 'Acute Kidney Injury' based on common medical knowledge and the context provided by the session title.
Step 4: The generic rule for multiple diseases was applied, using ';;' as a separator between the two distinct conditions.
Step 5: Title Case formatting was applied to both indications, ensuring short prepositions like 'of' and 'the' remain in lowercase as per the casing rules. The final output is a concatenation of the two normalized indications.",[],"[{'component': 'AKI', 'type': 'Disease', 'normalized_form': 'Acute Kidney Injury', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}, {'component': 'Spontaneous Rupture of the Urinary Collecting System', 'type': 'Disease', 'normalized_form': 'Spontaneous Rupture of the Urinary Collecting System', 'rule_applied': 'Title Case rule.'}]",1
394087,Oesophagogastric Cancer,Gut Microbiome And Metabolome Are Associated With The Response To Chemoradiotherapy In Patients With Esophageal Cancer,Esophageal Cancer,Esophageal Cancer,Esophageal Cancer,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. The abstract title contains the specific disease 'Esophageal Cancer', and the session title contains 'Oesophagogastric Cancer'.
Step 2: According to the single-source extraction principle, the abstract title is preferred as it contains a valid disease term.
Step 3: I identified the core disease 'Esophageal Cancer' from the abstract title.
Step 4: I applied the generic rules. The term is already in singular form and appropriate Title Case. Other parts of the title, such as 'Gut Microbiome And Metabolome' and 'Response To Chemoradiotherapy', are related to the study's methodology and findings, not the core medical indication, and were therefore excluded.
Step 5: The final extracted indication is 'Esophageal Cancer'.",[],"[{'component': 'Esophageal Cancer', 'type': 'Disease', 'normalized_form': 'Esophageal Cancer', 'rule_applied': 'Generic singular form and casing rules.'}]",1
394098,Oesophagogastric Cancer,Factors Associated With Uptake Of Adjuvant Nivolumab In A Nationwide Esophageal Cancer Patient Cohort,Esophageal Cancer,Esophageal Cancer,Esophageal Cancer,True,abstract_title,"Step 1: The abstract title contains the specific disease 'Esophageal Cancer', so it is selected as the primary source over the more general session title 'Oesophagogastric Cancer', following the single-source extraction principle.
Step 2: The core disease 'Esophageal Cancer' was identified in the selected title.
Step 3: The term 'Adjuvant' was identified as a treatment context. I retrieved rules for 'Treatment Set-up' to determine its inclusion. The general principle from the retrieved rule (for 'Monotherapy') and the generic rules is to exclude treatment modalities from the final indication.
Step 4: The drug name 'Nivolumab' and study descriptors like 'Nationwide... Patient Cohort' are excluded as per generic rules.
Step 5: The final indication was constructed by taking the core disease, applying Title Case, and ensuring it is in singular form. All other components were excluded.","[{'category': 'Treatment Set-up', 'subcategories': ['Treatment Modality'], 'reason': ""To determine if the treatment context 'Adjuvant' should be included in the indication.""}]","[{'component': 'Esophageal Cancer', 'type': 'Disease', 'normalized_form': 'Esophageal Cancer', 'rule_applied': 'Generic Casing and Singular Form rules.'}, {'component': 'Adjuvant', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': ""Generic exclusion rule for procedural/temporal qualifiers. The principle of excluding treatment modalities, supported by the retrieved rule for 'Monotherapy', was applied.""}]",2
181105,Outcomes Research-Non-Malignant Conditions: Poster I,Vaso-Occlusive Events in Pediatric Sickle Cell Disease: Quantifying Social Disadvantage and Its Impact on Hospitalizations,Pediatric;;Sickle Cell Disease,Pediatric Sickle Cell Disease,Pediatric Sickle Cell Disease,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'Vaso-Occlusive Events in Pediatric Sickle Cell Disease: Quantifying Social Disadvantage and Its Impact on Hospitalizations' was chosen over the session title 'Outcomes Research-Non-Malignant Conditions: Poster I' because it contains a specific disease name ('Sickle Cell Disease'), whereas the session title provides only a broad category.
2.  **Component Identification**: From the abstract title, I identified the core disease 'Sickle Cell Disease' and an age-based patient subgroup 'Pediatric'. The term 'Vaso-Occlusive Events' describes the clinical manifestation being studied within this patient population, rather than being part of the core indication name itself. Terms like 'Social Disadvantage' and 'Hospitalizations' are research outcomes and were excluded.
3.  **Rule Retrieval**: I retrieved rules for the 'Age Group' category, specifically for 'Pediatric', to ensure correct formatting.
4.  **Rule Application**: 
    *   The retrieved 'Pediatric' rule (ID: 295) confirms that the term should be normalized to 'Pediatric' and prepended to the disease name.
    *   Generic formatting rules were applied: The indication is presented in Title Case and singular form (which was already the case).
5.  **Indication Construction**: The age subgroup 'Pediatric' was combined with the core disease 'Sickle Cell Disease' to form the final indication.
6.  **Quality Check**: The final indication 'Pediatric Sickle Cell Disease' is clinically accurate, follows all formatting rules, and is derived from a single source. 'Vaso-Occlusive Events' was correctly interpreted as the study's focus within the patient group, not a component of the indication itself.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To handle the 'Pediatric' patient subgroup qualifier.""}, {'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': ""To check if 'Vaso-Occlusive Events' and 'Sickle Cell Disease' should be treated as two separate indications. No rules were found, supporting the decision to treat them as a single indication context.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule ID 295: Prepend 'Pediatric' to the disease name.""}, {'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}, {'component': 'Vaso-Occlusive Events', 'type': 'Symptom/Event', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Excluded as it represents the event being studied in the patient population, not a part of the core indication name.'}]",2
181110,Outcomes Research-Non-Malignant Conditions: Poster I,Sleep Characterization of Adolescent and Young Adult Patients with Sickle Cell Disease Using the Pittsburgh Sleep Quality Index,Adolescent;;Young Adult;;Sickle Cell Disease,Adolescent Young Adult Sickle Cell Disease,Adolescent Sickle Cell Disease;;Young Adult Sickle Cell Disease,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Sleep Characterization of Adolescent and Young Adult Patients with Sickle Cell Disease...') was chosen because it contains a specific disease ('Sickle Cell Disease'), whereas the session title ('Outcomes Research-Non-Malignant Conditions: Poster I') is a broad, non-specific category. This adheres to the Single-Source Extraction Principle.
2.  **Component Identification**: The selected title contains one disease and two distinct patient subgroups based on age: 
    - Disease: 'Sickle Cell Disease'
    - Age Groups: 'Adolescent' and 'Young Adult'.
3.  **Rule Retrieval**: To ensure correct formatting for the age groups, I retrieved rules for the 'Age Group' category, specifically for 'Adolescent', 'Young', and 'Adult' subcategories.
4.  **Rule Application**: 
    - The generic rule for singular form was applied, though 'Sickle Cell Disease' is already singular.
    - The generic rule for Title Case was applied.
    - The retrieved rules for 'Adolescent' (Rule 318) and 'Young Adult' (Rule 311) confirm they should be used as prefixes to the disease name.
    - The presence of 'and' connecting two distinct patient subgroups ('Adolescent and Young Adult') implies that the study covers both groups. Following the pattern for handling multiple distinct groups (similar to Rule 314 for 'Children/Adolescent'), the indication is split into two, one for each age group, with the core disease duplicated.
5.  **Indication Construction**: The two indications were constructed separately and then combined:
    - Indication 1: 'Adolescent' + 'Sickle Cell Disease' -> 'Adolescent Sickle Cell Disease'
    - Indication 2: 'Young Adult' + 'Sickle Cell Disease' -> 'Young Adult Sickle Cell Disease'
    - The final output was created by joining these with the required ';;' separator.
6.  **Quality Check**: The final indication correctly captures both patient subgroups as separate, standardized indications, adheres to all formatting rules (Title Case, singular, separator), and excludes non-indication elements like 'Patients' and study methodology details.","[{'category': 'Age Group', 'subcategories': ['Adolescent', 'Young', 'Adult'], 'reason': ""To determine the correct formatting for the identified age groups 'Adolescent' and 'Young Adult'.""}]","[{'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Adolescent', 'type': 'Age Group', 'normalized_form': 'Adolescent', 'rule_applied': ""Rule 318: Prepend 'Adolescent' to the disease name.""}, {'component': 'Young Adult', 'type': 'Age Group', 'normalized_form': 'Young Adult', 'rule_applied': ""Rule 311: Prepend 'Young Adult' to the disease name.""}]",2
181112,Outcomes Research-Non-Malignant Conditions: Poster I,Comparison of Clinical and Thrombotic Outcomes in Sars-Cov-2- Pneumonia Versus Other Viral Pneumonia in an Urban Academic Medical Center,Sars-Cov-2- Pneumonia,Sars-Cov-2- Pneumonia,Sars-Cov-2- Pneumonia;;Viral Pneumonia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Comparison of Clinical and Thrombotic Outcomes in Sars-Cov-2- Pneumonia Versus Other Viral Pneumonia in an Urban Academic Medical Center') was chosen as it contains specific disease names, unlike the session title ('Outcomes Research-Non-Malignant Conditions: Poster I') which is too general.
2.  **Component Identification**: The abstract title identifies two distinct medical conditions: 'Sars-Cov-2- Pneumonia' and 'Other Viral Pneumonia'. 'Thrombotic Outcomes' was identified as a study outcome, not a primary indication for a patient cohort.
3.  **Rule Application**: 
    *   **Multiple Diseases Rule**: Both identified diseases were extracted as separate indications, as per the rule to capture all distinct conditions mentioned.
    *   **Separator Rule**: The two indications are separated by ';;'.
    *   **Casing Rule**: The indications were formatted to Title Case. 'Sars-Cov-2' is maintained in its original form.
    *   **Standardization**: 'Other Viral Pneumonia' was simplified to 'Viral Pneumonia' as 'Other' is a comparative term from the study design and not part of the standard indication name.
    *   **Exclusion Rule**: Non-diagnostic and location-based terms like 'Comparison of Clinical and Thrombotic Outcomes' and 'in an Urban Academic Medical Center' were excluded.
4.  **Final Indication Construction**: The processed components were combined to form the final output: 'Sars-Cov-2- Pneumonia;;Viral Pneumonia'.",[],"[{'component': 'Sars-Cov-2- Pneumonia', 'type': 'Disease', 'normalized_form': 'Sars-Cov-2- Pneumonia', 'rule_applied': 'Generic Casing and Singular Form Rules'}, {'component': 'Other Viral Pneumonia', 'type': 'Disease', 'normalized_form': 'Viral Pneumonia', 'rule_applied': ""Generic Casing and Singular Form Rules, and removal of comparative term 'Other'""}]",1
181114,Outcomes Research-Non-Malignant Conditions: Poster I,Venous Thromboembolism Post-COVID-19 Among Individuals with Sickle Cell Disease,Sickle Cell Disease;;Venous Thromboembolism,Sickle Cell Disease;;Venous Thromboembolism,Venous Thromboembolism;;Sickle Cell Disease,True,abstract_title,"Step 1: The abstract title 'Venous Thromboembolism Post-COVID-19 Among Individuals with Sickle Cell Disease' was chosen as the source because it contains specific disease terms, unlike the session title which refers to a general category ('Non-Malignant Conditions').
Step 2: The title identifies three potential conditions: 'Venous Thromboembolism', 'COVID-19', and 'Sickle Cell Disease'.
Step 3: The term 'Post-COVID-19' is identified as a temporal qualifier, describing the timing of the VTE relative to a COVID-19 infection. According to the generic exclusion rules, temporal and procedural qualifiers (like 'post-surgery') should be excluded from the final indication. Therefore, 'Post-COVID-19' is removed.
Step 4: The remaining distinct diseases are 'Venous Thromboembolism' and 'Sickle Cell Disease'. The phrase 'Among Individuals with' indicates that Sickle Cell Disease describes the patient population in which Venous Thromboembolism is being studied. Following the generic rule for multiple diseases (e.g., 'Asthma with Cardiovascular Risk' -> 'Asthma;;Cardiovascular Risk'), both conditions are extracted as separate indications.
Step 5: The indications are formatted according to the rules: Title Case and singular form are already correct. They are separated by the ';;' delimiter, resulting in the final output.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To determine the correct formatting for co-occurring but distinct diseases mentioned in the title. No specific rules were found, so generic rules were applied.'}]","[{'component': 'Venous Thromboembolism', 'type': 'Disease', 'normalized_form': 'Venous Thromboembolism', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Post-COVID-19', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Procedural/Temporal Qualifiers'}]",3
164735,The Interplay Between COVID and other Infections,Reduction in Bloodborne Pathogen Splash Exposures After Implementation of Universal Masking and Eye Protection for COVID-19,,,COVID-19;;Infection,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract_title is 'Reduction in Bloodborne Pathogen Splash Exposures After Implementation of Universal Masking and Eye Protection for COVID-19'. The session_title is 'The Interplay Between COVID and other Infections'.
2.  **Select Source**: According to the Single-Source Extraction Principle, the abstract_title should be preferred if it contains a disease. The abstract_title mentions 'Bloodborne Pathogen Splash Exposures' and 'COVID-19'. However, 'Exposures' are explicitly listed as an exclusion in the generic rules. The title's focus is on an occupational safety outcome (reduction of exposure) rather than a clinical study of a disease state. The session_title, on the other hand, clearly mentions two disease concepts: 'COVID' and 'Infections'. Therefore, the session_title is selected as the more appropriate source for a clinically valid indication.
3.  **Identify Components**: The selected session_title contains two components: 'COVID' and 'other Infections'.
4.  **Apply Rules & Construct Indication**:
    *   The term 'COVID' is normalized to its standard clinical name, 'COVID-19'.
    *   For 'other Infections', the qualifier 'other' is removed as it is not part of the disease name. The plural 'Infections' is converted to its singular form, 'Infection', per the generic rules.
    *   The two distinct diseases are separated by the ';;' delimiter as required for multiple diseases.
    *   Title Case formatting is applied to both terms.
5.  **Final Indication**: The resulting indication is 'COVID-19;;Infection'.",[],"[{'component': 'COVID', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Standardization of disease name'}, {'component': 'other Infections', 'type': 'Disease', 'normalized_form': 'Infection', 'rule_applied': ""Generic rule: Singular Form; Exclusion of non-clinical qualifier 'other'""}, {'component': 'Bloodborne Pathogen Splash Exposures', 'type': 'Exposure (Excluded)', 'normalized_form': '', 'rule_applied': ""Generic rule: Exclude non-diagnostic items like 'Exposures'""}]",1
263044,Aggressive Non-Hodgkin lymphoma - Clinical,No Impact Of Statin Use On Response And Survival Rates In Newly Diagnosed Dlbcl Patients Treated With R-Da-Epoch,Newly Diagnosed;;Dlbcl,Newly Diagnosed Diffuse Large B-Cell Lymphoma,Newly Diagnosed Diffuse Large B-Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title contains a specific disease term ('Dlbcl'), so it was chosen as the primary source over the session title, following the single-source principle.
2. **Component Identification**: The key components identified in the abstract title were 'Newly Diagnosed' and 'Dlbcl'.
3. **Rule Retrieval**: A rule was retrieved for the 'Diagnosis Status' subcategory to correctly handle the 'Newly Diagnosed' qualifier. The rule specifies prefixing it to the disease name.
4. **Disease Normalization**: The abbreviation 'Dlbcl' was identified and expanded to its full, clinically standard name: 'Diffuse Large B-Cell Lymphoma'.
5. **Rule Application & Formatting**: 
   - The retrieved rule was applied, placing 'Newly Diagnosed' at the beginning of the indication.
   - Generic formatting rules were applied: Title Case for all clinically significant words ('Newly Diagnosed Diffuse Large B-Cell Lymphoma') and ensuring the disease is in singular form.
6. **Exclusion**: The phrase 'Patients Treated With R-Da-Epoch' was excluded as it describes the treatment modality and patient population, not the core indication itself, according to the generic exclusion rules for procedural qualifiers.
7. **Final Construction**: The normalized components were combined to form the final indication: 'Newly Diagnosed Diffuse Large B-Cell Lymphoma'.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To correctly format the 'Newly Diagnosed' patient subgroup qualifier.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID 193: Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'Dlbcl', 'type': 'Disease', 'normalized_form': 'Diffuse Large B-Cell Lymphoma', 'rule_applied': 'Standard clinical abbreviation expansion and Title Case formatting rule.'}]",2
344966,New Drug Targets,Development of an antibody-drug conjugate panel targeting high grade serous ovarian cancer,high grade;;serous ovarian cancer,High Grade Serous Ovarian Cancer,High Grade Serous Ovarian Cancer,True,abstract_title,"Step 1: The abstract title 'Development of an antibody-drug conjugate panel targeting high grade serous ovarian cancer' was chosen as the source because it contains a specific disease, whereas the session title 'New Drug Targets' is too general.
Step 2: The components identified in the abstract title are the disease 'ovarian cancer', the grade 'high grade', and the histological subtype 'serous'.
Step 3: Rules for 'Grade' and 'Patient Sub-Group' (specifically 'Disease Characterisation') were retrieved to handle the identified components.
Step 4: The generic rule for singular form was applied, though 'cancer' is already singular. The generic rule for Title Case was applied to the entire indication. The specific rule for 'High Grade' (ID: 115) was applied, standardizing 'high grade' to 'High Grade'. The subtype 'serous' was retained as it is a key clinical characteristic of the disease.
Step 5: The components were combined in the correct clinical order (Grade -> Subtype -> Disease) to form the final indication: 'High Grade Serous Ovarian Cancer'.
Step 6: A final quality check confirmed adherence to all formatting and extraction principles.","[{'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To correctly format the 'high grade' component.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for any rules regarding the histological subtype 'serous'.""}]","[{'component': 'high grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Grade Rule ID: 115 - Standardize to 'High Grade' with title case and no hyphen.""}, {'component': 'serous', 'type': 'Histological Subtype', 'normalized_form': 'Serous', 'rule_applied': 'General principle of retaining clinically significant histological subtypes.'}, {'component': 'ovarian cancer', 'type': 'Disease', 'normalized_form': 'Ovarian Cancer', 'rule_applied': 'Generic Rule - Title Case and Singular Form.'}]",2
295814,Gilead and Kite Oncology - Break Expectations: Novel approaches in triple-negative and HR+/HER2- metastatic breast cancer,Stepping into the emerging needs in metastatic breast cancer,metastatic;;breast cancer,Metastatic Breast Cancer,Triple-Negative Metastatic Breast Cancer;;HR+/HER2- Metastatic Breast Cancer,True,session_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Stepping into the emerging needs in metastatic breast cancer' and the session title is 'Gilead and Kite Oncology - Break Expectations: Novel approaches in triple-negative and HR+/HER2- metastatic breast cancer'.
2. **Select Source**: Both titles contain a disease. The session title provides significantly more specific and clinically relevant information, including key patient subgroups ('triple-negative', 'HR+/HER2-'), which are crucial for a precise medical indication. The abstract title is very general. Therefore, the session title was chosen as the source to generate a higher quality, more specific indication.
3. **Identify Components**: From the session title, I identified the core disease 'breast cancer', the occurrence qualifier 'metastatic', and two distinct patient subgroups: 'triple-negative' and 'HR+/HER2-'. The word 'and' indicates these are two separate populations.
4. **Retrieve Rules**: I retrieved rules for handling metastasis-related terms to confirm the placement and formatting of 'Metastatic'. I also mentally referenced rules for handling biomarker-defined subgroups like 'Triple-Negative' and 'HR+/HER2-'.
5. **Apply Rules & Construct Indication**: 
   - The generic rule for singular form was applied ('cancer' is already singular).
   - The generic rule for Title Case was applied.
   - The rule for multiple distinct patient groups requires separating them with ';;'.
   - The components were assembled into two distinct indications: 'Triple-Negative Metastatic Breast Cancer' and 'HR+/HER2- Metastatic Breast Cancer'.
6. **Final Output**: The two indications are combined with the ';;' separator, resulting in the final generated indication.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'metastatic' as a prefix to the disease name.""}]","[{'component': 'triple-negative', 'type': 'Patient Sub-Group (Biomarker)', 'normalized_form': 'Triple-Negative', 'rule_applied': 'Title Case rule'}, {'component': 'HR+/HER2-', 'type': 'Patient Sub-Group (Biomarker)', 'normalized_form': 'HR+/HER2-', 'rule_applied': 'Biomarker formatting rule (preserve case and symbols)'}, {'component': 'metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': 'Metastasis-Related Terms rule (ID: 141)'}, {'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Title Case rule, Singular form rule'}]",2
377741,Stem cell transplantation - Clinical,Unmanipulated Peripheral Haploidentical Haematopoietic Stem Cell Transplant Is An Effective Consolidative Strategy For High-Risk Acute Myeloid Leukaemia And Myelodysplastic Syndrome,High-Risk;;Acute Myeloid Leukaemia;;Myelodysplastic Syndrome,High-Risk Acute Myeloid Leukaemia;;High-Risk Myelodysplastic Syndrome,High-Risk Acute Myeloid Leukaemia;;High-Risk Myelodysplastic Syndrome,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Unmanipulated Peripheral Haploidentical Haematopoietic Stem Cell Transplant Is An Effective Consolidative Strategy For High-Risk Acute Myeloid Leukaemia And Myelodysplastic Syndrome') contains specific disease names, while the session title ('Stem cell transplantation - Clinical') is generic. Therefore, the abstract title was chosen as the source based on the Single-Source Extraction Principle.
2.  **Component Identification**: Two distinct diseases were identified: 'Acute Myeloid Leukaemia' and 'Myelodysplastic Syndrome'. A risk qualifier, 'High-Risk', was also identified. Procedural terms like 'Unmanipulated Peripheral Haploidentical Haematopoietic Stem Cell Transplant' and 'Consolidative Strategy' were marked for exclusion per generic rules.
3.  **Rule Retrieval**: Rules for the 'Risk' category (specifically 'High-Risk') were retrieved to ensure correct formatting. Rules for handling multiple diseases were also checked, which defaulted to the generic rule for using the ';;' separator.
4.  **Rule Application**: 
    *   The generic rule for multiple diseases was applied, requiring both diseases to be extracted and separated by ';;'.
    *   The 'High-Risk' qualifier precedes the coordinated noun phrase 'Acute Myeloid Leukaemia And Myelodysplastic Syndrome'. Grammatically and clinically, this modifier applies to both entities. Therefore, 'High-Risk' was prepended to both disease names.
    *   Procedural terms were excluded as per the generic exclusion rules.
    *   Formatting rules (Title Case, singular form) were applied. 'Leukaemia' and 'Syndrome' are already singular.
5.  **Indication Construction**: The two identified indications, 'High-Risk Acute Myeloid Leukaemia' and 'High-Risk Myelodysplastic Syndrome', were combined using the ';;' separator.
6.  **Quality Check**: The final output was verified against all generic and retrieved rules, ensuring correct formatting, source selection, and clinical accuracy.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To confirm the formatting and application of the 'High-Risk' qualifier.""}, {'category': 'Patient with two different Disease', 'subcategories': [], 'reason': ""To check for specific rules on how to handle two diseases connected by 'And'. No specific rules were found, so the generic separator rule was applied.""}]","[{'component': 'High-Risk Acute Myeloid Leukaemia', 'type': 'Disease with Risk', 'normalized_form': 'High-Risk Acute Myeloid Leukaemia', 'rule_applied': ""Generic rule for multiple diseases; Risk rule for 'High-Risk' formatting.""}, {'component': 'Myelodysplastic Syndrome', 'type': 'Disease', 'normalized_form': 'High-Risk Myelodysplastic Syndrome', 'rule_applied': ""The 'High-Risk' qualifier was applied to this second disease based on grammatical context ('High-Risk A and B').""}, {'component': 'Unmanipulated Peripheral Haploidentical Haematopoietic Stem Cell Transplant', 'type': 'Procedural Term', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/surgery terms.'}]",2
377743,Acute lymphoblastic leukemia - Clinical,Inotuzumab Ozogamicin Treatment In Adult Patients With Relapsed Or Refractory Philadelphia Chromosome-Negative Cd22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life French Study,Adult;;Relapsed;;Refractory;;Philadelphia Chromosome-Negative;;Cd22-Positive;;B-Cell Precursor Acute Lymphoblastic Leukemia,Adult Relapsed Or Refractory Ph-Negative Cd22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia,Adult Relapsed/Refractory Ph Chromosome-Negative CD22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step explanation of your extraction process:
1. **Analyze Input Titles**: The abstract title contains a detailed description of the disease and patient population, making it the preferred source over the more generic session title.
2. **Identify Components**: I identified several key components in the abstract title: 'Adult' (Age Group), 'Relapsed Or Refractory' (Disease State), 'Philadelphia Chromosome-Negative' (Chromosome Type), 'Cd22-Positive' (Biomarker), 'B-Cell Precursor' (Patient Subgroup), and 'Acute Lymphoblastic Leukemia' (Core Disease).
3. **Retrieve Relevant Rules**: I retrieved specific rules for each identified component using the `get_indication_rules` tool to ensure correct normalization and formatting.
4. **Apply Rules**: 
   - 'Adult' is kept as a leading descriptor based on Age Group rules.
   - 'Relapsed Or Refractory' is normalized to 'Relapsed/Refractory' per Occurrence rules.
   - 'Philadelphia Chromosome-Negative' is abbreviated to 'Ph Chromosome-Negative' as per Chromosome type rules.
   - 'Cd22-Positive' is a biomarker that is retained and formatted in Title Case as 'CD22-Positive'.
   - 'B-Cell Precursor' is a specific patient subgroup and is retained.
   - The core disease 'Acute Lymphoblastic Leukemia' is already in singular form and is formatted in Title Case.
   - Generic exclusion rules were applied to remove the treatment name ('Inotuzumab Ozogamicin') and the geographical descriptor ('French').
5. **Construct Indication**: The normalized components were assembled in a clinically logical order, starting with the patient population descriptors followed by the core disease.
6. **Quality Check**: The final indication was reviewed to ensure it adheres to the single-source principle, all formatting rules (Title Case, singular form), and exclusion criteria. The resulting indication is a complete and clinically accurate representation of the patient group from the abstract title.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'Adult' patient population descriptor.""}, {'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory', 'Relapse'], 'reason': ""To normalize the 'Relapsed Or Refractory' disease state.""}, {'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To handle the 'Philadelphia Chromosome-Negative' descriptor and its standard abbreviation.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To ensure correct formatting of the 'Cd22-Positive' biomarker.""}, {'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To confirm the inclusion of the 'B-Cell Precursor' patient subgroup.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule for 'Adult'""}, {'component': 'Relapsed Or Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': ""Occurrence rule for 'Recurrent/Refractory'""}, {'component': 'Philadelphia Chromosome-Negative', 'type': 'Chromosome Type', 'normalized_form': 'Ph Chromosome-Negative', 'rule_applied': ""Chromosome type rule for 'Philadelphia Chromosome-Negative'""}, {'component': 'Cd22-Positive', 'type': 'Biomarker', 'normalized_form': 'CD22-Positive', 'rule_applied': 'Generic rule for Title Case and biomarker formatting.'}, {'component': 'B-Cell Precursor', 'type': 'Patient Subgroup', 'normalized_form': 'B-Cell Precursor', 'rule_applied': ""Patient Sub-Group rule for 'B-Cell Precursor'""}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
164756,Updates in Mycobacteria,High-Dose Rifampin-containing Regimens for the Treatment of TB Meningitis,Tuberculous meningitis,Tuberculous Meningitis,TB Meningitis,True,abstract_title,"Step 1: The abstract title 'High-Dose Rifampin-containing Regimens for the Treatment of TB Meningitis' was chosen as the source because it contains a specific disease name ('TB Meningitis'), whereas the session title 'Updates in Mycobacteria' refers to a genus of bacteria, which is less specific.
Step 2: The core disease entity was identified as 'TB Meningitis'.
Step 3: The generic exclusion rule was applied to remove treatment-related information ('High-Dose Rifampin-containing Regimens for the Treatment of').
Step 4: The generic formatting rules were applied. The term 'TB Meningitis' is already in singular form. It was converted to Title Case, keeping the acronym 'TB' in its original uppercase form, resulting in 'TB Meningitis'. No specific rules were needed beyond the generic ones.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for any specific rules regarding disease characterization that might apply to 'TB Meningitis', although none were ultimately applicable.""}]","[{'component': 'TB Meningitis', 'type': 'Disease', 'normalized_form': 'TB Meningitis', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'High-Dose Rifampin-containing Regimens for the Treatment of', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclusion of procedural/temporal qualifiers'}]",2
263060,Aggressive Non-Hodgkin lymphoma - Clinical,Burkitt Lymphoma International Prognostic Index (Bl-Ipi): Is It Efficient Enough In Adult Burkitt Lymphoma Patients?,Adult;;Burkitt Lymphoma,Adult Burkitt Lymphoma,Adult Burkitt Lymphoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Burkitt Lymphoma International Prognostic Index (Bl-Ipi): Is It Efficient Enough In Adult Burkitt Lymphoma Patients?') was chosen as the primary source because it contains a specific disease term ('Burkitt Lymphoma'), making it more informative than the session title ('Aggressive Non-Hodgkin lymphoma - Clinical').
2.  **Component Identification**: I identified two key components in the abstract title: the disease 'Burkitt Lymphoma' and the patient subgroup 'Adult'. The phrase 'International Prognostic Index (Bl-Ipi)' was identified as a scoring methodology and excluded per generic rules.
3.  **Rule Retrieval**: To ensure correct formatting for the age group, I retrieved rules for the 'Age Group' category, specifically for the 'Adult' subcategory.
4.  **Rule Application**: The retrieved rules (e.g., Rule ID 289) specify that 'Adult' should be used as a capitalized prefix for the indication. Generic rules were applied to ensure the disease term is in singular form and Title Case ('Burkitt Lymphoma').
5.  **Indication Construction**: The components were combined according to the rules, placing the age group qualifier before the disease name.
6.  **Final Output**: The final indication is 'Adult Burkitt Lymphoma', which is clinically accurate and correctly formatted.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To confirm the correct formatting and placement of the 'Adult' patient subgroup descriptor.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule for 'Adult' (ID: 289)""}, {'component': 'Burkitt Lymphoma', 'type': 'Disease', 'normalized_form': 'Burkitt Lymphoma', 'rule_applied': 'Generic Casing and Singular Form rules'}, {'component': 'Burkitt Lymphoma International Prognostic Index (Bl-Ipi)', 'type': 'Scoring Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion rule for non-diagnostic items'}]",2
394135,Palliative Care,Integrated Palliative Care For Patients Referred For Chimeric Antigen Receptor T-Cell (Car-T) Therapy: A Service Evaluation,,,,True,none,"Neither the abstract title nor the session title contains a specific, clinically valid medical indication. The abstract title focuses on a type of therapy ('Chimeric Antigen Receptor T-Cell (Car-T) Therapy') and a type of care ('Palliative Care') for an unspecified group of patients. The session title is also a type of care ('Palliative Care'), not a disease. As per the rules, an indication must be a disease or disorder, and since none is explicitly mentioned, no indication can be extracted.",[],"[{'component': 'Chimeric Antigen Receptor T-Cell (Car-T) Therapy', 'type': 'Therapy', 'normalized_form': 'Chimeric Antigen Receptor T-Cell (Car-T) Therapy', 'rule_applied': 'Excluded as it is a treatment modality, not a disease.'}, {'component': 'Palliative Care', 'type': 'Medical Specialty', 'normalized_form': 'Palliative Care', 'rule_applied': 'Excluded as it is a type of care, not a disease.'}]",1
312224,Knowledge Bowl Preliminary Round,Alarcon's NETting Neutrophils,,,,True,none,"The abstract title 'Alarcon's NETting Neutrophils' refers to a biological process involving a type of white blood cell (neutrophils) but does not specify a disease or clinical condition. The session title 'Knowledge Bowl Preliminary Round' is non-medical and does not contain any health-related information. Since neither title contains a clinically valid medical indication, no extraction is possible.",[],[],1
344993,Innate Immunity to Tumors,Sex differences in the innate immune response to lung cancer,lung cancer,Lung Cancer,Lung Cancer,True,abstract_title,"Step 1: The abstract title ('Sex differences in the innate immune response to lung cancer') was chosen as the source because it contains a specific disease, 'lung cancer', which is more precise than the general term 'Tumors' in the session title.
Step 2: The component 'Sex differences' was identified as a sociodemographic descriptor (gender).
Step 3: The generic exclusion rule for sociodemographic descriptors was applied, leading to the removal of 'Sex differences'.
Step 4: The core disease 'lung cancer' was extracted and formatted according to the generic rules: converted to Title Case ('Lung Cancer') and ensured it was in singular form. The final indication is 'Lung Cancer'.",[],"[{'component': 'lung cancer', 'type': 'Disease', 'normalized_form': 'Lung Cancer', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Sex differences', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Sociodemographic Descriptors'}]",1
263082,Aggressive Non-Hodgkin lymphoma - Clinical,Zanubrutinib In Combination With Lenalidomide And Rituximab Versus R-Minichop In Unfit Or Frail Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Aged Over Or Equal To 70 Years,Newly Diagnosed Diffuse Large B-Cell Lymphoma,Elderly Newly Diagnosed Diffuse Large B-Cell Lymphoma,Elderly Newly Diagnosed Diffuse Large B-Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease, 'Diffuse Large B-Cell Lymphoma', which is more precise than the session title's 'Aggressive Non-Hodgkin lymphoma'.
2. **Component Identification**: The following components were identified in the abstract title: 
   - Disease: 'Diffuse Large B-Cell Lymphoma'
   - Diagnosis Status: 'Newly Diagnosed'
   - Age Group: 'Aged Over Or Equal To 70 Years'
   - Patient Condition: 'Unfit Or Frail'
3. **Rule Retrieval**: 
   - `get_indication_rules` was called for the 'Treatment based' category to handle 'Newly Diagnosed'. Rule ID 193 confirmed that 'Newly Diagnosed' should be used as a prefix.
   - `get_indication_rules` was called for the 'Age Group' category. Rule ID 303 ('Above 60') indicates that age descriptions like 'Aged Over Or Equal To 70 Years' should be standardized to the prefix 'Elderly'.
   - `get_indication_rules` was called for 'Patient Sub-Group' to check for rules on 'Unfit' or 'Frail'. No specific inclusion rule was found. These terms describe general patient fitness rather than a standard clinical subgroup for an indication, so they were excluded for conciseness.
4. **Indication Construction**: 
   - The core disease 'Diffuse Large B-Cell Lymphoma' was used as the base.
   - The diagnosis status 'Newly Diagnosed' was added as a prefix.
   - The age group 'Aged Over Or Equal To 70 Years' was standardized to 'Elderly' and added as a prefix.
   - The final indication was assembled by combining the standardized components in a clinically logical order (Age -> Diagnosis Status -> Disease).
5. **Quality Check**: The final indication was reviewed for compliance with all generic rules, including Title Case, singular form, and exclusion of non-standard descriptors. The result is a concise, standardized, and clinically accurate representation of the patient population.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To verify the handling of the term 'Newly Diagnosed'.""}, {'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To standardize the age descriptor 'Aged Over Or Equal To 70 Years'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding patient fitness descriptors like 'Unfit' or 'Frail'.""}]","[{'component': 'Diffuse Large B-Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Diffuse Large B-Cell Lymphoma', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease.""}, {'component': 'Aged Over Or Equal To 70 Years', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Rule ID: 303 - Standardize age thresholds >= 60 to 'Elderly'.""}, {'component': 'Unfit Or Frail', 'type': 'Patient Condition', 'normalized_form': '', 'rule_applied': 'Generic Exclusion: Excluded as a non-standard patient subgroup descriptor for indications.'}]",3
345008,Targeting Replication Stress and the Immune Microenvironment,POLE-specific variant classification strategy is critical for identifying patients who may benefit from immunotherapy,,,,True,none,"Neither the abstract title nor the session title contains a specific, clinically valid medical disease or disorder. The abstract title mentions a 'POLE-specific variant,' which defines a patient subgroup, but it does not specify the associated disease (e.g., cancer, tumor). According to the 'Single-Source Extraction Principle' and 'Handling Orphan PSUBs' rule, a patient subgroup without a core disease term in the same source title is insufficient to form a valid indication. The session title is also generic, focusing on biological mechanisms rather than a specific disease. Therefore, no indication can be extracted.",[],"[{'component': 'POLE-specific variant', 'type': 'Patient Sub-Group (Genetic)', 'normalized_form': 'POLE Variant', 'rule_applied': 'Handling Orphan PSUBs: This component was identified in the abstract title but could not be used because no corresponding disease term was present in the same title.'}]",2
148407,Sickle Cell Disease,Gbt021601 Improves The Pathophysiology Of Sickle Cell Disease In A Murine Model,Sickle Cell Disease,Sickle Cell Disease,Sickle Cell Disease,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: Both the abstract title ('Gbt021601 Improves The Pathophysiology Of Sickle Cell Disease In A Murine Model') and the session title ('Sickle Cell Disease') contain the disease term 'Sickle Cell Disease'.
2. **Select Source**: Following the Single-Source Extraction Principle, the abstract title is preferred as it contains a valid disease term. I will use the abstract title as the source.
3. **Identify Components**: The core disease component identified in the abstract title is 'Sickle Cell Disease'. The term 'Murine Model' indicates a pre-clinical study in an animal model, which is not a clinically valid human patient subgroup and must be excluded.
4. **Retrieve Rules**: No specific rules needed to be retrieved as the disease name is standard and there are no complex qualifiers.
5. **Apply Rules & Construct Indication**: The generic rules for formatting (Title Case, singular form) are applied. 'Sickle Cell Disease' is already in the correct format. The non-human study context ('Murine Model') is excluded as per the generic exclusion rules.
6. **Quality Check**: The final indication 'Sickle Cell Disease' is clinically accurate, correctly formatted, and adheres to all extraction principles.",[],"[{'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic rule: Use disease term from the selected source.'}, {'component': 'Murine Model', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude non-diagnostic items and study methodologies.'}]",1
181176,"Hemoglobinopathies, Excluding Thalassemia: Basic and Translational: Poster II",Identification of Small Molecules That Induce Therapeutic Levels of Fetal Hemoglobin for Treatment of Sickle Cell Disease By Pairing Machine Learning with High-Resolution Single Cell RNA Sequencing Maps of Adult and Fetal Human Erythropoiesis,Sickle Cell Disease,Sickle Cell Disease,Sickle Cell Disease,True,abstract_title,"Step 1: The abstract title contains the specific disease 'Sickle Cell Disease', while the session title contains a broader category 'Hemoglobinopathies'. Following the single-source principle, the abstract title is selected as the primary source.
Step 2: The core disease 'Sickle Cell Disease' was identified from the abstract title.
Step 3: No other patient subgroups, biomarkers, or staging information were present in the title.
Step 4: The generic formatting rules were applied. The disease name is already in singular form and Title Case.
Step 5: No terms requiring exclusion were found. The final indication is constructed from the identified disease.",[],"[{'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic singular form and Title Case rules.'}]",1
295865,"Mini Oral session: GI, lower digestive",Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer,resected;;stages I-III;;colorectal cancer,Resected Stage I-III Colorectal Cancer,Resected Stage I-III Colorectal Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The `abstract_title` was chosen as it contains a specific disease ('colorectal cancer'), whereas the `session_title` only refers to a general therapeutic area ('GI, lower digestive'). This adheres to the Single-Source Extraction Principle.
2. **Component Identification**: The key components identified in the abstract title were 'resected', 'stages I-III', and 'colorectal cancer'. The term 'cancer recurrence' was identified as a study endpoint or outcome, not a descriptor of the patient population, and was therefore excluded.
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for the identified components. I used `get_indication_rules` for 'Treatment Set-up' (subcategory 'Resectable') to handle 'resected' and for 'Stage' (subcategory 'Stage number') to handle 'stages I-III'.
4. **Rule Application**: 
   - **Treatment Status**: Based on the retrieved 'Resectable' rules (e.g., Rule ID 237), the past participle 'resected' is standardized to the Title Case adjective 'Resected' to describe the status of the cancer.
   - **Staging**: Based on the 'Stage number' rules (e.g., Rule ID 91), 'stages I-III' is normalized to 'Stage I-III'. Although the text of one rule mentioned converting to Arabic numerals, the examples provided consistently used Roman numerals, which is the standard clinical convention followed here.
   - **Disease Name**: The disease 'colorectal cancer' was converted to Title Case ('Colorectal Cancer') and confirmed to be in singular form, as per generic formatting rules.
5. **Indication Construction**: The normalized components were assembled in a clinically logical order, resulting in 'Resected Stage I-III Colorectal Cancer'.
6. **Final Quality Check**: The final indication was reviewed for compliance with all generic rules, including Title Case, singular form, and exclusion of non-indicative terms. The output is a single, concise, and clinically accurate indication.","[{'category': 'Treatment Set-up', 'subcategories': ['Resectable'], 'reason': ""To correctly format the treatment status 'resected'.""}, {'category': 'Stage', 'subcategories': ['Stage number'], 'reason': ""To correctly format the cancer stage range 'stages I-III'.""}]","[{'component': 'resected', 'type': 'Treatment Status', 'normalized_form': 'Resected', 'rule_applied': 'Treatment Set-up -> Resectable Rule ID 237'}, {'component': 'stages I-III', 'type': 'Stage', 'normalized_form': 'Stage I-III', 'rule_applied': 'Stage -> Stage number Rule ID 91 (following example format)'}, {'component': 'colorectal cancer', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic Casing and Singular Form Rules'}]",2
328644,Myelodysplastic Syndromes - Clinical and Epidemiological: Poster III,Validation of a Novel Algorithm with a High Specificity in Ruling out MDS,MDS,Myelodysplastic Syndrome,Myelodysplastic Syndrome,True,session_title,"Step 1: The abstract title mentions 'MDS', which is an abbreviation for Myelodysplastic Syndromes. The session title explicitly states 'Myelodysplastic Syndromes'. Both titles refer to the same disease.
Step 2: According to the single-source principle, the session title is chosen as it contains the full, unambiguous disease name.
Step 3: The generic rule for singularization is applied, converting 'Syndromes' to 'Syndrome'.
Step 4: The non-disease-related text '- Clinical and Epidemiological: Poster III' is excluded as it describes the session context, not the indication itself.
Step 5: The final indication is formatted in Title Case, resulting in 'Myelodysplastic Syndrome'.",[],"[{'component': 'Myelodysplastic Syndromes', 'type': 'Disease', 'normalized_form': 'Myelodysplastic Syndrome', 'rule_applied': 'Generic rule: Singular Form'}]",1
312263,Moving on Up: Changing How We Define Early Knee OA and Get People Moving,Biomarker-Based Stratification in Osteoarthritis Patients and in Those at Risk: Advances in the Field,Osteoarthritis ,Osteoarthritis ,Osteoarthritis;;At-Risk Osteoarthritis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title, ""Biomarker-Based Stratification in Osteoarthritis Patients and in Those at Risk: Advances in the Field"", contains the specific disease term ""Osteoarthritis"". The session title also mentions ""Knee OA"", but per the single-source principle, the abstract title is preferred as it contains a clear disease term.
2.  **Component Identification**: The abstract title identifies two distinct populations related to the same disease:
    *   ""Osteoarthritis Patients"": This directly indicates the disease `Osteoarthritis`.
    *   ""Those at Risk"": This identifies a patient subgroup defined by their risk status for the same disease.
3.  **Rule Retrieval**: I retrieved rules for the 'Risk' category to understand how to handle terms like ""at Risk"". While no specific rule exactly matched the general phrase ""at Risk"", the patterns for other risk types (e.g., High-Risk, Low-Risk) show that the risk qualifier should be prefixed to the disease name.
4.  **Indication Construction**: Based on the identified components and general principles, two separate indications were constructed:
    *   The first indication is the primary disease itself: `Osteoarthritis`.
    *   The second indication combines the risk subgroup with the disease. The phrase ""at Risk"" was normalized to the standardized prefix ""At-Risk"" and combined with the disease to form `At-Risk Osteoarthritis`.
5.  **Formatting and Finalization**: The two distinct indications were formatted according to the generic rules:
    *   **Separator**: The `;;` delimiter is used to separate the two indications.
    *   **Casing**: Both indications are formatted in Title Case.
    *   **Singular Form**: ""Osteoarthritis"" is already in its singular form.
    *   The final combined output is `Osteoarthritis;;At-Risk Osteoarthritis`.","[{'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': 'To determine the correct formatting for the patient subgroup ""at Risk"" identified in the abstract title.'}]","[{'component': 'Osteoarthritis Patients', 'type': 'Disease', 'normalized_form': 'Osteoarthritis', 'rule_applied': 'Generic rule: Singular Form, Title Case.'}, {'component': 'Those at Risk', 'type': 'Patient Subgroup (Risk)', 'normalized_form': 'At-Risk Osteoarthritis', 'rule_applied': 'General principle from Risk rules: Prefix the risk status to the disease name. The risk is implicitly for Osteoarthritis, the main subject of the title.'}]",2
394187,Pancreatic Cancer,Clinical And Molecular Features Of Young Onset Pancreatic Adenocarcinoma,Young Onset;;Pancreatic Adenocarcinoma,Young Onset Pancreatic Adenocarcinoma,Young Onset Pancreatic Adenocarcinoma,True,abstract_title,"Step 1: The abstract title 'Clinical And Molecular Features Of Young Onset Pancreatic Adenocarcinoma' was chosen as the source because it contains a specific disease term, 'Pancreatic Adenocarcinoma', making it more informative than the session title.
Step 2: The components identified in the title were the disease 'Pancreatic Adenocarcinoma' and the onset qualifier 'Young Onset'. The phrase 'Clinical And Molecular Features Of' was identified as descriptive of the study and marked for exclusion.
Step 3: To ensure correct handling of the onset qualifier, rules were retrieved using `get_indication_rules` for the category 'Onset' and subcategory 'Onset by Age'.
Step 4: The retrieved rules (specifically Rule ID 276 and 277) instruct to normalize 'Young Onset' and prepend it to the disease name. The generic rule for Title Casing was also applied.
Step 5: The final indication was constructed by combining the normalized qualifier and the disease name, resulting in 'Young Onset Pancreatic Adenocarcinoma'.
Step 6: A final quality check confirmed that the indication was derived from a single source, correctly formatted, and clinically accurate.","[{'category': 'Onset', 'subcategories': ['Onset by Age'], 'reason': ""To correctly handle the 'Young Onset' qualifier.""}, {'category': 'Age Group', 'subcategories': ['Young'], 'reason': ""To check for conflicting rules regarding the term 'Young' and confirm that 'Young Onset' is treated as a specific clinical entity.""}]","[{'component': 'Young Onset', 'type': 'Onset Qualifier', 'normalized_form': 'Young Onset', 'rule_applied': 'Onset rule (ID 276/277) for prepending the qualifier to the disease name.'}, {'component': 'Pancreatic Adenocarcinoma', 'type': 'Disease', 'normalized_form': 'Pancreatic Adenocarcinoma', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
230348,Central Nervous System Tumors,"Compliance, adverse events and quality of life of patients in a phase 3 study comparing temozolomide with PCV as adjuvant chemotherapy in grade 2 and 3 glioma.",Central Nervous System Tumors;;grade 2;;3 ,Grade 2 Grade 3 Central Nervous System Tumor,Grade II Glioma;;Grade III Glioma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Compliance, adverse events and quality of life of patients in a phase 3 study comparing temozolomide with PCV as adjuvant chemotherapy in grade 2 and 3 glioma.') was chosen over the session title ('Central Nervous System Tumors') because it contains a specific disease with qualifiers ('grade 2 and 3 glioma'), adhering to the Single-Source Extraction Principle.
2. **Component Identification**: The key components identified in the abstract title are the disease 'glioma' and the grade qualifiers 'grade 2 and 3'.
3. **Rule Retrieval**: The `get_indication_rules` tool was used for the 'Grade' category to understand how to handle numeric grades. Rule ID 119 (for Grade 2) and similar rules for other grades confirmed that Arabic numerals should be converted to Roman numerals (2 -> II, 3 -> III) and that multiple grades mentioned together should be split into separate indications.
4. **Rule Application**: 
   - The phrase 'grade 2 and 3 glioma' was identified as representing two distinct clinical indications.
   - The indications were separated: 'grade 2 glioma' and 'grade 3 glioma'.
   - The generic rule for singular form was applied, but 'glioma' is already singular.
   - The generic rule for Title Case was applied to capitalize 'Glioma'.
   - The retrieved grade-specific rules were applied to convert Arabic numerals to Roman numerals, resulting in 'Grade II' and 'Grade III'.
   - The multiple disease rule was applied to join the two final indications with the ';;' separator.
5. **Indication Construction**: The components were assembled into the final string: 'Grade II Glioma;;Grade III Glioma'.
6. **Quality Check**: The final output was verified for adherence to all formatting, exclusion, and content rules. It correctly captures the two distinct patient subgroups mentioned in the source title.","[{'category': 'Grade', 'subcategories': ['Grade', 'Grade group number', 'Grade number'], 'reason': ""To determine the correct formatting for 'grade 2 and 3'.""}]","[{'component': 'grade 2 glioma', 'type': 'Disease with Grade', 'normalized_form': 'Grade II Glioma', 'rule_applied': ""Grade number rule (convert to Roman numeral); Title Case rule; Multiple disease rule (split from 'and 3').""}, {'component': 'grade 3 glioma', 'type': 'Disease with Grade', 'normalized_form': 'Grade III Glioma', 'rule_applied': ""Grade number rule (convert to Roman numeral); Title Case rule; Multiple disease rule (split from '2 and').""}]",2
213966,"MP35: Sexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy I",Characteristics of Systemic Testosterone Therapy for Female Hypoactive Sexual Desire Disorder - A Claims Database Analysis,Hypoactive Sexual Desire Disorder,Hypoactive Sexual Desire Disorder,Hypoactive Sexual Desire Disorder,True,abstract_title,"Step 1: The abstract title 'Characteristics of Systemic Testosterone Therapy for Female Hypoactive Sexual Desire Disorder - A Claims Database Analysis' was chosen as the source because it contains a specific disease term, which is preferred over the broader category 'Sexual Function/Dysfunction' in the session title.
Step 2: The core disease 'Hypoactive Sexual Desire Disorder' was identified.
Step 3: The sociodemographic descriptor 'Female' was identified for exclusion based on the generic rules.
Step 4: The generic exclusion rule for gender was applied, removing 'Female' from the indication as it is not an integral part of the disease name.
Step 5: The remaining term was formatted to Title Case and checked for singularity, resulting in the final indication.",[],"[{'component': 'Female', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Gender'}, {'component': 'Hypoactive Sexual Desire Disorder', 'type': 'Disease', 'normalized_form': 'Hypoactive Sexual Desire Disorder', 'rule_applied': 'Generic Formatting Rule: Title Case'}]",1
148434,Stem Cell Transplantation - Clinical,Minimal Residual Disease Monitoring And Preemptive Immunotherapies For Frequent 11Q23 Rearranged Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation,11Q23;;Rearranged;;Acute Leukemia,11Q23 Rearranged Acute Leukemia,11q23-Rearranged Acute Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Minimal Residual Disease Monitoring And Preemptive Immunotherapies For Frequent 11Q23 Rearranged Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation' was chosen because it contains a specific disease ('Acute Leukemia'), whereas the session title is a general procedural category.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Acute Leukemia' and the chromosomal alteration '11Q23 Rearranged'. The phrase 'After Allogeneic Hematopoietic Stem Cell Transplantation' was identified as a treatment context.
3. **Rule Retrieval**: I retrieved rules for 'Chromosome type' to understand how to handle '11Q23 Rearranged' and for 'Treatment Set-up' (specifically 'Transplant Status') to handle the post-transplantation context.
4. **Rule Application**:
   - **Generic Exclusion Rule**: The terms 'Minimal Residual Disease Monitoring' and 'Preemptive Immunotherapies' are procedural/methodological and were excluded.
   - **Treatment Set-up Rule**: The retrieved rules for 'Transplant Status' (e.g., Rule ID 232, 233 for 'Post-Transplant') mandate the exclusion of temporal treatment statuses. 'After Allogeneic Hematopoietic Stem Cell Transplantation' falls into this category and was therefore excluded.
   - **Chromosome Type**: While no specific rule dictated the exact formatting for '11Q23 Rearranged', it is a critical clinical descriptor defining a specific subtype of leukemia. It was retained as a qualifier.
   - **Generic Formatting Rule**: The disease term 'Acute Leukemia' is already singular and was converted to Title Case. The qualifier '11Q23 Rearranged' was standardized to '11q23-Rearranged' for clarity and common clinical notation, prepending it to the disease name.
   - The term 'Frequent' was excluded as it describes the incidence of the rearrangement rather than being a standard clinical qualifier for the disease itself.
5. **Indication Construction**: The final indication was constructed by combining the standardized chromosomal qualifier with the disease name, resulting in '11q23-Rearranged Acute Leukemia'.","[{'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To determine the correct formatting and inclusion of the '11Q23 Rearranged' chromosomal alteration.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine how to handle the phrase 'After Allogeneic Hematopoietic Stem Cell Transplantation'.""}]","[{'component': 'Acute Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Leukemia', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': '11Q23 Rearranged', 'type': 'Chromosomal Alteration', 'normalized_form': '11q23-Rearranged', 'rule_applied': 'Standard clinical formatting for chromosomal alterations; prepended to the disease name.'}, {'component': 'After Allogeneic Hematopoietic Stem Cell Transplantation', 'type': 'Procedural/Temporal Qualifier', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule; Treatment Set-up Rule ID 232/233 for 'Post-Transplant' context.""}, {'component': 'Minimal Residual Disease Monitoring And Preemptive Immunotherapies', 'type': 'Procedural/Methodological Term', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for non-diagnostic items.'}, {'component': 'Frequent', 'type': 'Non-Clinical Qualifier', 'normalized_form': '', 'rule_applied': 'Excluded as it is not a standard clinical descriptor for an indication.'}]",2
394195,Pancreatic Cancer,Diagnostic Performance Of Blood-Based Dna Methylation Assay Using Epigenetic-Specific Peptide Nucleic Acid In Pancreatic Adenocarcinoma,Pancreatic Adenocarcinoma,Pancreatic Adenocarcinoma,Pancreatic Adenocarcinoma,True,abstract_title,"Step 1: The abstract title contains a more specific disease term ('Pancreatic Adenocarcinoma') compared to the session title ('Pancreatic Cancer'). Therefore, the abstract title is selected as the source based on the single-source extraction principle.
Step 2: The core disease entity identified in the abstract title is 'Pancreatic Adenocarcinoma'. Other parts of the title, such as 'Diagnostic Performance Of Blood-Based Dna Methylation Assay', describe the study's methodology and are not part of the medical indication.
Step 3: No specific rules needed to be retrieved as the extraction is straightforward.
Step 4: The generic formatting rules are applied. The term is already in singular form and is converted to Title Case, resulting in 'Pancreatic Adenocarcinoma'.
Step 5: The final indication is constructed from the normalized disease term.",[],"[{'component': 'Pancreatic Adenocarcinoma', 'type': 'Disease', 'normalized_form': 'Pancreatic Adenocarcinoma', 'rule_applied': 'Generic Casing and Singular Form Rules'}]",1
345045,Novel Antitumor Agents 1,Targeting CD73-adenosine axis for the treatment of multiple myeloma,multiple myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: The abstract title 'Targeting CD73-adenosine axis for the treatment of multiple myeloma' was chosen as the source because it contains a specific disease term ('multiple myeloma'), whereas the session title 'Novel Antitumor Agents 1' is less specific. 
Step 2: The core disease component identified was 'multiple myeloma'. The phrase 'Targeting CD73-adenosine axis' describes the drug's mechanism of action, not the patient indication, and 'for the treatment of' is a procedural phrase; both are excluded based on generic rules.
Step 3: No specific rules were needed from the tool as the extraction is straightforward.
Step 4: The generic formatting rules were applied. The disease term was converted to Title Case ('Multiple Myeloma') and confirmed to be in singular form.
Step 5: The final indication was constructed as 'Multiple Myeloma'.",[],"[{'component': 'multiple myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Casing Rule (Title Case)'}]",1
230358,Central Nervous System Tumors,Assessment of neurocognitive functions using ACE-III scale in patients with high-grade glioma receiving adjuvant chemoradiation.,high-grade;;glioma,High-Grade Glioma,High Grade Glioma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title because it contains a more specific disease term, 'glioma', compared to the broader 'Central Nervous System Tumors'.
2. **Component Identification**: The key components identified in the abstract title were 'high-grade' (a tumor grade) and 'glioma' (the disease).
3. **Rule Retrieval**: Rules for the 'Grade' category were retrieved to correctly format 'high-grade'. Rules for 'Treatment Set-up' were retrieved to determine if 'receiving adjuvant chemoradiation' should be included.
4. **Rule Application**: 
   - The specific rule for 'High Grade' (ID: 115) was applied, standardizing 'high-grade' to 'High Grade' (Title Case, no hyphen).
   - The generic rule for singularization was applied to 'glioma' (which was already singular).
   - The generic exclusion rule for procedural/temporal qualifiers was applied to 'receiving adjuvant chemoradiation', leading to its exclusion from the final indication.
5. **Indication Construction**: The standardized components were combined to form the final indication 'High Grade Glioma'.
6. **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form) and accurately represents the core clinical condition described in the source title.","[{'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To correctly format the 'high-grade' descriptor.""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To verify whether the treatment context 'receiving adjuvant chemoradiation' should be part of the indication.""}]","[{'component': 'high-grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Grade rule (ID: 115) requires standardizing to 'High Grade' with no hyphen.""}, {'component': 'glioma', 'type': 'Disease', 'normalized_form': 'Glioma', 'rule_applied': 'Generic rule: Use singular form for disease names.'}, {'component': 'receiving adjuvant chemoradiation', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Generic exclusion rule: Exclude procedural/temporal qualifiers like 'receiving'.""}]",2
230361,Central Nervous System Tumors,The effects of vascular endothelial cells on regulating post-irradiation microglia phenotype in irradiation-induced brain injury.,brain injury,Brain Injury,Central Nervous System Tumor,True,session_title,"Step 1: The abstract title mentions 'irradiation-induced brain injury'. This is a complication or adverse effect resulting from a procedure (irradiation) and not a primary disease. According to the exclusion rules, complications should be excluded. Therefore, the abstract title does not contain a valid primary indication.
Step 2: The session title, 'Central Nervous System Tumors', contains a clear and valid disease category. Based on the Single-Source Extraction Principle, I will use the session title as the source since the abstract title lacks a valid primary disease.
Step 3: I identified the disease term 'Central Nervous System Tumors' from the session title.
Step 4: I applied the generic rule for singular form, converting 'Tumors' to 'Tumor'.
Step 5: The final indication is constructed as 'Central Nervous System Tumor', adhering to Title Case and singular form rules.",[],"[{'component': 'Central Nervous System Tumors', 'type': 'Disease', 'normalized_form': 'Central Nervous System Tumor', 'rule_applied': 'Generic Rule: Singular Form'}]",1
345049,Adaptive Immunity to Tumors,Serological responses to tumor-associated adducts in pancreatic cancer,pancreatic cancer,Pancreatic Cancer,Pancreatic Cancer,True,abstract_title,"Step 1: The abstract title 'Serological responses to tumor-associated adducts in pancreatic cancer' was chosen as the source because it contains a specific disease, 'pancreatic cancer', which is more precise than the general term 'Tumors' in the session title.
Step 2: The core disease 'pancreatic cancer' was identified from the selected title.
Step 3: The phrases 'Serological responses' and 'tumor-associated adducts' were identified as non-diagnostic study details and excluded as per the generic exclusion rules.
Step 4: The generic formatting rules were applied. The extracted disease was converted to Title Case ('Pancreatic Cancer') and confirmed to be in singular form. No specific rules needed to be retrieved as there were no complex components like gene mutations or staging.",[],"[{'component': 'pancreatic cancer', 'type': 'Disease', 'normalized_form': 'Pancreatic Cancer', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Singular Form'}]",1
377819,Sickle cell disease,Characterisation Of Quality Of Life-Linked Patient-Reported Outcomes Through A Digital And Continuous Remote Monitoring Ecosystem In Sickle Cell Disease.,Sickle Cell Disease,Sickle Cell Disease,Sickle Cell Disease,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. Both contain the disease term 'Sickle Cell Disease'.
Step 2: Following the single-source principle, I selected the abstract title as the primary source because it contains a valid disease term.
Step 3: I identified the core disease as 'Sickle Cell Disease'. The remaining parts of the abstract title, such as 'Characterisation Of Quality Of Life-Linked Patient-Reported Outcomes Through A Digital And Continuous Remote Monitoring Ecosystem', describe the study's methodology and outcomes, not the patient subgroup or disease characteristics. 
Step 4: I applied the generic exclusion rules to remove the non-diagnostic, procedural, and methodological information.
Step 5: I applied the formatting rules, ensuring the final indication 'Sickle Cell Disease' is in Title Case and singular form.
Step 6: The final indication is a direct extraction of the disease name from the selected source, with all other non-clinical information removed.",[],"[{'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic Casing and Singular Form Rules'}, {'component': 'Characterisation Of Quality Of Life-Linked Patient-Reported Outcomes Through A Digital And Continuous Remote Monitoring Ecosystem', 'type': 'Non-Diagnostic Information', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for study methodologies'}]",1
181215,"Granulocytes, Monocytes, and Macrophages: Poster II",Safety of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Relationship to Treatment Exposure,Pediatric;;Primary;;Hemophagocytic Lymphohistiocytosis,Pediatric Primary Hemophagocytic Lymphohistiocytosis,Pediatric Primary Hemophagocytic Lymphohistiocytosis,True,abstract_title,"Step 1: The abstract title contains a clear disease term ('Primary Hemophagocytic Lymphohistiocytosis'), while the session title lists cell types. Therefore, the abstract title was selected as the source based on the single-source principle.
Step 2: The components identified in the abstract title are the age group 'Pediatric', the disease qualifier 'Primary', and the disease name 'Hemophagocytic Lymphohistiocytosis'.
Step 3: Rules for the 'Age Group' category, specifically 'Pediatric', were retrieved to ensure correct formatting. The generic rule for 'Primary' was also applied.
Step 4: The retrieved 'Pediatric' rule (ID: 295) dictates that 'Pediatric' should be used as a leading qualifier. The generic rule for 'Primary' confirms its inclusion as it directly precedes the disease name. Generic formatting rules for Title Case and singular form were applied. The abbreviation (HLH) and non-diagnostic phrases ('Safety of Emapalumab in', 'Patients with', ': Relationship to Treatment Exposure') were excluded.
Step 5: The components were combined in the correct order to form the final indication: 'Pediatric Primary Hemophagocytic Lymphohistiocytosis'.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly handle the 'Pediatric' patient subgroup qualifier.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group Rule ID: 295 - Retain 'Pediatric' as a leading qualifier.""}, {'component': 'Primary', 'type': 'Disease Qualifier', 'normalized_form': 'Primary', 'rule_applied': ""Generic Rule: Disease Characterization - Include 'Primary' when it is part of the disease name.""}, {'component': 'Hemophagocytic Lymphohistiocytosis (HLH)', 'type': 'Disease', 'normalized_form': 'Hemophagocytic Lymphohistiocytosis', 'rule_applied': 'Generic Rule: Formatting - Use Title Case and singular form. Exclude abbreviation.'}]",2
213985,MP36: Renal Transplantation & Vascular Surgery,Robotic Bilateral Nephrectomy for Large Kidneys with Adult Polycystic Kidney Disease with Da Vinci Xi and Da Vinci SP,Adult;;Polycystic Kidney Disease,Adult Polycystic Kidney Disease,Adult Polycystic Kidney Disease,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'Robotic Bilateral Nephrectomy for Large Kidneys with Adult Polycystic Kidney Disease with Da Vinci Xi and Da Vinci SP' was chosen as the source because it contains a specific disease term ('Adult Polycystic Kidney Disease'), whereas the session title 'MP36: Renal Transplantation & Vascular Surgery' describes procedures and a broader therapeutic area.

2.  **Component Identification**: The selected title contains the following components:
    *   Disease: 'Polycystic Kidney Disease'
    *   Age Group: 'Adult'
    *   Procedure: 'Robotic Bilateral Nephrectomy' (to be excluded)
    *   Disease Characteristic: 'Large Kidneys' (descriptive, to be excluded for standardization)
    *   Device: 'Da Vinci Xi and Da Vinci SP' (to be excluded)

3.  **Rule Retrieval**: Rules for the 'Age Group' category were retrieved to handle the term 'Adult'.

4.  **Rule Application**:
    *   **Generic Exclusion Rules**: The procedural term 'Robotic Bilateral Nephrectomy' and the device names 'Da Vinci Xi and Da Vinci SP' were excluded as they describe methodology, not the core indication.
    *   **Generic Standardization**: The descriptive characteristic 'Large Kidneys' was excluded to maintain a concise and standardized indication. While clinically relevant for the procedure, it is not typically part of the formal disease name.
    *   **Age Group Rule (ID: 289)**: The rule for 'Adult' was applied, which specifies prepending the capitalized term 'Adult' to the disease name.

5.  **Indication Construction**: The identified age group 'Adult' was combined with the core disease name 'Polycystic Kidney Disease'.

6.  **Final Formatting**: The final indication was formatted to 'Adult Polycystic Kidney Disease', adhering to Title Case and singular form rules.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'Adult' patient subgroup qualifier.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Rule ID: 289 - Prepend 'Adult' to the indication.""}, {'component': 'Polycystic Kidney Disease', 'type': 'Disease', 'normalized_form': 'Polycystic Kidney Disease', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}, {'component': 'Robotic Bilateral Nephrectomy', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural terms.'}, {'component': 'Large Kidneys', 'type': 'Disease Characteristic', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-standard descriptive qualifiers for conciseness.'}]",2
181218,Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II,Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma,B-Cell Lymphoma,B-Cell Lymphoma,B-Cell Lymphoma,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease, 'B-Cell Lymphoma', whereas the session title contains a broader, less specific category, 'Immunodeficiency Disorders'.
Step 2: The core disease entity 'B-Cell Lymphoma' was identified from the abstract title.
Step 3: The phrase 'Time Since Last Anti-CD20 Treatment' was identified as a procedural and temporal qualifier. According to the generic exclusion rules, such qualifiers, which describe the treatment history rather than the disease state itself, must be excluded from the final indication.
Step 4: The term 'Sars-Cov-2 Vaccine Response' was identified as a study outcome and not a medical indication, leading to its exclusion.
Step 5: The extracted disease term 'B-Cell Lymphoma' was formatted according to the generic rules: it is already in singular form and correctly formatted in Title Case. The final indication is the standardized disease name.","[{'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To verify the correct handling and formatting of 'B-Cell' as part of the disease name.""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To determine if 'Anti-CD20 Treatment' should be included as a qualifier. The rules confirmed that treatment history is generally excluded.""}]","[{'component': 'B-Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'B-Cell Lymphoma', 'rule_applied': 'Generic Rule: Singular Form, Title Case. Patient Sub-Group rule for B-Cell confirmed it is part of the disease name.'}, {'component': 'Anti-CD20 Treatment', 'type': 'Procedural/Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Procedural/Temporal Qualifiers must be excluded.'}]",2
181219,Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II,Chronically Elevated Interleukin-6 Disturbs the Coagulation Cascade in Mice,Acquired;;Congenital;;Immunodeficiency Disorders,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorder,Acquired/Congenital Immunodeficiency Disorder,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title, 'Chronically Elevated Interleukin-6 Disturbs the Coagulation Cascade in Mice', describes a physiological process in a preclinical model and does not contain a valid human medical indication. The session title, 'Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II', contains clear disease terms.
2.  **Principle Adherence**: Following the single-source principle, the session title was chosen for extraction.
3.  **Component Identification**: The core components identified in the session title are the diseases 'Acquired Immunodeficiency Disorders' and 'Congenital Immunodeficiency Disorders', connected by the word 'or'.
4.  **Rule Retrieval**: The presence of the connector 'or' prompted the retrieval of rules for 'Occurrence' -> 'Connectors'.
5.  **Rule Application**: Rule ID 146 for the connector 'or' was applied, which specifies replacing 'or' with a '/' to merge the descriptors. The generic rule for converting plural disease names to singular was also applied ('Disorders' -> 'Disorder').
6.  **Indication Construction**: The descriptors 'Acquired' and 'Congenital' were combined using '/', and then prepended to the singular, title-cased disease name, resulting in 'Acquired/Congenital Immunodeficiency Disorder'.
7.  **Exclusion**: Non-disease terms like 'Lymphocytes' and metadata 'Poster II' were correctly excluded.","[{'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To correctly handle the 'or' connector between 'Acquired' and 'Congenital'.""}]","[{'component': 'Acquired or Congenital Immunodeficiency Disorders', 'type': 'Disease', 'normalized_form': 'Acquired/Congenital Immunodeficiency Disorder', 'rule_applied': ""Connector rule (ID 146) to replace 'or' with '/'; Generic rule for singular form ('Disorders' -> 'Disorder'); Generic rule for Title Case.""}]",2
328676,Myelodysplastic Syndromes - Clinical and Epidemiological: Poster I,The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study,Myelodysplastic Syndrome,Myelodysplastic Syndrome,Cerebrovascular Accident;;Myelodysplastic Syndrome,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study') was chosen as it contains specific disease terms, which is preferred over the session title according to the single-source principle.
2.  **Component Identification**: Two distinct medical conditions were identified in the abstract title: 'Cerebrovascular Accident' and 'Myelodysplastic Syndrome'.
3.  **Rule Application**: The generic rule for 'MULTIPLE DISEASES' was applied. This rule states that when multiple distinct diseases are mentioned, both should be extracted and separated by a double semicolon (';;').
4.  **Exclusion Rules**: Sociodemographic and procedural qualifiers such as 'in the United States' and 'A Nationwide Population-Based Study' were excluded as per the generic exclusion rules.
5.  **Formatting Rules**: The extracted indications were checked for formatting. Both 'Cerebrovascular Accident' and 'Myelodysplastic Syndrome' are already in singular form and appropriate Title Case.
6.  **Final Construction**: The two identified and normalized indications were combined using the ';;' separator to form the final output.",[],"[{'component': 'Cerebrovascular Accident', 'type': 'Disease', 'normalized_form': 'Cerebrovascular Accident', 'rule_applied': 'Generic Rule - Multiple Diseases'}, {'component': 'Myelodysplastic Syndrome', 'type': 'Disease', 'normalized_form': 'Myelodysplastic Syndrome', 'rule_applied': 'Generic Rule - Multiple Diseases'}]",3
213989,MP37: Infections/Inflammation/Cystic Disease of the Genitourinary Tract: Prostate & Genitalia,Pilot Trial for PIVoT: Prevention of recurrent urinary tract Infection using Vaginal Testosterone,recurrent;;urinary tract Infection,Recurrent Urinary Tract Infection,Recurrent Urinary Tract Infection,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Pilot Trial for PIVoT: Prevention of recurrent urinary tract Infection using Vaginal Testosterone') was chosen as the source because it contains a specific, well-defined disease ('urinary tract Infection'), which is preferred over the broader categories listed in the session title.
2. **Component Identification**: The key components identified in the abstract title were the disease 'urinary tract Infection' and the occurrence qualifier 'recurrent'. The phrase 'Prevention of' was identified as a study goal and excluded. 'using Vaginal Testosterone' was identified as a treatment modality and excluded per generic rules.
3. **Rule Retrieval**: To ensure correct handling of the term 'recurrent', rules were retrieved for the 'Occurrence' category, specifically for 'Recurrence-Related Terms'.
4. **Rule Application**: 
   - The retrieved rule (e.g., ID 139) confirmed that 'recurrent' should be normalized to 'Recurrent' and placed before the disease name.
   - The generic casing rule was applied to convert 'urinary tract Infection' to 'Urinary Tract Infection'.
   - The generic singular form rule was applied, confirming that 'Infection' is already in the correct singular form.
5. **Indication Construction**: The normalized components were combined to form the final indication: 'Recurrent Urinary Tract Infection'.
6. **Quality Check**: The final output was verified against all generic and specific rules, ensuring adherence to formatting (Title Case, single spacing), exclusion of non-indication elements, and clinical accuracy.","[{'category': 'Occurrence', 'subcategories': ['Recurrence-Related Terms', 'Recurrent/Refractory'], 'reason': ""To correctly handle the term 'recurrent' found in the abstract title.""}]","[{'component': 'recurrent', 'type': 'Occurrence', 'normalized_form': 'Recurrent', 'rule_applied': ""Rule ID 139: Normalize 'Recurrent' to Title Case and place it before the disease name.""}, {'component': 'urinary tract Infection', 'type': 'Disease', 'normalized_form': 'Urinary Tract Infection', 'rule_applied': 'Generic Rule: Apply Title Case to clinically significant words.'}, {'component': 'Prevention of', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude study methodologies and non-diagnostic items.'}, {'component': 'using Vaginal Testosterone', 'type': 'Treatment', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude treatment-related terms.'}]",2
295910,How can we use ctDNA for early detection of cancer?,Discussion led by Chair,cancer,Cancer,Cancer,True,session_title,"Step 1: The abstract title 'Discussion led by Chair' contains no medical or disease terms. The session title 'How can we use ctDNA for early detection of cancer?' contains the disease term 'cancer'.
Step 2: Based on the single-source principle, the session title is selected for extraction.
Step 3: The components identified in the session title are the disease 'cancer' and the qualifier 'early detection'.
Step 4: The term 'early detection' describes a study methodology or a procedural context, not a characteristic of the disease itself (like 'Early-Stage Cancer'). According to the generic exclusion rules, study methodologies must be excluded.
Step 5: The remaining term 'cancer' is processed. It is already in singular form. Applying Title Case formatting results in 'Cancer'.
Step 6: The final generated indication is 'Cancer'.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To check for rules related to disease detection timing, such as 'early detection'. The retrieved rule for 'Newly Diagnosed' was not directly applicable but informed the analysis of diagnostic qualifiers.""}]","[{'component': 'cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Singular Form'}, {'component': 'early detection', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Study Methodologies'}]",2
213982,MP36: Renal Transplantation & Vascular Surgery,The effect of renal transplantation on erectile functions in patients with end-stage renal disease.,end-stage;;renal disease,End-Stage Renal Disease,End-Stage Renal Disease,True,abstract_title,"Step 1: The abstract title contains a specific disease ('end-stage renal disease'), while the session title refers to procedures ('Renal Transplantation', 'Vascular Surgery'). Therefore, the abstract title is selected as the source based on the single-source principle.
Step 2: The core disease entity identified in the abstract title is 'end-stage renal disease'. The term 'end-stage' is a critical disease characterizer indicating severity and stage, so it must be included.
Step 3: I retrieved rules for 'Stage Severity' to confirm how to handle descriptors like 'end-stage'. The rules confirm that such severity/stage descriptors should be preserved and capitalized.
Step 4: The term 'renal transplantation' is a procedure and is excluded as per the generic exclusion rules. 'Erectile functions' is a symptom/condition being studied within the patient group, not the primary indication defining the cohort, so it is also excluded.
Step 5: The final indication is constructed by applying Title Case and singular form rules to the identified disease. 'end-stage renal disease' is normalized to 'End-Stage Renal Disease'.","[{'category': 'Stage', 'subcategories': ['Stage Severity'], 'reason': ""To verify the correct handling of the 'end-stage' disease qualifier.""}]","[{'component': 'end-stage renal disease', 'type': 'Disease', 'normalized_form': 'End-Stage Renal Disease', 'rule_applied': 'Generic Casing Rule, Stage Severity Rule'}, {'component': 'renal transplantation', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Procedures'}, {'component': 'erectile functions', 'type': 'Symptom', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items'}]",2
295920,Oligometastatic disease and oligoprogression in breast cancer,Systemic therapeutic options,Oligometastatic disease;;breast cancer,Oligometastatic Disease;;Breast Cancer,Oligometastatic Breast Cancer;;Oligoprogressive Breast Cancer,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract_title ('Systemic therapeutic options') contains no disease term, only a treatment modality. The session_title ('Oligometastatic disease and oligoprogression in breast cancer') contains the disease 'breast cancer' and relevant clinical qualifiers. Therefore, the session_title was selected as the source based on the Single-Source Extraction Principle.
2.  **Component Identification**: The session_title contains one primary disease, 'breast cancer', and two distinct clinical states: 'Oligometastatic' and 'oligoprogression'.
3.  **Rule Retrieval**: To correctly format the clinical state qualifiers, rules were retrieved for 'Metastasis-Related Terms' and 'Progression-Related' from the 'Occurrence' category.
4.  **Rule Application**: 
    - The rule for 'Oligometastatic' (ID: 156) instructs to construct the indication as 'Oligometastatic <Disease>'. Applying this to 'breast cancer' yields 'Oligometastatic Breast Cancer'.
    - The term 'oligoprogression' is the noun form of the state described by the 'Oligoprogressive' rule (ID: 157). This rule guides the normalization of the term to the adjectival form 'Oligoprogressive' placed before the disease name. This results in 'Oligoprogressive Breast Cancer'.
    - The generic rule for multiple diseases was applied, using ';;' to separate the two distinct indications.
    - Generic formatting rules (Title Case, singular form) were applied to both indications.
5.  **Final Indication Construction**: The two extracted indications were combined into the final string: 'Oligometastatic Breast Cancer;;Oligoprogressive Breast Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms', 'Progression-Related'], 'reason': ""To handle the formatting of 'Oligometastatic' and 'oligoprogression' qualifiers.""}]","[{'component': 'Oligometastatic disease', 'type': 'Disease with Occurrence Qualifier', 'normalized_form': 'Oligometastatic Breast Cancer', 'rule_applied': ""Occurrence rule for 'Oligometastatic' (ID: 156) combined with the core disease 'Breast Cancer'.""}, {'component': 'oligoprogression in breast cancer', 'type': 'Disease with Progression Qualifier', 'normalized_form': 'Oligoprogressive Breast Cancer', 'rule_applied': ""Occurrence rule for 'Oligoprogressive' (ID: 157) applied to normalize 'oligoprogression' and combine it with 'Breast Cancer'.""}, {'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Title Case and singular form rules.'}]",2
263162,"Enzymopathies, membranopathies and other anemias",The Value Of Anemia For Organ Damage Evaluation In Systemic Sclerosis Patients:A Multi-Center Retrospective Study,Systemic Sclerosis,Systemic Sclerosis,Anemia;;Systemic Sclerosis,True,abstract_title,"Step 1: The abstract title contains specific disease terms ('Anemia', 'Systemic Sclerosis'), so it is selected as the source over the session title, following the single-source extraction principle.
Step 2: Two distinct medical conditions were identified in the abstract title: 'Anemia' and 'Systemic Sclerosis'.
Step 3: According to the generic rule for multiple diseases, when a title mentions more than one distinct disease, all should be extracted and separated by ';;'.
Step 4: The terms were checked against formatting rules. Both 'Anemia' and 'Systemic Sclerosis' are already in singular form and correctly capitalized (Title Case).
Step 5: Exclusion rules were applied. The phrase 'A Multi-Center Retrospective Study' describes the study methodology and is excluded. 'Organ Damage Evaluation' is a procedural context and not part of the core indication, so it is also excluded.
Step 6: The final indications are combined using the ';;' separator, resulting in 'Anemia;;Systemic Sclerosis'.","[{'category': 'Patient with two different Disease', 'subcategories': [], 'reason': 'To confirm the correct procedure for handling titles that mention two distinct diseases.'}]","[{'component': 'Anemia', 'type': 'Disease', 'normalized_form': 'Anemia', 'rule_applied': 'Generic rule for multiple diseases'}, {'component': 'Systemic Sclerosis', 'type': 'Disease', 'normalized_form': 'Systemic Sclerosis', 'rule_applied': 'Generic rule for multiple diseases'}]",2
410619,"Fluid, Electrolytes, and Acid-Base Disorders",A Rare Case of Zonisamide-Induced Distal Renal Tubular Acidosis (RTA),Distal Renal Tubular Acidosis,Distal Renal Tubular Acidosis,Distal Renal Tubular Acidosis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('A Rare Case of Zonisamide-Induced Distal Renal Tubular Acidosis (RTA)') was chosen over the session title ('Fluid, Electrolytes, and Acid-Base Disorders') because it contains a specific, identifiable disease, adhering to the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title were the disease 'Distal Renal Tubular Acidosis (RTA)' and the qualifiers 'Rare Case' and 'Zonisamide-Induced'.
3.  **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' and 'Disease Characterisation' to evaluate how to handle the term 'Rare'.
4.  **Rule Application & Refinement**:
    *   **Disease Term**: The core disease is 'Distal Renal Tubular Acidosis'. The parenthetical acronym '(RTA)' is redundant and was removed.
    *   **'Zonisamide-Induced'**: This qualifier describes the cause (etiology) of the disease, which falls under the category of an 'exposure'. According to the generic exclusion rules, exposures are not included in the final indication. Therefore, 'Zonisamide-Induced' was excluded.
    *   **'A Rare Case of'**: The phrase 'A Case of' is a study descriptor and not part of the clinical indication, so it was excluded. The term 'Rare' was evaluated using the retrieved rules. The rules indicate that 'Rare' should be included when it directly modifies the disease to define a specific subgroup (e.g., 'Rare Tumor'). In this context, 'Rare' modifies 'Case' ('A Rare Case'), describing the novelty of the report, not a clinical subtype of the disease itself. Therefore, 'Rare' was also excluded.
5.  **Final Construction**: After removing the excluded qualifiers, the core disease 'Distal Renal Tubular Acidosis' was formatted to Title Case and singular form (which it already was), resulting in the final indication.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To determine the correct handling of the keyword 'Rare' found in the abstract title.""}]","[{'component': 'Distal Renal Tubular Acidosis (RTA)', 'type': 'Disease', 'normalized_form': 'Distal Renal Tubular Acidosis', 'rule_applied': 'Generic rule: Remove parenthetical acronyms. Generic rule: Use Title Case.'}, {'component': 'Zonisamide-Induced', 'type': 'Etiology/Exposure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude exposures and procedural/temporal qualifiers.'}, {'component': 'A Rare Case of', 'type': 'Study Descriptor', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule: Exclude non-diagnostic items. The retrieved rule for 'Rare' (ID 530) was contextually applied to determine that 'Rare' modified 'Case' and not the disease, leading to its exclusion.""}]",2
410621,"Fluid, Electrolytes, and Acid-Base Disorders",Trimethoprim-Sulfamethoxazole-Associated Severe Hyponatremia,Severe;;Hyponatremia,Severe Hyponatremia,Severe Hyponatremia,True,abstract_title,"Step 1: The abstract title 'Trimethoprim-Sulfamethoxazole-Associated Severe Hyponatremia' was chosen as the source because it contains a specific medical condition, which is preferred over the broader categories in the session title.
Step 2: The components identified in the title are the disease 'Hyponatremia', the severity qualifier 'Severe', and the associated cause 'Trimethoprim-Sulfamethoxazole-Associated'.
Step 3: The generic exclusion rules guide the removal of procedural or contextual qualifiers. 'Trimethoprim-Sulfamethoxazole-Associated' describes the cause of the condition, similar to 'transplant-associated', and is therefore excluded from the final indication.
Step 4: The severity term 'Severe' is retained as it is a clinically significant descriptor that forms part of the specific diagnosis.
Step 5: The final indication is formatted to Title Case and checked for singularity, resulting in 'Severe Hyponatremia'.","[{'category': 'Risk', 'subcategories': ['severe'], 'reason': ""To check the rule for handling the severity keyword 'Severe'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': 'To check for rules regarding drug-associated conditions or other disease characterizations.'}]","[{'component': 'Severe Hyponatremia', 'type': 'Disease with Severity', 'normalized_form': 'Severe Hyponatremia', 'rule_applied': 'Generic rule to include severity when it is part of the clinical diagnosis.'}, {'component': 'Trimethoprim-Sulfamethoxazole-Associated', 'type': 'Etiological Qualifier', 'normalized_form': '', 'rule_applied': ""Generic exclusion rule for procedural/etiological qualifiers (similar to 'transplant-associated').""}]",2
263163,"Enzymopathies, membranopathies and other anemias",Clinical Characteristics And Risk Factors Of Anemia In Patients With Systemic Sclerosis From The Pkuph-Ssc Cohort,Systemic Sclerosis,Systemic Sclerosis,Anemia;;Systemic Sclerosis,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Clinical Characteristics And Risk Factors Of Anemia In Patients With Systemic Sclerosis From The Pkuph-Ssc Cohort' was chosen over the session title because it contains more specific disease information, adhering to the single-source principle.
2. **Component Identification**: The abstract title identifies two distinct medical conditions: 'Anemia' and 'Systemic Sclerosis'. The phrase 'Anemia In Patients With Systemic Sclerosis' indicates these are co-occurring conditions.
3. **Rule Application**: The generic rule for 'Multiple Diseases' was applied, which requires extracting all distinct diseases and separating them with ';;'. The terms 'Anemia' and 'Systemic Sclerosis' were already in singular form and proper Title Case.
4. **Exclusion Application**: Non-diagnostic phrases such as 'Clinical Characteristics And Risk Factors Of', 'In Patients With', and 'From The Pkuph-Ssc Cohort' were excluded as per the generic exclusion rules.
5. **Indication Construction**: The two identified and normalized disease terms were combined using the ';;' separator to form the final indication: 'Anemia;;Systemic Sclerosis'.",[],"[{'component': 'Anemia', 'type': 'Disease', 'normalized_form': 'Anemia', 'rule_applied': 'Generic rule for Multiple Diseases'}, {'component': 'Systemic Sclerosis', 'type': 'Disease', 'normalized_form': 'Systemic Sclerosis', 'rule_applied': 'Generic rule for Multiple Diseases'}]",3
214013,MP38: Sexual Function/Dysfunction: Basic Research & Pathophysiology,"Vascular, Neurologic and Hormonal Abnormalities in Men with Persistent Sexual Dysfunction after Discontinuation of Finasteride",Sexual Dysfunction,Sexual Dysfunction,Persistent Sexual Dysfunction,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title because it contains a more specific and complete medical condition ('Persistent Sexual Dysfunction'). The session title ('Sexual Function/Dysfunction') is broader.
2. **Component Identification**: The abstract title contains the core condition 'Persistent Sexual Dysfunction'. It also mentions 'Vascular, Neurologic and Hormonal Abnormalities', the patient group 'Men', and the context 'after Discontinuation of Finasteride'.
3. **Rule Application & Refinement**:
   - The primary indication is identified as 'Persistent Sexual Dysfunction'. The term 'Persistent' is a clinically relevant descriptor and is retained.
   - 'Vascular, Neurologic and Hormonal Abnormalities' are interpreted as findings or characteristics being studied within the patient group, not as separate, co-primary indications. The title structure 'A, B, and C in patients with D' suggests D is the core indication.
   - 'Men' is excluded based on the generic rule to remove sociodemographic (gender) descriptors.
   - 'after Discontinuation of Finasteride' is excluded as it's a procedural/temporal qualifier, specifying the context of the condition's onset, not defining the indication itself.
4. **Final Formatting**: The extracted indication 'Persistent Sexual Dysfunction' is already in singular form and is formatted using Title Case.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding disease characterization keywords like 'Persistent'. No specific rule was found for this term, so standard clinical interpretation was applied.""}]","[{'component': 'Persistent Sexual Dysfunction', 'type': 'Disease', 'normalized_form': 'Persistent Sexual Dysfunction', 'rule_applied': 'Generic rule: Retain clinically relevant disease descriptors. Formatting rule: Title Case.'}, {'component': 'Vascular, Neurologic and Hormonal Abnormalities', 'type': 'Clinical Finding', 'normalized_form': 'N/A', 'rule_applied': 'These were identified as findings within the patient group, not as the primary indication, and were therefore not extracted.'}, {'component': 'Men', 'type': 'Gender', 'normalized_form': 'N/A', 'rule_applied': 'Generic Exclusion Rule: Exclude sociodemographic descriptors.'}, {'component': 'after Discontinuation of Finasteride', 'type': 'Temporal Qualifier', 'normalized_form': 'N/A', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers.'}]",2
394242,Policy And Preventive Strategies,Young Adult Lung Cancer Demands More Attention In A Low-Resource Area: Bangladesh Perspective,Young Adult;;Lung Cancer,Young Adult Lung Cancer,Young Adult Lung Cancer,True,abstract_title,"Step 1: The abstract title contains the disease term 'Lung Cancer', while the session title does not. Therefore, the abstract title is selected as the source based on the single-source principle.
Step 2: The components identified in the abstract title are the disease 'Lung Cancer' and the age group descriptor 'Young Adult'. The phrases 'Low-Resource Area' and 'Bangladesh Perspective' are identified as geographic and sociodemographic descriptors.
Step 3: To determine how to handle the 'Young Adult' descriptor, I retrieved rules for the 'Age Group' category, specifically for 'Young'.
Step 4: Rule ID 311 specifically states that 'Young Adult' should be normalized to title case and prepended to the indication. The generic exclusion rules dictate that geographic and sociodemographic descriptors ('Low-Resource Area', 'Bangladesh Perspective') must be removed.
Step 5: The indication is constructed by combining the normalized age group 'Young Adult' with the disease 'Lung Cancer'.
Step 6: A final quality check confirms that all rules have been applied correctly, resulting in the final indication 'Young Adult Lung Cancer'.","[{'category': 'Age Group', 'subcategories': ['Young'], 'reason': ""To determine the correct handling of the term 'Young Adult'.""}]","[{'component': 'Young Adult', 'type': 'Age Group', 'normalized_form': 'Young Adult', 'rule_applied': ""Rule ID 311: Normalize 'Young Adult' to title case and prepend to the indication.""}, {'component': 'Lung Cancer', 'type': 'Disease', 'normalized_form': 'Lung Cancer', 'rule_applied': 'Generic Rule: Use singular form and title case.'}, {'component': 'Low-Resource Area: Bangladesh Perspective', 'type': 'Sociodemographic/Geographic', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude geographic and sociodemographic descriptors.'}]",2
328700,Chronic Lymphocytic Leukemias: Basic and Translational: Poster II,Metabolic Abnormalities Associated with T-Cell Exhaustion in CLL Eu-TCL1 Murine Model,CLL ,Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,True,session_title,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'Metabolic Abnormalities Associated with T-Cell Exhaustion in CLL Eu-TCL1 Murine Model', refers to a preclinical 'Murine Model', which is not a direct human medical indication. 
Step 2: The session title, 'Chronic Lymphocytic Leukemias: Basic and Translational: Poster II', contains a clear, clinically valid disease. Therefore, I selected the session title as the source based on the single-source principle, prioritizing clinical validity.
Step 3: I identified the disease component 'Chronic Lymphocytic Leukemias'.
Step 4: I applied the generic rule to convert the plural form 'Leukemias' to its singular form, 'Leukemia'.
Step 5: I constructed the final indication, ensuring it is in Title Case and free of extraneous information like ': Basic and Translational: Poster II'.",[],"[{'component': 'Chronic Lymphocytic Leukemias', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Generic Rule: Singular Form'}]",1
312328,Pediatric Thieves Market Poster,A Perplexing Situation,,,,True,none,"Neither the abstract title ('A Perplexing Situation') nor the session title ('Pediatric Thieves Market Poster') contains a recognizable medical disease or condition. The abstract title is generic and non-clinical. The session title contains the patient subgroup 'Pediatric', but it is an orphan subgroup without an associated disease, and 'Thieves Market Poster' is not a medical term. According to the single-source principle and the rule for handling orphan patient subgroups, no indication can be extracted.",[],"[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Orphan PSUB rule: A patient subgroup without an associated disease cannot form an indication.'}]",1
328712,Chronic Lymphocytic Leukemias: Basic and Translational: Poster III,High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,Chronic Lymphocytic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract title and session title contain a disease term. Following the Single-Source Extraction Principle, the abstract title ('High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia') is selected as it is more specific.
2.  **Component Identification**: The core disease identified is 'Chronic Lymphocytic Leukemia'. The phrase 'Inferior Treatment-Free Survival' was also identified.
3.  **Rule Retrieval**: I retrieved rules for 'Treatment based' and 'Risk' to determine how to handle 'Inferior Treatment-Free Survival'.
4.  **Rule Application**: The retrieved rules for treatment status (e.g., 'Previously Treated') and risk types (e.g., 'High-Risk') did not apply to 'Inferior Treatment-Free Survival'. This phrase describes a clinical outcome or a prognostic factor being studied, rather than a pre-existing characteristic of the patient subgroup. Therefore, it is not part of the medical indication.
5.  **Indication Construction**: The core disease 'Chronic Lymphocytic Leukemia' is extracted. Generic rules are applied: the term is already in singular form and correctly formatted in Title Case. No excludable terms are present.
6.  **Final Output**: The final generated indication is 'Chronic Lymphocytic Leukemia'.","[{'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To check if 'Treatment-Free Survival' corresponds to a standard treatment status descriptor.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To determine if 'Inferior Survival' is a recognized risk stratification.""}]","[{'component': 'Chronic Lymphocytic Leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Inferior Treatment-Free Survival', 'type': 'Clinical Outcome', 'normalized_form': '', 'rule_applied': 'Excluded as it represents a study endpoint/prognostic factor, not a patient subgroup characteristic.'}]",2
181258,Disorders of Coagulation or Fibrinolysis: Clinical and Epidemiological: Poster II,"Exposure-Response Relationship between Von Willebrand Factor (VWF) Activity and Bleeding Events Following Prophylaxis with Recombinant VWF (rVWF, vonicog alfa) in Patients with Severe Von Willebrand Disease (VWD)",Severe;;Von Willebrand Disease,Severe Von Willebrand Disease,Severe Von Willebrand Disease,True,abstract_title,"Step 1: The abstract title contains a specific disease ('Von Willebrand Disease'), while the session title refers to a broader category ('Disorders of Coagulation or Fibrinolysis'). Therefore, the abstract title is selected as the source based on the single-source principle.
Step 2: The core components identified in the abstract title are the disease 'Von Willebrand Disease (VWD)' and the severity qualifier 'Severe'. 'Bleeding Events' is identified as a symptom/complication and is excluded.
Step 3: A rule check was performed for the severity term 'Severe' using `get_indication_rules` with category 'Risk' and subcategory 'severe'. While the returned rule was for 'High-Risk', it reinforces the principle of including clinically significant risk/severity descriptors before the disease name.
Step 4: Generic rules are applied. The disease name is standardized to Title Case and kept in singular form. The procedural context ('Prophylaxis with Recombinant VWF') and patient descriptors ('Patients with') are excluded as per the generic exclusion rules.
Step 5: The final indication is constructed by combining the severity qualifier with the disease name, resulting in 'Severe Von Willebrand Disease'.","[{'category': 'Risk', 'subcategories': ['severe'], 'reason': ""To verify the correct formatting and inclusion of the severity descriptor 'Severe'.""}]","[{'component': 'Severe', 'type': 'Severity', 'normalized_form': 'Severe', 'rule_applied': 'Generic rule for disease characterization (inclusion of severity).'}, {'component': 'Von Willebrand Disease (VWD)', 'type': 'Disease', 'normalized_form': 'Von Willebrand Disease', 'rule_applied': 'Generic rule for singular form and Title Case.'}, {'component': 'Bleeding Events', 'type': 'Symptom/Complication', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic items (symptoms).'}]",2
345103,Cancer-associated Inflammation and Microbiome,Single-cell analysis of immune and stroma cell remodeling in renal cell carcinoma primary tumors and bone metastatic lesions,renal cell carcinoma,Renal Cell Carcinoma,Primary Renal Cell Carcinoma;;Bone Metastatic Lesion,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Single-cell analysis of immune and stroma cell remodeling in renal cell carcinoma primary tumors and bone metastatic lesions') was chosen as it contains specific disease terms ('renal cell carcinoma', 'bone metastatic lesions'), which is preferred over the more general session title ('Cancer-associated Inflammation and Microbiome').
2. **Component Identification**: The abstract title explicitly mentions two distinct clinical entities being analyzed: 'renal cell carcinoma primary tumors' and 'bone metastatic lesions'. The conjunction 'and' separates them, indicating they should be treated as separate indications.
3. **Rule Retrieval**: To correctly handle the term 'metastatic', I retrieved rules for the 'Occurrence' category, specifically for 'Metastasis-Related Terms'.
4. **Indication 1 Construction**: For 'renal cell carcinoma primary tumors':
   - The disease is 'renal cell carcinoma'.
   - The qualifier 'primary' is included as it specifies the nature of the tumor, distinguishing it from metastatic sites.
   - The plural 'tumors' was converted to its singular form 'Tumor' as per generic formatting rules.
   - Applying Title Case results in 'Primary Renal Cell Carcinoma'.
5. **Indication 2 Construction**: For 'bone metastatic lesions':
   - This describes a secondary disease site. The term 'metastatic' is a key descriptor.
   - The plural 'lesions' was converted to its singular form 'Lesion'.
   - Applying Title Case results in 'Bone Metastatic Lesion'.
6. **Final Assembly**: The two distinct indications were combined using the required ';;' separator, resulting in the final output.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'metastatic lesions' and understand its clinical context.""}]","[{'component': 'renal cell carcinoma primary tumors', 'type': 'Disease', 'normalized_form': 'Primary Renal Cell Carcinoma', 'rule_applied': 'Generic Rule: Singular Form (tumors -> Tumor); Generic Rule: Title Case; Generic Rule: Primary (included as it specifies tumor origin).'}, {'component': 'bone metastatic lesions', 'type': 'Disease', 'normalized_form': 'Bone Metastatic Lesion', 'rule_applied': 'Generic Rule: Singular Form (lesions -> Lesion); Generic Rule: Title Case; Occurrence Rule (Metastatic).'}]",2
377875,Bleeding disorders (congenital and acquired),Alloantibodies In Von Willebrand Disease: About 6 Cases In Southern Tunisia,Von Willebrand Disease,Von Willebrand Disease,Von Willebrand Disease,True,abstract_title,"Step 1: The abstract title was selected as the source because it contains a specific disease, 'Von Willebrand Disease', which is more precise than the general category 'Bleeding disorders' in the session title.
Step 2: The core disease entity was identified as 'Von Willebrand Disease'.
Step 3: The geographic descriptor 'Southern Tunisia' was excluded based on the generic sociodemographic exclusion rule.
Step 4: 'Alloantibodies' was identified as a related finding or complication, not part of the core disease indication, and was therefore excluded.
Step 5: The final indication was formatted to Title Case and singular form, resulting in 'Von Willebrand Disease'.",[],"[{'component': 'Von Willebrand Disease', 'type': 'Disease', 'normalized_form': 'Von Willebrand Disease', 'rule_applied': 'Generic Casing and Singular Form Rules'}, {'component': 'Southern Tunisia', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Sociodemographic Descriptors'}]",1
312341,Pediatric Thieves Market Poster,"Red but White, Itchy but Painful, Controlled yet Uncontrolled",,,,True,none,"Neither the abstract title nor the session title contains a clinically valid medical indication. The abstract title lists symptoms ('Red', 'White', 'Itchy', 'Painful') and states ('Controlled', 'Uncontrolled') but does not name a specific disease. The session title contains an age group ('Pediatric') but 'Thieves Market Poster' is not a recognized medical condition. According to the rules, if no disease term is present, no indication can be extracted.",[],"[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Generic Rule - An indication must be built from a title containing a disease term. 'Pediatric' is a patient subgroup, but no disease is present in the session title.""}, {'component': 'Red, White, Itchy, Painful', 'type': 'Symptoms', 'normalized_form': '', 'rule_applied': 'Exclusion Rule - Isolated symptoms are not extracted as indications.'}]",1
148508,Thalassemias,Possible Correlation Of Mixed Chimerism With Post-Transplant Outcome In Patients With B Thalassemia:Risk Of Graft Failure,B Thalassemia,B Thalassemia,B Thalassemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Possible Correlation Of Mixed Chimerism With Post-Transplant Outcome In Patients With B Thalassemia:Risk Of Graft Failure') was chosen over the session title ('Thalassemias') because it contains a more specific disease term ('B Thalassemia'), adhering to the Single-Source Extraction Principle.
2.  **Component Identification**: The key components identified in the abstract title were the disease 'B Thalassemia', the procedural qualifier 'Post-Transplant', and the outcome/complication 'Risk Of Graft Failure'.
3.  **Rule Retrieval**: To ensure proper handling of these components, I retrieved rules for 'Treatment Set-up' (specifically 'Transplant Status') to address 'Post-Transplant' and 'Risk' to evaluate 'Risk Of Graft Failure'.
4.  **Rule Application**:
    *   The retrieved rules for 'Transplant Status' (e.g., Rule ID 232, 233) explicitly state that 'Post-Transplant' should be excluded as it describes a temporal treatment status, not a core part of the indication.
    *   'Risk Of Graft Failure' was identified as a complication or study outcome rather than a distinct co-morbid disease defining the patient population. The title structure indicates a study of outcomes *in* patients with B Thalassemia. Therefore, it was excluded based on the generic rule to exclude complications and adverse effects.
    *   The core disease 'B Thalassemia' was retained.
5.  **Indication Construction**: After applying the exclusion rules, the remaining component is the disease itself. It was formatted according to the generic rules:
    *   **Casing**: 'B Thalassemia' is already in the correct Title Case format.
    *   **Singular Form**: The term is already singular.
6.  **Final Quality Check**: The final indication 'B Thalassemia' is clinically accurate, derived from a single source, and correctly formatted, with all non-indication elements removed.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine how to handle the 'Post-Transplant' qualifier.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To evaluate whether 'Risk Of Graft Failure' should be included as part of the indication.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': 'To check for any specific rules related to the disease name.'}]","[{'component': 'B Thalassemia', 'type': 'Disease', 'normalized_form': 'B Thalassemia', 'rule_applied': 'Generic Rule: Retain core disease term and apply Title Case.'}, {'component': 'Post-Transplant', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Treatment Set-up Rule (ID 232, 233): Exclude 'Post-Transplant' as it is a temporal treatment status.""}, {'component': 'Risk Of Graft Failure', 'type': 'Complication/Outcome', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude complications or adverse effects from the core indication.'}]",2
328738,Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II,The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge,CLL,Chronic Lymphocytic Leukemia,COVID-19;;Chronic Lymphocytic Leukemia,True,abstract_title,"Step 1: The abstract title 'The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge' was chosen as the source because it contains specific disease terms ('Covid-19', 'CLL'), following the single-source principle.
Step 2: Two distinct diseases were identified in the title: 'Covid-19' and 'CLL'.
Step 3: The abbreviation 'CLL' was expanded to 'Chronic Lymphocytic Leukemia' based on common medical knowledge and confirmed by its presence in the session title.
Step 4: The generic rule for multiple diseases was applied, which requires separating each distinct disease with a ';;' delimiter.
Step 5: The generic casing rules were applied. 'COVID-19' is maintained in its standard uppercase format as a proper noun/acronym, and 'Chronic Lymphocytic Leukemia' is formatted in Title Case.
Step 6: The final indication was constructed by combining the two normalized disease terms, resulting in 'COVID-19;;Chronic Lymphocytic Leukemia'.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To determine the correct formatting for a title mentioning two distinct diseases (COVID-19 and CLL).'}]","[{'component': 'Covid-19', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic Casing Rule for proper nouns/acronyms.'}, {'component': 'CLL', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Abbreviation expansion and Generic Title Case Rule.'}]",2
410659,Geriatric Nephrology,External Validation of a Risk Prediction Tool in Determining Early Death Among Elderly Patients Initiated on Dialysis,,,Geriatric Kidney Disease,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title, 'External Validation of a Risk Prediction Tool in Determining Early Death Among Elderly Patients Initiated on Dialysis', lacks a specific disease. 'Early Death' is an outcome, and 'Initiated on Dialysis' is a procedural qualifier, which should be excluded per generic rules. Therefore, I defaulted to the session title.
2.  **Component Identification (Session Title)**: The session title is 'Geriatric Nephrology'. I identified two components: 'Geriatric' (an age group) and 'Nephrology' (a therapeutic area).
3.  **Rule Retrieval**: I retrieved rules for the 'Age Group' category, specifically for 'Elderly' and 'Geriatric'. Rule ID 320 and 321 state that 'Geriatric' should be used as a capitalized prefix for the identified disease.
4.  **Rule Application**: 
    -   I applied the 'Therapeutic Area Fallback' generic rule to convert the therapeutic area 'Nephrology' into a standard disease term, 'Kidney Disease'.
    -   I applied the retrieved 'Geriatric' age group rule (ID 320/321) to prepend 'Geriatric' to the disease name.
5.  **Indication Construction**: Combining the components according to the rules resulted in 'Geriatric Kidney Disease'.
6.  **Final Quality Check**: The final indication adheres to all formatting rules: it is in Title Case, uses the singular form, and contains no excluded terms.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To handle the terms 'Geriatric' from the session title and 'Elderly' from the abstract title.""}]","[{'component': 'Geriatric', 'type': 'Age Group', 'normalized_form': 'Geriatric', 'rule_applied': ""Age Group Rule ID 320/321: Use 'Geriatric' as a prefix.""}, {'component': 'Nephrology', 'type': 'Therapeutic Area', 'normalized_form': 'Kidney Disease', 'rule_applied': 'Generic Rule: Therapeutic Area Fallback.'}]",2
263205,Indolent and mantle-cell non-Hodgkin lymphoma - Clinical,First-Line Treatment In Advanced Stage Folicular Lymphoma: A Single-Center Experience With R-Chop Vs Bendamustine-Rituximab.,First-Line;;Advanced Stage;;Folicular Lymphoma,First-Line Advanced Stage Folicular Lymphoma,First-Line Advanced Stage Follicular Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'First-Line Treatment In Advanced Stage Folicular Lymphoma: A Single-Center Experience With R-Chop Vs Bendamustine-Rituximab.' was chosen as it contains a specific disease ('Folicular Lymphoma'), following the single-source principle which prioritizes the abstract title.
2. **Component Identification**: The key components identified in the abstract title were 'First-Line' (line of treatment), 'Advanced Stage' (disease stage), and 'Folicular Lymphoma' (the core disease).
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Line of treatment' from the 'Treatment Set-up' category and for 'Stage Type' from the 'Stage' category.
4. **Rule Application**: 
   - Based on the 'Line of treatment' rules (specifically Rule ID 199 and 200), 'First-Line' was retained because it was followed by the generic word 'Treatment' and not a specific drug name. It was normalized to 'First-Line' and placed at the beginning of the indication.
   - 'Advanced Stage' was identified as a clinically significant stage descriptor and was retained and converted to Title Case.
   - 'Folicular Lymphoma' was already in the correct singular and Title Case format.
   - Specific drug names ('R-Chop', 'Bendamustine-Rituximab') and study-specific text ('A Single-Center Experience With') were excluded as per generic exclusion rules.
5. **Indication Construction**: The identified and normalized components were combined in a clinically standard order (Line -> Stage -> Disease) to form the final indication: 'First-Line Advanced Stage Follicular Lymphoma'.
6. **Quality Check**: The final output was verified against all generic rules, ensuring correct casing, singular form, and exclusion of non-indication elements.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine how to handle the 'First-Line' descriptor.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for specific rules regarding the 'Advanced Stage' descriptor.""}]","[{'component': 'First-Line', 'type': 'Line of Treatment', 'normalized_form': 'First-Line', 'rule_applied': 'Treatment Set-up, Line of treatment, Rule ID 200'}, {'component': 'Advanced Stage', 'type': 'Stage', 'normalized_form': 'Advanced Stage', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'Folicular Lymphoma', 'type': 'Disease', 'normalized_form': 'Follicular Lymphoma', 'rule_applied': 'Generic Rule: Singular Form, Title Case'}]",2
312364,Polymyalgia Rheumatica: New Tricks for an Old Disease,Balancing Risks and Benefits of Adding Immunosuppression to Steroids in PMR,PMR,Polymyalgia Rheumatica,Polymyalgia Rheumatica,True,abstract_title,"Step 1: The abstract title was chosen as the primary source because it contains a disease term (""PMR""), adhering to the single-source extraction principle.
Step 2: The disease term ""PMR"" was identified in the abstract title. The session title provided the full name, ""Polymyalgia Rheumatica"", which was used to expand the abbreviation found in the selected source.
Step 3: No other patient subgroups, stages, or biomarkers were mentioned in the abstract title.
Step 4: The expanded disease name was formatted according to the generic rules, applying Title Case and ensuring it was in singular form.
Step 5: The final indication is the standardized, full disease name.",[],"[{'component': 'PMR', 'type': 'Disease', 'normalized_form': 'Polymyalgia Rheumatica', 'rule_applied': 'Generic rule: Title Case, Singular Form. Abbreviation expanded using context from session title.'}]",1
295985,Novartis - Evidence-Based Practice in HR+/HER2 Advanced Breast Cancer: Illuminating the Treatment Path for Patients,Welcome and Introduction,HR+;;HER2;;Advanced;;Breast Cancer,HR-Positive HER2 Advanced Breast Cancer,HR+/HER2- Advanced Breast Cancer,True,session_title,"Step 1: The abstract title 'Welcome and Introduction' contains no medical information. The session title 'Novartis - Evidence-Based Practice in HR+/HER2 Advanced Breast Cancer: Illuminating the Treatment Path for Patients' contains a clear disease and patient subgroup. Therefore, the session title was selected as the source based on the Single-Source Extraction Principle.
Step 2: The following components were identified in the session title: 'HR+' (Hormone Receptor-Positive), 'HER2' (HER2-Negative), 'Advanced' (Stage), and 'Breast Cancer' (Disease).
Step 3: Rules for 'Hormone status', 'Biomarker', and 'Stage' were retrieved to ensure correct formatting and inclusion.
Step 4: The generic rules for casing and singular form were applied. 'Breast Cancer' is already singular and in Title Case. The identified components were combined in the standard clinical order: patient subgroup (biomarkers), then stage, then the disease name. The notation 'HR+/HER2-' is a standard, clinically recognized format for this specific breast cancer subtype and was retained for accuracy. The non-diagnostic parts of the title, such as 'Novartis - Evidence-Based Practice' and 'Illuminating the Treatment Path for Patients', were excluded.
Step 5: The final indication was constructed by combining the normalized components, resulting in 'HR+/HER2- Advanced Breast Cancer'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Hormone status'], 'reason': ""To check for rules regarding the formatting of hormone receptor status like 'HR+'.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To find rules for handling biomarker status, specifically 'HER2-'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To ensure the correct application of the stage descriptor 'Advanced'.""}]","[{'component': 'HR+', 'type': 'Hormone Status', 'normalized_form': 'HR+', 'rule_applied': 'Standard clinical abbreviation retained for accuracy.'}, {'component': 'HER2', 'type': 'Biomarker', 'normalized_form': 'HER2-', 'rule_applied': ""Standard clinical abbreviation retained for accuracy; unicode character '' normalized to hyphen '-'.""}, {'component': 'Advanced', 'type': 'Stage', 'normalized_form': 'Advanced', 'rule_applied': 'Generic Title Case rule.'}, {'component': 'Breast Cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Title Case and Singular Form rules.'}]",2
394296,Prostate Cancer,Impact Of Intensified Androgen Deprivation Therapy (Adti) In The Metastatic Castration-Sensitive Prostate Cancer (Mcspc) Setting On Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Disease Characteristics And Survival Outcomes,Metastatic;;Castration-Sensitive Prostate Cancer,Metastatic Castration-Sensitive Prostate Cancer,Metastatic Castration-Sensitive Prostate Cancer;;Metastatic Castration-Resistant Prostate Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title contains specific disease entities ('Metastatic Castration-Sensitive Prostate Cancer' and 'Metastatic Castration-Resistant Prostate Cancer'), while the session title is more general ('Prostate Cancer'). Based on the Single-Source Extraction Principle, the abstract title is selected as the source.
2.  **Identify Components**: The abstract title clearly mentions two distinct clinical indications: 'Metastatic Castration-Sensitive Prostate Cancer (Mcspc)' and 'Metastatic Castration-Resistant Prostate Cancer (Mcrpc)'. Both are valid and separate indications.
3.  **Retrieve Relevant Rules**: To ensure correct formatting, I retrieved rules for 'Metastasis-Related Terms' and 'Resistance' under the 'Occurrence' category, and for 'Hormone status' under 'Patient Sub-Group'.
4.  **Apply Rules**: 
    *   The rule for 'Metastatic' (ID: 141) confirms the standard format 'Metastatic <Disease>', which is already present in the title.
    *   No specific rules were found for 'Castration-Sensitive' or 'Castration-Resistant', so I proceeded with generic rules. These terms are standard clinical descriptors defining the disease state and are not excluded.
    *   The generic rule for multiple diseases is applied, requiring the use of ';;' as a separator.
    *   The generic rule for Title Case is applied to each component of the indications.
    *   The generic rule for singular form is applied; 'Cancer' is already singular.
5.  **Construct Indication**: The two identified indications are formatted and combined using the ';;' separator.
6.  **Quality Check**: The final output adheres to all formatting and content rules. It correctly identifies both distinct patient populations mentioned in the source title, uses the correct separator, and follows Title Case conventions.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms', 'Resistance'], 'reason': ""To verify the formatting for 'Metastatic' and check for any rules regarding 'Resistant' in the context of 'Castration-Resistant'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Hormone status'], 'reason': ""To check for specific rules related to hormone status terms like 'Castration-Sensitive' and 'Castration-Resistant'.""}]","[{'component': 'Metastatic Castration-Sensitive Prostate Cancer', 'type': 'Disease', 'normalized_form': 'Metastatic Castration-Sensitive Prostate Cancer', 'rule_applied': ""Generic Title Case and Singular Form rules. Occurrence rule for 'Metastatic'.""}, {'component': 'Metastatic Castration-Resistant Prostate Cancer', 'type': 'Disease', 'normalized_form': 'Metastatic Castration-Resistant Prostate Cancer', 'rule_applied': ""Generic Title Case and Singular Form rules. Occurrence rule for 'Metastatic'.""}]",2
345147,Innovative Approaches for Tumor Profiling and Data Analysis 1,Evaluation of a 293 gene oncology-focused exome sequencing panel for screening of ovarian cancer patients for BRCA mutations as a prerequisite for autologous cellular immunotherapy manufacturing,ovarian cancer,Ovarian Cancer,BRCA-Mutated Ovarian Cancer,True,abstract_title,"Step 1: The abstract title contains the specific disease 'ovarian cancer', while the session title has the less specific term 'Tumor'. Therefore, the abstract title is selected as the source based on the Single-Source Extraction Principle.
Step 2: The key components identified in the abstract title are 'ovarian cancer' (disease) and 'BRCA mutations' (patient subgroup).
Step 3: A query was made to `get_indication_rules` for 'Gene Mutation' to find the correct formatting for 'BRCA mutations'. Although no specific rule was returned, standard clinical nomenclature conventions are applied.
Step 4: The generic rules are applied. 'ovarian cancer' is converted to 'Ovarian Cancer' (Title Case, singular). 'BRCA mutations' is normalized to 'BRCA-Mutated' to act as a standard clinical qualifier. The procedural context ('screening', 'prerequisite for autologous cellular immunotherapy manufacturing') is excluded as per the generic exclusion rules.
Step 5: The components are combined, with the patient subgroup qualifier preceding the disease, resulting in 'BRCA-Mutated Ovarian Cancer'.
Step 6: A final quality check confirms adherence to all formatting, exclusion, and single-source rules.","[{'category': 'Gene type', 'subcategories': ['Gene Mutation', 'Gene Mutant', 'Gene Mutated'], 'reason': ""To determine the correct formatting for 'BRCA mutations'.""}]","[{'component': 'ovarian cancer', 'type': 'Disease', 'normalized_form': 'Ovarian Cancer', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'BRCA mutations', 'type': 'Gene Mutation', 'normalized_form': 'BRCA-Mutated', 'rule_applied': ""Standard clinical nomenclature for gene mutations (e.g., 'Gene-Mutated')""}, {'component': 'screening of ovarian cancer patients for BRCA mutations as a prerequisite for autologous cellular immunotherapy manufacturing', 'type': 'Procedural Context', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Procedural/Temporal Qualifiers'}]",2
377920,Myeloproliferative neoplasms - Clinical,Atypical Chronic Myeloid Leukemia (Acml) And Autoimmune Disease: Report Of Two Cases.,Atypical Chronic Myeloid Leukemia;;Autoimmune Disease,Atypical Chronic Myeloid Leukemia;;Autoimmune Disease,Atypical Chronic Myeloid Leukemia;;Autoimmune Disease,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title 'Atypical Chronic Myeloid Leukemia (Acml) And Autoimmune Disease: Report Of Two Cases.' contains specific disease terms. The session title 'Myeloproliferative neoplasms - Clinical' contains a broader category. Based on the Single-Source Extraction Principle, the abstract title is selected as the source.
2. **Identify Components**: The abstract title identifies two distinct medical conditions: 'Atypical Chronic Myeloid Leukemia' and 'Autoimmune Disease'. The word 'And' indicates that these are two separate indications.
3. **Retrieve Relevant Rules**: I retrieved rules for the 'Atypical' qualifier and for handling multiple diseases.
   - `get_indication_rules(category=""Patient Sub-Group"", subcategories=[""Atypical/Typical""])`: The retrieved rules confirm that 'Atypical' should be included when it immediately precedes a disease name.
   - `get_indication_rules(category=""Patient with two different Disease"", subcategories=[""General""])`: No specific rules were found, so the generic rule for multiple diseases applies.
4. **Apply Rules**:
   - **Multiple Diseases Rule**: The two identified diseases, 'Atypical Chronic Myeloid Leukemia' and 'Autoimmune Disease', must be extracted and separated by ';;'.
   - **Atypical Rule**: The term 'Atypical' is a direct qualifier for 'Chronic Myeloid Leukemia' and is retained.
   - **Chronic Rule**: The term 'Chronic' is an integral part of the disease name 'Chronic Myeloid Leukemia' and is retained.
   - **Exclusion Rule**: The parenthetical abbreviation '(Acml)' and the study descriptor 'Report Of Two Cases' are excluded from the final indication.
   - **Formatting Rules**: Both indications are converted to Title Case and are already in singular form.
5. **Construct Indication**: The two processed indications are combined using the ';;' separator, resulting in 'Atypical Chronic Myeloid Leukemia;;Autoimmune Disease'.
6. **Quality Check**: The final output adheres to all formatting, single-source, and content rules. It accurately reflects the clinically valid indications present in the source title.","[{'category': 'Patient Sub-Group', 'subcategories': ['Atypical/Typical'], 'reason': ""To verify the correct handling of the 'Atypical' qualifier.""}, {'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': 'To check for specific rules on handling multiple diseases, defaulting to generic rules when none are found.'}]","[{'component': 'Atypical Chronic Myeloid Leukemia (Acml)', 'type': 'Disease', 'normalized_form': 'Atypical Chronic Myeloid Leukemia', 'rule_applied': ""Patient Sub-Group rule for 'Atypical', Generic rule for 'Chronic', Exclusion of abbreviation.""}, {'component': 'Autoimmune Disease', 'type': 'Disease', 'normalized_form': 'Autoimmune Disease', 'rule_applied': 'Generic formatting rules (Title Case, Singular).'}]",2
148549,Transfusion Medicine,Evaluation Of Red Blood Cell Autoantibodies And Associated Thrombotic Risk In A Tertiary Care Centre In Spain,,,Red Blood Cell Autoantibody;;Thrombotic Risk,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Evaluation Of Red Blood Cell Autoantibodies And Associated Thrombotic Risk In A Tertiary Care Centre In Spain') contains specific medical conditions, while the session title ('Transfusion Medicine') is a broad therapeutic area. Therefore, the abstract title was selected as the source based on the Single-Source Extraction Principle.
2.  **Component Identification**: Two distinct medical concepts were identified in the abstract title: 'Red Blood Cell Autoantibodies' and 'Thrombotic Risk'. The conjunction 'And Associated' links them as separate entities for evaluation.
3.  **Rule Retrieval**: I retrieved rules for the 'Risk' category to correctly handle 'Thrombotic Risk'. While no specific rule matched 'Thrombotic Risk', the generic rule for multiple diseases (e.g., 'Cardiovascular Risk') indicates that it should be treated as a standalone indication.
4.  **Rule Application & Normalization**:
    *   **Multiple Diseases**: The two identified concepts are treated as separate indications, to be joined by ';;'.
    *   **Singular Form**: The plural term 'Autoantibodies' was converted to its singular form 'Autoantibody' as per generic formatting rules.
    *   **Title Case**: Both indications were formatted to Title Case: 'Red Blood Cell Autoantibody' and 'Thrombotic Risk'.
    *   **Exclusion**: Non-diagnostic and geographic information ('Evaluation Of', 'In A Tertiary Care Centre In Spain') was excluded.
5.  **Indication Construction**: The normalized components were combined to form the final output: `Red Blood Cell Autoantibody;;Thrombotic Risk`.","[{'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To check for specific rules on how to format 'Thrombotic Risk'.""}]","[{'component': 'Red Blood Cell Autoantibodies', 'type': 'Disease', 'normalized_form': 'Red Blood Cell Autoantibody', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Title Case'}, {'component': 'Thrombotic Risk', 'type': 'Disease', 'normalized_form': 'Thrombotic Risk', 'rule_applied': 'Generic Rule: Multiple Diseases; Generic Rule: Title Case'}]",2
263238,Infections in hematology (incl. supportive care/therapy),Protection Of Patients With Hematologic Malignancy From Severe Infection During Pandemia: Estonian Two Centres Experience,Hematologic Malignancy,Hematologic Malignancy,Hematologic Malignancy;;Severe Infection,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains specific disease terms ('Hematologic Malignancy', 'Severe Infection'), which is preferred over the broader session title ('Infections in hematology') per the single-source principle.
2. **Component Identification**: Two distinct medical conditions were identified in the abstract title: 'Hematologic Malignancy' and 'Severe Infection'.
3. **Rule Application (Generic)**:
   - **Multiple Diseases Rule**: The presence of two distinct conditions requires them to be extracted as separate indications, delimited by ';;'.
   - **Formatting Rules**: Both terms were converted to Title Case and confirmed to be in singular form.
   - **Exclusion Rules**: Non-diagnostic and contextual phrases such as 'Protection Of Patients', 'During Pandemia', and 'Estonian Two Centres Experience' were excluded as per the generic rules.
4. **Indication Construction**: The two normalized disease terms were combined using the ';;' separator to form the final output.
5. **Quality Check**: The final indication adheres to all formatting, separation, and content rules. It accurately reflects the core clinical conditions mentioned in the source title.",[],"[{'component': 'Hematologic Malignancy', 'type': 'Disease', 'normalized_form': 'Hematologic Malignancy', 'rule_applied': 'Generic Casing and Singular Form Rules'}, {'component': 'Severe Infection', 'type': 'Disease', 'normalized_form': 'Severe Infection', 'rule_applied': 'Generic Casing and Singular Form Rules'}]",2
410696,Glomerular Diseases,Late-Onset Lupus Nephritis Presenting as Acute Decompensated Heart Failure,Late-Onset;;Lupus Nephritis,Late-Onset Lupus Nephritis,Late Onset Lupus Nephritis;;Acute Decompensated Heart Failure,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Late-Onset Lupus Nephritis Presenting as Acute Decompensated Heart Failure' was chosen as it contains specific disease terms, which is preferred over the broader session title 'Glomerular Diseases' according to the single-source principle.
2. **Component Identification**: The abstract title identifies two distinct clinical conditions: 'Late-Onset Lupus Nephritis' and 'Acute Decompensated Heart Failure'. The phrase 'Presenting as' links them as separate entities.
3. **Rule Retrieval**: I retrieved rules for 'Onset' to handle 'Late-Onset' and for 'Patient with two different Disease' to confirm how to handle the two conditions. The 'Onset' rules confirmed the formatting for 'Late Onset', and the generic rules for multiple diseases were applied in the absence of a specific rule for the 'Presenting as' scenario.
4. **Rule Application**: 
   - **Multiple Diseases**: The generic rule was applied to extract both distinct diseases, separated by ';;'.
   - **Onset Rule (ID 287)**: The specific rule for 'Late Onset' was applied, standardizing 'Late-Onset' to 'Late Onset' (Title Case, no hyphen).
   - **Disease Characterization (Acute)**: The generic rule for 'Acute' was applied, retaining it as it is an integral part of the disease name 'Acute Decompensated Heart Failure'.
   - **Formatting**: All terms were converted to Title Case and singular form as required.
5. **Indication Construction**: The two processed components were combined to form the final indication: 'Late Onset Lupus Nephritis' and 'Acute Decompensated Heart Failure', joined by ';;'.
6. **Quality Check**: The final output was verified against all generic and specific rules, ensuring compliance with formatting, single-source principle, and clinical accuracy.","[{'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To correctly format the 'Late-Onset' qualifier.""}, {'category': 'Patient with two different Disease', 'subcategories': [], 'reason': ""To check for specific rules on how to handle two diseases linked by 'Presenting as'. No specific rules were found, so generic rules were applied.""}]","[{'component': 'Late-Onset Lupus Nephritis', 'type': 'Disease with Onset Qualifier', 'normalized_form': 'Late Onset Lupus Nephritis', 'rule_applied': ""Onset by Time rule for 'Late Onset' (ID 287) and Generic Casing/Singular rules.""}, {'component': 'Acute Decompensated Heart Failure', 'type': 'Disease', 'normalized_form': 'Acute Decompensated Heart Failure', 'rule_applied': ""Generic rule for 'Acute' and Generic Casing/Singular rules.""}]",2
164938,ID Complications associated with Novel Cellular & Immunotherapies in Cancer,Infectious Complications of CD19-targeted Chimeric Antigen Receptor-modified T (CAR-T)-cell Immunotherapy,Cancer,Cancer,Cancer,True,session_title,"Step 1: The abstract title 'Infectious Complications of CD19-targeted Chimeric Antigen Receptor-modified T (CAR-T)-cell Immunotherapy' does not contain a specific disease. It describes complications of a therapy. 
Step 2: The session title 'ID Complications associated with Novel Cellular & Immunotherapies in Cancer' contains the disease term 'Cancer'.
Step 3: Following the single-source extraction principle, the session title is selected as the source for the indication.
Step 4: The term 'Cancer' is extracted from the session title. The surrounding terms 'ID Complications associated with Novel Cellular & Immunotherapies in' are excluded as they describe the context and not the core indication.
Step 5: The generic formatting rules (Title Case, singular form) are applied. 'Cancer' is already in the correct format. The final indication is 'Cancer'.",[],"[{'component': 'Cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Therapeutic Area Fallback'}]",1
345167,Cancer Cachexia,Integrin-mediated lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia,cancer;;associated;;cachexia,Cancer-Associated Cachexia,Pancreatic Cancer;;Cancer-Associated Cachexia,True,abstract_title,"Step 1: The abstract title was selected as the source because it contains more specific disease information ('pancreatic cancer', 'cancer-associated cachexia') than the session title ('Cancer Cachexia').
Step 2: The abstract title identifies two distinct but related clinical conditions: 'pancreatic cancer' and 'cancer-associated cachexia'.
Step 3: According to the generic rule for multiple diseases, both conditions must be extracted as separate indications.
Step 4: The terms were normalized according to formatting rules: 'pancreatic cancer' becomes 'Pancreatic Cancer' (Title Case) and 'cancer-associated cachexia' becomes 'Cancer-Associated Cachexia' (Title Case).
Step 5: The two normalized indications are joined using the required ';;' separator, resulting in the final output.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To determine the correct way to handle the presence of both pancreatic cancer and cachexia in the title.'}]","[{'component': 'pancreatic cancer', 'type': 'Disease', 'normalized_form': 'Pancreatic Cancer', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Singular Form'}, {'component': 'cancer-associated cachexia', 'type': 'Disease', 'normalized_form': 'Cancer-Associated Cachexia', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Multiple Diseases'}]",2
263249,Lymphoma Biology & Translational Research,Tp53 Gene Mutation Diversity In Russian Patients With B-Cell Lymphomas,B-Cell Lymphomas,B-Cell Lymphoma,Tp53-Mutated B-Cell Lymphoma,True,abstract_title,"Step 1: The abstract title 'Tp53 Gene Mutation Diversity In Russian Patients With B-Cell Lymphomas' was chosen as the source because it contains a specific disease ('B-Cell Lymphomas'), which is more precise than the session title's broader term ('Lymphoma').
Step 2: The components identified in the abstract title were 'Tp53 Gene Mutation' (gene mutation), 'Russian Patients' (sociodemographic descriptor), and 'B-Cell Lymphomas' (disease).
Step 3: Rules for 'Gene Name' and 'Patient Sub-Group' were retrieved to handle 'Tp53' and 'B-Cell' respectively.
Step 4: The generic sociodemographic exclusion rule was applied to remove 'Russian Patients'. The retrieved 'Gene Name' rule (ID: 27) guided the formatting of 'Tp53 Gene Mutation' into 'Tp53-Mutated'. The generic singularization rule was applied to convert 'Lymphomas' to 'Lymphoma'. The 'B-Cell' qualifier was retained as it is an integral part of the disease name.
Step 5: The components were combined and formatted according to Title Case rules, resulting in the final indication 'Tp53-Mutated B-Cell Lymphoma'.","[{'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To determine how to handle the gene 'Tp53' and its qualifier 'Mutation'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To verify the correct handling of the 'B-Cell' qualifier for the lymphoma.""}]","[{'component': 'Tp53 Gene Mutation', 'type': 'Gene Mutation', 'normalized_form': 'Tp53-Mutated', 'rule_applied': ""Gene Name Rule ID: 27 requires combining the gene symbol with its qualifier, formatted as '<GeneSymbol>-<Qualifier>'.""}, {'component': 'B-Cell Lymphomas', 'type': 'Disease', 'normalized_form': 'B-Cell Lymphoma', 'rule_applied': ""Generic rule for singular form was applied ('Lymphomas' -> 'Lymphoma'). 'B-Cell' is retained as an essential disease specifier.""}, {'component': 'Russian Patients', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for ethnicity/region was applied.'}]",3
263250,Lymphoma Biology & Translational Research,"Surgical Specimens Of Indolent And Aggressive B-Nhls Show Differences In Their Flow-Cytometry Profile Of Ploidy, Proliferating Fraction And Proportion Of Tumor-Associated Myeloid And T-Cell Subsets",Indolent;;Aggressive;;B-Nhls,Indolent Aggressive B-cell non-Hodgkin lymphoma,Indolent B-Cell Non-Hodgkin's Lymphoma;;Aggressive B-Cell Non-Hodgkin's Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains specific disease terms ('Indolent And Aggressive B-Nhls'), which is more precise than the broader term 'Lymphoma' in the session title. This adheres to the Single-Source Extraction Principle.
2. **Component Identification**: The key components identified in the abstract title were the disease 'B-Nhls' and its characterizations 'Indolent' and 'Aggressive'.
3. **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' under the 'Disease Characterisation' subcategory to understand how to handle descriptors like 'Indolent' and 'Aggressive'. While no specific rule existed for these exact terms, the general principle is to include clinically significant descriptors that define a patient subgroup.
4. **Rule Application and Normalization**:
   - **Multiple Indications**: 'Indolent' and 'Aggressive' describe distinct clinical behaviors of the lymphoma, so they were treated as separate indications.
   - **Abbreviation Expansion**: The abbreviation 'B-Nhls' was expanded to its full clinical term 'B-Cell Non-Hodgkin's Lymphoma'.
   - **Singular Form**: The plural 'Lymphomas' (implied by 'B-Nhls') was converted to the singular 'Lymphoma' as per generic formatting rules.
   - **Casing**: The final indications were formatted in Title Case.
   - **Separator**: The two distinct indications were separated by the required ';;' delimiter.
5. **Indication Construction**: The normalized components were combined to form two clinically distinct indications: 'Indolent B-Cell Non-Hodgkin's Lymphoma' and 'Aggressive B-Cell Non-Hodgkin's Lymphoma'.
6. **Quality Check**: The final output was reviewed to ensure it is clinically accurate, follows all formatting rules, and adheres to the single-source principle. All methodological terms like 'Surgical Specimens' and 'Flow-Cytometry' were correctly excluded.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules on handling disease characterization keywords like 'Indolent' and 'Aggressive'.""}]","[{'component': 'Indolent B-Nhls', 'type': 'Disease', 'normalized_form': ""Indolent B-Cell Non-Hodgkin's Lymphoma"", 'rule_applied': ""Generic rule: Singular form, Title Case, Abbreviation Expansion. 'Indolent' is a clinically significant descriptor and was retained.""}, {'component': 'Aggressive B-Nhls', 'type': 'Disease', 'normalized_form': ""Aggressive B-Cell Non-Hodgkin's Lymphoma"", 'rule_applied': ""Generic rule: Singular form, Title Case, Abbreviation Expansion. 'Aggressive' is a clinically significant descriptor and was retained.""}]",2
410708,Glomerular Diseases,Porphyria Cutanea Tarda and Systemic Lupus Erythematosus: An Unusual Association in a Patient with Nephritic Syndrome,Porphyria Cutanea Tarda;;Systemic Lupus Erythematosus;;Nephritic Syndrome,Porphyria Cutanea Tarda;;Systemic Lupus Erythematosus;;Nephritic Syndrome,Porphyria Cutanea Tarda;;Systemic Lupus Erythematosus;;Nephritic Syndrome,True,abstract_title,"Step 1: The abstract title contains specific disease names ('Porphyria Cutanea Tarda', 'Systemic Lupus Erythematosus', 'Nephritic Syndrome'), making it the preferred source over the more general session title ('Glomerular Diseases').
Step 2: I identified three distinct medical conditions mentioned in the abstract title.
Step 3: According to the generic rule for multiple diseases, all identified conditions must be extracted and separated by ';;'.
Step 4: I applied the formatting rules. The disease names are already in Title Case and singular form. No components needed to be excluded.
Step 5: The final indication was constructed by joining the three identified conditions with the ';;' separator.",[],"[{'component': 'Porphyria Cutanea Tarda', 'type': 'Disease', 'normalized_form': 'Porphyria Cutanea Tarda', 'rule_applied': 'Generic Rule - Multiple Diseases'}, {'component': 'Systemic Lupus Erythematosus', 'type': 'Disease', 'normalized_form': 'Systemic Lupus Erythematosus', 'rule_applied': 'Generic Rule - Multiple Diseases'}, {'component': 'Nephritic Syndrome', 'type': 'Disease', 'normalized_form': 'Nephritic Syndrome', 'rule_applied': 'Generic Rule - Multiple Diseases'}]",3
279637,Gilead and Kite Oncology: Chimeric antigen receptor T cells case studies: navigating patient management,Managing relapsed/refractory mantle cell lymphoma: a case study,relapsed;;refractory;;mantle cell lymphoma,Relapsed/Refractory Mantle Cell Lymphoma,Relapsed/Refractory Mantle Cell Lymphoma,True,abstract_title,"Step 1: The abstract title 'Managing relapsed/refractory mantle cell lymphoma: a case study' was chosen as the source because it contains a specific disease ('mantle cell lymphoma'), whereas the session title only contains a broad therapeutic area ('Oncology').
Step 2: I identified the core disease as 'mantle cell lymphoma' and a patient subgroup qualifier 'relapsed/refractory'.
Step 3: I retrieved rules for 'Occurrence' to understand how to handle terms like 'relapsed/refractory'. The rules suggest normalizing such terms and placing them before the disease name.
Step 4: I applied the generic rules. I converted the disease to Title Case ('Mantle Cell Lymphoma') and ensured it was in singular form. I normalized the qualifier to 'Relapsed/Refractory'. I excluded the procedural term 'Managing' and the study descriptor 'a case study'.
Step 5: I combined the normalized components to construct the final indication: 'Relapsed/Refractory Mantle Cell Lymphoma'.
Step 6: A final quality check confirmed that all formatting, exclusion, and single-source rules were followed, resulting in a clinically accurate and standardized indication.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To determine the correct formatting for the 'relapsed/refractory' patient subgroup qualifier.""}]","[{'component': 'relapsed/refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Normalization based on Occurrence rules for similar terms (e.g., Recurrent/Refractory).'}, {'component': 'mantle cell lymphoma', 'type': 'Disease', 'normalized_form': 'Mantle Cell Lymphoma', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
181344,Bone Marrow Failure: Poster II,Intensive Immunosupressive Therapy Combining with Eltrombopag for Adult Chinese Patients with Severe Aplastic Anemia,Adult;;Severe Aplastic Anemia,Adult Severe Aplastic Anemia,Adult Severe Aplastic Anemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Intensive Immunosupressive Therapy Combining with Eltrombopag for Adult Chinese Patients with Severe Aplastic Anemia') was chosen over the session title ('Bone Marrow Failure: Poster II') because it contains a more specific and complete medical indication.
2.  **Component Identification**: I identified the following components in the abstract title: 'Adult' (Age Group), 'Chinese' (Sociodemographic), and 'Severe Aplastic Anemia' (Disease with Severity).
3.  **Rule Retrieval**: I retrieved rules for 'Age Group' (specifically 'Adult') and 'Risk' (for 'Severe') to ensure correct formatting.
4.  **Rule Application**:
    *   **Generic Exclusion Rule**: The sociodemographic descriptor 'Chinese' was excluded as per the generic rules.
    *   **Generic Exclusion Rule**: The procedural/therapy information 'Intensive Immunosupressive Therapy Combining with Eltrombopag' was excluded.
    *   **Age Group Rule**: The term 'Adult' was identified as a patient subgroup and prepended to the indication in Title Case.
    *   **Disease & Severity**: 'Severe Aplastic Anemia' is a recognized clinical entity. The severity 'Severe' is integral to the indication and was retained. The disease name was kept in Title Case and singular form.
5.  **Indication Construction**: The components were combined in the correct order (Age Group + Severity + Disease) to form the final indication: 'Adult Severe Aplastic Anemia'.
6.  **Final Quality Check**: The final output adheres to all formatting and exclusion rules, resulting in a clinically valid indication.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To validate the formatting and placement of the 'Adult' patient subgroup descriptor.""}, {'category': 'Risk', 'subcategories': ['severe'], 'reason': ""To confirm that 'Severe' should be included as part of the disease characterization.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group rule to prepend the capitalized term to the indication.'}, {'component': 'Chinese', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for ethnicity.'}, {'component': 'Severe Aplastic Anemia', 'type': 'Disease', 'normalized_form': 'Severe Aplastic Anemia', 'rule_applied': ""Generic rule to use singular form and Title Case. 'Severe' is retained as it is an integral part of this specific disease's name.""}]",2
148578,Acute Lymphoblastic Leukemia - Clinical,L-Asparaginase Associated Acute Pancreatitis In Children With Acute Lymphoblastic Leukemia,Children;;Acute Pancreatitis;;Acute Lymphoblastic Leukemia,Childhood Acute Pancreatitis;;Acute Lymphoblastic Leukemia,Childhood Acute Pancreatitis;;Childhood Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('L-Asparaginase Associated Acute Pancreatitis In Children With Acute Lymphoblastic Leukemia') was chosen over the session title ('Acute Lymphoblastic Leukemia - Clinical') because it is more specific and contains more detailed information, including multiple conditions and a patient subgroup, adhering to the 'Abstract Title first' principle.

2. **Component Identification**: The abstract title contains two distinct medical conditions: 'Acute Pancreatitis' and 'Acute Lymphoblastic Leukemia'. It also identifies a patient subgroup: 'Children'. The phrase 'L-Asparaginase Associated' is identified as a descriptor for Acute Pancreatitis.

3. **Rule Retrieval & Application**:
   - **Age Group**: Rules for 'Childhood' were retrieved using `get_indication_rules(category=""Age Group"", subcategories=[""Childhood""])`. Rule ID 294 directs the replacement of 'Children' with the prefix 'Childhood' before the associated disease name.
   - **Multiple Diseases**: The generic rules for multiple diseases were applied, requiring the extraction of all distinct conditions and separating them with ';;'.
   - **Exclusion Rule**: The descriptor 'L-Asparaginase Associated' indicates that the pancreatitis is a complication or adverse effect of a treatment. According to the generic exclusion rules, 'Complications or adverse effects' should be excluded from the final indication. Therefore, this phrase was removed.

4. **Indication Construction**:
   - The patient subgroup 'Children' is linked to the patients who have Acute Lymphoblastic Leukemia, and the pancreatitis occurs within this group. Therefore, the 'Childhood' qualifier applies to both conditions.
   - 'Acute Pancreatitis' combined with the age qualifier becomes 'Childhood Acute Pancreatitis'.
   - 'Acute Lymphoblastic Leukemia' combined with the age qualifier becomes 'Childhood Acute Lymphoblastic Leukemia'.
   - The two indications are combined using the ';;' separator.

5. **Final Quality Check**: The final output `Childhood Acute Pancreatitis;;Childhood Acute Lymphoblastic Leukemia` adheres to all formatting rules (Title Case, singular form, no trailing spaces) and accurately reflects the clinically valid indications present in the source title after applying the necessary rules.","[{'category': 'Age Group', 'subcategories': ['Childhood'], 'reason': ""To handle the 'Children' patient subgroup.""}, {'category': 'Patient with two different Disease', 'subcategories': None, 'reason': 'To check for specific rules on handling multiple diseases, though a tool error occurred and generic rules were used instead.'}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To determine if 'L-Asparaginase Associated' is a valid clinical qualifier.""}]","[{'component': 'Acute Pancreatitis', 'type': 'Disease', 'normalized_form': 'Acute Pancreatitis', 'rule_applied': 'Generic disease identification.'}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic disease identification.'}, {'component': 'Children', 'type': 'Age Group', 'normalized_form': 'Childhood', 'rule_applied': ""Age Group Rule ID 294: Replace 'Children' with 'Childhood' and prepend to the disease name.""}, {'component': 'L-Asparaginase Associated', 'type': 'Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude complications or adverse effects.'}]",2
410725,"Health Maintenance, Nutrition, and Metabolism",Intradialytic Amino Acids Improved Malnutrition Markers in ESRD with Complex Congenital Heart Disease on Peritoneal Dialysis,,,End-Stage Renal Disease;;Complex Congenital Heart Disease,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Intradialytic Amino Acids Improved Malnutrition Markers in ESRD with Complex Congenital Heart Disease on Peritoneal Dialysis') was chosen over the session title ('Health Maintenance, Nutrition, and Metabolism') because it contains specific disease terms, adhering to the single-source principle.
2. **Component Identification**: Two distinct diseases were identified in the abstract title: 'ESRD' and 'Complex Congenital Heart Disease'. The term 'with' connects them, indicating a patient population with both conditions.
3. **Rule Application (Generic)**:
   - **Multiple Diseases**: The generic rule for multiple diseases was applied, requiring both conditions to be extracted and separated by ';;'.
   - **Standardization**: 'ESRD' was expanded to its full standard name 'End-Stage Renal Disease'.
   - **Exclusion**: The procedural qualifier 'on Peritoneal Dialysis' and the non-diagnostic term 'Malnutrition Markers' were excluded as per generic exclusion rules.
   - **Formatting**: Both indications were converted to Title Case and singular form.
4. **Rule Retrieval (Tool-based)**:
   - A rule check for 'Patient with two different Disease' was performed, but no specific rules were found, defaulting to the generic separator rule.
   - A rule check for 'Disease Characterisation' was done for the term 'Complex'. No specific rule exists, so the clinically significant descriptor 'Complex' was retained.
   - A rule check for 'Genetic Origin' was done for 'Congenital'. No specific rule exists, so this standard medical term, being part of the disease name, was retained.
5. **Indication Construction**: The two standardized disease names were combined using the ';;' separator, resulting in the final indication.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To determine the correct formatting for a title describing patients with two concurrent diseases (ESRD and Heart Disease).'}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for specific rules on handling the qualifier 'Complex'.""}, {'category': 'Occurrence', 'subcategories': ['Genetic Origin'], 'reason': ""To check for specific rules on handling the qualifier 'Congenital'.""}]","[{'component': 'ESRD', 'type': 'Disease', 'normalized_form': 'End-Stage Renal Disease', 'rule_applied': 'Standard medical acronym expansion and Title Case rule.'}, {'component': 'Complex Congenital Heart Disease', 'type': 'Disease', 'normalized_form': 'Complex Congenital Heart Disease', 'rule_applied': ""Title Case and singular form rules. 'Complex' and 'Congenital' were retained as they are clinically significant parts of the disease name.""}, {'component': 'on Peritoneal Dialysis', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/treatment context.'}]",2
328806,Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster II,Inhibition of Oxidative Phosphorylation and Glycolysis Reduces Viability in Multiple Myeloma By Affecting mTOR-Mediated Protein Synthesis,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: I analyzed both the abstract and session titles.
Step 2: The abstract title contains the disease term 'Multiple Myeloma'. The session title contains 'Multiple Myeloma' and 'Plasma Cell Dyscrasias'.
Step 3: According to the Single-Source Extraction Principle, the abstract title is the preferred source if it contains a disease term. Therefore, I selected the abstract title.
Step 4: I identified 'Multiple Myeloma' as the core indication from the abstract title.
Step 5: I excluded phrases like 'Inhibition of Oxidative Phosphorylation and Glycolysis' and 'mTOR-Mediated Protein Synthesis' as they describe biological mechanisms and study details, not patient subgroups or disease characteristics.
Step 6: I applied the generic formatting rules. The term 'Multiple Myeloma' is already in Title Case and singular form, requiring no changes.",[],"[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic formatting rules (Title Case, Singular Form).'}]",1
312429,Review Course,Wrap-Up,,,,True,none,"Neither the abstract title ('Wrap-Up') nor the session title ('Review Course') contains any specific disease, disorder, or therapeutic area. Both titles are generic and describe the nature of the presentation rather than a clinical subject. Therefore, no medical indication can be extracted.",[],[],1
214129,MP45: Prostate Cancer: Markers,MicroRNA 185-5p is a novel biomarker associated with high-risk pathology at radical prostatectomy in patients with low-risk disease at diagnosis,Prostate Cancer,Prostate Cancer,Prostate Cancer,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The `abstract_title` is 'MicroRNA 185-5p is a novel biomarker associated with high-risk pathology at radical prostatectomy in patients with low-risk disease at diagnosis'. The `session_title` is 'MP45: Prostate Cancer: Markers'.
2.  **Select Source**: According to the Single-Source Extraction Principle, the abstract title is preferred if it contains a disease term. The abstract title contains patient subgroup information ('low-risk', 'high-risk') but only the generic term 'disease', which is not a specific, clinically valid indication. The session title, however, provides the clear and specific disease 'Prostate Cancer'. To generate a clinically valid indication, the abstract title is discarded for its lack of a specific disease, and the session title is used as the source.
3.  **Identify Components**: From the selected `session_title` ('MP45: Prostate Cancer: Markers'), the core disease component is 'Prostate Cancer'. The terms 'MP45' and 'Markers' are session identifiers and topics, not part of the medical indication, and are therefore excluded.
4.  **Retrieve Rules**: No specific category rules were needed for this straightforward extraction.
5.  **Apply Generic Rules**: The generic rules for formatting (Title Case, singular form) are applied. 'Prostate Cancer' is already in the correct format.
6.  **Construct Indication**: The final indication is constructed from the identified component, resulting in 'Prostate Cancer'.
7.  **Quality Check**: The final output adheres to all formatting and clinical validity requirements. It is derived from a single source and is a recognized medical condition.","[{'category': 'Risk', 'subcategories': ['High-Risk', 'Low-Risk', 'Risk Types'], 'reason': ""To evaluate the terms 'high-risk' and 'low-risk' found in the abstract title.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To evaluate the phrase 'at diagnosis' found in the abstract title.""}, {'category': 'Treatment Set-up', 'subcategories': ['Operative Status'], 'reason': ""To evaluate the procedural term 'radical prostatectomy' found in the abstract title.""}]","[{'component': 'Prostate Cancer', 'type': 'Disease', 'normalized_form': 'Prostate Cancer', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}, {'component': 'low-risk disease', 'type': 'Patient Subgroup with Disease', 'normalized_form': 'Low-Risk Disease', 'rule_applied': ""Risk rule for 'Low-Risk'. This component was discarded because 'disease' is not a specific clinical entity and the source (abstract_title) was rejected.""}, {'component': 'radical prostatectomy', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers. This component was discarded.'}]",2
296059,"Breast cancer, early stage","Cosmesis (CA), late effects (LE) and Patient reported outcome measures (PROM) in high risk breast cancer (BC) treated with hypo-fractionated radiotherapy (RT): real world outcome from a developing country.",high risk;;breast cancer ,High Risk Breast Cancer ,High-Risk Breast Cancer,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease, 'breast cancer', along with a patient subgroup qualifier, 'high risk'. The session title also contains 'Breast cancer' but the abstract title is more specific.
Step 2: The core disease 'breast cancer' was identified. Per generic rules, it was converted to singular and Title Case, resulting in 'Breast Cancer'.
Step 3: The qualifier 'high risk' was identified. The `get_indication_rules` tool was used for the 'Risk' category.
Step 4: Rule ID 122 for 'High-Risk' was applied, which standardizes 'high risk' to 'High-Risk' and places it before the disease name.
Step 5: Other elements in the title such as 'Cosmesis (CA)', 'late effects (LE)', 'Patient reported outcome measures (PROM)', treatment details ('hypo-fractionated radiotherapy'), and geographic descriptors ('developing country') were excluded as per generic exclusion rules.
Step 6: The final indication was constructed by combining the normalized risk qualifier and the disease: 'High-Risk Breast Cancer'.","[{'category': 'Risk', 'subcategories': ['High-Risk', 'Risk Types'], 'reason': ""To correctly format the 'high risk' patient subgroup qualifier.""}]","[{'component': 'high risk', 'type': 'Risk Qualifier', 'normalized_form': 'High-Risk', 'rule_applied': ""Rule ID 122: Normalize 'high risk' to 'High-Risk' and prepend to the disease.""}, {'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Rule: Convert to singular form and Title Case.'}]",2
296071,Melanoma and other skin tumours,Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: a phase II clinical trial (NeoBCC),primary;;basal cell carcinoma,Primary Basal Cell Carcinoma,Unresectable Primary Basal Cell Carcinoma,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease ('primary basal cell carcinoma'), which is preferred over the broader categories in the session title ('Melanoma and other skin tumours').
Step 2: The core disease was identified as 'primary basal cell carcinoma'. The qualifier 'difficult to resect' was also identified.
Step 3: Rules for resectability were retrieved using `get_indication_rules(category='Treatment Set-up', subcategories=['Resectable', 'Unresectable'])` to understand how to handle terms related to surgical status.
Step 4: The phrase 'difficult to resect' is a clinical descriptor indicating that the tumor is not easily removable. Based on the retrieved rules for 'Unresectable' and 'Non-Resectable', this term was normalized to the standard clinical qualifier 'Unresectable'.
Step 5: The generic rule for 'Primary' was applied, keeping it as part of the disease name. The generic rules for Title Case and singular form were applied to format the final indication.
Step 6: The components were combined to form the final indication: 'Unresectable Primary Basal Cell Carcinoma'.","[{'category': 'Treatment Set-up', 'subcategories': ['Resectable', 'Unresectable'], 'reason': ""To determine the correct handling and normalization of the phrase 'difficult to resect'.""}]","[{'component': 'difficult to resect', 'type': 'Resectability Status', 'normalized_form': 'Unresectable', 'rule_applied': ""Normalization based on retrieved 'Unresectable' rules (e.g., Rule ID 245), as 'difficult to resect' implies a state of unresectability.""}, {'component': 'primary basal cell carcinoma', 'type': 'Disease', 'normalized_form': 'Primary Basal Cell Carcinoma', 'rule_applied': ""Generic rule for 'Primary' and generic formatting rules (Title Case, Singular Form).""}]",2
394376,Renal Cancer,Adjuvant Everolimus (Eve) In Patients (Pts) With Completely Resected Very High-Risk Renal Cell Cancer (Rcc) And Clear Cell Histology: Results From The Phase Iii Swog S0931 (Everest) Trial,Resected;;Very High-Risk;;Renal Cell Cancer,Resected Very High-Risk Renal Cell Cancer,Very High-Risk Clear Cell Renal Cell Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title because it contains a more specific and detailed description of the medical indication, including risk level and histology, which aligns with the Single-Source Extraction Principle.

2. **Component Identification**: I identified the following key components in the abstract title: 
   - Disease: 'Renal Cell Cancer (Rcc)'
   - Risk Qualifier: 'Very High-Risk'
   - Histology/Subtype: 'Clear Cell Histology'
   - Treatment/Procedural Context: 'Adjuvant', 'Completely Resected'

3. **Rule Retrieval**: I retrieved rules for 'Treatment Set-up' (Operative Status), 'Risk' (Risk Types), and 'Patient Sub-Group' (Disease Characterisation) to guide the extraction.

4. **Rule Application and Component Normalization**:
   - **Disease**: 'Renal Cell Cancer' was kept as the core disease, and the abbreviation '(Rcc)' was removed. The term is already in singular form.
   - **Risk Qualifier**: Based on the pattern from retrieved 'Risk Types' rules, 'Very High-Risk' was identified as a critical patient subgroup qualifier and was prepended to the disease name. It was formatted in Title Case.
   - **Histology/Subtype**: 'Clear Cell' is a crucial histological subtype of Renal Cell Cancer. The term 'Histology' was dropped as it is descriptive of the analysis type, not the disease itself. 'Clear Cell' was included in the indication.
   - **Exclusions**: Following generic exclusion rules and the patterns in the retrieved 'Treatment Set-up' rules (e.g., for 'Post Operative'), the terms 'Adjuvant' (treatment timing) and 'Completely Resected' (procedural status) were excluded as they describe the treatment context rather than defining the core indication.

5. **Indication Construction**: The identified and normalized components were assembled in the standard clinical order: [Risk] [Histology/Subtype] [Disease]. This resulted in 'Very High-Risk Clear Cell Renal Cell Cancer'.

6. **Final Quality Check**: The final indication was reviewed for compliance with all formatting rules (Title Case, singular form, no extra spaces) and clinical accuracy. The result is a concise, standardized, and clinically valid medical indication.","[{'category': 'Treatment Set-up', 'subcategories': ['Operative Status', 'Treatment Modality'], 'reason': ""To determine how to handle the term 'Completely Resected' and 'Adjuvant'.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To correctly format and include the 'Very High-Risk' qualifier.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To determine how to handle the 'Clear Cell Histology' descriptor.""}]","[{'component': 'Renal Cell Cancer', 'type': 'Disease', 'normalized_form': 'Renal Cell Cancer', 'rule_applied': 'Generic singular form and Title Case rule.'}, {'component': 'Very High-Risk', 'type': 'Risk Qualifier', 'normalized_form': 'Very High-Risk', 'rule_applied': 'Risk category rule pattern for prepending risk status.'}, {'component': 'Clear Cell Histology', 'type': 'Disease Subtype', 'normalized_form': 'Clear Cell', 'rule_applied': ""Patient Sub-Group rule pattern to include clinically significant subtypes and exclude descriptive terms like 'Histology'.""}, {'component': 'Adjuvant', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}, {'component': 'Completely Resected', 'type': 'Operative Status', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers, supported by Treatment Set-up rule patterns.'}]",2
230538,Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology,Comparative oncology analysis using genomic profiling of canine cancers by tissue and liquid biopsy testing reveals actionable somatic alterations with orthologs in human cancers.,cancers,Cancer,Tumor,True,session_title,"Step-by-step extraction process:
1.  **Analyze Titles**: The abstract title mentions ""canine cancers"" and ""human cancers"". The session title mentions ""Tumor"".
2.  **Select Source**: According to the Single-Source Extraction Principle, the abstract title is preferred if it contains a disease. However, the primary focus of the abstract title is on ""canine cancers,"" which is not a human medical indication. The mention of ""human cancers"" is secondary and for comparative purposes. Therefore, the abstract title is not a suitable source for a clinically valid human indication.
3.  **Fallback to Session Title**: The session title, ""Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology"", contains the valid disease term ""Tumor"".
4.  **Extract and Normalize**: The term ""Tumor"" is extracted from the session title. It is already in singular form and Title Case, adhering to the generic rules.
5.  **Final Indication**: The final generated indication is ""Tumor"".",[],"[{'component': 'canine cancers', 'type': 'Disease', 'normalized_form': 'Canine Cancer', 'rule_applied': 'Excluded as it is a non-human (veterinary) indication.'}, {'component': 'human cancers', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Not selected as it was mentioned in a comparative context, not as the primary disease of study.'}, {'component': 'Tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': 'Extracted from the session title as the primary source was unsuitable. Generic formatting rules applied.'}]",1
345226,"Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies",Extracellular vesicles (EV) - mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses,,,Cancer,True,session_title,"Step 1: The abstract title 'Extracellular vesicles (EV) - mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses' does not contain a specific disease or condition. It describes a biological process and study methodology.
Step 2: The session title 'Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies' contains the term 'Anticancer', which points to the therapeutic area of Oncology.
Step 3: According to the Single-Source Extraction Principle, the session title is used as a fallback. 
Step 4: The generic rule for 'Therapeutic Area Fallback' is applied, which states that 'Oncology' or related terms should be mapped to the overarching disease 'Cancer'. The other terms in the title refer to treatment modalities and are excluded.
Step 5: The final indication is standardized to 'Cancer' in Title Case and singular form.",[],"[{'component': 'Anticancer', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': 'Therapeutic Area Fallback'}]",1
165004,Controversies and Challenges in Pediatric Transplant ID,The Impact of Molecular Diagnostics on the Management of Viral Infections in Pediatric Transplant Recipients,Viral Infection;;Pediatric,Pediatric Viral Infection,Pediatric Viral Infection,True,abstract_title,"Step 1: The abstract title 'The Impact of Molecular Diagnostics on the Management of Viral Infections in Pediatric Transplant Recipients' was chosen as the source because it contains a specific disease term ('Viral Infections'), which is preferred over the session title.
Step 2: The components identified in the abstract title are 'Viral Infections' (disease), 'Pediatric' (age group), and 'Transplant Recipients' (treatment status).
Step 3: Rules for 'Age Group' and 'Treatment Set-up' were retrieved. The 'Pediatric' rule (ID: 295) states to retain 'Pediatric' as a leading qualifier. The 'Transplant Status' rules (e.g., ID: 232 for 'Post-Transplant') and the generic exclusion rule for procedural qualifiers indicate that 'Transplant Recipients' should be excluded as it describes a patient's procedural history rather than a core part of the disease indication.
Step 4: The generic rule for singularization was applied, converting 'Viral Infections' to 'Viral Infection'. The age group rule was applied to prepend 'Pediatric'. The exclusion rule was applied to remove 'Transplant Recipients'.
Step 5: The final indication was constructed by combining the components according to the rules, resulting in 'Pediatric Viral Infection' in Title Case.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To determine how to handle the 'Pediatric' patient subgroup qualifier.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine if 'Transplant Recipients' should be included in the indication.""}]","[{'component': 'Viral Infections', 'type': 'Disease', 'normalized_form': 'Viral Infection', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group Rule (ID: 295) - Retain as a leading qualifier.'}, {'component': 'Transplant Recipients', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule & Treatment Set-up Rule (ID: 232) - Exclude procedural/temporal qualifiers.'}]",2
345225,"Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies",Sensitizing breast cancers to immune checkpoint inhibitors through CD27 agonism and vaccination against tumor-associated antigen,breast cancers,Breast Cancer,Breast Cancer,True,abstract_title,"Step 1: The abstract title contains the specific disease term 'breast cancers', while the session title lists general therapeutic approaches. Therefore, the abstract title is selected as the source based on the single-source principle.
Step 2: The core disease component identified is 'breast cancers'.
Step 3: The generic rules for formatting are applied. The plural 'cancers' is converted to the singular 'Cancer', and Title Case is applied, resulting in 'Breast Cancer'.
Step 4: All other information in the title, such as 'Sensitizing', 'immune checkpoint inhibitors', 'CD27 agonism', and 'vaccination', describes treatment modalities or study methodologies and is excluded as per the generic exclusion rules.",[],"[{'component': 'breast cancers', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Casing'}]",1
263309,Myeloma and other monoclonal gammopathies - Biology & Translational Research,Crispr-Cas9 Knockout Screen Identifies Rna Modification Enzymes Essential For Cell Survival In Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: The abstract title contains a specific disease, 'Multiple Myeloma', so it is selected as the primary source over the session title, following the single-source principle.
Step 2: The disease term 'Multiple Myeloma' was identified within the abstract title.
Step 3: The remaining parts of the title, such as 'Crispr-Cas9 Knockout Screen' and 'Rna Modification Enzymes Essential For Cell Survival', were identified as study methodology and biological processes, which must be excluded according to the generic exclusion rules for non-diagnostic items.
Step 4: The generic formatting rules were applied. The term 'Multiple Myeloma' is already in singular form and correct Title Case.
Step 5: The final indication was constructed by extracting the clean disease name.",[],"[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rules for formatting (Title Case, Singular Form) and exclusion of non-diagnostic information.'}]",1
263312,Myeloma and other monoclonal gammopathies - Clinical,"Trial-In-Progress: Phase Ii Study Of Phe885, A B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy, In Adults With Relapsed And/Or Refractory Multiple Myeloma",Adults;;Relapsed;;Refractory;;Multiple Myeloma,Adult Relapsed/Refractory Multiple Myeloma,Adult Relapsed/Refractory Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease ('Multiple Myeloma') and detailed patient subgroup information, making it the primary source according to the single-source principle.
2. **Component Identification**: I identified three key components in the abstract title: the disease 'Multiple Myeloma', the age group 'Adults', and the disease status 'Relapsed And/Or Refractory'.
3. **Rule Retrieval**: I retrieved rules for the 'Age Group' category to handle 'Adults' and for the 'Occurrence' category to standardize 'Relapsed And/Or Refractory'.
4. **Rule Application**: 
   - **Generic Rules**: Applied Title Case and converted the plural 'Adults' to the singular 'Adult'. Excluded non-indication elements like 'Trial-In-Progress' and therapy names.
   - **Age Group Rule (ID: 290)**: The keyword 'Adults' was normalized to the singular, capitalized term 'Adult' and placed at the beginning of the indication.
   - **Occurrence Standardization**: The phrase 'Relapsed And/Or Refractory' was normalized to the standard clinical format 'Relapsed/Refractory' based on common terminology patterns for this type of descriptor.
5. **Indication Construction**: The identified and normalized components were combined in the standard order: Age Group + Disease Status + Disease. This resulted in 'Adult Relapsed/Refractory Multiple Myeloma'.
6. **Quality Check**: The final indication adheres to all formatting and content rules. It is clinically accurate, concise, and derived from a single source.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the patient age group 'Adults'.""}, {'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To standardize the disease status 'Relapsed And/Or Refractory'.""}]","[{'component': 'Adults', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group Rule ID: 290 - Normalize to singular, capitalized prefix.'}, {'component': 'Relapsed And/Or Refractory', 'type': 'Disease Status', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Standard clinical terminology normalization for occurrence.'}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Use Title Case.'}]",2
296081,Colorectal cancer,Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal Cancer (mCRC): Patient-reported outcomes (PROs) from ph 2 study MOUNTAINEER,HER2;;positive;;metastatic;;colorectal Cancer,HER2-Positive Metastatic Colorectal Cancer,HER2-Positive Metastatic Colorectal Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal Cancer (mCRC): Patient-reported outcomes (PROs) from ph 2 study MOUNTAINEER') was chosen over the session title ('Colorectal cancer') because it contains a specific disease and additional, crucial patient subgroup information, adhering to the single-source principle.
2.  **Component Identification**: I identified three key components in the abstract title: the disease 'colorectal Cancer', the biomarker 'HER2-positive', and the disease occurrence 'metastatic'.
3.  **Rule Retrieval**: I retrieved rules for 'Biomarker' to understand the formatting of terms like 'HER2-positive' and for 'Occurrence' with the subcategory 'Metastasis-Related Terms' to correctly handle 'metastatic'.
4.  **Rule Application**: 
    *   **Generic Rules**: I applied Title Case, converting 'colorectal Cancer' to 'Colorectal Cancer'. The term is already singular. Treatment names ('Tucatinib plus trastuzumab') and study details were marked for exclusion.
    *   **Biomarker Rules**: Following standard formatting for biomarkers, 'HER2-positive' was normalized to 'HER2-Positive', keeping the gene symbol in its original case.
    *   **Occurrence Rules**: The rule for 'Metastatic' (ID: 141) was applied, which dictates prefixing the disease with 'Metastatic'.
5.  **Indication Construction**: The components were assembled in the standard order (Biomarker -> Occurrence -> Disease) to form the final indication: 'HER2-Positive Metastatic Colorectal Cancer'.
6.  **Quality Check**: The final indication was verified against all rules: it originates from a single source, uses correct Title Case and singular form, excludes non-indication elements, and correctly formats the biomarker and occurrence qualifiers.","[{'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To ensure correct formatting for the 'HER2-positive' biomarker.""}, {'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To apply the correct rule for the term 'metastatic'.""}]","[{'component': 'HER2-positive', 'type': 'Biomarker', 'normalized_form': 'HER2-Positive', 'rule_applied': 'Generic Title Case rule and standard biomarker formatting.'}, {'component': 'metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': 'Rule ID: 141 for Metastasis-Related Terms.'}, {'component': 'colorectal Cancer', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic Title Case and Singular Form rules.'}]",2
197778,Mitochondrial Interventions: Small Molecule and Gene Therapy (Mitochondrial Interventions: Small Molecule and Gene Therapy),Mitochondrial Interventions: Small Molecule and Gene Therapy,,,,True,none,"Both the abstract title and the session title describe therapeutic modalities ('Small Molecule and Gene Therapy') and a biological target ('Mitochondrial Interventions'), but they do not name a specific disease, disorder, or clinical condition. According to the extraction rules, an indication must be a clinically valid medical condition. Since no disease is mentioned, a valid indication cannot be extracted from the provided text.",[],[],1
296082,"NSCLC, metastatic",A multicenter study of incidence of drug-induced lung disease in first-line osimertinib therapy and continuation of osimertinib administration,lung disease,Lung Disease,Metastatic Non-Small Cell Lung Cancer,True,session_title,"Step 1: The abstract title focuses on a complication ('drug-induced lung disease'), while the session title ('NSCLC, metastatic') clearly identifies the primary disease and its stage. Therefore, the session title was chosen as the source based on the Single-Source Extraction Principle.
Step 2: The components identified in the session title are the disease 'NSCLC' and the occurrence qualifier 'metastatic'.
Step 3: To ensure correct formatting for the qualifier, rules for 'Metastasis-Related Terms' were retrieved using the `get_indication_rules` tool.
Step 4: The retrieved rule (ID: 141) for 'Metastatic' dictates the format 'Metastatic <Primary-Disease-Name>'. The acronym 'NSCLC' was expanded to its full, standardized form 'Non-Small Cell Lung Cancer' for clinical clarity.
Step 5: The components were combined and formatted according to the rules, resulting in the final indication 'Metastatic Non-Small Cell Lung Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'metastatic' as a prefix to the disease.""}]","[{'component': 'NSCLC', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Standardization of medical acronyms for clarity.'}, {'component': 'metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': ""Rule ID: 141 - Format as 'Metastatic <Primary-Disease-Name>'.""}]",2
296084,Colorectal cancer,"The prognostic value of pre-treatment circulating biomarkers of systemic inflammation (CRP, neutrophil-to-lymphocyte ratio, IL-6, and YKL-40) in vulnerable older patients with metastatic colorectal cancer - the randomized NORDIC9-study",older;;metastatic colorectal cancer,Elderly Metastatic Colorectal Cancer,Elderly Metastatic Colorectal Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains the disease ('metastatic colorectal cancer') and is more specific than the session title, adhering to the single-source principle.
2. **Component Identification**: The key components identified in the abstract title were 'older patients' (Age Group), 'metastatic' (Occurrence), and 'colorectal cancer' (Disease).
3. **Rule Retrieval**: Rules were retrieved for 'Metastasis-Related Terms', 'Age Group' (specifically 'Elderly'), and 'Patient Sub-Group' to handle these components.
4. **Rule Application & Normalization**:
   - **Disease**: 'colorectal cancer' was normalized to 'Colorectal Cancer' using Title Case and singular form rules.
   - **Occurrence**: The term 'metastatic' was prepended to the disease name as per the 'Metastasis-Related Terms' rule (ID: 141), resulting in 'Metastatic Colorectal Cancer'.
   - **Age Group**: The term 'older' was identified as an age descriptor. The 'Age Group' rule for 'Older' (ID: 302) specifies standardizing it to 'Elderly' and placing it at the beginning of the indication.
   - **Exclusions**: The term 'vulnerable' was excluded as it is a non-specific patient descriptor without a standard clinical definition for indications. The term 'pre-treatment' was excluded as it is a temporal qualifier related to treatment status, not a core part of the disease indication. Biomarkers and study details were also excluded per generic rules.
5. **Final Construction**: The normalized components were combined in the correct order (Age Group -> Occurrence -> Disease) to form the final indication: 'Elderly Metastatic Colorectal Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'metastatic'.""}, {'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To standardize the patient descriptor 'older'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check if 'vulnerable' is a valid clinical subgroup (it was determined not to be).""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To determine how to handle the term 'pre-treatment' (it was excluded as a temporal qualifier).""}]","[{'component': 'metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': ""Occurrence rule (ID: 141) for 'Metastatic'.""}, {'component': 'colorectal cancer', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic rules for Title Case and singular form.'}, {'component': 'older patients', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group rule (ID: 302) for 'Older'.""}, {'component': 'vulnerable', 'type': 'Patient Descriptor', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-specific descriptors.'}, {'component': 'pre-treatment', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
263316,Myeloma and other monoclonal gammopathies - Clinical,Chemo Or Chemo-Free Regimens In Heavily Pretreated Multiple Myeloma? Role Of Bendamustine-Bortezomib-Dexamethasone (Bvd) In Novel Agents' Era,Heavily Pretreated;;Multiple Myeloma,Heavily Pretreated Multiple Myeloma,Heavily Pretreated Multiple Myeloma,True,abstract_title,"Step 1: The abstract title contains the specific disease 'Multiple Myeloma', so it is selected as the source over the more general session title, following the single-source principle.
Step 2: I identified the core disease 'Multiple Myeloma' and a patient subgroup descriptor 'Heavily Pretreated' in the abstract title.
Step 3: I retrieved rules for 'Treatment based' to understand how to handle terms like 'Pretreated'. The rules for 'Previously Treated' indicate that such descriptors should be normalized and placed before the disease name.
Step 4: I applied the generic rules. The disease term 'Multiple Myeloma' is already in the correct singular and Title Case format. The patient subgroup 'Heavily Pretreated' is a key clinical characteristic and must be included. I normalized it to 'Heavily Pretreated' and placed it at the beginning of the indication, consistent with the pattern from the retrieved rules.
Step 5: I combined the components to form the final indication: 'Heavily Pretreated Multiple Myeloma'.
Step 6: A final quality check confirmed that all formatting, casing, and content rules were followed, resulting in a clinically accurate indication.","[{'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To find rules for handling the patient status 'Heavily Pretreated'.""}]","[{'component': 'Heavily Pretreated', 'type': 'Patient Subgroup', 'normalized_form': 'Heavily Pretreated', 'rule_applied': ""Adapted from 'Treatment based' rules, which place treatment status descriptors before the disease name.""}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic singular form and Title Case rules.'}]",2
148631,Aggressive Non-Hodgkin Lymphoma - Clinical,Relationship Between Genetic Aberrations In The 17P13/Tp53 Locus And Immunohistochemical Protein P53 Expression In Tumor Cells Of Diffuse Large B-Cell Lymphoma,Diffuse Large B-Cell Lymphoma,Diffuse Large B-Cell Lymphoma,Diffuse Large B-Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: Both the session title ('Aggressive Non-Hodgkin Lymphoma - Clinical') and the abstract title ('Relationship Between Genetic Aberrations In The 17P13/Tp53 Locus And Immunohistochemical Protein P53 Expression In Tumor Cells Of Diffuse Large B-Cell Lymphoma') contain disease terms. The abstract title is more specific.
2.  **Select Source**: Based on the Single-Source Extraction Principle, the abstract title is selected as it contains a more specific disease term.
3.  **Identify Components**: The core disease identified is 'Diffuse Large B-Cell Lymphoma'. The title also mentions 'Tp53' and 'P53 Expression'.
4.  **Retrieve Rules**: I retrieved rules for 'Gene Name', 'Biomarker', and 'Patient Sub-Group' to determine how to handle these components.
5.  **Apply Rules**:
    *   The 'Gene Name' rules (ID: 28, 29) state that a gene name should be excluded if it appears without a specific functional qualifier (e.g., 'mutated', 'positive'). The title discusses a 'relationship' involving 'genetic aberrations' and 'expression' but does not define the patient cohort by a specific TP53 status. Therefore, 'Tp53' and 'P53' are excluded from the indication.
    *   The term 'B-Cell' is an integral part of the disease name 'Diffuse Large B-Cell Lymphoma' and is correctly retained.
    *   Generic rules for formatting are applied: The indication is already in singular form and Title Case.
6.  **Construct Indication**: After excluding the non-qualifying gene and protein mentions, the final indication is the disease name itself.
7.  **Quality Check**: The final indication adheres to all formatting and exclusion rules, is clinically accurate, and is derived from a single source.","[{'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To check if 'B-Cell' should be handled as a separate subgroup.""}, {'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To determine how to handle the mention of 'Tp53'.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To determine how to handle 'P53 Expression'.""}]","[{'component': 'Diffuse Large B-Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Diffuse Large B-Cell Lymphoma', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Tp53', 'type': 'Gene Name', 'normalized_form': '', 'rule_applied': ""Gene Name Rule (ID: 29) - Excluded because it lacks a specific functional qualifier like 'mutated' or 'positive'.""}, {'component': 'P53 Expression', 'type': 'Biomarker', 'normalized_form': '', 'rule_applied': ""General principle from Gene Name rules - Excluded because it lacks a specific status (e.g., 'positive', 'negative') and is part of a descriptive analysis, not a patient subgroup definition.""}]",2
312472,The Ears Have It: Autoimmune Hearing Loss and Relapsing Polychondritis,A New Classification of Ear Chondritis Revealed by Genetic Studies,Ear Chondritis,Ear Chondritis,Ear Chondritis,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'A New Classification of Ear Chondritis Revealed by Genetic Studies', contains the specific disease term 'Ear Chondritis'. The session title also contains disease terms ('Autoimmune Hearing Loss', 'Relapsing Polychondritis').
Step 2: According to the single-source extraction principle, the abstract title is the preferred source since it contains a valid disease term. I therefore selected the abstract title and disregarded the session title.
Step 3: I identified the core disease component in the abstract title, which is 'Ear Chondritis'. The phrases 'A New Classification of' and 'Revealed by Genetic Studies' are related to study methodology and must be excluded based on the generic rules.
Step 4: I applied the generic formatting rules. The term 'Ear Chondritis' was already in singular form and correctly capitalized (Title Case).
Step 5: After removing the excluded methodological phrases, the final extracted indication is 'Ear Chondritis'.",[],"[{'component': 'Ear Chondritis', 'type': 'Disease', 'normalized_form': 'Ear Chondritis', 'rule_applied': 'Generic rule: Exclude study methodologies. Generic rule: Apply Title Case and singular form.'}]",1
410777,Pediatric Nephrology,Ravulizumab De Novo in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS): First Worldwide Cases,De Novo;;Pediatric;;Atypical Hemolytic Uremic Syndrome,De Novo Pediatric Atypical Hemolytic Uremic Syndrome,De Novo Pediatric Atypical Hemolytic Uremic Syndrome,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Ravulizumab De Novo in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS): First Worldwide Cases' was chosen as it contains a specific disease name, 'Atypical Hemolytic Uremic Syndrome', making it more informative than the session title 'Pediatric Nephrology'.

2. **Component Identification**: I identified three key components in the abstract title:
   - Age Group: 'Pediatric'
   - Diagnosis Status: 'De Novo'
   - Disease Name: 'Atypical Hemolytic Uremic Syndrome'

3. **Rule Retrieval**: To ensure correct formatting and inclusion, I retrieved rules for the identified components:
   - `get_indication_rules(category=""Age Group"", subcategories=[""Pediatric""])`: Confirmed that 'Pediatric' should be used as a prefix.
   - `get_indication_rules(category=""Treatment based"", subcategories=[""Diagnosis Status""])`: Although no specific rule for 'De Novo' exists, the rule for the similar term 'Newly Diagnosed' indicates it should be prepended to the indication.
   - `get_indication_rules(category=""Patient Sub-Group"", subcategories=[""Atypical/Typical""])`: Confirmed that 'Atypical' is an integral part of the disease name and should be retained.

4. **Rule Application and Construction**:
   - **Generic Rules**: Applied Title Case, converted 'Patients' to singular and removed it, and excluded the non-clinical study descriptor 'First Worldwide Cases'. The acronym '(aHUS)' was also removed in favor of the full disease name.
   - **Specific Rules**: 
     - The 'Pediatric' rule (ID: 295, 296) was applied to place 'Pediatric' at the beginning of the indication.
     - The 'Atypical' rule (ID: 464) was applied to retain 'Atypical' as part of the disease name.
     - The logic from the 'Newly Diagnosed' rule (ID: 193) was applied to 'De Novo', placing it as a leading qualifier.

5. **Final Indication Assembly**: The components were combined in the correct order (Diagnosis Status -> Age Group -> Disease Name) to form the final indication: 'De Novo Pediatric Atypical Hemolytic Uremic Syndrome'. This construction is clinically accurate and adheres to all formatting and content rules.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To validate the handling of the 'Pediatric' patient subgroup qualifier.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To find rules for handling diagnosis timing, specifically for 'De Novo', using 'Newly Diagnosed' as a proxy.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Atypical/Typical'], 'reason': ""To confirm that 'Atypical' should be retained as part of the disease name.""}]","[{'component': 'De Novo', 'type': 'Diagnosis Status', 'normalized_form': 'De Novo', 'rule_applied': ""Based on proxy rule for 'Newly Diagnosed' (ID: 193), retained as a prefix.""}, {'component': 'Pediatric Patients', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule (ID: 295) to retain 'Pediatric' as a prefix and remove 'Patients'.""}, {'component': 'Atypical Hemolytic Uremic Syndrome', 'type': 'Disease', 'normalized_form': 'Atypical Hemolytic Uremic Syndrome', 'rule_applied': ""Patient Sub-Group rule (ID: 464) to retain 'Atypical' as part of the disease name. Generic rule to use full name over acronym.""}]",2
345240,"Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies","CRB-601, an avb8 blocking antibody, prevents activation of TGFb and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment",,,Tumor,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains the disease-related term ""anti-tumor"", while the session title only lists therapy types.
Step 2: The component ""anti-tumor activity"" was identified in the abstract title.
Step 3: Generic rules were applied. The prefix ""anti-"" was removed, and the term ""tumor"" was converted to Title Case and singular form, resulting in ""Tumor"".
Step 4: No other patient subgroups, stages, or qualifiers were mentioned in the title, so the final indication is the standalone disease term.",[],"[{'component': 'anti-tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': ""Generic rule: Convert to singular form and Title Case. Removed 'anti-' prefix as it describes activity against the disease.""}]",1
148636,Aggressive Non-Hodgkin Lymphoma - Clinical,Health-Related Quality Of Life Effect Of Mogamulizumab By Patient Blood Involvement,Aggressive;;Non-Hodgkin Lymphoma,Aggressive Non-Hodgkin Lymphoma,Aggressive Non-Hodgkin Lymphoma,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The session title is 'Aggressive Non-Hodgkin Lymphoma - Clinical' and the abstract title is 'Health-Related Quality Of Life Effect Of Mogamulizumab By Patient Blood Involvement'.
2.  **Select Source**: The session title contains a clear disease term ('Non-Hodgkin Lymphoma'), while the abstract title does not contain a specific disease. Therefore, according to the single-source principle, the session title is selected for extraction.
3.  **Identify Components**: The components identified in the session title are the disease 'Non-Hodgkin Lymphoma' and the qualifier 'Aggressive'. The term '- Clinical' is identified as a session descriptor and not part of the indication.
4.  **Retrieve Rules**: I retrieved rules for 'Patient Sub-Group' under 'Disease Characterisation' and 'Severity' to check for any specific handling of the term 'Aggressive'. No specific rule was found, so it is treated as a standard clinical descriptor.
5.  **Apply Rules**: 
    *   The generic rule for exclusion is applied to remove '- Clinical' as it's a non-diagnostic session qualifier.
    *   The generic rule for Title Case is applied. The phrase 'Aggressive Non-Hodgkin Lymphoma' is already in correct Title Case.
    *   The generic rule for singular form is applied. 'Lymphoma' is already in its singular form.
6.  **Construct Indication**: The qualifier 'Aggressive' is prepended to the disease name 'Non-Hodgkin Lymphoma' to form the final indication.
7.  **Quality Check**: The final indication 'Aggressive Non-Hodgkin Lymphoma' is a clinically valid entity, adheres to all formatting rules, and is correctly derived from a single source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation', 'Severity'], 'reason': ""To check for specific rules on handling the qualifier 'Aggressive'.""}]","[{'component': 'Aggressive Non-Hodgkin Lymphoma', 'type': 'Disease with Qualifier', 'normalized_form': 'Aggressive Non-Hodgkin Lymphoma', 'rule_applied': 'Generic Title Case and Singular Form rules.'}, {'component': '- Clinical', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for procedural/methodological terms.'}]",2
263328,Myeloma and other monoclonal gammopathies - Clinical,Opportunities Of Therapy In Patients With Newly Diagnosed Multiple Myeloma With Dialysis-Dependent Renal Impairment,Newly Diagnosed;;Multiple Myeloma,Newly Diagnosed Multiple Myeloma,Newly Diagnosed Multiple Myeloma with Dialysis-Dependent Renal Impairment,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Opportunities Of Therapy In Patients With Newly Diagnosed Multiple Myeloma With Dialysis-Dependent Renal Impairment') was chosen over the session title ('Myeloma and other monoclonal gammopathies - Clinical') because it contains a more specific and detailed description of the patient population and disease state, adhering to the single-source principle.
2. **Component Identification**: I identified three key components in the abstract title:
    - Diagnosis Status: 'Newly Diagnosed'
    - Core Disease: 'Multiple Myeloma'
    - Patient Subgroup: 'With Dialysis-Dependent Renal Impairment'
3. **Rule Retrieval**: I retrieved rules for 'Diagnosis Status' (specifically 'Newly Diagnosed') which confirmed that this term should be prefixed to the disease name. I also checked rules for patient subgroups and connectors to guide the inclusion of the renal impairment detail.
4. **Rule Application and Construction**:
    - The rule for 'Newly Diagnosed' (ID: 193) was applied, placing it at the beginning of the indication.
    - The core disease 'Multiple Myeloma' was kept as is, already in correct singular and Title Case format.
    - The patient subgroup 'With Dialysis-Dependent Renal Impairment' is a clinically significant descriptor that defines a specific, high-risk patient population in the context of Multiple Myeloma. It was included to maintain clinical accuracy.
    - Generic formatting rules were applied: Title Case for all significant words, with the preposition 'with' in lower case as per the guidelines.
5. **Final Quality Check**: The final indication was reviewed to ensure it is concise, clinically accurate, correctly formatted, and derived from a single source. The resulting indication accurately reflects the patient population described in the abstract title.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To verify the correct handling and formatting of the term 'Newly Diagnosed'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding specific patient conditions like 'Renal Impairment' or 'Dialysis-Dependent'.""}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To determine the standard formatting for the connector 'With' when linking a disease to a patient characteristic.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Rule - Use singular form and Title Case.'}, {'component': 'With Dialysis-Dependent Renal Impairment', 'type': 'Patient Subgroup', 'normalized_form': 'with Dialysis-Dependent Renal Impairment', 'rule_applied': ""Generic Rule - Include clinically valid patient subgroups and use lower case for prepositions like 'with'.""}]",2
296096,SCLC,"DeLLphi-303: phase 1b first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)",extensive stage;;small cell lung cancer ,Extensive Stage Small Cell Lung Cancer ,First-Line Extensive Stage Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease and patient population description ('extensive stage small cell lung cancer'), which is more detailed than the session title ('SCLC'). The Single-Source Extraction Principle mandates using the more informative title.
2. **Component Identification**: I identified three key components in the abstract title: the treatment line ('first-line'), the disease stage ('extensive stage'), and the disease itself ('small cell lung cancer').
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Stage' and 'Treatment Set-up'.
   - For 'extensive stage', I used `get_indication_rules(category=""Stage"", subcategories=[""Stage Type""])`.
   - For 'first-line', I used `get_indication_rules(category=""Treatment Set-up"", subcategories=[""Line of treatment""])`.
4. **Rule Application**:
   - **Disease Normalization**: Applied generic rules to convert 'small cell lung cancer' to 'Small Cell Lung Cancer' (Title Case, singular form).
   - **Stage Rule**: Based on the retrieved rule (ID: 99), 'extensive stage' was normalized to 'Extensive Stage' and placed before the disease name.
   - **Treatment Line Rule**: Based on the retrieved rule (ID: 200), 'first-line' was normalized to 'First-Line' and placed at the beginning of the indication, as it describes the patient population setting.
5. **Indication Construction**: The components were assembled in the standard order: Treatment Line -> Stage -> Disease. This resulted in 'First-Line Extensive Stage Small Cell Lung Cancer'.
6. **Final Quality Check**: The final indication adheres to all formatting rules (Title Case, singular, no excluded terms) and accurately represents the patient population described in the abstract title.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To correctly format the 'extensive stage' component.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To correctly format the 'first-line' component.""}]","[{'component': 'first-line', 'type': 'Line of treatment', 'normalized_form': 'First-Line', 'rule_applied': 'Treatment Set-up Rule ID: 200'}, {'component': 'extensive stage', 'type': 'Stage', 'normalized_form': 'Extensive Stage', 'rule_applied': 'Stage Rule ID: 99'}, {'component': 'small cell lung cancer', 'type': 'Disease', 'normalized_form': 'Small Cell Lung Cancer', 'rule_applied': 'Generic Casing and Singular Form Rules'}]",2
165030,The Tiny but Fierce Beasts of COVID-19 & Healthcare Epidemiology - Controversies in Pediatric Infection Prevention,To See or Not To See: COVID-19 Visitor Restrictions in Pediatric Healthcare Settings,COVID-19,COVID-19 Infection,Pediatric COVID-19,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: Both the abstract title ('To See or Not To See: COVID-19 Visitor Restrictions in Pediatric Healthcare Settings') and the session title ('The Tiny but Fierce Beasts of COVID-19 & Healthcare Epidemiology - Controversies in Pediatric Infection Prevention') contain the disease term 'COVID-19' and the patient subgroup 'Pediatric'.
2.  **Select Source**: According to the single-source principle, the abstract title is preferred as it contains a clear disease term. I selected the abstract title as the source.
3.  **Identify Components**: From the abstract title, I identified the disease 'COVID-19' and the patient subgroup 'Pediatric'. Other terms like 'Visitor Restrictions' and 'Healthcare Settings' are non-diagnostic and marked for exclusion.
4.  **Retrieve Rules**: I retrieved rules for the 'Age Group' category with the subcategory 'Pediatric' to ensure correct formatting.
5.  **Apply Rules**: The retrieved rules (e.g., Rule ID 295, 296) confirm that 'Pediatric' should be used as a singular, title-cased prefix to the disease name. Generic rules for exclusion were applied to remove non-diagnostic information.
6.  **Construct Indication**: The patient subgroup 'Pediatric' was prepended to the disease 'COVID-19' as per the retrieved rules.
7.  **Quality Check**: The final indication 'Pediatric COVID-19' adheres to all formatting (Title Case, singular form) and exclusion rules. It correctly combines the patient subgroup with the disease from a single source.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly format the 'Pediatric' patient subgroup qualifier.""}]","[{'component': 'COVID-19', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic disease identification.'}, {'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Rule ID 296: Place 'Pediatric' as the first word of the indication.""}]",2
328871,Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I,Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: The abstract title contains a specific disease, 'Multiple Myeloma', so it is selected as the source based on the single-source principle.
Step 2: The components identified in the abstract title are 'Bortezomib Resistant' and 'Multiple Myeloma'.
Step 3: To determine how to handle 'Bortezomib Resistant', I retrieved rules for drug resistance using `get_indication_rules` with the category 'Occurrence' and subcategory 'Resistance'.
Step 4: The retrieved rules (ID 164, 165) state that drug-resistance descriptors should be excluded from the final indication because they represent a treatment-response status rather than a distinct clinical indication.
Step 5: Applying this rule, 'Bortezomib Resistant' is removed. The core disease 'Multiple Myeloma' is retained. Generic rules for Title Case and singular form are already met.
Step 6: The final indication is constructed as 'Multiple Myeloma'.","[{'category': 'Occurrence', 'subcategories': ['Resistance'], 'reason': ""To verify the correct handling of the term 'Bortezomib Resistant'.""}]","[{'component': 'Bortezomib Resistant', 'type': 'Treatment Resistance', 'normalized_form': '', 'rule_applied': 'Occurrence rule (ID 164, 165) for Drug/Drug Class-Resistant states to exclude this term.'}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule for Title Case.'}]",2
148649,Aggressive Non-Hodgkin Lymphoma - Clinical,Dose-Adjusted Edoch-Rituximab In Elderly Patients With High Grade Diffuse Large B-Cell Lymphoma,Elderly;;High Grade;;Diffuse Large B-Cell Lymphoma,Elderly High Grade Diffuse Large B-Cell Lymphoma,Elderly High Grade Diffuse Large B-Cell Lymphoma,True,abstract_title,"Step 1: The abstract title contains a specific disease ('Diffuse Large B-Cell Lymphoma') and is therefore selected as the source over the more general session title, following the single-source principle.

Step 2: The components identified in the abstract title are the age group 'Elderly', the tumor grade 'High Grade', and the disease 'Diffuse Large B-Cell Lymphoma'. The treatment regimen 'Dose-Adjusted Edoch-Rituximab' is excluded as it is not part of the medical indication.

Step 3: Rules were retrieved for the 'Age Group' and 'Grade' categories to ensure correct formatting and placement of these qualifiers.

Step 4: The retrieved rules were applied. Rule ID 299 for 'Elderly' confirms it should be capitalized and placed at the beginning of the indication. Rule ID 115 for 'High Grade' confirms it should be formatted as 'High Grade' (Title Case, no hyphen) and placed before the disease name. Generic rules for singular form and Title Casing were also applied.

Step 5: The final indication was constructed by combining the standardized components in the correct order: Age Group + Grade + Disease, resulting in 'Elderly High Grade Diffuse Large B-Cell Lymphoma'.

Step 6: A quality check confirmed that all rules were followed, including single-source selection, exclusion of non-indication elements, and correct formatting.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To standardize the formatting and placement of the age group descriptor 'Elderly'.""}, {'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To standardize the formatting and placement of the tumor grade descriptor 'High Grade'.""}]","[{'component': 'Elderly', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group Rule ID 299: Standardize to 'Elderly' and place at the beginning of the indication.""}, {'component': 'High Grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Grade Rule ID 115: Standardize to 'High Grade' with Title Case and no hyphen.""}, {'component': 'Diffuse Large B-Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Diffuse Large B-Cell Lymphoma', 'rule_applied': 'Generic Rule: Use Title Case and singular form.'}]",2
148651,Aggressive Non-Hodgkin Lymphoma - Clinical,"Front-Mind: A Phase Iii, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy And Safety Of R-Chop + Tafasitamab + Lenalidomide Vs R-Chop Alone For Newly-Diagnosed High-Risk Dlbcl",Newly-Diagnosed;;High-Risk;;Dlbcl,Newly-Diagnosed High-Risk Diffuse Large B-Cell Lymphoma,Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease ('Dlbcl') and detailed patient subgroup information ('Newly-Diagnosed High-Risk'), making it more informative than the session title.
2. **Component Identification**: I identified three key components in the abstract title: the diagnosis status 'Newly-Diagnosed', the risk level 'High-Risk', and the disease abbreviation 'Dlbcl'.
3. **Rule Retrieval**: I retrieved rules for 'Diagnosis Status' and 'Risk' to ensure correct formatting. The rule for 'Newly Diagnosed' (ID: 193) confirms it should be used as a prefix. The rules for 'High-Risk' (e.g., ID: 122) confirm its placement before the disease.
4. **Component Normalization & Application of Generic Rules**:
   - 'Newly-Diagnosed' was normalized to 'Newly Diagnosed' as per the retrieved rule and Title Case generic rule.
   - 'High-Risk' was kept as is, following standard formatting for risk qualifiers.
   - 'Dlbcl' is a standard medical abbreviation that was expanded to its full, clinically accurate name: 'Diffuse Large B-Cell Lymphoma'.
   - Generic rules for Title Casing and singular form were applied.
5. **Indication Construction**: The normalized components were assembled in a clinically logical order: Diagnosis Status -> Risk -> Disease Name. This resulted in the final indication: 'Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma'.
6. **Quality Check**: The final indication adheres to all formatting rules, accurately reflects the patient population from the source title, and excludes irrelevant study design details.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To validate the formatting and placement of the 'Newly-Diagnosed' keyword.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To ensure the correct formatting and inclusion of the 'High-Risk' qualifier.""}]","[{'component': 'Newly-Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'High-Risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': 'Rule ID: 122 - Standardize risk level and attach to the associated disease.'}, {'component': 'Dlbcl', 'type': 'Disease', 'normalized_form': 'Diffuse Large B-Cell Lymphoma', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}]",2
230572,Gastrointestinal Cancer-Colorectal and Anal,A multiple centers real-world study of regorafenib treatment modalities in Chinese metastatic colorectal cancer patients.,metastatic;;colorectal cancer,Metastatic Colorectal Cancer,Metastatic Colorectal Cancer,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease term ('metastatic colorectal cancer'), following the single-source extraction principle.
Step 2: The core disease 'colorectal cancer' and the occurrence qualifier 'metastatic' were identified from the title.
Step 3: The sociodemographic descriptor 'Chinese' was identified and marked for exclusion based on generic rules.
Step 4: Rules for 'Metastasis-Related Terms' were retrieved to ensure correct formatting. Rule ID 141 confirmed that 'Metastatic' should be the prefix in Title Case.
Step 5: The generic rule for singular form was applied, converting 'patients' to the singular disease entity.
Step 6: The final indication was constructed by combining the qualifier and the disease, applying Title Case, and excluding the sociodemographic term, resulting in 'Metastatic Colorectal Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'metastatic'.""}]","[{'component': 'metastatic colorectal cancer', 'type': 'Disease', 'normalized_form': 'Metastatic Colorectal Cancer', 'rule_applied': 'Rule 141 for Metastasis-Related Terms and Generic Rule for Title Case and Singular Form.'}, {'component': 'Chinese', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for ethnicity.'}]",2
181422,Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II,The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models,B-Cell Lymphoma,B-Cell Lymphoma,B-Cell Lymphoma,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease, 'B-Cell Lymphoma', which is more precise than 'Lymphoid Neoplasms' from the session title.
Step 2: The core disease term identified was 'B-Cell Lymphoma'.
Step 3: The term 'Preclinical' was identified as a study characteristic, not a patient subgroup. According to the generic exclusion rules, study methodologies and non-diagnostic items must be excluded.
Step 4: The identified disease 'B-Cell Lymphoma' was processed according to formatting rules. It is already in singular form and Title Case. 'B-Cell' is an essential descriptor of the lymphoma type and was retained.
Step 5: The final indication was constructed by taking the core disease and removing the excluded preclinical context.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules related to disease characteristics like 'B-Cell' or contextual descriptors like 'Preclinical'.""}]","[{'component': 'B-Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'B-Cell Lymphoma', 'rule_applied': 'Generic rule: Retain core disease name. Formatting rule: Apply Title Case and singular form.'}, {'component': 'Preclinical', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic items and study methodologies.'}]",2
296109,Investigational immunotherapy,Early mortality in patients with cancer treated with immunotherapy in routine practice,cancer ,Cancer,Cancer,True,abstract_title,"Step 1: The abstract title 'Early mortality in patients with cancer treated with immunotherapy in routine practice' was chosen as the source because it contains the specific disease term 'cancer', whereas the session title 'Investigational immunotherapy' only mentions a treatment modality.
Step 2: The core disease term 'cancer' was identified from the abstract title.
Step 3: Generic exclusion rules were applied. The phrases 'Early mortality in patients with', 'treated with immunotherapy', and 'in routine practice' were excluded as they describe study outcomes, treatment context, and setting, not the core medical indication.
Step 4: Generic formatting rules were applied. The term 'cancer' was converted to Title Case ('Cancer') and confirmed to be in singular form.
Step 5: The final indication was constructed as 'Cancer'.",[],"[{'component': 'cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic Casing Rule; Generic Singular Form Rule'}, {'component': 'treated with immunotherapy', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Procedural/Temporal Qualifiers'}]",1
148656,Bleeding Disorders (Congenital And Acquired),Inhibitors In Mild Haemophilia A: Experience Of A Single Spanish Center,Mild;;Haemophilia A,Mild Haemophilia A,Mild Haemophilia A With Inhibitors,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Inhibitors In Mild Haemophilia A: Experience Of A Single Spanish Center' was chosen as the source because it contains a specific disease ('Haemophilia A'), which is preferred over the broader category in the session title ('Bleeding Disorders').
2. **Component Identification**: The selected title contains three key clinical components: the disease 'Haemophilia A', the severity 'Mild', and the patient subgroup descriptor 'Inhibitors'. The phrase 'Experience Of A Single Spanish Center' was identified as non-clinical context (study methodology and geography) and marked for exclusion per generic rules.
3. **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' with subcategories 'Severity' and 'Disease Characterisation' to guide the handling of 'Mild' and 'Inhibitors'. Although no specific rule for 'Mild' was found, the general principle of prepending severity descriptors to the disease name was applied.
4. **Component Normalization & Application of Rules**:
   - **Disease**: 'Haemophilia A' is a standard medical term and was kept as is, formatted in Title Case.
   - **Severity**: 'Mild' was identified as a direct modifier of the disease and prepended to it, resulting in 'Mild Haemophilia A'.
   - **Patient Subgroup**: 'Inhibitors' in the context of haemophilia is a critical clinical specifier defining a patient subgroup. The phrase 'Inhibitors In' was standardized to the more common clinical phrasing 'With Inhibitors' to create a clear and standard indication.
   - **Exclusions**: The geographic descriptor 'Spanish' and the methodological phrase 'Experience Of A Single Center' were excluded based on generic rules.
5. **Final Construction**: The normalized components were combined in the standard order of [Severity] [Disease] [Subgroup] to form the final indication: 'Mild Haemophilia A With Inhibitors'. This indication is clinically precise, follows all formatting rules, and is derived solely from the selected source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Severity', 'Disease Characterisation'], 'reason': ""To check for rules on handling severity keywords like 'Mild' and other disease characteristics like the presence of inhibitors.""}]","[{'component': 'Mild', 'type': 'Severity', 'normalized_form': 'Mild', 'rule_applied': 'General principle for severity descriptors: prepend to the disease name.'}, {'component': 'Haemophilia A', 'type': 'Disease', 'normalized_form': 'Haemophilia A', 'rule_applied': 'Generic Rule: Title Case formatting.'}, {'component': 'Inhibitors', 'type': 'Patient Subgroup', 'normalized_form': 'With Inhibitors', 'rule_applied': ""Standardization of clinical phrasing for patient subgroups. 'Inhibitors in' was converted to the standard 'With Inhibitors'.""}, {'component': 'Spanish Center', 'type': 'Geographic/Study Info', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude geographic and sociodemographic descriptors.'}]",2
279728,YoungEHA Research Meeting - Session 5: Microenvironment in benign and malignant hematology & Closing,Deciphering the role of the bone marrow microenvironment in hematological malignancies using 3D Human Organotypic Marrow Environment (3D-HOMEs),hematological malignancies,Hematological Malignancy ,Hematological Malignancy,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Deciphering the role of the bone marrow microenvironment in hematological malignancies using 3D Human Organotypic Marrow Environment (3D-HOMEs)'. The session title is 'YoungEHA Research Meeting - Session 5: Microenvironment in benign and malignant hematology & Closing'.
2.  **Select Source**: Both titles contain disease terms. The abstract title contains 'hematological malignancies', and the session title contains 'benign and malignant hematology'. According to the Single-Source Extraction Principle, the abstract title is preferred as it contains a specific disease term relevant to the study.
3.  **Identify Components**: The core disease term in the abstract title is 'hematological malignancies'. The other parts of the title describe the research context ('bone marrow microenvironment') and methodology ('3D Human Organotypic Marrow Environment'), which are not part of the indication.
4.  **Apply Rules**: 
    *   **Generic Rule (Singular Form)**: The plural 'malignancies' is converted to its singular form, 'Malignancy'.
    *   **Generic Rule (Casing)**: The term is converted to Title Case, resulting in 'Hematological Malignancy'.
5.  **Construct Indication**: The final indication is constructed from the normalized component.
6.  **Quality Check**: The final indication 'Hematological Malignancy' is clinically accurate, follows all formatting rules, and is correctly derived from the preferred source.",[],"[{'component': 'hematological malignancies', 'type': 'Disease', 'normalized_form': 'Hematological Malignancy', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Title Case'}]",1
214197,MP48: Prostate Cancer: Advanced (including Drug Therapy) III,When Node-Positive Prostate Cancer Should Be Considered A Systemic Disease? Assessing The Prognostic Role Of Preoperative 68Ga-PSMA PET/CT Results In Patients With Lymph Node Invasion At Final Pathology,Node-Positive;;Prostate Cancer,Node-Positive Prostate Cancer,Node-Positive Prostate Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: Both the `abstract_title` and `session_title` contain the disease term 'Prostate Cancer'. Following the Single-Source Extraction Principle, the `abstract_title` is selected as it is more specific.
2.  **Identify Components**: The `abstract_title` contains the disease 'Prostate Cancer', the patient subgroup 'Node-Positive', and a temporal qualifier 'Preoperative'.
3.  **Retrieve Relevant Rules**: Rules were retrieved for 'Node Status' to handle 'Node-Positive' and for 'Operative Status' to handle 'Preoperative'.
4.  **Apply Rules**:
    *   The generic rule for singular form is applied, keeping 'Prostate Cancer' as is.
    *   The retrieved 'Node Status' rule (ID: 191) confirms that 'Node-Positive' should be normalized to 'Node-Positive' and placed at the beginning of the indication.
    *   The retrieved 'Operative Status' rule (ID: 256) explicitly states to exclude 'Pre Operative' from the final indication.
    *   The generic rule for Title Case is applied.
5.  **Construct Indication**: The components are combined according to the rules: 'Node-Positive' is prefixed to 'Prostate Cancer', and 'Preoperative' is excluded.
6.  **Quality Check**: The final indication 'Node-Positive Prostate Cancer' is verified against all formatting, inclusion, and exclusion criteria. It is clinically accurate and derived from a single source.","[{'category': 'Occurrence', 'subcategories': ['Node Status'], 'reason': ""To correctly format the 'Node-Positive' descriptor.""}, {'category': 'Treatment Set-up', 'subcategories': ['Operative Status'], 'reason': ""To determine whether 'Preoperative' should be included or excluded.""}]","[{'component': 'Node-Positive Prostate Cancer', 'type': 'Disease with Patient Subgroup', 'normalized_form': 'Node-Positive Prostate Cancer', 'rule_applied': ""Rule ID: 191 (Node Status) - Mapped 'Node-Positive' and placed it at the beginning.""}, {'component': 'Preoperative', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': ""Rule ID: 256 (Operative Status) - Excluded 'Pre Operative' from the final indication.""}]",2
230598,Gastrointestinal Cancer-Colorectal and Anal,Clinical and prognostic features of BRAF V600E-mutant resectable colorectal cancer: A single-center retrospective analysis of Chinese patients.,BRAF V600E-mutant;;resectable;;colorectal cancer,BRAF V600E-mutated Resectable Colorectal Cancer,Resectable BRAF V600E-Mutated Colorectal Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the primary source because it contains a specific disease term ('colorectal cancer'), following the single-source extraction principle.
2. **Component Identification**: The key components identified in the abstract title were 'BRAF V600E-mutant', 'resectable', and 'colorectal cancer'. The sociodemographic descriptor 'Chinese patients' was also identified for exclusion.
3. **Rule Retrieval**: To ensure correct formatting, rules were retrieved for gene mutations ('Gene type') and resectability status ('Treatment Set-up').
4. **Rule Application**:
   - **Generic Exclusion Rule**: The term 'Chinese patients' was excluded as it is an ethnicity-based descriptor.
   - **Gene Type Rule (ID: 31)**: The phrase 'BRAF V600E-mutant' was normalized to 'BRAF V600E-Mutated' by replacing 'mutant' with '-Mutated'.
   - **Treatment Set-up Rule (ID: 236)**: The term 'resectable' was identified as a patient subgroup qualifier and capitalized to 'Resectable'.
   - **Generic Formatting Rules**: The disease 'colorectal cancer' was converted to singular Title Case 'Colorectal Cancer'.
5. **Indication Construction**: The normalized components were assembled in the standard clinical order: [Operative Status] [Gene Status] [Disease]. This resulted in 'Resectable BRAF V600E-Mutated Colorectal Cancer'.
6. **Quality Check**: The final indication was verified against all formatting, casing, and exclusion rules. It adheres to the single-source principle and accurately represents the clinical information in the title.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the 'BRAF V600E-mutant' component.""}, {'category': 'Treatment Set-up', 'subcategories': ['Resectable'], 'reason': ""To handle the 'resectable' patient subgroup descriptor.""}]","[{'component': 'BRAF V600E-mutant', 'type': 'Gene Mutation', 'normalized_form': 'BRAF V600E-Mutated', 'rule_applied': ""Gene type rule (ID: 31) for 'Gene Mutant' keyword.""}, {'component': 'resectable', 'type': 'Operative Status', 'normalized_form': 'Resectable', 'rule_applied': ""Treatment Set-up rule (ID: 236) for 'Resectable' keyword.""}, {'component': 'colorectal cancer', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic rules for Title Case and singular form.'}, {'component': 'Chinese patients', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for ethnicity.'}]",2
378058,You have a new match! Pairing treatments and patients together for optimal treatment in chronic lymphocytic leukaemia (CLL),Tailoring treatment in CLL: Selecting the right treatment and duration for the right patient in relapse setting,CLL,Chronic Lymphocytic Leukemia,Relapsed Chronic Lymphocytic Leukemia,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains both a disease term (CLL) and a specific patient subgroup ('relapse setting'), making it more informative than the session title.
Step 2: The components identified were the disease 'CLL' and the patient status 'relapse setting'.
Step 3: Rules for handling relapse-related terms were retrieved using the `get_indication_rules` tool for the 'Occurrence' category. Rule 144 (Relapsed) indicates that terms like 'relapsed' should be standardized to 'Relapsed' and placed before the disease name.
Step 4: The abbreviation 'CLL' was expanded to 'Chronic Lymphocytic Leukemia' based on the session title's full name. The term 'relapse setting' was normalized to the standard qualifier 'Relapsed' as per the retrieved rules.
Step 5: The components were combined and formatted according to generic rules. 'Relapsed' was placed before the disease, and the entire indication was converted to Title Case, resulting in 'Relapsed Chronic Lymphocytic Leukemia'.","[{'category': 'Occurrence', 'subcategories': ['Relapse', 'Recurrence-Related Terms'], 'reason': ""To determine the correct formatting for the term 'relapse setting'.""}]","[{'component': 'CLL', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Expanded abbreviation based on session title context.'}, {'component': 'relapse setting', 'type': 'Occurrence', 'normalized_form': 'Relapsed', 'rule_applied': ""Rule 144: Standardized term to 'Relapsed' and positioned it as a prefix to the disease.""}]",2
279755,Jazz Pharmaceuticals: Should we expect long term survival in high-risk Acute Myeloid Leukaemia (AML)?,How should Measurable Residual Disease (MRD) assessment inform treatment decisions?,high-risk;;Acute Myeloid Leukaemia,High-Risk Acute Myeloid Leukemia,High-Risk Acute Myeloid Leukaemia,True,session_title,"Step 1: The abstract title 'How should Measurable Residual Disease (MRD) assessment inform treatment decisions?' lacks a specific disease, as MRD is a measure of disease burden, not the disease itself. The session title 'Jazz Pharmaceuticals: Should we expect long term survival in high-risk Acute Myeloid Leukaemia (AML)?' clearly contains the disease 'Acute Myeloid Leukaemia'. Therefore, the session title was chosen as the source based on the single-source principle.
Step 2: Components identified in the session title are the disease 'Acute Myeloid Leukaemia' and the risk qualifier 'high-risk'.
Step 3: The `get_indication_rules` tool was used for the 'Risk' category to ensure correct formatting of 'high-risk'.
Step 4: The retrieved rule (ID: 122) confirmed that 'high-risk' should be normalized to 'High-Risk' and prepended to the disease name.
Step 5: Applying generic rules, the disease name was kept in singular form and Title Case. The company name 'Jazz Pharmaceuticals' and the context 'long term survival' were excluded.
Step 6: The final indication was constructed by combining the normalized risk qualifier and the disease name, resulting in 'High-Risk Acute Myeloid Leukaemia'.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To verify the correct formatting and placement of the 'high-risk' qualifier.""}]","[{'component': 'high-risk', 'type': 'Risk Qualifier', 'normalized_form': 'High-Risk', 'rule_applied': ""Rule ID: 122 - Normalize 'high-risk' to 'High-Risk' and place it before the disease name.""}, {'component': 'Acute Myeloid Leukaemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukaemia', 'rule_applied': 'Generic Rule - Use Title Case and singular form.'}]",2
181452,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II",Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,Philadelphia Chromosome;;Positive;;Acute Lymphoblastic Leukemia,Ph-Positive Acute Lymphoblastic Leukemia,Ph Chromosome-Positive Acute Lymphoblastic Leukemia,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease ('Acute Lymphoblastic Leukemia') and is more detailed than the session title, adhering to the single-source principle.
Step 2: The components identified in the abstract title are the disease 'Acute Lymphoblastic Leukemia' and the genetic marker 'Philadelphia Chromosome-Positive'.
Step 3: The `get_indication_rules` tool was used for the category 'Chromosome type' to find the correct formatting for 'Philadelphia Chromosome-Positive'.
Step 4: Rule ID 81 was applied, which standardizes 'Philadelphia Chromosome-Positive' to 'Ph Chromosome-Positive'. Generic rules for singularization and title case were also applied. The term 'Patients with' was excluded as it is a general descriptor.
Step 5: The standardized genetic marker was combined with the disease name to form the final indication.
Step 6: A quality check confirmed that all rules were followed, including single-source selection, correct formatting, and exclusion of non-indication elements.","[{'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To correctly format the 'Philadelphia Chromosome-Positive' genetic marker.""}]","[{'component': 'Philadelphia Chromosome-Positive', 'type': 'Genetic Marker', 'normalized_form': 'Ph Chromosome-Positive', 'rule_applied': ""Rule ID 81: Convert 'Philadelphia Chromosome-Positive' to the standardized abbreviation 'Ph Chromosome-Positive'.""}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}]",2
181453,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II",A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia,Measurable Residual Disease-Positive;;B-Cell Acute Lymphoblastic Leukemia,MRD-Positive B-Cell Acute Lymphoblastic Leukemia,Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease, 'Acute Lymphoblastic Leukemia', which is more detailed than the session title. The single-source principle dictates using the abstract title.
2. **Component Identification**: The abstract title contains the core disease 'Acute Lymphoblastic Leukemia' and two key patient subgroup qualifiers: 'Measurable Residual Disease-Positive' and 'B-Cell'.
3. **Rule Retrieval**: Rules for 'Patient Sub-Group' were retrieved, specifically for 'B-Cell Precursor' and 'Disease Characterisation', to validate the inclusion of these qualifiers.
4. **Rule Application**: 
   - The rule for 'B-Cell Precursor' (ID 420) confirms that 'B-Cell' should be retained as it forms a recognized disease subtype when combined with the core disease.
   - 'Measurable Residual Disease-Positive' is a critical clinical descriptor defining a specific patient population for treatment and is not listed under any exclusion rules. Therefore, it must be included.
   - Generic rules were applied: The final indication was converted to Title Case, and non-clinical text like 'A Phase II Study of...' was excluded.
5. **Indication Construction**: The components were combined in the correct clinical order: the disease status qualifier, followed by the cell type, and then the core disease name.
6. **Final Quality Check**: The resulting indication is clinically precise, adheres to all formatting rules, and is derived from a single source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding disease status qualifiers like 'Measurable Residual Disease-Positive'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To verify the correct handling of the 'B-Cell' qualifier for Acute Lymphoblastic Leukemia.""}]","[{'component': 'Measurable Residual Disease-Positive', 'type': 'Patient Sub-Group (Disease Status)', 'normalized_form': 'Measurable Residual Disease-Positive', 'rule_applied': 'General inclusion principle for clinically significant patient subgroups not explicitly excluded.'}, {'component': 'B-Cell', 'type': 'Patient Sub-Group (Cell Type)', 'normalized_form': 'B-Cell', 'rule_applied': ""Rule ID 420: Retain 'B-Cell Precursor' (and by extension, 'B-Cell') when it is part of a formal disease name.""}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}]",2
263373,Myeloproliferative neoplasms - Clinical,"Primary Myelofibrosis In Young Patients <=50 Years: Clinicopathological Characteristics, Genetic Landscape And Disease Outcome. A Single Center Experience",Primary Myelofibrosis;;Young,Adult Primary Myelofibrosis,Primary Myelofibrosis,True,abstract_title,"Step 1: The abstract title 'Primary Myelofibrosis In Young Patients <=50 Years...' was selected as the source because it contains a specific disease term, 'Primary Myelofibrosis', making it more suitable than the broader session title 'Myeloproliferative neoplasms - Clinical'.
Step 2: The components identified in the abstract title are the disease 'Primary Myelofibrosis' and the patient subgroup 'Young Patients <=50 Years'.
Step 3: The `get_indication_rules` tool was used for the category 'Age Group' and subcategory 'Young' to determine how to handle the patient descriptor.
Step 4: The retrieved rules (e.g., ID 308) state that non-quantified age descriptors like 'Young' should be excluded from the final indication to maintain standardization. The generic rule for 'Primary' confirms its inclusion as it is part of the disease name.
Step 5: The indication was constructed by taking the core disease 'Primary Myelofibrosis' and excluding the age-related patient subgroup as per the rules.
Step 6: A quality check confirmed that the single-source principle was followed, formatting is correct (Title Case, singular), and excluded elements were properly removed, resulting in a clinically accurate indication.","[{'category': 'Age Group', 'subcategories': ['Young'], 'reason': ""To determine the correct handling of the term 'Young Patients' found in the abstract title.""}]","[{'component': 'Primary Myelofibrosis', 'type': 'Disease', 'normalized_form': 'Primary Myelofibrosis', 'rule_applied': ""Generic rule for 'Primary' - include when part of the disease name.""}, {'component': 'Young Patients <=50 Years', 'type': 'Age Group', 'normalized_form': '', 'rule_applied': ""Age Group rule (ID: 308) - Exclude non-standard age descriptors like 'Young'.""}]",2
148685,Chronic Lymphocytic Leukemia And Related Disorders - Clinical,Clinical Features Of Large Granular Lymphocytic Leukemia-Associated Pure Red Cell Aplasia: Results From A Single Center In China,Large Granular Lymphocytic Leukemia;;Pure Red Cell Aplasia,Large Granular Lymphocytic Leukemia;;Pure Red Cell Aplasia,Large Granular Lymphocytic Leukemia;;Pure Red Cell Aplasia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Clinical Features Of Large Granular Lymphocytic Leukemia-Associated Pure Red Cell Aplasia: Results From A Single Center In China') was chosen as the source because it contains specific disease terms, which is preferred over the session title.
2. **Component Identification**: The abstract title identifies two distinct medical conditions: 'Large Granular Lymphocytic Leukemia' and 'Pure Red Cell Aplasia'. The term '-Associated' links them. It also contains a geographic descriptor 'In China'.
3. **Rule Retrieval**: I attempted to retrieve rules for handling two associated diseases by calling `get_indication_rules(category='Patient with two different Disease', subcategories=['General'])`, but no specific rules were found. Therefore, I proceeded with the generic rules.
4. **Rule Application**:
   - **Multiple Diseases Rule**: The generic rule for multiple diseases states that all distinct diseases should be extracted and separated by ';;'.
   - **Exclusion Rule**: The sociodemographic descriptor 'In China' was excluded as per the generic exclusion rules.
   - **Formatting Rules**: The disease names were already in the correct singular form and Title Case.
5. **Indication Construction**: The two identified diseases, 'Large Granular Lymphocytic Leukemia' and 'Pure Red Cell Aplasia', were combined into the final indication string, separated by ';;'.
6. **Quality Check**: The final output adheres to all formatting and content rules. It correctly captures the two distinct clinical entities mentioned in the source title.","[{'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': 'To check for specific rules on how to handle two associated diseases mentioned in the same title.'}]","[{'component': 'Large Granular Lymphocytic Leukemia', 'type': 'Disease', 'normalized_form': 'Large Granular Lymphocytic Leukemia', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Pure Red Cell Aplasia', 'type': 'Disease', 'normalized_form': 'Pure Red Cell Aplasia', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'In China', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude geographic/ethnic descriptors.'}]",2
279766,Takeda: Long term proteasome inhibition for multiple myeloma in the era of COVID,Current challenges for patient management, COVID;;multiple myeloma, COVID;;Multiple Myeloma,Multiple Myeloma,True,session_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title ('Current challenges for patient management') contains no disease term. The session title ('Takeda: Long term proteasome inhibition for multiple myeloma in the era of COVID') contains the disease term 'multiple myeloma'.
2. **Select Source**: Based on the Single-Source Extraction Principle, the session title is selected as it is the only one containing a disease.
3. **Identify Components**: The core disease component identified is 'multiple myeloma'. Other phrases like 'Long term proteasome inhibition' (a treatment modality) and 'in the era of COVID' (a temporal context) are identified for exclusion.
4. **Retrieve Rules**: No specific category rules were needed for this straightforward extraction, but I performed a proactive check on 'Disease State/Severity' to ensure no qualifiers were missed. The primary rules applied are the generic ones.
5. **Apply Rules & Construct Indication**: 
   - The disease term 'multiple myeloma' is extracted.
   - The generic Title Case rule is applied, converting it to 'Multiple Myeloma'.
   - The generic Singular Form rule is applied, but 'myeloma' is already singular.
   - The generic Exclusion Rule is applied to remove the company name ('Takeda'), the treatment description ('Long term proteasome inhibition'), and the temporal context ('in the era of COVID').
6. **Quality Check**: The final indication 'Multiple Myeloma' is clinically accurate, correctly formatted, and adheres to all rules.","[{'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': 'Proactively checked for any disease state keywords in the title, although none were present.'}]","[{'component': 'multiple myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Singular Form'}, {'component': 'Long term proteasome inhibition', 'type': 'Treatment Modality', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of procedural/temporal qualifiers'}, {'component': 'in the era of COVID', 'type': 'Temporal Context', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of non-diagnostic items'}]",2
214230,MP50: Kidney Cancer: Localized: Surgical Therapy III,Implications of Positive Surgical Margins following Robotic Partial Nephrectomy,Kidney Cancer,Kidney Cancer,Localized Kidney Cancer,True,session_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The session title is 'MP50: Kidney Cancer: Localized: Surgical Therapy III' and the abstract title is 'Implications of Positive Surgical Margins following Robotic Partial Nephrectomy'.
2. **Select Source**: The session title contains the explicit disease term 'Kidney Cancer'. The abstract title describes a surgical procedure and its outcome but does not name the underlying disease. Based on the single-source principle, the session title is selected as it contains the disease term.
3. **Identify Components**: From the session title, the core disease is 'Kidney Cancer' and a disease qualifier is 'Localized'. 'MP50' and 'Surgical Therapy III' are metadata and procedural context, which should be excluded.
4. **Retrieve Rules**: I retrieved rules for the 'Stage' category to see if 'Localized' had a specific rule. No specific rule was found for 'Localized', so I proceeded with generic rules.
5. **Apply Rules**: The generic rules for formatting and exclusion are applied. 'Kidney Cancer' is already in singular form and Title Case. 'Localized' is a standard clinical descriptor for the stage of a cancer and is included. The procedural context 'Surgical Therapy' is excluded as per the generic exclusion rules.
6. **Construct Indication**: The qualifier 'Localized' is combined with the disease 'Kidney Cancer' to form the final indication.
7. **Quality Check**: The final indication 'Localized Kidney Cancer' is clinically accurate, follows all formatting rules, and adheres to the single-source principle.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for specific rules governing the term 'Localized' as a disease stage descriptor.""}]","[{'component': 'Kidney Cancer', 'type': 'Disease', 'normalized_form': 'Kidney Cancer', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Localized', 'type': 'Stage Qualifier', 'normalized_form': 'Localized', 'rule_applied': 'Generic Rule: Disease Characterization'}, {'component': 'Surgical Therapy III', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of procedural terms'}]",2
230619,Gastrointestinal Cancer-Colorectal and Anal,Modifiable and non-modifiable risk factors associated with early-onset colorectal cancer: Analysis of the National Health Interview Survey.,early-onset;;colorectal cancer,Early-Onset Colorectal Cancer,Early Onset Colorectal Cancer,True,abstract_title,"Step 1: The abstract title 'Modifiable and non-modifiable risk factors associated with early-onset colorectal cancer: Analysis of the National Health Interview Survey.' was chosen as the source because it contains a specific disease, which is preferred over the session title.
Step 2: The components identified in the title were 'early-onset' (an onset qualifier) and 'colorectal cancer' (the disease). The phrases 'Modifiable and non-modifiable risk factors' and 'Analysis of the National Health Interview Survey' were identified as study methodology and excluded.
Step 3: The `get_indication_rules` tool was used for the category 'Onset' and subcategory 'Onset by Time' to handle the 'early-onset' term.
Step 4: The retrieved rules (e.g., Rule ID 265) specify normalizing 'early-onset' to 'Early Onset' and prepending it to the disease name. Generic rules for Title Case and singular form were also applied.
Step 5: The components were combined according to the rules, resulting in 'Early Onset' + 'Colorectal Cancer'.
Step 6: A final quality check confirmed adherence to all formatting and extraction principles, leading to the final indication 'Early Onset Colorectal Cancer'.","[{'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To correctly handle the 'early-onset' qualifier.""}]","[{'component': 'early-onset', 'type': 'Onset Qualifier', 'normalized_form': 'Early Onset', 'rule_applied': ""Onset by Time Rule ID 265: Standardize to capitalized, space-separated form 'Early Onset'.""}, {'component': 'colorectal cancer', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic Casing Rule: Apply Title Case.'}]",2
197852,Accelerated Brain Aging in Neuropsychiatric Disorders: Methodological Challenges and and Potential Applications to Prognosticate Clinical Outcomes,Accelerated Brain Aging is Independently Associated with Increased Likelihood of All-Cause Mortality: Findings from the Second Wave of Dallas Heart Study (DHS-2),Neuropsychiatric Disorders,Neuropsychiatric Disorder,Neuropsychiatric Disorder,True,session_title,"Step 1: Analyze Input Titles. The abstract title contains 'Accelerated Brain Aging', which is a pathophysiological process but not a standard clinical indication. The session title contains both 'Accelerated Brain Aging' and 'Neuropsychiatric Disorders'.
Step 2: Select the Source. According to the Single-Source Extraction Principle, the abstract title should be preferred if it contains a disease term. However, 'Accelerated Brain Aging' is a borderline condition and more of a finding. The session title provides a clearer, clinically valid patient population: 'Neuropsychiatric Disorders'. The phrasing 'in Neuropsychiatric Disorders' suggests this is the core patient group being studied. Therefore, the session title is selected as the more appropriate source for a clinically valid indication.
Step 3: Identify Components. The core disease component identified in the session title is 'Neuropsychiatric Disorders'.
Step 4: Retrieve and Apply Rules. The generic rule for singular form is applied, converting 'Disorders' to 'Disorder'. The generic rule for Title Case is applied.
Step 5: Construct Indication. The final indication is constructed from the normalized component.
Step 6: Quality Check. The final indication 'Neuropsychiatric Disorder' is a single, clinically recognized condition, correctly formatted in Title Case and singular form, and derived from a single source.",[],"[{'component': 'Neuropsychiatric Disorders', 'type': 'Disease', 'normalized_form': 'Neuropsychiatric Disorder', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Title Case'}]",1
328928,Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II,Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma'. The session title is 'Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II'.
2.  **Select Source**: Both titles contain disease terms. As per the single-source principle, the abstract title is prioritized because it contains a specific disease context for the study.
3.  **Identify Components**: The core disease identified in the abstract title is 'Multiple Myeloma'. The term 'COVID-19-Associated Proteins' describes the methodology of the analysis, not a co-morbidity of the patient population being treated. Therefore, it is not part of the indication.
4.  **Retrieve Rules**: I checked for rules regarding patients with two different diseases to see how to handle the mention of COVID-19, but no specific rules were found. I will rely on the generic exclusion rules.
5.  **Apply Rules**: The generic exclusion rules state to remove non-diagnostic items and study methodologies. 'COVID-19-Associated Proteins' and 'TANK-Binding Kinase 1 As an Immunotherapeutic Target' fall into this category and are excluded. The core disease 'Multiple Myeloma' is retained.
6.  **Construct Indication**: The extracted disease is formatted according to the generic rules (Title Case, singular form). The final indication is 'Multiple Myeloma'.
7.  **Quality Check**: The final indication adheres to all formatting and exclusion rules, and the single-source principle was followed.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': ""To determine how to handle the mention of 'COVID-19' alongside 'Multiple Myeloma'.""}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Casing and Singular Form rules.'}, {'component': 'COVID-19-Associated Proteins', 'type': 'Methodology/Context', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items.'}]",2
296164,Colorectal cancer,Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial,microsatellite stable;;pMMR;;Colorectal cancer,Microsatellite Stable pMMR Colorectal cancer,Class II Expressing Microsatellite Stable Colorectal Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains the disease ('colorectal cancer') and specific patient subgroup information ('class II expressing', 'microsatellite stable (pMMR)'), making it more detailed than the session title.
2.  **Component Identification**: The key components identified in the abstract title are the disease 'colorectal cancer (CRC)', and two patient subgroup descriptors: 'class II expressing' and 'microsatellite stable (pMMR)'.
3.  **Rule Retrieval**: I initiated a search for rules related to biomarkers to correctly format 'microsatellite stable (pMMR)'. Although the retrieved rules for 'Biomarker' were not directly applicable to 'microsatellite stable', I proceeded using general knowledge and standard formatting rules.
4.  **Rule Application & Normalization**:
    *   **Disease**: 'colorectal cancer (CRC)' was normalized to 'Colorectal Cancer' using Title Case and singular form rules.
    *   **Biomarker 1**: 'microsatellite stable (pMMR)' was normalized to 'Microsatellite Stable'. 'pMMR' (proficient Mismatch Repair) is a synonym for Microsatellite Stable, so the full, more common term was used.
    *   **Biomarker 2**: 'class II expressing' was normalized to 'Class II Expressing' using Title Case.
5.  **Indication Construction**: The normalized components were combined in the order they appeared in the title to form a single, specific indication. The qualifiers describe a single patient cohort and are therefore prepended to the disease name.
6.  **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form), follows the single-source principle, and accurately represents the specific patient population described in the abstract title.","[{'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To check for specific formatting rules for biomarkers like 'microsatellite stable (pMMR)'.""}]","[{'component': 'colorectal cancer (CRC)', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic Rule: Title Case, Singular Form, and removal of abbreviation.'}, {'component': 'class II expressing', 'type': 'Biomarker', 'normalized_form': 'Class II Expressing', 'rule_applied': 'Generic Rule: Title Case.'}, {'component': 'microsatellite stable (pMMR)', 'type': 'Biomarker', 'normalized_form': 'Microsatellite Stable', 'rule_applied': 'Normalization based on clinical terminology, where pMMR is equivalent to Microsatellite Stable. Generic Title Case rule applied.'}]",2
197861,"Cannabis, Developmental periods, Neurocognitive and Mental Health Outcomes",Prenatal Cannabis Exposure and Outcomes during Middle Childhood,Prenatal;;Cannabis Exposure,Prenatal Cannabis Exposure,,True,none,"Neither the abstract title nor the session title contains a specific, clinically valid medical indication. The abstract title, 'Prenatal Cannabis Exposure and Outcomes during Middle Childhood', describes an exposure and a patient age group, but not a disease. According to the generic exclusion rules, exposures are not considered valid indications. The session title, 'Cannabis, Developmental periods, Neurocognitive and Mental Health Outcomes', similarly lists an exposure and broad categories of outcomes, not a specific disorder. Therefore, no indication can be extracted.",[],"[{'component': 'Prenatal Cannabis Exposure', 'type': 'Exposure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude exposures.'}, {'component': 'Neurocognitive and Mental Health Outcomes', 'type': 'Outcome Category', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic items. This is a broad category of outcomes, not a specific disease.'}]",1
197863,"Cannabis, Developmental periods, Neurocognitive and Mental Health Outcomes",Differential Effects of Adolescent versus Early Adult Cannabis Initiation on Longitudinal Brain Development: Evidence for Adolescence as a Period of Vulnerability,,,,True,none,"Neither the abstract title nor the session title contains a specific, clinically valid medical indication. The abstract title focuses on 'longitudinal brain development,' which is a physiological process, not a disease. The session title lists broad topics including 'Neurocognitive and Mental Health Outcomes,' which is a high-level category of outcomes rather than a specific, diagnosable disorder. According to the exclusion rules, physiologic processes and non-diagnostic items are not to be extracted as indications. Therefore, no valid indication can be generated from the provided text.",[],"[{'component': 'longitudinal brain development', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Exclusion of Non-Diagnostic Items'}, {'component': 'Neurocognitive and Mental Health Outcomes', 'type': 'Outcome Category', 'normalized_form': '', 'rule_applied': 'Exclusion of Non-Diagnostic Items'}]",1
148704,Chronic Lymphocytic Leukemia And Related Disorders - Clinical,Subcutaneous Immunoglobulins Use In Immunodeficiency Secondary To Chronic Lymphocytic Leukaemia: Monocentric Experience In Covid-19 Era,Chronic Lymphocytic Leukaemia,Chronic Lymphocytic Leukaemia,Immunodeficiency;;Chronic Lymphocytic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains specific disease terms ('Immunodeficiency', 'Chronic Lymphocytic Leukaemia'), making it the preferred source over the session title.
2. **Component Identification**: The abstract title identifies two distinct medical conditions: 'Immunodeficiency' and 'Chronic Lymphocytic Leukaemia'. The phrase 'Secondary To' connects them.
3. **Rule Application**: 
   - According to the generic exclusion rules, phrases like 'secondary to' must be excluded. This means the relationship between the two diseases is not part of the final indication.
   - The 'Multiple Diseases' rule is applied, which requires extracting all distinct diseases and separating them with ';;'.
   - The term 'Leukaemia' was normalized to the standard American spelling 'Leukemia'.
   - Title Case and singular form rules were applied to both conditions.
4. **Indication Construction**: The two extracted and normalized diseases, 'Immunodeficiency' and 'Chronic Lymphocytic Leukemia', are formatted as two separate indications joined by the ';;' delimiter.
5. **Final Output**: The resulting indication is 'Immunodeficiency;;Chronic Lymphocytic Leukemia', accurately reflecting the two distinct clinical entities mentioned in the source title while adhering to all formatting and exclusion rules.","[{'category': 'Patient with two different Disease', 'subcategories': [], 'reason': ""To check for rules on how to handle indications where one disease is secondary to another. No specific rules were found, so the generic rule for excluding 'secondary to' was applied.""}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To check for rules on handling connectors between disease states, although 'Secondary To' was ultimately handled by a generic exclusion rule.""}]","[{'component': 'Immunodeficiency', 'type': 'Disease', 'normalized_form': 'Immunodeficiency', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Chronic Lymphocytic Leukaemia', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Generic Rule: Title Case, Singular Form, Spelling Normalization'}, {'component': 'Secondary To', 'type': 'Connector', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule: Exclude 'secondary to' phrases""}]",2
148706,Chronic Myeloid Leukemia - Biology & Translational Research,Pattern Of Minimal Residual Disease In Tunisian Chronic Myeloid Leukemia Patients,Chronic Myeloid Leukemia,Chronic Myeloid Leukemia,Chronic Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: Both the abstract and session titles contain the disease term 'Chronic Myeloid Leukemia'. Following the Single-Source Extraction Principle, the abstract title is prioritized.
2. **Component Identification**: The selected abstract title is 'Pattern Of Minimal Residual Disease In Tunisian Chronic Myeloid Leukemia Patients'. The components identified are the disease 'Chronic Myeloid Leukemia', the sociodemographic descriptor 'Tunisian', and the disease characteristic 'Minimal Residual Disease'.
3. **Rule Application**: 
   - The generic exclusion rule for sociodemographic descriptors was applied to remove 'Tunisian'.
   - 'Minimal Residual Disease' is a measure of disease burden after treatment, not a standard clinical subgroup for defining an indication. It describes a state being studied within the patient group rather than defining the indication itself. Therefore, it is excluded to maintain a concise and standardized indication.
   - The core disease term 'Chronic Myeloid Leukemia' is already in the correct Title Case and singular form as required by the generic formatting rules.
4. **Indication Construction**: Based on the rules, only the core disease is retained, resulting in the final indication 'Chronic Myeloid Leukemia'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check if 'Minimal Residual Disease' is a standard disease characterisation.""}, {'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To check for rules regarding disease states like 'Minimal Residual Disease'.""}]","[{'component': 'Chronic Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Myeloid Leukemia', 'rule_applied': 'Generic formatting rule (Title Case, Singular)'}, {'component': 'Tunisian', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for ethnicity/region'}, {'component': 'Minimal Residual Disease', 'type': 'Disease Characteristic', 'normalized_form': '', 'rule_applied': 'Exclusion based on principle of concise, standard indication. This is a measure/state, not a subgroup qualifier.'}]",2
296166,"Breast cancer, early stage",Prognosis of pregnancy after breast cancer diagnosis according to the type of treatment: A population-based study in Korea by the SMARTSHIP group,breast cancer,Breast Cancer,Breast Cancer,True,abstract_title,"Step 1: Analyze Input Titles
- The abstract_title is: 'Prognosis of pregnancy after breast cancer diagnosis according to the type of treatment: A population-based study in Korea by the SMARTSHIP group'
- The session_title is: 'Breast cancer, early stage'

Step 2: Select the Source
- The Single-Source Extraction Principle dictates using the abstract title first if it contains a disease term.
- The abstract title contains 'breast cancer'. Therefore, the abstract title is selected as the exclusive source for the indication.
- The session title, despite containing more specific information ('early stage'), must be disregarded according to the rules.

Step 3: Identify Components in the Selected Source
- Disease Term: 'breast cancer'
- Other Terms: 'pregnancy after... diagnosis' (temporal/procedural qualifier), 'Korea' (geographic descriptor), 'population-based study' (study methodology).

Step 4: Apply Rules
- Generic Rule (Casing): 'breast cancer' is converted to 'Breast Cancer'.
- Generic Rule (Singular Form): The term is already in singular form.
- Generic Rule (Exclusion): The terms 'pregnancy after... diagnosis', 'Korea', and 'population-based study' are excluded as they represent a patient state, a geographic location, and study methodology, respectively, not a core part of the clinical indication.

Step 5: Construct Indication
- Based on the application of the rules to the selected source, the final indication is 'Breast Cancer'.

Step 6: Quality Check
- The extraction adheres strictly to the single-source principle. All formatting and exclusion rules have been applied correctly. The resulting indication is clinically valid, though less specific than the information available in the ignored session title.",[],"[{'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'pregnancy after breast cancer diagnosis', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Procedural/Temporal Qualifiers'}, {'component': 'Korea', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Sociodemographic Descriptors (Region)'}]",1
296175,Colorectal cancer,Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST),first-line;;metastatic;;colorectal cancer,First-Line Metastatic Colorectal Cancer,First-Line Metastatic Colorectal Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)') was chosen over the session title ('Colorectal cancer') because it contains a more specific and complete description of the medical indication, including disease stage and line of treatment, adhering to the single-source principle.
2. **Component Identification**: I identified three key components in the abstract title: 'first-line' (line of treatment), 'metastatic' (disease occurrence), and 'colorectal cancer' (the core disease).
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Metastasis-Related Terms' from the 'Occurrence' category and for 'Line of treatment' from the 'Treatment Set-up' category.
4. **Rule Application**:
   - **Generic Rules**: The disease term 'colorectal cancer' was converted to Title Case ('Colorectal Cancer') and confirmed to be in singular form.
   - **Metastasis Rule (ID: 141)**: The term 'metastatic' was prepended to the disease name, resulting in 'Metastatic Colorectal Cancer'.
   - **Line of Treatment Rule (ID: 200)**: The term 'first-line' was identified. Since it describes the treatment setting for the disease rather than a specific drug, the rule dictates it should be normalized to 'First-Line' and placed at the beginning of the indication.
5. **Indication Construction**: The components were assembled in the correct order: Line of Treatment + Occurrence + Disease. This resulted in the final indication: 'First-Line Metastatic Colorectal Cancer'.
6. **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form), correctly applies specific rules for staging and treatment line, and excludes non-relevant information like study design and drug names.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'metastatic'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To correctly format and position the 'first-line' descriptor.""}]","[{'component': 'first-line', 'type': 'Line of Treatment', 'normalized_form': 'First-Line', 'rule_applied': 'Treatment Set-up, ID: 200'}, {'component': 'metastatic', 'type': 'Disease Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': 'Occurrence, ID: 141'}, {'component': 'colorectal cancer', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic Casing and Singular Form Rules'}]",2
197874,Cell-Type Specific Molecular Biology of Addiction,Neuron Subtype Specific Molecular Mechanisms in Fentanyl Abstinence,,,Addiction,True,session_title,"The abstract title, 'Neuron Subtype Specific Molecular Mechanisms in Fentanyl Abstinence', describes a biological mechanism and a state (abstinence) rather than a core disease. The session title, 'Cell-Type Specific Molecular Biology of Addiction', contains the clinically valid medical indication 'Addiction'. Following the single-source principle, the session title was chosen. The descriptive terms 'Cell-Type Specific Molecular Biology' were excluded as they relate to research methodology, not the disease itself. The final indication was formatted to Title Case.",[],"[{'component': 'Addiction', 'type': 'Disease', 'normalized_form': 'Addiction', 'rule_applied': 'Generic exclusion of non-diagnostic items; Title Case formatting.'}, {'component': 'Fentanyl Abstinence', 'type': 'State/Process', 'normalized_form': '', 'rule_applied': 'Excluded as it is a state/process, not a primary disease.'}]",1
197882,Evidence of adult neurogenesis in human brain and its changes with aging and disease,Altered Adult Neurogenesis and Cognition in Mesial Temporal Lobe Epilepsy Patients,Mesial Temporal Lobe Epilepsy,Mesial Temporal Lobe Epilepsy,Mesial Temporal Lobe Epilepsy,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Altered Adult Neurogenesis and Cognition in Mesial Temporal Lobe Epilepsy Patients') was chosen as it contains a specific disease, 'Mesial Temporal Lobe Epilepsy', whereas the session title ('Evidence of adult neurogenesis in human brain and its changes with aging and disease') only mentions 'disease' generically. This adheres to the Single-Source Extraction Principle.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Mesial Temporal Lobe Epilepsy' and the associated findings 'Altered Adult Neurogenesis' and 'Cognition'.
3. **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' under the 'Disease Characterisation' subcategory to check if any specific rules applied to the descriptive terms. No specific rules were found for the identified components.
4. **Rule Application**: Generic rules were applied. 'Mesial Temporal Lobe' is an integral part of the specific epilepsy syndrome's name and was retained. The terms 'Altered Adult Neurogenesis' and 'Cognition' were identified as non-diagnostic findings or physiological processes, not the core indication, and were excluded as per the exclusion rules. The term 'Patients' was also excluded.
5. **Indication Construction**: The final indication was constructed using the specific disease name. It was formatted to Title Case and singular form as required. The result is 'Mesial Temporal Lobe Epilepsy'.
6. **Quality Check**: The final indication is clinically accurate, follows all formatting and exclusion rules, and is derived from a single source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify if descriptive terms like 'Altered' or anatomical locators like 'Mesial' have specific handling rules.""}]","[{'component': 'Mesial Temporal Lobe Epilepsy', 'type': 'Disease', 'normalized_form': 'Mesial Temporal Lobe Epilepsy', 'rule_applied': 'Generic Rule: Retain core disease name.'}, {'component': 'Altered Adult Neurogenesis', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic items and physiologic processes.'}, {'component': 'Cognition', 'type': 'Symptom/Function', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude isolated symptoms or functions.'}]",2
148732,"Enzymopathies, Membranopathies And Other Anemias",Diagnostic Importance Of Bone Marrow Aspiration In Children With Anemia Of Unknown Etiology,Children;;Anemia ,Childhood Anemia,Pediatric Anemia Of Unknown Etiology,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Diagnostic Importance Of Bone Marrow Aspiration In Children With Anemia Of Unknown Etiology') contains a specific disease ('Anemia Of Unknown Etiology') and is therefore selected over the session title, following the single-source principle.
2.  **Component Identification**: The abstract title contains the disease 'Anemia Of Unknown Etiology' and the patient subgroup 'Children'. The phrase 'Bone Marrow Aspiration' is identified as a diagnostic procedure and is marked for exclusion.
3.  **Rule Retrieval**: To correctly handle the age group 'Children', I retrieved rules for the 'Age Group' category, specifically for 'Pediatric', as 'Children' is a synonym. The retrieved rules (e.g., ID 295, 296) confirm that age-group qualifiers like 'Pediatric' should be prepended to the indication.
4.  **Rule Application and Normalization**:
    *   The patient subgroup 'Children' is normalized to the standard medical term 'Pediatric'.
    *   The procedural term 'Bone Marrow Aspiration' is excluded as per the generic exclusion rules.
    *   The disease term 'Anemia Of Unknown Etiology' is retained.
    *   Generic formatting rules are applied: Title Case is used, and the disease is already in singular form.
5.  **Indication Construction**: The normalized age-group qualifier 'Pediatric' is placed at the beginning of the indication, resulting in 'Pediatric Anemia Of Unknown Etiology'.
6.  **Quality Check**: The final indication is derived from a single source, correctly formatted, includes the relevant patient subgroup, and excludes non-diagnostic information.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To determine the correct formatting for the age group 'Children', which normalizes to 'Pediatric'.""}]","[{'component': 'Children', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule (ID: 295, 296) - Normalize 'Children' to 'Pediatric' and place it as a prefix.""}, {'component': 'Anemia Of Unknown Etiology', 'type': 'Disease', 'normalized_form': 'Anemia Of Unknown Etiology', 'rule_applied': 'Generic Rule - Retain disease name and apply Title Case.'}, {'component': 'Bone Marrow Aspiration', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule - Exclude procedural/diagnostic terms.'}]",2
394495,Sclc,Novel Nomogram Based On The Expression Of Dll3 And Pd-L1 For Predicting The Prognosis Of Small Cell Lung Cancer Patients,Small Cell Lung Cancer,Small Cell Lung Cancer,Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ""Novel Nomogram Based On The Expression Of Dll3 And Pd-L1 For Predicting The Prognosis Of Small Cell Lung Cancer Patients"" was chosen as the source because it contains a full, unambiguous disease name (""Small Cell Lung Cancer""), which is preferable to the abbreviated form ""Sclc"" in the session title.
2.  **Component Identification**: The core disease identified is ""Small Cell Lung Cancer"". The title also mentions biomarkers ""Dll3"" and ""Pd-L1"".
3.  **Rule Retrieval**: I retrieved rules for the 'Biomarker' category to determine how to handle ""Expression Of Dll3 And Pd-L1"".
4.  **Rule Application**: The generic exclusion rules and the retrieved biomarker rules guide the exclusion of biomarker information when it's part of a prognostic model or study methodology rather than defining a specific patient subgroup for treatment. The phrase ""Based On The Expression Of Dll3 And Pd-L1"" describes the components of the nomogram, not the patient's condition itself. Therefore, these biomarkers are not included in the final indication. The term ""Patients"" is a generic descriptor and is excluded.
5.  **Indication Construction**: The indication is constructed from the core disease term. Generic formatting rules are applied: the term is already in singular form and Title Case.
6.  **Final Indication**: The final, standardized indication is ""Small Cell Lung Cancer"".","[{'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': 'To determine if the expression of Dll3 and PD-L1 should be included in the indication.'}]","[{'component': 'Small Cell Lung Cancer', 'type': 'Disease', 'normalized_form': 'Small Cell Lung Cancer', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Expression Of Dll3 And Pd-L1', 'type': 'Biomarker', 'normalized_form': '', 'rule_applied': 'Biomarker rule: Excluded as it describes the basis for a prognostic model, not a patient subgroup characteristic for the indication.'}, {'component': 'Patients', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-specific patient descriptors.'}]",2
181510,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications,Childhood;;AML,Childhood Acute Myeloid Leukemia,Childhood Acute Myeloid Leukemia,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications', contains a specific disease (AML) and a patient subgroup (Childhood).
Step 2: Following the single-source principle, I selected the abstract title as it contains a clear disease entity.
Step 3: I identified the core components: 'Childhood' as an age group and 'AML' as the disease. 'AML' is a standard abbreviation for Acute Myeloid Leukemia.
Step 4: I retrieved rules for the 'Age Group' category, specifically for 'Childhood', to ensure correct formatting. The rules confirm that 'Childhood' should be used as a prefix for the disease.
Step 5: I applied the generic rules. I expanded 'AML' to 'Acute Myeloid Leukemia' and converted it to singular form (which it already is). I applied Title Case to all clinically significant words. The term 'ETS Family Transcription Factor Fusions' was excluded as it describes the specific molecular focus of the study rather than a standard clinical patient subgroup for the indication.
Step 6: I constructed the final indication by combining the age group prefix with the full disease name, resulting in 'Childhood Acute Myeloid Leukemia'.","[{'category': 'Age Group', 'subcategories': ['Childhood'], 'reason': ""To confirm the correct formatting and placement of the 'Childhood' age group qualifier.""}]","[{'component': 'Childhood', 'type': 'Age Group', 'normalized_form': 'Childhood', 'rule_applied': ""Age Group rule ID 291: Position 'Childhood' as the first word of the indication.""}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}]",2
181511,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Functional Consequence and Therapeutic Targeting of Cryptic ALK Fusions (ALKfus) in Monosomy7 AML,AML,Acute Myeloid Leukemia,ALK Fusion-Positive Monosomy 7 Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'Functional Consequence and Therapeutic Targeting of Cryptic ALK Fusions (ALKfus) in Monosomy7 AML' was chosen as it contains a specific disease (AML) and patient subgroups, making it more informative than the session title.
2.  **Component Identification**: I identified three key components in the abstract title:
    *   Disease: 'AML'
    *   Gene Alteration: 'ALK Fusions (ALKfus)'
    *   Chromosomal Abnormality: 'Monosomy7'
3.  **Rule Retrieval**: I performed a search for specific rules related to 'Gene Fusions' and 'Monosomy' but found no specific rules. Therefore, I proceeded using the generic rules.
4.  **Rule Application and Normalization**:
    *   **Disease Name**: Expanded the abbreviation 'AML' to its full form, 'Acute Myeloid Leukemia', per standard practice.
    *   **Gene Alteration**: Converted 'ALK Fusions' to the singular 'ALK Fusion' and then to the standard adjectival form 'ALK Fusion-Positive' to accurately describe the patient subgroup being targeted.
    *   **Chromosomal Abnormality**: Normalized 'Monosomy7' to 'Monosomy 7' by adding a space for clarity and standardization.
    *   **Casing**: Applied Title Case to the entire indication.
5.  **Indication Construction**: The normalized components were combined in the order of [Gene Alteration] [Chromosomal Abnormality] [Disease Name] to form the final, clinically precise indication: 'ALK Fusion-Positive Monosomy 7 Acute Myeloid Leukemia'.
6.  **Final Quality Check**: The final indication adheres to all formatting and clinical accuracy requirements, including the single-source principle, singularization, and proper casing.","[{'category': 'Gene type', 'subcategories': ['Gene Fusions'], 'reason': ""To check for specific formatting rules for gene fusions like 'ALK Fusions'.""}, {'category': 'Chromosome type', 'subcategories': ['Monosomy'], 'reason': ""To check for specific formatting rules for chromosomal abnormalities like 'Monosomy7'.""}]","[{'component': 'ALK Fusions', 'type': 'Gene Fusion', 'normalized_form': 'ALK Fusion-Positive', 'rule_applied': ""Generic rule: Convert to singular and use standard '-Positive' suffix for patient subgroup characterization.""}, {'component': 'Monosomy7', 'type': 'Chromosomal Abnormality', 'normalized_form': 'Monosomy 7', 'rule_applied': 'Generic rule: Standardize formatting for readability.'}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic rule: Expand common medical abbreviations.'}]",2
328968,Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III,"Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study",Relapsed/Refractory;;Multiple Myeloma,Relapsed/Refractory Multiple Myeloma,Relapsed/Refractory Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Multiple Myeloma') and detailed patient subgroup information ('Relapsed/Refractory', '1-3 Prior Therapies'), making it more informative than the session title.

2. **Component Identification**: The key components identified in the abstract title were:
   - Disease: 'Multiple Myeloma'
   - Disease State: 'Relapsed/Refractory' (abbreviated as RRMM)
   - Treatment History: '1-3 Prior Therapies'

3. **Rule Retrieval**: To handle the identified components, I retrieved rules for:
   - 'Occurrence' (subcategories: 'Recurrent/Refractory', 'Relapse', 'Refractory') to correctly format 'Relapsed/Refractory'.
   - 'Treatment Set-up' (subcategory: 'Line of treatment') to determine how to handle '1-3 Prior Therapies'.

4. **Rule Application**:
   - **Generic Rules**: The disease term 'Multiple Myeloma' was already in the correct singular form. Standard Title Case formatting was applied. Non-diagnostic information like drug names ('Ixazomib', 'Daratumumab', 'Dexamethasone') and patient descriptors ('Patients (Pts)') were marked for exclusion.
   - **Occurrence Rule**: The term 'Relapsed/Refractory' is a standard clinical descriptor. The retrieved rules confirm that this combination should be preserved and formatted in Title Case.
   - **Treatment Set-up Rule (ID: 207)**: This rule explicitly states that phrases describing the number of prior lines of therapy (e.g., '1-3 prior lines', '1-3 Prior Therapies') should be excluded from the final indication as they describe treatment history, not a distinct clinical subgroup for this purpose.

5. **Indication Construction**: The indication was built by combining the standardized disease state with the disease name: 'Relapsed/Refractory' + 'Multiple Myeloma'. The phrase '1-3 Prior Therapies' was excluded as per the specific rule.

6. **Final Quality Check**: The final indication 'Relapsed/Refractory Multiple Myeloma' adheres to all formatting and exclusion rules. It is clinically accurate and derived from a single source.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory', 'Relapse', 'Refractory'], 'reason': ""To correctly handle the 'Relapsed/Refractory' descriptor.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine the correct handling of the phrase '1-3 Prior Therapies'.""}]","[{'component': 'Relapsed/Refractory Multiple Myeloma', 'type': 'Disease with Occurrence Status', 'normalized_form': 'Relapsed/Refractory Multiple Myeloma', 'rule_applied': ""Generic Title Case and Singular Form rules; Occurrence rules for 'Relapsed/Refractory'.""}, {'component': '1-3 Prior Therapies', 'type': 'Treatment History', 'normalized_form': '', 'rule_applied': 'Treatment Set-up Rule ID: 207, which mandates the exclusion of prior line counts.'}]",2
165128,Adult Vaccines,Modeled Impact of the COVID-19 Pandemic and Associated Reduced Adult Vaccinations on Herpes Zoster in the United States,Herpes Zoster,Herpes Zoster Infection,Adult Herpes Zoster,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease term, 'Herpes Zoster', while the session title 'Adult Vaccines' is a therapeutic area, not a specific indication.
Step 2: The disease 'Herpes Zoster' was identified. The term 'Adult' was identified as a patient subgroup qualifier.
Step 3: Rules for the 'Age Group' category, specifically for 'Adult', were retrieved to ensure correct formatting. The rules confirm that 'Adult' should be used as a capitalized prefix.
Step 4: Generic rules were applied. The disease term was converted to Title Case ('Herpes Zoster'). The geographic location 'United States' and contextual information like 'COVID-19 Pandemic' and 'Reduced Adult Vaccinations' were excluded as per the exclusion rules.
Step 5: The final indication was constructed by combining the patient subgroup with the disease, resulting in 'Adult Herpes Zoster'.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To confirm the correct formatting for the 'Adult' patient subgroup.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule for 'Adult' (ID: 289)""}, {'component': 'Herpes Zoster', 'type': 'Disease', 'normalized_form': 'Herpes Zoster', 'rule_applied': 'Generic rule for Title Case and Singular Form'}]",2
296202,Basic Science,Gene expression profile (GEP) of extensive small-cell lung cancer (eSCLC) patients (pts) receiving first-line platinum-etoposide plus atezolizumab (PEA),extensive;;small-cell lung cancer,Extensive Stage Small-Cell Lung Cancer,Extensive Small-Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The `abstract_title` ('Gene expression profile (GEP) of extensive small-cell lung cancer (eSCLC) patients (pts) receiving first-line platinum-etoposide plus atezolizumab (PEA)') was chosen as it contains a specific disease ('small-cell lung cancer'), whereas the `session_title` ('Basic Science') is too generic.
2.  **Component Identification**: The key components identified in the abstract title are the disease 'small-cell lung cancer', the disease state 'extensive', and the treatment line 'first-line'.
3.  **Rule Retrieval**: Rules for 'Occurrence' (Disease State/Severity) and 'Treatment Set-up' (Line of treatment) were retrieved to handle 'extensive' and 'first-line' respectively.
4.  **Rule Application**:
    *   **Disease State**: 'extensive' is a standard clinical descriptor for the stage of small-cell lung cancer. It is retained and capitalized.
    *   **Treatment Line**: The term 'first-line' is followed by specific drug names ('platinum-etoposide plus atezolizumab'). According to the retrieved rule (ID: 199 for Treatment Set-up), line-of-treatment descriptors should be excluded when they describe the study treatment rather than defining the patient population. Therefore, 'first-line' was excluded.
    *   **Generic Rules**: The disease term was converted to Title Case and singular form (already singular). The standard hyphenation for 'Small-Cell' was applied. Non-diagnostic information such as 'Gene expression profile (GEP)', 'patients (pts)', and specific drug names were excluded.
5.  **Indication Construction**: The retained components 'Extensive' and 'Small-Cell Lung Cancer' were combined to form the final indication, resulting in 'Extensive Small-Cell Lung Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To determine how to handle the disease qualifier 'extensive'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine whether to include or exclude the 'first-line' descriptor.""}]","[{'component': 'extensive small-cell lung cancer', 'type': 'Disease', 'normalized_form': 'Extensive Small-Cell Lung Cancer', 'rule_applied': ""Generic Title Case and singular form rules. 'Extensive' is retained as a standard disease stage qualifier.""}, {'component': 'first-line', 'type': 'Line of treatment', 'normalized_form': '', 'rule_applied': 'Treatment Set-up Rule ID: 199 - Exclude line-of-treatment when followed by a specific drug/regimen name.'}, {'component': 'patients (pts)', 'type': 'Patient Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule - Exclude non-diagnostic items.'}, {'component': 'platinum-etoposide plus atezolizumab (PEA)', 'type': 'Treatment', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule - Exclude specific treatment names.'}]",2
148747,Hodgkin Lymphoma - Clinical,Prognostic Factors Of Worse Survival In Newly Diagnosed Advanced-Stage Hodgkin Lymphoma In Taiwan: A Nationwide Retrospective Study,Newly Diagnosed;;Advanced-Stage;;Hodgkin Lymphoma,Newly Diagnosed Advanced-Stage Hodgkin Lymphoma,Newly Diagnosed Advanced Stage Hodgkin Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Prognostic Factors Of Worse Survival In Newly Diagnosed Advanced-Stage Hodgkin Lymphoma In Taiwan: A Nationwide Retrospective Study') was chosen over the session title ('Hodgkin Lymphoma - Clinical') because it is more specific and contains a clear disease entity with patient subgroups, adhering to the single-source principle.
2. **Component Identification**: The key clinical components identified in the abstract title were 'Newly Diagnosed', 'Advanced-Stage', and 'Hodgkin Lymphoma'. The geographic location 'In Taiwan' and the study type 'A Nationwide Retrospective Study' were identified for exclusion.
3. **Rule Retrieval**: To ensure correct formatting, rules for 'Diagnosis Status' (for 'Newly Diagnosed') and 'Stage Type' (for 'Advanced-Stage') were retrieved using the `get_indication_rules` tool.
4. **Rule Application**: 
   - The rule for 'Newly Diagnosed' (ID: 193) confirms it should be used as a prefix to the disease name.
   - The general principle for staging terms like 'Advanced-Stage' is to place them before the disease name and normalize formatting. 'Advanced-Stage' was converted to 'Advanced Stage'.
   - The generic exclusion rule was applied to remove the geographic descriptor 'In Taiwan'.
   - The generic singular form and Title Case rules were applied to the entire indication.
5. **Indication Construction**: The identified components were assembled in a clinically logical order: Diagnosis Status -> Stage -> Disease. This resulted in 'Newly Diagnosed' + 'Advanced Stage' + 'Hodgkin Lymphoma'.
6. **Final Quality Check**: The final indication was reviewed to ensure it met all formatting and clinical accuracy requirements. It is a single, concise indication derived from the selected source, with all rules correctly applied.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To validate the handling of the term 'Newly Diagnosed'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To determine the correct formatting and placement of 'Advanced-Stage'.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'Advanced-Stage', 'type': 'Stage', 'normalized_form': 'Advanced Stage', 'rule_applied': 'Generic stage rule - Normalize hyphenation and place before the disease name.'}, {'component': 'Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'Hodgkin Lymphoma', 'rule_applied': 'Generic rule - Use singular form and Title Case.'}, {'component': 'In Taiwan', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic/geographic descriptors.'}]",2
312583,Detection/Diagnosis: Detection/Diagnosis - Other,Improving The Performance Of Early Breast Cancer Diagnosis By A Model Combining Breast Ultrasound With Methylation Markers In Non-Invasive Circulating Tumor Dna,Early;;Breast Cancer,Early Breast Cancer,Breast Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Improving The Performance Of Early Breast Cancer Diagnosis...') contains the specific disease term 'Breast Cancer', while the session title is generic. Therefore, the abstract title was selected as the source based on the Single-Source Extraction Principle.
2.  **Component Identification**: The key components identified in the abstract title are 'Early' and 'Breast Cancer'. Other terms like 'Diagnosis', 'Ultrasound', and 'Methylation Markers' are related to methodology and are excluded.
3.  **Rule Retrieval**: To correctly handle the term 'Early', I retrieved rules for the 'Onset' category, specifically 'Onset by Time'.
4.  **Rule Application**: The retrieved rules (e.g., Rule 267, 268) specify that 'Early' should be excluded if it modifies a non-disease concept like 'detection' or 'diagnosis'. In the phrase 'Early Breast Cancer Diagnosis', 'Early' modifies 'Diagnosis'. Therefore, 'Early' is not part of the indication and must be excluded.
5.  **Indication Construction**: The remaining disease term is 'Breast Cancer'. Generic rules are applied: the term is already in singular form and Title Case.
6.  **Final Output**: The final, standardized indication is 'Breast Cancer'.","[{'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To determine how to handle the keyword 'Early' and verify if it applies to the disease onset or the diagnosis timing.""}]","[{'component': 'Early', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': ""Onset by Time rule (e.g., ID 267, 268) - Exclude 'Early' when it modifies non-disease concepts like 'diagnosis'.""}, {'component': 'Breast Cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic rule - Use singular form and Title Case.'}]",2
378125,Adult acute lymphoblastic leukemia (EWALL),The US experience in ALL,ALL,Acute Lymphoblastic Leukemia,Adult Acute Lymphoblastic Leukemia,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'The US experience in ALL' and the session title is 'Adult acute lymphoblastic leukemia (EWALL)'.
2.  **Select Source**: Both titles contain a disease term ('ALL' and 'acute lymphoblastic leukemia'). The session title is more specific as it includes the patient subgroup 'Adult'. Therefore, the session title is selected as the source based on the single-source principle, prioritizing the more descriptive title.
3.  **Identify Components**: From the session title, the components are 'Adult' (age group) and 'acute lymphoblastic leukemia' (disease). The acronym '(EWALL)' is identified as a probable study group name and marked for exclusion.
4.  **Retrieve Rules**: To ensure correct formatting for the age group, I retrieved rules for the 'Age Group' category, specifically for the 'Adult' subcategory. The rules confirm that 'Adult' should be used as a capitalized prefix.
5.  **Apply Generic Rules**: 
    - **Casing**: 'acute lymphoblastic leukemia' is converted to Title Case: 'Acute Lymphoblastic Leukemia'.
    - **Singular Form**: The disease is already in singular form.
    - **Exclusion**: The acronym '(EWALL)' is excluded as it is not part of the clinical indication.
6.  **Construct Indication**: The components are combined according to the rules: the age group 'Adult' is prefixed to the disease 'Acute Lymphoblastic Leukemia'.
7.  **Final Output**: The final generated indication is 'Adult Acute Lymphoblastic Leukemia'.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To validate the correct formatting and placement of the 'Adult' patient subgroup descriptor.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule for 'Adult' requires it to be a capitalized prefix.""}, {'component': 'acute lymphoblastic leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}, {'component': '(EWALL)', 'type': 'Other', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic items like study group names.'}]",2
312590,Detection/Diagnosis: Detection/Diagnosis - Other,Orphan Non-Coding Rnas For Early Detection Of Breast Cancer With Liquid Biopsy,Breast Cancer,Breast Cancer,Breast Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title 'Orphan Non-Coding Rnas For Early Detection Of Breast Cancer With Liquid Biopsy' contains the specific disease 'Breast Cancer'. The session title 'Detection/Diagnosis: Detection/Diagnosis - Other' is generic. Therefore, the abstract title is selected as the source based on the Single-Source Extraction Principle.
2. **Identify Components**: The key components identified in the abstract title are the disease 'Breast Cancer' and the qualifier 'Early Detection'.
3. **Retrieve Relevant Rules**: To determine how to handle the term 'Early', I retrieved rules for the 'Onset' category, specifically 'Onset by Time'.
4. **Apply Rules**: The retrieved rules (specifically Rule IDs 267 and 268) state that when 'Early' modifies a non-disease concept like 'detection' or 'diagnostic timing', it should be excluded from the final indication. The phrase in the title is 'Early Detection', which falls under this exclusion criterion. The generic rules for exclusion also apply, removing the methodological terms 'Orphan Non-Coding Rnas' and 'Liquid Biopsy'. The generic formatting rules for Title Case and singular form are applied to 'Breast Cancer'.
5. **Construct Indication**: Based on the rules, 'Early Detection' is excluded. The core disease 'Breast Cancer' is extracted and formatted.
6. **Quality Check**: The final indication 'Breast Cancer' is clinically accurate, adheres to all formatting and exclusion rules, and is correctly derived from a single source.","[{'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To determine the correct handling of the term 'Early' found in the abstract title.""}]","[{'component': 'Breast Cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic rule: Title Case, Singular Form.'}, {'component': 'Early Detection', 'type': 'Diagnostic Qualifier', 'normalized_form': '', 'rule_applied': ""Onset Rule ID 267/268: Exclude 'Early' when it modifies non-disease concepts like 'detection'.""}, {'component': 'Orphan Non-Coding Rnas', 'type': 'Methodology/Biomarker', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude non-diagnostic items.'}, {'component': 'Liquid Biopsy', 'type': 'Procedure/Methodology', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude procedural/temporal qualifiers.'}]",2
263441,Sickle cell disease,Variant Haemoglobin Assessment And Correlation With Phenotypic Presentation At Diagnosis In Sickle Cell Disease : A Single Centre Retrospective Analysis Of Central Gujarat Cohort,Sickle Cell Disease,Sickle Cell Disease,Sickle Cell Disease,True,abstract_title,"Step 1: Analyze Input Titles. Both the abstract title ('Variant Haemoglobin Assessment And Correlation With Phenotypic Presentation At Diagnosis In Sickle Cell Disease...') and the session title ('Sickle cell disease') contain the same core disease term.
Step 2: Select Source. Following the single-source principle, the abstract title is preferred as it contains a valid disease term.
Step 3: Identify Components. The abstract title contains the disease 'Sickle Cell Disease' and a temporal qualifier 'At Diagnosis'.
Step 4: Retrieve and Apply Rules. I retrieved rules for 'Diagnosis Status' to understand how to handle 'At Diagnosis'. While there is a rule for 'Newly Diagnosed', 'At Diagnosis' is a more general temporal qualifier describing the patient cohort for the study. According to the generic exclusion rules, procedural/temporal qualifiers that are not part of a standard disease name should be excluded. Therefore, 'At Diagnosis' is excluded.
Step 5: Construct Indication. The core disease term from the abstract title is 'Sickle Cell Disease'. All other parts of the title, such as 'Variant Haemoglobin Assessment', 'Phenotypic Presentation', and 'Central Gujarat Cohort', are related to study methodology or sociodemographic details and are excluded per generic rules.
Step 6: Quality Check. The final indication 'Sickle Cell Disease' is correctly formatted in Title Case and singular form. It accurately represents the core medical condition discussed.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To check how to handle the term 'At Diagnosis' found in the abstract title.""}]","[{'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic rule: Use disease term from the selected source.'}, {'component': 'At Diagnosis', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers that are not part of a standard disease entity.'}, {'component': 'Central Gujarat Cohort', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude geographic and regional descriptors.'}]",2
296214,Melanoma and other skin tumours,Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma,metastatic;;uveal melanoma,Metastatic Uveal Melanoma,Metastatic Uveal Melanoma,True,abstract_title,"Step 1: The abstract title 'Safety and efficacy of infrequent tebentafusp treatment omissions in patients with metastatic uveal melanoma' was chosen as the source because it contains a specific disease ('uveal melanoma') and is more detailed than the session title ('Melanoma and other skin tumours').
Step 2: The components identified in the abstract title are 'metastatic' (an occurrence qualifier) and 'uveal melanoma' (the disease). The phrase 'patients with' is a generic descriptor and is excluded.
Step 3: To ensure correct formatting for 'metastatic', I retrieved rules for metastasis-related terms.
Step 4: The retrieved rule (ID: 141) for 'Metastatic' specifies the format 'Metastatic <Primary-Disease-Name>'. Generic rules for Title Case and singular form were also applied.
Step 5: The components were combined according to the rules, resulting in 'Metastatic Uveal Melanoma'.
Step 6: A final quality check confirmed that all rules were followed, including the single-source principle, correct formatting, and exclusion of non-indication elements.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'metastatic' as a prefix to the disease.""}]","[{'component': 'metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': ""Rule ID: 141 - Format as 'Metastatic <Primary-Disease-Name>'.""}, {'component': 'uveal melanoma', 'type': 'Disease', 'normalized_form': 'Uveal Melanoma', 'rule_applied': 'Generic Rule - Title Case and singular form.'}]",2
165143,Adult Vaccines,Immunologic Hyporesponsiveness with Subsequent Dosing of Meningococcal Vaccines: Re-Evaluating the Current Paradigm,,,Meningococcal Disease,True,abstract_title,"Step 1: The abstract title contains a specific disease context ('Meningococcal Vaccines'), while the session title ('Adult Vaccines') is a broad therapeutic area. Therefore, the abstract title is selected as the source.
Step 2: The term 'Meningococcal Vaccines' directly implies the indication is the prevention of the disease caused by meningococcus, which is 'Meningococcal Disease'.
Step 3: The term 'Immunologic Hyporesponsiveness' is identified as a physiologic process or a response to the vaccine, not the primary disease indication itself. According to the generic exclusion rules, physiologic processes are excluded.
Step 4: The phrase 'Subsequent Dosing' is a procedural/temporal qualifier and is excluded based on generic rules.
Step 5: The final indication is constructed by taking the core disease, applying Title Case, and ensuring it is in singular form, resulting in 'Meningococcal Disease'.",[],"[{'component': 'Meningococcal Vaccines', 'type': 'Disease', 'normalized_form': 'Meningococcal Disease', 'rule_applied': 'Generic rule: Extracted core disease from vaccine context.'}, {'component': 'Immunologic Hyporesponsiveness', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic items and physiologic processes.'}]",1
378137,Mesenchymal stromal cells: Progress in biology and engineering of mesenchymal stromal cells,Regulation of GvHD in the hematopoietic niche,GvHD ,Graft-Versus-Host Disease,Graft-Versus-Host Disease,True,abstract_title,"Step 1: The abstract title 'Regulation of GvHD in the hematopoietic niche' was chosen as the source because it contains a specific disease term ('GvHD'), whereas the session title does not.
Step 2: The component 'GvHD' was identified as the core disease. The surrounding text 'Regulation of' and 'in the hematopoietic niche' describe a biological process and context, not a patient subgroup, and are therefore excluded based on generic exclusion rules.
Step 3: The acronym 'GvHD' was expanded to its full clinical name, 'Graft-versus-Host Disease'.
Step 4: The final indication was formatted to Title Case as per the generic formatting rules, resulting in 'Graft-Versus-Host Disease'.",[],"[{'component': 'GvHD', 'type': 'Disease', 'normalized_form': 'Graft-Versus-Host Disease', 'rule_applied': 'Acronym expansion and Title Case formatting.'}]",2
296217,Melanoma and other skin tumours,Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase 3 trial,high-risk;;stage III;;melanoma,High-Risk Stage III Melanoma,High-Risk Stage III Melanoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('melanoma') and is more detailed than the session title, adhering to the single-source principle.
2. **Component Identification**: The key components identified in the abstract title were 'high-risk', 'stage III', and 'melanoma'. The phrase 'after complete resection' was identified as a procedural/temporal qualifier.
3. **Rule Retrieval**: I retrieved rules for 'Risk', 'Stage', and 'Treatment Set-up' to handle the identified components.
4. **Rule Application**:
   - **Generic Rules**: Applied Title Case and ensured the disease term was singular.
   - **Risk Rule (ID: 122)**: The term 'high-risk' was normalized to 'High-Risk'.
   - **Stage Rule**: The term 'stage III' was normalized to 'Stage III' using Roman numerals as per standard staging nomenclature rules.
   - **Exclusion Rule**: The phrase 'after complete resection' was excluded as it describes a post-operative status, which is a procedural/temporal qualifier that should not be part of the final indication.
5. **Indication Construction**: The normalized components were combined in a clinically standard order (Risk -> Stage -> Disease) to form the final indication.
6. **Quality Check**: The final indication was reviewed to ensure it followed all formatting rules, exclusion criteria, and was clinically accurate. The result 'High-Risk Stage III Melanoma' is a precise and standard clinical indication.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To correctly format the 'high-risk' qualifier.""}, {'category': 'Stage', 'subcategories': ['Stage number'], 'reason': ""To correctly format 'stage III' into standard Roman numeral format.""}, {'category': 'Treatment Set-up', 'subcategories': ['Operative Status'], 'reason': ""To determine how to handle the phrase 'after complete resection'.""}]","[{'component': 'high-risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': ""Risk rule for 'High-Risk' (ID: 122)""}, {'component': 'stage III', 'type': 'Stage', 'normalized_form': 'Stage III', 'rule_applied': 'Stage rule for numeric stages'}, {'component': 'melanoma', 'type': 'Disease', 'normalized_form': 'Melanoma', 'rule_applied': 'Generic Casing and Singular Form rules'}, {'component': 'after complete resection', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for procedural/temporal qualifiers'}]",2
279835,Aging and Hematology: Real-world evidence of CAR T-cell therapy in older adults in Europe,RWD of CAR T-cell therapy in older adults: The UK experience,,,Older Adult Hematologic Malignancy,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('RWD of CAR T-cell therapy in older adults: The UK experience') does not contain a specific disease or a therapeutic area, only a patient subgroup ('older adults'). The session title ('Aging and Hematology: Real-world evidence of CAR T-cell therapy in older adults in Europe') contains the therapeutic area 'Hematology' and the same patient subgroup. According to the single-source principle, the session title is selected as it contains a disease-related term, whereas the abstract title does not.
2.  **Component Identification**: From the session title, two key components were identified: the patient subgroup 'older adults' and the therapeutic area 'Hematology'.
3.  **Rule Retrieval**: To standardize the patient subgroup, rules for age groups were retrieved using `get_indication_rules(category=""Age Group"", subcategories=[""Elderly""])`.
4.  **Rule Application**: 
    *   **Patient Subgroup**: Based on the retrieved rules (specifically Rule ID 331 for 'Older adult'), the term 'older adults' is normalized to the singular, title-case form 'Older Adult'.
    *   **Therapeutic Area**: The generic 'Therapeutic Area Fallback' rule is applied. 'Hematology' is a therapeutic area, and in the context of CAR T-cell therapy, it refers to cancers of the blood. It is mapped to the standard overarching disease term 'Hematologic Malignancy'.
    *   **Exclusion**: The geographic descriptor 'Europe' is excluded as per the generic exclusion rules.
5.  **Indication Construction**: The normalized patient subgroup is prepended to the standardized disease term, resulting in 'Older Adult Hematologic Malignancy'.
6.  **Formatting**: The final indication is formatted in Title Case and singular form as required.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To handle the normalization of the patient subgroup 'older adults'.""}]","[{'component': 'older adults', 'type': 'Age Group', 'normalized_form': 'Older Adult', 'rule_applied': ""Age Group rule for 'Older adult' (ID: 331) - Normalize to singular, title-case form.""}, {'component': 'Hematology', 'type': 'Therapeutic Area', 'normalized_form': 'Hematologic Malignancy', 'rule_applied': 'Generic rule: Therapeutic Area Fallback.'}]",2
378147,Diagnosis in hematological diseases: Morphology and flow cytometry: 2.0 diagnostics in hematology: The role of artificial intelligence,AI approach for advanced analysis of flow-cytometryc data,,,Hematological Disease,True,session_title,"Step 1: The abstract title 'AI approach for advanced analysis of flow-cytometryc data' does not contain a specific disease or condition. 
Step 2: The session title 'Diagnosis in hematological diseases: Morphology and flow cytometry: 2.0 diagnostics in hematology: The role of artificial intelligence' contains the term 'hematological diseases'.
Step 3: Following the single-source principle, the session title is selected as it is the only source containing a disease term.
Step 4: The term 'hematological diseases' is extracted. 
Step 5: Applying the generic rules, the plural 'diseases' is converted to the singular 'Disease', and Title Case is applied, resulting in 'Hematological Disease'. The surrounding text describes diagnostic methods and topics, not the core indication, and is therefore excluded.",[],"[{'component': 'hematological diseases', 'type': 'Disease', 'normalized_form': 'Hematological Disease', 'rule_applied': 'Generic rule: Singular Form; Generic rule: Casing'}]",1
410917,"AI, Digital Health, Data Science - I",Integrating Electronic Health Data Records to Develop and Validate a Predictive Model of Hospital-Acquired AKI in Non-Critically Ill Patients,AKI,Acute Kidney Injury,Hospital-Acquired Acute Kidney Injury,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The `session_title` ('AI, Digital Health, Data Science - I') contains no medical terms. The `abstract_title` ('Integrating Electronic Health Data Records to Develop and Validate a Predictive Model of Hospital-Acquired AKI in Non-Critically Ill Patients') contains the medical condition 'Hospital-Acquired AKI'.
2. **Select Source**: Based on the Single-Source Extraction Principle, the `abstract_title` is selected as it contains the disease term.
3. **Identify Components**: The key components identified in the abstract title are 'Hospital-Acquired AKI' (disease) and 'Non-Critically Ill Patients' (patient subgroup).
4. **Retrieve Rules**: I retrieved rules for 'Patient Sub-Group' under the 'Disease Characterisation' subcategory to understand how to handle qualifiers like 'Hospital-Acquired' and 'Non-Critically Ill'. While no specific rule matched these exact terms, the general principles of clinical validity were applied.
5. **Apply Rules & Construct Indication**:
   - **Disease Term**: 'AKI' is expanded to its full form 'Acute Kidney Injury'.
   - **Qualifier**: 'Hospital-Acquired' is a clinically significant qualifier that specifies the origin of the condition and is retained.
   - **Patient Subgroup**: 'Non-Critically Ill' is a general descriptor of the patient's overall state, not a specific characteristic of the disease itself. Similar to excluding terms like 'pre-hospital' or sociodemographic data, this is considered a study population descriptor rather than a core part of the indication and is therefore excluded.
   - **Formatting**: The final indication is converted to Title Case and singular form as per generic rules.
6. **Final Indication**: Combining the components results in 'Hospital-Acquired Acute Kidney Injury'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding disease qualifiers like 'Hospital-Acquired' and patient state descriptors like 'Non-Critically Ill'.""}]","[{'component': 'Hospital-Acquired AKI', 'type': 'Disease', 'normalized_form': 'Hospital-Acquired Acute Kidney Injury', 'rule_applied': ""Generic rule: Expand acronyms. Retained 'Hospital-Acquired' as a clinically significant qualifier.""}, {'component': 'Non-Critically Ill Patients', 'type': 'Patient Subgroup', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Excluded as it describes the general patient state rather than a specific, defining characteristic of the disease indication.'}]",2
230700,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Initial efficacy and biomarker analysis of a phase 1b study targeting IL-1b and PD-1 with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).,metastatic;;pancreatic cancer,Metastatic Pancreatic Cancer,Metastatic Pancreatic Cancer,True,abstract_title,"Step 1: The abstract title contains a specific disease ('metastatic pancreatic cancer'), so it is chosen as the primary source over the session title, following the single-source principle.
Step 2: The core components identified in the abstract title are the disease 'pancreatic cancer' and the occurrence qualifier 'metastatic'.
Step 3: I retrieved rules for 'Metastasis-Related Terms' from the 'Occurrence' category to ensure correct formatting. Rule ID 141 for 'Metastatic' confirms the format 'Metastatic <Primary-Disease-Name>'.
Step 4: The generic rules for singular form and Title Case were applied. 'pancreatic cancer' is already singular. The phrase was converted to 'Metastatic Pancreatic Cancer'.
Step 5: All non-diagnostic information, such as study phase ('phase 1b'), biomarkers ('IL-1b', 'PD-1'), and treatments ('chemotherapy'), were excluded as per the generic exclusion rules.
Step 6: The final indication was constructed by combining the normalized components, resulting in 'Metastatic Pancreatic Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To verify the correct formatting for the term 'metastatic'.""}]","[{'component': 'metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': ""Rule ID: 141 - 'Metastatic' should be in Title Case and precede the disease name.""}, {'component': 'pancreatic cancer', 'type': 'Disease', 'normalized_form': 'Pancreatic Cancer', 'rule_applied': 'Generic rule: Use Title Case and singular form for disease names.'}]",2
197935,Poster Session I (In-Person),No Signs of Neurodegenerative Effects in 15q11.2 BP1-BP2 Copy Number Variant Carriers,,,,True,none,"Step 1: The session title 'Poster Session I (In-Person)' is generic and contains no medical information. The abstract title 'No Signs of Neurodegenerative Effects in 15q11.2 BP1-BP2 Copy Number Variant Carriers' was selected for analysis.
Step 2: The abstract title identifies a patient subgroup, '15q11.2 BP1-BP2 Copy Number Variant Carriers', which is a genetic characteristic, not a disease. The main finding is the *absence* of a condition ('No Signs of Neurodegenerative Effects').
Step 3: I retrieved rules for 'Chromosome type' to understand how to handle the copy number variant. The rules suggest that chromosomal alterations without a specific disease context are generally excluded.
Step 4: A medical indication must be a clinically valid disease or disorder. The title explicitly states the absence of neurodegenerative effects, and the carrier status itself is not a disease. Therefore, no valid medical indication can be extracted.","[{'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To determine how to handle the '15q11.2 BP1-BP2 Copy Number Variant'.""}]","[{'component': 'Neurodegenerative Effects', 'type': 'Potential Disease', 'normalized_form': None, 'rule_applied': ""The title states 'No Signs of', negating the presence of this condition, making it invalid as an indication.""}, {'component': '15q11.2 BP1-BP2 Copy Number Variant Carriers', 'type': 'Patient Subgroup', 'normalized_form': None, 'rule_applied': ""This describes a genetic carrier status, not a disease or disorder. Per 'Chromosome type' rules, such genetic markers without a specific disease are not considered a valid indication.""}]",2
230706,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary","Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).",second-line;;advanced;;metastatic;;esophageal squamous cell carcinoma,Second-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma,Second-Line Advanced Metastatic Esophageal Squamous Cell Carcinoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains a specific disease ('esophageal squamous cell carcinoma'), whereas the session title contains broader categories. This adheres to the Single-Source Extraction Principle.
2.  **Component Identification**: The key components identified in the abstract title were 'second-line' (treatment line), 'advanced or metastatic' (stage/occurrence), and 'esophageal squamous cell carcinoma' (disease).
3.  **Rule Retrieval**: I retrieved rules for 'Line of treatment', 'Stage Type', and 'Metastasis-Related Terms' to handle the identified components.
4.  **Rule Application**:
    *   **Treatment Line**: Based on Treatment Set-up Rule ID 199, 'second-line' was retained because it is followed by the word 'treatment'. Rule ID 202 was then applied to normalize it to 'Second-Line'.
    *   **Stage/Occurrence**: The terms 'advanced' and 'metastatic' were identified as disease state descriptors. Following the pattern of Occurrence Rule ID 177, which consolidates similar terms (e.g., 'locally advanced, or metastatic' into 'Locally Advanced Metastatic'), I combined 'advanced or metastatic' into the standardized phrase 'Advanced Metastatic'.
    *   **Disease Name**: The disease 'esophageal squamous cell carcinoma' was standardized to 'Esophageal Squamous Cell Carcinoma' by applying the generic Title Case and singular form rules.
5.  **Indication Construction**: The normalized components were assembled in the standard order: Line of Treatment + Stage/Occurrence + Disease Name.
6.  **Final Indication**: The final constructed indication is 'Second-Line Advanced Metastatic Esophageal Squamous Cell Carcinoma'.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To correctly handle the 'second-line' descriptor.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To handle the 'advanced' stage descriptor.""}, {'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To handle the 'metastatic' occurrence descriptor and its combination with 'advanced'.""}]","[{'component': 'second-line', 'type': 'Line of Treatment', 'normalized_form': 'Second-Line', 'rule_applied': 'Treatment Set-up Rule ID 202'}, {'component': 'advanced or metastatic', 'type': 'Stage/Occurrence', 'normalized_form': 'Advanced Metastatic', 'rule_applied': 'Occurrence Rule ID 177 (by pattern)'}, {'component': 'esophageal squamous cell carcinoma', 'type': 'Disease', 'normalized_form': 'Esophageal Squamous Cell Carcinoma', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}]",2
214324,MP55: Prostate Cancer: Localized: Ablative Therapy,Using Magnetic Resonance Imaging to Define Focal Therapy Templates in Patients with Intermediate-Risk Prostate Cancer,Intermediate-Risk;;Prostate Cancer,Intermediate-Risk Prostate Cancer,Intermediate-Risk Prostate Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Using Magnetic Resonance Imaging to Define Focal Therapy Templates in Patients with Intermediate-Risk Prostate Cancer') was chosen as the primary source because it contains a specific disease ('Prostate Cancer') and patient subgroup information, making it more detailed than the session title.
2. **Component Identification**: The key clinical components identified in the abstract title are 'Intermediate-Risk' (a risk stratification qualifier) and 'Prostate Cancer' (the disease).
3. **Rule Retrieval**: To ensure correct formatting for the risk qualifier, I retrieved rules for the 'Risk' category, specifically for 'Risk Types'. This confirmed the standard format is 'Intermediate-Risk'.
4. **Rule Application**: 
   - The generic rule for singular form was applied, though 'Prostate Cancer' is already singular.
   - The generic rule for Title Case was applied.
   - The generic exclusion rule was applied to remove procedural and methodological phrases like 'Using Magnetic Resonance Imaging to Define Focal Therapy Templates in Patients with...'.
   - The specific rule for 'Intermediate-Risk' (ID: 129) was applied, which dictates standardizing the term to 'Intermediate-Risk' and prepending it to the disease name.
5. **Indication Construction**: The standardized risk qualifier 'Intermediate-Risk' was combined with the disease 'Prostate Cancer' to form the final indication.
6. **Quality Check**: The final indication 'Intermediate-Risk Prostate Cancer' adheres to all formatting and clinical accuracy requirements. It is derived from a single source and correctly captures the specified patient subgroup.","[{'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To validate the formatting and placement of the 'Intermediate-Risk' qualifier.""}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To check if the word 'with' required special handling as a connector, which it did not.""}]","[{'component': 'Intermediate-Risk', 'type': 'Risk Qualifier', 'normalized_form': 'Intermediate-Risk', 'rule_applied': ""Rule ID 129: Standardize to 'Intermediate-Risk' and place before the disease name.""}, {'component': 'Prostate Cancer', 'type': 'Disease', 'normalized_form': 'Prostate Cancer', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}]",2
329014,Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III,Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study,Monoclonal Gammopathy,Monoclonal Gammopathy,Hypercalcemia;;Monoclonal Gammopathy of Undetermined Significance,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains specific disease terms ('Hypercalcemia', 'Monoclonal Gammopathy of Undetermined Significance'), following the single-source extraction principle.
Step 2: Two distinct clinical conditions were identified in the title: 'Hypercalcemia' and 'Monoclonal Gammopathy of Undetermined Significance'. The phrase 'in Individuals with' indicates these are concurrent conditions within the study population.
Step 3: The generic rule for handling multiple diseases was applied, which requires separating each distinct indication with a double semicolon ';;'.
Step 4: All components were formatted according to the generic rules: Title Case was maintained, and the terms were already in singular form. Non-diagnostic phrases like 'in Individuals with' and 'Results from the Istopmm Study' were excluded.
Step 5: The final indication was constructed by combining the two identified conditions, separated by ';;'.",[],"[{'component': 'Hypercalcemia', 'type': 'Disease', 'normalized_form': 'Hypercalcemia', 'rule_applied': 'Generic rule for disease identification and Title Case.'}, {'component': 'Monoclonal Gammopathy of Undetermined Significance', 'type': 'Disease', 'normalized_form': 'Monoclonal Gammopathy of Undetermined Significance', 'rule_applied': 'Generic rule for disease identification and Title Case.'}]",2
181569,Lymphomas: Translational-Non-Genetic: Poster II,Low Percentage of Microenvironment Immune Cells in Bone Marrow and Lymph Node Measured By Flow Cytometry Is Associated with Inferior Overall Survival in Diffuse Large B Cell Lymphoma,Diffuse Large B Cell Lymphoma,Diffuse Large B Cell Lymphoma,Diffuse Large B Cell Lymphoma,True,abstract_title,"Step 1: The abstract title contains a specific disease, 'Diffuse Large B Cell Lymphoma', which is more precise than the broader term 'Lymphomas' in the session title. Therefore, the abstract title was chosen as the source.
Step 2: The core disease was identified as 'Diffuse Large B Cell Lymphoma'.
Step 3: Other phrases in the title, such as 'Low Percentage of Microenvironment Immune Cells', 'in Bone Marrow and Lymph Node', and 'Inferior Overall Survival', were identified as study findings, anatomical locations for measurement, and clinical outcomes, respectively. These are not part of the core medical indication and were excluded as per the generic rules.
Step 4: The extracted disease name was checked against formatting rules. It is already in singular form and appropriate Title Case. No further modifications were needed.",[],"[{'component': 'Diffuse Large B Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Diffuse Large B Cell Lymphoma', 'rule_applied': 'Generic rule: Use disease term from the selected source.'}]",1
197955,Poster Session I (In-Person),Mutations in Kalrn Disrupt Gamma-Band Oscillations in the Auditory Cortex of Adult Mice,,,,True,none,"The abstract title describes a preclinical study in mice ('Adult Mice') and focuses on a physiological process ('Gamma-Band Oscillations') rather than a specific human disease. The session title is purely logistical and contains no medical information. According to the guidelines, indications must be clinically valid medical conditions in humans. Therefore, no indication can be extracted.",[],"[{'component': 'Adult Mice', 'type': 'Subject', 'normalized_form': 'Adult Mice', 'rule_applied': 'Exclusion of non-human subjects for clinical indications.'}, {'component': 'Gamma-Band Oscillations', 'type': 'Physiologic Process', 'normalized_form': 'Gamma-Band Oscillations', 'rule_applied': 'Exclusion of non-diagnostic items and physiologic processes.'}]",1
148806,Myelodysplastic Syndromes - Biology & Translational Research,Suppression Of Akr1B1 Reduces Cell Proliferation And Enhances Sensitivity To Hypomethylating Agents By Inhibiting Mtorc1 Signaling Pathway In High-Risk Myelodysplastic Syndrome,High-Risk;;Myelodysplastic Syndrome,High-Risk Myelodysplastic Syndrome,High-Risk Myelodysplastic Syndrome,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease term ('Myelodysplastic Syndrome'), which is preferred over the session title according to the single-source principle.
Step 2: The components identified in the abstract title are the disease 'Myelodysplastic Syndrome' and the patient subgroup qualifier 'High-Risk'. Other elements like gene names ('Akr1B1'), treatment types ('Hypomethylating Agents'), and biological pathways ('Mtorc1 Signaling Pathway') were identified for exclusion.
Step 3: To ensure correct formatting for the risk qualifier, the `get_indication_rules` tool was called with `category='Risk'` and `subcategories=['High-Risk']`.
Step 4: The retrieved rule (ID: 122) confirmed that 'High-Risk' should be normalized to 'High-Risk' and prepended to the disease name. Generic rules for Title Case and singular form were also applied. The disease term 'Myelodysplastic Syndrome' is already in the correct singular and title case format.
Step 5: The final indication was constructed by combining the normalized risk qualifier and the disease name, resulting in 'High-Risk Myelodysplastic Syndrome'.
Step 6: A quality check confirmed that all rules were followed, including the exclusion of non-indication elements and adherence to formatting standards.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To validate the correct formatting and placement of the 'High-Risk' qualifier.""}]","[{'component': 'High-Risk', 'type': 'Risk Qualifier', 'normalized_form': 'High-Risk', 'rule_applied': 'Risk rule (ID: 122) for normalization and placement.'}, {'component': 'Myelodysplastic Syndrome', 'type': 'Disease', 'normalized_form': 'Myelodysplastic Syndrome', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
148807,Myelodysplastic Syndromes - Biology & Translational Research,"Polymorphism Of Gstm1, Gstt1 And Cytokine Genes In Patients With Myelodysplastic Syndrome",Myelodysplastic Syndrome,Myelodysplastic Syndrome,Myelodysplastic Syndrome,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract title and session title contain the disease term 'Myelodysplastic Syndrome(s)'. As per the single-source principle, the abstract title is prioritized.
2.  **Component Identification**: The abstract title contains the disease 'Myelodysplastic Syndrome' and gene names 'Gstm1', 'Gstt1', and 'Cytokine Genes' associated with 'Polymorphism'.
3.  **Rule Retrieval**: I retrieved rules for 'Gene Name' and 'Gene type' to determine how to handle the gene information.
4.  **Rule Application**: 
    *   The generic rule for singularization converts 'Syndromes' (from session title, if used) to 'Syndrome'. The abstract title already uses the singular form.
    *   The generic rule for casing is applied, resulting in 'Myelodysplastic Syndrome'.
    *   According to the retrieved 'Gene Name' rules (specifically Rule ID 28 and 29), gene names should not be included in the indication if they lack a specific, clinically actionable qualifier like 'mutated', 'positive', 'altered', or 'fusion'. 'Polymorphism' is a genetic variation but is not considered a standard clinical qualifier for defining an indication in this context. Therefore, 'Gstm1', 'Gstt1', and 'Cytokine Genes' are excluded from the final output.
5.  **Indication Construction**: Based on the rules, only the core disease is extracted from the abstract title.
6.  **Quality Check**: The final indication 'Myelodysplastic Syndrome' is correctly formatted (Title Case, singular), adheres to the single-source principle, and accurately reflects the core disease discussed.","[{'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': 'To determine if the gene names Gstm1, Gstt1 should be included.'}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To check if 'Polymorphism' is a valid qualifier for a gene.""}]","[{'component': 'Myelodysplastic Syndrome', 'type': 'Disease', 'normalized_form': 'Myelodysplastic Syndrome', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Polymorphism Of Gstm1, Gstt1 And Cytokine Genes', 'type': 'Gene Information', 'normalized_form': '', 'rule_applied': ""Gene Name Rule ID 28/29: Exclude gene names without a specific clinical qualifier (e.g., mutated, positive). 'Polymorphism' is not a standard qualifier for inclusion.""}]",2
214345,MP56: Bladder Cancer: Invasive V,The role of FDG PET in the staging of bladder cancer patients candidate for radical cystectomy,bladder cancer,Bladder Cancer,Bladder Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: Both the `abstract_title` ('bladder cancer') and `session_title` ('Bladder Cancer') contain a valid disease term.
2.  **Select Source**: According to the single-source principle, the `abstract_title` is preferred when it contains a disease. Therefore, the `abstract_title` was chosen as the source for extraction.
3.  **Identify Components**: The selected title is 'The role of FDG PET in the staging of bladder cancer patients candidate for radical cystectomy'. The core disease is 'bladder cancer'. The phrase 'patients candidate for radical cystectomy' is a patient subgroup descriptor.
4.  **Apply Rules**:
    *   **Generic Disease Rule**: The disease 'bladder cancer' is identified.
    *   **Generic Formatting Rule (Casing)**: 'bladder cancer' is converted to 'Bladder Cancer'.
    *   **Generic Formatting Rule (Singular)**: The term is already in singular form.
    *   **Generic Exclusion Rule (Procedural Qualifiers)**: The phrase 'candidate for radical cystectomy' describes patients based on their suitability for a surgical procedure. This is a procedural qualifier and must be excluded from the final indication as it does not define a distinct clinical entity.
    *   The term 'Invasive' from the `session_title` is ignored because the `abstract_title` was selected as the single source.
5.  **Construct Indication**: Based on the rules, only the core disease 'Bladder Cancer' is retained.
6.  **Quality Check**: The final indication adheres to all formatting and exclusion rules, resulting in a concise and clinically accurate term.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding disease characteristics like 'Invasive', although this term was ultimately not used as it was in the non-selected source title.""}]","[{'component': 'bladder cancer', 'type': 'Disease', 'normalized_form': 'Bladder Cancer', 'rule_applied': 'Generic Casing and Singular Form Rules'}, {'component': 'candidate for radical cystectomy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Procedural/Temporal Qualifiers'}]",2
312650,Treatment - Surgery And Radiotherapy: Radiotherapy,Role Of Postmastectomy Radiation Therapy In Breast Cancer Patients According To Pathologic Nodal Status After Neoadjuvant Chemotherapy,Breast Cancer,Breast Cancer,Breast Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'Role Of Postmastectomy Radiation Therapy In Breast Cancer Patients According To Pathologic Nodal Status After Neoadjuvant Chemotherapy' contains the specific disease 'Breast Cancer'. The session title 'Treatment - Surgery And Radiotherapy: Radiotherapy' is generic. Therefore, the abstract title was selected as the source.
2.  **Component Identification**: The key components identified in the abstract title are 'Breast Cancer' (disease), 'Postmastectomy' (operative status), 'After Neoadjuvant Chemotherapy' (treatment status), and 'Pathologic Nodal Status' (patient characteristic).
3.  **Rule Retrieval**: Rules for 'Treatment Set-up' (subcategories: Operative Status, Treatment Status) and 'Occurrence' (subcategory: Node Status) were retrieved to handle the identified components.
4.  **Rule Application**: 
    -   **Generic Exclusion Rule**: Procedural and temporal qualifiers are excluded. This applies to 'Postmastectomy' and 'After Neoadjuvant Chemotherapy'.
    -   **Specific Rule (Operative Status)**: Rule ID 255 for 'Post Operative' confirms that such terms should be excluded from the final indication as they describe treatment timing, not the core disease.
    -   **Specific Rule (Treatment Status)**: Rules for treatment history (e.g., 'Post-Treatment') confirm that 'After Neoadjuvant Chemotherapy' should be excluded.
    -   **Specific Rule (Node Status)**: Rule ID 191 shows how to format specific statuses like 'Node-Positive' or 'Node-Negative'. The title mentions 'Pathologic Nodal Status' as a variable being studied ('According To'), not as a defining characteristic of the entire patient cohort. Therefore, it is not included in the indication.
5.  **Indication Construction**: After applying the exclusion rules, the only remaining clinically valid component is the disease itself.
6.  **Formatting**: The term 'Breast Cancer Patients' was converted to its singular, Title Case form: 'Breast Cancer'.
7.  **Final Output**: The final generated indication is 'Breast Cancer', as all other terms were identified as procedural, temporal, or analytical context rather than core indication qualifiers.","[{'category': 'Treatment Set-up', 'subcategories': ['Operative Status', 'Treatment Status'], 'reason': ""To verify the handling of 'Postmastectomy' and 'After Neoadjuvant Chemotherapy'.""}, {'category': 'Occurrence', 'subcategories': ['Node Status'], 'reason': ""To determine how to handle 'Pathologic Nodal Status'.""}]","[{'component': 'Breast Cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Singular Form and Title Case rules.'}, {'component': 'Postmastectomy', 'type': 'Operative Status', 'normalized_form': '', 'rule_applied': 'Exclusion rule for procedural/temporal qualifiers (confirmed by Treatment Set-up Rule ID 255).'}, {'component': 'After Neoadjuvant Chemotherapy', 'type': 'Treatment Status', 'normalized_form': '', 'rule_applied': 'Exclusion rule for procedural/temporal qualifiers.'}, {'component': 'Pathologic Nodal Status', 'type': 'Patient Characteristic', 'normalized_form': '', 'rule_applied': 'Excluded as it is a variable under investigation, not a defining subgroup for the entire cohort in the title.'}]",2
181581,"Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II","Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma",High-Risk;;Elderly;;Mantle Cell Lymphoma,High-Risk Elderly Mantle Cell Lymphoma,Elderly High-Risk Mantle Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Mantle Cell Lymphoma'), adhering to the single-source principle. The session title was disregarded.
2. **Component Identification**: From the abstract title, the following components were identified: the disease 'Mantle Cell Lymphoma', the age group 'Elderly', and the risk stratification 'High-Risk'. The treatment information ('Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC)') and the term 'Patients' were identified for exclusion.
3. **Rule Retrieval**: To ensure correct formatting and standardization, rules were retrieved for the identified patient subgroups. Specifically, `get_indication_rules` was called for the 'Risk' category (subcategory 'High-Risk') and the 'Age Group' category (subcategory 'Elderly').
4. **Rule Application**: 
   - The generic rule for singular form was applied, though 'Mantle Cell Lymphoma' is already singular.
   - The generic rule for Title Case was applied to all components.
   - The retrieved 'Age Group' rules (e.g., ID 299) confirmed that 'Elderly' should be standardized and placed at the beginning of the indication.
   - The retrieved 'Risk' rules (e.g., ID 122) confirmed that 'High-Risk' should be standardized and prepended to the disease name.
5. **Indication Construction**: The components were assembled in the standard order: Age Group -> Risk -> Disease. This resulted in 'Elderly' + 'High-Risk' + 'Mantle Cell Lymphoma'.
6. **Final Quality Check**: The final indication 'Elderly High-Risk Mantle Cell Lymphoma' was checked for compliance with all formatting rules (Title Case, no trailing spaces, no excluded terms), resulting in the final output.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To validate the formatting and placement of the 'High-Risk' qualifier.""}, {'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To validate the formatting and placement of the 'Elderly' patient subgroup.""}]","[{'component': 'Mantle Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Mantle Cell Lymphoma', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'High-Risk', 'type': 'Risk Qualifier', 'normalized_form': 'High-Risk', 'rule_applied': 'Risk rule ID 122: Standardize and attach to the disease name.'}, {'component': 'Elderly', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': 'Age Group rule ID 299: Standardize and place at the beginning of the indication.'}]",2
148814,Myelodysplastic Syndromes - Clinical,A Phase 3 Study Of The Efficacy And Safety Of Luspatercept Versus Epoetin Alfa For The Treatment Of Anemia Due To Lower-Risk Mds In Esa-Naive Patients Requiring Rbc Transfusions (The Commands Trial),Lower-Risk;;Mds,Low-Risk Myelodysplastic Syndrome,ESA-Naive Anemia due to Lower-Risk Myelodysplastic Syndrome Requiring RBC Transfusions,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains specific disease and patient subgroup information ('Anemia Due To Lower-Risk Mds', 'Esa-Naive Patients Requiring Rbc Transfusions'), which is more detailed than the session title ('Myelodysplastic Syndromes - Clinical').

2.  **Component Identification**: I identified the following key components from the abstract title:
    *   Core Condition: 'Anemia'
    *   Underlying Disease: 'Lower-Risk Mds'
    *   Patient Treatment Status: 'Esa-Naive'
    *   Patient Subgroup: 'Requiring Rbc Transfusions'

3.  **Rule Retrieval**: I mentally reviewed the rules for handling risk, treatment status, and multiple conditions.
    *   **Risk**: The term 'Lower-Risk' needs to be standardized in Title Case with a hyphen.
    *   **Treatment Status**: 'Esa-Naive' is a critical descriptor of treatment history and should be placed at the beginning of the indication. 'ESA' is an acronym and should be capitalized.
    *   **Disease Normalization**: 'Mds' is a standard abbreviation for Myelodysplastic Syndromes. It should be expanded and converted to singular Title Case: 'Myelodysplastic Syndrome'.
    *   **Patient Subgroup**: 'Requiring Rbc Transfusions' is a key clinical characteristic defining the patient population and must be included.

4.  **Indication Construction**: I assembled the components based on clinical and grammatical conventions:
    *   The primary condition being treated is 'Anemia'. The cause is 'Lower-Risk Mds'. The title explicitly links them with 'Due To'.
    *   The patient population is defined by being 'Esa-Naive' and 'Requiring Rbc Transfusions'.
    *   I started with the treatment status 'ESA-Naive' as it's a primary qualifier.
    *   I then constructed the core indication 'Anemia due to Lower-Risk Myelodysplastic Syndrome'.
    *   Finally, I appended the patient characteristic 'Requiring RBC Transfusions' to complete the description.

5.  **Final Formatting**: I applied the generic formatting rules:
    *   **Title Case**: Capitalized all significant words (e.g., 'Anemia', 'Myelodysplastic Syndrome'). Short prepositions like 'due to' are in lower case.
    *   **Acronyms**: Kept 'ESA' and 'RBC' in their original all-caps form.
    *   **Singular Form**: Used 'Syndrome' instead of 'Syndromes'.
    *   **Spacing**: Ensured single spaces between all words.

The final indication accurately and concisely captures all the specific clinical details from the source title.","[{'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To correctly format the 'Lower-Risk' descriptor.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To handle the 'Esa-Naive' patient status correctly.""}, {'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': ""To determine how to handle 'Anemia Due To... Mds'.""}]","[{'component': 'Anemia', 'type': 'Condition', 'normalized_form': 'Anemia', 'rule_applied': 'Generic Casing Rule'}, {'component': 'Lower-Risk Mds', 'type': 'Disease with Risk', 'normalized_form': 'Lower-Risk Myelodysplastic Syndrome', 'rule_applied': 'Risk Types rule, Singular Form rule, Abbreviation Expansion'}, {'component': 'Esa-Naive', 'type': 'Treatment Status', 'normalized_form': 'ESA-Naive', 'rule_applied': 'Treatment Status rule, Acronym Casing'}, {'component': 'Requiring Rbc Transfusions', 'type': 'Patient Subgroup', 'normalized_form': 'Requiring RBC Transfusions', 'rule_applied': 'Generic Casing Rule, Acronym Casing'}]",2
394576,Supportive Care,Prevention Of Taxane Chemotherapy Induced Nail Changes And Peripheral Neuropathy By Application Of Extremity Cooling: A Prospective Single Center Study With Intrapatient Comparison,Peripheral Neuropathy,Peripheral Neuropathy,,True,none,"Step 1: The abstract title was selected as the primary source because it contains specific medical terms, unlike the generic session title ""Supportive Care"".
Step 2: The abstract title mentions ""Taxane Chemotherapy Induced Nail Changes"" and ""Taxane Chemotherapy Induced Peripheral Neuropathy"". These are identified as complications or adverse effects resulting from a treatment (chemotherapy).
Step 3: According to the generic exclusion rules, 'Complications or adverse effects' should always be excluded from the final indication. The focus of the study is on preventing these side effects, which falls under supportive care, rather than treating a primary disease.
Step 4: Since the only potential conditions mentioned in the title are excluded by the rules, and the session title is too broad, no valid medical indication can be extracted.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': 'Initial check to see if treatment-induced conditions are handled as a specific patient subgroup. The retrieved rules did not apply, reinforcing the decision to use the generic exclusion rule.'}]","[{'component': 'Taxane Chemotherapy Induced Nail Changes', 'type': 'Adverse Effect', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude complications or adverse effects.'}, {'component': 'Taxane Chemotherapy Induced Peripheral Neuropathy', 'type': 'Adverse Effect', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude complications or adverse effects.'}]",3
263509,Presidential Symposium,Genetic And Epigenetic Factors Driving Primary Mediastinal B-Cell Lymphoma Pathogenesis And Outcome,Primary Mediastinal B-Cell Lymphoma,Primary Mediastinal B-Cell Lymphoma,Primary Mediastinal B-Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title contains a specific disease ('Primary Mediastinal B-Cell Lymphoma'), while the session title ('Presidential Symposium') does not. Therefore, the abstract title was selected as the source based on the single-source principle.
2. **Component Identification**: The key components identified in the abstract title are 'Primary', 'Mediastinal', and 'B-Cell Lymphoma'.
3. **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' to verify the handling of 'B-Cell'. The rules confirm that 'B-Cell' should be retained when it is part of a formal disease name.
4. **Rule Application**: 
   - The generic rule for 'Primary' was applied, retaining the term as it is part of the disease name.
   - 'Mediastinal' is an anatomical descriptor that is integral to the specific lymphoma type and is retained.
   - 'B-Cell Lymphoma' is the core disease. The retrieved rules support keeping 'B-Cell' as a descriptor.
   - The generic formatting rules (Title Case, singular form) were applied. The source text was already compliant.
5. **Indication Construction**: The components were combined to form the final indication.
6. **Quality Check**: The final indication is clinically accurate, follows all formatting and exclusion rules, and is derived from a single source.","[{'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To confirm the correct handling of 'B-Cell' as part of the lymphoma name.""}]","[{'component': 'Primary Mediastinal B-Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Primary Mediastinal B-Cell Lymphoma', 'rule_applied': ""Generic rule for 'Primary'; Rule for 'B-Cell' as part of a disease name.""}]",2
394584,Supportive Care,Initial Geriatric Assessment And Chemotherapy Tolerability Treatment In Brazilian Patients With Malignant Neoplasm Of The Digestive System.,Malignant;;Neoplasm,Malignant Neoplasm,Geriatric Malignant Neoplasm of the Digestive System,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease ('Malignant Neoplasm Of The Digestive System'), whereas the session title ('Supportive Care') is a general therapeutic area.
2. **Component Identification**: The key components identified in the abstract title were the disease 'Malignant Neoplasm Of The Digestive System' and the patient subgroup 'Geriatric'. The descriptor 'Brazilian Patients' was also identified.
3. **Rule Retrieval**: Rules for the 'Age Group' category were retrieved to handle the term 'Geriatric'.
4. **Rule Application**:
   - **Generic Exclusion Rule**: The sociodemographic descriptor 'Brazilian' was excluded as per the generic rules.
   - **Generic Formatting Rule**: The disease name was converted to Title Case, with prepositions like 'of' and 'the' remaining in lowercase.
   - **Age Group Rule (Geriatric)**: Based on the retrieved rules (e.g., ID 320), 'Geriatric' was identified as an age-group qualifier and prepended to the disease name.
   - **Exclusion of Non-Diagnostic Items**: The phrases 'Initial Geriatric Assessment' and 'Chemotherapy Tolerability Treatment' were excluded as they describe study methodology and procedures, not the core indication.
5. **Indication Construction**: The components were combined according to the rules, resulting in 'Geriatric' + 'Malignant Neoplasm of the Digestive System'.
6. **Final Quality Check**: The final indication adheres to all formatting and clinical accuracy requirements. It is singular, in Title Case, and correctly includes the patient subgroup while excluding non-essential information.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To correctly handle the patient descriptor 'Geriatric'.""}]","[{'component': 'Geriatric', 'type': 'Age Group', 'normalized_form': 'Geriatric', 'rule_applied': ""Age Group rule for 'Geriatric' (ID: 320, 321)""}, {'component': 'Malignant Neoplasm Of The Digestive System', 'type': 'Disease', 'normalized_form': 'Malignant Neoplasm of the Digestive System', 'rule_applied': 'Generic Casing Rule'}, {'component': 'Brazilian Patients', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Ethnicity/Region'}]",2
263513,From biology to preclinical models in ALL,Ubtf-Atxn7L3 Gene Fusion Due To 17Q21.31 Deletion Defines Novel High-Risk All Subtype Amenable To Mrd-Based Treatment Intensification,High-Risk;;All,High-Risk Acute Lymphoblastic Leukemia,Ubtf-Atxn7L3 Fusion-Positive High-Risk Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains a specific disease ('All') and detailed patient subgroup information, making it superior to the more general session title, in accordance with the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title were 'Ubtf-Atxn7L3 Gene Fusion', '17Q21.31 Deletion', 'High-Risk', and 'All'.
3.  **Rule Retrieval**: I retrieved rules for the 'High-Risk' category, which confirmed that 'High-Risk' should be normalized to title case and prepended to the disease name.
4.  **Component Normalization and Application**:
    *   **Disease**: The abbreviation 'All' was expanded to its full, clinically standard name 'Acute Lymphoblastic Leukemia' and converted to singular form.
    *   **Risk**: Based on the retrieved rules and generic formatting, 'High-Risk' was kept as a prefix to the disease.
    *   **Genetic Marker**: The title states that the 'Ubtf-Atxn7L3 Gene Fusion' *defines* the subtype. This is the most critical patient subgroup characteristic. I formatted this using the standard convention '-Positive' to create 'Ubtf-Atxn7L3 Fusion-Positive'. The underlying cause ('17Q21.31 Deletion') was excluded to maintain conciseness, as the gene fusion is the direct defining feature of the subtype.
5.  **Exclusions**: The term 'Novel' was excluded as it describes the research finding, not the clinical condition. The phrase 'Amenable To Mrd-Based Treatment Intensification' was excluded as it describes a procedural/methodological context, not the indication itself.
6.  **Final Construction**: The normalized components were assembled in the standard order (genetic marker -> risk level -> disease) to form the final indication: 'Ubtf-Atxn7L3 Fusion-Positive High-Risk Acute Lymphoblastic Leukemia'. This indication is clinically precise, follows all formatting rules, and accurately reflects the specific disease subtype described in the source title.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To validate the formatting and placement of the 'High-Risk' qualifier.""}]","[{'component': 'Ubtf-Atxn7L3 Gene Fusion', 'type': 'Gene Fusion', 'normalized_form': 'Ubtf-Atxn7L3 Fusion-Positive', 'rule_applied': 'Standard clinical formatting for genetic markers defining a subtype.'}, {'component': 'High-Risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': 'Risk rule ID 122: Normalize and attach to the disease entity.'}, {'component': 'All', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic Rule: Abbreviation expansion and singular form.'}]",3
345435,Tumor Organoids for Therapeutic Testing,Cellos: High-throughput deconvolution of 3D organoid dynamics at cellular resolution for cancer pharmacology,,,Cancer,True,abstract_title,"Step 1: The abstract title contains the term 'cancer', which is a valid disease. According to the single-source principle, the abstract title is prioritized over the session title.
Step 2: The relevant phrase in the abstract title is 'cancer pharmacology'. The term 'pharmacology' describes a field of study, not a patient or disease characteristic, and is therefore excluded.
Step 3: The core disease term 'cancer' is extracted.
Step 4: Applying the generic formatting rules, 'cancer' is converted to Title Case, resulting in 'Cancer'. The term is already in singular form. This aligns with the Therapeutic Area Fallback rule where 'Oncology' maps to 'Cancer'.",[],"[{'component': 'cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Therapeutic Area Fallback'}]",1
230744,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Genomic determinants and clinical relevance of cancer-associated thrombosis in biliary tract cancers.,cancer-associated;;thrombosis;;biliary tract cancers,Cancer-Associated Thrombosis;;Biliary Tract Cancer,Biliary Tract Cancer;;Cancer-Associated Thrombosis,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: Both the abstract title and session title contain disease terms. According to the single-source extraction principle, the abstract title is the preferred source.
2.  **Select Source**: The abstract title, ""Genomic determinants and clinical relevance of cancer-associated thrombosis in biliary tract cancers,"" was selected.
3.  **Identify Components**: The title contains two distinct medical conditions: ""cancer-associated thrombosis"" and ""biliary tract cancers"".
4.  **Retrieve Rules**: I checked for rules regarding multiple diseases. The generic rules specify that multiple distinct diseases should be extracted and separated by ';;'.
5.  **Apply Rules & Construct Indication**:
    *   The term ""biliary tract cancers"" was normalized. The plural ""cancers"" was converted to the singular ""Cancer"" and Title Case was applied, resulting in ""Biliary Tract Cancer"".
    *   The term ""cancer-associated thrombosis"" was normalized by applying Title Case, resulting in ""Cancer-Associated Thrombosis"".
    *   The two indications were combined using the ';;' separator as per the generic rule for multiple diseases.
6.  **Quality Check**: The final indication adheres to all formatting and content rules. It correctly identifies both clinical conditions mentioned in the source title and excludes non-diagnostic terms like ""Genomic determinants"" and ""clinical relevance"".","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To confirm the correct procedure for handling two distinct diseases mentioned in the same title.'}]","[{'component': 'biliary tract cancers', 'type': 'Disease', 'normalized_form': 'Biliary Tract Cancer', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Casing Rules'}, {'component': 'cancer-associated thrombosis', 'type': 'Disease', 'normalized_form': 'Cancer-Associated Thrombosis', 'rule_applied': 'Generic Rule: Casing Rules'}]",2
197976,Poster Session I (In-Person),Early-Life Trauma Exposure: The Role of vmPFC in Resilience to Trauma,Trauma,Trauma,,True,none,"Step 1: The abstract title was selected as the potential source because the session title is generic ('Poster Session I (In-Person)') and contains no medical terms.
Step 2: The abstract title 'Early-Life Trauma Exposure: The Role of vmPFC in Resilience to Trauma' was analyzed. The key term identified was 'Trauma'.
Step 3: The term 'Trauma' in this context refers to 'Trauma Exposure', which is an event or an exposure, and 'Resilience to Trauma', which is a physiological process. According to the generic exclusion rules, exposures and physiologic processes are not considered clinically valid medical indications.
Step 4: The title does not specify a diagnosable disorder resulting from trauma (e.g., Post-Traumatic Stress Disorder). Therefore, a specific, clinically valid indication cannot be extracted.
Step 5: Since neither the abstract title nor the session title provides a valid medical indication, the generated indication is empty.","[{'category': 'Onset', 'subcategories': ['Onset by Age'], 'reason': ""To check for rules on handling 'Early-Life' as a potential onset qualifier.""}]","[{'component': 'Trauma Exposure', 'type': 'Exposure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude exposures.'}, {'component': 'Resilience to Trauma', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude physiologic processes.'}]",2
296288,"Head and neck cancer, excluding thyroid",Real World Evidence of First-line Cetuximab (CX) plus Paclitaxel (PX) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN),Recurrent;;Metastatic;;Squamous Cell Carcinoma of the Head and Neck,Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Squamous Cell Carcinoma of the Head and Neck'), which is more precise than the broader category in the session title ('Head and neck cancer').
2. **Component Identification**: I identified the following components in the abstract title: the disease 'Squamous Cell Carcinoma of the Head and Neck', the occurrence qualifiers 'Recurrent or Metastatic', and the treatment context 'First-line'.
3. **Rule Retrieval**: I retrieved rules for 'Occurrence' and 'Treatment Set-up'.
4. **Rule Application and Construction**:
   - **Disease**: The disease name 'Squamous Cell Carcinoma of the Head and Neck' was normalized to Title Case.
   - **Occurrence Qualifiers**: The phrase 'Recurrent or Metastatic' was normalized to 'Recurrent/Metastatic' based on standard rules for combining disease state qualifiers (e.g., Rule ID 139).
   - **Treatment Context**: The term 'First-line' was identified. According to the retrieved 'Line of treatment' rules (e.g., Rule ID 199), line-of-treatment descriptors must be excluded when they are immediately followed by a specific drug name. In the title, 'First-line' is followed by 'Cetuximab (CX) plus Paclitaxel (PX)', so it was excluded from the final indication.
   - **Assembly**: The normalized components were combined to form the final indication.
5. **Quality Check**: The final indication was checked against all generic rules. It adheres to the single-source principle, uses Title Case, is in singular form, and correctly excludes the treatment-line descriptor. The result is a clinically accurate and well-formatted indication.","[{'category': 'Occurrence', 'subcategories': ['Recurrence-Related Terms', 'Metastasis-Related Terms', 'Recurrent/Refractory'], 'reason': ""To handle the terms 'Recurrent or Metastatic' and format them correctly.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine whether to include or exclude the 'First-line' descriptor.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for any specific rules related to 'Squamous Cell Carcinoma'.""}]","[{'component': 'Recurrent or Metastatic', 'type': 'Occurrence', 'normalized_form': 'Recurrent/Metastatic', 'rule_applied': ""Occurrence rule (ID 139) for concatenating multiple qualifiers with a '/'.""}, {'component': 'Squamous Cell Carcinoma of the Head and Neck', 'type': 'Disease', 'normalized_form': 'Squamous Cell Carcinoma of the Head and Neck', 'rule_applied': 'Generic rule for Title Case.'}, {'component': 'First-line', 'type': 'Line of Treatment', 'normalized_form': '', 'rule_applied': 'Treatment Set-up rule (ID 199) to exclude line-of-treatment when followed by a specific drug name.'}]",2
148828,Myeloma And Other Monoclonal Gammopathies - Biology & Translational Research,Validation Of Algorithms To Identify First-Line Therapy (Induction And Maintenance) For Multiple Myeloma For Use In Electronic Healthcare Databases,First-Line;;Multiple Myeloma,First-Line Multiple Myeloma,First-Line Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Validation Of Algorithms To Identify First-Line Therapy (Induction And Maintenance) For Multiple Myeloma For Use In Electronic Healthcare Databases') was chosen as the source because it contains a specific disease term, 'Multiple Myeloma', which is preferred over the session title.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Multiple Myeloma' and the treatment context 'First-Line Therapy'.
3. **Rule Retrieval**: To correctly handle the treatment context, rules for 'Line of treatment' were retrieved using `get_indication_rules(category='Treatment Set-up', subcategories=['Line of treatment'])`.
4. **Rule Application**: 
   - Based on the retrieved rules (specifically Rule ID 198 and 199), the term 'First-Line' is retained because it is followed by the generic word 'Therapy', not a specific drug name. 
   - The rules dictate that it should be standardized to 'First-Line' (Title Case with a hyphen) and placed before the disease name.
   - The disease term 'Multiple Myeloma' is already in the correct singular and Title Case format.
   - The terms 'Induction And Maintenance' are identified as procedural/temporal qualifiers describing the type of therapy and are excluded per generic rules.
5. **Indication Construction**: The standardized qualifier 'First-Line' is prepended to the disease 'Multiple Myeloma' to form the final indication.
6. **Quality Check**: The final indication 'First-Line Multiple Myeloma' adheres to all formatting and clinical accuracy requirements. It is singular, in Title Case, and correctly represents the patient subgroup defined in the title.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment', 'Treatment Status'], 'reason': ""To determine the correct handling and formatting of the 'First-Line Therapy' descriptor.""}]","[{'component': 'First-Line Therapy', 'type': 'Line of treatment', 'normalized_form': 'First-Line', 'rule_applied': ""Rule ID 199: Retain the descriptor when it is followed by the generic words 'treatment', 'therapy', 'management', 'setting'.""}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}, {'component': '(Induction And Maintenance)', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural or temporal qualifiers.'}]",2
230749,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Clinical utility of immunotherapy hyperprogressive genes in hepatocellular carcinoma patients.,hepatocellular carcinoma,Hepatocellular Carcinoma,Hyperprogressive Hepatocellular Carcinoma,True,abstract_title,"Step 1: The abstract title contains a specific disease ('hepatocellular carcinoma'), so it is selected as the source over the more general session title, following the single-source principle.
Step 2: The components identified in the abstract title are the disease 'hepatocellular carcinoma' and the qualifier 'hyperprogressive'.
Step 3: To correctly format the qualifier, I retrieved rules for disease progression by calling `get_indication_rules(category='Occurrence', subcategories=['Progression-Related'])`. While no specific rule for 'hyperprogressive' exists, the rules for similar terms like 'Progressive' and 'Oligoprogressive' indicate that such qualifiers should be prepended to the disease name in Title Case.
Step 4: Applying this pattern and the generic rules, 'hyperprogressive' is normalized to 'Hyperprogressive', and 'hepatocellular carcinoma' is converted to 'Hepatocellular Carcinoma'. The term 'patients' is excluded as per generic rules.
Step 5: The final indication is constructed by combining the normalized qualifier and the disease name.
Step 6: A quality check confirms the indication adheres to all formatting and clinical accuracy requirements.","[{'category': 'Occurrence', 'subcategories': ['Progression-Related'], 'reason': ""To determine the correct formatting for the term 'hyperprogressive' by checking rules for similar progression-related keywords.""}]","[{'component': 'hyperprogressive', 'type': 'Disease Qualifier', 'normalized_form': 'Hyperprogressive', 'rule_applied': ""Analogy from Progression-Related rules (e.g., 'Progressive' rule ID: 184) and Title Case rule.""}, {'component': 'hepatocellular carcinoma', 'type': 'Disease', 'normalized_form': 'Hepatocellular Carcinoma', 'rule_applied': 'Title Case rule and Singular Form rule (already singular).'}]",2
148829,Myeloma And Other Monoclonal Gammopathies - Clinical,A Clinical-Decision Tool To Improve The Strategy Of Multiple Myeloma Treatment,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. Both contain disease terms.
Step 2: Based on the single-source principle, the abstract title is preferred as it contains a specific disease term, 'Multiple Myeloma'.
Step 3: I identified the core disease component in the abstract title, which is 'Multiple Myeloma'. The surrounding text, 'A Clinical-Decision Tool To Improve The Strategy Of...Treatment', describes the study's methodology and is not part of the indication.
Step 4: I applied the generic rules. The term 'Multiple Myeloma' is already in Title Case and singular form. No specific category rules were needed for this extraction.
Step 5: I constructed the final indication by extracting the standardized disease name.
Step 6: The final quality check confirms that the extraction adheres to all formatting and exclusion rules, resulting in the indication 'Multiple Myeloma'.",[],"[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Title Case and Singular Form'}]",2
296292,Hepatocellular carcinoma (HCC),Prognosis-related molecular subtypes and immune features associated with hepatocellular carcinoma,hepatocellular carcinoma,hepatocellular carcinoma,Hepatocellular Carcinoma,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. Both contain the disease term 'hepatocellular carcinoma'.
Step 2: Following the single-source extraction principle, I selected the 'abstract_title' as the primary source because it contains a valid disease term.
Step 3: I identified the core disease component in the abstract title, which is 'hepatocellular carcinoma'. The phrases 'Prognosis-related molecular subtypes' and 'immune features associated with' were identified as study-specific descriptors and not as clinically valid patient subgroups that should be part of the indication.
Step 4: I retrieved rules for 'Disease Characterisation' to confirm that these types of descriptors are generally excluded. While no specific rule matched, the generic exclusion rule for 'Study methodologies' applies.
Step 5: I applied the generic formatting rules. I converted 'hepatocellular carcinoma' to Title Case, resulting in 'Hepatocellular Carcinoma'. The term is already in singular form.
Step 6: The final indication was constructed by taking the normalized core disease, resulting in 'Hepatocellular Carcinoma'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check if descriptors like 'molecular subtypes' or 'immune features' should be included in the indication.""}]","[{'component': 'hepatocellular carcinoma', 'type': 'Disease', 'normalized_form': 'Hepatocellular Carcinoma', 'rule_applied': 'Generic Casing Rule (Title Case)'}, {'component': 'Prognosis-related molecular subtypes and immune features associated with', 'type': 'Study Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule (Non-Diagnostic Items/Study Methodologies)'}]",2
279909,Pediatric hematology: Immunodeficiency-related lymphoproliferative disorders,Classification of immunodeficiency-related lymphoproliferative disorders,immunodeficiency-related lymphoproliferative disorders,Immunodeficiency-Related Lymphoproliferative Disorder,Pediatric Immunodeficiency-Related Lymphoproliferative Disorder,True,session_title,"Step-by-step extraction process:
1. **Analyze Titles**: Both the abstract and session titles contain the disease term 'Immunodeficiency-related lymphoproliferative disorders'. The session title also includes the patient subgroup 'Pediatric'.
2. **Select Source**: Based on the Single-Source Extraction Principle, the session title is chosen as it provides a more specific and complete indication by including the patient subgroup.
3. **Identify Components**: The selected source contains the disease 'Immunodeficiency-related lymphoproliferative disorders' and the age group 'Pediatric'.
4. **Retrieve Rules**: The `get_indication_rules` tool was used for the 'Age Group' category with the subcategory 'Pediatric' to ensure correct formatting.
5. **Apply Rules**: 
   - The retrieved rule (ID: 295) confirms that 'Pediatric' should be used as a prefix.
   - The generic rule for singular form was applied, converting 'disorders' to 'Disorder'.
   - The generic rule for Title Case was applied to the entire indication.
   - The term 'hematology' is a broad therapeutic area and is excluded in favor of the more specific disease name.
6. **Construct Indication**: The components were combined according to the rules, resulting in 'Pediatric Immunodeficiency-Related Lymphoproliferative Disorder'.
7. **Quality Check**: The final indication was verified against all formatting, inclusion, and exclusion criteria.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To confirm the correct formatting and placement of the 'Pediatric' age group qualifier.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group Rule ID: 295'}, {'component': 'Immunodeficiency-related lymphoproliferative disorders', 'type': 'Disease', 'normalized_form': 'Immunodeficiency-Related Lymphoproliferative Disorder', 'rule_applied': 'Generic Singular Form Rule, Generic Title Case Rule'}]",2
378207,Interactive Session: Chronic Lymphocytic Leukemia (CLL) and Beyond - Management of the Infection Burden,Interactive Panel Discussion: Challenging Cases Involving Infections Associated with CLL,CLL,Chronic Lymphocytic Leukemia,Infection;;Chronic Lymphocytic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Interactive Panel Discussion: Challenging Cases Involving Infections Associated with CLL' and the session title is 'Interactive Session: Chronic Lymphocytic Leukemia (CLL) and Beyond - Management of the Infection Burden'.
2. **Select Source**: Both titles contain disease terms. According to the single-source principle, the abstract title is the preferred source. It contains 'Infections' and 'CLL'.
3. **Identify Components**: The abstract title identifies two distinct clinical conditions: 'Infections' and 'CLL'. The phrase 'Associated with' links them, indicating co-occurrence.
4. **Retrieve Relevant Rules**: I retrieved rules for 'Patient with two different Disease' to understand how to handle co-occurring conditions and 'Occurrence' for connector words. The retrieved rules did not specifically cover 'Associated with', so I fell back to the generic rule for multiple diseases.
5. **Apply Rules**:
   - **Generic Rule (Multiple Diseases)**: The title mentions two distinct conditions, 'Infections' and 'CLL'. They must be extracted as separate indications, delimited by ';;'.
   - **Generic Rule (Singular Form)**: The plural 'Infections' is converted to its singular form, 'Infection'.
   - **Generic Rule (Casing)**: All terms are converted to Title Case.
   - **Standardization**: The abbreviation 'CLL' is expanded to its full name, 'Chronic Lymphocytic Leukemia', for clinical clarity. This is supported by the context from the session title.
6. **Construct Indication**: The identified and normalized components are combined using the ';;' separator, resulting in 'Infection;;Chronic Lymphocytic Leukemia'.
7. **Quality Check**: The final output adheres to all formatting and content rules. It correctly identifies both clinical conditions from the chosen source, uses the correct separator, and applies proper casing and singularization.","[{'category': 'Patient with two different Disease', 'subcategories': [''], 'reason': ""To check for rules on how to handle two diseases mentioned together, linked by 'Associated with'.""}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To check if 'Associated with' is a standard connector with specific formatting rules.""}]","[{'component': 'Infections', 'type': 'Disease', 'normalized_form': 'Infection', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'CLL', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Standardization of abbreviation to full disease name.'}, {'component': 'Associated with', 'type': 'Connector', 'normalized_form': ';;', 'rule_applied': ""Generic Rule: Multiple Diseases - indicates two separate conditions to be delimited by ';;'.""}]",3
394614,Supportive Care,"Mortality Within 30 Days After Last Dose Of Intravenous Systemic Anti-Cancer Therapy: Single-Center, One-Year, Retrospective Analysis",,,Cancer,True,abstract_title,"Step 1: The abstract title contains the term 'Anti-Cancer Therapy', which points to a disease context, while the session title 'Supportive Care' does not specify a disease. Therefore, the abstract title is selected as the source.
Step 2: The term 'Anti-Cancer Therapy' implies the therapeutic area is Oncology. According to the generic rules (Therapeutic Area Fallback), when a specific disease is not named, the overarching disease for Oncology should be used.
Step 3: The generic rule states 'Oncology' -> 'Cancer'.
Step 4: All other parts of the title, such as 'Mortality Within 30 Days After Last Dose', describe study outcomes or methodology and are excluded as per the exclusion rules.
Step 5: The final indication is formatted to Title Case and singular, resulting in 'Cancer'.",[],"[{'component': 'Anti-Cancer Therapy', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': 'Therapeutic Area Fallback'}]",3
345465,Mouse Models of Human Cancer,A non-surgical approach to develop an orthotopic colorectal cancer mouse model,colorectal cancer,Colorectal Cancer,Colorectal Cancer,True,abstract_title,"Step 1: The abstract title contains a specific disease ('colorectal cancer'), making it the preferred source over the more general session title ('Human Cancer').
Step 2: The core disease term 'colorectal cancer' was identified from the abstract title.
Step 3: The terms 'non-surgical', 'orthotopic', and 'mouse model' were identified as descriptors of the study's methodology and not part of the clinical indication, and were therefore excluded based on the generic exclusion rules.
Step 4: The extracted disease term was formatted according to the generic rules: converted to Title Case ('Colorectal Cancer') and confirmed to be in singular form.",[],"[{'component': 'colorectal cancer', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic Casing Rule (Title Case)'}, {'component': 'non-surgical approach', 'type': 'Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule (Non-Diagnostic Items)'}, {'component': 'mouse model', 'type': 'Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule (Non-Diagnostic Items)'}]",1
214394,MP58: Prostate Cancer: Detection & Screening VII,ATM mutations are associated with high-risk architectural features in men with familial prostate cancer,familial;;prostate cancer,Familial Prostate Cancer ,Familial ATM-Mutated High-Risk Prostate Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract and session titles mention 'Prostate Cancer'. The abstract title is more specific, containing details about gene mutations, risk, and patient subgroups, so it was chosen as the source based on the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title were 'ATM mutations' (gene mutation), 'high-risk' (risk stratification), 'familial' (patient subgroup), and 'prostate cancer' (disease). The term 'men' was identified as a sociodemographic descriptor to be excluded.
3.  **Rule Retrieval**: I retrieved rules for 'Gene type' to handle 'ATM mutations', 'Risk' for 'high-risk', and 'Patient Sub-Group' for 'familial'.
4.  **Rule Application**: 
    *   **Exclusion Rule**: The gender descriptor 'men' was removed.
    *   **Gene Type Rule**: 'ATM mutations' was normalized to 'ATM-Mutated' based on the retrieved rule for gene mutations.
    *   **Risk Rule**: 'high-risk' was normalized to 'High-Risk'.
    *   **Patient Subgroup Rule**: 'familial' was normalized to 'Familial' and identified as a primary qualifier.
    *   **Formatting Rules**: The final indication was converted to Title Case and singular form.
5.  **Indication Construction**: The normalized components were combined in a clinically logical order: Patient Subgroup -> Gene Mutation -> Risk -> Disease. This resulted in 'Familial ATM-Mutated High-Risk Prostate Cancer'. The phrasing of the title suggests these are all characteristics of the patient population being studied.
6.  **Quality Check**: The final indication was reviewed to ensure it adheres to all formatting, inclusion, and exclusion criteria, resulting in a high-confidence, clinically valid indication.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the 'ATM mutations' component.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To correctly format the 'high-risk' component.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Familial'], 'reason': ""To correctly format the 'familial' component.""}]","[{'component': 'ATM mutations', 'type': 'Gene Mutation', 'normalized_form': 'ATM-Mutated', 'rule_applied': ""Gene type rule for 'Gene Mutation' (ID: 30)""}, {'component': 'high-risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': 'Risk rule for standardizing risk levels.'}, {'component': 'familial', 'type': 'Patient Sub-Group', 'normalized_form': 'Familial', 'rule_applied': ""Patient Sub-Group rule for 'Familial' (ID: 392)""}, {'component': 'prostate cancer', 'type': 'Disease', 'normalized_form': 'Prostate Cancer', 'rule_applied': 'Generic rule for Title Case and singular form.'}, {'component': 'men', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for gender.'}]",2
394619,Supportive Care,Venous Thromboembolism (Vte) In Patients With Advanced High Grade Ovarian Carcinoma (Ahgoc) Receiving Parp Inhibitors,Advanced;;High Grade;;Ovarian Carcinoma,Advanced High Grade Ovarian Carcinoma,Venous Thromboembolism;;Advanced High Grade Ovarian Carcinoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'Venous Thromboembolism (Vte) In Patients With Advanced High Grade Ovarian Carcinoma (Ahgoc) Receiving Parp Inhibitors' was chosen over the session title 'Supportive Care' because it contains specific disease terms, adhering to the single-source principle.
2.  **Component Identification**: The abstract title identifies two distinct medical conditions: 'Venous Thromboembolism' and 'Advanced High Grade Ovarian Carcinoma'. The phrase 'In Patients With' indicates these are comorbidities.
3.  **Rule Retrieval**: I retrieved rules for 'Patient with two different Disease', 'Stage', 'Grade', and 'Treatment Set-up'.
4.  **Rule Application**: 
    *   **Multiple Diseases**: The generic rule for multiple diseases was applied, requiring both conditions to be extracted and separated by ';;'.
    *   **Grade**: The specific rule for 'High Grade' (ID: 115) confirmed it should be normalized to 'High Grade' and placed before the disease name.
    *   **Stage**: 'Advanced' was kept as a standard clinical qualifier for the carcinoma.
    *   **Exclusion**: The phrase 'Receiving Parp Inhibitors' was excluded as it describes a procedural/temporal treatment context, which is a standard exclusion criterion.
    *   **Formatting**: Abbreviations (Vte, Ahgoc) were removed, and the final output was formatted to Title Case and singular form as required.
5.  **Indication Construction**: The first indication was normalized to 'Venous Thromboembolism'. The second indication was constructed by combining the stage ('Advanced'), grade ('High Grade'), and disease ('Ovarian Carcinoma') to form 'Advanced High Grade Ovarian Carcinoma'. The two indications were then combined with the ';;' separator.
6.  **Final Quality Check**: The final output was reviewed for compliance with all formatting, accuracy, and completeness rules.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To handle the comorbidity context of VTE in patients with ovarian cancer.'}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for rules regarding the term 'Advanced'.""}, {'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To apply the correct formatting for 'High Grade'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To confirm the exclusion of 'Receiving Parp Inhibitors'.""}]","[{'component': 'Venous Thromboembolism (Vte)', 'type': 'Disease', 'normalized_form': 'Venous Thromboembolism', 'rule_applied': 'Generic rule: Remove abbreviations and apply Title Case.'}, {'component': 'Advanced High Grade Ovarian Carcinoma (Ahgoc)', 'type': 'Disease', 'normalized_form': 'Advanced High Grade Ovarian Carcinoma', 'rule_applied': ""Combination of generic rules (Title Case, remove abbreviation) and specific rule for 'High Grade' (ID: 115).""}, {'component': 'Receiving Parp Inhibitors', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
148861,Myeloma And Other Monoclonal Gammopathies - Clinical,Lenalidomide Versus Thalidomide Or Bortezomib As Maintenance Regimen For Non-Transplant Patients With Multiple Myeloma: Multi-Center Real World Experiences In China,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease, 'Multiple Myeloma', which is preferred over the broader terms in the session title.
Step 2: The components identified in the abstract title were the disease 'Multiple Myeloma' and the patient subgroup 'Non-Transplant Patients'. The geographic descriptor 'In China' was also noted for exclusion.
Step 3: To correctly handle 'Non-Transplant', I retrieved rules for the 'Treatment Set-up' category and 'Transplant Status' subcategory.
Step 4: The retrieved rules (ID 230, 231) explicitly state that terms like 'Non-Transplant' should be excluded from the final indication as they describe treatment suitability rather than the clinical condition itself. The generic exclusion rule was applied to remove the geographic location 'In China'.
Step 5: The final indication was constructed by taking the core disease 'Multiple Myeloma' and removing the excluded qualifiers, resulting in a clean, standardized indication.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine how to handle the 'Non-Transplant' patient descriptor.""}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic formatting rules (Title Case, Singular)'}, {'component': 'Non-Transplant Patients', 'type': 'Patient Subgroup', 'normalized_form': '', 'rule_applied': ""Rule ID 230: Exclude 'Non-Transplant' from the indication.""}, {'component': 'In China', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude geographic descriptors.'}]",2
148877,Myeloma And Other Monoclonal Gammopathies - Clinical,Analysis Of Delay In The Diagnosis Of Multiple Myeloma In A Sanitary Region Of Southern Spain.,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: The abstract title contains a specific disease term, 'Multiple Myeloma', so it is selected as the primary source over the session title, which contains broader terms ('Myeloma', 'Monoclonal Gammopathies').
Step 2: The disease term 'Multiple Myeloma' was identified in the abstract title.
Step 3: Generic exclusion rules were applied. The geographic descriptor 'Southern Spain' was identified and excluded from the final indication.
Step 4: Generic formatting rules were applied. The indication 'Multiple Myeloma' is already in the correct Title Case and singular form. No changes were needed.
Step 5: The final indication was constructed as 'Multiple Myeloma'.",[],"[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Casing and Singular Form rules'}, {'component': 'Southern Spain', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Sociodemographic Exclusion rule'}]",1
198028,Poster Session I (In-Person),Exposure to Prenatal Stress Induces Sex-Specific Vulnerability to Psychopathologic Domains in Adolescent Rats,,,,True,none,"The abstract title describes a study conducted in ""Adolescent Rats"", which is an animal model. Medical indications must be for human diseases. Additionally, ""Psychopathologic Domains"" is a broad, non-specific category rather than a clinically valid indication. The term ""Sex-Specific"" is a gender descriptor and is excluded by generic rules. The session title does not contain any disease information. Therefore, no valid indication can be extracted.","[{'category': 'Age Group', 'subcategories': ['Adolescent'], 'reason': ""To check rules for the keyword 'Adolescent'.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To check rules for the keyword 'Vulnerability'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check rules for the keyword 'Psychopathologic'.""}]","[{'component': 'Adolescent Rats', 'type': 'Animal Model', 'normalized_form': '', 'rule_applied': 'Exclusion of non-human studies. A medical indication must be for a human disease.'}, {'component': 'Sex-Specific', 'type': 'Gender Descriptor', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic descriptors (gender).'}, {'component': 'Psychopathologic Domains', 'type': 'Non-Specific Disease Category', 'normalized_form': '', 'rule_applied': 'Exclusion of non-diagnostic items. The term is too broad and not a clinically valid indication.'}]",2
279967,Janssen: Immunotherapy: evolution or revolution in the cure of multiple myeloma,How will we treat high-risk multiple myeloma in the future?,high-risk;;multiple myeloma,High-Risk Multiple Myeloma,High-Risk Multiple Myeloma,True,abstract_title,"Step 1: The abstract title 'How will we treat high-risk multiple myeloma in the future?' was chosen as the source because it contains a specific disease and patient subgroup, making it more informative than the session title.
Step 2: The components identified in the abstract title were the disease 'multiple myeloma' and the risk qualifier 'high-risk'.
Step 3: The `get_indication_rules` tool was used for the category 'Risk' and subcategory 'High-Risk' to ensure correct formatting.
Step 4: The retrieved rule (ID: 122) confirmed that 'high-risk' should be normalized to 'High-Risk' and prepended to the disease name. Generic rules for Title Case ('Multiple Myeloma') and singular form were also applied.
Step 5: The components were combined to form the final indication 'High-Risk Multiple Myeloma'.
Step 6: A quality check confirmed adherence to all formatting, exclusion, and single-source principles.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To validate the correct formatting and placement of the 'high-risk' qualifier.""}]","[{'component': 'high-risk', 'type': 'Risk Qualifier', 'normalized_form': 'High-Risk', 'rule_applied': ""Rule ID 122: Normalize 'high-risk' to 'High-Risk'.""}, {'component': 'multiple myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Rule: Apply Title Case to disease names.'}]",2
312718,Treatment - Types And Sites Of Breast Cancer: Brain Metastases,Efficacy And Safety Of Pyrotinib-Based Therapy In The Treatment Of Her2-Positive Breast Cancer Patients With Brain Metastases:A Multi-Center Real-World Study,Her2;;Positive;;Breast Cancer;;Brain Metastases,Brain Metastasis;;Her2-Positive Breast Cancer,HER2-Positive Breast Cancer with Brain Metastasis,True,abstract_title,"The extraction process followed these steps:
1. **Source Selection**: The 'abstract_title' was chosen over the 'session_title' as it provides a more detailed and specific description of the medical indication.
2. **Component Identification**: The key clinical components identified in the abstract title were 'Her2-Positive', 'Breast Cancer', and 'Brain Metastases'.
3. **Rule Application and Normalization**:
   - **Biomarker**: 'Her2-Positive' was identified as a biomarker. The standard format for gene symbols/biomarkers is all-caps, so it was normalized to 'HER2-Positive'.
   - **Disease**: 'Breast Cancer' is the core disease and is already in the correct singular, Title Case format.
   - **Metastasis**: 'Brain Metastases' describes a specific patient subgroup. The generic rule for singularization was applied, converting 'Metastases' to 'Metastasis'.
4. **Indication Construction**: The components were combined to form a single, clinically precise indication. The phrase 'Patients With' explicitly links the brain metastasis to the primary breast cancer, defining a specific patient population rather than two separate diseases. The final indication is structured as '[Biomarker] [Disease] with [Metastatic Site]'.
5. **Exclusions**: Non-clinical terms such as 'Efficacy And Safety', 'Pyrotinib-Based Therapy', 'Treatment Of', and 'Multi-Center Real-World Study' were excluded as per the generic rules.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To understand how to handle terms related to metastasis, which guided the decision to treat 'Brain Metastases' as a characteristic of the primary cancer.""}]","[{'component': 'Her2-Positive', 'type': 'Biomarker', 'normalized_form': 'HER2-Positive', 'rule_applied': 'Generic Casing Rule for Biomarkers'}, {'component': 'Breast Cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Formatting Rule (Title Case, Singular)'}, {'component': 'Brain Metastases', 'type': 'Patient Subgroup (Metastasis)', 'normalized_form': 'Brain Metastasis', 'rule_applied': 'Generic Singular Form Rule'}]",4
329101,Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II,Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance'. The session title is 'Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II'.
2.  **Select Source**: The abstract title contains the specific disease 'Multiple Myeloma'. According to the single-source principle, the abstract title is preferred and will be used exclusively.
3.  **Identify Components**: The core disease identified is 'Multiple Myeloma'. Other phrases include 'Free from Maintenance Drug Therapy', 'Minimal Residual Disease (MRD)-Driven', and 'Discontinuation of Maintenance'.
4.  **Retrieve Rules**: I retrieved rules for 'Patient Sub-Group' and 'Treatment Set-up' to determine how to handle the identified components.
5.  **Apply Rules**: 
    *   The core disease 'Multiple Myeloma' is kept. It is already in singular form and Title Case.
    *   'Free from Maintenance Drug Therapy' and 'Discontinuation of Maintenance' are procedural/temporal qualifiers describing the study's intervention, not the patient's baseline indication. Based on the generic exclusion rules, these are removed.
    *   'Minimal Residual Disease (MRD)-Driven' describes the methodology used to guide treatment decisions within the trial. It is not a standard patient subgroup that defines the indication itself. No specific rule mandates its inclusion, so it is excluded under the generic rule for non-diagnostic/methodological items.
6.  **Construct Indication**: After excluding the non-indication components, the only remaining element is the core disease.
7.  **Final Indication**: The final generated indication is 'Multiple Myeloma'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check if 'Minimal Residual Disease (MRD)-Driven' is a standard patient subgroup.""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To verify how to handle terms like 'Free from Maintenance Drug Therapy' and 'Discontinuation of Maintenance'.""}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Identify core disease.'}, {'component': 'Free from Maintenance Drug Therapy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers.'}, {'component': 'Minimal Residual Disease (MRD)-Driven', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic/methodological items.'}]",2
